<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="https://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0' xmlns:georss='http://www.georss.org/georss'><id>tag:blogger.com,1999:blog-2993346515708552092.archive</id><updated>2016-09-04T13:06:57.937-03:00</updated><title type='text'>Pharmakon</title><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/archive'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/archive'/><link rel='http://schemas.google.com/g/2005#post' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/archive'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><generator version='7.00' uri='https://www.blogger.com'>Blogger</generator><entry><id>tag:blogger.com,1999:blog-2993346515708552092.layout</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#template'/><title type='text'>Modelo: Pharmakon</title><content type='text'>&lt;?xml version="1.0" encoding="UTF-8" ?&gt;
&lt;!DOCTYPE html&gt;
&lt;html b:version='2' class='v2' expr:dir='data:blog.languageDirection' xmlns='http://www.w3.org/1999/xhtml' xmlns:b='http://www.google.com/2005/gml/b' xmlns:data='http://www.google.com/2005/gml/data' xmlns:expr='http://www.google.com/2005/gml/expr'&gt;
  
&lt;!-- Google Analytics --&gt;
&lt;script&gt;
(function(i,s,o,g,r,a,m){i[&amp;#39;GoogleAnalyticsObject&amp;#39;]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,&amp;#39;script&amp;#39;,&amp;#39;//www.google-analytics.com/analytics.js&amp;#39;,&amp;#39;ga&amp;#39;);

ga(&amp;#39;create&amp;#39;, &amp;#39;UA-5668193-3&amp;#39;, &amp;#39;auto&amp;#39;);
ga(&amp;#39;send&amp;#39;, &amp;#39;pageview&amp;#39;);
&lt;/script&gt;
&lt;!-- End Google Analytics --&gt;

&lt;head&gt;
    &lt;meta expr:content='data:blog.isMobile         ? &amp;quot;width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0&amp;quot;         : &amp;quot;width=1100&amp;quot;' name='viewport'/&gt;
    &lt;b:include data='blog' name='all-head-content'/&gt;
    &lt;title&gt;&lt;data:blog.pageTitle/&gt;&lt;/title&gt;

    &lt;b:skin&gt;&lt;![CDATA[/*
-----------------------------------------------
Blogger Template Style
Name:     Simple
Designer: Josh Peterson
URL:      www.noaesthetic.com
----------------------------------------------- */

/* Variable definitions
   ====================
   &lt;Variable name="keycolor" description="Main Color" type="color" default="#66bbdd" value="#66bbdd"/&gt;

   &lt;Group description="Page Text" selector="body"&gt;
     &lt;Variable name="body.font" description="Font" type="font"
         default="normal normal 12px Arial, Tahoma, Helvetica, FreeSans, sans-serif" value="normal normal 12px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/&gt;
     &lt;Variable name="body.text.color" description="Text Color" type="color" default="#222222" value="#222222"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Backgrounds" selector=".body-fauxcolumns-outer"&gt;
     &lt;Variable name="body.background.color" description="Outer Background" type="color" default="#66bbdd" value="#66bbdd"/&gt;
     &lt;Variable name="content.background.color" description="Main Background" type="color" default="#ffffff" value="#ffffff"/&gt;
     &lt;Variable name="header.background.color" description="Header Background" type="color" default="transparent" value="transparent"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Links" selector=".main-outer"&gt;
     &lt;Variable name="link.color" description="Link Color" type="color" default="#2288bb" value="#2288bb"/&gt;
     &lt;Variable name="link.visited.color" description="Visited Color" type="color" default="#888888" value="#888888"/&gt;
     &lt;Variable name="link.hover.color" description="Hover Color" type="color" default="#33aaff" value="#33aaff"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Blog Title" selector=".header h1"&gt;
     &lt;Variable name="header.font" description="Font" type="font"
         default="normal normal 60px Arial, Tahoma, Helvetica, FreeSans, sans-serif" value="normal normal 60px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/&gt;
     &lt;Variable name="header.text.color" description="Title Color" type="color" default="#3399bb"  value="#3399bb"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Blog Description" selector=".header .description"&gt;
     &lt;Variable name="description.text.color" description="Description Color" type="color"
         default="#777777"  value="#777777"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Tabs Text" selector=".tabs-inner .widget li a"&gt;
     &lt;Variable name="tabs.font" description="Font" type="font"
         default="normal normal 14px Arial, Tahoma, Helvetica, FreeSans, sans-serif" value="normal normal 14px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/&gt;
     &lt;Variable name="tabs.text.color" description="Text Color" type="color" default="#999999" value="#999999"/&gt;
     &lt;Variable name="tabs.selected.text.color" description="Selected Color" type="color" default="#000000" value="#000000"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Tabs Background" selector=".tabs-outer .PageList"&gt;
     &lt;Variable name="tabs.background.color" description="Background Color" type="color" default="#f5f5f5" value="#f5f5f5"/&gt;
     &lt;Variable name="tabs.selected.background.color" description="Selected Color" type="color" default="#eeeeee" value="#eeeeee"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Post Title" selector="h3.post-title, .comments h4"&gt;
     &lt;Variable name="post.title.font" description="Font" type="font"
         default="normal normal 22px Arial, Tahoma, Helvetica, FreeSans, sans-serif" value="normal normal 22px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Date Header" selector=".date-header"&gt;
     &lt;Variable name="date.header.color" description="Text Color" type="color"
         default="$(body.text.color)" value="#222222"/&gt;
     &lt;Variable name="date.header.background.color" description="Background Color" type="color"
         default="transparent" value="transparent"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Post Footer" selector=".post-footer"&gt;
     &lt;Variable name="post.footer.text.color" description="Text Color" type="color" default="#666666" value="#666666"/&gt;
     &lt;Variable name="post.footer.background.color" description="Background Color" type="color"
         default="#f9f9f9" value="#f9f9f9"/&gt;
     &lt;Variable name="post.footer.border.color" description="Shadow Color" type="color" default="#eeeeee" value="#eeeeee"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Gadgets" selector="h2"&gt;
     &lt;Variable name="widget.title.font" description="Title Font" type="font"
        default="normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif" value="normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/&gt;
     &lt;Variable name="widget.title.text.color" description="Title Color" type="color" default="#000000" value="#000000"/&gt;
     &lt;Variable name="widget.alternate.text.color" description="Alternate Color" type="color" default="#999999" value="#999999"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Images" selector=".main-inner"&gt;
     &lt;Variable name="image.background.color" description="Background Color" type="color" default="#ffffff" value="#ffffff"/&gt;
     &lt;Variable name="image.border.color" description="Border Color" type="color" default="#eeeeee" value="#eeeeee"/&gt;
     &lt;Variable name="image.text.color" description="Caption Text Color" type="color" default="$(body.text.color)" value="#222222"/&gt;
   &lt;/Group&gt;

   &lt;Group description="Accents" selector=".content-inner"&gt;
     &lt;Variable name="body.rule.color" description="Separator Line Color" type="color" default="#eeeeee" value="#eeeeee"/&gt;
     &lt;Variable name="tabs.border.color" description="Tabs Border Color" type="color" default="$(body.rule.color)" value="#eeeeee"/&gt;
   &lt;/Group&gt;

   &lt;Variable name="body.background" description="Body Background" type="background"
       color="$(body.background.color)" default="$(color) none repeat scroll top left" value="$(color) none repeat scroll top left"/&gt;
   &lt;Variable name="body.background.override" description="Body Background Override" type="string" default="" value=""/&gt;

   &lt;Variable name="body.background.gradient.cap" description="Body Gradient Cap" type="url"
       default="url(http://www.blogblog.com/1kt/simple/gradients_light.png)" value="url(http://www.blogblog.com/1kt/simple/gradients_light.png)"/&gt;
   &lt;Variable name="body.background.gradient.tile" description="Body Gradient Tile" type="url"
       default="url(http://www.blogblog.com/1kt/simple/body_gradient_tile_light.png)" value="url(http://www.blogblog.com/1kt/simple/body_gradient_tile_light.png)"/&gt;

   &lt;Variable name="content.background.color.selector" description="Content Background Color Selector" type="string" default=".content-inner" value=".content-inner"/&gt;
   &lt;Variable name="content.padding" description="Content Padding" type="length" default="10px" value="10px"/&gt;
   &lt;Variable name="content.padding.horizontal" description="Content Horizontal Padding" type="length" default="$(content.padding)" value="10px"/&gt;
   &lt;Variable name="content.shadow.spread" description="Content Shadow Spread" type="length" default="40px" value="40px"/&gt;
   &lt;Variable name="content.shadow.spread.webkit" description="Content Shadow Spread (WebKit)" type="length" default="5px" value="5px"/&gt;
   &lt;Variable name="content.shadow.spread.ie" description="Content Shadow Spread (IE)" type="length" default="10px" value="10px"/&gt;

   &lt;Variable name="main.border.width" description="Main Border Width" type="length" default="0" value="0"/&gt;

   &lt;Variable name="header.background.gradient" description="Header Gradient" type="url" default="none" value="none"/&gt;
   &lt;Variable name="header.shadow.offset.left" description="Header Shadow Offset Left" type="length" default="-1px" value="-1px"/&gt;
   &lt;Variable name="header.shadow.offset.top" description="Header Shadow Offset Top" type="length" default="-1px" value="-1px"/&gt;
   &lt;Variable name="header.shadow.spread" description="Header Shadow Spread" type="length" default="1px" value="1px"/&gt;
   &lt;Variable name="header.padding" description="Header Padding" type="length" default="30px" value="30px"/&gt;

   &lt;Variable name="header.border.size" description="Header Border Size" type="length" default="1px" value="1px"/&gt;
   &lt;Variable name="header.bottom.border.size" description="Header Bottom Border Size" type="length" default="$(header.border.size)" value="1px"/&gt;
   &lt;Variable name="header.border.horizontalsize" description="Header Horizontal Border Size" type="length" default="0" value="0"/&gt;

   &lt;Variable name="description.text.size" description="Description Text Size" type="string" default="140%" value="140%"/&gt;

   &lt;Variable name="tabs.margin.top" description="Tabs Margin Top" type="length" default="0"  value="0"/&gt;
   &lt;Variable name="tabs.margin.side" description="Tabs Side Margin" type="length" default="30px"  value="30px"/&gt;
   &lt;Variable name="tabs.background.gradient" description="Tabs Background Gradient" type="url"
       default="url(http://www.blogblog.com/1kt/simple/gradients_light.png)" value="url(http://www.blogblog.com/1kt/simple/gradients_light.png)"/&gt;
   &lt;Variable name="tabs.border.width" description="Tabs Border Width" type="length" default="1px" value="1px"/&gt;
   &lt;Variable name="tabs.bevel.border.width" description="Tabs Bevel Border Width" type="length" default="1px" value="1px"/&gt;

   &lt;Variable name="date.header.padding" description="Date Header Padding" type="string" default="inherit" value="inherit"/&gt;
   &lt;Variable name="date.header.letterspacing" description="Date Header Letter Spacing" type="string" default="inherit" value="inherit"/&gt;
   &lt;Variable name="date.header.margin" description="Date Header Margin" type="string" default="inherit" value="inherit"/&gt;

   &lt;Variable name="post.margin.bottom" description="Post Bottom Margin" type="length" default="25px" value="25px"/&gt;

   &lt;Variable name="image.border.small.size" description="Image Border Small Size" type="length" default="2px" value="2px"/&gt;
   &lt;Variable name="image.border.large.size" description="Image Border Large Size" type="length" default="5px" value="5px"/&gt;

   &lt;Variable name="page.width.selector" description="Page Width Selector" type="string" default=".region-inner" value=".region-inner"/&gt;
   &lt;Variable name="page.width" description="Page Width" type="string" default="auto" value="auto"/&gt;

   &lt;Variable name="main.section.margin" description="Main Section Margin" type="length" default="15px" value="15px"/&gt;
   &lt;Variable name="main.padding" description="Main Padding" type="length" default="15px" value="15px"/&gt;
   &lt;Variable name="main.padding.top" description="Main Padding Top" type="length" default="30px" value="30px"/&gt;
   &lt;Variable name="main.padding.bottom" description="Main Padding Bottom" type="length" default="30px" value="30px"/&gt;

   &lt;Variable name="paging.background"
       color="$(content.background.color)"
       description="Background of blog paging area" type="background"
       default="transparent none no-repeat scroll top center" value="transparent none no-repeat scroll top center"/&gt;

   &lt;Variable name="footer.bevel" description="Bevel border length of footer" type="length" default="0" value="0"/&gt;

   &lt;Variable name="mobile.background.overlay" description="Mobile Background Overlay" type="string"
       default="transparent none repeat scroll top left" value="transparent none repeat scroll top left"/&gt;
   &lt;Variable name="mobile.background.size" description="Mobile Background Size" type="string" default="auto" value="auto"/&gt;
   &lt;Variable name="mobile.button.color" description="Mobile Button Color" type="color" default="#ffffff"  value="#ffffff"/&gt;

   &lt;Variable name="startSide" description="Side where text starts in blog language" type="automatic" default="left" value="left"/&gt;
   &lt;Variable name="endSide" description="Side where text ends in blog language" type="automatic" default="right" value="right"/&gt;
*/

/* Content
----------------------------------------------- */
body {
  font: $(body.font);
  color: $(body.text.color);
  background: $(body.background);
  padding: 0 $(content.shadow.spread) $(content.shadow.spread) $(content.shadow.spread);
  $(body.background.override)
}

html body $(page.width.selector) {
  min-width: 0;
  max-width: 100%;
  width: $(page.width);
}

a:link {
  text-decoration:none;
  color: $(link.color);
}

a:visited {
  text-decoration:none;
  color: $(link.visited.color);
}

a:hover {
  text-decoration:underline;
  color: $(link.hover.color);
}

.body-fauxcolumn-outer .fauxcolumn-inner {
  background: transparent $(body.background.gradient.tile) repeat scroll top left;
  _background-image: none;
}

.body-fauxcolumn-outer .cap-top {
  position: absolute;
  z-index: 1;
  height: 400px;
  width: 100%;
  background: $(body.background);
  $(body.background.override)
}

.body-fauxcolumn-outer .cap-top .cap-left {
  width: 100%;
  background: transparent $(body.background.gradient.cap) repeat-x scroll top left;
  _background-image: none;
}

.content-outer {
  -moz-box-shadow: 0 0 $(content.shadow.spread) rgba(0, 0, 0, .15);
  -webkit-box-shadow: 0 0 $(content.shadow.spread.webkit) rgba(0, 0, 0, .15);
  -goog-ms-box-shadow: 0 0 $(content.shadow.spread.ie) #333333;
  box-shadow: 0 0 $(content.shadow.spread) rgba(0, 0, 0, .15);

  margin-bottom: 1px;
}

.content-inner {
  padding: $(content.padding) $(content.padding.horizontal);
}

$(content.background.color.selector) {
  background-color: $(content.background.color);
}

/* Header
----------------------------------------------- */
.header-outer {
  background: $(header.background.color) $(header.background.gradient) repeat-x scroll 0 -400px;
  _background-image: none;
}

.Header h1 {
  font: $(header.font);
  color: $(header.text.color);
  text-shadow: $(header.shadow.offset.left) $(header.shadow.offset.top) $(header.shadow.spread) rgba(0, 0, 0, .2);
}

.Header h1 a {
  color: $(header.text.color);
}

.Header .description {
  font-size: $(description.text.size);
  color: $(description.text.color);
}

.header-inner .Header .titlewrapper {
  padding: 22px $(header.padding);
}

.header-inner .Header .descriptionwrapper {
  padding: 0 $(header.padding);
}

/* Tabs
----------------------------------------------- */
.tabs-inner .section:first-child {
  border-top: $(header.bottom.border.size) solid $(tabs.border.color);
}

.tabs-inner .section:first-child ul {
  margin-top: -$(header.border.size);
  border-top: $(header.border.size) solid $(tabs.border.color);
  border-left: $(header.border.horizontalsize) solid $(tabs.border.color);
  border-right: $(header.border.horizontalsize) solid $(tabs.border.color);
}

.tabs-inner .widget ul {
  background: $(tabs.background.color) $(tabs.background.gradient) repeat-x scroll 0 -800px;
  _background-image: none;
  border-bottom: $(tabs.border.width) solid $(tabs.border.color);

  margin-top: $(tabs.margin.top);
  margin-left: -$(tabs.margin.side);
  margin-right: -$(tabs.margin.side);
}

.tabs-inner .widget li a {
  display: inline-block;

  padding: .6em 1em;

  font: $(tabs.font);
  color: $(tabs.text.color);

  border-$startSide: $(tabs.border.width) solid $(content.background.color);
  border-$endSide: $(tabs.bevel.border.width) solid $(tabs.border.color);
}

.tabs-inner .widget li:first-child a {
  border-$startSide: none;
}

.tabs-inner .widget li.selected a, .tabs-inner .widget li a:hover {
  color: $(tabs.selected.text.color);
  background-color: $(tabs.selected.background.color);
  text-decoration: none;
}

/* Columns
----------------------------------------------- */
.main-outer {
  border-top: $(main.border.width) solid $(body.rule.color);
}

.fauxcolumn-left-outer .fauxcolumn-inner {
  border-right: 1px solid $(body.rule.color);
}

.fauxcolumn-right-outer .fauxcolumn-inner {
  border-left: 1px solid $(body.rule.color);
}

/* Headings
----------------------------------------------- */
h2 {
  margin: 0 0 1em 0;

  font: $(widget.title.font);
  color: $(widget.title.text.color);
  text-transform: uppercase;
}

/* Widgets
----------------------------------------------- */
.widget .zippy {
  color: $(widget.alternate.text.color);
  text-shadow: 2px 2px 1px rgba(0, 0, 0, .1);
}

.widget .popular-posts ul {
  list-style: none;
}

/* Posts
----------------------------------------------- */
.date-header span {
  background-color: $(date.header.background.color);
  color: $(date.header.color);
  padding: $(date.header.padding);
  letter-spacing: $(date.header.letterspacing);
  margin: $(date.header.margin);
}

.main-inner {
  padding-top: $(main.padding.top);
  padding-bottom: $(main.padding.bottom);
}

.main-inner .column-center-inner {
  padding: 0 $(main.padding);
}

.main-inner .column-center-inner .section {
  margin: 0 $(main.section.margin);
}

.post {
  margin: 0 0 $(post.margin.bottom) 0;
}

h3.post-title, .comments h4 {
  font: $(post.title.font);
  margin: .75em 0 0;
  float: none;
}

.post-body {
  font-size: 110%;
  line-height: 1.4;
  position: relative;
  top: 5px;
}

.post-body img, .post-body .tr-caption-container, .Profile img, .Image img,
.BlogList .item-thumbnail img {
  padding: $(image.border.small.size);

  background: $(image.background.color);
  border: 1px solid $(image.border.color);

  -moz-box-shadow: 1px 1px 5px rgba(0, 0, 0, .1);
  -webkit-box-shadow: 1px 1px 5px rgba(0, 0, 0, .1);
  box-shadow: 1px 1px 5px rgba(0, 0, 0, .1);
}

.post-body img, .post-body .tr-caption-container {
  padding: $(image.border.large.size);
}

.post-body .tr-caption-container {
  color: $(image.text.color);
}

.post-body .tr-caption-container img {
  padding: 0;

  background: transparent;
  border: none;

  -moz-box-shadow: 0 0 0 rgba(0, 0, 0, .1);
  -webkit-box-shadow: 0 0 0 rgba(0, 0, 0, .1);
  box-shadow: 0 0 0 rgba(0, 0, 0, .1);
}

.post-header {
  margin: 0 0 1.5em;

  line-height: 1.6;
  font-size: 90%;
}

.post-footer {
  margin: 20px -2px 0;
  padding: 5px 10px;

  color: $(post.footer.text.color);
  background-color: $(post.footer.background.color);
  border-bottom: 1px solid $(post.footer.border.color);

  line-height: 1.6;
  font-size: 90%;
}

#comments .comment-author {
  padding-top: 1.5em;

  border-top: 1px solid $(body.rule.color);
  background-position: 0 1.5em;
}

#comments .comment-author:first-child {
  padding-top: 0;
  border-top: none;
}

.avatar-image-container {
  margin: .2em 0 0;
}

#comments .avatar-image-container img {
  border: 1px solid $(image.border.color);
}

/* Comments
----------------------------------------------- */
.comments .comments-content .icon.blog-author {
  background-repeat: no-repeat;
  background-image: url(data:image/png;base64,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);
}

.comments .comments-content .loadmore a {
  border-top: 1px solid $(widget.alternate.text.color);
  border-bottom: 1px solid $(widget.alternate.text.color);
}

.comments .comment-thread.inline-thread {
  background-color: $(post.footer.background.color);
}

.comments .continue {
  border-top: 2px solid $(widget.alternate.text.color);
}

/* Accents
---------------------------------------------- */
.section-columns td.columns-cell {
  border-$startSide: 1px solid $(body.rule.color);
}

.blog-pager {
  background: $(paging.background);
}

.blog-pager-older-link, .home-link,
.blog-pager-newer-link {
  background-color: $(content.background.color);
  padding: 5px;
}

.footer-outer {
  border-top: $(footer.bevel) dashed #bbbbbb;
}

/* Mobile
----------------------------------------------- */
body.mobile  {
  background-size: $(mobile.background.size);
}

.mobile .body-fauxcolumn-outer {
  background: $(mobile.background.overlay);
}

.mobile .body-fauxcolumn-outer .cap-top {
  background-size: 100% auto;
}

.mobile .content-outer {
  -webkit-box-shadow: 0 0 3px rgba(0, 0, 0, .15);
  box-shadow: 0 0 3px rgba(0, 0, 0, .15);
  padding: 0 $(content.shadow.spread);
}

body.mobile .AdSense {
  margin: 0 -$(content.shadow.spread);
}

.mobile .tabs-inner .widget ul {
  margin-left: 0;
  margin-right: 0;
}

.mobile .post {
  margin: 0;
}

.mobile .main-inner .column-center-inner .section {
  margin: 0;
}

.mobile .date-header span {
  padding: 0.1em 10px;
  margin: 0 -10px;
}

.mobile h3.post-title {
  margin: 0;
}

.mobile .blog-pager {
  background: transparent none no-repeat scroll top center;
}

.mobile .footer-outer {
  border-top: none;
}

.mobile .main-inner, .mobile .footer-inner {
  background-color: $(content.background.color);
}

.mobile-index-contents {
  color: $(body.text.color);
}

.mobile-link-button {
  background-color: $(link.color);
}

.mobile-link-button a:link, .mobile-link-button a:visited {
  color: $(mobile.button.color);
}

.mobile .tabs-inner .section:first-child {
  border-top: none;
}

.mobile .tabs-inner .PageList .widget-content {
  background-color: $(tabs.selected.background.color);
  color: $(tabs.selected.text.color);
  border-top: $(tabs.border.width) solid $(tabs.border.color);
  border-bottom: $(tabs.border.width) solid $(tabs.border.color);
}

.mobile .tabs-inner .PageList .widget-content .pagelist-arrow {
  border-$startSide: 1px solid $(tabs.border.color);
}
]]&gt;&lt;/b:skin&gt;

    &lt;b:template-skin&gt;
      &lt;b:variable default='960px' name='content.width' type='length'/&gt;
      &lt;b:variable default='0' name='main.column.left.width' type='length'/&gt;
      &lt;b:variable default='310px' name='main.column.right.width' type='length'/&gt;

      &lt;![CDATA[
      body {
        min-width: $(content.width);
      }

      .content-outer, .content-fauxcolumn-outer, .region-inner {
        min-width: $(content.width);
        max-width: $(content.width);
        _width: $(content.width);
      }

      .main-inner .columns {
        padding-left: $(main.column.left.width);
        padding-right: $(main.column.right.width);
      }

      .main-inner .fauxcolumn-center-outer {
        left: $(main.column.left.width);
        right: $(main.column.right.width);
        /* IE6 does not respect left and right together */
        _width: expression(this.parentNode.offsetWidth -
            parseInt("$(main.column.left.width)") -
            parseInt("$(main.column.right.width)") + 'px');
      }

      .main-inner .fauxcolumn-left-outer {
        width: $(main.column.left.width);
      }

      .main-inner .fauxcolumn-right-outer {
        width: $(main.column.right.width);
      }

      .main-inner .column-left-outer {
        width: $(main.column.left.width);
        right: 100%;
        margin-left: -$(main.column.left.width);
      }

      .main-inner .column-right-outer {
        width: $(main.column.right.width);
        margin-right: -$(main.column.right.width);
      }

      #layout {
        min-width: 0;
      }

      #layout .content-outer {
        min-width: 0;
        width: 800px;
      }

      #layout .region-inner {
        min-width: 0;
        width: auto;
      }
      ]]&gt;
    &lt;/b:template-skin&gt;
    &lt;b:include data='blog' name='google-analytics'/&gt;
  &lt;/head&gt;

  &lt;body expr:class='&amp;quot;loading&amp;quot; + data:blog.mobileClass'&gt;
  &lt;b:section class='navbar' id='navbar' maxwidgets='1' name='Navbar' showaddelement='no'&gt;
    &lt;b:widget id='Navbar1' locked='true' title='Navbar' type='Navbar' visible='true'&gt;
      &lt;b:includable id='main'&gt;&amp;lt;script type=&amp;quot;text/javascript&amp;quot;&amp;gt;
    function setAttributeOnload(object, attribute, val) {
      if(window.addEventListener) {
        window.addEventListener(&amp;#39;load&amp;#39;,
          function(){ object[attribute] = val; }, false);
      } else {
        window.attachEvent(&amp;#39;onload&amp;#39;, function(){ object[attribute] = val; });
      }
    }
  &amp;lt;/script&amp;gt;
&amp;lt;div id=&amp;quot;navbar-iframe-container&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;
&amp;lt;script type=&amp;quot;text/javascript&amp;quot; src=&amp;quot;https://apis.google.com/js/plusone.js&amp;quot;&amp;gt;&amp;lt;/script&amp;gt;
&amp;lt;script type=&amp;quot;text/javascript&amp;quot;&amp;gt;
      gapi.load(&amp;quot;gapi.iframes:gapi.iframes.style.bubble&amp;quot;, function() {
        if (gapi.iframes &amp;amp;&amp;amp; gapi.iframes.getContext) {
          gapi.iframes.getContext().openChild({
              url: &amp;#39;https://www.blogger.com/navbar.g?targetBlogID\x3d2993346515708552092\x26blogName\x3dPharmakon\x26publishMode\x3dPUBLISH_MODE_BLOGSPOT\x26navbarType\x3dLIGHT\x26layoutType\x3dLAYOUTS\x26searchRoot\x3dhttps://pharmak.blogspot.com/search\x26blogLocale\x3dpt_BR\x26v\x3d2\x26homepageUrl\x3dhttps://pharmak.blogspot.com/\x26vt\x3d7944545517179844130&amp;#39;,
              where: document.getElementById(&amp;quot;navbar-iframe-container&amp;quot;),
              id: &amp;quot;navbar-iframe&amp;quot;
          });
        }
      });
    &amp;lt;/script&amp;gt;&amp;lt;script type=&amp;quot;text/javascript&amp;quot;&amp;gt;
(function() {
var script = document.createElement(&amp;#39;script&amp;#39;);
script.type = &amp;#39;text/javascript&amp;#39;;
script.src = &amp;#39;//pagead2.googlesyndication.com/pagead/js/google_top_exp.js&amp;#39;;
var head = document.getElementsByTagName(&amp;#39;head&amp;#39;)[0];
if (head) {
head.appendChild(script);
}})();
&amp;lt;/script&amp;gt;
&lt;/b:includable&gt;
    &lt;/b:widget&gt;
  &lt;/b:section&gt;

  &lt;b:if cond='data:blog.pageType == &amp;quot;index&amp;quot;'&gt;
    &lt;div itemscope='itemscope' itemtype='http://schema.org/Blog' style='display: none;'&gt;
      &lt;meta expr:content='data:blog.title' itemprop='name'/&gt;
      &lt;b:if cond='data:blog.metaDescription'&gt;
        &lt;meta expr:content='data:blog.metaDescription' itemprop='description'/&gt;
      &lt;/b:if&gt;
    &lt;/div&gt;
  &lt;/b:if&gt;

  &lt;div class='body-fauxcolumns'&gt;
    &lt;div class='fauxcolumn-outer body-fauxcolumn-outer'&gt;
    &lt;div class='cap-top'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;div class='fauxborder-left'&gt;
    &lt;div class='fauxborder-right'/&gt;
    &lt;div class='fauxcolumn-inner'&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;div class='cap-bottom'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;

  &lt;div class='content'&gt;
  &lt;div class='content-fauxcolumns'&gt;
    &lt;div class='fauxcolumn-outer content-fauxcolumn-outer'&gt;
    &lt;div class='cap-top'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;div class='fauxborder-left'&gt;
    &lt;div class='fauxborder-right'/&gt;
    &lt;div class='fauxcolumn-inner'&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;div class='cap-bottom'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;

  &lt;div class='content-outer'&gt;
  &lt;div class='content-cap-top cap-top'&gt;
    &lt;div class='cap-left'/&gt;
    &lt;div class='cap-right'/&gt;
  &lt;/div&gt;
  &lt;div class='fauxborder-left content-fauxborder-left'&gt;
  &lt;div class='fauxborder-right content-fauxborder-right'/&gt;
  &lt;div class='content-inner'&gt;

    &lt;header&gt;
    &lt;div class='header-outer'&gt;
    &lt;div class='header-cap-top cap-top'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;div class='fauxborder-left header-fauxborder-left'&gt;
    &lt;div class='fauxborder-right header-fauxborder-right'/&gt;
    &lt;div class='region-inner header-inner'&gt;
      &lt;b:section class='header' id='header' maxwidgets='1' name='Header' showaddelement='no'&gt;
        &lt;b:widget id='Header1' locked='true' title='Pharmakon (Cabeçalho)' type='Header' visible='true'&gt;
          &lt;b:includable id='main'&gt;

  &lt;b:if cond='data:useImage'&gt;
    &lt;b:if cond='data:imagePlacement == &amp;quot;BEHIND&amp;quot;'&gt;
      &lt;!--
      Show image as background to text. You can't really calculate the width
      reliably in JS because margins are not taken into account by any of
      clientWidth, offsetWidth or scrollWidth, so we don't force a minimum
      width if the user is using shrink to fit.
      This results in a margin-width's worth of pixels being cropped. If the
      user is not using shrink to fit then we expand the header.
      --&gt;
      &lt;b:if cond='data:mobile'&gt;
        &lt;div id='header-inner'&gt;
          &lt;div class='titlewrapper' style='background: transparent'&gt;
            &lt;h1 class='title' style='background: transparent; border-width: 0px'&gt;
              &lt;b:include name='title'/&gt;
            &lt;/h1&gt;
          &lt;/div&gt;
          &lt;b:include name='description'/&gt;
        &lt;/div&gt;
      &lt;b:else/&gt;
        &lt;div expr:style='&amp;quot;background-image: url(\&amp;quot;&amp;quot; + data:sourceUrl + &amp;quot;\&amp;quot;); &amp;quot;                      + &amp;quot;background-position: &amp;quot;                      + data:backgroundPositionStyleStr + &amp;quot;; &amp;quot;                      + data:widthStyleStr                      + &amp;quot;min-height: &amp;quot; + data:height                      + &amp;quot;_height: &amp;quot; + data:height                      + &amp;quot;background-repeat: no-repeat; &amp;quot;' id='header-inner'&gt;
          &lt;div class='titlewrapper' style='background: transparent'&gt;
            &lt;h1 class='title' style='background: transparent; border-width: 0px'&gt;
              &lt;b:include name='title'/&gt;
            &lt;/h1&gt;
          &lt;/div&gt;
          &lt;b:include name='description'/&gt;
        &lt;/div&gt;
      &lt;/b:if&gt;
    &lt;b:else/&gt;
      &lt;!--Show the image only--&gt;
      &lt;div id='header-inner'&gt;
        &lt;a expr:href='data:blog.homepageUrl' style='display: block'&gt;
          &lt;img expr:alt='data:title' expr:height='data:height' expr:id='data:widget.instanceId + &amp;quot;_headerimg&amp;quot;' expr:src='data:sourceUrl' expr:width='data:width' style='display: block'/&gt;
        &lt;/a&gt;
        &lt;!--Show the description--&gt;
        &lt;b:if cond='data:imagePlacement == &amp;quot;BEFORE_DESCRIPTION&amp;quot;'&gt;
          &lt;b:include name='description'/&gt;
        &lt;/b:if&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;
  &lt;b:else/&gt;
    &lt;!--No header image --&gt;
    &lt;div id='header-inner'&gt;
      &lt;div class='titlewrapper'&gt;
        &lt;h1 class='title'&gt;
          &lt;b:include name='title'/&gt;
        &lt;/h1&gt;
      &lt;/div&gt;
      &lt;b:include name='description'/&gt;
    &lt;/div&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
          &lt;b:includable id='description'&gt;
  &lt;div class='descriptionwrapper'&gt;
    &lt;p class='description'&gt;&lt;span&gt;&lt;data:description/&gt;&lt;/span&gt;&lt;/p&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
          &lt;b:includable id='title'&gt;
  &lt;b:if cond='data:blog.url == data:blog.homepageUrl'&gt;
    &lt;data:title/&gt;
  &lt;b:else/&gt;
    &lt;a expr:href='data:blog.homepageUrl'&gt;&lt;data:title/&gt;&lt;/a&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
        &lt;/b:widget&gt;
      &lt;/b:section&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;div class='header-cap-bottom cap-bottom'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;/header&gt;

    &lt;div class='tabs-outer'&gt;
    &lt;div class='tabs-cap-top cap-top'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;div class='fauxborder-left tabs-fauxborder-left'&gt;
    &lt;div class='fauxborder-right tabs-fauxborder-right'/&gt;
    &lt;div class='region-inner tabs-inner'&gt;
      &lt;b:section class='tabs' id='crosscol' maxwidgets='1' name='Cross-Column' showaddelement='yes'/&gt;
      &lt;b:section class='tabs' id='crosscol-overflow' name='Cross-Column 2' showaddelement='no'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;div class='tabs-cap-bottom cap-bottom'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;

    &lt;div class='main-outer'&gt;
    &lt;div class='main-cap-top cap-top'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;

    &lt;div class='fauxborder-left main-fauxborder-left'&gt;
    &lt;div class='fauxborder-right main-fauxborder-right'/&gt;
    &lt;div class='region-inner main-inner'&gt;

      &lt;div class='columns fauxcolumns'&gt;

        &lt;div class='fauxcolumn-outer fauxcolumn-center-outer'&gt;
        &lt;div class='cap-top'&gt;
          &lt;div class='cap-left'/&gt;
          &lt;div class='cap-right'/&gt;
        &lt;/div&gt;
        &lt;div class='fauxborder-left'&gt;
        &lt;div class='fauxborder-right'/&gt;
        &lt;div class='fauxcolumn-inner'&gt;
        &lt;/div&gt;
        &lt;/div&gt;
        &lt;div class='cap-bottom'&gt;
          &lt;div class='cap-left'/&gt;
          &lt;div class='cap-right'/&gt;
        &lt;/div&gt;
        &lt;/div&gt;

        &lt;div class='fauxcolumn-outer fauxcolumn-left-outer'&gt;
        &lt;div class='cap-top'&gt;
          &lt;div class='cap-left'/&gt;
          &lt;div class='cap-right'/&gt;
        &lt;/div&gt;
        &lt;div class='fauxborder-left'&gt;
        &lt;div class='fauxborder-right'/&gt;
        &lt;div class='fauxcolumn-inner'&gt;
        &lt;/div&gt;
        &lt;/div&gt;
        &lt;div class='cap-bottom'&gt;
          &lt;div class='cap-left'/&gt;
          &lt;div class='cap-right'/&gt;
        &lt;/div&gt;
        &lt;/div&gt;

        &lt;div class='fauxcolumn-outer fauxcolumn-right-outer'&gt;
        &lt;div class='cap-top'&gt;
          &lt;div class='cap-left'/&gt;
          &lt;div class='cap-right'/&gt;
        &lt;/div&gt;
        &lt;div class='fauxborder-left'&gt;
        &lt;div class='fauxborder-right'/&gt;
        &lt;div class='fauxcolumn-inner'&gt;
        &lt;/div&gt;
        &lt;/div&gt;
        &lt;div class='cap-bottom'&gt;
          &lt;div class='cap-left'/&gt;
          &lt;div class='cap-right'/&gt;
        &lt;/div&gt;
        &lt;/div&gt;

        &lt;!-- corrects IE6 width calculation --&gt;
        &lt;div class='columns-inner'&gt;

        &lt;div class='column-center-outer'&gt;
        &lt;div class='column-center-inner'&gt;
          &lt;b:section class='main' id='main' name='Main' showaddelement='no'&gt;
            &lt;b:widget id='Blog1' locked='true' title='Postagens no blog' type='Blog' visible='true'&gt;
              &lt;b:includable id='main' var='top'&gt;
  &lt;b:if cond='!data:mobile'&gt;
    &lt;!-- posts --&gt;
    &lt;div class='blog-posts hfeed'&gt;

      &lt;b:include data='top' name='status-message'/&gt;

      &lt;b:loop values='data:posts' var='post'&gt;
        &lt;b:if cond='data:post.isDateStart and not data:post.isFirstPost'&gt;
          &amp;lt;/div&amp;gt;&amp;lt;/div&amp;gt;
        &lt;/b:if&gt;
        &lt;b:if cond='data:post.isDateStart'&gt;
          &amp;lt;div class=&amp;quot;date-outer&amp;quot;&amp;gt;
        &lt;/b:if&gt;
        &lt;b:if cond='data:post.dateHeader'&gt;
          &lt;h2 class='date-header'&gt;&lt;span&gt;&lt;data:post.dateHeader/&gt;&lt;/span&gt;&lt;/h2&gt;
        &lt;/b:if&gt;
        &lt;b:if cond='data:post.isDateStart'&gt;
          &amp;lt;div class=&amp;quot;date-posts&amp;quot;&amp;gt;
        &lt;/b:if&gt;
        &lt;div class='post-outer'&gt;
          &lt;b:include data='post' name='post'/&gt;
          &lt;b:include cond='data:blog.pageType in {&amp;quot;static_page&amp;quot;,&amp;quot;item&amp;quot;}' data='post' name='comment_picker'/&gt;
        &lt;/div&gt;

        &lt;!-- Ad --&gt;
        &lt;b:if cond='data:post.includeAd'&gt;
          &lt;div class='inline-ad'&gt;
            &lt;data:adCode/&gt;
          &lt;/div&gt;
        &lt;/b:if&gt;
      &lt;/b:loop&gt;
      &lt;b:if cond='data:numPosts != 0'&gt;
        &amp;lt;/div&amp;gt;&amp;lt;/div&amp;gt;
      &lt;/b:if&gt;
    &lt;/div&gt;

    &lt;!-- navigation --&gt;
    &lt;b:include name='nextprev'/&gt;

    &lt;!-- feed links --&gt;
    &lt;b:include name='feedLinks'/&gt;

  &lt;b:else/&gt;
    &lt;b:include name='mobile-main'/&gt;
  &lt;/b:if&gt;

  &lt;b:if cond='data:top.showPlusOne'&gt;
    &lt;data:top.googlePlusBootstrap/&gt;
  &lt;/b:if&gt;

&lt;/b:includable&gt;
              &lt;b:includable id='backlinkDeleteIcon' var='backlink'&gt;
  &lt;span expr:class='&amp;quot;item-control &amp;quot; + data:backlink.adminClass'&gt;
    &lt;a expr:href='data:backlink.deleteUrl' expr:title='data:top.deleteBacklinkMsg'&gt;
      &lt;img src='https://resources.blogblog.com/img/icon_delete13.gif'/&gt;
    &lt;/a&gt;
  &lt;/span&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='backlinks' var='post'&gt;
  &lt;a name='links'/&gt;&lt;h4&gt;&lt;data:post.backlinksLabel/&gt;&lt;/h4&gt;
  &lt;b:if cond='data:post.numBacklinks != 0'&gt;
    &lt;dl class='comments-block' id='comments-block'&gt;
      &lt;b:loop values='data:post.backlinks' var='backlink'&gt;
        &lt;div class='collapsed-backlink backlink-control'&gt;
          &lt;dt class='comment-title'&gt;
            &lt;span class='backlink-toggle-zippy'&gt;&amp;#160;&lt;/span&gt;
            &lt;a expr:href='data:backlink.url' rel='nofollow'&gt;&lt;data:backlink.title/&gt;&lt;/a&gt;
            &lt;b:include data='backlink' name='backlinkDeleteIcon'/&gt;
          &lt;/dt&gt;
          &lt;dd class='comment-body collapseable'&gt;
            &lt;data:backlink.snippet/&gt;
          &lt;/dd&gt;
          &lt;dd class='comment-footer collapseable'&gt;
            &lt;span class='comment-author'&gt;&lt;data:post.authorLabel/&gt; &lt;data:backlink.author/&gt;&lt;/span&gt;
            &lt;span class='comment-timestamp'&gt;&lt;data:post.timestampLabel/&gt; &lt;data:backlink.timestamp/&gt;&lt;/span&gt;
          &lt;/dd&gt;
        &lt;/div&gt;
      &lt;/b:loop&gt;
    &lt;/dl&gt;
  &lt;/b:if&gt;
  &lt;p class='comment-footer'&gt;
    &lt;a class='comment-link' expr:href='data:post.createLinkUrl' expr:id='data:widget.instanceId + &amp;quot;_backlinks-create-link&amp;quot;' target='_blank'&gt;&lt;data:post.createLinkLabel/&gt;&lt;/a&gt;
  &lt;/p&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='comment-form' var='post'&gt;
  &lt;div class='comment-form'&gt;
    &lt;a name='comment-form'/&gt;
    &lt;b:if cond='data:mobile'&gt;
      &lt;h4 id='comment-post-message'&gt;
        &lt;a expr:id='data:widget.instanceId + &amp;quot;_comment-editor-toggle-link&amp;quot;' href='javascript:void(0)'&gt;&lt;data:postCommentMsg/&gt;&lt;/a&gt;&lt;/h4&gt;
      &lt;p&gt;&lt;data:blogCommentMessage/&gt;&lt;/p&gt;
      &lt;data:blogTeamBlogMessage/&gt;
      &lt;a expr:href='data:post.commentFormIframeSrc' id='comment-editor-src'/&gt;
      &lt;iframe allowtransparency='true' class='blogger-iframe-colorize blogger-comment-from-post' expr:height='data:cmtIframeInitialHeight' frameborder='0' id='comment-editor' name='comment-editor' src='' style='display: none' width='100%'/&gt;
    &lt;b:else/&gt;
      &lt;h4 id='comment-post-message'&gt;&lt;data:postCommentMsg/&gt;&lt;/h4&gt;
      &lt;p&gt;&lt;data:blogCommentMessage/&gt;&lt;/p&gt;
      &lt;data:blogTeamBlogMessage/&gt;
      &lt;a expr:href='data:post.commentFormIframeSrc' id='comment-editor-src'/&gt;
      &lt;iframe allowtransparency='true' class='blogger-iframe-colorize blogger-comment-from-post' expr:height='data:cmtIframeInitialHeight' frameborder='0' id='comment-editor' name='comment-editor' src='' width='100%'/&gt;
    &lt;/b:if&gt;
    &lt;data:post.friendConnectJs/&gt;
    &lt;data:post.cmtfpIframe/&gt;
    &lt;script type='text/javascript'&gt;
      BLOG_CMT_createIframe(&amp;#39;&lt;data:post.appRpcRelayPath/&gt;&amp;#39;);
    &lt;/script&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='commentDeleteIcon' var='comment'&gt;
  &lt;span expr:class='&amp;quot;item-control &amp;quot; + data:comment.adminClass'&gt;
    &lt;b:if cond='data:showCmtPopup'&gt;
      &lt;div class='goog-toggle-button'&gt;
        &lt;div class='goog-inline-block comment-action-icon'/&gt;
      &lt;/div&gt;
    &lt;b:else/&gt;
      &lt;a class='comment-delete' expr:href='data:comment.deleteUrl' expr:title='data:top.deleteCommentMsg'&gt;
        &lt;img src='https://resources.blogblog.com/img/icon_delete13.gif'/&gt;
      &lt;/a&gt;
    &lt;/b:if&gt;
  &lt;/span&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='comment_count_picker' var='post'&gt;
  &lt;b:if cond='data:post.commentSource == 1'&gt;
    &lt;span class='cmt_count_iframe_holder' expr:data-count='data:post.numComments' expr:data-onclick='data:post.addCommentOnclick' expr:data-post-url='data:post.url' expr:data-url='data:post.url.canonical.http'&gt;
    &lt;/span&gt;
  &lt;b:else/&gt;
    &lt;a class='comment-link' expr:href='data:post.addCommentUrl' expr:onclick='data:post.addCommentOnclick'&gt;
      &lt;data:post.commentLabelFull/&gt;:
    &lt;/a&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='comment_picker' var='post'&gt;
  &lt;b:if cond='data:post.commentSource == 1'&gt;
    &lt;b:include data='post' name='iframe_comments'/&gt;
  &lt;b:elseif cond='data:post.showThreadedComments'/&gt;
    &lt;b:include data='post' name='threaded_comments'/&gt;
  &lt;b:else/&gt;
    &lt;b:include data='post' name='comments'/&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='comments' var='post'&gt;
  &lt;div class='comments' id='comments'&gt;
    &lt;a name='comments'/&gt;
    &lt;b:if cond='data:post.allowComments'&gt;
      &lt;h4&gt;&lt;data:post.commentLabelFull/&gt;:&lt;/h4&gt;

      &lt;b:if cond='data:post.commentPagingRequired'&gt;
        &lt;span class='paging-control-container'&gt;
          &lt;b:if cond='data:post.hasOlderLinks'&gt;
            &lt;a expr:class='data:post.oldLinkClass' expr:href='data:post.oldestLinkUrl'&gt;&lt;data:post.oldestLinkText/&gt;&lt;/a&gt;
              &amp;#160;
            &lt;a expr:class='data:post.oldLinkClass' expr:href='data:post.olderLinkUrl'&gt;&lt;data:post.olderLinkText/&gt;&lt;/a&gt;
              &amp;#160;
          &lt;/b:if&gt;

          &lt;data:post.commentRangeText/&gt;

          &lt;b:if cond='data:post.hasNewerLinks'&gt;
            &amp;#160;
            &lt;a expr:class='data:post.newLinkClass' expr:href='data:post.newerLinkUrl'&gt;&lt;data:post.newerLinkText/&gt;&lt;/a&gt;
            &amp;#160;
            &lt;a expr:class='data:post.newLinkClass' expr:href='data:post.newestLinkUrl'&gt;&lt;data:post.newestLinkText/&gt;&lt;/a&gt;
          &lt;/b:if&gt;
        &lt;/span&gt;
      &lt;/b:if&gt;

      &lt;div expr:id='data:widget.instanceId + &amp;quot;_comments-block-wrapper&amp;quot;'&gt;
        &lt;dl expr:class='data:post.avatarIndentClass' id='comments-block'&gt;
          &lt;b:loop values='data:post.comments' var='comment'&gt;
            &lt;dt expr:class='&amp;quot;comment-author &amp;quot; + data:comment.authorClass' expr:id='data:comment.anchorName'&gt;
              &lt;b:if cond='data:comment.favicon'&gt;
                &lt;img expr:src='data:comment.favicon' height='16px' style='margin-bottom:-2px;' width='16px'/&gt;
              &lt;/b:if&gt;
              &lt;a expr:name='data:comment.anchorName'/&gt;
              &lt;b:if cond='data:blog.enabledCommentProfileImages'&gt;
                &lt;data:comment.authorAvatarImage/&gt;
              &lt;/b:if&gt;
              &lt;b:if cond='data:comment.authorUrl'&gt;
                &lt;a expr:href='data:comment.authorUrl' rel='nofollow'&gt;&lt;data:comment.author/&gt;&lt;/a&gt;
              &lt;b:else/&gt;
                &lt;data:comment.author/&gt;
              &lt;/b:if&gt;
              &lt;data:commentPostedByMsg/&gt;
            &lt;/dt&gt;
            &lt;dd class='comment-body' expr:id='data:widget.instanceId + data:comment.cmtBodyIdPostfix'&gt;
              &lt;b:if cond='data:comment.isDeleted'&gt;
                &lt;span class='deleted-comment'&gt;&lt;data:comment.body/&gt;&lt;/span&gt;
              &lt;b:else/&gt;
                &lt;p&gt;
                  &lt;data:comment.body/&gt;
                &lt;/p&gt;
              &lt;/b:if&gt;
            &lt;/dd&gt;
            &lt;dd class='comment-footer'&gt;
              &lt;span class='comment-timestamp'&gt;
                &lt;a expr:href='data:comment.url' title='comment permalink'&gt;
                  &lt;data:comment.timestamp/&gt;
                &lt;/a&gt;
                &lt;b:include data='comment' name='commentDeleteIcon'/&gt;
              &lt;/span&gt;
            &lt;/dd&gt;
          &lt;/b:loop&gt;
        &lt;/dl&gt;
      &lt;/div&gt;

      &lt;b:if cond='data:post.commentPagingRequired'&gt;
        &lt;span class='paging-control-container'&gt;
          &lt;a expr:class='data:post.oldLinkClass' expr:href='data:post.oldestLinkUrl'&gt;
            &lt;data:post.oldestLinkText/&gt;
          &lt;/a&gt;
          &lt;a expr:class='data:post.oldLinkClass' expr:href='data:post.olderLinkUrl'&gt;
            &lt;data:post.olderLinkText/&gt;
          &lt;/a&gt;
          &amp;#160;
          &lt;data:post.commentRangeText/&gt;
          &amp;#160;
          &lt;a expr:class='data:post.newLinkClass' expr:href='data:post.newerLinkUrl'&gt;
            &lt;data:post.newerLinkText/&gt;
          &lt;/a&gt;
          &lt;a expr:class='data:post.newLinkClass' expr:href='data:post.newestLinkUrl'&gt;
            &lt;data:post.newestLinkText/&gt;
          &lt;/a&gt;
        &lt;/span&gt;
      &lt;/b:if&gt;

      &lt;p class='comment-footer'&gt;
        &lt;b:if cond='data:post.embedCommentForm'&gt;
          &lt;b:if cond='data:post.allowNewComments'&gt;
            &lt;b:include data='post' name='comment-form'/&gt;
          &lt;b:else/&gt;
            &lt;data:post.noNewCommentsText/&gt;
          &lt;/b:if&gt;
        &lt;b:elseif cond='data:post.allowComments'/&gt;
          &lt;a expr:href='data:post.addCommentUrl' expr:onclick='data:post.addCommentOnclick'&gt;&lt;data:postCommentMsg/&gt;&lt;/a&gt;
        &lt;/b:if&gt;
      &lt;/p&gt;
    &lt;/b:if&gt;
    &lt;b:if cond='data:showCmtPopup'&gt;
      &lt;div id='comment-popup'&gt;
        &lt;iframe allowtransparency='true' frameborder='0' id='comment-actions' name='comment-actions' scrolling='no'&gt;
        &lt;/iframe&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

    &lt;div id='backlinks-container'&gt;
    &lt;div expr:id='data:widget.instanceId + &amp;quot;_backlinks-container&amp;quot;'&gt;
       &lt;b:include cond='data:post.showBacklinks' data='post' name='backlinks'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='feedLinks'&gt;
  &lt;b:if cond='data:blog.pageType != &amp;quot;item&amp;quot;'&gt; &lt;!-- Blog feed links --&gt;
    &lt;b:if cond='data:feedLinks'&gt;
      &lt;div class='blog-feeds'&gt;
        &lt;b:include data='feedLinks' name='feedLinksBody'/&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

  &lt;b:else/&gt; &lt;!--Post feed links --&gt;
    &lt;div class='post-feeds'&gt;
      &lt;b:loop values='data:posts' var='post'&gt;
        &lt;b:include cond='data:post.allowComments and data:post.feedLinks' data='post.feedLinks' name='feedLinksBody'/&gt;
      &lt;/b:loop&gt;
    &lt;/div&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='feedLinksBody' var='links'&gt;
  &lt;div class='feed-links'&gt;
  &lt;data:feedLinksMsg/&gt;
  &lt;b:loop values='data:links' var='f'&gt;
     &lt;a class='feed-link' expr:href='data:f.url' expr:type='data:f.mimeType' target='_blank'&gt;&lt;data:f.name/&gt; (&lt;data:f.feedType/&gt;)&lt;/a&gt;
  &lt;/b:loop&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='iframe_comments' var='post'&gt;

  &lt;b:if cond='data:post.allowIframeComments'&gt;
    &lt;script expr:src='data:post.iframeCommentSrc' type='text/javascript'/&gt;
    &lt;div class='cmt_iframe_holder' expr:data-href='data:post.url.canonical' expr:data-viewtype='data:post.viewType'/&gt;

    &lt;b:if cond='data:post.embedCommentForm == &amp;quot;false&amp;quot;'&gt;
      &lt;a expr:href='data:post.addCommentUrl' expr:onclick='data:post.addCommentOnclick'&gt;&lt;data:postCommentMsg/&gt;&lt;/a&gt;
    &lt;/b:if&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='mobile-index-post' var='post'&gt;
  &lt;div class='mobile-date-outer date-outer'&gt;
    &lt;b:if cond='data:post.dateHeader'&gt;
      &lt;div class='date-header'&gt;
        &lt;span&gt;&lt;data:post.dateHeader/&gt;&lt;/span&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

    &lt;div class='mobile-post-outer'&gt;
      &lt;a expr:href='data:post.url'&gt;
        &lt;h3 class='mobile-index-title entry-title' itemprop='name'&gt;
          &lt;data:post.title/&gt;
        &lt;/h3&gt;

        &lt;div class='mobile-index-arrow'&gt;&amp;amp;rsaquo;&lt;/div&gt;

        &lt;div class='mobile-index-contents'&gt;
          &lt;b:if cond='data:post.thumbnailUrl'&gt;
            &lt;div class='mobile-index-thumbnail'&gt;
              &lt;div class='Image'&gt;
                &lt;img expr:src='data:post.thumbnailUrl'/&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/b:if&gt;

          &lt;div class='post-body'&gt;
            &lt;b:if cond='data:post.snippet'&gt;&lt;data:post.snippet/&gt;&lt;/b:if&gt;
          &lt;/div&gt;
        &lt;/div&gt;

        &lt;div style='clear: both;'/&gt;
      &lt;/a&gt;

      &lt;div class='mobile-index-comment'&gt;
        &lt;b:include cond='data:blog.pageType != &amp;quot;static_page&amp;quot;                          and data:post.allowComments                          and data:post.numComments != 0' data='post' name='comment_count_picker'/&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='mobile-main' var='top'&gt;
    &lt;!-- posts --&gt;
    &lt;div class='blog-posts hfeed'&gt;

      &lt;b:include data='top' name='status-message'/&gt;

      &lt;b:if cond='data:blog.pageType == &amp;quot;index&amp;quot;'&gt;
        &lt;b:loop values='data:posts' var='post'&gt;
          &lt;b:include data='post' name='mobile-index-post'/&gt;
        &lt;/b:loop&gt;
      &lt;b:else/&gt;
        &lt;b:loop values='data:posts' var='post'&gt;
          &lt;b:include data='post' name='mobile-post'/&gt;
        &lt;/b:loop&gt;
      &lt;/b:if&gt;
    &lt;/div&gt;

   &lt;b:include name='mobile-nextprev'/&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='mobile-nextprev'&gt;
  &lt;div class='blog-pager' id='blog-pager'&gt;
    &lt;b:if cond='data:newerPageUrl'&gt;
      &lt;div class='mobile-link-button' id='blog-pager-newer-link'&gt;
      &lt;a class='blog-pager-newer-link' expr:href='data:newerPageUrl' expr:id='data:widget.instanceId + &amp;quot;_blog-pager-newer-link&amp;quot;' expr:title='data:newerPageTitle'&gt;&amp;amp;lsaquo;&lt;/a&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

    &lt;b:if cond='data:olderPageUrl'&gt;
      &lt;div class='mobile-link-button' id='blog-pager-older-link'&gt;
      &lt;a class='blog-pager-older-link' expr:href='data:olderPageUrl' expr:id='data:widget.instanceId + &amp;quot;_blog-pager-older-link&amp;quot;' expr:title='data:olderPageTitle'&gt;&amp;amp;rsaquo;&lt;/a&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

    &lt;div class='mobile-link-button' id='blog-pager-home-link'&gt;
    &lt;a class='home-link' expr:href='data:blog.homepageUrl'&gt;&lt;data:homeMsg/&gt;&lt;/a&gt;
    &lt;/div&gt;

    &lt;div class='mobile-desktop-link'&gt;
      &lt;a class='home-link' expr:href='data:desktopLinkUrl'&gt;&lt;data:desktopLinkMsg/&gt;&lt;/a&gt;
    &lt;/div&gt;

  &lt;/div&gt;
  &lt;div class='clear'/&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='mobile-post' var='post'&gt;
  &lt;div class='date-outer'&gt;
    &lt;b:if cond='data:post.dateHeader'&gt;
      &lt;h2 class='date-header'&gt;&lt;span&gt;&lt;data:post.dateHeader/&gt;&lt;/span&gt;&lt;/h2&gt;
    &lt;/b:if&gt;
    &lt;div class='date-posts'&gt;
      &lt;div class='post-outer'&gt;

        &lt;div class='post hentry uncustomized-post-template' itemscope='itemscope' itemtype='http://schema.org/BlogPosting'&gt;
          &lt;b:if cond='data:post.thumbnailUrl'&gt;
            &lt;meta expr:content='data:post.thumbnailUrl' itemprop='image_url'/&gt;
          &lt;/b:if&gt;
          &lt;meta expr:content='data:blog.blogId' itemprop='blogId'/&gt;
          &lt;meta expr:content='data:post.id' itemprop='postId'/&gt;

          &lt;a expr:name='data:post.id'/&gt;
          &lt;b:if cond='data:post.title'&gt;
            &lt;h3 class='post-title entry-title' itemprop='name'&gt;
              &lt;b:if cond='data:post.link'&gt;
                &lt;a expr:href='data:post.link'&gt;&lt;data:post.title/&gt;&lt;/a&gt;
              &lt;b:elseif cond='data:post.url and data:blog.url != data:post.url'/&gt;
                &lt;a expr:href='data:post.url'&gt;&lt;data:post.title/&gt;&lt;/a&gt;
              &lt;b:else/&gt;
                &lt;data:post.title/&gt;
              &lt;/b:if&gt;
            &lt;/h3&gt;
          &lt;/b:if&gt;

          &lt;div class='post-header'&gt;
            &lt;div class='post-header-line-1'/&gt;
          &lt;/div&gt;

          &lt;div class='post-body entry-content' expr:id='&amp;quot;post-body-&amp;quot; + data:post.id' itemprop='articleBody'&gt;
            &lt;data:post.body/&gt;
            &lt;div style='clear: both;'/&gt; &lt;!-- clear for photos floats --&gt;
          &lt;/div&gt;

          &lt;div class='post-footer'&gt;
            &lt;div class='post-footer-line post-footer-line-1'&gt;
              &lt;span class='post-author vcard'&gt;
                &lt;b:if cond='data:top.showAuthor'&gt;
                  &lt;b:if cond='data:post.authorProfileUrl'&gt;
                    &lt;span class='fn' itemprop='author' itemscope='itemscope' itemtype='http://schema.org/Person'&gt;
                      &lt;meta expr:content='data:post.authorProfileUrl' itemprop='url'/&gt;
                      &lt;a expr:href='data:post.authorProfileUrl' rel='author' title='author profile'&gt;
                        &lt;span itemprop='name'&gt;&lt;data:post.author/&gt;&lt;/span&gt;
                      &lt;/a&gt;
                    &lt;/span&gt;
                  &lt;b:else/&gt;
                    &lt;span class='fn' itemprop='author' itemscope='itemscope' itemtype='http://schema.org/Person'&gt;
                      &lt;span itemprop='name'&gt;&lt;data:post.author/&gt;&lt;/span&gt;
                    &lt;/span&gt;
                  &lt;/b:if&gt;
                &lt;/b:if&gt;
              &lt;/span&gt;

              &lt;span class='post-timestamp'&gt;
                &lt;b:if cond='data:top.showTimestamp'&gt;
                  &lt;data:top.timestampLabel/&gt;
                  &lt;b:if cond='data:post.url'&gt;
                    &lt;meta expr:content='data:post.url.canonical' itemprop='url'/&gt;
                    &lt;a class='timestamp-link' expr:href='data:post.url' rel='bookmark' title='permanent link'&gt;&lt;abbr class='published' expr:title='data:post.timestampISO8601' itemprop='datePublished'&gt;&lt;data:post.timestamp/&gt;&lt;/abbr&gt;&lt;/a&gt;
                  &lt;/b:if&gt;
                &lt;/b:if&gt;
              &lt;/span&gt;

              &lt;span class='post-comment-link'&gt;
                &lt;b:include cond='data:blog.pageType not in {&amp;quot;item&amp;quot;,&amp;quot;static_page&amp;quot;}                                  and data:post.allowComments' data='post' name='comment_count_picker'/&gt;
              &lt;/span&gt;
            &lt;/div&gt;

            &lt;div class='post-footer-line post-footer-line-2'&gt;
              &lt;b:if cond='data:top.showMobileShare'&gt;
                &lt;div class='mobile-link-button goog-inline-block' id='mobile-share-button'&gt;
                  &lt;a href='javascript:void(0);'&gt;&lt;data:shareMsg/&gt;&lt;/a&gt;
                &lt;/div&gt;
              &lt;/b:if&gt;
              &lt;b:if cond='data:top.showDummy'&gt;
                &lt;div class='goog-inline-block dummy-container'&gt;&lt;data:post.dummyTag/&gt;&lt;/div&gt;
              &lt;/b:if&gt;
            &lt;/div&gt;

          &lt;/div&gt;
        &lt;/div&gt;

        &lt;b:include cond='data:blog.pageType in {&amp;quot;static_page&amp;quot;,&amp;quot;item&amp;quot;}' data='post' name='comment_picker'/&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='nextprev'&gt;
  &lt;div class='blog-pager' id='blog-pager'&gt;
    &lt;b:if cond='data:newerPageUrl'&gt;
      &lt;span id='blog-pager-newer-link'&gt;
      &lt;a class='blog-pager-newer-link' expr:href='data:newerPageUrl' expr:id='data:widget.instanceId + &amp;quot;_blog-pager-newer-link&amp;quot;' expr:title='data:newerPageTitle'&gt;&lt;data:newerPageTitle/&gt;&lt;/a&gt;
      &lt;/span&gt;
    &lt;/b:if&gt;

    &lt;b:if cond='data:olderPageUrl'&gt;
      &lt;span id='blog-pager-older-link'&gt;
      &lt;a class='blog-pager-older-link' expr:href='data:olderPageUrl' expr:id='data:widget.instanceId + &amp;quot;_blog-pager-older-link&amp;quot;' expr:title='data:olderPageTitle'&gt;&lt;data:olderPageTitle/&gt;&lt;/a&gt;
      &lt;/span&gt;
    &lt;/b:if&gt;

    &lt;a class='home-link' expr:href='data:blog.homepageUrl'&gt;&lt;data:homeMsg/&gt;&lt;/a&gt;

    &lt;b:if cond='data:mobileLinkUrl'&gt;
      &lt;div class='blog-mobile-link'&gt;
        &lt;a expr:href='data:mobileLinkUrl'&gt;&lt;data:mobileLinkMsg/&gt;&lt;/a&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

  &lt;/div&gt;
  &lt;div class='clear'/&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='post' var='post'&gt;
  &lt;div class='post hentry'&gt;
    &lt;a expr:name='data:post.id'/&gt;
    &lt;b:if cond='data:post.title'&gt;
      &lt;h3 class='post-title entry-title'&gt;
      &lt;b:if cond='data:post.link'&gt;
        &lt;a expr:href='data:post.link'&gt;&lt;data:post.title/&gt;&lt;/a&gt;
      &lt;b:else/&gt;
        &lt;b:if cond='data:post.url'&gt;
          &lt;b:if cond='data:blog.url != data:post.url'&gt;
            &lt;a expr:href='data:post.url'&gt;&lt;data:post.title/&gt;&lt;/a&gt;
          &lt;b:else/&gt;
            &lt;data:post.title/&gt;
          &lt;/b:if&gt;
        &lt;b:else/&gt;
          &lt;data:post.title/&gt;
        &lt;/b:if&gt;
      &lt;/b:if&gt;
      &lt;/h3&gt;
    &lt;/b:if&gt;

    &lt;div class='post-header'&gt;
    &lt;div class='post-header-line-1'/&gt;
    &lt;/div&gt;

    &lt;div class='post-body entry-content' expr:id='&amp;quot;post-body-&amp;quot; + data:post.id'&gt;
      &lt;data:post.body/&gt;
      &lt;div style='clear: both;'/&gt; &lt;!-- clear for photos floats --&gt;
    &lt;/div&gt;

    &lt;b:if cond='data:post.hasJumpLink'&gt;
      &lt;div class='jump-link'&gt;
        &lt;a expr:href='data:post.url + &amp;quot;#more&amp;quot;' expr:title='data:post.title'&gt;&lt;data:post.jumpText/&gt;&lt;/a&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

    &lt;div class='post-footer'&gt;
    &lt;div class='post-footer-line post-footer-line-1'&gt;&lt;span class='post-author vcard'&gt;
        &lt;b:if cond='data:top.showAuthor'&gt;
          &lt;data:top.authorLabel/&gt;
            &lt;b:if cond='data:post.authorProfileUrl'&gt;
              &lt;span class='fn'&gt;
                &lt;a expr:href='data:post.authorProfileUrl' rel='author' title='author profile'&gt;
                  &lt;data:post.author/&gt;
                &lt;/a&gt;
              &lt;/span&gt;
            &lt;b:else/&gt;
              &lt;span class='fn'&gt;&lt;data:post.author/&gt;&lt;/span&gt;
            &lt;/b:if&gt;
        &lt;/b:if&gt;
      &lt;/span&gt; &lt;span class='post-timestamp'&gt;
        &lt;b:if cond='data:top.showTimestamp'&gt;
          &lt;data:top.timestampLabel/&gt;
        &lt;b:if cond='data:post.url'&gt;
          &lt;a class='timestamp-link' expr:href='data:post.url' rel='bookmark' title='permanent link'&gt;&lt;abbr class='published' expr:title='data:post.timestampISO8601'&gt;&lt;data:post.timestamp/&gt;&lt;/abbr&gt;&lt;/a&gt;
        &lt;/b:if&gt;
        &lt;/b:if&gt;
      &lt;/span&gt; &lt;span class='post-comment-link'&gt;
        &lt;b:if cond='data:blog.pageType != &amp;quot;item&amp;quot;'&gt;
          &lt;b:if cond='data:blog.pageType != &amp;quot;static_page&amp;quot;'&gt;
            &lt;b:if cond='data:post.allowComments'&gt;
              &lt;a class='comment-link' expr:href='data:post.addCommentUrl' expr:onclick='data:post.addCommentOnclick'&gt;&lt;b:if cond='data:post.numComments == 1'&gt;1 &lt;data:top.commentLabel/&gt;&lt;b:else/&gt;&lt;data:post.numComments/&gt; &lt;data:top.commentLabelPlural/&gt;&lt;/b:if&gt;&lt;/a&gt;
            &lt;/b:if&gt;
          &lt;/b:if&gt;
        &lt;/b:if&gt;
      &lt;/span&gt; &lt;span class='post-icons'&gt;
        &lt;!-- email post links --&gt;
        &lt;b:if cond='data:post.emailPostUrl'&gt;
          &lt;span class='item-action'&gt;
          &lt;a expr:href='data:post.emailPostUrl' expr:title='data:top.emailPostMsg'&gt;
              &lt;img alt='' class='icon-action' height='13' src='http://img1.blogblog.com/img/icon18_email.gif' width='18'/&gt;
          &lt;/a&gt;
          &lt;/span&gt;
        &lt;/b:if&gt;

        &lt;!-- quickedit pencil --&gt;
        &lt;b:include data='post' name='postQuickEdit'/&gt;
      &lt;/span&gt; &lt;span class='post-backlinks post-comment-link'&gt;
         &lt;b:if cond='data:blog.pageType != &amp;quot;item&amp;quot;'&gt;
           &lt;b:if cond='data:blog.pageType != &amp;quot;static_page&amp;quot;'&gt;
             &lt;b:if cond='data:post.showBacklinks'&gt;
               &lt;a class='comment-link' expr:href='data:post.url + &amp;quot;#links&amp;quot;'&gt;&lt;data:top.backlinkLabel/&gt;&lt;/a&gt;
             &lt;/b:if&gt;
           &lt;/b:if&gt;
         &lt;/b:if&gt;
       &lt;/span&gt; &lt;div class='post-share-buttons goog-inline-block'&gt;
        &lt;b:if cond='data:post.sharePostUrl'&gt;
          &lt;b:include data='post' name='shareButtons'/&gt;
        &lt;/b:if&gt;
      &lt;/div&gt; &lt;/div&gt;

      &lt;div class='post-footer-line post-footer-line-2'/&gt;

      &lt;div class='post-footer-line post-footer-line-3'/&gt;
    &lt;/div&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='postQuickEdit' var='post'&gt;
  &lt;b:if cond='data:post.editUrl'&gt;
    &lt;span expr:class='&amp;quot;item-control &amp;quot; + data:post.adminClass'&gt;
      &lt;a expr:href='data:post.editUrl' expr:title='data:top.editPostMsg'&gt;
        &lt;img alt='' class='icon-action' height='18' src='https://resources.blogblog.com/img/icon18_edit_allbkg.gif' width='18'/&gt;
      &lt;/a&gt;
    &lt;/span&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='shareButtons' var='post'&gt;
  &lt;b:if cond='data:top.showEmailButton'&gt;&lt;a class='goog-inline-block share-button sb-email' expr:href='data:post.sharePostUrl + &amp;quot;&amp;amp;target=email&amp;quot;' expr:title='data:top.emailThisMsg' target='_blank'&gt;&lt;span class='share-button-link-text'&gt;&lt;data:top.emailThisMsg/&gt;&lt;/span&gt;&lt;/a&gt;&lt;/b:if&gt;&lt;b:if cond='data:top.showBlogThisButton'&gt;&lt;a class='goog-inline-block share-button sb-blog' expr:href='data:post.sharePostUrl + &amp;quot;&amp;amp;target=blog&amp;quot;' expr:onclick='&amp;quot;window.open(this.href, \&amp;quot;_blank\&amp;quot;, \&amp;quot;height=270,width=475\&amp;quot;); return false;&amp;quot;' expr:title='data:top.blogThisMsg' target='_blank'&gt;&lt;span class='share-button-link-text'&gt;&lt;data:top.blogThisMsg/&gt;&lt;/span&gt;&lt;/a&gt;&lt;/b:if&gt;&lt;b:if cond='data:top.showTwitterButton'&gt;&lt;a class='goog-inline-block share-button sb-twitter' expr:href='data:post.sharePostUrl + &amp;quot;&amp;amp;target=twitter&amp;quot;' expr:title='data:top.shareToTwitterMsg' target='_blank'&gt;&lt;span class='share-button-link-text'&gt;&lt;data:top.shareToTwitterMsg/&gt;&lt;/span&gt;&lt;/a&gt;&lt;/b:if&gt;&lt;b:if cond='data:top.showFacebookButton'&gt;&lt;a class='goog-inline-block share-button sb-facebook' expr:href='data:post.sharePostUrl + &amp;quot;&amp;amp;target=facebook&amp;quot;' expr:onclick='&amp;quot;window.open(this.href, \&amp;quot;_blank\&amp;quot;, \&amp;quot;height=430,width=640\&amp;quot;); return false;&amp;quot;' expr:title='data:top.shareToFacebookMsg' target='_blank'&gt;&lt;span class='share-button-link-text'&gt;&lt;data:top.shareToFacebookMsg/&gt;&lt;/span&gt;&lt;/a&gt;&lt;/b:if&gt;&lt;b:if cond='data:top.showPinterestButton'&gt;&lt;a class='goog-inline-block share-button sb-pinterest' expr:href='data:post.sharePostUrl + &amp;quot;&amp;amp;target=pinterest&amp;quot;' expr:title='data:top.shareToPinterestMsg' target='_blank'&gt;&lt;span class='share-button-link-text'&gt;&lt;data:top.shareToPinterestMsg/&gt;&lt;/span&gt;&lt;/a&gt;&lt;/b:if&gt;&lt;b:if cond='data:top.showPlusOne'&gt;&lt;div class='goog-inline-block google-plus-share-container'&gt;&lt;data:post.googlePlusShareTag/&gt;&lt;/div&gt;&lt;/b:if&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='status-message'&gt;
  &lt;b:if cond='data:navMessage'&gt;
  &lt;div class='status-msg-wrap'&gt;
    &lt;div class='status-msg-body'&gt;
      &lt;data:navMessage/&gt;
    &lt;/div&gt;
    &lt;div class='status-msg-border'&gt;
      &lt;div class='status-msg-bg'&gt;
        &lt;div class='status-msg-hidden'&gt;&lt;data:navMessage/&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style='clear: both;'/&gt;
  &lt;/b:if&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='threaded-comment-form' var='post'&gt;
  &lt;div class='comment-form'&gt;
    &lt;a name='comment-form'/&gt;
    &lt;b:if cond='data:mobile'&gt;
      &lt;p&gt;&lt;data:blogCommentMessage/&gt;&lt;/p&gt;
      &lt;data:blogTeamBlogMessage/&gt;
      &lt;a expr:href='data:post.commentFormIframeSrc' id='comment-editor-src'/&gt;
      &lt;iframe allowtransparency='true' class='blogger-iframe-colorize blogger-comment-from-post' expr:height='data:cmtIframeInitialHeight' frameborder='0' id='comment-editor' name='comment-editor' src='' style='display: none' width='100%'/&gt;
    &lt;b:else/&gt;
      &lt;p&gt;&lt;data:blogCommentMessage/&gt;&lt;/p&gt;
      &lt;data:blogTeamBlogMessage/&gt;
      &lt;a expr:href='data:post.commentFormIframeSrc' id='comment-editor-src'/&gt;
      &lt;iframe allowtransparency='true' class='blogger-iframe-colorize blogger-comment-from-post' expr:height='data:cmtIframeInitialHeight' frameborder='0' id='comment-editor' name='comment-editor' src='' width='100%'/&gt;
    &lt;/b:if&gt;
    &lt;data:post.friendConnectJs/&gt;
    &lt;data:post.cmtfpIframe/&gt;
    &lt;script type='text/javascript'&gt;
      BLOG_CMT_createIframe(&amp;#39;&lt;data:post.appRpcRelayPath/&gt;&amp;#39;);
    &lt;/script&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='threaded_comment_js' var='post'&gt;
  &lt;script async='async' expr:src='data:post.commentSrc' type='text/javascript'/&gt;

  &lt;script type='text/javascript'&gt;
    (function() {
      var items = &lt;data:post.commentJso/&gt;;
      var msgs = &lt;data:post.commentMsgs/&gt;;
      var config = &lt;data:post.commentConfig/&gt;;

// &lt;![CDATA[
      var cursor = null;
      if (items &amp;&amp; items.length &gt; 0) {
        cursor = parseInt(items[items.length - 1].timestamp) + 1;
      }

      var bodyFromEntry = function(entry) {
        if (entry.gd$extendedProperty) {
          for (var k in entry.gd$extendedProperty) {
            if (entry.gd$extendedProperty[k].name == 'blogger.contentRemoved') {
              return '&lt;span class="deleted-comment"&gt;' + entry.content.$t + '&lt;/span&gt;';
            }
          }
        }
        return entry.content.$t;
      }

      var parse = function(data) {
        cursor = null;
        var comments = [];
        if (data &amp;&amp; data.feed &amp;&amp; data.feed.entry) {
          for (var i = 0, entry; entry = data.feed.entry[i]; i++) {
            var comment = {};
            // comment ID, parsed out of the original id format
            var id = /blog-(\d+).post-(\d+)/.exec(entry.id.$t);
            comment.id = id ? id[2] : null;
            comment.body = bodyFromEntry(entry);
            comment.timestamp = Date.parse(entry.published.$t) + '';
            if (entry.author &amp;&amp; entry.author.constructor === Array) {
              var auth = entry.author[0];
              if (auth) {
                comment.author = {
                  name: (auth.name ? auth.name.$t : undefined),
                  profileUrl: (auth.uri ? auth.uri.$t : undefined),
                  avatarUrl: (auth.gd$image ? auth.gd$image.src : undefined)
                };
              }
            }
            if (entry.link) {
              if (entry.link[2]) {
                comment.link = comment.permalink = entry.link[2].href;
              }
              if (entry.link[3]) {
                var pid = /.*comments\/default\/(\d+)\?.*/.exec(entry.link[3].href);
                if (pid &amp;&amp; pid[1]) {
                  comment.parentId = pid[1];
                }
              }
            }
            comment.deleteclass = 'item-control blog-admin';
            if (entry.gd$extendedProperty) {
              for (var k in entry.gd$extendedProperty) {
                if (entry.gd$extendedProperty[k].name == 'blogger.itemClass') {
                  comment.deleteclass += ' ' + entry.gd$extendedProperty[k].value;
                } else if (entry.gd$extendedProperty[k].name == 'blogger.displayTime') {
                  comment.displayTime = entry.gd$extendedProperty[k].value;
                }
              }
            }
            comments.push(comment);
          }
        }
        return comments;
      };

      var paginator = function(callback) {
        if (hasMore()) {
          var url = config.feed + '?alt=json&amp;v=2&amp;orderby=published&amp;reverse=false&amp;max-results=50';
          if (cursor) {
            url += '&amp;published-min=' + new Date(cursor).toISOString();
          }
          window.bloggercomments = function(data) {
            var parsed = parse(data);
            cursor = parsed.length &lt; 50 ? null
                : parseInt(parsed[parsed.length - 1].timestamp) + 1
            callback(parsed);
            window.bloggercomments = null;
          }
          url += '&amp;callback=bloggercomments';
          var script = document.createElement('script');
          script.type = 'text/javascript';
          script.src = url;
          document.getElementsByTagName('head')[0].appendChild(script);
        }
      };
      var hasMore = function() {
        return !!cursor;
      };
      var getMeta = function(key, comment) {
        if ('iswriter' == key) {
          var matches = !!comment.author
              &amp;&amp; comment.author.name == config.authorName
              &amp;&amp; comment.author.profileUrl == config.authorUrl;
          return matches ? 'true' : '';
        } else if ('deletelink' == key) {
          return config.baseUri + '/delete-comment.g?blogID='
               + config.blogId + '&amp;postID=' + comment.id;
        } else if ('deleteclass' == key) {
          return comment.deleteclass;
        }
        return '';
      };

      var replybox = null;
      var replyUrlParts = null;
      var replyParent = undefined;

      var onReply = function(commentId, domId) {
        if (replybox == null) {
          // lazily cache replybox, and adjust to suit this style:
          replybox = document.getElementById('comment-editor');
          if (replybox != null) {
            replybox.height = '250px';
            replybox.style.display = 'block';
            replyUrlParts = replybox.src.split('#');
          }
        }
        if (replybox &amp;&amp; (commentId !== replyParent)) {
          replybox.src = '';
          document.getElementById(domId).insertBefore(replybox, null);
          replybox.src = replyUrlParts[0]
              + (commentId ? '&amp;parentID=' + commentId : '')
              + '#' + replyUrlParts[1];
          replyParent = commentId;
        }
      };

      var hash = (window.location.hash || '#').substring(1);
      var startThread, targetComment;
      if (/^comment-form_/.test(hash)) {
        startThread = hash.substring('comment-form_'.length);
      } else if (/^c[0-9]+$/.test(hash)) {
        targetComment = hash.substring(1);
      }

      // Configure commenting API:
      var configJso = {
        'maxDepth': config.maxThreadDepth
      };
      var provider = {
        'id': config.postId,
        'data': items,
        'loadNext': paginator,
        'hasMore': hasMore,
        'getMeta': getMeta,
        'onReply': onReply,
        'rendered': true,
        'initComment': targetComment,
        'initReplyThread': startThread,
        'config': configJso,
        'messages': msgs
      };

      var render = function() {
        if (window.goog &amp;&amp; window.goog.comments) {
          var holder = document.getElementById('comment-holder');
          window.goog.comments.render(holder, provider);
        }
      };

      // render now, or queue to render when library loads:
      if (window.goog &amp;&amp; window.goog.comments) {
        render();
      } else {
        window.goog = window.goog || {};
        window.goog.comments = window.goog.comments || {};
        window.goog.comments.loadQueue = window.goog.comments.loadQueue || [];
        window.goog.comments.loadQueue.push(render);
      }
    })();
// ]]&gt;
  &lt;/script&gt;
&lt;/b:includable&gt;
              &lt;b:includable id='threaded_comments' var='post'&gt;
  &lt;div class='comments' id='comments'&gt;
    &lt;a name='comments'/&gt;
    &lt;h4&gt;&lt;data:post.commentLabelFull/&gt;:&lt;/h4&gt;

    &lt;div class='comments-content'&gt;
      &lt;b:include cond='data:post.embedCommentForm' data='post' name='threaded_comment_js'/&gt;
      &lt;div id='comment-holder'&gt;
         &lt;data:post.commentHtml/&gt;
      &lt;/div&gt;
    &lt;/div&gt;

    &lt;p class='comment-footer'&gt;
      &lt;b:if cond='data:post.allowNewComments'&gt;
        &lt;b:include data='post' name='threaded-comment-form'/&gt;
      &lt;b:else/&gt;
        &lt;data:post.noNewCommentsText/&gt;
      &lt;/b:if&gt;
    &lt;/p&gt;

    &lt;b:if cond='data:showCmtPopup'&gt;
      &lt;div id='comment-popup'&gt;
        &lt;iframe allowtransparency='true' frameborder='0' id='comment-actions' name='comment-actions' scrolling='no'&gt;
        &lt;/iframe&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

    &lt;div id='backlinks-container'&gt;
    &lt;div expr:id='data:widget.instanceId + &amp;quot;_backlinks-container&amp;quot;'&gt;
      &lt;b:include cond='data:post.showBacklinks' data='post' name='backlinks'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
            &lt;/b:widget&gt;
            &lt;b:widget id='Label1' locked='false' title='Clique aqui!' type='Label' visible='true'&gt;
              &lt;b:includable id='main'&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;
  &lt;div expr:class='&amp;quot;widget-content &amp;quot; + data:display + &amp;quot;-label-widget-content&amp;quot;'&gt;
    &lt;b:if cond='data:display == &amp;quot;list&amp;quot;'&gt;
      &lt;ul&gt;
        &lt;b:loop values='data:labels' var='label'&gt;
          &lt;li&gt;
            &lt;b:if cond='data:blog.url == data:label.url'&gt;
              &lt;span expr:dir='data:blog.languageDirection'&gt;&lt;data:label.name/&gt;&lt;/span&gt;
            &lt;b:else/&gt;
              &lt;a expr:dir='data:blog.languageDirection' expr:href='data:label.url'&gt;&lt;data:label.name/&gt;&lt;/a&gt;
            &lt;/b:if&gt;
            &lt;b:if cond='data:showFreqNumbers'&gt;
              &lt;span dir='ltr'&gt;(&lt;data:label.count/&gt;)&lt;/span&gt;
            &lt;/b:if&gt;
          &lt;/li&gt;
        &lt;/b:loop&gt;
      &lt;/ul&gt;
    &lt;b:else/&gt;
      &lt;b:loop values='data:labels' var='label'&gt;
        &lt;span expr:class='&amp;quot;label-size label-size-&amp;quot; + data:label.cssSize'&gt;
          &lt;b:if cond='data:blog.url == data:label.url'&gt;
            &lt;span expr:dir='data:blog.languageDirection'&gt;&lt;data:label.name/&gt;&lt;/span&gt;
          &lt;b:else/&gt;
            &lt;a expr:dir='data:blog.languageDirection' expr:href='data:label.url'&gt;&lt;data:label.name/&gt;&lt;/a&gt;
          &lt;/b:if&gt;
          &lt;b:if cond='data:showFreqNumbers'&gt;
            &lt;span class='label-count' dir='ltr'&gt;(&lt;data:label.count/&gt;)&lt;/span&gt;
          &lt;/b:if&gt;
        &lt;/span&gt;
      &lt;/b:loop&gt;
    &lt;/b:if&gt;
    &lt;b:include name='quickedit'/&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
            &lt;/b:widget&gt;
            &lt;b:widget id='PopularPosts1' locked='false' title='Postagens populares' type='PopularPosts' visible='true'&gt;
              &lt;b:includable id='main'&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;&lt;h2&gt;&lt;data:title/&gt;&lt;/h2&gt;&lt;/b:if&gt;
  &lt;div class='widget-content popular-posts'&gt;
    &lt;ul&gt;
      &lt;b:loop values='data:posts' var='post'&gt;
      &lt;li&gt;
        &lt;b:if cond='!data:showThumbnails'&gt;
          &lt;b:if cond='!data:showSnippets'&gt;
            &lt;!-- (1) No snippet/thumbnail --&gt;
            &lt;a expr:href='data:post.href'&gt;&lt;data:post.title/&gt;&lt;/a&gt;
          &lt;b:else/&gt;
            &lt;!-- (2) Show only snippets --&gt;
            &lt;div class='item-title'&gt;&lt;a expr:href='data:post.href'&gt;&lt;data:post.title/&gt;&lt;/a&gt;&lt;/div&gt;
            &lt;div class='item-snippet'&gt;&lt;data:post.snippet/&gt;&lt;/div&gt;
          &lt;/b:if&gt;
        &lt;b:else/&gt;
          &lt;!-- (3) Show only thumbnails or (4) Snippets and thumbnails. --&gt;
          &lt;div expr:class='data:showSnippets ? &amp;quot;item-content&amp;quot; : &amp;quot;item-thumbnail-only&amp;quot;'&gt;
            &lt;b:if cond='data:post.featuredImage.isResizable or data:post.thumbnail'&gt;
              &lt;div class='item-thumbnail'&gt;
                &lt;a expr:href='data:post.href' target='_blank'&gt;
                  &lt;b:with value='data:post.featuredImage.isResizable                                  ? resizeImage(data:post.featuredImage, 72, &amp;quot;1:1&amp;quot;)                                  : data:post.thumbnail' var='image'&gt;
                    &lt;img alt='' border='0' expr:src='data:image'/&gt;
                  &lt;/b:with&gt;
                &lt;/a&gt;
              &lt;/div&gt;
            &lt;/b:if&gt;
            &lt;div class='item-title'&gt;&lt;a expr:href='data:post.href'&gt;&lt;data:post.title/&gt;&lt;/a&gt;&lt;/div&gt;
            &lt;b:if cond='data:showSnippets'&gt;
              &lt;div class='item-snippet'&gt;&lt;data:post.snippet/&gt;&lt;/div&gt;
            &lt;/b:if&gt;
          &lt;/div&gt;
          &lt;div style='clear: both;'/&gt;
        &lt;/b:if&gt;
      &lt;/li&gt;
      &lt;/b:loop&gt;
    &lt;/ul&gt;
    &lt;b:include name='quickedit'/&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
            &lt;/b:widget&gt;
          &lt;/b:section&gt;
        &lt;/div&gt;
        &lt;/div&gt;

        &lt;div class='column-left-outer'&gt;
        &lt;div class='column-left-inner'&gt;
          &lt;aside&gt;
          &lt;macro:include id='main-column-left-sections' name='sections'&gt;
            &lt;macro:param default='0' name='num' value='0'/&gt;
            &lt;macro:param default='sidebar-left' name='idPrefix'/&gt;
            &lt;macro:param default='sidebar' name='class'/&gt;
            &lt;macro:param default='true' name='includeBottom'/&gt;
          &lt;/macro:include&gt;
          &lt;/aside&gt;
        &lt;/div&gt;
        &lt;/div&gt;

        &lt;div class='column-right-outer'&gt;
        &lt;div class='column-right-inner'&gt;
          &lt;aside&gt;
          &lt;macro:include id='main-column-right-sections' name='sections'&gt;
            &lt;macro:param default='2' name='num' value='1'/&gt;
            &lt;macro:param default='sidebar-right' name='idPrefix'/&gt;
            &lt;macro:param default='sidebar' name='class'/&gt;
            &lt;macro:param default='true' name='includeBottom'/&gt;
          &lt;/macro:include&gt;
          &lt;/aside&gt;
        &lt;/div&gt;
        &lt;/div&gt;

        &lt;/div&gt;

        &lt;div style='clear: both'/&gt;
      &lt;!-- columns --&gt;
      &lt;/div&gt;

    &lt;!-- main --&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;div class='main-cap-bottom cap-bottom'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;

    &lt;footer&gt;
    &lt;div class='footer-outer'&gt;
    &lt;div class='footer-cap-top cap-top'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;div class='fauxborder-left footer-fauxborder-left'&gt;
    &lt;div class='fauxborder-right footer-fauxborder-right'/&gt;
    &lt;div class='region-inner footer-inner'&gt;
      &lt;macro:include id='footer-sections' name='sections'&gt;
        &lt;macro:param default='2' name='num'/&gt;
        &lt;macro:param default='footer' name='idPrefix'/&gt;
        &lt;macro:param default='foot' name='class'/&gt;
        &lt;macro:param default='false' name='includeBottom'/&gt;
      &lt;/macro:include&gt;
      &lt;!-- outside of the include in order to lock Attribution widget --&gt;
      &lt;b:section class='foot' id='footer-3' name='Footer' showaddelement='no'&gt;
        &lt;b:widget id='Attribution1' locked='true' title='' type='Attribution' visible='true'&gt;
          &lt;b:includable id='main'&gt;
    &lt;b:if cond='data:feedbackSurveyLink'&gt;
      &lt;div class='mobile-survey-link' style='text-align: center;'&gt;
        &lt;data:feedbackSurveyLink/&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;

    &lt;div class='widget-content' style='text-align: center;'&gt;
      &lt;b:if cond='data:attribution != &amp;quot;&amp;quot;'&gt;
       &lt;data:attribution/&gt;
      &lt;/b:if&gt;
    &lt;/div&gt;

    &lt;b:include name='quickedit'/&gt;
  &lt;/b:includable&gt;
        &lt;/b:widget&gt;
      &lt;/b:section&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;div class='footer-cap-bottom cap-bottom'&gt;
      &lt;div class='cap-left'/&gt;
      &lt;div class='cap-right'/&gt;
    &lt;/div&gt;
    &lt;/div&gt;
    &lt;/footer&gt;

  &lt;!-- content --&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;div class='content-cap-bottom cap-bottom'&gt;
    &lt;div class='cap-left'/&gt;
    &lt;div class='cap-right'/&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;/div&gt;

  &lt;script type='text/javascript'&gt;
    window.setTimeout(function() {
        document.body.className = document.body.className.replace(&amp;#39;loading&amp;#39;, &amp;#39;&amp;#39;);
      }, 10);
  &lt;/script&gt;
&lt;/body&gt;

&lt;macro:includable id='sections' var='col'&gt;
  &lt;macro:if cond='data:col.num == 0'&gt;
  &lt;macro:else/&gt;
    &lt;b:section mexpr:class='data:col.class' mexpr:id='data:col.idPrefix + &amp;quot;-1&amp;quot;' preferred='yes' showaddelement='yes'/&gt;

    &lt;macro:if cond='data:col.num &amp;gt;= 2'&gt;
      &lt;table border='0' cellpadding='0' cellspacing='0' mexpr:class='&amp;quot;section-columns columns-&amp;quot; + data:col.num'&gt;
      &lt;tbody&gt;
      &lt;tr&gt;
        &lt;td class='first columns-cell'&gt;
          &lt;b:section mexpr:class='data:col.class' mexpr:id='data:col.idPrefix + &amp;quot;-2-1&amp;quot;'/&gt;
        &lt;/td&gt;

        &lt;td class='columns-cell'&gt;
          &lt;b:section mexpr:class='data:col.class' mexpr:id='data:col.idPrefix + &amp;quot;-2-2&amp;quot;'/&gt;
        &lt;/td&gt;

        &lt;macro:if cond='data:col.num &amp;gt;= 3'&gt;
          &lt;td class='columns-cell'&gt;
            &lt;b:section mexpr:class='data:col.class' mexpr:id='data:col.idPrefix + &amp;quot;-2-3&amp;quot;'/&gt;
          &lt;/td&gt;
        &lt;/macro:if&gt;

        &lt;macro:if cond='data:col.num &amp;gt;= 4'&gt;
          &lt;td class='columns-cell'&gt;
            &lt;b:section mexpr:class='data:col.class' mexpr:id='data:col.idPrefix + &amp;quot;-2-4&amp;quot;'/&gt;
          &lt;/td&gt;
        &lt;/macro:if&gt;
      &lt;/tr&gt;
      &lt;/tbody&gt;
      &lt;/table&gt;

      &lt;macro:if cond='data:col.includeBottom'&gt;
        &lt;b:section mexpr:class='data:col.class' mexpr:id='data:col.idPrefix + &amp;quot;-3&amp;quot;' showaddelement='no'/&gt;
      &lt;/macro:if&gt;
    &lt;/macro:if&gt;
  &lt;/macro:if&gt;
&lt;/macro:includable&gt;

&lt;b:section-contents id='sidebar-right-1'&gt;
  &lt;b:widget id='HTML6' locked='false' title='' type='HTML' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;!-- only display title if it's non-empty --&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2 class='title'&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;
  &lt;div class='widget-content'&gt;
    &lt;data:content/&gt;
  &lt;/div&gt;

  &lt;b:include name='quickedit'/&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='HTML2' locked='false' title='Google Website Translator Gadget' type='HTML' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;!-- only display title if it's non-empty --&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2 class='title'&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;
  &lt;div class='widget-content'&gt;
    &lt;data:content/&gt;
  &lt;/div&gt;

  &lt;b:include name='quickedit'/&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='HTML7' locked='false' title='' type='HTML' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;!-- only display title if it's non-empty --&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2 class='title'&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;
  &lt;div class='widget-content'&gt;
    &lt;data:content/&gt;
  &lt;/div&gt;

  &lt;b:include name='quickedit'/&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='BlogArchive1' locked='false' title='Arquivo do blog' type='BlogArchive' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;
  &lt;div class='widget-content'&gt;
  &lt;div id='ArchiveList'&gt;
  &lt;div expr:id='data:widget.instanceId + &amp;quot;_ArchiveList&amp;quot;'&gt;
    &lt;b:include cond='data:style == &amp;quot;HIERARCHY&amp;quot;' data='data' name='interval'/&gt;
    &lt;b:include cond='data:style == &amp;quot;FLAT&amp;quot;' data='data' name='flat'/&gt;
    &lt;b:include cond='data:style == &amp;quot;MENU&amp;quot;' data='data' name='menu'/&gt;
  &lt;/div&gt;
  &lt;/div&gt;
  &lt;b:include name='quickedit'/&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
    &lt;b:includable id='flat' var='data'&gt;
  &lt;ul class='flat'&gt;
    &lt;b:loop values='data:data' var='i'&gt;
      &lt;li class='archivedate'&gt;
        &lt;a expr:href='data:i.url'&gt;&lt;data:i.name/&gt;&lt;/a&gt; (&lt;data:i.post-count/&gt;)
      &lt;/li&gt;
    &lt;/b:loop&gt;
  &lt;/ul&gt;
&lt;/b:includable&gt;
    &lt;b:includable id='interval' var='intervalData'&gt;
  &lt;b:loop values='data:intervalData' var='interval'&gt;
    &lt;ul class='hierarchy'&gt;
      &lt;li expr:class='&amp;quot;archivedate &amp;quot; + data:interval.expclass'&gt;
        &lt;b:include cond='data:interval.toggleId' data='interval' name='toggle'/&gt;
        &lt;a class='post-count-link' expr:href='data:interval.url'&gt;
          &lt;data:interval.name/&gt;
        &lt;/a&gt;
        &lt;span class='post-count' dir='ltr'&gt;(&lt;data:interval.post-count/&gt;)&lt;/span&gt;
        &lt;b:include cond='data:interval.data' data='interval.data' name='interval'/&gt;
        &lt;b:include cond='data:interval.posts' data='interval.posts' name='posts'/&gt;
      &lt;/li&gt;
    &lt;/ul&gt;
  &lt;/b:loop&gt;
&lt;/b:includable&gt;
    &lt;b:includable id='menu' var='data'&gt;
  &lt;select expr:id='data:widget.instanceId + &amp;quot;_ArchiveMenu&amp;quot;'&gt;
    &lt;option value=''&gt;&lt;data:title/&gt;&lt;/option&gt;
    &lt;b:loop values='data:data' var='i'&gt;
      &lt;option expr:value='data:i.url'&gt;&lt;data:i.name/&gt; (&lt;data:i.post-count/&gt;)&lt;/option&gt;
    &lt;/b:loop&gt;
  &lt;/select&gt;
&lt;/b:includable&gt;
    &lt;b:includable id='posts' var='posts'&gt;
  &lt;ul class='posts'&gt;
    &lt;b:loop values='data:posts' var='post'&gt;
      &lt;li&gt;&lt;a expr:href='data:post.url'&gt;&lt;data:post.title/&gt;&lt;/a&gt;&lt;/li&gt;
    &lt;/b:loop&gt;
  &lt;/ul&gt;
&lt;/b:includable&gt;
    &lt;b:includable id='toggle' var='interval'&gt;
  &lt;a class='toggle' href='javascript:void(0)'&gt;
    &lt;span expr:class='&amp;quot;zippy&amp;quot; + (data:interval.expclass == &amp;quot;expanded&amp;quot; ? &amp;quot; toggle-open&amp;quot; : &amp;quot;&amp;quot;)'&gt;
      &lt;b:if cond='data:interval.expclass == &amp;quot;expanded&amp;quot;'&gt;
        &amp;#9660;&amp;#160;
      &lt;b:elseif cond='data:blog.languageDirection == &amp;quot;rtl&amp;quot;'/&gt;
        &amp;#9668;&amp;#160;
      &lt;b:else/&gt;
        &amp;#9658;&amp;#160;
      &lt;/b:if&gt;
    &lt;/span&gt;
  &lt;/a&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='Slideshow1' locked='false' title='Preparação de Medicamentos no Egito Antigo' type='Slideshow' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;!-- only display title if it's non-empty --&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2 class='title'&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;

  &lt;div class='widget-content'&gt;
    &lt;div class='slideshow-wrapper'&gt;
      &lt;div class='slideshow-spacer'&gt;
        &lt;div class='slideshow-container' expr:id='data:widget.instanceId + &amp;quot;_slideshow&amp;quot;'&gt;
          &lt;span class='slideshow-status'&gt;Loading...&lt;/span&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  &lt;/div&gt;

  &lt;b:include name='quickedit'/&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='LinkList1' locked='false' title='Links' type='LinkList' visible='true'&gt;
    &lt;b:includable id='main'&gt;

&lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;&lt;h2&gt;&lt;data:title/&gt;&lt;/h2&gt;&lt;/b:if&gt;
 &lt;div class='widget-content'&gt;
   &lt;ul&gt;
     &lt;b:loop values='data:links' var='link'&gt;
       &lt;li&gt;&lt;a expr:href='data:link.target'&gt;&lt;data:link.name/&gt;&lt;/a&gt;&lt;/li&gt;
     &lt;/b:loop&gt;
   &lt;/ul&gt;
   &lt;b:include name='quickedit'/&gt;
 &lt;/div&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='Feed1' locked='false' title='Pediatrics - AAP - Latest Articles' type='Feed' visible='true'&gt;
    &lt;b:includable id='main'&gt;
    &lt;h2&gt;&lt;data:title/&gt;&lt;/h2&gt;
    &lt;div class='widget-content' expr:id='data:widget.instanceId + &amp;quot;_feedItemListDisplay&amp;quot;'&gt;
      &lt;span style='filter: alpha(25); opacity: 0.25;'&gt;
        &lt;a expr:href='data:feedUrl'&gt;&lt;data:loadingMsg/&gt;&lt;/a&gt;
      &lt;/span&gt;
    &lt;/div&gt;
    &lt;b:include name='quickedit'/&gt;
  &lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='Stats1' locked='false' title='Visitas a Pharmakon Pediatrics' type='Stats' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;&lt;h2&gt;&lt;data:title/&gt;&lt;/h2&gt;&lt;/b:if&gt;
  &lt;div class='widget-content'&gt;
    &lt;!-- Content is going to be visible when data will be fetched from server. --&gt;
    &lt;div expr:id='data:widget.instanceId + &amp;quot;_content&amp;quot;' style='display: none;'&gt;
      &lt;!-- Counter and image will be injected later via AJAX call. --&gt;
      &lt;b:if cond='data:showSparkline'&gt;
        &lt;img alt='Sparkline' expr:id='data:widget.instanceId + &amp;quot;_sparkline&amp;quot;' height='30' width='75'/&gt;
      &lt;/b:if&gt;
      &lt;span expr:class='&amp;quot;counter-wrapper &amp;quot; + (data:showGraphicalCounter ? &amp;quot;graph-counter-wrapper&amp;quot; : &amp;quot;text-counter-wrapper&amp;quot;)' expr:id='data:widget.instanceId + &amp;quot;_totalCount&amp;quot;'&gt;
      &lt;/span&gt;
      &lt;b:include name='quickedit'/&gt;
    &lt;/div&gt;
  &lt;/div&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='Profile1' locked='false' title='Quem sou eu' type='Profile' visible='true'&gt;
    &lt;b:includable id='main'&gt;
    &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
      &lt;h2&gt;&lt;data:title/&gt;&lt;/h2&gt;
    &lt;/b:if&gt;
    &lt;div class='widget-content'&gt;
    &lt;b:if cond='data:team'&gt; &lt;!-- team blog profile --&gt;
      &lt;ul&gt;
        &lt;b:loop values='data:authors' var='i'&gt;
          &lt;li&gt;&lt;a class='profile-name-link g-profile' expr:href='data:i.userUrl' expr:style='&amp;quot;background-image: url(&amp;quot; + data:i.profileLogo + &amp;quot;);&amp;quot;'&gt;&lt;data:i.display-name/&gt;&lt;/a&gt;&lt;/li&gt;
        &lt;/b:loop&gt;
      &lt;/ul&gt;

    &lt;b:else/&gt; &lt;!-- normal blog profile --&gt;

      &lt;b:if cond='data:photo.url != &amp;quot;&amp;quot;'&gt;
        &lt;a expr:href='data:userUrl'&gt;&lt;img class='profile-img' expr:alt='data:messages.myPhoto' expr:height='data:photo.height' expr:src='data:photo.url' expr:width='data:photo.width'/&gt;&lt;/a&gt;
      &lt;/b:if&gt;

      &lt;dl class='profile-datablock'&gt;
        &lt;dt class='profile-data'&gt;
          &lt;a class='profile-name-link g-profile' expr:href='data:userUrl' expr:style='&amp;quot;background-image: url(&amp;quot; + data:profileLogo + &amp;quot;);&amp;quot;' rel='author'&gt;
            &lt;data:displayname/&gt;
          &lt;/a&gt;
          &lt;b:if cond='data:hasgoogleprofile'&gt;
            &lt;br/&gt;
            &lt;div class='g-follow' data-annotation='bubble' data-height='20' expr:data-href='data:userUrl'/&gt;
          &lt;/b:if&gt;
        &lt;/dt&gt;

        &lt;b:if cond='data:showlocation'&gt;
          &lt;dd class='profile-data'&gt;&lt;data:location/&gt;&lt;/dd&gt;
        &lt;/b:if&gt;

        &lt;b:if cond='data:aboutme != &amp;quot;&amp;quot;'&gt;&lt;dd class='profile-textblock'&gt;&lt;data:aboutme/&gt;&lt;/dd&gt;&lt;/b:if&gt;
      &lt;/dl&gt;
      &lt;a class='profile-link' expr:href='data:userUrl' rel='author'&gt;&lt;data:viewProfileMsg/&gt;&lt;/a&gt;
    &lt;/b:if&gt;

     &lt;b:include name='quickedit'/&gt;
    &lt;/div&gt;
  &lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='HTML4' locked='false' title='Entre em contato' type='HTML' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;!-- only display title if it's non-empty --&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2 class='title'&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;
  &lt;div class='widget-content'&gt;
    &lt;data:content/&gt;
  &lt;/div&gt;

  &lt;b:include name='quickedit'/&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
  &lt;b:widget id='HTML5' locked='false' title='Entre na era da computação em nuvem!' type='HTML' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;!-- only display title if it's non-empty --&gt;
  &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
    &lt;h2 class='title'&gt;&lt;data:title/&gt;&lt;/h2&gt;
  &lt;/b:if&gt;
  &lt;div class='widget-content'&gt;
    &lt;data:content/&gt;
  &lt;/div&gt;

  &lt;b:include name='quickedit'/&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
&lt;/b:section-contents&gt;&lt;b:section-contents id='footer-1'&gt;
  &lt;b:widget id='Gadget2' locked='false' title='PubMed / NCBI Search' type='Gadget' visible='true'&gt;
    &lt;b:includable id='main'&gt;
  &lt;!-- only display title if it's non-empty --&gt;
  &lt;b:if cond='data:renderingUrl != &amp;quot;&amp;quot;'&gt;
    &lt;b:if cond='data:title != &amp;quot;&amp;quot;'&gt;
      &lt;h2 class='title'&gt;&lt;data:title/&gt;&lt;/h2&gt;
    &lt;/b:if&gt;
    &lt;b:if cond='data:gadgetSnippet != &amp;quot;&amp;quot;'&gt;
       &lt;data:gadgetSnippet/&gt;
    &lt;b:else/&gt;
      &lt;div class='widget-content'&gt;
        &lt;b:if cond='data:nonSocialFragment != &amp;quot;&amp;quot;'&gt;
          &lt;data:nonSocialFragment/&gt;
        &lt;/b:if&gt;
      &lt;/div&gt;
    &lt;/b:if&gt;
  &lt;b:else/&gt;
    &lt;data:errorMessage/&gt;
  &lt;/b:if&gt;

  &lt;b:include name='quickedit'/&gt;
&lt;/b:includable&gt;
  &lt;/b:widget&gt;
&lt;/b:section-contents&gt;&lt;b:section-contents id='footer-2-1'/&gt;&lt;b:section-contents id='footer-2-2'/&gt;&lt;/html&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/template/default'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/template/default'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_PUBLISHING_MODE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O tipo de publicação selecionado para esse blog.</title><content type='text'>PUBLISH_MODE_BLOGSPOT</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_PUBLISHING_MODE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_PUBLISHING_MODE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_ADMIN_PERMISSION</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>A lista de e-mails de administradores para o blog.</title><content type='text'>heldercfelix@gmail.com</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ADMIN_PERMISSION'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ADMIN_PERMISSION'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_ADULT_CONTENT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se este blog contém conteúdo para adultos</title><content type='text'>false</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ADULT_CONTENT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ADULT_CONTENT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_ALTERNATE_JSRENDER_ALLOWED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se renderizações JS alternadas devem ser permitidas</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ALTERNATE_JSRENDER_ALLOWED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ALTERNATE_JSRENDER_ALLOWED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_ANALYTICS_ACCOUNT_NUMBER</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Número da conta do Google Analytics do blog</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ANALYTICS_ACCOUNT_NUMBER'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ANALYTICS_ACCOUNT_NUMBER'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_ARCHIVE_DATE_FORMAT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O número do formato da data no índice do arquivo</title><content type='text'>9</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ARCHIVE_DATE_FORMAT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ARCHIVE_DATE_FORMAT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_ARCHIVE_FREQUENCY</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Com que freqüência este blog deve ser arquivado</title><content type='text'>MONTHLY</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ARCHIVE_FREQUENCY'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_ARCHIVE_FREQUENCY'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_AUTHOR_PERMISSION</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>A lista de e-mails de autores que têm permissão para publicar.</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_AUTHOR_PERMISSION'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_AUTHOR_PERMISSION'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_BACKLINKS_ALLOWED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se os backlinks de comentários devem ser exibidos neste blog</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_BACKLINKS_ALLOWED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_BACKLINKS_ALLOWED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_BY_POST_ARCHIVING</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se uma página de arquivo deve ser exibida para cada postagem</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_BY_POST_ARCHIVING'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_BY_POST_ARCHIVING'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_ACCESS</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Quem pode comentar</title><content type='text'>REGISTERED</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_ACCESS'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_ACCESS'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_CAPTCHA</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se comentaristas devem ser solicitador a preencher uma captcha</title><content type='text'>false</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_CAPTCHA'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_CAPTCHA'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_EMAIL</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Lista de endereços de e-mail para enviar notificações de novos comentários para</title><content type='text'>heldercfelix@gmail.com</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_EMAIL'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_EMAIL'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_FEED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O tipo de feed a ser fornecido para os comentários do blog</title><content type='text'>SHORT</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_FEED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_FEED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_FORM_LOCATION</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Local do formulário de comentário do blog</title><content type='text'>EMBEDDED_IFRAME</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_FORM_LOCATION'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_FORM_LOCATION'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_MESSAGE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Mensagem de comentário do blog</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MESSAGE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MESSAGE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_MODERATION</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se a mediação de comentário deve ser ativada</title><content type='text'>ENABLED</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MODERATION'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MODERATION'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_MODERATION_DELAY</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Número de dias depois que os novos comentários estarão sujeitos à moderação</title><content type='text'>14</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MODERATION_DELAY'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MODERATION_DELAY'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_MODERATION_EMAIL</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Endereço de e-mail para enviar notificações de novos comentários que precisam ser moderados</title><content type='text'>heldercfelix@gmail.com</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MODERATION_EMAIL'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_MODERATION_EMAIL'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENT_PROFILE_IMAGES</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se imagens de perfil devem ser exibidas em comentários</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_PROFILE_IMAGES'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENT_PROFILE_IMAGES'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENTS_ALLOWED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se os comentários serão exibidos</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENTS_ALLOWED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENTS_ALLOWED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_COMMENTS_TIME_STAMP_FORMAT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Número de formato de data e hora do comentário</title><content type='text'>29</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENTS_TIME_STAMP_FORMAT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_COMMENTS_TIME_STAMP_FORMAT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_CONVERT_LINE_BREAKS</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se as quebras de linha serão convertidas em &lt;br /&gt; tags no editor de postagem</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CONVERT_LINE_BREAKS'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CONVERT_LINE_BREAKS'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_CUSTOM_PAGE_NOT_FOUND</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O conteúdo exibido quando a postagem ou página solicitada não é encontrada.</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CUSTOM_PAGE_NOT_FOUND'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CUSTOM_PAGE_NOT_FOUND'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_CUSTOM_ROBOTS_TXT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O conteúdo robots.txt personalizado do blog veiculado aos mecanismos de pesquisa.</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CUSTOM_ROBOTS_TXT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CUSTOM_ROBOTS_TXT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_CUSTOM_ROBOTS_TXT_ENABLED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se este blog exibe conteúdo robots.txt personalizado para os mecanismos de pesquisa.</title><content type='text'>false</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CUSTOM_ROBOTS_TXT_ENABLED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_CUSTOM_ROBOTS_TXT_ENABLED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_DATE_FORMAT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O número do formato do cabeçalho de data</title><content type='text'>26</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DATE_FORMAT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DATE_FORMAT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_DEFAULT_BACKLINKS_MODE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Modo padrão de backlinks para as postagens</title><content type='text'>DEFAULT_HAVE_BACKLINKS</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DEFAULT_BACKLINKS_MODE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DEFAULT_BACKLINKS_MODE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_DEFAULT_COMMENTS_MODE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Modo padrão de comentários para as postagens</title><content type='text'>DEFAULT_HAVE_COMMENTS</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DEFAULT_COMMENTS_MODE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DEFAULT_COMMENTS_MODE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_DESCRIPTION</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Uma descrição do blog</title><content type='text'>Ciência médica e não médica.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DESCRIPTION'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_DESCRIPTION'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_EMAIL_POST_LINKS</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se um link para envio de postagens dos usuários por e-mail será exibido</title><content type='text'>false</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_EMAIL_POST_LINKS'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_EMAIL_POST_LINKS'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_FEED_REDIRECT_URL</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>URL para redirecionar as solicitações de feed de postagem para</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_FEED_REDIRECT_URL'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_FEED_REDIRECT_URL'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_FLOAT_ALIGNMENT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se o alinhamento flutuante está disponível para o blog</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_FLOAT_ALIGNMENT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_FLOAT_ALIGNMENT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_LOCALE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Idioma deste blog</title><content type='text'>pt_BR</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_LOCALE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_LOCALE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_M2B_WHITELIST_EMAIL</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Lista de endereços de e-mail que podem postar no blog via e-mail.</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_M2B_WHITELIST_EMAIL'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_M2B_WHITELIST_EMAIL'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_MAX_NUM</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Número máximo de itens que serão exibidos na página principal"</title><content type='text'>1</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_MAX_NUM'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_MAX_NUM'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_MAX_UNIT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Grupo de itens que serão exibidos na página principal</title><content type='text'>POSTS</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_MAX_UNIT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_MAX_UNIT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_META_DESCRIPTION</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>A metadescrição do blog exibida aos mecanismos de pesquisa.</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_META_DESCRIPTION'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_META_DESCRIPTION'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_META_DESCRIPTION_ENABLED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Indica se este blog é exibido com metadescrições.</title><content type='text'>false</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_META_DESCRIPTION_ENABLED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_META_DESCRIPTION_ENABLED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_NAME</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O nome do blog</title><content type='text'>Pharmakon</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_NAME'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_NAME'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_PER_POST_FEED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O tipo de feed a ser fornecido por comentários de postagem</title><content type='text'>SHORT</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_PER_POST_FEED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_PER_POST_FEED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_POST_FEED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O tipo de feed a ser fornecido para as postagens do blog</title><content type='text'>SHORT</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_POST_FEED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_POST_FEED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_POST_FEED_FOOTER</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Rodapé para anexar ao fim de cada entrada no feed da postagem</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_POST_FEED_FOOTER'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_POST_FEED_FOOTER'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_POST_TEMPLATE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O modelo para as postagens do blog</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_POST_TEMPLATE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_POST_TEMPLATE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_PROMOTED</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se este blog pode ser promovido no Blogger</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_PROMOTED'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_PROMOTED'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_QUICK_EDITING</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se a Edição rápida está ativada</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_QUICK_EDITING'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_QUICK_EDITING'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_READ_ACCESS_MODE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O tipo de acesso dos leitores do blog.</title><content type='text'>PUBLIC</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_READ_ACCESS_MODE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_READ_ACCESS_MODE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_READER_PERMISSION</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>A lista de e-mails para os usuários que têm permissão para ler o blog.</title><content type='text'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_READER_PERMISSION'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_READER_PERMISSION'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_SEARCHABLE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se este blog deve ser indexado pelos mecanismos de pesquisa</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SEARCHABLE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SEARCHABLE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_SEND_EMAIL</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Lista de e-mails separados por vírgula para enviar novas postagens de blog para</title><content type='text'>gedeon-onco@googlegroups.com,gedeonco@groups.facebook.com,heldercfelix@gmail.com</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SEND_EMAIL'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SEND_EMAIL'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_SHOW_TITLE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se o campo do título será exibido</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SHOW_TITLE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SHOW_TITLE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_SHOW_URL</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Se uma caixa de links relacionados deve ser exibida no criador de postagens</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SHOW_URL'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SHOW_URL'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_SUBDOMAIN</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O subdomínio do BlogSpot no qual deseja publicar seu blog</title><content type='text'>pharmak</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SUBDOMAIN'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_SUBDOMAIN'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_TIME_STAMP_FORMAT</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O formato de número de data e hora</title><content type='text'>27</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_TIME_STAMP_FORMAT'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_TIME_STAMP_FORMAT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_TIME_ZONE</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>O fuso horário para este blog</title><content type='text'>America/Fortaleza</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_TIME_ZONE'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_TIME_ZONE'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.settings.BLOG_USE_LIGHTBOX</id><published>2007-09-21T10:27:37.801-03:00</published><updated>2016-09-04T13:06:57.937-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#settings'/><title type='text'>Mostrar ou não as imagens na Lightbox quando forem clicadas</title><content type='text'>true</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_USE_LIGHTBOX'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/settings/BLOG_USE_LIGHTBOX'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1605599810764702557</id><published>2016-09-04T13:06:00.000-03:00</published><updated>2016-09-04T13:06:57.988-03:00</updated><app:control xmlns:app='http://purl.org/atom/app#'><app:draft>yes</app:draft></app:control><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Blogger'/><category scheme='http://www.blogger.com/atom/ns#' term='Mac OS X'/><category scheme='http://www.blogger.com/atom/ns#' term='CLI'/><title type='text'>Minha nova postagem</title><content type='html'>&lt;p&gt;Esta postagem está sendo escrita em Markdown usando &lt;strong&gt;Vim&lt;/strong&gt; e &lt;a href="https://atom.io"&gt;&lt;strong&gt;Atom&lt;/strong&gt;&lt;/a&gt; e será interpretada para HTML com &lt;a href="http://pandoc.org"&gt;&lt;strong&gt;pandoc&lt;/strong&gt;&lt;/a&gt;, para depois ser postada com &lt;a href="http://www.crankyotaku.com/2016/03/command-line-blogger.html"&gt;&lt;strong&gt;crankyblogger&lt;/strong&gt;&lt;/a&gt;, um CLI para blogger.com escrito em &lt;a href="https://www.python.org"&gt;&lt;strong&gt;Python&lt;/strong&gt;&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Ele é muito simples e capaz basicamente apenas de criar novas postagens no blogger. Desde que se tenha uma conta nele, claro. Para usá-lo, eu tive que instalar algumas&lt;br /&gt;dependências. Estes são os pacotes que crankyblogger.py chama ao inicializar:&lt;/p&gt;&lt;pre class="{python}"&gt;&lt;code&gt;import json, webbrowser, getopt, os.path, sys&lt;br /&gt;import httplib2&lt;br /&gt;from oauth2client import client&lt;br /&gt;from apiclient.discovery import build&lt;br /&gt;from oauth2client.file import Storage&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Meu sistema é &lt;em&gt;Mac OS X 10.11.6 El Capitan&lt;/em&gt;. A versão de Python que vem embarcada é 2.7.10, instalada no diretório &lt;code&gt;/usr/bin/python&lt;/code&gt;. Por definição, o sistema protege as pastas &lt;code&gt;/System /bin /sbin /usr&lt;/code&gt; contra edição, mesmo usando usuário &lt;em&gt;root&lt;/em&gt;. A Apple chama isso de &lt;em&gt;SIP - System Integrity Protection&lt;/em&gt;. Na verdade, é uma característica interessante do ponto de vista de organização. Usando o &lt;a href="http://brew.sh"&gt;&lt;em&gt;Homebrew&lt;/em&gt;&lt;/a&gt; é possível fazer instalações seguras e funcionais que ficarão localizadas na pasta &lt;code&gt;/usr/local/bin&lt;/code&gt;, eliminando problemas de compatibilidade. Como eu não poderia instalar as dependências necessárias no Python nativo do OS X, tive que instalar a última versão estável do Python 2.7. Antes de fazer isso, é necessário instalar as ferramentas de desenvolvedor do &lt;em&gt;Xcode&lt;/em&gt; (via Apple Store) e o &lt;em&gt;Command Line Tools&lt;/em&gt;:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ xcode-select --install&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Depois, é só instalar o Homebrew, se já não estiver no sistema:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ ruby -e &amp;quot;$(curl -fsSL https://raw.githubusercontent.com/Homebrew/install/master/install)&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;E, antes de instalar o Python, colocar a pasta de destino no $PATH:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;export PATH=/usr/local/bin:$PATH&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Esta linha pode ser acrescentada no &lt;code&gt;~/.bash_profile&lt;/code&gt; para maior comodidade.&lt;br /&gt;Por fim, para instalar a nova versão do Python:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ brew install python&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Checando a versão e o local:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ which python&lt;br /&gt;/usr/local/bin/&lt;br /&gt;&lt;br /&gt;$ python --version&lt;br /&gt;Python 2.7.12&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Usar o Homebrew para instalar outra versão de Python permite que a versão nativa conviva harmoniosamente com a nova. É possível até instalar o &lt;em&gt;Python 3.X&lt;/em&gt; e usá-lo separadamente, sem interferir com as outras. As instruções de &lt;a href="http://www.marinamele.com/python"&gt;&lt;em&gt;Marina Mele&lt;/em&gt;&lt;/a&gt; são esclarecedoras. A melhor forma de instalar dependências específicas no Python é usando um ambiente virtual, para assegurar separação e organização das diversas instâncias.&lt;/p&gt;&lt;p&gt;Para instalar &lt;em&gt;virtualenv&lt;/em&gt; e &lt;em&gt;virtualenvwrapper&lt;/em&gt;:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ pip install virtualenv&lt;br /&gt;$ pip install virtualenvwrapper&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Em seguida, criar uma pasta que vai conter os ambientes virtuais.&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ mkdir ~/.virtualenvs&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Abrir ou criar o arquivo ~/.bashrc e colocar:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;export WORKON_HOME=~/.virtualenvs&lt;br /&gt;source /usr/local/bin/virtualenvwrapper.sh&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Por fim, ativar estas mudanças:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ source ~/.bashrc&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Dessa forma, será possível criar um novo ambiente virtual:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ mkvirtualenv myenviroment&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Na pasta &lt;code&gt;~/.vitualenvs/myenvironment&lt;/code&gt; que será criada pelo script. O ambiente será automaticamente ativo. Trocar de ambiente é simples como:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ workon myenvironment&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;E, para desativar os ambientes:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ deactivate&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Deletar e listar os ambientes:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ rmvirtualenv &amp;lt;nome_do_ambiente&amp;gt;&lt;br /&gt;$ lsvirtualenv&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Finalmente, instalar pacotes à vontade será fácil apenas usando o comando &lt;code&gt;pip install&lt;/code&gt;. Instalei as dependências do crankyblogger.py dessa forma e pude usá-lo.&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ pip install httplib2&lt;br /&gt;$ pip install oauth2client&lt;br /&gt;$ pip install --upgrade google-api-python-client&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Seu uso também é muito simples, consistindo apenas numa ferramenta para publicar novas postagens em formato rascunho (padrão) ou publicação final. Igualmente, pode-se configurar o título e marcadores para a postagem. A publicação é realmente simples com o uso desta ferramenta bem básica. Sua &lt;a href="http://www.crankyotaku.com/2016/03/command-line-blogger.html"&gt;documentação&lt;/a&gt; traz uma explicação sumária, porém suficiente para usá-lo. Para minha comodidade, mudei o nome do executável para &lt;code&gt;bloggercli&lt;/code&gt; e copiei-o para a pasta &lt;code&gt;/usr/local/bin&lt;/code&gt;. Dessa forma, posso usar o comando em qualquer local. Usei-o com um ambiente virtual:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ workon myenvironment&lt;br /&gt;$ bloggercli -f &amp;quot;newpost.html&amp;quot; -t &amp;quot;Usando um CLI para blogger (instalando Python no Mac OS X)&amp;quot; -l &amp;quot;Mac OS X, Blogger, CLI, Python&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Para criar o arquivo em html, escrevi &lt;code&gt;newpost.txt&lt;/code&gt; usando Markdown e usei o pandoc para convertê-lo:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ pandoc -f markdown_strict -t html -o newpost.html newpost.txt&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Este é meu primeiro teste.&lt;/p&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1605599810764702557'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1605599810764702557'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8168546768034897038</id><published>2016-09-03T21:12:00.000-03:00</published><updated>2016-09-03T21:12:22.942-03:00</updated><app:control xmlns:app='http://purl.org/atom/app#'><app:draft>yes</app:draft></app:control><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Blogger'/><category scheme='http://www.blogger.com/atom/ns#' term='Mac OS X'/><category scheme='http://www.blogger.com/atom/ns#' term='CLI'/><title type='text'>Usando um CLI para blogger (instalando Python no Mac OS X) - updated</title><content type='html'>&lt;p&gt;Esta postagem está sendo escrita em Markdown usando &lt;strong&gt;Vim&lt;/strong&gt; e &lt;a href="https://atom.io"&gt;&lt;strong&gt;Atom&lt;/strong&gt;&lt;/a&gt; e será interpretada para HTML com &lt;a href="http://pandoc.org"&gt;&lt;strong&gt;pandoc&lt;/strong&gt;&lt;/a&gt;, para depois ser postada com &lt;a href="http://www.crankyotaku.com/2016/03/command-line-blogger.html"&gt;&lt;strong&gt;crankyblogger&lt;/strong&gt;&lt;/a&gt;, um CLI para blogger.com escrito em &lt;a href="https://www.python.org"&gt;&lt;strong&gt;Python&lt;/strong&gt;&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Ele é muito simples e capaz basicamente apenas de criar novas postagens no blogger. Desde que se tenha uma conta nele, claro. Para usá-lo, eu tive que instalar algumas&lt;br /&gt;dependências. Estes são os pacotes que crankyblogger.py chama ao inicializar:&lt;/p&gt;&lt;pre class="{python}"&gt;&lt;code&gt;import json, webbrowser, getopt, os.path, sys&lt;br /&gt;import httplib2&lt;br /&gt;from oauth2client import client&lt;br /&gt;from apiclient.discovery import build&lt;br /&gt;from oauth2client.file import Storage&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Meu sistema é &lt;em&gt;Mac OS X 10.11.6 El Capitan&lt;/em&gt;. A versão de Python que vem embarcada é 2.7.10, instalada no diretório &lt;code&gt;/usr/bin/python&lt;/code&gt;. Por definição, o sistema protege as pastas &lt;code&gt;/System /bin /sbin /usr&lt;/code&gt; contra edição, mesmo usando usuário &lt;em&gt;root&lt;/em&gt;. A Apple chama isso de &lt;em&gt;SIP - System Integrity Protection&lt;/em&gt;. Na verdade, é uma característica interessante do ponto de vista de organização. Usando o &lt;a href="http://brew.sh"&gt;&lt;em&gt;Homebrew&lt;/em&gt;&lt;/a&gt; é possível fazer instalações seguras e funcionais que ficarão localizadas na pasta &lt;code&gt;/usr/local/bin&lt;/code&gt;, eliminando problemas de compatibilidade. Como eu não poderia instalar as dependências necessárias no Python nativo do OS X, tive que instalar a última versão estável do Python 2.7. Antes de fazer isso, é necessário instalar as ferramentas de desenvolvedor do &lt;em&gt;Xcode&lt;/em&gt; (via Apple Store) e o &lt;em&gt;Command Line Tools&lt;/em&gt;:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ xcode-select --install&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Depois, é só instalar o Homebrew, se já não estiver no sistema:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ ruby -e &amp;quot;$(curl -fsSL https://raw.githubusercontent.com/Homebrew/install/master/install)&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;E, antes de instalar o Python, colocar a pasta de destino no $PATH:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;export PATH=/usr/local/bin:$PATH&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Esta linha pode ser acrescentada no &lt;code&gt;~/.bash_profile&lt;/code&gt; para maior comodidade.&lt;br /&gt;Por fim, para instalar a nova versão do Python:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ brew install python&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Checando a versão e o local:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ which python&lt;br /&gt;/usr/local/bin/&lt;br /&gt;&lt;br /&gt;$ python --version&lt;br /&gt;Python 2.7.12&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Usar o Homebrew para instalar outra versão de Python permite que a versão nativa conviva harmoniosamente com a nova. É possível até instalar o &lt;em&gt;Python 3.X&lt;/em&gt; e usá-lo separadamente, sem interferir com as outras. As instruções de &lt;a href="http://www.marinamele.com/python"&gt;&lt;em&gt;Marina Mele&lt;/em&gt;&lt;/a&gt; são esclarecedoras. A melhor forma de instalar dependências específicas no Python é usando um ambiente virtual, para assegurar separação e organização das diversas instâncias.&lt;/p&gt;&lt;p&gt;Para instalar &lt;em&gt;virtualenv&lt;/em&gt; e &lt;em&gt;virtualenvwrapper&lt;/em&gt;:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ pip install virtualenv&lt;br /&gt;$ pip install virtualenvwrapper&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Em seguida, criar uma pasta que vai conter os ambientes virtuais.&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ mkdir ~/.virtualenvs&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Abrir ou criar o arquivo ~/.bashrc e colocar:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;export WORKON_HOME=~/.virtualenvs&lt;br /&gt;source /usr/local/bin/virtualenvwrapper.sh&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Por fim, ativar estas mudanças:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ source ~/.bashrc&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Dessa forma, será possível criar um novo ambiente virtual:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ mkvirtualenv myenviroment&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Na pasta &lt;code&gt;~/.vitualenvs/myenvironment&lt;/code&gt; que será criada pelo script. O ambiente será automaticamente ativo. Trocar de ambiente é simples como:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ workon myenvironment&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;E, para desativar os ambientes:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ deactivate&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Deletar e listar os ambientes:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ rmvirtualenv &amp;lt;nome_do_ambiente&amp;gt;&lt;br /&gt;$ lsvirtualenv&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Finalmente, instalar pacotes à vontade será fácil apenas usando o comando &lt;code&gt;pip install&lt;/code&gt;. Instalei as dependências do crankyblogger.py dessa forma e pude usá-lo.&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ pip install httplib2&lt;br /&gt;$ pip install oauth2client&lt;br /&gt;$ pip install --upgrade google-api-python-client&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Seu uso também é muito simples, consistindo apenas numa ferramenta para publicar novas postagens em formato rascunho (padrão) ou publicação final. Igualmente, pode-se configurar o título e marcadores para a postagem. A publicação é realmente simples com o uso desta ferramenta bem básica. Sua &lt;a href="http://www.crankyotaku.com/2016/03/command-line-blogger.html"&gt;documentação&lt;/a&gt; traz uma explicação sumária, porém suficiente para usá-lo. Para minha comodidade, mudei o nome do executável para &lt;code&gt;bloggercli&lt;/code&gt; e copiei-o para a pasta &lt;code&gt;/usr/local/bin&lt;/code&gt;. Dessa forma, posso usar o comando em qualquer local. Usei-o com um ambiente virtual:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ workon myenvironment&lt;br /&gt;$ bloggercli -f &amp;quot;newpost.html&amp;quot; -t &amp;quot;Usando um CLI para blogger (instalando Python no Mac OS X)&amp;quot; -l &amp;quot;Mac OS X, Blogger, CLI, Python&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Para criar o arquivo em html, escrevi &lt;code&gt;newpost.txt&lt;/code&gt; usando Markdown e usei o pandoc para convertê-lo:&lt;/p&gt;&lt;pre&gt;&lt;code&gt;$ pandoc -f markdown_strict -t html -o newpost.html newpost.txt&lt;/code&gt;&lt;/pre&gt;&lt;p&gt;Este é meu primeiro teste.&lt;/p&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8168546768034897038'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8168546768034897038'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6294509227596024793</id><published>2016-09-03T12:36:00.001-03:00</published><updated>2016-09-03T20:59:56.878-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Blogger'/><category scheme='http://www.blogger.com/atom/ns#' term='Python'/><category scheme='http://www.blogger.com/atom/ns#' term='Mac OS X'/><category scheme='http://www.blogger.com/atom/ns#' term='CLI'/><title type='text'>Usando um CLI para blogger (instalando Python no Mac OS X)</title><content type='html'>Esta postagem está sendo escrita em Markdown usando &lt;strong&gt;Vim&lt;/strong&gt; e &lt;a href="https://atom.io/"&gt;&lt;strong&gt;Atom&lt;/strong&gt;&lt;/a&gt; e será interpretada para HTML com &lt;a href="http://pandoc.org/"&gt;&lt;strong&gt;pandoc&lt;/strong&gt;&lt;/a&gt;, para depois ser postada com &lt;a href="http://www.crankyotaku.com/2016/03/command-line-blogger.html"&gt;&lt;strong&gt;crankyblogger&lt;/strong&gt;&lt;/a&gt;, um CLI para blogger.com escrito em &lt;a href="https://www.python.org/"&gt;&lt;strong&gt;Python&lt;/strong&gt;&lt;/a&gt;.&lt;br /&gt;Ele é muito simples e capaz basicamente apenas de criar novas postagens no blogger. Desde que se tenha uma conta nele, claro. Para usá-lo, eu tive que instalar algumas&lt;br /&gt;dependências. Estes são os pacotes que crankyblogger.py chama ao inicializar:&lt;br /&gt;&lt;pre class="{python}"&gt;&lt;code&gt;import json, webbrowser, getopt, os.path, sys&lt;br /&gt;import httplib2&lt;br /&gt;from oauth2client import client&lt;br /&gt;from apiclient.discovery import build&lt;br /&gt;from oauth2client.file import Storage&lt;/code&gt;&lt;/pre&gt;Meu sistema é &lt;em&gt;Mac OS X 10.11.6 El Capitan&lt;/em&gt;. A versão de Python que vem embarcada é 2.7.10, instalada no diretório &lt;code&gt;/usr/bin/python&lt;/code&gt;. Por definição, o sistema protege as pastas &lt;code&gt;/System /bin /sbin /usr&lt;/code&gt; contra edição, mesmo usando usuário &lt;em&gt;root&lt;/em&gt;. A Apple chama isso de &lt;em&gt;SIP - System Integrity Protection&lt;/em&gt;. Na verdade, é uma característica interessante do ponto de vista de organização. Usando o &lt;a href="http://brew.sh/"&gt;&lt;em&gt;Homebrew&lt;/em&gt;&lt;/a&gt; é possível fazer instalações seguras e funcionais que ficarão localizadas na pasta &lt;code&gt;/usr/local/bin&lt;/code&gt;, eliminando problemas de compatibilidade. Como eu não poderia instalar as dependências necessárias no Python nativo do OS X, tive que instalar a última versão estável do Python 2.7. Antes de fazer isso, é necessário instalar as ferramentas de desenvolvedor do &lt;em&gt;Xcode&lt;/em&gt; (via Apple Store) e o &lt;em&gt;Command Line Tools&lt;/em&gt;:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ xcode-select --install&lt;/code&gt;&lt;/pre&gt;Depois, é só instalar o Homebrew, se já não estiver no sistema:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ ruby -e "$(curl -fsSL https://raw.githubusercontent.com/Homebrew/install/master/install)"&lt;/code&gt;&lt;/pre&gt;E, antes de instalar o Python, colocar a pasta de destino no $PATH:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;export PATH=/usr/local/bin:$PATH&lt;/code&gt;&lt;/pre&gt;Esta linha pode ser acrescentada no &lt;code&gt;~/.bash_profile&lt;/code&gt; para maior comodidade.&lt;br /&gt;Por fim, para instalar a nova versão do Python:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ brew install python&lt;/code&gt;&lt;/pre&gt;Checando a versão e o local:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ which python&lt;br /&gt;/usr/local/bin/&lt;br /&gt;&lt;br /&gt;$ python --version&lt;br /&gt;Python 2.7.12&lt;/code&gt;&lt;/pre&gt;Usar o Homebrew para instalar outra versão de Python permite que a versão nativa conviva harmoniosamente com a nova. É possível até instalar o &lt;em&gt;Python 3.X&lt;/em&gt; e usá-lo separadamente, sem interferir com as outras. As instruções de &lt;a href="http://www.marinamele.com/python"&gt;&lt;em&gt;Marina Mele&lt;/em&gt;&lt;/a&gt; são esclarecedoras. A melhor forma de instalar dependências específicas no Python é usando um ambiente virtual, para assegurar separação e organização das diversas instâncias.&lt;br /&gt;Para instalar &lt;em&gt;virtualenv&lt;/em&gt; e &lt;em&gt;virtualenvwrapper&lt;/em&gt;:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ pip install virtualenv&lt;br /&gt;$ pip install virtualenvwrapper&lt;/code&gt;&lt;/pre&gt;Em seguida, criar uma pasta que vai conter os ambientes virtuais.&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ mkdir ~/.virtualenvs&lt;/code&gt;&lt;/pre&gt;Abrir ou criar o arquivo ~/.bashrc e colocar:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;export WORKON_HOME=~/.virtualenvs&lt;br /&gt;source /usr/local/bin/virtualenvwrapper.sh&lt;/code&gt;&lt;/pre&gt;Por fim, ativar estas mudanças:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ source ~/.bashrc&lt;/code&gt;&lt;/pre&gt;Dessa forma, será possível criar um novo ambiente virtual:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ mkvirtualenv myenviroment&lt;/code&gt;&lt;/pre&gt;Na pasta &lt;code&gt;~/.vitualenvs/myenvironment&lt;/code&gt; que será criada pelo script. O ambiente será automaticamente ativo. Trocar de ambiente é simples como:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ workon myenvironment&lt;/code&gt;&lt;/pre&gt;E, para desativar os ambientes:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ deactivate&lt;/code&gt;&lt;/pre&gt;Deletar e listar os ambientes:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ rmvirtualenv &amp;lt;nome_do_ambiente&amp;gt;&lt;br /&gt;$ lsvirtualenv&lt;/code&gt;&lt;/pre&gt;Finalmente, instalar pacotes à vontade será fácil apenas usando o comando &lt;code&gt;pip install&lt;/code&gt;. Instalei as dependências do crankyblogger.py dessa forma e pude usá-lo.&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ pip install httplib2&lt;br /&gt;$ pip install oauth2client&lt;br /&gt;$ pip install --upgrade google-api-python-client&lt;/code&gt;&lt;/pre&gt;Seu uso também é muito simples, consistindo apenas numa ferramenta para publicar novas postagens em formato rascunho (padrão) ou publicação final. Igualmente, pode-se configurar o título e marcadores para a postagem. A publicação é realmente simples com o uso desta ferramenta bem básica. Sua &lt;a href="http://www.crankyotaku.com/2016/03/command-line-blogger.html"&gt;documentação&lt;/a&gt; traz uma explicação sumária, porém suficiente para usá-lo. Para minha comodidade, mudei o nome do executável para &lt;code&gt;bloggercli&lt;/code&gt; e copiei-o para a pasta &lt;code&gt;/usr/local/bin&lt;/code&gt;. Dessa forma, posso usar o comando em qualquer local. Usei-o com um ambiente virtual:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ workon myenvironment&lt;br /&gt;$ bloggercli -f "newpost.html" -t "Usando um CLI para blogger (instalando Python no Mac OS X)" -l "Mac OS X, Blogger, CLI, Python"&lt;/code&gt;&lt;/pre&gt;Para criar o arquivo em html, escrevi &lt;code&gt;newpost.txt&lt;/code&gt; usando Markdown e usei o pandoc para convertê-lo:&lt;br /&gt;&lt;pre&gt;&lt;code&gt;$ pandoc -f markdown_strict -t html -o newpost.html newpost.txt&lt;/code&gt;&lt;/pre&gt;Este é meu primeiro teste.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6294509227596024793/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2016/09/usando-um-cli-para-blogger-instalando.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6294509227596024793'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6294509227596024793'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2016/09/usando-um-cli-para-blogger-instalando.html' title='Usando um CLI para blogger (instalando Python no Mac OS X)'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3830359583542524238</id><published>2016-02-27T23:28:00.000-03:00</published><updated>2016-02-27T23:28:00.832-03:00</updated><app:control xmlns:app='http://purl.org/atom/app#'><app:draft>yes</app:draft></app:control><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Your new academic repository: Zenodo</title><content type='html'></content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3830359583542524238'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3830359583542524238'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1879809826225422165</id><published>2016-01-02T10:27:00.000-03:00</published><updated>2016-01-17T11:51:40.051-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='self-archiving'/><category scheme='http://www.blogger.com/atom/ns#' term='Figshare'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='academic journals'/><category scheme='http://www.blogger.com/atom/ns#' term='postprints'/><category scheme='http://www.blogger.com/atom/ns#' term='predatory publishers'/><title type='text'>Figshare received (and deleted) postprints of 'predatory' journals about a 'mystical effect' (updated)</title><content type='html'>Recently, I've &lt;a href="http://pharmak.blogspot.com/2015/12/usando-o-figshare.html"&gt;posted&lt;/a&gt;&amp;nbsp;about the self-archiving of academic conference posters in &lt;a href="http://figshare.com/"&gt;Figshare&lt;/a&gt;. I've pointed out many advantages of Figshare comparing to similar services that allow the archiving of preprints, conference posters, datasets and other types of academic production. I myself have published &lt;a href="http://dx.doi.org/10.6084/m9.figshare.2007588"&gt;posters&lt;/a&gt; and &lt;a href="http://dx.doi.org/10.6084/m9.figshare.2059851"&gt;postprints&lt;/a&gt; in Figshare, and maintain my opinion about this service's versatility and utility. For me, it is still superior in many aspects to other alternative academic publishing venues. However... Well, there seems always to be some catch! Look to what I saw today when I opened Figshare's site:&lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://1.bp.blogspot.com/-w6vEEIldTl4/VofBpt5dUgI/AAAAAAAAgMY/VyoVw3_lkmk/s1600/fig-omics.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="222" src="http://1.bp.blogspot.com/-w6vEEIldTl4/VofBpt5dUgI/AAAAAAAAgMY/VyoVw3_lkmk/s400/fig-omics.png" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;The blue pointers are showing my recently uploaded postprints. They were published in small, local academic journals, and do not even have a doi number. I have deposited them in Figshare as self-archiving to ensure a wider visibility to them. I retain the author rights of all the papers, so it is strictly legal. But let's see what the red pointers are depicting. They are all &lt;a href="https://figshare.com/search?q=trivedi&amp;amp;quick=1"&gt;papers&lt;/a&gt; published in journals of the infamous &lt;a href="http://scholarlyoa.com/?s=omics+group"&gt;Omics Group&lt;/a&gt;, classified by the librarian &lt;a href="http://scholarlyoa.com/about/"&gt;Jeffrey Beall&lt;/a&gt; as a "&lt;a href="http://scholarlyoa.com/2015/01/02/bealls-list-of-predatory-publishers-2015/"&gt;predatory publisher&lt;/a&gt;". And they are dozens of postprints!!! Even more weird, they are all papers about this "mystical phenomenon" called the "Trivedi effect&lt;span style="color: #7f7f7f; font-family: Verdana, Arial, _sans; font-size: 11.6667px; line-height: 25px;"&gt;®&lt;/span&gt;". In the words of &lt;a href="http://www.trivedieffect.com/"&gt;Mahendra Trivedi&lt;/a&gt;, the owner of the trademark, discoverer and "Trivedi Master&lt;span style="color: #7f7f7f; font-family: Verdana, Arial, _sans; font-size: 11.6667px; line-height: 25px;"&gt;™&lt;/span&gt;":&lt;br /&gt;&lt;br /&gt;'&lt;span style="color: #7f7f7f; font-family: Verdana, Arial, _sans; font-size: 14px; line-height: 25px;"&gt;The Trivedi Effect&lt;/span&gt;&lt;sup style="color: #7f7f7f; font-family: Verdana, Arial, _sans; line-height: 25px;"&gt;®&lt;/sup&gt;&lt;span style="color: #7f7f7f; font-family: Verdana, Arial, _sans; font-size: 14px; line-height: 25px;"&gt;&amp;nbsp;is a natural phenomenon that exists within our universe. It is a Divine, intelligent energy that is harnessed by Mahendra Trivedi (or a Trivedi Master&lt;/span&gt;&lt;sup style="color: #7f7f7f; font-family: Verdana, Arial, _sans; line-height: 25px;"&gt;™&lt;/sup&gt;&lt;span style="color: #7f7f7f; font-family: Verdana, Arial, _sans; font-size: 14px; line-height: 25px;"&gt;) and has the ability to transform all living organisms and nonliving materials at the atomic level so as to surpass the ordinary and function at their most potent and unlimited potential for greatness.&lt;/span&gt;'&lt;br /&gt;&lt;br /&gt;Well, uh, this is not the usual academic, scientific report of facts. So, I care not about Omics Group being 'predatory' or if the "Trivedi effect&lt;span style="color: #7f7f7f; font-family: Verdana, Arial, _sans; font-size: 11.6667px; line-height: 25px;"&gt;®&lt;/span&gt;" works this way or that. In my view, Omics journals are of low quality, regardless of being anything else, and these papers seem to be commercial advertising disguised as "academic". I am not very pleased to see my own publications posted alongside this kind of material. I thought Figshare would have an editorial check to ensure the overall quality of their repository. This is the kind of occurrence that makes serious researchers unease to use some online service.&lt;br /&gt;&lt;br /&gt;In my previous evaluation, I was too tough with &lt;a href="http://f1000research.com/"&gt;F1000research&lt;/a&gt;, and I am aware that it has indeed &lt;a href="http://scholarlyoa.com/?s=f1000research"&gt;problems&lt;/a&gt;&amp;nbsp;with content and editorial checking, but I bet this kind of stuff would never be accepted by F1000research, let alone be publicized in its main page! An advice to researchers: choose wisely the online channel for your academic material. Some "neighbors" are quite bothersome. &lt;br /&gt;&lt;br /&gt;Update (01/17/2016): to my happiness, all troublesome uploads about the "Trivedi Effect" were most likely withdrawn from figshare. A quick search in its repository for these terms has got no results. Thank you, figshare team!</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1879809826225422165'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1879809826225422165'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2016/01/figshare-receives-postprints-of.html' title='Figshare received (and deleted) postprints of &apos;predatory&apos; journals about a &apos;mystical effect&apos; (updated)'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/-w6vEEIldTl4/VofBpt5dUgI/AAAAAAAAgMY/VyoVw3_lkmk/s72-c/fig-omics.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8581918562410676622</id><published>2015-12-18T13:43:00.000-03:00</published><updated>2015-12-18T18:30:35.633-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='crime virtual'/><category scheme='http://www.blogger.com/atom/ns#' term='journal hijack'/><category scheme='http://www.blogger.com/atom/ns#' term='editoras predatórias'/><category scheme='http://www.blogger.com/atom/ns#' term='fraude eletrônica'/><category scheme='http://www.blogger.com/atom/ns#' term='plágio'/><category scheme='http://www.blogger.com/atom/ns#' term='fraude acadêmica'/><category scheme='http://www.blogger.com/atom/ns#' term='predatory publishers'/><category scheme='http://www.blogger.com/atom/ns#' term='sequestro de periódico científico'/><title type='text'>Revista científica do Brasil sequestrada!!</title><content type='html'>No controverso blog de Jeffrey Beall foi &lt;a href="http://scholarlyoa.com/2015/12/15/mit-journal-hijacked/" target="_blank"&gt;publicado&lt;/a&gt;, há 3 dias, a notícia de que um periódico científico brasileiro foi &lt;a href="https://pt.wikipedia.org/wiki/Sequestro_de_peri%C3%B3dico_cient%C3%ADfico" target="_blank"&gt;sequestrado&lt;/a&gt;. A fraude eletrônica em jornais ou revistas científicas é um fenômeno recente, que tem trazido preocupação crescente aos editores de periódicos &lt;a href="http://blog.scielo.org/blog/2014/03/31/a-principio-era-os-plagios-agora-tambem-papers-automaticos-falsos/" target="_blank"&gt;conceituados&lt;/a&gt;. Neste meio de "novidades" na publicação científica, o sequestro de periódicos é um dos irmãos mais novos. Aparentemente, o primeiro periódico a ser sequestrado foi um jornal suíço publicado apenas em forma impressa, sem versão digital, em 2012. De lá para cá, muitas dezenas de exemplos desta nova modalidade de fraude editorial científica tem sido descobertas.&lt;br /&gt;&lt;br /&gt;A última notícia é esta do blog de Beall que dá conta do sequestro da Revista Brasileira de Medicina do Esporte, ó&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;rgão oficial da &amp;nbsp;Sociedade Brasileira de Medicina do Exercício e do Esporte, fundada em 1995, e principal veículo de divulgação da produção científica nas áreas da Medicina do Esporte e das Ciências do Exercício em nosso país, de acordo com a sua página &lt;a href="http://rbme.org/historia" target="_blank"&gt;oficial&lt;/a&gt;. Beall relata a denúncia da&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;div style="text-align: center;"&gt;&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;&lt;a href="http://1.bp.blogspot.com/-VCkg-BRgDkI/VnLkqs1eakI/AAAAAAAAgME/-Cc2uR0H-Gk/s1600/vero.png" imageanchor="1"&gt;&lt;img border="0" height="185" src="http://1.bp.blogspot.com/-VCkg-BRgDkI/VnLkqs1eakI/AAAAAAAAgME/-Cc2uR0H-Gk/s400/vero.png" width="400" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;Acima, o logo da revista verdadeira, abaixo, a versão falsa.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="https://scholarlyoa.files.wordpress.com/2015/12/revista-brasileira-de-medicina-do-esporte.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="https://scholarlyoa.files.wordpress.com/2015/12/revista-brasileira-de-medicina-do-esporte.jpg" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;existência de uma cópia &lt;i&gt;fake&lt;/i&gt;, usando o mesmo nome e ISSN da revista brasileira configurando o sequestro. Não tenho idéia se os editores da revista ou o staff do Scielo sabem deste cybercrime em andamento. Aos pesquisadores brasileiros recomendamos cuidado e checar cuidadosamente se a revista para a qual estão submetendo um trabalho é aquilo que diz ser!&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: inherit;"&gt;&lt;span style="font-size: 15px; line-height: 21px;"&gt;A partir de hoje, receberei e reportarei relatos de problemas dessa natureza com revistas brasileiras, fraudes, sequestros, plágio, publicações predatórias. Os interessados em denunciar casos podem enviá-los para meu email (heldercfelix@gmail.com) ou meu twitter (@cmprsk).&lt;/span&gt;&lt;/span&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8581918562410676622'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8581918562410676622'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/12/revista-cientifica-do-brasil-sequestrada.html' title='Revista científica do Brasil sequestrada!!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/-VCkg-BRgDkI/VnLkqs1eakI/AAAAAAAAgME/-Cc2uR0H-Gk/s72-c/vero.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6679960266040497065</id><published>2015-12-17T12:01:00.001-03:00</published><updated>2015-12-17T12:01:32.329-03:00</updated><app:control xmlns:app='http://purl.org/atom/app#'><app:draft>yes</app:draft></app:control><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Fosfoetanolamina: o que é real?</title><content type='html'>Não é preciso apresentar a fosfoetanolamina, uma substância cujo nome vem sendo tão divulgado quanto pouco compreendido.</content><link rel='related' href='http://f1000research.com/posters/4-1370#.Vmiva0r4OTY.blogger' title='Fosfoetanolamina: o que é real?'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6679960266040497065'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6679960266040497065'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8134695793632940032</id><published>2015-12-17T11:56:00.000-03:00</published><updated>2015-12-17T17:40:27.350-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='Jeffrey Beall'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='editoras predatórias'/><category scheme='http://www.blogger.com/atom/ns#' term='publicação científica'/><category scheme='http://www.blogger.com/atom/ns#' term='Scholarly Open Access'/><category scheme='http://www.blogger.com/atom/ns#' term='via dourada'/><category scheme='http://www.blogger.com/atom/ns#' term='predatory publishers'/><category scheme='http://www.blogger.com/atom/ns#' term='acesso aberto'/><title type='text'>Recebendo emails de jornais científicos falsos ou de qualidade duvidosa - ClinMedlibrary.org</title><content type='html'>Hoje, em dia, a rotina de muitos pesquisadores brasileiros e de outros países da América Latina é perder um tempo considerável abrindo, avaliando e deletando emails com convites de publicação em jornais de editoras de qualidade desconhecida ou duvidosa. Algumas destas editoras, a maioria publicando "periódicos" de acesso aberto e que cobram taxas de "processamento de artigos" aos autores, são chamados coletivamente pelo bibliotecário Jeffrey Beall de "&lt;a href="http://scholarlyoa.com/publishers/" target="_blank"&gt;predatory publishers&lt;/a&gt;". Embora &lt;a href="http://circuitoacademico.com.br/2015/08/13/fast-food-nao-obrigado/" target="_blank"&gt;criticado&lt;/a&gt; por muitos pelas suas posições radicalmente contra o acesso aberto (via dourada) e acusado de &lt;a href="http://blog.scielo.org/blog/2015/08/04/jeffrey-beall-e-as-listas-negras/" target="_blank"&gt;preconceito&lt;/a&gt; contra países do mundo em desenvolvimento, sua lista é rotineiramente checada por pesquisadores do mundo inteiro, preocupados em não desperdiçar tempo e recursos.&lt;br /&gt;&lt;br /&gt;&lt;div style="text-align: center;"&gt;&lt;a href="http://3.bp.blogspot.com/-OQ5AcJm9FlI/VnLB_0pjYTI/AAAAAAAAgLo/jC7dKv0TMDI/s1600/soa.png" imageanchor="1"&gt;&lt;img border="0" height="95" src="http://3.bp.blogspot.com/-OQ5AcJm9FlI/VnLB_0pjYTI/AAAAAAAAgLo/jC7dKv0TMDI/s400/soa.png" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;Cabeçalho do &lt;a href="http://scholarlyoa.com/" target="_blank"&gt;blog&lt;/a&gt; de Jeffrey Beall.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Não existem iniciativas oficiais de instituições, governos ou mesmo de outros particulares que se assemelhem à de Beall. Por enquanto, ele continua a ser o único a "clamar no deserto" contra as publicações científicas de qualidade duvidosa e cunho desproporcionalmente comercial. Enquanto isso, as caixas de entrada de pesquisadores por todo o Brasil são inundadas com propraganda de caráter malicioso oriunda destas "entidades".&lt;br /&gt;&lt;br /&gt;Essa semana, recebi o email que reproduzo aqui. Devido a minha experiência anterior em receber e me livrar de &lt;b&gt;editoras predatórias&lt;/b&gt;, desconfiei imediatamente da correspondência. Em geral, não é difícil desconfiar: são emails pouco profissionais, com linguagem com erros flagrantes ou pouco técnica, ou mesmo usando terminologia estranha à pesquisa científica. Além disso, sua estrutura costuma ser repetitiva (muitas "editoras predatórias", na verdade, são nomes de fachadas para os mesmos grupos de "empresários"), quando não simplesmente copiada &lt;i&gt;ad literam&lt;/i&gt;. Uma análise mais detalhada, em geral, mostra que o nome do remetente é de fantasia, não se trata de uma pessoa real (às vezes, o nome é tão &lt;i&gt;sui generis&lt;/i&gt; que sua característica ficcional é óbvia). Além disso, uma busca rápida na internet pelo endereço notificado mostra resultados que vão de estranhos a hilários (este ano, recebi uma comunicação que veio, aparentemente, de um lar de idosos na Inglaterra - velhinhos bem ativos!).&lt;br /&gt;&lt;br /&gt;Este foi o email que recebi:&lt;br /&gt;&lt;div style="text-align: center;"&gt;&lt;a href="http://4.bp.blogspot.com/-4fyVo1bL11c/VnLGdWSq20I/AAAAAAAAgL0/F15zBrhh-tI/s1600/email.png" imageanchor="1"&gt;&lt;img border="0" src="http://4.bp.blogspot.com/-4fyVo1bL11c/VnLGdWSq20I/AAAAAAAAgL0/F15zBrhh-tI/s1600/email.png" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;Na verdade, este exemplar não parece particularmente rico em erros de linguagem, mas é muito similar a outros emails que já recebi. Essa similaridade foi que me levou a desconfiar. meu próximo passo foi checar se esse jornal ou sua editora está listada por Beall e se o mesmo tem alguma informação útil. Não demorei a encontrar. Este "jornal" está listado como um dos 16 publicados pela editora predatória &lt;a href="http://clinmedjournals.org/" target="_blank"&gt;ClinMed International Library&lt;/a&gt;, cuja sede é desconhecida (o registro do site está no nome do provedor de proxy GoDaddy.com, que vende domínios por baixos preços). O endereço, no entanto, remete-nos a uma pequena imobiliária que, além de ser sede de um conglomerado editorial, é também endereço de duas "universidades", como denunciado nos comentários da &lt;a href="http://scholarlyoa.com/2014/09/09/open-access-publisher-sends-extremely-annoying-spam-emails/#more-4151" target="_blank"&gt;postagem&lt;/a&gt; de Beall.&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;Desde a publicação de Beall, esta editora predatória passou, aparentemente, a contratar o auxílio de alguém para melhorar sua linguagem (o que não impediu de manter o endereço falso e com informações estranhas - county?!?) e alterou o domínio de .com para .org.&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left;"&gt;Independentemente de sua opinião sobre o blog de Beall e sua "lista negra", essa empresa parece ser muito duvidosa e de qualidade científica questionável. Sugiro que nunca publique, editore ou revise para esta empresa. Isso vai apenas manchar seu bom nome. Nem ao menos responda seus emails, nem que seja para pedir a sua retirada de sua lista de envio (isso funciona ao contrário, eles passam a enviar mais, pois sabem que você é um destinatário real!). Apenas bloqueie os emails deles em seu programa/site de email.&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;Um bom dia de trabalho!&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8134695793632940032'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8134695793632940032'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/12/recebendo-emails-de-jornais-cientificos.html' title='Recebendo emails de jornais científicos falsos ou de qualidade duvidosa - ClinMedlibrary.org'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/-OQ5AcJm9FlI/VnLB_0pjYTI/AAAAAAAAgLo/jC7dKv0TMDI/s72-c/soa.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-211445703380933841</id><published>2015-12-15T18:02:00.000-03:00</published><updated>2016-01-02T10:31:17.519-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='Figshare'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='slides'/><category scheme='http://www.blogger.com/atom/ns#' term='posters'/><category scheme='http://www.blogger.com/atom/ns#' term='publication'/><title type='text'>Usando o figshare</title><content type='html'>Bem &lt;a href="http://pharmak.blogspot.com/2013/09/gliomas-em-criancas-aula-de-atualizacao.html" target="_blank"&gt;antes&lt;/a&gt; de me interessar por repositórios institucionais para pôsteres e slides, eu já havia começado a depositá-los no &lt;a href="http://pt.slideshare.net/?ss"&gt;Slideshare&lt;/a&gt;, serviço de armazenamento na nuvem que permite a visualização de slides em sites, blogs, redes sociais, etc. Esta funcionalidade do Slideshare sempre me agradou muito. Ele tinha tudo o que eu achava interessante para difusão de idéias: integração automática com o LinkedIn e outras redes sociais, snippets para incorporação fácil em blogs, páginas pessoais, institucionais e outras, além de uma página pessoal que centralizava todos os meus carregamentos. Além de todas estas facilidades, funcionalidades de edição online e análise de tráfego. Mas o Slideshare não é uma via de publicação. Seu conteúdo não tem facilidades para citação científica.  &lt;br /&gt;Quando conheci o &lt;a href="http://f1000research.com/"&gt;F1000Research&lt;/a&gt;, achei sua proposta interessante e que preenchia uma lacuna nesta forma não tradicional de publicação. Logo notei várias diferenças em relação ao Slideshare: à parte o armazenamento público de uma apresentação, todo o resto das funcionalidades encontradas no Slideshare faltam no F1000Research. A maior diferença é que nesta última plataforma, o pôster recebe um DOI citável. Bem, buscando alternativas, encontrei uma plataforma que reúne o melhor do F1000Research com o melhor (quase tudo) do Slideshare: o &lt;a href="https://figshare.com/"&gt;Figshare&lt;/a&gt;.  &lt;br /&gt;Ao postar apresentações de slides naquela plataforma, fiquei impressionado com sua interface simples e direta, permitindo uma submissão em poucos minutos. É possível escolher marcadores (ao contrário do F1000Research, o que me rendeu um &lt;a href="http://pharmak.blogspot.com/2015/12/minha-experiencia-com-f1000research.html"&gt;problema&lt;/a&gt;), escolher o nível de compartilhamento e a licença de publicação, como no Slideshare (no F1000Research as publicações são sempre públicas e com licença CC-BY). Além disso, tem espaço para metadados, controle completo de versões (pode ser editado), aplicativo uploader para desktop, permite escolher se vai usar um DOI ou não, entre outras funcionalidades. Parece-me que a única coisa que o Slideshare tem que o Figshare não tem são as ferramentas de análise de tráfego.&lt;br /&gt;Não há limites quanto à linguagem e tipo de material a ser submetido, EXCETO que precisa necessariamente ser material acadêmico. Preprints, artigos publicados (desde que não firam direitos autorais), teses, dissertações, monografias, aulas, notas, dados de pesquisa, qualquer coisa relacionada ao mundo da academia. Não é permitido uso comercial ou corporativo, nem propaganda, ou material considerado inapropriado. O conteúdo é publicado imediatamente. Posteriormente, qualquer coisa que infrinja os termos de uso é deletado sem aviso. &lt;br /&gt;O Figshare tem uma página pessoal com suas publicações e snippets para incorporação em sites e blogs e tem facilidades para redes sociais. Veja aqui embaixo uma das aulas que publiquei no Figshare: &lt;br /&gt;&lt;iframe frameborder="0" height="426" src="https://widgets.figshare.com/articles/2007588/embed?show_title=1" width="568"&gt;&lt;/iframe&gt; O número de DOI atribuído pelo Figshare é do DataCite, e não do CrossRef, se isso fizer realmente alguma diferença. Concluindo, em minha opinião, a plataforma acadêmica ideal para depositar material alternativo, incluindo pôsteres, slides, textos variados, etc é o Figshare. Apesar das características positivas do F1000Research, sua plataforma tem muito que crescer para fazer frente ao Figshare.&lt;br /&gt;&lt;br /&gt;Atualização: infelizmente, conheci posteriormente uma característica negativa do Figshare. Veja &lt;a href="http://pharmak.blogspot.com/2016/01/figshare-receives-postprints-of.html"&gt;aqui&lt;/a&gt;&amp;nbsp;na minha postagem.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/211445703380933841'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/211445703380933841'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/12/usando-o-figshare.html' title='Usando o figshare'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-111998937939690888</id><published>2015-12-13T17:16:00.000-03:00</published><updated>2015-12-13T17:16:20.654-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='slides'/><category scheme='http://www.blogger.com/atom/ns#' term='posters'/><category scheme='http://www.blogger.com/atom/ns#' term='publication'/><category scheme='http://www.blogger.com/atom/ns#' term='F1000Research'/><title type='text'>Minha experiência com F1000Research: pôsteres e slides</title><content type='html'>Há poucos dias, &lt;a href="http://pharmak.blogspot.com/2015/12/minha-experiencia-com-o-peerj-preprints.html"&gt;falei&lt;/a&gt; da minha experiência de publicação de preprints com o PeerJ e porque acredito nessa modalidade de divulgação científica. Agora, vou apresentar outra nova forma de apresentar os resultados científicos: a publicação de pôsteres e slides no F1000Research. Este serviço é uma plataforma de acesso aberto para a publicação de resultados de cientistas da área de ciências biológicas e da saúde. Seu principal diferencial é a suposta não interferência de um corpo editorial nas publicações. O staff do &lt;a href="http://f1000research.com/"&gt;F1000Research&lt;/a&gt; afirma que ele não é um periódico, ou um jornal. Eles usam o termo "plataforma de publicação" para dar a entender essa diferença, mas ainda sim deixar vago o suficiente para permitir variadas interpretações. As publicações passam por uma avaliação editorial sucinta e são publicadas rapidamente (às vezes, em poucas horas!) após a submissão. A avaliação inicial é obrigatória e serve para filtrar casos de desvio flagrante das regras editoriais. Não existe revisão por pares pré-publicação. Apesar disso, o F1000Research insiste que suas publicações "não são preprints". Com efeito, uma vez que você publica seu material lá, não pode mais editá-lo, diferentemente do &lt;a href="https://peerj.com/preprints/"&gt;PeerJ Preprints&lt;/a&gt;, onde essa funcionalidade ainda persiste.&lt;br /&gt;No caso de artigos científicos, ocorre uma revisão por pares "pós-publicação" e identificada. Os relatos das experiências com o F1000Research são variados, indo desde aqueles que adoraram, até aqueles que jamais submeterão novamente. O bibliotecário Jeffrey Beall já &lt;a href="http://scholarlyoa.com/2015/01/06/im-following-a-fringe-science-paper-on-f1000research/"&gt;citou&lt;/a&gt; o F1000Research em seu blog Scholarly Open Access, pela aceitação de um possível relato fronteiriço entre a ciência e a fraude ("fringe paper"). Tal ocorrência não deve, na verdade, denegrir aquela plataforma de publicação, uma vez que sua política é publicar primeiro e revisar depois. Checando a &lt;a href="http://f1000research.com/articles/3-309/"&gt;publicação&lt;/a&gt;, nós podemos ver que ela recebeu 1 aprovação e 2 rejeições, levando a entender que a avaliação de Beall é correta: pode ser um "fringe paper". Devido á natureza do processo editorial do F1000Research, todavia, isso não significa que esta plataforma tem menor qualidade. Artigos de qualidade questionável &lt;i&gt;a posteriori&lt;/i&gt; também têm sido publicados em muitos jornais tradicionais e a refutação de suas afirmações faz parte do desenvolvimento da ciência como um todo.&lt;br /&gt;Eu particularmente gosto da proposta de publicar todos os pôsteres apresentados em congressos num repositório. No momento, este serviço do F1000Research é gratuito e sem limites. Podem ser publicados pôsteres em qualquer língua, porém os metadados devem ser descritos em inglês. Após a submissão, uma avaliação é realizada para homogeneidade editorial, marcadores são atribuídos e o pôster é publicado (fica disponível publicamente, com DOI e pode ser citado). Este tipo de proposta tem a vantagem de promover a disseminação de dados ainda preliminares, mas que podem ser úteis. Além disso, pode ajudar a diminuir o viés de publicação ao estimular a publicação de dados negativos que, após a apresentação em eventos, raramente são publicados em periódicos convencionais. Os pôsteres publicados no F1000Research não são indexados nas plataformas mais populares, como o Google Acadêmico.&lt;br /&gt;O processo de submissão foi bem simples e rápido. Existe a opção de acrescentar um resumo do pôster, além do título e palavras chaves. Também informa-se onde e quando o trabalho foi apresentado. O tempo entre a submissão e sua aprovação variou, no meu caso, de 6 a 60 horas, ou próximo disso. Nenhuma de minhas submissões foi rejeitada, mas alguns resumos (metadados) em inglês foram truncados, geralmente deixando a introdução e a conclusão e deletando o resto. Talvez tenha sido por problemas na redação em inglês, mas acredito que o pessoal do F1000Research não tem homogeneidade de julgamento neste ponto, pois todos os resumos foram escritos mais ou menos no mesmo estilo e inclusive com alguns textos semelhantes, devido à proximidade entre os temas abordados. Mesmo assim, enquanto alguns foram publicados sem nenhuma alteração, outros foram truncados na maior parte do texto. Outra coisa que notei foi uma variação na atribuição de marcadores, prerrogativa do pessoal do F1000Research (no PeerJ, por exemplo, o autor escolhe). A escolha de marcadores pareceu, às vezes, aleatória. Em alguns de meus pôsters, o marcador neuro-oncologia foi corretamente atribuído. Em cinco deles, um número excessivo para quem se propôe a um processo com poucos erros, o marcador escolhido foi "tumores de cabeça e pescoço". Isso me obrigou a entrar em contato com o suporte por duas vezes, e na segunda ocorreu uma demora na resposta. Embora tenha sido um contratempo, não diminuiu muito a minha impressão sobre a qualidade do F1000Research.&lt;br /&gt;Em conjunto, classifico minha experiência com a publicação de pôsteres (e slides) no F1000Research positiva. Esta proposta é interessante e existem vários serviços alternativos surgindo, como o Figshare. Pretendo avaliar outros repositórios para pôsteres, slides e outros materiais de pesquisa geralmente não publicados de forma tradicional. &lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;figure&gt;  &lt;img alt="f1000" src="http://2.bp.blogspot.com/-X3fVz7UFgMk/Vm3MY8S9OGI/AAAAAAAAgK0/GC7tvgVlPLQ/s1600/f1000.png" width="550" /&gt;&lt;img border="0" /&gt;  &lt;figcaption&gt;&lt;br /&gt;Minhas submissões já publicadas no F1000Research.&lt;/figcaption&gt;&lt;/figure&gt;&lt;br /&gt;Link para o último pôster que publiquei naquela plataforma: &lt;a href="http://f1000research.com/posters/4-1370#.Vmiva0r4OTY.blogger"&gt;Descriptive longitudinal study of pediatric patients with primary brain tumors: establishment... - F1000Research&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/111998937939690888'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/111998937939690888'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/12/minha-experiencia-com-f1000research.html' title='Minha experiência com F1000Research: pôsteres e slides'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-X3fVz7UFgMk/Vm3MY8S9OGI/AAAAAAAAgK0/GC7tvgVlPLQ/s72-c/f1000.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2956862652730329693</id><published>2015-12-13T13:24:00.002-03:00</published><updated>2015-12-17T17:50:34.821-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='sildenafil'/><category scheme='http://www.blogger.com/atom/ns#' term='tratamento'/><category scheme='http://www.blogger.com/atom/ns#' term='linfangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='anomalias vasculares'/><title type='text'>Sildenafila para linfangiomas infantis: a promessa não cumprida</title><content type='html'>Em uma &lt;a href="http://pharmak.blogspot.com/2012/02/novo-tratamento-para-linfangiomas-da.html" target="_blank"&gt;postagem&lt;/a&gt; anterior, relatei uma &lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMc1112482#t=article" target="_blank"&gt;publicação&lt;/a&gt;&amp;nbsp;de 2012 no prestigiado jornal New England Journal of Medicine (NEJM) que dava conta de 3 casos de crianças com graves &lt;a href="https://pt.wikipedia.org/wiki/Linfangioma" target="_blank"&gt;mal-formações linfáticas&lt;/a&gt;&amp;nbsp;(ML) tratados com &lt;a href="https://pt.wikipedia.org/wiki/Sildenafila" target="_blank"&gt;sildenafila&lt;/a&gt;, uma droga inibidora de fosfodiesterase tipo 5 que aumenta a produção de óxido nítrico em alguns tecidos. Essa medicação é usada no tratamento de disfunção erétil em adultos e para tratar hipertensão pulmonar em bebês (aprovada desde 2005). A dra. Glenda Swetman relatou o caso de um bebê que recebeu o diagnóstico de uma ML torácica com 10 semanas de vida. Aos nove meses, a criança recebeu o diagnóstico de hipertensão pulmonar, causando insuficiência cardíaca. A sildenafila foi iniciada na dose usual e, num prazo de 4 meses, tanto a ML quanto a hipertensão pulmonar haviam se resolvido completamente. Este caso animou a dermatologista de Stanford a tratar com sildenafila outras duas crianças com ML refratárias. Em ambos os casos, ocorreu resposta parcial. Essa publicação lembrou a todos imediatamente da descoberta recente do uso de beta-bloqueadores para tratar &lt;a href="https://pt.wikipedia.org/wiki/Hemangioma"&gt;hemangiomas&lt;/a&gt; infantis, também &lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMc0708819" target="_blank"&gt;reportada&lt;/a&gt; no NEJM. A expectativa que se seguiu, no entanto, não obteve como resposta um sem número de relatos de casos bem-sucedidos e trabalhos científicos mostrando eficácia, como no caso do propranolol.&lt;br /&gt;Este ano, em julho, Koshy &lt;i&gt;et al&lt;/i&gt; publicaram no &lt;a href="http://linkinghub.elsevier.com/retrieve/pii/S0165-5876(15)00159-7"&gt;International Journal of Pediatric Otorhinolaryngology&lt;/a&gt; os resultados de um ensaio clínico piloto que testou a eficácia da sildenafila em cinco crianças com ML refratárias a outros tratamentos. Usando medidas objetivas com imagens de ressonância magnética, o grupo mostrou que, neste pequeno conjunto de pacientes, a sildenafila não mostrou nenhum efeito. Entre 2012 e este ano, alguns outros relatos de caso foram publicados, mostrando efeitos variáveis, geralmente positivos, em pacientes com ML graves, refratárias a outros tratamentos. Um estudo &lt;i&gt;open-label&lt;/i&gt; que envolveu sete crianças com ML de difícil tratamento foi relatado ano passado por &lt;a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024322/"&gt;Danial &lt;i&gt;et al&lt;/i&gt;&lt;/a&gt;. Os autores concluíram que a sildenafila "pode reduzir o volume e sintomas de ML em crianças". Ao examinarmos mais de perto os resultados reportados, porém, podemos ver que, de 4 crianças que obtiveram "redução" das ML, apenas uma criança mostrou resposta com redução de mais de 25% da lesão. O critério normalmente padronizado para medir a resposta de lesões tumorais a um determiando tratamento estipula que uma resposta menor ou igual a 25% deve ser considerada "doença estável". Dessa forma, das sete crianças reportadas neste trabalho, uma análise crítica mostra apenas uma resposta, de cerca de 30% apenas.  &lt;br /&gt;Existe uma grande dificuldade ao se analisar resultados como esses: é necessário levar em consideração a evolução natural da doença. Casos de regressão "espontânea" de ML, às vezes gigantes, não são incomuns, e correspondem ao esvaziamento de suas cavidades cheias de linfa. Como as ML não são realmente neoplasias, como o termo "linfangioma" pode erroneamente induzir a se acreditar, não ocorre proliferação celular em seus tecidos. Um tratamento farmacológico poderia afetar seu volume se modificasse o modo como a lesão se enche ou se esvazia de linfa, algo que alguns trabalhos preliminares mostram que o &lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMc1013217?viewType=Print" target="_blank"&gt;propranolol&lt;/a&gt; poderia fazer. Mesmo assim, daí a se afirmar que um tratamento é "eficaz" vai uma longa distância. Especialmente quando se espera que parte das lesões reduza sem tratamento. Avaliações equivocadas semelhantes já levaram à proposição de tratamentos estapafúrdios para &lt;a href="https://pt.wikipedia.org/wiki/Hemangioma"&gt;hemangioma&lt;/a&gt;, por exemplo, um tumor vascular que é autolimitado e que somente necessita de tratamento em casos complicados.&lt;br /&gt;&lt;br /&gt;&lt;figure&gt;  &lt;img alt="sildenafil" height="400" src="https://upload.wikimedia.org/wikipedia/commons/9/97/Viagra_in_Pack.jpg" width="335" /&gt;&lt;img border="0" /&gt;  &lt;figcaption&gt;Sildenafila não tem efeito em linfangiomas (fonte da foto: Wikipedia).&lt;/figcaption&gt;&lt;/figure&gt;&lt;br /&gt;Assim, a não ser com a realização de estudos científicos desenhados especialmente para descobrir exatamente o efeito de uma medicação sobre uma doença como essa, não é possível concluir sobre a eficácia de nenhum tratamento. Neste caso específico, apesar de um pequeno número de casos relatados com aparente efeito positivo (que poderiam ter se resolvido "espontaneamente"), este ensaio clínico recente joga água na fervura do interesse pela sildenafila para o tratamento de linfangiomas da infância. Tal fato, ficando patente 3 anos após a publicação inicial do NEJM, nos leva a interrogar: o que foi feito das crianças que porventura foram tratadas com sildenafila ao redor do mundo? Alguma terá apresentado algum efeito colateral? Terá alguma sofrido atraso na instituição de um tratamento realmente eficaz? Isso jamais saberemos, devido a uma das características mais negativas da ciência: o viés de publicação. Isto significa, de forma bem direta, que nem sempre os resultados cientificamente "comprovados" correspondem à realidade. O principal responsável por esta distorção que tem magnitude desconhecida é a não publicação dos chamados "resultados negativos". Em bom português: tudo o que não dá certo. Fontes de financiamento e pesquisadores têm menos estímulo para submeter resultados negativos à publicação. Adicionalmente, os editores dos periódicos científicos costumam aceitar raramente resultados negativos, pois preferem a mensagem "achamos algo incrível" estampada em seus jornais do que "não descobrimos nada, não deu resultado". A mídia leiga é ainda mais influenciada por este tipo de viés, que é amplificado sem a menor discussão crítica. Então, a mensagem importante: quando ouvir na televisão ou na internet a notícia sobre um "novo tratamento", primeiro fale com seu médico, ou médicos. Do contrário, arrisca-se a usar um tratamento que depois se mostrará ineficaz ou, pior, danoso.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2956862652730329693'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2956862652730329693'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/12/sildenafil-para-linfangiomas-infantis.html' title='Sildenafila para linfangiomas infantis: a promessa não cumprida'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-347813578717112270</id><published>2015-12-07T00:10:00.001-03:00</published><updated>2015-12-30T22:07:35.085-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='arXiv'/><category scheme='http://www.blogger.com/atom/ns#' term='via verde'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='auto-arquivamento'/><category scheme='http://www.blogger.com/atom/ns#' term='publicação'/><category scheme='http://www.blogger.com/atom/ns#' term='bioRxiv'/><category scheme='http://www.blogger.com/atom/ns#' term='Preprints'/><category scheme='http://www.blogger.com/atom/ns#' term='PeerJ'/><category scheme='http://www.blogger.com/atom/ns#' term='revisão por pares'/><category scheme='http://www.blogger.com/atom/ns#' term='ciências biológicas e da saúde'/><category scheme='http://www.blogger.com/atom/ns#' term='acesso aberto'/><title type='text'>Minha experiência com o PeerJ Preprints</title><content type='html'>&lt;div style="text-indent: 30px;"&gt;Sempre tive curiosidade sobre o repositório de &lt;i&gt;preprints&lt;/i&gt; das ciências exatas, o &lt;a href="http://arxiv.org/"&gt;arXiv&lt;/a&gt; (lê-se 'arquaive'). Criado por &lt;a href="https://en.wikipedia.org/wiki/Paul_Ginsparg"&gt;Paul Ginsparg&lt;/a&gt;, um físico da Universidade de Cornell que é mundialmente conhecido por sua gênese do repositório &lt;i&gt;open access&lt;/i&gt; de arquivos de física, originalmente sediado no &lt;a href="http://www.nature.com/nature/debates/e-access/Articles/ginsparg.html"&gt;Los Alamos National Laboratory (LANL)&lt;/a&gt;. Ele lançou a primeira versão do que viria a ser o arXiv em 14 de agosto de 1991 (coincidentemente, no dia de meu aniversário de 20 anos - sabe o que isso significa? Acertou, NADA!). &lt;br /&gt;&lt;br /&gt;&lt;i&gt;Preprints&lt;/i&gt; são documentos ainda não publicados, que não passaram pela revisão por pares e processo editorial de periódicos científicos. São, comumente, considerados rascunhos, versões preliminares de trabalhos que, posteriormente, serão avaliados apropriadamente para publicação em revistas convencionais. A origem dos preprints é antiga. Habitualmente, os físicos sempre trocaram correspondências entre si para discutir detalhes de trabalhos em andamento, ou para pedir auxílio para corrigir um manuscrito (eu quero dizer &lt;i&gt;manuscrito&lt;/i&gt; mesmo!). Entre mas cartas famosas de físicos, as mais conhecidas talvez sejam as de &lt;a href="https://pt.wikipedia.org/wiki/Isaac_Newton"&gt;Newton&lt;/a&gt; (por causa das quais nós hoje sabemos que ele era um fanático anglicano criacionista, anti-católico e alquimista que, nas horas vagas, descobriu a Gravitação Universal) e as de Einstein. Na era do email. tornou-se comum distribuir &lt;i&gt;preprints&lt;/i&gt; em formato eletrônico, às vezes para muita gente. Com o intuito de padronizar o formato e diminuir o tamanho dos arquivos, os físicos passaram a usar, rotineiramente, arquivos no formato &lt;a href="https://en.wikipedia.org/wiki/TeX"&gt;TeX&lt;/a&gt; ('tek'), criado por Donald Knuth. Mesmo assim, logo as caixas de entrada de emails estavam lotadas de &lt;i&gt;preprints&lt;/i&gt;.  &lt;br /&gt;&lt;br /&gt;Esse problema levou Paul Ginsparg a criar uma caixa de entrada de email centralizada no LANL, acessível a qualquer computador. Rapidamente, o serviço cresceu, adicionando funcionalidades (ftp, gopher, www) e passou a receber preprints de outras áreas além de física: astronomia, matemática, ciência da computação, biologia quantitativa, ciência não linear e, mais recentemente, estatística. Em algumas áreas da física, praticamente todos os artigos publicados passam, antes, pelo arXiv. As motivações para os cientistas publicarem &lt;i&gt;preprints&lt;/i&gt; no arXiv continuam basicamente as mesmas de séculos atrás: solicitar opiniões e revisões de colegas e assegurar a originalidade e prioridade de seus trabalhos. &lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;figure&gt;  &lt;img alt="LANL" height="400" src="https://upload.wikimedia.org/wikipedia/en/8/8f/ArXiv_1994.gif" style="margin-left: 1em; margin-right: 1em;" width="392" /&gt;&lt;img border="0" /&gt;  &lt;figcaption&gt;Fig1. - Tela do arXiv em 1994, navegador Mosaic. Naquela época, formulários em html eram novidade (fonte: Wikipedia).&lt;/figcaption&gt;&lt;/figure&gt;&lt;br /&gt;&lt;br /&gt;&lt;div style="text-indent: 30px;"&gt;A distribuição dos manuscritos arquivados no arXiv é de &lt;a href="https://pt.wikipedia.org/wiki/Acesso_aberto"&gt;acesso aberto&lt;/a&gt; ("open access"). Na verdade, o arXiv foi criado bem antes do surgimento deste termo, e sua existência motivou o movimento de acesso livre de publicações acadêmicas da chamada "Via Verde". Neste modelo, o autor auto-arquiva em formato eletrônico seu trabalho num repositório institucional ou público e o disponibiliza sem custo para download. Isto pode ser feito antes da revisão por pares (caso dos preprints e do arXiv), ou após a revisão por pares e publicação (caso do &lt;a href="https://en.wikipedia.org/wiki/PubMed_Central"&gt;Pubmed Central&lt;/a&gt;). Esta modalidade de acesso aberto foi a proposta original de Steve Harnard no seu blog &lt;a href="https://en.wikipedia.org/wiki/Subversive_Proposal"&gt;&lt;i&gt;Subversive Proposal&lt;/i&gt;&lt;/a&gt;, em 1994, o qual levou à criação dos primeiros repositórios para &lt;a href="https://en.wikipedia.org/wiki/Self-archiving"&gt;auto-arquivamento&lt;/a&gt;. No Brasil, existem alguns repositórios institucionais, como o &lt;a href="http://base.repositorio.unesp.br/"&gt;&lt;b&gt;Repositório Institucional UNESP&lt;/b&gt;&lt;/a&gt;, o &lt;a href="https://pt.wikipedia.org/wiki/Reposit%C3%B3rio_institucional"&gt;&lt;b&gt;LUME - repositório digital da UFRGS&lt;/b&gt;&lt;/a&gt; e o &lt;b&gt;&lt;a href="http://www.teses.ufc.br/tde_busca/index.php"&gt;TEDE - Biblioteca Digital de Teses e Dissertações da UFC&lt;/a&gt;&lt;/b&gt;. Um exemplo: &lt;a href="http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=34"&gt;este&lt;/a&gt; é o link para download da minha dissertação de mestrado, armazenada no TEDE. &lt;br /&gt;&lt;br /&gt;A publicação em acesso aberto, todavia, tomou proporções imprevisíveis, ao ser abraçada por diversas editoras de publicações acadêmicas. Essa modalidade é conhecida como a "Via Dourada" do acesso aberto. Normalmente, empresas como a &lt;a href="https://www.plos.org/"&gt;Public Library of Science (PLOS)&lt;/a&gt; e &lt;a href="http://www.biomedcentral.com/"&gt;Biomed Central&lt;/a&gt; disponibilizam eletronicamente o conteúdo completo de suas publicações sem custos para o leitor. Para cobrir os 'custos editoriais', estas empresas costumam cobrar "taxas de processamento de arquivo", da ordem de centenas a milhares de dólares por manuscrito. Usualmente, estas taxas são cobertas pelas instituições ou órgãos de fomento dos projetos de pesquisa. Críticas têm sido feitas ao peso que estas taxas podem representar ao orçamento de C&amp;amp;T, em contraste com o modelo tradicional, onde o leitor paga pelo trabalho científico. Na verdade, transferiu-se o custo institucional de setor: das bibliotecas para as agências de fomento, mas são as instituições (universidades, centros de pesquisa, etc) que continuam a pagar a maior parte da conta. Alguns dados parecem indicar que, ao contrário do que alguns acham, as publicações de acesso aberto são menos onerosas para o sistema como um todo. Veja &lt;a href="http://blog.scielo.org/blog/2013/09/18/quanto-custa-publicar-em-acesso-aberto/"&gt;esta&lt;/a&gt; postagem sobre o assunto. No Brasil, bem como na maior parte da América Latina, o modelo de acesso aberto é o mais utilizado, graças à plataforma &lt;a href="https://www.scielo.org/"&gt;Scientific Eletronic Library Online (SciELO)&lt;/a&gt;, criada em 1998 em uma parceria entre FAPESP e Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde (BIREME/OPAS/OMS) e que tornou-se a maior provedora de acesso aberto do planeta. Hoje em dia, graças ao SciELO, quase toda a produção científica do Brasil é disponível em acesso aberto.  &lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;figure&gt;  &lt;img alt="arXiv" src="http://3.bp.blogspot.com/-ePTVa6wafTI/VmRbyVYfMnI/AAAAAAAAgJY/UCOTKsx1i5k/s1600/Captura%2Bde%2BTela%2B2015-12-06%2Ba%25CC%2580s%2B11.47.32.png" width="550" /&gt;&lt;img border="0" /&gt;  &lt;figcaption&gt;Fig2. - Tela atual do arXiv, navegador Safari.&lt;/figcaption&gt;&lt;/figure&gt;&lt;br /&gt;&lt;div style="text-indent: 30px;"&gt;Uma experiência recente e algo diferente foi lançada recentemente: o &lt;a href="https://en.wikipedia.org/wiki/PeerJ"&gt;PeerJ&lt;/a&gt;. Esta empresa, criada por nomes egressos de outras empresas do mundo do acesso aberto, como Peter Binfield (PLOS ONE), Jason Hoyt (Mendeley) e Tim O'Reilly, mega-empresário especialista em financiar iniciativas de public ação eletrônica. PeerJ lançou duas novidades: planos vitalícios de publicação (pague uma vez, publique para toda a vida) com preços bem abaixo da média de acesso aberto e um repositório de &lt;i&gt;preprints&lt;/i&gt; para a área da saúde e biologia, o &lt;a href="https://peerj.com/preprints/"&gt;PeerJ Preprints&lt;/a&gt;. Não foi o primeiro repositório desta natureza, mas os arquivos de &lt;i&gt;preprint&lt;/i&gt; em biologia e saúde costumam ter vida curta. Existem  muitas razões para isso, mas a principal, a meu ver, é a ausência de uma tradição de troca de informações não publicadas entre colegas, como existe na física e matemática. Na verdade, a maioria dos cientistas das áreas biológicas e saúde evitam divulgar seus resultados antes da publicação formal. Talvez isso se deva à ênfase muito maior no empirismo do que na modelagem matemática ou lógica, eu não tenho certeza. Talvez, tenha a ver com um perfil básico sociodemográfico de profissionais que acaba senso "selecionado" para trabalhar nesta área. Isto, sem dúvida, é extremamente especulativo, mas a experiência comum indica que existem diferenças sociais entre os cientistas da área de física e matemática e aqueles de biológicas e saúde. De toda forma, os hábitos destas duas "sociedades" informais diferem.  &lt;br /&gt;&lt;br /&gt;Repositórios de preprints para a área de saúde e ciências biológicas incluem o bioRxiv, operado pelo Cold Spring Harbor Laboratory desde novembro de 2013 e com a participação de ninguém menos do que Paul Ginsparg em seu Advisory Board. Outros repositórios: &lt;a href="http://precedings.nature.com/"&gt;Nature Precedings&lt;/a&gt;, que já deixou de receber novos preprints mas ainda está no ar e pode ser consultado, e o PeerJ Preprints. Uma outra iniciativa foi o &lt;a href="http://sciencecommons.org/about/"&gt;Science Commons&lt;/a&gt;, projeto-filho do Creative Commons que pretendia estimular e integrar o uso de licença de acesso aberto para a maior parte do mundo acadêmico. Criado em 2005, o projeto foi reintegrado ao Creative Commons em 2009, na forma de seu portal &lt;a href="http://creativecommons.org/science"&gt;Science&lt;/a&gt;, que tenta centralizar e estimular o uso de licenças CC pelos provedores de conteúdo de acesso aberto. Uma outra iniciativa com nome parecido, mas que nada tinha a ver com o CC foi a &lt;a href="https://en.wikipedia.org/wiki/ScientificCommons"&gt;Scientific Commons&lt;/a&gt;, um agregador de repositórios de acesso aberto. Desde 2013, sua página na internet não está mais ativa. Como se vê, repositórios e iniciativas de &lt;i&gt;preprint&lt;/i&gt; voltadas para áreas que não as servidas pelo arXiv, como saúde e biologia, não costumam ter boa vitalidade por muito tempo. No entanto, a proliferação de provedores de publicações de acesso aberto nesta áreas mostra que os pesquisadores aceitaram muito bem a Via Dourada, apesar de não o terem feito da mesma maneira quanto à Via Verde e auto-arquivamento.  &lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;figure&gt;  &lt;img alt="bioRxiv" src="http://www.biorxiv.org/sites/default/files/bioRxiv_logo.png" height="138" width="400" /&gt;&lt;img border="0" /&gt;  &lt;figcaption&gt;Fig3. - Logo do bioRxiv.&lt;/figcaption&gt;&lt;/figure&gt;&lt;br /&gt;&lt;div style="text-indent: 30px;"&gt;Isso vinha me deixando frustrado nos últimos anos. A falta de interesse de meus colegas na Via Verde e num sistema de &lt;i&gt;preprints&lt;/i&gt; e a ênfase em publicações da Via Dourada com tendências comerciais e sem qualidade (chamadas pelo bibliotecário &lt;a href="https://en.wikipedia.org/wiki/Jeffrey_Beall"&gt;Jeffrey Beall&lt;/a&gt; de &lt;a href="https://en.wikipedia.org/wiki/Predatory_open_access_publishing"&gt;predatórias&lt;/a&gt;) deixava a impressão de que ninguém mais se importava com a pesquisa em si, com a ciência e com o avanço de resultados, mas sim meramente com carreiras acadêmicas vazias. É por isso que defendo os servidores de &lt;i&gt;preprint&lt;/i&gt; na área das ciências biológicas e saúde. Eles estimulam a discussão e a criatividade e aumentam a qualidade geral dos trabalhos. Além disso, desestimulam a proliferação das "editoras" e publicações predatórias. &lt;br /&gt;&lt;br /&gt;Resolvi, assim, me aventurar a postar um trabalho no qual havia me debruçado alguns anos atrás e que estava "na gaveta", esperando tempo para ser novamente desenvolvido. Peguei um manuscrito que estava sendo corrigido e resolvi enviá-lo para o PeerJ Preprints. Logo ao entrar em sua página, notei que sua interface preza pela funcionalidade, com visual limpo e poucos elementos de fácil interação. Parece, na verdade, um simples blog. O processo de cadastramento é rápido e fácil. Todos os autores precisam se cadastrar. Ninguém paga nada nesta fase: a publicação de preprints é gratuita. Na página principal, um &lt;i&gt;preprint&lt;/i&gt; é definido como "um rascunho de um artigo, resumo ou pôster, ainda não submetido ao processo de revisão por pares". Já nas instruções para autores, a redação é sutilmente diferente: "um &lt;i&gt;preprint&lt;/i&gt; é um rascunho ainda não submetido ao processo de revisão por pares, não é uma publicação no prelo, nem um formato eletrônico de um artigo aceito para publicação". Nas instruções mais detalhadas, somos informados que o PeerJ Preprints aceita trabalhos em ciências biológicas, médicas, da saúde e da computação. Não aceita, no entanto, quaisquer trabalhos com implicações terapêuticas ou ensaios clínicos, de qualquer fase. Entre os formatos aceitos, estão artigos de pesquisa, "pôsteres" (as aspas são do original), revisões, opiniões, relatos de caso, etc. Logicamente, trabalhos já publicados ou aceitos para publicação não são permitidos. A publicação final é disponível sob licença CC-BY. À parte a ausência de revisão por pares, os demais processos editoriais são seguidos com rigor, então todas as submissões são avaliadas para ver se estão de acordo com a ética e com as normas de publicação. &lt;br /&gt;&lt;br /&gt;Bom, depois de ler as &lt;a href="https://peerj.com/about/preprints/scope-and-instructions/"&gt;instruções&lt;/a&gt;, que são bastante completas e merecem uma lida cuidadosa, procedemos ao processo de submissão. É importante relembrar que todos os autores devem ser avisados da submissão e todos eles irão receber um email confirmatório, solicitando que os mesmos se inscrevam no PeerJ Preprints. Na primeira tela, escolhemos a área de estudo e o tipo de publicação.  &lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;figure&gt;  &lt;img alt="PeerJ" src="http://2.bp.blogspot.com/-m9WB-5cqYtQ/VmTyi0b-kYI/AAAAAAAAgJs/cOBOLOo0Rs8/s1600/Captura%2Bde%2BTela%2B2015-12-06%2Ba%25CC%2580s%2B23.43.39.png" width="550" /&gt;&lt;img border="0" /&gt;  &lt;figcaption&gt;Fig4. - Primeira tela para submissão no PeerJ.&lt;/figcaption&gt;&lt;/figure&gt;&lt;br /&gt;&lt;div style="text-indent: 30px;"&gt;Ao iniciar o processo, vamos para uma tela onde existem diversos campos a serem preenchidos com as informações do manuscrito, divididos em várias abas. Vai-se passando de uma a outra ao completar as informações, até chegar ao final e enviar. O processo pode ser interrompido e reiniciado a qualquer momento. Ao terminá-lo, somos informados que o artigo aguarda avaliação editorial e somente após será publicado. Depois de um tempo que pode ser tão curto quanto 24h, mas que pode durar alguns dias, o resultado da checagem é informado via email: aceito ou não. A taxa de aceitação é alta, e basicamente apenas os manuscritos que não aderem às normas de publicação serão rejeitados.  &lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;figure&gt;  &lt;img alt="PeerJ" src="http://1.bp.blogspot.com/-q1XJ2XYSrVU/VmT16rXxLMI/AAAAAAAAgJ4/isVsFCv377o/s1600/Captura%2Bde%2BTela%2B2015-12-06%2Ba%25CC%2580s%2B23.49.41.png" width="550" /&gt;&lt;img border="0" /&gt;  &lt;figcaption&gt;Fig5. - Tela para submissão no PeerJ Preprints.&lt;/figcaption&gt;&lt;/figure&gt;&lt;br /&gt;&lt;div style="text-indent: 30px;"&gt;O resultado final: podem ver &lt;a href="https://peerj.com/preprints/1544/?td=bl"&gt;aqui&lt;/a&gt; no meu &lt;i&gt;preprint&lt;/i&gt;, publicado em 30/11. Minha avaliação final como cliente é de um processo editorial muito satisfatório, rápido, com ajuda em todos os passos até o final. Eu recomendo a utilização do PeerJ Preprints como repositório para auto-arquivamento de trabalhos ainda não publicados. O único cuidado a se ter é checar se os jornais onde se pretende publicar depois aceitam trabalhos já tornados públicos na forma de preprints. Consciente disso, vale a pena colocar seu trabalho num repositório de preprints e estimular a discussão e a troca de idéias. Meu manuscrito já está no ar! Aguardo suas análises críticas! &lt;br /&gt;&lt;br /&gt;Atualização (30/12/15): publiquei uma &lt;a href="https://peerj.com/preprints/1544/?td=bl" target="_blank"&gt;nova versão&lt;/a&gt; do meu primeiro preprint no PeerJ Preprints, uma funcionalidade muito interessante desta plataforma. Também publiquei meu &lt;a href="https://peerj.com/preprints/1613/?td=bl" target="_blank"&gt;segundo preprint&lt;/a&gt;.&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/347813578717112270'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/347813578717112270'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/12/minha-experiencia-com-o-peerj-preprints.html' title='Minha experiência com o PeerJ Preprints'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/-ePTVa6wafTI/VmRbyVYfMnI/AAAAAAAAgJY/UCOTKsx1i5k/s72-c/Captura%2Bde%2BTela%2B2015-12-06%2Ba%25CC%2580s%2B11.47.32.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5871814733024746877</id><published>2015-10-06T20:22:00.000-03:00</published><updated>2015-12-07T20:26:36.143-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='artemisinina'/><category scheme='http://www.blogger.com/atom/ns#' term='2015'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='doenças parasitárias'/><category scheme='http://www.blogger.com/atom/ns#' term='Youyou Tu'/><category scheme='http://www.blogger.com/atom/ns#' term='Satoshi Ömura'/><category scheme='http://www.blogger.com/atom/ns#' term='Fisiologia e Medicina'/><category scheme='http://www.blogger.com/atom/ns#' term='ivermectina'/><category scheme='http://www.blogger.com/atom/ns#' term='William C. Campbell'/><category scheme='http://www.blogger.com/atom/ns#' term='avermectina'/><category scheme='http://www.blogger.com/atom/ns#' term='Nobel'/><title type='text'>Prêmio Nobel de Fisiologia e Medicina 2015</title><content type='html'>&lt;span style="font-family: inherit;"&gt;O Prêmio Nobel de Fisiologia e Medicina de 2015 foi agraciado a 3 cientistas pelos seus trabalhos na área de tratamento de doenças parasitárias.&amp;nbsp;&lt;strong style="box-sizing: border-box; line-height: inherit; text-align: -webkit-center;"&gt;William C. Campbell &lt;/strong&gt;&lt;span style="box-sizing: border-box; line-height: inherit; text-align: -webkit-center;"&gt;e&lt;/span&gt;&lt;strong style="box-sizing: border-box; line-height: inherit; text-align: -webkit-center;"&gt; Satoshi&amp;nbsp;&lt;/strong&gt;&lt;strong style="box-sizing: border-box; line-height: inherit; text-align: -webkit-center;"&gt;Ōmura &lt;/strong&gt;&lt;span style="box-sizing: border-box; line-height: inherit; text-align: -webkit-center;"&gt;desenvolveram a avermectina, uma droga antiparasitária cujos derivados são largamente usados para tratar diversas doenças endêmicas causadas por vermes nematódeos, as quais causam grande morbidade em países pobres e em desenvolvimento.&amp;nbsp;&lt;/span&gt;&lt;strong style="box-sizing: border-box; line-height: inherit; text-align: -webkit-center;"&gt;Youyou Tu &lt;/strong&gt;&lt;span style="box-sizing: border-box; line-height: inherit; text-align: -webkit-center;"&gt;foi agraciada pelo desenvolvimento da artemisinina, droga que revolucionou o tratamento da malária.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Satoshi Ömura, microbiologista japonês da Kiwasato University, desenvolveu inovadoras técnicas para isolar milhares de espécies e cepas de bactérias do gênero &lt;i&gt;Streptomyces&lt;/i&gt; do solo. As cepas mais promissoras foram utilizadas por William C. Campbell, biólogo irlandês que terminou sua educação e trabalha nos EUA, na Drew University, Madison. Campbell, especialista em parasitologia, isolou um composto com excelente atividade contra diversos parasitas, a avermectina. Seu derivado mais conhecido, a ivermectina, é hoje largamente usada para trata um grande número de doenças parasitárias, inclusive algumas previamente intratáveis. A descoberta dos dois deu origem a uma nova classe de medicamentos antiparasitários.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Na década de 60, devido à emergência de cepas de plasmódio resistentes a drogas, o tratamento da malária era difícil. Youyou Tu procurou medicamentos tradicionais chineses, tentando isolar deles substâncias ativas. Ela conseguiu isolar a artemisinina a partir do extrato da planta &lt;i&gt;Artemisia annua&lt;/i&gt;, um composto com potente efeito contra plasmódios resistentes a outras drogas. Devido a sua descoberta, que deu origem a uma nova classe de drogas antimaláricas, ela foi agraciada com o Nobel.&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;img alt="Map." src="https://upload.wikimedia.org/wikipedia/commons/f/fc/Tu_Youyou_and_Lou_Zhicen_in_1951.TIF" /&gt;&lt;br /&gt;&lt;br /&gt;&lt;div class="photo-gallery-caption"&gt;&lt;em&gt;Figure 1&lt;/em&gt;: &lt;em&gt;Tu Youyou (direita) e seu professor Lou Zhicen (楼之岑) (esquerda) em 1951. Fotógrafo anônimo (Em 1951, a China não tinha leis de direitos autorais. A foto está no domínio público há mais de 50 anos.) (WenxueCity), via Wikimedia Commons.&lt;/em&gt;&lt;/div&gt;&lt;table cellpadding="2" cellspacing="2" summary="Key publications"&gt;  &lt;tbody&gt;&lt;tr&gt;   &lt;td&gt;&lt;h3 br=""&gt;&lt;br /&gt;&lt;br /&gt;Publicações relevantes:&lt;/h3&gt;&lt;/td&gt;  &lt;/tr&gt;&lt;tr&gt;   &lt;td&gt;Burg et al., &lt;em&gt;Antimicrobial Agents and Chemotherapy&lt;/em&gt; (1979) 15:361-367.&lt;/td&gt;  &lt;/tr&gt;&lt;tr&gt;    &lt;td&gt;Egerton et al., &lt;em&gt;Antimicrobial Agents and Chemotherapy&lt;/em&gt; (1979) 15:372-378.&lt;/td&gt;  &lt;/tr&gt;&lt;tr&gt;    &lt;td&gt;Tu et al., &lt;em&gt;Yao Xue Xue Bao&lt;/em&gt; (1981) 16, 366-370 (Chinês) &lt;/td&gt;  &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nobelprize.org/nobel_prizes/medicine/laureates/2015/press.html#.VmYKPz3jMoc.blogger"&gt;The 2015 Nobel Prize in Physiology or Medicine - Press Release&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5871814733024746877'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5871814733024746877'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/10/premio-nobel-de-fisiologia-e-medicina.html' title='Prêmio Nobel de Fisiologia e Medicina 2015'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1184548318418048033</id><published>2015-09-29T18:39:00.001-03:00</published><updated>2015-12-13T13:27:49.480-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='Carlos Chagas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Milton Santos'/><category scheme='http://www.blogger.com/atom/ns#' term='ciência brasileira'/><category scheme='http://www.blogger.com/atom/ns#' term='cientistas influentes'/><category scheme='http://www.blogger.com/atom/ns#' term='Osvaldo Cruz'/><category scheme='http://www.blogger.com/atom/ns#' term='Google Books'/><category scheme='http://www.blogger.com/atom/ns#' term='ngram viewer'/><title type='text'>Os cientistas brasileiros mais influentes no mundo</title><content type='html'>Recentemente, vi uma postagem em outro &lt;a href="http://hypescience.com/11-cientistas-brasileiros-que-merecem-nosso-respeito/" target="_blank"&gt;blog&lt;/a&gt; que lista 13 cientistas brasileiros cujo trabalho repercutiu internacionalmente. Já conhecia quase todos eles e sabia as linhas gerais de seu trabalho. Tive a curiosidade, então, de levar os nomes dos 13 para o &lt;a href="https://books.google.com/ngrams" target="_blank"&gt;Ngram Viewer&lt;/a&gt; do Google, um instrumento de pesquisa linguística que permite buscar palavras e construções simples no enorme &lt;i&gt;corpus&lt;/i&gt; de palavras do Google Books, cuja última &lt;a href="http://aclweb.org/anthology/P/P12/P12-3029.pdf" target="_blank"&gt;edição&lt;/a&gt; inclui mais de 8 milhões de livros, ou cerca de 6% de toda a produção bibliográfica publicada até 2008. Os resultados de uma busca no Ngram Viewer mostram a frequência com que um dado termo é mencionado no corpus completo, através do tempo. Coloquei todos os 13 nomes de pesquisadores citados na busca, dentro do corpus da língua inglesa. Usei os nomes sem acentuação, para não atrapalhar a busca (testei com acentuação antes, e não obtive resultados). Quando não encontrei nada, tentei variantes dos nomes. Eliminei os nomes que não eram citados ou cujas curvas eram tão reduzidas em relação à maior curva (Carlos Chagas) que não podiam ser visualizadas. O resultado é este:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;div&gt;&lt;iframe frameborder="0" height="300" hspace="0" marginheight="0" marginwidth="0" name="ngram_chart" scrolling="no" src="https://books.google.com/ngrams/interactive_chart?content=Carlos+Chagas%2CCesar+Lattes%2CMilton+Santos%2COsvaldo+Cruz%2CMiguel+Nicolelis%2CJose+Leite+Lopes&amp;amp;year_start=1900&amp;amp;year_end=2008&amp;amp;corpus=15&amp;amp;smoothing=3&amp;amp;share=&amp;amp;direct_url=t1%3B%2CCarlos%20Chagas%3B%2Cc0%3B.t1%3B%2CCesar%20Lattes%3B%2Cc0%3B.t1%3B%2CMilton%20Santos%3B%2Cc0%3B.t1%3B%2COsvaldo%20Cruz%3B%2Cc0%3B.t1%3B%2CMiguel%20Nicolelis%3B%2Cc0%3B.t1%3B%2CJose%20Leite%20Lopes%3B%2Cc0" vspace="0" width="600"&gt;&lt;/iframe&gt;&lt;/div&gt;&lt;br /&gt;&lt;div&gt;Ao observar as curvas, notamos o destaque de Carlos Chagas. Com efeito, ele tem uma frequência de citação no corpus da língua inglesa semelhante àquela de vários ganhadores de prêmio Nobel, como Salvador Luria, César Milstein, Harold Varmus e Luc Montagnier. O restante dos pesquisadores citados tem uma curva bem menor, da ordem de personagens conhecidos, porém não tanto, da cena científica mundial, como Shinya Yamanaka, Jack Szostak, Robert Horvitz, todos nobelistas.&lt;/div&gt;&lt;div&gt;&lt;iframe frameborder="0" height="300" hspace="0" marginheight="0" marginwidth="0" name="ngram_chart" scrolling="no" src="https://books.google.com/ngrams/interactive_chart?content=Salvador+Luria%2CCarlos+Chagas%2CCesar+Milstein%2CHarold+Varmus%2CLuc+Montagnier&amp;amp;year_start=1900&amp;amp;year_end=2008&amp;amp;corpus=15&amp;amp;smoothing=3&amp;amp;share=&amp;amp;direct_url=t1%3B%2CSalvador%20Luria%3B%2Cc0%3B.t1%3B%2CCarlos%20Chagas%3B%2Cc0%3B.t1%3B%2CCesar%20Milstein%3B%2Cc0%3B.t1%3B%2CHarold%20Varmus%3B%2Cc0%3B.t1%3B%2CLuc%20Montagnier%3B%2Cc0" vspace="0" width="600"&gt;&lt;/iframe&gt;&lt;iframe frameborder="0" height="300" hspace="0" marginheight="0" marginwidth="0" name="ngram_chart" scrolling="no" src="https://books.google.com/ngrams/interactive_chart?content=Cesar+Lattes%2CShinya+Yamanaka%2CJack+W.+Szostak%2CH.+Robert+Horvitz&amp;amp;year_start=1940&amp;amp;year_end=2008&amp;amp;corpus=15&amp;amp;smoothing=3&amp;amp;share=&amp;amp;direct_url=t1%3B%2CCesar%20Lattes%3B%2Cc0%3B.t1%3B%2CShinya%20Yamanaka%3B%2Cc0%3B.t1%3B%2CJack%20W.%20Szostak%3B%2Cc0%3B.t1%3B%2CH.%20Robert%20Horvitz%3B%2Cc0" vspace="0" width="600"&gt;&lt;/iframe&gt;&lt;/div&gt;&lt;br /&gt;O restante dos pesquisadores citados no post não surgiram com nenhuma citação identificável no Ngram Viewer. Não que isto seja prova de algo, pois vários dos ganhadores de Nobel em Medicina que não têm expressão internacional também não retornam nenhuma citação nessa máquina de busca. A conclusão, se é que podemos chegar a alguma, é que vários dos pesquisadores brasileiros mostram terem um impacto na literatura em inglês semelhante a de alguns dos maiores pesquisadores dos EUA e Europa. No entanto, jamais um brasileiro recebeu um Nobel de Medicina e Fisiologia. Idéias sobre as razões? Apostando no velho&amp;nbsp;&lt;a href="https://pt.wikipedia.org/wiki/Guilherme_de_Ockham" style="color: #660099; cursor: pointer; text-decoration: none; white-space: nowrap;"&gt;Guilherme de Ockham&lt;/a&gt;, podemos levantar como hipótese mais simples, e portanto mais plausível, uma baixa confiabilidade do Ngram Viewer em prever, a partir do impacto em citações que ele mostra, certa forma de "sucesso" das personalidades citadas. Uma hipótese alternativa bem razoável pode ser de enviesamento cultural, análogo ao conceito de "publication bias". Na falta de algum procedimento que garanta comparabilidade a estas duas hipóteses, não ouso concluir qual deve ser a mais provável. A&amp;nbsp;&lt;a href="http://hypescience.com/11-cientistas-brasileiros-que-merecem-nosso-respeito/" target="_blank"&gt;postagem&lt;/a&gt; original é&amp;nbsp;interessante, embora um tanto superficial e &lt;i&gt;naïve&lt;/i&gt;, recomendo a leitura.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1184548318418048033'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1184548318418048033'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2015/09/os-cientistas-brasileiros-mais.html' title='Os cientistas brasileiros mais influentes no mundo'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2586473522897428400</id><published>2014-03-19T22:03:00.000-03:00</published><updated>2015-12-07T22:20:06.976-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='propranolol'/><category scheme='http://www.blogger.com/atom/ns#' term='regressão espontânea'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='tratamento'/><category scheme='http://www.blogger.com/atom/ns#' term='Mulliken'/><category scheme='http://www.blogger.com/atom/ns#' term='escleroterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='cirurgia'/><category scheme='http://www.blogger.com/atom/ns#' term='hemangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='cauterização'/><category scheme='http://www.blogger.com/atom/ns#' term='anomalias vasculares'/><title type='text'>O Tratamento de Hemangiomas Há 200 Anos Atrás</title><content type='html'>&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://4.bp.blogspot.com/-OsJc9f__W2s/UynC-rNiobI/AAAAAAAAZ_Q/7AAE-94urB8/s1600/Captura+de+Tela+2014-03-19+a%CC%80s+11.13.04.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="http://4.bp.blogspot.com/-OsJc9f__W2s/UynC-rNiobI/AAAAAAAAZ_Q/7AAE-94urB8/s320/Captura+de+Tela+2014-03-19+a%CC%80s+11.13.04.png" height="335" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://4.bp.blogspot.com/-psMv09JO_0c/UynC_otufTI/AAAAAAAAZ_Y/Uo7_XSXyx4Q/s1600/Captura+de+Tela+2014-03-19+a%CC%80s+11.24.00.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="http://4.bp.blogspot.com/-psMv09JO_0c/UynC_otufTI/AAAAAAAAZ_Y/Uo7_XSXyx4Q/s320/Captura+de+Tela+2014-03-19+a%CC%80s+11.24.00.png" height="290" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://1.bp.blogspot.com/-GPDrIbpSG7g/UynC_NBDKxI/AAAAAAAAZ_U/2p36_vgf8XU/s1600/Captura+de+Tela+2014-03-19+a%CC%80s+12.27.19.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;br /&gt;&lt;/a&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;Figuras retiradas do livro Mulliken &amp;amp; Young's Vascular Anomalies, Hemangiomas and Malformations, 2 ed., Oxford University Press, 2013 (protegidas por direitos autorais).&lt;/div&gt;&lt;div style="text-align: justify;"&gt;O professor John B. Mulliken, considerado uma das maiores autoridades em anomalias vasculares do mundo e discípulo de Judah Folkman (1933-2008), o descobridor da angiogênese, nos mostra, na introdução do capítulo sobre tratamento de hemangiomas, um interessante histórico.  Logo no começo, ele avisa: "o hemangioma vermelho brilhante de rápido crescimento nos leva a tomar uma providência, a fazer algo, qualquer coisa". Assim, a ansiedade relacionada com esta lesão ordinariamente benigna e que não requer tratamento na maioria dos casos (sabemos bem hoje) sempre levou mães e médicos ansiosos a tentar as mais estapafúrdias terapias possíveis. No século XVIII, era comum a "queimação" com "ferro quente" (cautério), ou ainda a extirpação cirúrgica de lesões que, muitas vezes, regrediriam espontaneamente. Vários casos de hemorragias graves com óbito de crianças com hemangiomas, mesmo pequenos, foram descritas na literatura antiga, como resultado de técnicas abstrusas de tratamento.&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;Relatos mostram que desde os anos 1500 se realizavam extirpações cirúrgicas de hemangiomas em pequenos pacientes. Numa das passagens, o Dr. Mulliken descreve: "Daniel Turner (...), precursor da dermatologia (...), [em 1714] recomendou o "ferro quente" para um (...) caso, uma jovem empregada com uma "marca em forma de lagosta" na bochecha. Amedrontada, a garota tomou a sábia decisão de procurar outra opinião".  Citando W. A. Lister (1938): "toda a nossa atitude em relação ao tratamento dos nevos em morango [strawberry - hemangiomas] deve se basear no conhecimento de sua invariável tendência à regressão espontânea". Mesmo hoje em dia, mães ansiosas devido à marca vermelho-vivo, usualmente na face de seus bebês, procuram "cirurgia", alheias ao grande risco que estão oferecendo a seus filhos. Cabe aos profissionais de hoje esclarecer adequadamente as mães e, nos casos que necessitem, encaminhar a um especialista em anomalias vasculares.&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;Ainda é preocupante a tendência de alguns médicos de voltar aos velhos tratamentos de 200 anos atrás, como a cauterização (até recentemente realizada esporadicamente com bisturi elétrico). A cauterização, deve-se frisar, seja com que instrumento for, é totalmente contra-indicada, pois, além de vários riscos associados à anatomia do local de surgimento do hemangioma, deixa uma cicatriz indelével para o resto da vida.&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;A quem procurar quando uma criança tem um hemangioma? Os maiores especialistas nestas lesões são os cirurgiões plásticos (como o dr. Mulliken), os onco-hematologistas pediátricos (como a dra. Adams, outra das maiores autoridades mundiais) e os dermatologistas (como a dra. Leauté-Labréze, a qual descobriu recentemente o uso de propranolol para hemangiomas). Todos os médicos, porém, podem e devem ter noções gerais sobre anomalias vasculares, incluindo quando referir para um especialista.&lt;/div&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://1.bp.blogspot.com/-oSJ6nNh9FAQ/Uyo_xbeZT_I/AAAAAAAAZ_w/7v4oePhAcrg/s1600/Captura+de+Tela+2014-03-19+a%CC%80s+12.26.43.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="http://1.bp.blogspot.com/-oSJ6nNh9FAQ/Uyo_xbeZT_I/AAAAAAAAZ_w/7v4oePhAcrg/s1600/Captura+de+Tela+2014-03-19+a%CC%80s+12.26.43.png" height="145" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;br /&gt;Essa imagem parcial, retirada do capítulo do dr. Mulliken, mostra uma jovem que desenvolveu um grande hemangioma infantil na face. O seguimento, ABSOLUTAMENTE SEM NENHUM TRATAMENTO, é testemunho de que a regressão espontânea dos hemangiomas, que pode demorar vários anos, muitas vezes não deixa nenhuma marca posterior.&lt;br /&gt;&lt;br /&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2586473522897428400'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2586473522897428400'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2014/03/o-tratamento-de-hemangiomas-ha-200-anos.html' title='O Tratamento de Hemangiomas Há 200 Anos Atrás'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/-OsJc9f__W2s/UynC-rNiobI/AAAAAAAAZ_Q/7AAE-94urB8/s72-c/Captura+de+Tela+2014-03-19+a%CC%80s+11.13.04.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6867877635058108799</id><published>2013-12-15T17:59:00.000-03:00</published><updated>2015-12-07T22:34:30.082-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='propranolol'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='eficácia'/><category scheme='http://www.blogger.com/atom/ns#' term='tratamento'/><category scheme='http://www.blogger.com/atom/ns#' term='meta-análise'/><category scheme='http://www.blogger.com/atom/ns#' term='hemangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='retrospectiva'/><title type='text'>Eficácia do propranolol no tratamento de hemangiomas capilares é comprovada</title><content type='html'>A utilidade do propranolol no tratamento de crianças com hemangiomas infantis, ou hemangiomas capilares, foi proposta há cerca de 5 anos por um grupo de dermatologistas franceses da cidade de Bordeaux, numa revolucionária &lt;a href="http://pharmak.blogspot.com.br/2009/03/uso-de-propranolol-revoluciona.html"&gt;publicação &lt;/a&gt;no New England Journal of Medicine. De lá para cá, um grande número de trabalhos científicos exploraram o efeito desta medicação no tratamento de casos complicados de hemangiomas da infância. A maioria destes trabalhos foi de natureza observacional, ou seja, pesquisadores apenas coletaram informações sobre séries de casos previamente tratados com a medicação. A avaliação, realizada posteriormente ao tratamento, é chamada de "retrospectiva". Este tipo de trabalho científico não tem capacidade de responder muitas perguntas importantes sobre um novo tratamento, pois muitas variáveis envolvidas não podem ser previstas (não são controladas) e, via de regra, não existem grupos comparativos (grupos controle). A fim de estabelecer com certeza a eficácia de um tratamento, o ideal é planejar um estudo, controlando todos os seus detalhes, e utilizar um grupo comparativo (controle) que pode ser não tratado ou tratado com o padrão já aceito. Uma forma ainda melhor de avaliar a eficácia de um novo tratamento é agrupar os resultados de vários estudos, formando assim, um conjunto com um grupo maior de pacientes, o que reduz as chances de conclusões erradas. Uma das formas de realizar isto é chamada de "meta-análise". Um grupo de pesquisadores de Ho-fei, na China, acaba de publicar no British Journal of Clinical Pharmacology uma meta-análise reunindo 35 estudos de eficácia do propranolol em pacientes com hemangiomas infantis. O estudo reuniu 324 pacientes tratados com propranolol e 248 pacientes não tratados com ele (controle). A conclusão do estudo é que o propranolol tem grande eficácia para o tratamento de hemangiomas capilares e que ele é melhor do que o tratamento padrão atualmente (corticosteróides) na maioria dos casos. Os autores recomendam fortemente que o propranolol seja usado como tratamento inicial para crianças com hemangiomas capilares complicados. Essa pesquisa vem confirmar e comprovar os resultados anteriores de estudos realizados no mundo inteiro, inclusive &lt;a href="http://pharmak.blogspot.com.br/2011/10/primeiros-resultados-do-tratamento-de.html"&gt;aqui&lt;/a&gt;.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6867877635058108799'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6867877635058108799'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/12/eficacia-do-propranolol-no-tratamento.html' title='Eficácia do propranolol no tratamento de hemangiomas capilares é comprovada'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4599161624947558300</id><published>2013-11-19T18:11:00.000-03:00</published><updated>2014-03-19T15:05:26.418-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>The problem with p values: how significant are they, really? via Geoff
Cumming</title><content type='html'>&lt;h1&gt;The problem with p values: how significant are they, really?&lt;/h1&gt; &lt;p&gt;&lt;span&gt;By &lt;a href="http://theconversation.com/profiles/geoff-cumming-4100"&gt;Geoff Cumming&lt;/a&gt;&lt;em&gt;, La Trobe University&lt;/em&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;For researchers there’s a lot that turns on the &lt;em&gt;p&lt;/em&gt; value, the number used to determine whether a result is statistically significant. The current consensus is that if &lt;em&gt;p&lt;/em&gt; is less than .05, a study has reached the holy grail of being statistically significant, and therefore likely to be published. Over .05 and it’s usually back to the drawing board.&lt;/p&gt; &lt;p&gt;But today, Texas A&amp;amp;M University professor &lt;a href="http://www.stat.tamu.edu/directory-details.php?directoryid=321"&gt;Valen Johnson&lt;/a&gt;, writing in the prestigious journal Proceedings of the National Academy of Sciences, &lt;a href="http://www.pnas.org/cgi/doi/10.1073/pnas.1313476110"&gt;argues&lt;/a&gt; that &lt;em&gt;p&lt;/em&gt; less than .05 is far too weak a standard.&lt;/p&gt; &lt;p&gt;Using .05 is, he contends, a key reason why false claims are published and many published results fail to replicate. He advocates requiring .005 or even .001 as the criterion for statistical significance.&lt;/p&gt; &lt;h2&gt;What is a &lt;em&gt;p&lt;/em&gt; value anyway?&lt;/h2&gt; &lt;p&gt;The &lt;em&gt;p&lt;/em&gt; value is at the heart of the most common approach to data analysis – null hypothesis significance testing (NHST). Think of NHST as a waltz with three steps:&lt;/p&gt; &lt;ol&gt;&lt;li&gt;State a &lt;a href="http://www.null-hypothesis.co.uk/science/item/what_is_a_null_hypothesis/"&gt;null hypothesis&lt;/a&gt;: that is, there is no effect.&lt;/li&gt;&lt;li&gt;Calculate the &lt;em&gt;p&lt;/em&gt; value, which is the probability of getting results like ours – &lt;em&gt;if&lt;/em&gt; the null hypothesis is true.&lt;/li&gt;&lt;li&gt;If &lt;em&gt;p&lt;/em&gt; is sufficiently small, reject the null hypothesis and sound the trumpets: our effect is not zero, it’s statistically significant!&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;British statistician and geneticist &lt;a href="http://en.wikipedia.org/wiki/Ronald_Fisher"&gt;Sir Ronald Fisher&lt;/a&gt; introduced &lt;a href="http://psychclassics.yorku.ca/Fisher/Methods/index.htm"&gt;the &lt;em&gt;p&lt;/em&gt; value&lt;/a&gt; in 1925. He adopted .05 as a reference point for rejecting a null hypothesis. For him it was not a sharp cutoff: a thoughtful researcher should consider the context, and other results as well.&lt;/p&gt; &lt;p&gt;NHST has, however, become deeply entrenched in medicine and numerous other disciplines. The precise value .05 has become a bar to wriggle under to achieve publication in top journals. Generations of students have been inducted into the rituals of .05 meaning “significant”, and .01 “highly significant”.&lt;/p&gt; &lt;h2&gt;Sounds good. What’s the problem?&lt;/h2&gt; &lt;p&gt;The trouble is there are &lt;a href="http://www.apastyle.org/manual/related/kline-2004.pdf"&gt;numerous deep flaws&lt;/a&gt; in NHST.&lt;/p&gt; &lt;p&gt;There’s &lt;a href="http://tiny.cc/nhstohdear"&gt;evidence&lt;/a&gt; that students, researchers and even many teachers of statistics don’t understand NHST properly. More worryingly, there’s &lt;a href="http://www.nature.com/neuro/journal/v14/n9/full/nn.2886.html"&gt;evidence&lt;/a&gt; it’s widely misused, even in top journals.&lt;/p&gt; &lt;p&gt;Most researchers don’t appreciate that &lt;em&gt;p&lt;/em&gt; is highly unreliable. Repeat your experiment and you’ll get a &lt;em&gt;p&lt;/em&gt; value that could be extremely different. Even more surprisingly, &lt;em&gt;p&lt;/em&gt; is highly unreliable even for &lt;a href="http://tiny.cc/pintervals"&gt;very large samples&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;NHST may be a waltz, but the dance of &lt;em&gt;p&lt;/em&gt; is highly frenetic. Here’s a demonstration of why we simply shouldn’t trust any &lt;em&gt;p&lt;/em&gt; value:&lt;/p&gt; &lt;p&gt;&lt;/p&gt;&lt;figure&gt;&lt;iframe width="440" height="260" src="//www.youtube.com/embed/5OL1RqHrZQ8?wmode=transparent&amp;amp;start=0" frameborder="0" allowfullscreen=""&gt;&lt;/iframe&gt;&lt;/figure&gt;&lt;p&gt;&lt;/p&gt; &lt;p&gt;Despite all those problems, NHST persists, perhaps because we yearn for certainty. Declaring a result “significant” suggests certainty, even though our results almost always contain considerable uncertainty.&lt;/p&gt; &lt;h2&gt;Should we require stronger evidence?&lt;/h2&gt; &lt;p&gt;Johnson makes a cogent argument that .05 provides only weak evidence against the null hypothesis: perhaps only odds of 3 or 4 to 1 against reasonable alternative hypotheses.&lt;/p&gt; &lt;p&gt;He suggests we should require more persuasive odds, say 50 to 1 or even 200 to 1.&lt;/p&gt; &lt;p&gt;To do this, we need to adopt .005 or .001 as our &lt;em&gt;p&lt;/em&gt; value criterion for statistical significance.&lt;/p&gt; &lt;p&gt;He recognises there’s a price to pay for demanding stronger evidence. In typical cases, we’d need to roughly double our sample sizes to still have a reasonable chance of finding true effects. Using larger samples would indeed be highly desirable, but sometimes that’s simply not possible. And are research grants about to double?&lt;/p&gt; &lt;p&gt;Johnson is correct that .05 corresponds to weak evidence, and .005 or .001 to evidence that’s usefully stronger. Adopting his stricter criterion would, however, mean that the majority of all published research analysed using NHST would fail the new test, and suddenly be statistically non-significant!&lt;/p&gt; &lt;p&gt;&lt;/p&gt;&lt;figure class="align-left zoomable"&gt;&lt;a href="https://c479107.ssl.cf2.rackcdn.com/files/34853/area14mp/kzzxq98g-1384132459.jpg"&gt;&lt;img alt="" src="https://c479107.ssl.cf2.rackcdn.com/files/34853/width237/kzzxq98g-1384132459.jpg"&gt;&lt;/a&gt;      &lt;figcaption&gt;&lt;span class="caption"&gt; &lt;span class="source"&gt;shutupyourface&lt;/span&gt;&lt;/span&gt;&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;&lt;/p&gt; &lt;p&gt;More fundamentally, merely shifting the criterion does not overcome the unreliability of &lt;em&gt;p&lt;/em&gt;, or most of the other deep flaws of NHST. The core problem is that NHST panders to our yearning for certainty by presenting the world as black or white — an effect is statistically significant or not; it exists or it doesn’t.&lt;/p&gt; &lt;p&gt;In fact our world is many shades of grey — I won’t pretend to know how many. We need something more nuanced than NHST, and fortunately there are good alternatives.&lt;/p&gt; &lt;h2&gt;A better way: estimation and meta-analysis&lt;/h2&gt; &lt;p&gt;&lt;a href="http://www.indiana.edu/~kruschke/DoingBayesianDataAnalysis/"&gt;Bayesian techniques&lt;/a&gt; are highly promising and becoming widely used. Most readily available and already widely used is estimation based on &lt;a href="http://tiny.cc/GeoffConversation"&gt;confidence intervals&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;A confidence interval gives us the best estimate of the true effect, and also indicates the extent of uncertainty in our results. Confidence intervals are also what we need to use &lt;a href="http://tiny.cc/GeoffConversation"&gt;meta-analysis&lt;/a&gt;, which allows us to integrate results from a number of experiments that investigate the same issue.&lt;/p&gt; &lt;p&gt;We often need to make clear decisions — whether or not to licence the new drug, for example — but NHST provides a poor basis for such decisions. It’s far better to use the integration of all available evidence to guide decisions, and estimation and meta-analysis provides that.&lt;/p&gt; &lt;p&gt;Merely shifting the NHST goal posts simply won’t do. &lt;br&gt;&lt;/p&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;Further reading: &lt;a href="https://theconversation.com/give-p-a-chance-significance-testing-is-misunderstood-20207"&gt;Give p a chance: significance testing is misunderstood&lt;/a&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&lt;em&gt;Geoff Cumming has received funding from the Australian Research Council.&lt;/em&gt;&lt;/p&gt;&lt;img alt="The Conversation" height="1" src="https://counter.theconversation.edu.au/content/20029/count.gif" width="1"&gt;&lt;p&gt;This article was originally published at &lt;a href="http://theconversation.com"&gt;The Conversation&lt;/a&gt;.           Read the &lt;a href="http://theconversation.com/the-problem-with-p-values-how-significant-are-they-really-20029"&gt;original article&lt;/a&gt;.         &lt;/p&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4599161624947558300'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4599161624947558300'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/11/the-problem-with-p-values-how.html' title='The problem with p values: how significant are they, really? via Geoff&#xA;Cumming'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8670877904239602995</id><published>2013-10-27T13:45:00.000-03:00</published><updated>2013-10-27T13:45:02.594-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Terapia Alvo na Pediatria</title><content type='html'>&lt;iframe allowfullscreen="" frameborder="0" height="356" marginheight="0" marginwidth="0" scrolling="no" src="http://www.slideshare.net/slideshow/embed_code/27615673" style="border-width: 1px 1px 0; border: 1px solid #CCC; margin-bottom: 5px;" width="427"&gt; &lt;/iframe&gt; &lt;br /&gt;&lt;div style="margin-bottom: 5px;"&gt;&lt;strong&gt; &lt;a href="https://www.slideshare.net/FranciscoFelix6/terapia-alvo-pediatria" target="_blank" title="Terapia alvo na cancerologia pediátrica"&gt;Terapia alvo na cancerologia pediátrica&lt;/a&gt; &lt;/strong&gt; from &lt;strong&gt;&lt;a href="http://www.slideshare.net/FranciscoFelix6" target="_blank"&gt;Francisco Felix&lt;/a&gt;&lt;/strong&gt; &lt;br /&gt;&lt;br /&gt;Essa foi a aula sobre terapia alvo na prática oncológica pediátrica, mostrando a atualidade e perspectivas. Essa aula foi apresentada no Outubro Médico 2013, que ocorreu aqui em Fortaleza, de 16 a 19 deste mês.&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8670877904239602995'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8670877904239602995'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/10/terapia-alvo-na-pediatria.html' title='Terapia Alvo na Pediatria'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1203202653389663539</id><published>2013-10-11T23:10:00.003-03:00</published><updated>2013-10-11T23:10:59.709-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Urgências em crianças com tumores cerebrais - uma aula para o pediatra</title><content type='html'>Essa aula foi apresentada no Curso de Pediatria do Hospital Infantil Albert Sabin, em junho deste ano.&lt;br /&gt;&lt;iframe frameborder="0" height="400" marginheight="0" marginwidth="0" scrolling="no" src="http://www.slideshare.net/slideshow/embed_code/27116511" width="476"&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1203202653389663539'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1203202653389663539'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/10/urgencias-em-criancas-com-tumores.html' title='Urgências em crianças com tumores cerebrais - uma aula para o pediatra'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2141391452734099612</id><published>2013-09-29T17:51:00.000-03:00</published><updated>2015-12-13T18:21:43.720-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://www.blogger.com/atom/ns#' term='atualização'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='aula'/><category scheme='http://www.blogger.com/atom/ns#' term='gliomas'/><category scheme='http://www.blogger.com/atom/ns#' term='neuro-oncologia'/><category scheme='http://www.blogger.com/atom/ns#' term='cancerologia pediátrica'/><title type='text'>Gliomas em crianças: aula de atualização</title><content type='html'>&lt;a href="http://www.blogger.com/%3Ciframe%20src=%22http://www.slideshare.net/slideshow/embed_code/26671435%22%20width=%22476%22%20height=%22400%22%20frameborder=%220%22%20marginwidth=%220%22%20marginheight=%220%22%20scrolling=%22no%22%3E%3C/iframe%3E" target="_blank"&gt;&lt;iframe frameborder="0" height="400" marginheight="0" marginwidth="0" scrolling="no" src="http://www.slideshare.net/slideshow/embed_code/26671435" width="476"&gt;&lt;/iframe&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Essa aula de atualização em gliomas de crianças e adolescentes foi apresentada em 15 de setembro de 2011, dois anos atrás, na Liga do Câncer da Universidade Federal do Ceará. Na oportunidade, expus o conhecimento mais recente sobre o tratamento e o diagnóstico molecular em gliomas pediátricos, tanto tumores de baixo grau, quanto lesões de alto grau. Alterei discretamente o layout da aula, mas o conteúdo é, essencialmente, o mesmo. A maioria dos slides é fácil de entender, mas achei interessante acrescentar comentários sobre os principais slides:&lt;br /&gt;&lt;br /&gt;Slide 1: título&lt;br /&gt;&lt;br /&gt;Slide 2: tipos de gliomas de baixo grau. A variedade de diagnósticos que podem ser arbitrariamente designados de "gliomas de baixo grau" é grande. Basicamente, são tumores formados pela predominância de células astrocitárias, olidendrocitárias ou uma mistura de ambas as linhagens celulares. Astrocitomas são, de longe, os mais comuns. Oligodendrogliomas e os tumores mistos (oligoastrocitomas) são bem mais raros. O subtipo de astrocitoma mais frequente em crianças é o pilocítico, o qual pode ocorrer em qualquer localização do sistema nervoso central, mas surge principalmente no cerebelo.&lt;br /&gt;&lt;br /&gt;Slide 3: o paradigma de tratamento de gliomas de baixo grau em crianças: cirurgia, quando possível. Tumores cerebelares pode ser retirados em virtualmente 100% dos casos, em metade deles completamente. A ressecção completa destes tumores é curativa. Tumores de hipotálamo e vias ópticas (diencéfalo) hoje em dia são diagnosticados apenas por imagem, devido ao risco de complicações. Quando existe dúvida diagnóstica, deve-se realizar apenas uma biópsia, estereotáxica de preferência. Estas lesões são tratadas tanto com quimioterapia quanto com radioterapia, mas o tratamento ideal ainda encontra-se por definir. Tumores focais do tronco são comumente ressecados parcialmente, ou apenas biopsiados. No caso deles, a confirmação histológica é importante para afastar a possibilidade de lesões de alto grau. Seu tratamento ainda é discutido, mas os pacientes costumam ter sobrevida longa com quimioterapia e/ou radioterapia. Tumores hemisféricos podem recidivar se não forem completamente ressecados (basta um resíduo mínimo). Apenas após a recidiva ou progressão indica-se tratamento com quimio ou radioterapia.&lt;br /&gt;&lt;br /&gt;Slide 5: gliomas de baixo grau são os tumores cerebrais mais frequentes em crianças, adolescentes e adultos jovens, ao contrário dos idosos, em quem são raros. São tumores indolentes e de crescimento lento, com raras exceções. O tratamento é bem sucedido na maioria dos casos, seja com cirurgia apenas, ou combinado com quimioterapia e/ou radioterapia. Infelizmente, exceto no caso dos astrocitomas pilocíticos cerebelares (quase nunca recidivam), recorrências são muito comuns. Os efeitos colaterais a longo prazo das diversas modalidades de tratamento ainda são pouco estudados.&lt;br /&gt;&lt;br /&gt;Slide 6: gráfico da publicação sobre o banco de dados de gliomas do SEER, mostrando o efeito do grau de malignidade na sobrevida. Lesões de baixo grau (I e II) têm bom prognóstico, ao contrário de lesões de alto grau (III e IV).&lt;br /&gt;&lt;br /&gt;Slide 7: em 2008, Fischer et al publicaram um trabalho relatando um grupo de crianças que foi seguido sem tratamento após a cirurgia, completa ou parcial. Neste gráfico vemos a sobrevida livre de progressão, a qual foi de 55% em 5 anos (48% em tumores ressecados parcialmente). Este trabalho demonstra o crescimento indolente das lesões e indica que parte dos pacientes vai permanecer livre de progressão de doença sem terapia adjuvante, mesmo após ressecção parcial.&lt;br /&gt;&lt;br /&gt;Slide 8: quando é possível, a cirurgia é curativa em 80-90% dos casos. Nos gliomas de vias ópticas e tálamo, a ressecção completa não costuma ser possível. Hoje em dia, os gliomas de vias ópticas, &lt;i&gt;&lt;b&gt;em pacientes com pouco ou nenhum déficit&lt;/b&gt;&lt;/i&gt;, não são nem mesmo biopsiados.&lt;br /&gt;&lt;br /&gt;Slide 9: 3 gráficos sucessivos de uma publicação de 2010, mostrando a importância da ressecção completa em gliomas de baixo grau.&lt;br /&gt;&lt;br /&gt;Slide 13: a radioterapia é indicada em pré-adolescentes e adolescentes, e é contra-indicada em qualquer idade em pacientes com NF-1, devido ao risco de vasculopatia. Evidências recentes mostram que é um tratamento definitivo em 80% dos pacientes. Ensaios em andamento no SIOP e COG vão esclarecer melhor seu papel.&lt;br /&gt;&lt;br /&gt;Slide 15: incidência cumulativa de déficits neuro-hormonais em pacientes que realizaram radioterapia na série de Merchant. Infelizmente, o preço pela eficiência da radio ainda é a ocorrência de múltiplos déficits hormonais pelo resto da vida do paciente.&lt;br /&gt;&lt;br /&gt;Slide 16: gráfico mostrando a perda de QI ao longo do tempo após radioterapia para glioma de baixo grau na série de Merchant. Crianças com 4 anos de idade perdem até 20 pontos de QI ao longo de 5 anos, enquanto crianças de 12 anos perdem pouco ou não perdem. Idades intermediárias mostram um gradação deste efeito. Ainda não está definida a idade ótima para realizar radio em crianças e adolescentes com glioma de baixo grau.&lt;br /&gt;&lt;br /&gt;Slide 17: a quimioterapia foi usada originalmente para estabilizar a perda visual em pacientes com gliomas de vias ópticas, adiando o uso da radioterapia em crianças pequenas. Seus melhores resultados têm sido a estabilização das lesões e o adiamento da radio para idades com menor risco. A menor experiência com quimioterapia nesta doença não permite vislumbrar ainda seus possíveis efeitos a longo prazo.&lt;br /&gt;&lt;br /&gt;Slide 18: o esquema mais usado inclui carboplatina e vincristina, mas os resultados do ensaio do COG publicados recentemente mostraram que o esquema TPCV é algo superior. O esquema TPCV, mais antigo, usa carmustina, uma droga muito relacionada à ocorrência de segundas neoplasias, a maioria leucemias. Isso inibe seu uso atual como primeira escolha. Infelizmente, um terço ou mais dos pacientes desenvolve alergia à carboplatina durante o tratamento. Estudos recentes com poucos pacientes têm mostrados eficácia de alguns esquemas alternativos.&lt;br /&gt;&lt;br /&gt;Slide 19: a terapia-alvo tornou-se realidade para tumores cerebrais em crianças com a aprovação pelo FDA do everolimo (inibidor da via mTOR) para tratar SEGA, um raro tumor astrocítico, mais comum em pacientes com esclerose tuberosa.&lt;br /&gt;&lt;br /&gt;Slide 21: tipos de gliomas de alto grau, as variantes malignas dos gliomas de baixo grau. Ao contrário de idosos, são raros em crianças, adolescentes e adultos jovens.&lt;br /&gt;&lt;br /&gt;Slide 22: infelizmente, seu tratamento tem resultados insatisfatórios, com sobrevida relativamente curta em quase todos os pacientes, independente do esquema usado.&lt;br /&gt;&lt;br /&gt;Slide 23: Finlay, em 1995, mostrou que a ressecção cirúrgica é importante para crianças com gliomas de alto grau.&lt;br /&gt;&lt;br /&gt;Slide 24: em 2003, Pollack et al reviram sua série clássica de crianças com glioma maligno, mostrando que a sobrevida era, na verdade, pior do que se supunha antes, alcançando menos de 20% em 10 anos.&lt;br /&gt;&lt;br /&gt;Slide 25: a superexpressão da enzima MGMT nos tumores também é fator de prognóstico em crianças&lt;br /&gt;&lt;br /&gt;Slide 26 e 27: o mais recente ensaio do COG confirmou o péssimo prognóstico, com sobrevida livre de doença menor que 10% em 5 anos.&lt;br /&gt;&lt;br /&gt;Slide 28: o ensaio do grupo germânico GPOH (HIT-GBM-C) mostrou um resultado melhor, mas apenas em pacientes onde a ressecção completa (sem nenhuma lesão residual) foi possível.&lt;br /&gt;&lt;br /&gt;Slide 29 e 30: a maior novidade molecular recente em gliomas de alto grau foi a descoberta da importância prognóstica dos genes que codificam a enzima isocitrato-desidrogenase (IDH), através de estudos de genômica.&lt;br /&gt;&lt;br /&gt;Slide 32: a IDH participa do ciclo de Krebs&lt;br /&gt;&lt;br /&gt;Slide 33 a 36: a mutação de IDH confere melhor prognóstico aos pacientes com gliomas de alto grau&lt;br /&gt;&lt;br /&gt;Slide 37: também em gliomas de baixo grau a IDH parece ter importância prognóstica&lt;br /&gt;&lt;br /&gt;Espero que tenham apreciado a aula! Obrigado!</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2141391452734099612'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2141391452734099612'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/09/gliomas-em-criancas-aula-de-atualizacao.html' title='Gliomas em crianças: aula de atualização'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1030706698232301821</id><published>2013-09-19T20:33:00.001-03:00</published><updated>2013-09-29T17:55:01.627-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>The 3-Year Medical School — Change or Shortchange? — NEJM</title><content type='html'>&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;Excerpts from a text published in this week's edition of NEJM:&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;"Shortening medical school to 3 years, some observers argue, would increase the supply of physicians — perhaps particularly primary care physicians — and reduce the cost of medical training, without compromising clinical care.&amp;nbsp;Data from many years of experiments in shortening medical education, however, suggest that doing so is unwise — a conclusion supported by assessments of the readiness of today's medical school graduates to assume increased clinical responsibility as they enter residency programs.&amp;nbsp;There may be exceptional students capable of accelerated learning and small programs that create unusual opportunities for such students, but we believe that for the typical student seeking an M.D. degree, the duration of medical school should not be shortened."&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;(...)&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;"In addition, access to global health experiences; instruction in medical ethics, principles of patient safety, and health policy; and advanced clinical experiences are extremely valuable components of the current fourth year. Moreover, there is a recent trend toward students' seeking even longer terms for medical school, with the opportunity to gain additional credentials, including master's degrees, certificates of added competence, and prolonged research-training experiences. All these activities speak to students' sense of an expanding leadership role for physicians on future health care teams."&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;(...)&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;"To better prepare students for residency, we believe that more intensive clinical experiences in both outpatient and inpatient settings are needed and that innovative advising and mentoring programs should be created to enhance the transition to residency. Given the growing complexity of medicine, it seems counterproductive to compress the curriculum into 3 years, reducing both preclinical and clinical experiences. The limited opportunity for students to participate meaningfully in patient care during their undergraduate careers is the problem that needs correction; the solution is not to rush students into residency after allowing them even less involvement with patients."&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;(...)&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;"Teams of physicians, nurse practitioners, physician assistants, and pharmacists can develop new paradigms for delivering higher-quality clinical care, even with a predicted shortage of primary care physicians. Physicians may need even more advanced education — in health policy, public health needs, clinical research, and medical ethics — in order to lead such teams. (...) That requires enhancement, not shortening, of medical school."&lt;/span&gt;&lt;br /&gt;-&amp;nbsp;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;Interview with Dr. Richard Schwartzstein on the pros and cons of three-year medical school programs.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;&lt;span style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;br /&gt;&lt;/span&gt;Copyright © 2013&amp;nbsp;&lt;a href="http://www.massmed.org/" style="border: 0px; font-style: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"&gt;Massachusetts Medical Society&lt;/a&gt;. All rights reserved.&lt;br /&gt;&lt;br /&gt;This makes us think about today's Brazil experience. Shortage of primare care providers? Changes in medical education, not all of them very wise? Worries about medical students competence? It's all the same, here and there. The solution is never simple, and should not be pursued or decided unilaterally. &lt;br /&gt;&lt;div id="copyright" style="border: 0px; margin: 0px auto; outline: 0px; padding: 0px; vertical-align: baseline; width: 969px;"&gt;&lt;div style="border: 0px; font-style: inherit; outline: 0px; padding: 0px; text-align: -webkit-auto; vertical-align: baseline;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;&lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMp1306457#.UjuEqeuYaIg.blogger"&gt;The 3-Year Medical School — Change or Shortchange? — NEJM&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1030706698232301821'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1030706698232301821'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/09/the-3-year-medical-school-change-or.html' title='The 3-Year Medical School — Change or Shortchange? — NEJM'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8332515732964472666</id><published>2013-02-14T23:14:00.003-03:00</published><updated>2013-02-14T23:14:41.562-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>International Childhood Cancer Day</title><content type='html'>&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://2.bp.blogspot.com/-Pcpyrrv89-M/UR2ZnzAg6CI/AAAAAAAAQl0/iut8V1aB7ko/s1600/International+Childhood+Cancer+Day.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="640" src="http://2.bp.blogspot.com/-Pcpyrrv89-M/UR2ZnzAg6CI/AAAAAAAAQl0/iut8V1aB7ko/s640/International+Childhood+Cancer+Day.png" width="452" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8332515732964472666'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8332515732964472666'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/02/international-childhood-cancer-day.html' title='International Childhood Cancer Day'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-Pcpyrrv89-M/UR2ZnzAg6CI/AAAAAAAAQl0/iut8V1aB7ko/s72-c/International+Childhood+Cancer+Day.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1206931626742154643</id><published>2013-02-14T20:13:00.000-03:00</published><updated>2013-02-14T20:17:02.684-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>O tratamento moderno de tumores cerebrais em crianças</title><content type='html'>Os tumores cerebrais em crianças são raros - em Fortaleza, CE pouco mais de 1 criança em cada 100 mil vai ter um tumor cerebral, algo em torno de 30 casos por ano. Ainda sim, representa um terço da incidência de tumores cerebrais em São Paulo e no mundo desenvolvido, talvez pela existência de casos que não são diagnosticados a tempo. No Hospital Infantil Albert Sabin, único hospital do Ceará a contar com o tratamento multidisciplinar completo para crianças com tumores cerebrais, a sobrevida global das crianças com tumores cerebrais, cinco anos após o diagnóstico, é em torno de 50% (Araújo, 2011). Isso significa que cerca de metade das crianças diagnosticadas com tumor cerebral vai viver mais de 5 anos, o que geralmente corresponde à cura clínica para pacientes com tumores.&lt;br /&gt;&lt;br /&gt;A chance de sobrevida varia radicalmente com o tipo de tumor. Enquanto mais de 85-90% dos pacientes com gliomas de baixo grau alcançam sobrevida prolongada, pacientes com gliomas de alto grau ou gliomas difusos da ponte têm um prognóstico ruim - menos de 10% vivem mais de 2 anos nas séries internacionais (Felix, 2013).&amp;nbsp;A chance de sobrevida depende, fundamentalmente, do diagnóstico e tratamento adequados os quais somente podem ser oferecidos em centros especializados e multidisciplinares. É importante que os pacientes recebam a atenção de profissionais com experiência e conhecimento e tenham ao seu alcance os recursos necessários ao tratamento. O maior determinante do resultado é o tipo de tumor a ser tratado. A tabela que acompanha este texto mostra o tratamento mais adequado de acordo com a literatura mais recente, para os principais tipos de tumores cerebrais.&lt;br /&gt;&lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://2.bp.blogspot.com/-Ajg5_IzHEH8/UR1np9MvDII/AAAAAAAAQlg/pimvLNYMglU/s1600/n-o.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="276" src="http://2.bp.blogspot.com/-Ajg5_IzHEH8/UR1np9MvDII/AAAAAAAAQlg/pimvLNYMglU/s400/n-o.png" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://3.bp.blogspot.com/-bI-Z7SMwcO4/UR1nptMm9vI/AAAAAAAAQlc/X_W6YefFq64/s1600/n-o2.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="265" src="http://3.bp.blogspot.com/-bI-Z7SMwcO4/UR1nptMm9vI/AAAAAAAAQlc/X_W6YefFq64/s400/n-o2.png" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;Na tabela, as colunas mostram a classificacação clínica do paciente (Diagnóstico), o tratamento mais indicado pela literatura científica mais recente (Recomendação), o tipo do tumor (Histopatológico), grau da Organização Mundial da Saúde (OMS), características do grupo de pacientes (Estadiamento), referência do trabalho científico mais importante (Ref) e sobrevida esperada (EFS - pacientes sem doença 5 anos após o diagnóstico; OS - pacientes sobreviventes 5 anos após o diagnóstico).&lt;br /&gt;Abreviaturas: RT (radioterapia), RNM (ressonância nuclear magnética), NF1 (neurofibromatose tipo 1), &amp;nbsp;Chang (classificação de metástases, criada para Meduloblastomas, pode ser aplicada para Ependimomas, M0 é sem metástase), PNET (tumor neuroectodérmico primitivo), TCG (tumor de células germinativas), QT (quimioterapia). As demais referem-se a esquemas de quimioterapia ou exames especializados.&lt;br /&gt;&lt;br /&gt;Nota: todas as informações nestas tabelas foram retiradas da literatura científica citada, porém não necessariamente refletem a prática e a opinião de todos os profissionais e todos os centros envolvidos no tratamento de crianças com tumores cerebrais. Cada centro especializado ou profissional individual pode utilizar informações ou referências diferentes e pode informar chances de sobrevida diferentes, dependendo de suas experiências individuais.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1206931626742154643'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1206931626742154643'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2013/02/o-tratamento-moderno-de-tumores.html' title='O tratamento moderno de tumores cerebrais em crianças'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-Ajg5_IzHEH8/UR1np9MvDII/AAAAAAAAQlg/pimvLNYMglU/s72-c/n-o.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5515270554039103916</id><published>2012-10-09T22:25:00.000-03:00</published><updated>2012-10-18T15:53:54.394-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Aulas da Pós-graduação</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Caros  alunos da disciplina de Farmacologia Molecular e Autonômica, turma  2012.2, Programa de Pós-Graduação em Ciências Farmacêuticas, estes são  os links dos artigos científicos correspondentes à aula do dia  19/10/2012 (confirmado). Cada link dá acesso a um artigo. Um deles é de  revisão e os outros 2 são artigos originais. Dois são sobre  farmacogenômica enfocando a oncologia e o outro é sobre o  desenvolvimento de terapias-alvo para a oncologia. A ordem dos links  corresponde à ordem de apresentação dos trabalhos. Uma breve sinopse  acompanha cada link, que é de livre acesso. Uma diretriz geral para a  apresentação é informada, mas outros elementos podem ser inseridos à  vontade, respeitando-se o tempo de apresentação do seminário.&lt;br /&gt;&lt;/div&gt;&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;1. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrYjg5NDI2NmItN2UxMi00ZDYxLWE3YTAtNDJmYjJmM2Q0MTNj&amp;amp;hl=pt_BR&amp;amp;authkey=CK3RrZ4I" target="_blank"&gt;Buchdunger, 1996&lt;/a&gt;.  Os autores descrevem, pela primeira vez, o composto experimental da  CIBA, CGP 57148, depois chamado STI 571, depois denominado imatinib,  hoje a droga de baixo peso molecular com atividade inibidora de  tirosina-cinase de maior sucesso. Descreva a validação deste composto em  termos de sua especificidade pela enzima ABLK e atividade  antiproliferativa.&lt;br /&gt;2. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrMTdkMjY1YzYtM2RlNS00ZDcwLTk5MjEtNjZjOTY4MzhhZmNl&amp;amp;hl=pt_BR&amp;amp;authkey=CJS17pcD" target="_blank"&gt;Evans, 2003&lt;/a&gt;.  Revisão sobre farmacogenética e farmacogenômica. Apresentar breve  histórico, teoria geral da interação gene-fármaco e dar exemplos da  importância deste tópico (polimorfismos genéticos influenciando a  farmacocinética, polimorfismos genéticos de alvos). Mostrar as  possibilidades do diagnóstico molecular para individualizar a  farmacoterapia.&lt;br /&gt;3. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrNTJhYzIyYzEtM2JjYS00MWJkLWFlNGQtOTVjNjYxMTZhNGZl&amp;amp;hl=pt_BR&amp;amp;authkey=CKLjzYEM" target="_blank"&gt;Trevino, 2009&lt;/a&gt;.  Trabalho original do grupo do Saint Jude Children's Research Hospital e  centros associados, validando através de farmacogenômica um marcador  capaz de prever a resposta de crianças com leucemia linfóide aguda ao  metotrexato, incluindo efeitos colaterais e eficácia do tratamento.  Descreva a metodologia genômica sucintamente e seus resultados.&lt;br /&gt;&lt;br /&gt;Os  seminaristas podem incluir informações de outras fontes a critério.  Também estou à disposição para ajudar com material de apoio e tirando  dúvidas. Basta entrar em contato pelo e-mail.&lt;br /&gt;&lt;br /&gt;Os slides da aula estão disponíveis &lt;u&gt;&lt;a href="https://docs.google.com/present/edit?id=0AYDURVFZqBRrZHpuNWZyd18yMDdnaGc2NjdmNQ&amp;amp;hl=pt_BR"&gt;aqui&lt;/a&gt;&lt;/u&gt;.&lt;i&gt; &lt;/i&gt;&lt;br /&gt;Complemento: segundo arquivo de slides clique &lt;a href="https://docs.google.com/present/edit?id=0AYDURVFZqBRrZHpuNWZyd18yMzFnaDRqdnZkNg&amp;amp;hl=pt_BR"&gt;aqui&lt;/a&gt;.&lt;br /&gt;&lt;br /&gt;Atenciosamente,&lt;br /&gt;&lt;br /&gt;Helder Felix&lt;br /&gt;Palestrante da aula "Desenvolvimento de Terapias-alvo e Farmacogenômica aplicada à oncologia".&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5515270554039103916'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5515270554039103916'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/10/aulas-da-pos-graduacao.html' title='Aulas da Pós-graduação'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2519810235627132465</id><published>2012-06-30T19:16:00.000-03:00</published><updated>2012-06-30T19:16:08.280-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='monoclonais'/><category scheme='http://www.blogger.com/atom/ns#' term='survival'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='monoclonal antibody'/><category scheme='http://www.blogger.com/atom/ns#' term='biologicals'/><category scheme='http://www.blogger.com/atom/ns#' term='leukemia'/><category scheme='http://www.blogger.com/atom/ns#' term='sobrevida'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='leucemia'/><title type='text'>Novo tratamento para Leucemia Linfóide Aguda recidivada e refratária</title><content type='html'>A prestigiada revista Lancet Oncology publicou recentemente o resultado de um &lt;a href="http://pt.wikipedia.org/wiki/Ensaio_cl%C3%ADnico" target="_blank"&gt;ensaio clínico&lt;/a&gt; fase II que avaliou um novo tratamento em pacientes com &lt;a href="http://pt.wikipedia.org/wiki/Leucemia_linfoide_aguda" target="_blank"&gt;LLA&lt;/a&gt; recidivada, refratária a outros tratamentos. Trata-se do inotuzumab ozogamicina, um anticorpo monoclonal dirigido contra a proteína transmembrana &lt;a href="http://en.wikipedia.org/wiki/CD22" target="_blank"&gt;CD22&lt;/a&gt;, conjugado com a &lt;a href="http://en.wikipedia.org/wiki/Calicheamicin" target="_blank"&gt;caliqueamicina&lt;/a&gt;, um antibiótico citotóxico. A caliqueamicina já foi utilizada em outra terapia-alvo em pacientes com leucemias, o &lt;a href="http://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin" target="_blank"&gt;gemtuzumab ozogamicina&lt;/a&gt; (Mylotarg - Wyeth), um anticorpo monoclonal conjugado com o antibiótico que tem como alvo a molécula &lt;a href="http://en.wikipedia.org/wiki/CD33" target="_blank"&gt;CD33&lt;/a&gt;. Enquanto o CD33 é encontrado na superfície de células de &lt;a href="http://en.wikipedia.org/wiki/Haematopoiesis#Lineages" target="_blank"&gt;linhagem mielóide&lt;/a&gt;, o CD22 é expressado principalmente por &lt;a href="http://pt.wikipedia.org/wiki/Linf%C3%B3cito_B" target="_blank"&gt;linfócitos B&lt;/a&gt; maduros, sendo linhagem-específico. O Mylotarg, usado no tratamento da Leucemia Mielóide Aguda entre 2000 e 2010, foi retirado do mercado pela Wyeth a pedido do FDA, quando saíram os resultados de um ensaio clínico fase III (SWOG S0106), o qual mostrou uma mortalidade inaceitável nos pacientes tratados com a droga.&lt;br /&gt;O presente estudo testou o inotuzumab ozogamicina em 49 pacientes, adultos e crianças, com LLA recidivada e refratária. Parte dos pacientes já sofrera transplante de células progenitoras (&lt;a href="http://en.wikipedia.org/wiki/Stem_cell" target="_blank"&gt;stem cells&lt;/a&gt;). A mediana de &lt;a href="http://pt.wikipedia.org/wiki/Progn%C3%B3stico_%28medicina%29#An.C3.A1lise_de_Sobrevida" target="_blank"&gt;sobrevida&lt;/a&gt; dos pacientes foi de 5,1 meses (7,9 meses nos pacientes que responderam). Vinte e oito pacientes alcançaram remissão medular completa, 16 pacientes tiveram remissão citogenética completa e 17 tiveram pesquisa de &lt;a href="http://pt.wikipedia.org/wiki/Doen%C3%A7a_residual_m%C3%ADnima" target="_blank"&gt;doença residual mínima&lt;/a&gt; negativa. Um total de 32 pacientes faleceu e o restante estava em seguimento. Apesar da mediana de sobrevida reduzida, o grupo de pacientes do ensaio era pesadamente tratado, com pelo menos 2 tratamentos anteriores. Pacientes com LLA com recidiva múltipla usualmente têm sobrevida muito curta ( mediana de 2-3 meses). O grupo que realizou o ensaio, do MD Anderson Cancer Center e financiado pela Pfizer, considera que o inotuzumab ozogamicina é muito promissor e merece ser ensaiado num número maior de pacientes, num desenho fase III.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2519810235627132465'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2519810235627132465'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/06/novo-tratamento-para-leucemia-linfoide.html' title='Novo tratamento para Leucemia Linfóide Aguda recidivada e refratária'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8033872520103518598</id><published>2012-06-30T12:39:00.000-03:00</published><updated>2012-06-30T12:39:09.327-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='survival'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='adverse drug reactions'/><category scheme='http://www.blogger.com/atom/ns#' term='medicina personalizada'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacogenética'/><category scheme='http://www.blogger.com/atom/ns#' term='personalized medicine'/><category scheme='http://www.blogger.com/atom/ns#' term='sobrevida'/><category scheme='http://www.blogger.com/atom/ns#' term='efeitos adversos'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacogenetics'/><title type='text'>Novidade no Tratamento de Osteossarcoma: quando a toxicidade é "melhor"</title><content type='html'>O objetivo do tratamento oncológico é obter a maior &lt;a href="http://pt.wikipedia.org/wiki/Progn%C3%B3stico_%28medicina%29#An.C3.A1lise_de_Sobrevida" target="_blank"&gt;sobrevida&lt;/a&gt; possível para os pacientes. Em última análise, procura-se curar o máximo número de pacientes. Adicionalmente, procura-se minimizar a toxicidade dos esquemas de tratamento utilizados, ou reduzindo doses ou usando drogas para prevenir &lt;a href="http://pt.wikipedia.org/wiki/Efeito_adverso" target="_blank"&gt;efeitos adversos&lt;/a&gt;. Esses têm sido, também, os objetivos gerais do tratamento dos pacientes com &lt;a href="http://pt.wikipedia.org/wiki/Osteossarcoma" target="_blank"&gt;osteossarcoma&lt;/a&gt;, o mais comum dos tumores ósseos da infância e adolescência. Resultados recentemente publicados, porém, podem indicar que os efeitos colaterais da terapia para osteossarcoma podem ser, de certa forma, "bem vindos".&lt;br /&gt;O grupo cooperativo europeu para o tratamento do osteossarcoma, European Osteosarcoma Intergroup (EOI) realizou três &lt;a href="http://pt.wikipedia.org/wiki/Ensaio_cl%C3%ADnico" target="_blank"&gt;ensaios clínicos&lt;/a&gt; &lt;a href="http://pt.wikipedia.org/wiki/Tipos_de_estudo_epidemiol%C3%B3gico" target="_blank"&gt;controlados&lt;/a&gt; e &lt;a href="http://usuarios.cultura.com.br/jmrezende/randomizar.htm" target="_blank"&gt;randomizados&lt;/a&gt; entre 1982 e 2002, incluindo 1067 pacientes, criando o maior grupo de pacientes com osteossarcoma seguidos prospectivamente. Os autores do estudo em questão usaram as informações combinadas de 533 pacientes que foram tratados com o "tratamento padrão" (grupo controle) nestes ensaios. O maior grau de toxicidade que cada paciente experimentou foi usado nos estudos comparativos. Os autores realizaram uma análise retrospectiva&amp;nbsp; comparando a toxicidade com a sobrevida e com a resposta à quimioterapia (avaliada na cirurgia, realizada após a quimioterapia).&lt;br /&gt;Os resultados indicam que os pacientes que experimentaram &lt;a href="http://www.einstein.br/Hospital/oncologia/nossos-servicos/odontologia/Paginas/mucosite-oral.aspx" target="_blank"&gt;mucosite&lt;/a&gt; grave (grau 3-4) tiveram melhor sobrevida que os demais (quase 75% com mucosite grave tiveram sobrevida prolongada, contra menos de 50% daqueles que não tiveram mucosite). Também tiveram impacto favorável na sobrevida a ocorrência de &lt;a href="http://www.oncoguia.com.br/site/interna.php?cat=108&amp;amp;id=2453&amp;amp;menu=3" target="_blank"&gt;neuropatia periférica&lt;/a&gt; e &lt;a href="http://pt.wikipedia.org/wiki/Trombocitopenia" target="_blank"&gt;trombocitopenia&lt;/a&gt;. A ocorrência de efeitos colaterais também teve impacto favorável na &lt;a href="http://www.fosp.saude.sp.gov.br/epidemiologia/sobrevida.html" target="_blank"&gt;sobrevida livre de progressão&lt;/a&gt;.&lt;br /&gt;A relação entre toxicidade e prognóstico em pacientes com câncer não é nova. Desde a década de 80, evidências acumulam-se mostrando que a toxicidade hematológica, especialmente a &lt;a href="http://www.cancer.net/patient/All+About+Cancer/Treating+Cancer/Managing+Side+Effects/Neutropenia" target="_blank"&gt;neutropenia&lt;/a&gt;, têm valor prognóstico em pacientes com câncer de mama, ovário, estômago e pulmão, além de crianças com leucemia linfóide aguda. A novidade neste trabalho foi a comprovação da associação da toxicidade da quimioterapia com o prognóstico em pacientes com osteossarcoma, além do papel mais importante da toxicidade não hematológica, verificada pela primeira vez. Por quê ocorre esta associação? Supostamente, pacientes que metabolizam mais rápido os quimioterápicos, ou são relativamente resistentes a seus efeitos, podem apresentar um menor efeito antitumoral do tratamento. Muito pouco é conhecido sobre a variação de resposta e metabolismo à quimioterapia entre os pacientes com osteossarcoma. Existem estudos de &lt;a href="http://pt.wikipedia.org/wiki/Farmacogen%C3%A9tica" target="_blank"&gt;farmacogenética&lt;/a&gt; em andamento, os quais podem esclarecer o papel da variação individual na resposta ao tratamento em pacientes com osteossarcoma. No futuro, será possível individualizar as doses e esquemas de tratamento para cada paciente, baseado em seu perfil farmacogenético, uma conquista que é chamada genericamente de "&lt;a href="http://www.einstein.br/espaco-saude/tecnologia-e-inovacao/Paginas/medicina-personalizada-e-nova-revolucao-na-saude.aspx" target="_blank"&gt;medicina personalizada&lt;/a&gt;".</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8033872520103518598'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8033872520103518598'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/06/novidade-no-tratamento-de-osteossarcoma.html' title='Novidade no Tratamento de Osteossarcoma: quando a toxicidade é &quot;melhor&quot;'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2637716745436365076</id><published>2012-03-19T13:20:00.001-03:00</published><updated>2012-03-19T13:20:45.346-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>A Successful and Sustainable Health System — How to Get There from Here — via NEJM</title><content type='html'>This is only a fragment of a very interesting essay on the current pitfalls of US health system, but one can see lessons to Brazil, as well. The entire text is worth a read.&lt;br /&gt;&lt;br /&gt;In his famous essay on Tolstoy entitled “The  Hedgehog and the Fox,” Isaiah Berlin compared a number of historical  figures to one or the other animal.&lt;span class="ref"&gt;&lt;/span&gt;  Foxes know many things, whereas the hedgehog knows one big thing.  Tolstoy, concluded Berlin, was a fox masquerading as a hedgehog:  although he believed that history demanded a unifying theme, he could  not resist his tendency to see many threads rather than one big cord.&lt;br /&gt;To  achieve a successful and sustainable health system, we must be able and  willing to try many different things. But therein lies a unifying idea:  do many things. No single stroke will solve this problem. A successful  and sustainable health system will not be achieved by supporting  prevention, it will not be achieved by championing competition, it will  not be achieved by comparing the effectiveness of different practices,  it will not be achieved by striking commercial influence from  professional decision making, it will not be achieved by changing the  way we pay doctors, and it will not be achieved by just reengineering  the system. It requires all these changes and more. We need the  cleverness of the fox and the persistence of the hedgehog. We must be  willing to adopt many strategies and use them to reach one big goal.&lt;br /&gt;&lt;div class="boxed-text-float" id="_e1"&gt; &lt;div class="section"&gt; &lt;h3 id="articleSources of Inefficiency in U.S. Health Care"&gt;Sources of Inefficiency in U.S. Health Care&lt;/h3&gt;&lt;table border="0" class="listgroup"&gt;&lt;tbody&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Payment for wrong outputs (units of service rather than episode of illness, health outcomes, or covered lives)&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Financial incentives that reward inefficiency (complications or readmissions)&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Lack of price information and incentives for patients&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Indifference of providers to induced costs&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Dysfunctional competition rather than performance-based competition&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Lack of personal or professional ethos to care about societal costs of health care&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Failure to take full advantage of professional skills of nurses&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Lack of uniform systems and processes to ensure safe and high-quality care&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Uneven patient flows, resulting in overcrowding, suboptimal care, and waste&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Insufficient involvement of patients in decision making (as in end-of-life care)&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Insufficient attention to prevention, disparities, primary care, health literacy, population health, and long-term results&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Fragmented and uncoordinated delivery, without continuity of care&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Lack of information on resource costs, performance, comparative effectiveness, quality of care, and health outcomes&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Scientific uncertainty about effectiveness and cost, especially of newer tests and treatments&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Cultural predisposition to believe that more care is better&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Administrative complexity of coping with multiple forms, regimens, and requirements of different insurers&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;•  Rewarding of inventors and entrepreneurs for possible performance  advantage more than for significant savings in overall system cost&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Regulatory regime that can only retard and not accelerate innovation&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Insufficient reliance on competitive bidding for drugs and devices&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1 last"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Distortions resulting from fraud, conflict of interest, and a dysfunctional malpractice system&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="boxed-text-float" id="_e2"&gt; &lt;div class="section"&gt; &lt;h3 id="articlePotential Uses of Health IT"&gt;Potential Uses of Health IT&lt;/h3&gt;&lt;table border="0" class="listgroup"&gt;&lt;tbody&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Personal medical records&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Personalized health reminders and follow-up&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Personal health, diet, and activity monitoring and motivation&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Pre-degree and continuing medical education&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Real-time clinical decision support&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Remote professional consultation and care&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Monitoring and advising of patients with chronic disease&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Quality assurance&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Performance assessment of providers and institutions&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Comparative outcomes research&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Matching of potential participants to clinical trials&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Monitoring for safety (or unanticipated benefits) of drugs, devices, diagnostic tests, surgery, and other treatments&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Enhanced peer-to-peer and professional–patient support&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Comparative health assessments across populations, communities, cities, and states&lt;/td&gt;&lt;/tr&gt;&lt;tr class="li1 last"&gt;&lt;td class="lilabel" valign="top"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="last" colspan="5" valign="top"&gt;• Public health surveillance for disease outbreaks, environmental risks, and potential bioterrorism&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="section"&gt; &lt;/div&gt;Disclosure forms provided by the author are available with the full text of this article at NEJM.org.&lt;br /&gt;&lt;div class="section"&gt;&lt;div class="sourceInfo"&gt;&lt;h3&gt;Source Information&lt;/h3&gt;From the Institute of Medicine, Washington, DC.&lt;br /&gt;Address reprint requests to Dr. Fineberg at the Institute of Medicine, 500 Fifth St., NW, Washington, DC 20001. &lt;/div&gt;&lt;/div&gt;&lt;br /&gt;Link to the full text: &lt;a href="http://bit.ly/xPLo3A"&gt;http://bit.ly/xPLo3A&lt;/a&gt; &lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMsa1114777?query=TOC#.T2dbmXGKeAE.blogger"&gt;A Successful and Sustainable Health System — How to Get There from Here — NEJM&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2637716745436365076/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2012/03/successful-and-sustainable-health.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2637716745436365076'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2637716745436365076'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/successful-and-sustainable-health.html' title='A Successful and Sustainable Health System — How to Get There from Here — via NEJM'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7131539168849989004</id><published>2012-03-19T13:12:00.001-03:00</published><updated>2012-03-19T13:12:59.962-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia — via NEJM</title><content type='html'>&lt;h1&gt;Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia&lt;/h1&gt;&lt;div class="authors"&gt;Jay  P. Patel, Mithat Gönen, Ph.D., Maria E. Figueroa, M.D., Hugo Fernandez,  M.D., Zhuoxin Sun, Ph.D., Janis Racevskis, Ph.D., Pieter Van  Vlierberghe, Ph.D., Igor Dolgalev, B.S., Sabrena Thomas, B.S., Olga  Aminova, B.S., Kety Huberman, B.S., Janice Cheng, B.S., Agnes Viale,  Ph.D., Nicholas D. Socci, Ph.D., Adriana Heguy, Ph.D., Athena Cherry,  Ph.D., Gail Vance, M.D., Rodney R. Higgins, Ph.D., Rhett P. Ketterling,  M.D., Robert E. Gallagher, M.D., Mark Litzow, M.D., Marcel R.M. van den  Brink, M.D., Ph.D., Hillard M. Lazarus, M.D., Jacob M. Rowe, M.D.,  Selina Luger, M.D., Adolfo Ferrando, M.D., Ph.D., Elisabeth Paietta,  Ph.D., Martin S. Tallman, M.D., Ari Melnick, M.D., Omar Abdel-Wahab,  M.D., and Ross L. Levine, M.D.&lt;/div&gt;&lt;div class="citationLine"&gt;March 14, 2012                     (10.1056/NEJMoa1112304)                 &lt;/div&gt;&lt;h3 id="abstractBackground"&gt;Background&lt;/h3&gt;Acute myeloid leukemia  (AML) is a heterogeneous disease with respect to presentation and  clinical outcome. The prognostic value of recently identified somatic  mutations has not been systematically evaluated in a phase 3 trial of  treatment for AML.&lt;br /&gt;&lt;h3 id="abstractMethods"&gt;Methods&lt;/h3&gt;We performed a mutational  analysis of 18 genes in 398 patients younger than 60 years of age who  had AML and who were randomly assigned to receive induction therapy with  high-dose or standard-dose daunorubicin. We validated our prognostic  findings in an independent set of 104 patients.&lt;br /&gt;&lt;div class="section"&gt; &lt;/div&gt;&lt;div class="section"&gt; &lt;h3 id="abstractResults"&gt;Results&lt;/h3&gt;We identified at least one somatic alteration in 97.3% of the patients. We found that internal tandem duplication in &lt;em&gt;FLT3&lt;/em&gt; (&lt;em&gt;FLT3&lt;/em&gt;-ITD), partial tandem duplication in &lt;em&gt;MLL&lt;/em&gt; (&lt;em&gt;MLL-&lt;/em&gt;PTD), and mutations in &lt;em&gt;ASXL1&lt;/em&gt; and &lt;em&gt;PHF6&lt;/em&gt; were associated with reduced overall survival (P=0.001 for &lt;em&gt;FLT3&lt;/em&gt;-ITD, P=0.009 for &lt;em&gt;MLL-&lt;/em&gt;PTD, P=0.05 for &lt;em&gt;ASXL1,&lt;/em&gt; and P=0.006 for &lt;em&gt;PHF6&lt;/em&gt;); &lt;em&gt;CEBPA&lt;/em&gt; and &lt;em&gt;IDH2&lt;/em&gt; mutations were associated with improved overall survival (P=0.05 for &lt;em&gt;CEBPA&lt;/em&gt; and P=0.01 for &lt;em&gt;IDH2&lt;/em&gt;). The favorable effect of &lt;em&gt;NPM1&lt;/em&gt; mutations was restricted to patients with co-occurring &lt;em&gt;NPM1&lt;/em&gt; and &lt;em&gt;IDH1&lt;/em&gt; or &lt;em&gt;IDH2&lt;/em&gt;  mutations. We identified genetic predictors of outcome that improved  risk stratification among patients with AML, independently of age,  white-cell count, induction dose, and post-remission therapy, and  validated the significance of these predictors in an independent cohort.  High-dose daunorubicin, as compared with standard-dose daunorubicin,  improved the rate of survival among patients with &lt;em&gt;DNMT3A&lt;/em&gt; or &lt;em&gt;NPM1&lt;/em&gt; mutations or &lt;em&gt;MLL&lt;/em&gt; translocations (P=0.001) but not among patients with wild-type &lt;em&gt;DNMT3A, NPM1,&lt;/em&gt; and &lt;em&gt;MLL&lt;/em&gt; (P=0.67).&lt;br /&gt;&lt;h3 id="abstractConclusions"&gt;Conclusions&lt;/h3&gt;We found that &lt;em&gt;DNMT3A&lt;/em&gt; and &lt;em&gt;NPM1&lt;/em&gt; mutations and &lt;em&gt;MLL&lt;/em&gt;  translocations predicted an improved outcome with high-dose induction  chemotherapy in patients with AML. These findings suggest that  mutational profiling could potentially be used for risk stratification  and to inform prognostic and therapeutic decisions regarding patients  with AML. (Funded by the National Cancer Institute and others.)&lt;br /&gt;&lt;/div&gt;Link to full article: &lt;a href="http://bit.ly/yXoDjc"&gt;http://bit.ly/yXoDjc&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1112304?query=TOC#.T2daO2kfYiw.blogger"&gt;Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia — NEJM&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7131539168849989004/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2012/03/prognostic-relevance-of-integrated.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7131539168849989004'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7131539168849989004'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/prognostic-relevance-of-integrated.html' title='Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia — via NEJM'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3489497736808882538</id><published>2012-03-19T12:18:00.001-03:00</published><updated>2012-03-19T12:18:04.380-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Consumir carne vermelha todo dia aumenta risco de morte, diz estudo - via Consulfarma</title><content type='html'>Especialistas de Harvard ouviram 120 mil pessoas dos  Estados Unidos. Carne processada pode elevar risco de morte prematura  em até 20%.&lt;br /&gt;Uma pesquisa norte-americana afirma que comer uma porção diária de carne  vermelha processada (como salsichas e bacon) pode aumentar o risco de  morte prematura em até 20%, enquanto que ingerir carne sem processamento  elevaria em 13% este risco. &lt;br /&gt;As informações foram divulgadas nesta segunda-feira (12), em estudo  realizado por especialistas da Universidade Harvard, que contou com  dados de mais de 120 mil pessoas dos Estados Unidos.&lt;br /&gt;O estudo oferece evidências de que comer carne vermelha aumenta o risco  de enfermidades cardíacas e câncer. Além disso, sugere que substituí-la  por peixe e carne de aves poderia reduzir o risco de mortalidade.&lt;br /&gt;Foram analisadas informações de 37.698 homens e 83.644 mulheres durante  22 anos e 28 anos, respectivamente. Os participantes foram entrevistados  sobre seus hábitos alimentares a cada quatro anos.&lt;br /&gt;Especialistas recomendam reduzir consumo diário de carne vermelha para evitar morte prematura&lt;br /&gt;Cardápio mais saudável&lt;br /&gt;Aqueles que comiam uma porção diária de carne vermelha sem processamento  (carne comum) registraram um risco 13% maior do que aqueles que não  comiam com tanta frequência este alimento.&lt;br /&gt;E se a carne vermelha era processada, o risco aumentava em 20%.&lt;br /&gt;No entanto, substituir a carne vermelha por nozes provou que o risco de  mortalidade cairia em 19%, enquanto que o consumo de grãos inteiros e  aves diminuíram o risco em 14%. Já o consumo de peixes fez cair o risco  em 7%.&lt;br /&gt;Mortes que poderiam ser evitadas&lt;br /&gt;Os autores disseram quem entre 7% e 9% das mortes que ocorreram durante o  estudo “poderiam ser evitadas se todos os participantes consumissem  menos 0,5 porção diária de carne vermelha.&lt;br /&gt;A carne vermelha processada contém ingredientes como a gordura saturada,  sódio, nitratos e outras substâncias cancerígenas que estão ligadas a  muitas doenças crônicas, incluindo doenças cardíacas e câncer.&lt;br /&gt;"Mais de 75% dos US$ 2,6 bilhões gastos anualmente com saúde nos Estados  Unidos são por motivos de doença crônica", disse Dean Ornish, médico e  nutricionista da Universidade da Califórnia, em San Francisco. "Consumir  menos carne vermelha pode ajudar a reduzir a mortalidade devido a essas  doenças e reduzindo, assim, os custos com saúde”, complementa.&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;strong&gt;Fonte:&lt;/strong&gt; G1&lt;/span&gt;                   &lt;br /&gt;&amp;nbsp;                   &lt;br /&gt;Link para o post original: &lt;a href="http://bit.ly/FR3oEQ"&gt;http://bit.ly/FR3oEQ&lt;/a&gt;&lt;br /&gt;&lt;a href="http://www.consulfarma.com/detalhes_noticias.php?id=133717#.T2dNqYoA_OU.blogger"&gt;Consulfarma - Notícias - Consumir carne vermelha todo dia aumenta risco de morte, diz estudo.&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3489497736808882538/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2012/03/consumir-carne-vermelha-todo-dia.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3489497736808882538'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3489497736808882538'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/consumir-carne-vermelha-todo-dia.html' title='Consumir carne vermelha todo dia aumenta risco de morte, diz estudo - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7888746387234882953</id><published>2012-03-19T12:15:00.001-03:00</published><updated>2012-03-19T12:15:07.365-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Remédio contra a Aids voltado para crianças será testado no Brasil - via Consulfarma</title><content type='html'>Doses e sabores foram adaptados para os pacientes  infantis. Se aprovado, medicamento pode estar disponível em três anos.&lt;br /&gt;A Fundação Oswaldo Cruz (Fiocruz) começará a testar em seres humanos um  remédio desenvolvido especialmente para tratar a Aids em crianças.&lt;br /&gt;O medicamento desenvolvido pela Instituto de Tecnologia em Fármacos da  Fiocruz (Farmanguinhos) é um antirretroviral, que tem como objetivos  suprimir a carga viral, restaurar o sistema imune e, assim, retardar a  progressão da doença.&lt;br /&gt;Os testes terão início ainda no segundo semestre de 2012, em seis  centros de pesquisa em São Paulo, Rio de Janeiro e Minas Gerais. Se eles  tiverem sucesso, o remédio estará disponível no mercado em três anos,  de acordo com os cientistas dessa instituição pública.&lt;br /&gt;Os pesquisadores reuniram em um único comprimido os princípios ativos  lamivudina, zidovudina e nevirapina, usados normalmente no combate  contra a Aids. Ao todo, há 16 substâncias que são usadas nesse  tratamento, mas a maioria delas não pode ser aplicada em crianças.&lt;br /&gt;Esse comprimido contém doses adequadas para crianças e foi adoçado com  outros componentes com o objetivo de tornar o sabor mais agradável. Com  as mudanças, os cientistas esperam melhorar a adesão dos mais jovens ao  tratamento.&lt;br /&gt;Pelos dados oficiais, entre 1980 e 2010 foram registrados no Brasil 14  mil casos de Aids em crianças menores de 13 anos, que em sua maioria  herdaram a doença de suas mães durante a gravidez ou contraíram no  momento do parto.&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;strong&gt;Fonte:&lt;/strong&gt; G1&lt;/span&gt;                   &lt;br /&gt;&amp;nbsp;                   &lt;br /&gt;Link para o post original:&amp;nbsp; &lt;a href="http://bit.ly/AwA7E1"&gt;http://bit.ly/AwA7E1&lt;/a&gt;&lt;br /&gt;&lt;a href="http://www.consulfarma.com/detalhes_noticias.php?id=133718#.T2dNCyQH1r0.blogger"&gt;Consulfarma - Notícias - Remédio contra a Aids voltado para crianças será testado no Brasil.&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7888746387234882953/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2012/03/remedio-contra-aids-voltado-para.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7888746387234882953'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7888746387234882953'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/remedio-contra-aids-voltado-para.html' title='Remédio contra a Aids voltado para crianças será testado no Brasil - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6776756026403015617</id><published>2012-03-19T12:12:00.001-03:00</published><updated>2015-12-07T20:29:18.489-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='ensino e pesquisa'/><category scheme='http://www.blogger.com/atom/ns#' term='Curtis Harris'/><category scheme='http://www.blogger.com/atom/ns#' term='A.C. Camargo'/><category scheme='http://www.blogger.com/atom/ns#' term='conselho internacional'/><category scheme='http://www.blogger.com/atom/ns#' term='Nobel em Medicina ou Fisiologia'/><category scheme='http://www.blogger.com/atom/ns#' term='Harald zur Hausen'/><title type='text'>Nobel avalia pesquisa do câncer em SP - via Consulfarma</title><content type='html'>Alemão vencedor do maior prêmio da ciência, junto com colegas internacionais, integra conselho do A.C. Camargo, um dos principais centros do Brasil na área da oncologia.&lt;br /&gt;&lt;br /&gt;Em iniciativa inédita no país, o Hospital A.C. Camargo, de São Paulo,  passou a ter um conselho internacional para avaliar suas pesquisas. A  instituição responde por 60% da produção científica oncológica  brasileira. &lt;br /&gt;Seis pesquisadores de renome mundial, entre eles o virologista alemão  Harald zur Hausen, Prêmio Nobel em Medicina ou Fisiologia de 2008, e  Curtis Harris, diretor do Instituto Nacional do Câncer dos EUA, integram  o conselho, que foi idealizado pelo oncologista Ricardo Brentani, morto  em novembro.&lt;br /&gt;Nos últimos dois dias, o grupo analisou os projetos científicos, as  instalações e as condições de ensino e pesquisa do hospital. Agora,  prepara um relatório com a avaliação e as possíveis recomendações. Um em  cada três oncologistas brasileiros se especializou no hospital.&lt;br /&gt;"Eles vão nos dizer o que acharam de bom e o que precisa ser melhorado",  resume o patologista Fernando Soares, diretor da pós-graduação do  hospital. Os conselheiros não serão remunerados.&lt;br /&gt;Dentro de um ano, eles devem retornar ao Brasil para checar se as  mudanças sugeridas foram feitas e se surtiram o efeito esperado.&lt;br /&gt;Segundo o americano Curtis Harris, as pesquisas no hospital têm nível de  qualidade internacional e, por isso, despertaram o interesse do grupo.  "Existem muitas potencialidades por aqui. Jovens pesquisadores que estão  no início de suas carreiras e que logo vão desabrochar", disse ele à  Folha.&lt;br /&gt;Hausen, ganhador do Nobel, afirmou estar "entusiasmado". "Há pesquisas  de qualidade, especialmente na área genômica. Mas, como em qualquer  outro lugar, sempre é possível melhorar."&lt;br /&gt;Uma das pesquisas desenvolvidas no hospital investiga os genes  associados a tumores hereditários, como o de cólon e de mama, e os  marcadores que poderão ser utilizados no diagnóstico e no tratamento da  doença.&lt;br /&gt;"Investigamos novas mutações do câncer familiar para fazer um  aconselhamento genético precoce e poder tratar a pessoa adequadamente,  com base no tipo de tumor que ela tem", explica a bióloga Silvia  Rogatto.&lt;br /&gt;Para o imunologista português António Amaral Coutinho, porta-voz do  grupo internacional, submeter pesquisas ao crivo de pares internacionais  ajuda a melhorar a qualidade delas.&lt;br /&gt;"É o momento de o Brasil investir em ciência e tecnologia e descobrir  melhores maneiras de fazer as coisas. Não se inventa nada sem saber  muito. Não adianta só exportar gado. É preciso exportar cabeças",  afirmou Coutinho.&lt;br /&gt;Ele não quis adiantar o parecer do grupo sobre as pesquisas do A.C. Camargo.&lt;br /&gt;&lt;br /&gt;CONHEÇA OS MEMBROS DA COMISSÃO&lt;br /&gt;ALAN ASHWORTH&lt;br /&gt;Professor do Instituto de Pesquisa do Câncer do Reino Unido&lt;br /&gt;&lt;br /&gt;ANTÓNIO COUTINHO&lt;br /&gt;Diretor do Instituto Gulbenkian, em Portugal&lt;br /&gt;&lt;br /&gt;CURTIS HARRIS&lt;br /&gt;Diretor do Instituto Nacional do Câncer dos Estados Unidos&lt;br /&gt;&lt;br /&gt;HARALD ZUR HAUSEN&lt;br /&gt;Ganhador do Prêmio Nobel em Medicina ou Fisiologia (2008) por estudos sobre vírus HPV e câncer&lt;br /&gt;&lt;br /&gt;KAI SIMONS&lt;br /&gt;Diretor emérito do Instituto Max Planck de Biologia Molecular, Celular e Genética&lt;br /&gt;&lt;br /&gt;MARTIN RAFF&lt;br /&gt;Professor emérito do britânico University College&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;strong&gt;Fonte:&lt;/strong&gt; FOLHA DE SÃO PAULO – SP&lt;/span&gt;                   &lt;br /&gt;&amp;nbsp;                   &lt;br /&gt;Post original: &lt;a href="http://bit.ly/AtskHn"&gt;http://bit.ly/AtskHn&lt;/a&gt;&lt;br /&gt;&lt;a href="http://www.consulfarma.com/detalhes_noticias.php?id=133721#.T2dLaaEwTfE.blogger"&gt;Consulfarma - Notícias - Nobel avalia pesquisa do câncer em SP.&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6776756026403015617'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6776756026403015617'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/nobel-avalia-pesquisa-do-cancer-em-sp.html' title='Nobel avalia pesquisa do câncer em SP - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1021422328933534678</id><published>2012-03-17T09:32:00.000-03:00</published><updated>2012-03-17T09:32:05.436-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Scientists go Social - via ScienceInsider</title><content type='html'>Three Finnish researchers have created an online service that  could eventually replace or supplement the current way journals get  scientists to peer review submitted manuscripts. Already partnered with the ecology journal&lt;i&gt; &lt;a href="http://www.wiley.com/bw/journal.asp?ref=0906-7590"&gt;Ecography&lt;/a&gt;, &lt;/i&gt;published by Wiley&lt;i&gt;,&lt;/i&gt;        &lt;a href="http://www.peerageofscience.org/"&gt;Peerage of Science&lt;/a&gt;&lt;i&gt;  &lt;/i&gt;is  an innovative social network of scientists to which researchers submit         their manuscripts; other members with relevant expertise,  alerted by keywords in the papers, will then provide reviews that  scientific journals can use         to decide whether to publish the work. University of Jyväskylä  and the University of Eastern Finland, where the three creators of the  service are         based, have sponsored the company founded to further build up  the service this year.     &lt;br /&gt;              The current peer review system in which journal editors send  potentially publishable manuscripts to experts for review is hotly  debated. Many         scientists complain that the system is slow, inefficient, of  variable quality, and prone to favoritism. Moreover, there's growing  resentment in some         quarters about being asked to take valuable time to provide free  reviews to journals that are operated by for-profit publishers or that  don't make         their papers open-access. Several suggestions have been made to  improve the peer review system, such as introducing credits for  reviewers, using social         media, and making the process more transparent.     &lt;br /&gt;                 Peerage of Science aims to combine these ideas, explains co-founder&lt;b&gt; &lt;/b&gt;Mikko  Mönkkönen, an applied ecologist at the University of Jyväskylä. A         researcher would initially upload a manuscript to Peerage of  Science. It will then be made anonymous and posted on a Web site that is  exclusively         accessible to other members, which currently stands at around  500 scientists. Along with the manuscript, the authors can add a short  pitch explaining         why peers should review this manuscript.     &lt;br /&gt;                                                                        Potential reviewers receive an e-mail if tagged keywords  reflecting the manuscript match their expertise—bird migration, for  example. After         reviewing a paper, peers are allowed to grade the quality of the  other reviews, by awarding a grade between one and five.&amp;nbsp; Editors of  journals partnering with Peerage of Science can anonymously track  reviews, get automated updates on the paper and make an offer to publish  the paper, perhaps after a requested revision. Authors are free to  accept or decline their offers. &lt;br /&gt;                   To prevent favoritism, peers are not allowed to review  manuscripts submitted by colleagues of the same university or  researchers they cooperated with         in the last 3 years. This excludes many potentially suitable  reviewers, however, so the service founders will monitor if this rule is  needed. "We want         to create a system that people can trust. But if this rule turns  out to be too strict, we are willing to change it," says Mönkkönen.     &lt;br /&gt;      Transparency is another way Peerage of Science aims to prevent bias. If  reviewers agree, their reviews will be published in an online journal  called        &lt;i&gt;Proceedings of Peerage of Science&lt;/i&gt;. The founders  hope this will create a career incentive for scientists to do  high-quality reviews: they can         boost their reputation. "One cannot just get away with an  unrealistically positive or negative review without justification," says  Seppänen.     &lt;br /&gt;The founders of Peerage of Science, who include evolutionary  ecologist Janne Kotiaho of University of Jyväskylä, initially aimed  their service at their         own field, ecology. But their goal is to eventually expand it to  all scientific areas.&amp;nbsp;&lt;i&gt;&lt;/i&gt;&lt;br /&gt;Read the full story: &lt;a href="http://bit.ly/A0GZkC"&gt;http://bit.ly/A0GZkC&lt;/a&gt;&lt;br /&gt;&lt;a href="http://news.sciencemag.org/scienceinsider/2012/01/online-social-network-seeks-to.html?ref=em&amp;amp;elq=293f8d9172214522b030bbe33e7c8303#.Tx7Jl1YlmSw.blogger"&gt;Online Social Network Seeks to Overhaul Peer Review in Scientific Publishing - ScienceInsider&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1021422328933534678'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1021422328933534678'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/scientists-go-social-via-scienceinsider.html' title='Scientists go Social - via ScienceInsider'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-727916470321813884</id><published>2012-03-17T09:23:00.000-03:00</published><updated>2012-03-17T09:23:16.084-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Massage's Mystery Mechanism Unmasked - via ScienceNOW</title><content type='html'>&lt;br /&gt;&lt;div class="content-main"&gt;   Massage's healing touch may have more to do with DNA than with good  hands. A new study has revealed for the first time how kneading eases  sore muscles—by turning off genes associated with inflammation and  turning on genes that help muscles heal. The discovery contradicts  popular claims that massage squeezes lactic acid or waste products out  of tired muscles and could bring new medical credibility to the  practice.&lt;br /&gt;  Despite massage's widespread popularity, researchers know  surprisingly little about its effects on muscles. The scant evidence makes many physicians  unsure, if not outright skeptical, of the method. &lt;br /&gt;  Mark Tarnopolsky, a neurometabolic researcher at McMaster University  in Hamilton, Canada, recruited 11 young healthy men for his research. The subjects underwent a workout session and a  massage therapist massaged one of their legs. Tissue samples from the volunteers' quadriceps muscles were taken—once before  the workout, once 10 minutes after the massage, and once 3 hours after  the workout—and compared the genetic profiles of each sample.&lt;br /&gt;  The researchers detected more indicators of cell repair and  inflammation in the post-workout samples than in the pre-workout  samples. Exercise  activates genes associated with repair and inflammation. However, there were clear differences between the massaged legs and the  unmassaged ones after exercise. The massaged legs had more genes associated with cellular energy and less genes associated with inflammation. &lt;br /&gt;  The results, published in &lt;i&gt;Science Translational Medicine&lt;/i&gt;, suggest that &lt;a href="http://stm.sciencemag.org/content/4/119/119ra13.abstract"&gt;massage suppresses the inflammation that follows exercise while promoting faster healing&lt;/a&gt;. &lt;/div&gt;&lt;br /&gt;Read the full story: &lt;a href="http://bit.ly/xqmGRq"&gt;http://bit.ly/xqmGRq&lt;/a&gt;&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2012/02/massages-mystery-mechanism-unmas.html?ref=em"&gt;Massage's Mystery Mechanism Unmasked - ScienceNOW&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Read the article: &lt;a href="http://bit.ly/y9Bzzb"&gt;http://bit.ly/y9Bzzb&lt;/a&gt;</content><link rel='related' href='http://news.sciencemag.org/sciencenow/2012/02/massages-mystery-mechanism-unmas.html?ref=em' title='Massage&apos;s Mystery Mechanism Unmasked - via ScienceNOW'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/727916470321813884'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/727916470321813884'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/massages-mystery-mechanism-unmasked-via.html' title='Massage&apos;s Mystery Mechanism Unmasked - via ScienceNOW'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4794469811779152931</id><published>2012-03-12T16:21:00.000-03:00</published><updated>2012-03-19T16:22:14.132-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Aspirina modificada pode ser a nova arma contra o câncer - via Consulfarma</title><content type='html'>Segundo cientistas nova-iorquinos, ela poderia chegar a substituir remédios tradicionais.&lt;br /&gt;NOVA YORK — A aspirina, quem diria, que já ficou famosa por ajudar a  prevenir problemas cardiovasculares, está prestes a ganhar um papel  importante também na luta contra o câncer. Cientistas da The City  College, uma universidade de Nova York, desenvolveram um novo composto à  base da droga que, a médio prazo, pode se tornar uma poderosa arma  contra o câncer, e bem mais segura do que os remédios usados atualmente  para tratar a doença.&lt;br /&gt;Já havia indícios de que a aspirina poderia ajudar no combate ao câncer;  o problema eram os graves efeitos colaterais que sua utilização para  este fim poderia causar. As modificações realizadas em sua composição,  porém, parecem fazer os efeitos adversos desaparecerem, além de tornarem  a droga bem mais potente.&lt;br /&gt;A equipe da Escola Biomédia Sophie Davis, instalada na The City College,  relatou que a nova aspirina inibiu o crescimento de 11 diferentes tipos  de células cancerígenas em cultura, sem prejudicar as células saudáveis  ao seu redor. Entre elas, estavam células causadoras dos cânceres de  cólon, pâncreas, pulmão, próstata e mama, além de leucemia.&lt;br /&gt;— Os componentes-chaves deste novo composto são muito, muito potentes, e  ainda tem toxicidade mínima para as outras células — disse o professor  associado Khosrow Kashfi, principal responsável pela pesquisa.&lt;br /&gt;O composto de aspirina também reduziu tumores de cóloln em 85% em animais, sem efeitos adversos.&lt;br /&gt;— Se o que vimos em animais puder ser transporto para homens, (o  composto) poderia ser usado junto com outros remédios antes da  quimioterapia ou de uma cirurgia — explicou Kashfi.&lt;br /&gt;Usada principalmente como analgésicos, a aspirina e outras drogas  chamadas anti-inflamatórias não esteroidais (Aines), como o ibuprofeno e  o naproxeno, são conhecidos por sua capacidade de reduzir inflamações.  Nos anos 1980, concluiu-se que uma aspirina por dia é capaz de diminuir  os riscos de infarto e derrame. Estudos mais recentes demonstraram sua  potencialidade também para inibir o desenvolvimento de câncer.&lt;br /&gt;— Há muitos dados mostrando que, quando tomada regularmente, a aspirina  reduz o risco de câncer de cólon em 50% — lembrou o professor Kashfi.&lt;br /&gt;O problema é que o uso prolongado desta droga tem seus próprios riscos:  os efeitos colaterais vão de úlceras hemorrágicas a falência dos rins.  Para contornar a situação, os pesquisdores criaram um híbrido de duas  formulações antigas, que chamaram de Nosh-aspirina. Eles usaram a  aspirina como um suporte para duas moléculas que comprovadamente  aumentam sua segurança e sua potência.&lt;br /&gt;Uma delas, o óxido nítrico, ajuda a proteger o estômago. A outra é o  sulfeto de hidrogênio, que, já se sabia, aumenta a capacidade da  aspirina de combater o câncer. Os pesquisadores suspeitam de que o  composto híbrido seria mais eficaz do que apenas uma das drogas  isoladamente para elevar o potencial da aspirina contra a doença: apenas  24 horas depois de usada contra culturas de células cancerosas, a  Nosh-aspirina demonstrou ser cem mil vezes mais potente que a aspirina  comum.&lt;br /&gt;— O híbrido é muito mais potente: 72 horas depois, ele já tinha 250 mil  vezes mais força que a aspirina comum contra células humanas de câncer  de cólon in vitro. Então, você precisa de uma quantidade menor para  obter o mesmo resultado — afirmou Kashfi, o que leva a concluir que,  usando doses menores, seria possível conseguir o efeito desejado contra o  câncer minimizando ou eliminando efeitos colaterais.&lt;br /&gt;O híbrido também mostrou ser 15 mil vezes mais potente do que a já  conhecida No-aspirina e o equivalente a 80 vezes mais forte do que o  composto que incorpora H{-2}S.&lt;br /&gt;Na segunda parte do trabalho, quando ratos portadores de células humanas  causadoras dos tumores de cólon receberam Nosh-aspirina oralmente, o  composto destruiu células, inibiu sua proliferação e reduziu  significativamente o crescimento do tumor, sem que houvesse qualquer  sinal de toxicidade nos animais.&lt;br /&gt;A expectativa é de que se possa criar uma droga baseada na  Nosh-aspirina. Kashfi, porém, observa que os próximos passos serão  testes de toxicidade e ensaios clínicos, e que a possibilidade de um  tratamento deste tipo passar a ser oferecido em hospitais e consultórios  ainda pode demorar anos até se tornar realidade.&lt;br /&gt;Os estudos foram financiados pelo Instituto Nacional do Câncer e pela  Fundação Nacional de Ciência americanos. A equipe, agora, apresentará  suas descobertas no evento anual promovido pela Associação Americana  para a Pesquisa do Câncer, a ser realizado no fim do mês, em Chicago.&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; O GLOBO – RJ&amp;nbsp; &lt;/span&gt;                   &lt;br /&gt;&lt;br /&gt;Link para o post original: &lt;a href="http://bit.ly/FQFEMZ"&gt;http://bit.ly/FQFEMZ&lt;/a&gt;&lt;br /&gt;&lt;a href="http://consulfarma.com/detalhes_noticias.php?id=133672#.T2eGwO7Qx7k.blogger"&gt;Consulfarma - Notícias - Aspirina modificada pode ser a nova arma contra o câncer.&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4794469811779152931'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4794469811779152931'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/aspirina-modificada-pode-ser-nova-arma.html' title='Aspirina modificada pode ser a nova arma contra o câncer - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3715678968310571804</id><published>2012-03-12T16:15:00.000-03:00</published><updated>2012-03-19T16:17:42.297-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Médico não é garoto-propaganda - via Consulfarma</title><content type='html'>É cruel e macula a classe viajar à custa de  laboratórios, sonegar impostos (´com recibo ou sem?´), cobrar ´por fora´  do convênio e ganhar percentual por próteses.&lt;br /&gt;O novo Código de Ética Médica, em vigor desde abril de 2010, foi  unanimemente saudado como um documento atual, abordando temas polêmicos  com coragem e lucidez.&lt;br /&gt;Foi, portanto, com tristeza e decepção que a sociedade brasileira tomou  conhecimento de uma emenda a um ponto importante do código, sobre a  relação dos médicos com os laboratórios farmacêuticos.&lt;br /&gt;No artigo 69 do código de 2010, foi vedado ao médico "obter vantagem  pelo encaminhamento de procedimentos, pela comercialização de  medicamentos, órteses e próteses ou implantes, cuja compra decorra de  influência direta em virtude de sua atividade profissional". A intenção  era coibir essa relação indigna que denigre a categoria médica.&lt;br /&gt;Na emenda divulgada na semana passada, o Conselho Federal de Medicina  corrigiu a norma, sob a alegação lamentável de que não conseguiu conter a  pressão dos laboratórios e de determinado segmento de médicos.&lt;br /&gt;Agora, permanece a velha relação indigna entre médicos e laboratórios,  tornando alguns profissionais -felizmente a minoria- garotos-propaganda  comerciais.&lt;br /&gt;Sou radicalmente contra essa prática, pelos seguintes motivos:&lt;br /&gt;1) Os médicos são profissionais que têm, em geral, uma remuneração digna e suficiente para manter uma vida de boa qualidade.&lt;br /&gt;Não precisam desses subterfúgios de ética duvidosa e às vezes ilegais:  viajar às custas de laboratórios, sonegar imposto de renda em conluio  constrangedor com os pacientes ("com recibo ou sem recibo?"), cobrar  "por fora" em convênios de planos de saúde, receber percentual para  colocar próteses indicadas especificamente, entre outros. Tais práticas  maculam a categoria.&lt;br /&gt;2) Afirmar, como foi feito na argumentação para a referida emenda, que  os médicos não direcionam suas prescrições em função da prática de  receber viagens gratuitas é de uma ingenuidade e de uma desfaçatez  inaceitáveis.&lt;br /&gt;Além de pesquisas já feitas em outros países que demonstram que ocorre  efetivamente esse receituário dirigido, é uma dedução óbvia: os  laboratórios visam, com essa prática, a fidelidade comercial.&lt;br /&gt;3) O dado mais importante é que, no final das contas, quem vai pagar as  viagens dos médicos são os pacientes, em situação de sofrimento físico e  psíquico, muitas vezes incapacitados e frequentemente hipossuficientes.  É uma crueldade inominável, pois o custo das viagens obviamente será  repassado para o preço dos medicamentos.&lt;br /&gt;É aceitável que sejam financiadas viagens relacionadas a pesquisas dos  laboratórios feitas por médicos, necessárias à própria pesquisa ou  destinadas a relatar em eventos médicos os resultados obtidos. É  importante, entretanto, fazer ainda as ressalvas nesses casos,  destinadas a evitar a simples propaganda de um produto comercial  específico.&lt;br /&gt;O Conselho Federal de Medicina deveria rever a emenda anunciada agora,  retornando ao texto original do código de 2010. Se houver polêmica,  sugiro realizar uma pesquisa de opinião entre os médicos brasileiros,  que certamente irão apontar para a decisão de manter a categoria fora do  conflito de interesses e reafirmar a dignidade profissional.&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; FOLHA DE SÃO PAULO – SP&lt;/span&gt;                   &lt;br /&gt;&lt;br /&gt;Link para o post original: &lt;a href="http://bit.ly/FQues1"&gt;http://bit.ly/FQues1&lt;/a&gt;&lt;br /&gt;&lt;a href="http://consulfarma.com/detalhes_noticias.php?id=133673#.T2eFVjn1o7s.blogger"&gt;Consulfarma - Notícias - Médico não é garoto-propaganda.&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3715678968310571804'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3715678968310571804'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/medico-nao-e-garoto-propaganda-via.html' title='Médico não é garoto-propaganda - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7455247216007265690</id><published>2012-03-08T17:50:00.000-03:00</published><updated>2012-03-19T17:50:47.868-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Novartis apresenta resultados de fármaco experimental para a mielofibrose - via Consulfarma</title><content type='html'>O NEJM publicou esta quinta-feira  os resultados de dois estudos de Fase III relativos ao tratamento com o  Janus Quinase (JAK) inibidor INC424 (ruxolitinib), ainda em  investigação, demonstrando uma redução significativa da doença em  doentes com mielofibrose, avança comunicado de imprensa.&lt;br /&gt;&lt;br /&gt;Os resultados do COMFORT-I e COMFORT-II foram apresentados, pela  primeira vez, na 47ª Reunião Anual da Sociedade Americana de Oncologia  Clínica (ASCO), em Junho de 2011.&lt;br /&gt;&lt;br /&gt;A mielofibrose é um cancro raro do sangue, com risco de vida,  caracterizado pela falência da medula óssea, aumento do baço  (esplenomegalia), sintomas debilitantes, tais como fadiga, suores  nocturnos e prurido intratável (comichão), má qualidade de vida e perda  de peso, bem como reduzida sobrevida.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; RCMPHARMA&amp;nbsp; &lt;/span&gt;                   &lt;br /&gt;&lt;br /&gt;Link para o post original: &lt;a href="http://bit.ly/FQ2UQ2"&gt;http://bit.ly/FQ2UQ2&lt;/a&gt;&lt;br /&gt;&lt;a href="http://consulfarma.com/detalhes_noticias.php?id=133639#.T2ebuT5CWOQ.blogger"&gt;Consulfarma - Notícias - Novartis apresenta resultados de fármaco experimental para a mielofibrose.&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7455247216007265690'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7455247216007265690'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/novartis-apresenta-resultados-de.html' title='Novartis apresenta resultados de fármaco experimental para a mielofibrose - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5034074119620710648</id><published>2012-03-08T17:43:00.000-03:00</published><updated>2012-03-19T17:45:29.899-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Mecanismo antirrejeição - via Consulfarma</title><content type='html'>Experiência em humanos "engana" o  sistema imunológico de receptores de transplantes e evita ataque aos  novos órgãos. Uma outra consequência foi a diminuição a quase zero da  necessidade de tomar imunossupressores para o resto da vida.&lt;br /&gt;O transplante de órgãos traz vida nova a portadores de doenças crônicas,  mas o preço que se paga ainda é alto. Para evitar rejeição, eles  precisam tomar, durante toda a vida, medicamentos imunossupressores.  Esses remédios têm uma série de efeitos colaterais, deixando o paciente,  inclusive, mais suscetível a infecções e a tumores malignos. Um estudo  publicado hoje na revista especializada Science Translational Medicine  relata uma experiência bem-sucedida realizada em humanos, que poderá  significar o fim da rotina de pílulas e mais pílulas ingeridas pelos  transplantados. Os pesquisadores conseguiram, a partir de  células-tronco, desenvolver uma técnica pela qual o organismo,  naturalmente, se adapta ao novo órgão, sem reconhecê-lo como um intruso.&lt;br /&gt;Proporcionar maior qualidade de vida após o transplante é o objeto de  estudo do cirurgião Joseph Leventhal, do Northwestern Medicine Hospital,  em Chicago, nos Estados Unidos, há mais de uma década. Ele se dedica a  pesquisar maneiras de evitar que o corpo do receptor rejeite o novo  órgão, sem a necessidade de se tomar imunossupressores por longos  períodos. “Pense em uma criança que recebe um transplante. Ela tem a  vida toda pela frente, o que faz com que os efeitos tóxicos desses  medicamentos se acumulem por muito tempo. O risco que, mais tarde, ela  tenha um câncer, por exemplo, é imenso, pois esse é um dos efeitos  colaterais dos imunossupressores. Por isso, quando temos um candidato a  receber o transplante, sempre pesamos os benefícios potenciais e os  malefícios que o pós-operatório pode trazer”, explica.&lt;br /&gt;Diretor do programa de transplante renal da Universidade de  Northwestern, Leventhal uniu seus conhecimentos ao da cientista Suzanne  Ildstad, chefe do Instituto de Terapias Celulares da Universidade de  Louisville (também nos EUA). Ela é uma das mais reconhecidas  pesquisadoras mundiais na área de células-tronco e, em 1994, descobriu  raras estruturas presentes na medula óssea, as células facilitadoras,  que ajudam a evitar a doença do enxerto contra o hospedeiro, como é  chamada a rejeição de órgãos transplantados. “O que muitas pessoas não  sabem é que, depois de um transplante, o receptor tem de tomar entre 20 e  25 pílulas por dia. A vida dos pacientes transplantados, atualmente,  não é fácil”, reconhece Ildstad. &lt;br /&gt;A médica afirma que as pesquisas no campo de transplantes têm se focado  em métodos que “enganem” o sistema imunológico do receptor. “O que  tentamos fazer é que o organismo do paciente ache que aquele novo órgão é  algo bom e, assim, não tente expulsá-lo. Na nossa pesquisa, em  particular, acreditamos no potencial das células facilitadoras como  agentes da tolerância nos transplantes. Outra área onde essa tecnologia  poderá ter grande impacto é a de reconstituição do tecido de queimados,  algo que pode beneficiar milhões de pessoas em todo o mundo”, destaca.  Ildstad diz que o método poderá ser útil, ainda, no tratamento de  doenças autoimunes, quando o corpo rejeita suas próprias estruturas e  começa a se atacar. &lt;br /&gt;Compatibilidade&lt;br /&gt;Com Leventhal, Suzanne Ildstad coordenou uma equipe multidisciplinar  formada por 55 pesquisadores de oito diferentes instituições para  desenvolver a nova técnica, que já está na fase 2 de estudos. Depois de  bem-sucedido em modelos animais, o procedimento foi testado em pacientes  humanos para checar a segurança. &lt;br /&gt;Na pesquisa, oito pacientes com idades entre 29 e 59 anos, todos  portadores de doenças renais crônicas, receberam do doador não apenas um  rim, mas parte de seu sistema imunológico. A ideia dos cientistas era  alcançar o quimerismo completo pós-transplante, entre pessoas com mesmo  tipo sanguíneo, mas sem a necessidade de compartilhar os mesmos  antígenos leucocitários humanos. Essas proteínas contidas na superfície  celular fazem com que dois tecidos sejam compatíveis imunologicamente. O  paciente e o doador, porém, precisam fazer um teste chamado crossmatch,  para checar se o receptor não tem antígenos que rejeitem as células do  órgão que vai receber. &lt;br /&gt;Geradas na medula óssea, as células-tronco escapam do tecido gelatinoso e  podem ser coletadas no sangue do doador. Antes do transplante, os  médicos retiraram essas estruturas e as misturaram a células-tronco  facilitadoras. A essa altura, o receptor já passa por um tratamento para  esvaziar parte do tutano e, dessa forma, ter espaço para que as  células-tronco da medula do doador possam crescer e se desenvolver (veja  infografia). “O que buscamos nesse protocolo foi reeducar o sistema  imunológico do receptor, de forma que as suas células e as do doador  pudessem coexistir em harmonia. Assim, o órgão transplantado não é  rejeitado e, ao mesmo tempo, não há necessidade de se tomarem remédios  que inibam essa rejeição”, explica Leventhal. &lt;br /&gt;Dos oito pacientes que se submeteram à técnica, aplicada entre 2009 e  2010, todos antingiram o quimerismo em um mês. Cinco não tomavam mais  medicamentos à época da redação do artigo, e os outros três precisaram  continuar com os imunossupressores, mas em doses menores. “Mesmo um ano  depois que os cinco pacientes pararam de usar os remédios, exames na  medula óssea mostram que o quimerismo era de 100%, e esse é um resultado  extremamente animador”, conta Leventhal. Ele reconhece que o número de  pessoas submetidas à técnica é pequeno, mas está entusiasmado com o  potencial do transplante duplo. O próximo passo, segundo o pesquisador, é  testar se o sucesso se aplica também a pessoas que já fizeram o  transplante de rim. &lt;br /&gt;Em uma análise perspectiva escrita para a Science Translational  Magazine, James F. Markmann e Tatsuo Kawai, do Hospital Geral de  Massachusetts, em Boston, consideram “fascinante” a pesquisa de  Leventhal e Ildstad. “Se os resultados se sustentarem e se expandirem em  número, eles podem ter um enorme impacto no transplante de órgãos  sólidos”, escreveram. “Muitas coisas ainda têm de ser aperfeiçoadas,  mas, nos últimos 50 anos, nenhuma outra técnica de transplante foi tão  promissora quanto essa.” &lt;br /&gt;Coexistência&lt;br /&gt;Quimerismo é a condição na qual as células do doador e do receptor  coexistem, um pré-requisito para o sucesso de um transplante de órgão.  As células-tronco podem, no lugar dos imunossupressores, desenvolver  esse papel, de acordo com o novo estudo.&lt;br /&gt;Conscientização&lt;br /&gt;Hoje é comemorado o dia mundial do rim, data que pretende conscientizar  as pessoas sobre a importância da prevenção e do tratamento de doenças  renais. Em Brasília, a Unidade de Nefrologia do Hospital Regional de  Taguatinga (HRT) programou uma série de atividades, que ocorrem entre 8h  e 17h. A iniciativa conta com a parceria da Sociedade Brasileira de  Nefrologia.&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; CORREIO BRASILIENSE &lt;/span&gt;                   &lt;br /&gt;&lt;br /&gt;Link para o post original: &lt;a href="http://bit.ly/FQ23yO"&gt;http://bit.ly/FQ23yO&lt;/a&gt;&lt;br /&gt;&lt;a href="http://consulfarma.com/detalhes_noticias.php?id=133653#.T2eZ1D91fG8.blogger"&gt;Consulfarma - Notícias - Mecanismo antirrejeição.&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5034074119620710648'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5034074119620710648'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/mecanismo-antirrejeicao-via-consulfarma.html' title='Mecanismo antirrejeição - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5804910547774687347</id><published>2012-03-08T17:38:00.000-03:00</published><updated>2012-03-19T17:38:39.904-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Malhar reduz risco cardíaco mesmo para os gordinhos - via Consulfarma</title><content type='html'>Efeito, embora menor que o de emagrecer e fazer exercício, é significativo.&lt;br /&gt;Pesquisa americana acompanhou 3.000 pessoas na casa dos 40; ser ´gordinho ativo´ seria meta mais realista&lt;br /&gt;Emagrecer traz benefícios óbvios à saúde, mas gordinhos fisicamente  ativos também têm boas chances de evitar os problemas cardiovasculares  normalmente associados ao excesso de peso.&lt;br /&gt;A boa notícia está em pesquisa no "Journal of the American College of  Cardiology". Se os dados levantados no estudo estiverem corretos, eles  ajudarão a esclarecer uma dúvida que ainda divide os especialistas.&lt;br /&gt;A questão é saber até que ponto um estilo de vida ativo é capaz de proteger alguém dos problemas de saúde ligados à obesidade.&lt;br /&gt;Alguns trabalhos indicavam que o exercício poderia praticamente eliminar  esses riscos, enquanto outros diziam que o excesso de peso é o fator  preponderante, mesmo se a pessoa se esforça para não ser sedentária.&lt;br /&gt;Parte da dúvida parece estar ligada ao fato de que a maioria desses  estudos levava em conta a saúde cardiovascular dos pacientes em um único  ponto do tempo. Ficava difícil saber como os efeitos do exercício e do  peso afetavam o organismo das pessoas a longo prazo.&lt;br /&gt;Para preencher essa lacuna, uma equipe da Universidade da Carolina do  Sul, liderada por Duck-Chul Lee, obteve os registros médicos de mais de  3.000 pacientes (em geral, na casa dos 40 anos) da clínica Cooper, no  Texas.&lt;br /&gt;Esses pacientes faziam check-ups na clínica, com intervalos de dois ou  três anos entre cada avaliação médica. Na maior parte dos casos, os  pesquisadores conseguiram avaliar o estado de saúde dos pacientes ao  longo de três check-ups consecutivos.&lt;br /&gt;SÍNDROME&lt;br /&gt;O objetivo era verificar como e quando os membros do grupo desenvolviam a  chamada síndrome metabólica, um conjunto de características (como  pressão alta e triglicérides em nível elevado) diretamente ligado ao  surgimento de doenças do coração e diabetes, por exemplo.&lt;br /&gt;Lee e companhia verificaram que pouco mudava do primeiro check-up para o  segundo. A maioria dos pacientes ganhou peso, mas nenhum desenvolveu a  temida síndrome metabólica.&lt;br /&gt;Do segundo para o terceiro check-up, o problema apareceu no grupo  testado. Quem tinha se exercitado menos e ganhado peso, obviamente,  tinha risco aumentado (71%) de ter a síndrome.&lt;br /&gt;Contudo, quem engordava mas continuava fisicamente ativo corria risco  22% menor do que o grupo dos gordinhos inativos. E não era preciso  melhorar o condicionamento físico nesse período. Bastava mantê-lo para  ter alguma proteção.&lt;br /&gt;"Existe uma tendência de ressaltar a necessidade de perder peso, mas  emagrecer em geral é difícil. Manter-se ativo é tão importante quanto  perder peso e é uma meta mais fácil de atingir", diz Lee. Com "New York  Times"&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; FOLHA DE SÃO PAULO&amp;nbsp; &lt;/span&gt;                   &lt;br /&gt;&lt;br /&gt;Link para o post original: &lt;a href="http://bit.ly/xffwTt"&gt;http://bit.ly/xffwTt&lt;/a&gt;&lt;br /&gt;&lt;a href="http://www.consulfarma.com/detalhes_noticias.php?id=133656#.T2eXXlKg2aw.blogger"&gt;Consulfarma - Notícias - Malhar reduz risco cardíaco mesmo para os gordinhos.&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5804910547774687347'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5804910547774687347'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/malhar-reduz-risco-cardiaco-mesmo-para.html' title='Malhar reduz risco cardíaco mesmo para os gordinhos - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3961593161350501068</id><published>2012-03-07T19:34:00.001-03:00</published><updated>2012-03-07T19:34:59.729-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Prescrições são afetadas por ações das farmacêuticas - via Consulfarma</title><content type='html'>&amp;nbsp;O relacionamento entre médicos e  farmacêuticas pode influenciar, de forma negativa ou desnecessária, as  prescrições de medicamentos e as decisões de tratamento médico.&lt;br /&gt;Vários estudos demonstram que os gastos com ações dirigidas aos médicos  são repassados ao preço final dos medicamentos e têm impacto no bolso  dos cidadãos e nos custos do sistema de saúde.&lt;br /&gt;&lt;br /&gt;Nos EUA, os laboratórios dedicam ao marketing cerca de 25% de seus orçamentos, contra menos de 15% destinados à pesquisa.&lt;br /&gt;&lt;br /&gt;A maioria dos médicos assegura que não se deixa influenciar por brindes  em suas decisões clínicas. Aceitar presentes em nada prejudicaria os  pacientes.&lt;br /&gt;&lt;br /&gt;Pesquisa Datafolha feita em 2010 mostrou que a maioria dos médicos no  Estado de São Paulo aceita brindes e avalia como positiva a relação com a  indústria farmacêutica. &lt;br /&gt;Também não vê problemas com eventuais conflitos de interesses.&lt;br /&gt;&lt;br /&gt;Mas um estudo clássico de 2000, publicado no "Jama" (periódico da  Associação Médica Americana), concluiu que a distribuição de brindes,  amostras grátis e subvenções para viagens tem efeito sobre as atitudes  dos médicos.&lt;br /&gt;&lt;br /&gt;Pagar uma viagem para um médico aumentaria entre 4,5 e dez vezes a  probabilidade de que ele receite as drogas feitas pela patrocinadora. &lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;strong&gt;Fonte:&lt;/strong&gt; FOLHA DE SÃO PAULO – SP&lt;/span&gt;                   &lt;br /&gt;&lt;br /&gt;Link para a reportagem original: &lt;a href="http://bit.ly/xU5YLe"&gt;http://bit.ly/xU5YLe&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.consulfarma.com/detalhes_noticias.php?id=133615#.T1fiKwUpxak.blogger"&gt;Consulfarma - Notícias - Prescrições são afetadas por ações das farmacêuticas.&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3961593161350501068/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2012/03/prescricoes-sao-afetadas-por-acoes-das.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3961593161350501068'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3961593161350501068'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/prescricoes-sao-afetadas-por-acoes-das.html' title='Prescrições são afetadas por ações das farmacêuticas - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1275724662330010441</id><published>2012-03-07T19:32:00.001-03:00</published><updated>2012-03-07T19:32:34.095-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Droga para Alzheimer pode render bilhões - via Consulfarma</title><content type='html'>&amp;nbsp;Grandes farmacêuticas têm batalhado há anos para desenvolver um  medicamento que interrompa o progresso do mal de Alzheimer, uma doença  neurológica terrível que começa com perda de memória e inexoravelmente  rouba as funções cerebrais do paciente, levando à demência e morte.  Conseguir a droga teria um enorme impacto na sociedade e ajudaria a  conter o custo da crescente população de pacientes de Alzheimer,  estimada em 26 milhões de pessoas em todo o mundo.&lt;br /&gt;&lt;br /&gt;Também haveria um impacto enorme sobre a saúde da indústria  farmacêutica, que tem suado para substituir o faturamento perdido com a  expiração de patentes de alguns dos remédios que mais vendem. Dois  compostos, agora em testes clínicos de última etapa, têm o potencial  para isso. Há quem ache que um tratamento de sucesso para Alzheimer  poderia gerar entre US$ 10 bilhões e US$ 20 bilhões em faturamento  anual.&lt;br /&gt;&lt;br /&gt;Resultados desses testes para o solanezumab, desenvolvido pela Eli Lilly  &amp;amp; Co., e para o bapineuzumab, desenvolvido pela Pfizer Inc., pela  Elan Corp. PLC e pela Johnson &amp;amp; Johnson, devem sair no terceiro  trimestre deste ano. Se algum desses compostos funcionar e for aprovado  pela agência de vigilância sanitária dos Estados Unidos, a FDA, pode  chegar ao mercado já no ano que vem. "Se essas drogas para Alzheimer  forem um sucesso, elas podem se tornar o novo Lípitor", observa Tim  Anderson, que cobre a indústria farmacêutica para a firma de análises  Bernstein Research. Mas as chances de sucesso não são muito altas.  Anderson põe a chance de sucesso para a droga da Eli Lilly em não mais  do que 20%, chamando o solanezumab de "loteria" com um possível retorno  graúdo. O bapineuzumab tem melhores chances, embora a maioria dos  analistas ponha suas chances em menos de 50%.&lt;br /&gt;&lt;br /&gt;Outro remédio promissor é o Gammagard, da Baxter International Inc., que  mostrou resultados encorajadores num teste de Fase II e está em dois  testes separados de Fase III, um dos quais deve ser concluído no ano que  vem. E há várias outras drogas em testes de Fase II. Mas o bapineuzumab  e o solanezumab são os mais avançados no processo.&lt;br /&gt;A Eli Lilly não tem muito mais além do solanezumab com que contar. As  ações do laboratório podem até subir nos próximos meses, com a  expectativa de um resultado favorável dos testes.&lt;br /&gt;&lt;br /&gt;É importante notar que provavelmente nenhum desses remédios será capaz  de curar ou reverter o curso da doença. As farmacêuticas simplesmente  esperam que os tratamentos adiem a evolução do Alzheimer. Mas isso já  seria uma vitória diante da série de fracassos na busca por um remédio  para a doença. Os tratamentos atuais, como o Aricept e o Namenda,  combatem alguns sintomas da doença mas não impedem sua evolução.&lt;br /&gt;"O verdadeiro objetivo do solanezumab é desacelerar o declínio", disse  Eric Siemers, diretor sênior de medicina da equipe de pesquisas sobre  Alzheimer da Eli Lilly, numa teleconferência com investidores  patrocinada pela Bernstein em dezembro.&lt;br /&gt;&lt;br /&gt;Mesmo assim, um produto aprovado pela FDA que consiga retardar os  efeitos da doença tem o potencial de gerar receita anual de bilhões de  dólares, diante do desespero dos pacientes de Alzheimer e de suas  famílias. A maioria dos pacientes tem mais de 65 anos. O número mundial  de pessoas com Alzheimer pode chegar a 100 milhões em 2050. O custo de  tratar os pacientes atuais é calculado em US$ 150 bilhões por ano.&lt;br /&gt;&lt;br /&gt;A doença, porém, apesar de atingir pessoas no mundo todo, ainda não é  totalmente compreendida pelos cientistas, o que complica a formulação de  qualquer tratamento. Entre os mistérios que persistem estão a causa do  Alzheimer e o que provoca sua disseminação no cérebro e a morte das  células nervosas. "É muito diferente da diabetes ou da hipertensão", diz  Arnold. "Há um grande debate entre os especialistas sobre como a doença  evolui e produz seus sintomas. Você pode ouvir cinco hipóteses  diferentes se conversar com acadêmicos e formadores de opinião."&lt;br /&gt;&lt;br /&gt;O mal de Alzheimer geralmente é diagnosticado com base em dois testes  clínicos, um de cognição e outro de tarefas cotidianas. Os pacientes com  Alzheimer perdem em média quatro pontos por ano no teste cognitivo (a  escala tem 70 pontos).&lt;br /&gt;Um exemplo da dificuldade de tratar a doença é a declaração dos cien&lt;br /&gt;tistas da Eli Lilly de que ficarão felizes se o remédio deles conseguir  reduzir a deterioração em um terço, de seis pontos para quatro pontos  nos 18 meses dos testes clínicos da Fase III.&lt;br /&gt;&lt;br /&gt;Leia o texto completo neste link: &lt;a href="http://bit.ly/ywKoS4"&gt;http://bit.ly/ywKoS4&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.consulfarma.com/detalhes_noticias.php?id=133617#.T1fghftobwg.blogger"&gt;Consulfarma - Notícias - Droga para Alzheimer pode render bilhões.&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1275724662330010441/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2012/03/droga-para-alzheimer-pode-render.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1275724662330010441'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1275724662330010441'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/03/droga-para-alzheimer-pode-render.html' title='Droga para Alzheimer pode render bilhões - via Consulfarma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7453958469387583894</id><published>2012-02-23T15:17:00.000-03:00</published><updated>2012-02-23T15:17:28.984-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Nicotina transdérmica para el tratamiento del deterioro cognitivo leve - via Revista de Neurología</title><content type='html'>&lt;div style="line-height:20px;"&gt;             &lt;p&gt; &lt;span style="font-family: Arial; line-height: 150%; font-size: 9pt"&gt;La  nicotina transdérmica puede administrarse con seguridad a sujetos con  deterioro cognitivo leve (DCL) no fumadores durante seis meses, con una  mejoría en las medidas cognitivas primarias y secundarias de atención,  memoria y procesamiento mental, aunque no en la calificación de la  impresión clínica global, según un estudio publicado en la revista &lt;em&gt;Neurology&lt;/em&gt;.&lt;/span&gt; &lt;/p&gt; &lt;p&gt; &lt;span style="font-family: Arial; line-height: 150%; font-size: 9pt"&gt;El  estudio aleatorizado contó con una muestra de 74 personas con DCL, 39 de  ellas asignadas al grupo de tratamiento (15 mg/día de nicotina  transdérmica durante seis meses) y 35 al grupo con placebo. La principal  prueba del resultado cognitivo (&lt;em&gt;Connors Continuous Performance Test&lt;/em&gt;)  mostró una significativa mejoría inducida por la nicotina. Se llegó a  la conclusión de que este primer estudio proporciona evidencia de mejora  cognitiva inducida por la nicotina en sujetos con DCL, pero se  requieren estudios más amplios para comprobar si estos efectos son  clínicamente relevantes.&lt;br /&gt;&lt;/span&gt; &lt;/p&gt;             &lt;/div&gt;                                                                                                                       &lt;a target="_blank" href="http://www.neurology.org/content/78/2/91.abstract?etoc"&gt;[Neurology 2012]&lt;/a&gt; - http://www.neurology.org/content/78/2/91.abstract?etoc&lt;br /&gt;                                                            &lt;span class="txPeque"&gt;Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, et al&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=3305#.T0aCSDYsByU.blogger"&gt;Nicotina transdérmica para el tratamiento del deterioro cognitivo leve - Revista de Neurología&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7453958469387583894/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2012/02/nicotina-transdermica-para-el.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7453958469387583894'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7453958469387583894'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/02/nicotina-transdermica-para-el.html' title='Nicotina transdérmica para el tratamiento del deterioro cognitivo leve - via Revista de Neurología'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1056883543385702748</id><published>2012-02-02T00:43:00.000-03:00</published><updated>2015-12-13T13:23:51.371-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='sildenafil'/><category scheme='http://www.blogger.com/atom/ns#' term='tratamento'/><category scheme='http://www.blogger.com/atom/ns#' term='linfangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='anomalias vasculares'/><title type='text'>Possível tratamento para linfangiomas da infância</title><content type='html'>&lt;a href="https://pt.wikipedia.org/wiki/Linfangioma" target="_blank"&gt;Malformações linfáticas&lt;/a&gt; (ML), também conhecidas como linfangiomas, são anomalias vasculares congênitas incomuns, representando muitas vezes um desafio terapêutico. Seu tratamento é cirúrgico, via de regra, mas muitas vezes elas são difíceis, quando não impossíveis, de ressecar completamente. Outras estratégias envolvem a injeção de substâncias capazes de causar dano celular ou inflamação dentro dos linfangiomas - uma modalidade de tratamento conhecida coletivamente como escleroterapia. Na maioria dos casos, porém, o resultado de todos estes tratamentos é uma regressão parcial, com lesões residuais de tamanhos às vezes significativos persistindo por toda a vida. Estas lesões residuais podem desfigurar permanentemente os pacientes, ou causar-lhes danos à saúde.&lt;br /&gt;&lt;br /&gt;Agora, na edição de 26 de janeiro de 2012 do New England Journal of Medicine, um grupo de pesquisadores da Universidade de Stanford, Universidade de Washington e Universidade do Colorado relataram, pela primeira vez, um tratamento farmacológico bem sucedido para crianças com linfangioma. Trata-se da droga &lt;a href="https://pt.wikipedia.org/wiki/Sildenafila" target="_blank"&gt;sildenafila&lt;/a&gt;, utilizada para tratar uma condição relativamente rara, a hipertensão pulmonar idiopática, além de seu uso mais conhecido e popular no tratamento da disfunção erétil. Quando uma criança portadora de linfangioma torácico extenso (de parede e intratorácico) foi diagnosticada com hipertensão pulmonar idiopática, a medicação foi prescrita. Com o passar do tempo, porém, notou-se que, além do esperado efeito na doença pulmonar, a lesão vascular passou a regredir, vindo a entrar em remissão completa.&lt;br /&gt;&lt;br /&gt;O grupo, liderado por Glenda L. Swetman, testou a sildenafila em duas outras crianças com linfangiomas gigantes, já tratados anteriormente com escleroterapia com resposta parcial. No ensaio piloto, as crianças receberam sildenafil diariamente por 12 semanas, obtendo regressão importante das lesões (75% ou mais). Esses resultados foram encaminhados para publicação no NEJM e imediatamente após sua divulgação viraram notícia. Os autores da pesquisa já iniciaram um ensaio clínico duplo-cego randomizado para investigar em definitivo esta nova aplicação da sildenafila, uma nova esperança para as crianças portadoras de linfangioma! O uso de sildenafila pode revolucionar o tratamento de linfangiomas da infância, de uma forma análoga ao que ocorreu a alguns anos quando o propranolol mostrou um importante efeito em hemangiomas infantis. Lesões vasculares mais comuns na infância, hemangiomas e linfangiomas em conjunto poderão, em breve, ter tratamento fácil, eficaz e seguro, mudando para sempre esta página na história da medicina!&lt;br /&gt;&lt;br /&gt;Link para o trabalho na íntegra: &lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMc1112482"&gt;http://www.nejm.org/doi/full/10.1056/NEJMc1112482&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Atualização: em 2015 novos resultados mostraram que, na verdade, a sildenafila não tem efeito em ML (linfangiomas) da infância e sua promessa como novo tratamento não se cumpriu!</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1056883543385702748'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1056883543385702748'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/02/novo-tratamento-para-linfangiomas-da.html' title='Possível tratamento para linfangiomas da infância'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5452828220815843675</id><published>2012-02-02T00:06:00.000-03:00</published><updated>2012-02-02T00:06:03.260-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>For Its New Science Minister Brazil Picks ... A Scientist - via ScienceInsider</title><content type='html'>&lt;b&gt;SÃO PAULO, BRAZIL—&lt;/b&gt;Brazil has announced that Marco Antônio Raupp, currently president of the Brazilian Space Agency, will become the new minister of science, technology and innovation on 24 January. Unlike the man he will replace,  Aloizio Mercadante, a leading figure in the Worker's Party with little background in science, Raupp, 73, has more than 40 years of experience in the field. His appointment has pleased the scientific community, which never warmed to his predecessor.&lt;br /&gt;&lt;br /&gt;    &lt;br /&gt;A native of the relatively developed south of the country, Raupp graduated in physics from the Federal University of Rio Grande do Sul  and got his Ph.D. in mathematics from the University of Chicago. He has taught at universities in Brazil's three most important cities, São  Paulo, Rio de Janeiro,and Brasília, and has worked on a number of important scientific and research institutions.&lt;br /&gt;&lt;br /&gt;Raupp said he was honored by the president's decision and called it "a crucial moment" in the ministry's development. "I am totally  aware of the unprecedented demands being made on science, technology and innovation to contribute as an essential part of Brazil's social and  economic development," he said in a statement.&lt;br /&gt;&lt;br /&gt;Raupp's appointment marks a cascade of cabinet changes. Mercadante is leaving the science ministry to take charge of the  education ministry and a much larger budget. The departing education minister, Fernando Haddad, is stepping down to run for mayor of São Paulo in an October election.&lt;br /&gt;&lt;br /&gt;&lt;i&gt;&lt;span class="byline"&gt;by Andrew Downie &lt;/span&gt;on &lt;abbr class="published" title="19 January 2012"&gt;19 January 2012&lt;/abbr&gt;&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;&lt;abbr class="published" title="19 January 2012"&gt;posted on ScienceInsider blog&amp;nbsp;&lt;/abbr&gt;&lt;br /&gt;&lt;abbr class="published" title="19 January 2012"&gt;Link: &lt;/abbr&gt;&lt;a href="http://news.sciencemag.org/scienceinsider/2012/01/for-its-new-science-minister-brazil.html?ref=em&amp;amp;elq=d1a660422f4848d4a77c708c00983f03#.Tx8so0vt1iQ.blogger"&gt;For Its New Science Minister Brazil Picks ... A Scientist - ScienceInsider&lt;/a&gt;&lt;br /&gt;&lt;a href="http://bit.ly/A0tBiQ"&gt;http://bit.ly/A0tBiQ&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5452828220815843675'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5452828220815843675'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/02/for-its-new-science-minister-brazil.html' title='For Its New Science Minister Brazil Picks ... A Scientist - via ScienceInsider'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2137334643687469982</id><published>2012-02-01T23:52:00.000-03:00</published><updated>2012-02-01T23:52:44.494-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Una dieta rica en antioxidantes para la prevención del accidente cerebrovascular - via Revista de Neurología</title><content type='html'>&lt;div style="line-height: 20px;"&gt;&lt;span style="font-size: small;"&gt;&lt;span style="font-family: Arial; line-height: 150%;"&gt;El  uso de una dieta rica en antioxidantes puede reducir significativamente  el riesgo de padecer un accidente cerebrovascular en mujeres.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;span style="font-family: Arial; line-height: 150%;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height: 20px;"&gt;&lt;span style="font-size: small;"&gt;&lt;span style="font-family: Arial; line-height: 150%;"&gt;Un estudio prospectivo, publicado en la revista &lt;i&gt;Stroke&lt;/i&gt;,  encontró que las mujeres sin antecedentes de enfermedades  cardiovasculares que consumían una mayor cantidad de antioxidantes en  alimentos como las frutas, verduras, té, cereales integrales y chocolate  presentaban una disminución del 17% en el riesgo de padecer un  accidente cerebrovascular que aquéllas que ingerían una menor cantidad.  Entre las mujeres con antecedentes de enfermedades cardiovasculares, las  que consumieron una mayor cantidad de antioxidantes mostraban un 45%  menos de probabilidad de padecer un accidente cerebrovascular  hemorrágico.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;span style="font-family: Arial; line-height: 150%;"&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;span style="font-family: Arial; line-height: 150%;"&gt;Los  investigadores analizaron las 31.035 mujeres que estaban libres de  enfermedad cardiovascular al inicio del estudio por separado de las  5.680 mujeres con antecedentes de enfermedad cardiovascular. El riesgo  de accidente cardiovascular se ajustó por edad, educación, tabaquismo,  índice de masa corporal, actividad física, hipertensión,  hipercolesterolemia, diabetes, antecedentes familiares de infarto de  miocardio, el uso de la aspirina, el uso de suplementos dietéticos y la  ingesta de energía total, el alcohol y el café.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;span style="font-family: Arial; line-height: 150%;"&gt;&amp;nbsp;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;a href="http://stroke.ahajournals.org/content/early/2011/11/30/STROKEAHA.111.635557.abstract" target="_blank"&gt;[Stroke 2011]&lt;/a&gt;&lt;br /&gt;&lt;span class="txPeque"&gt;Rautiainen S, Larsson S, Vitarmo J y Wolk A &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=3258#.Tx9jlIUOFiA.blogger"&gt;Una dieta rica en antioxidantes para la prevención del accidente cerebrovascular - Revista de Neurología&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2137334643687469982'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2137334643687469982'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/02/una-dieta-rica-en-antioxidantes-para-la.html' title='Una dieta rica en antioxidantes para la prevención del accidente cerebrovascular - via Revista de Neurología'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3130846523056732541</id><published>2012-02-01T23:46:00.003-03:00</published><updated>2012-02-01T23:46:58.565-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>El pescado, café y alcohol pueden retrasar la progresión de la esclerosis múltiple - via Revista de Neurología</title><content type='html'>El consumo regular de pescado, alcohol y café puede ayudar a retrasar la aparición y progresión de la enfermedad en pacientes con esclerosis múltiple de recaídas múltiples (EM). Sin embargo, el consumo de estos alimentos no parece afectar al desarrollo de la enfermedad en pacientes con EM de inicio progresivo.&lt;br /&gt;&lt;br /&gt;El estudio, publicado en la revista European Journal of Neurology incluyó datos de 1.372 pacientes con EM que completaron cuestionarios que recogían información sobre sus datos demográficos, características de la enfermedad, consumo de alcohol, vino, café, té y pescado, y tabaquismo.&lt;br /&gt;&lt;br /&gt;Los investigadores observaron que en la EM recidivante, el consumo de alcohol, vino, café y pescado se asociaba con una reducción del tiempo necesario para llegar a una puntuación de 6 en la Expanded Disability Status Scale (EDSS). Aunque el análisis sugiere un efecto relacionado con la dosis de café, pescado y alcohol, los resultados deben ser interpretados con precaución.&lt;br /&gt;&lt;br /&gt;[&lt;a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2011.03596.x/abstract"&gt;Eur J Neurol 2011&lt;/a&gt;]&lt;br /&gt;D´hooghe MB, Haentjens P, Nagels G y De Keyser J&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=3262#.Tx9jsW3pvEA.blogger"&gt;El pescado, café y alcohol pueden retrasar la progresión de la esclerosis múltiple - Revista de Neurología&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3130846523056732541'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3130846523056732541'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2012/02/el-pescado-cafe-y-alcohol-pueden.html' title='El pescado, café y alcohol pueden retrasar la progresión de la esclerosis múltiple - via Revista de Neurología'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1928839158361785399</id><published>2011-12-06T17:05:00.000-03:00</published><updated>2011-12-06T17:44:22.358-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Brazil in the Top 20 Countries in Scientific Research - ScienceWatch.com - Thomson Reuters</title><content type='html'>According to a new update from            &lt;a href="http://thomsonreuters.com/products_services/science/science_products/scholarly_research_analysis/research_evaluation/"&gt;         &lt;i&gt;Essential Science Indicators&lt;/i&gt;&lt;/a&gt;&lt;sup&gt;SM&lt;/sup&gt;, a publication of         &lt;a href="http://scientific.thomsonreuters.com/"&gt;Thomson         Reuters&lt;/a&gt;, the &lt;i&gt;ScienceWatch.com&lt;/i&gt; blog Webmaster Spyder Schafer presents the 10th            annual "Top 20" listings of countries which achieved         particular distinction based on their papers published in indexed journals from January 2001 through August 31, 2011. Out of the 147 countries in the &lt;i&gt;Essential Science Indicators&lt;/i&gt;         database, 60 published at least 10,000 papers during the period.         Countries are listed by three separate measures in the tables below:         number of citations, total papers, and cites per paper. (Note: For         articles with multiple authors representing different countries, each         listed country receives full, not fractional, citation credit for the         given paper.)&lt;br /&gt;Brazil has been cited for the first time in this listing in 2010, in the 15th rank, with 190,801 published papers and an average citation per paper of 6.28 (&lt;a href="http://bit.ly/ezIKY2"&gt;http://bit.ly/ezIKY2&lt;/a&gt;). In the new 2011 listing, Brazil has mantained its rank and has risen its published papers to more than 210,000 and the citation average to 6.41 per paper. With this result, Brazil has got a significant place in the world scientific community, along with other countries of the emergent &lt;a href="http://en.wikipedia.org/wiki/BRIC" target="_blank"&gt;BRIC&lt;/a&gt; group.&lt;br /&gt;&lt;br /&gt;&lt;h3&gt;         Listed by Papers &lt;/h3&gt;&lt;table border="0" cellpadding="2" class="datatable" style="height: 558px; width: 600px;"&gt;&lt;tbody&gt;&lt;tr&gt;                 &lt;th class="cell_center" scope="col" style="text-align: left;" width="8%"&gt;Rank                 &lt;/th&gt;                 &lt;th scope="col" style="text-align: left;" width="38%"&gt;Country                 &lt;/th&gt;                 &lt;th scope="col" style="text-align: left;" width="18%"&gt;Papers                 &lt;/th&gt;                 &lt;th scope="col" style="text-align: left;" width="18%"&gt;Citations                 &lt;/th&gt;                 &lt;th scope="col" style="text-align: left;" width="18%"&gt;Cites per paper                 &lt;/th&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;1                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;USA                  &lt;/td&gt;                 &lt;td class="number"&gt;3,049,662                 &lt;/td&gt;                 &lt;td class="number"&gt;48,862,100                 &lt;/td&gt;                 &lt;td class="number"&gt;16.02                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;2                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;PEOPLES R CHINA                  &lt;/td&gt;                 &lt;td class="number"&gt;836,255                 &lt;/td&gt;                 &lt;td class="number"&gt;5,191,358                 &lt;/td&gt;                 &lt;td class="number"&gt;6.21                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;3                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;GERMANY                  &lt;/td&gt;                 &lt;td class="number"&gt;784,316                 &lt;/td&gt;                 &lt;td class="number"&gt;10,518,133                 &lt;/td&gt;                 &lt;td class="number"&gt;13.41                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;4                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;JAPAN                  &lt;/td&gt;                 &lt;td class="number"&gt;771,548                 &lt;/td&gt;                 &lt;td class="number"&gt;8,084,145                 &lt;/td&gt;                 &lt;td class="number"&gt;10.48                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;5                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;ENGLAND                  &lt;/td&gt;                 &lt;td class="number"&gt;697,763                 &lt;/td&gt;                 &lt;td class="number"&gt;10,508,202                 &lt;/td&gt;                 &lt;td class="number"&gt;15.06                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;6                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;FRANCE                  &lt;/td&gt;                 &lt;td class="number"&gt;557,322                 &lt;/td&gt;                 &lt;td class="number"&gt;7,007,693                 &lt;/td&gt;                 &lt;td class="number"&gt;12.57                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;7                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;CANADA                  &lt;/td&gt;                 &lt;td class="number"&gt;451,588                 &lt;/td&gt;                 &lt;td class="number"&gt;6,019,195                 &lt;/td&gt;                 &lt;td class="number"&gt;13.33                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;8                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;ITALY                  &lt;/td&gt;                 &lt;td class="number"&gt;429,301                 &lt;/td&gt;                 &lt;td class="number"&gt;5,151,675                 &lt;/td&gt;                 &lt;td class="number"&gt;12.00                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;9                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;SPAIN                  &lt;/td&gt;                 &lt;td class="number"&gt;339,164                 &lt;/td&gt;                 &lt;td class="number"&gt;3,588,655                 &lt;/td&gt;                 &lt;td class="number"&gt;10.58                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;10                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;AUSTRALIA                  &lt;/td&gt;                 &lt;td class="number"&gt;304,160                 &lt;/td&gt;                 &lt;td class="number"&gt;3,681,695                 &lt;/td&gt;                 &lt;td class="number"&gt;12.10                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;11                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;INDIA                  &lt;/td&gt;                 &lt;td class="number"&gt;293,049                 &lt;/td&gt;                 &lt;td class="number"&gt;1,727,973                 &lt;/td&gt;                 &lt;td class="number"&gt;5.90                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;12                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;SOUTH KOREA                  &lt;/td&gt;                 &lt;td class="number"&gt;282,328                 &lt;/td&gt;                 &lt;td class="number"&gt;2,024,609                 &lt;/td&gt;                 &lt;td class="number"&gt;7.17                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;13                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;RUSSIA                  &lt;/td&gt;                 &lt;td class="number"&gt;265,721                 &lt;/td&gt;                 &lt;td class="number"&gt;1,282,281                 &lt;/td&gt;                 &lt;td class="number"&gt;4.83                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;14                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;NETHERLANDS                  &lt;/td&gt;                 &lt;td class="number"&gt;252,242                 &lt;/td&gt;                 &lt;td class="number"&gt;3,974,719                 &lt;/td&gt;                 &lt;td class="number"&gt;15.76                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong" style="color: red;"&gt;&lt;b&gt;15                 &lt;/b&gt;&lt;/td&gt;                 &lt;td style="color: red; text-align: left;"&gt;&lt;b&gt;BRAZIL                  &lt;/b&gt;&lt;/td&gt;                 &lt;td class="number" style="color: red;"&gt;&lt;b&gt;212,243                 &lt;/b&gt;&lt;/td&gt;                 &lt;td class="number" style="color: red;"&gt;&lt;b&gt;1,360,097                 &lt;/b&gt;&lt;/td&gt;                 &lt;td class="number" style="color: red;"&gt;&lt;b&gt;6.41                 &lt;/b&gt;&lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;16                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;SWITZERLAND                  &lt;/td&gt;                 &lt;td class="number"&gt;181,636                 &lt;/td&gt;                 &lt;td class="number"&gt;3,070,458                 &lt;/td&gt;                 &lt;td class="number"&gt;16.9                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;17                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;SWEDEN                  &lt;/td&gt;                 &lt;td class="number"&gt;179,126                 &lt;/td&gt;                 &lt;td class="number"&gt;2,686,304                 &lt;/td&gt;                 &lt;td class="number"&gt;15.00                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;18                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;TAIWAN                  &lt;/td&gt;                 &lt;td class="number"&gt;177,929                 &lt;/td&gt;                 &lt;td class="number"&gt;1,273,682                 &lt;/td&gt;                 &lt;td class="number"&gt;7.16                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="centerstrong"&gt;19                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;TURKEY                  &lt;/td&gt;                 &lt;td class="number"&gt;155,276                 &lt;/td&gt;                 &lt;td class="number"&gt;819,071                 &lt;/td&gt;                 &lt;td class="number"&gt;5.27                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr&gt;                 &lt;td class="centerstrong"&gt;20                 &lt;/td&gt;                 &lt;td style="text-align: left;"&gt;POLAND                  &lt;/td&gt;                 &lt;td class="number"&gt;154,016                 &lt;/td&gt;                 &lt;td class="number"&gt;1,036,062                 &lt;/td&gt;                 &lt;td class="number"&gt;6.73                 &lt;/td&gt;             &lt;/tr&gt;&lt;tr class="trbg"&gt;                 &lt;td class="credit" colspan="6"&gt;Source:                     &lt;a href="http://thomsonreuters.com/products_services/science/science_products/scholarly_research_analysis/research_evaluation/"&gt;                     &lt;i&gt;Essential Science Indicators&lt;/i&gt;&lt;/a&gt;&lt;sup&gt;SM&lt;/sup&gt; from                     &lt;a href="http://scientific.thomsonreuters.com/"&gt;Thomson                     Reuters&lt;/a&gt;, time period: 2001-August 31, 2011 (fourth                     bimonthly period of 2011).                 &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.sciencewatch.com/dr/cou/2011/11decALL/#.Tt5x3WYSDfE.blogger"&gt;Top 20 Countries in ALL FIELDS, 2001-August 31, 2011 - ScienceWatch.com - Thomson Reuters&lt;/a&gt;&lt;br /&gt;&lt;a href="http://bit.ly/t4Q5DN"&gt;http://bit.ly/t4Q5DN&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1928839158361785399/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/12/brazil-in-top-20-countries-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1928839158361785399'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1928839158361785399'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/12/brazil-in-top-20-countries-in.html' title='Brazil in the Top 20 Countries in Scientific Research - ScienceWatch.com - Thomson Reuters'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5544444034286385040</id><published>2011-12-03T15:10:00.001-03:00</published><updated>2016-09-03T17:02:23.962-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='fraude acadêmica'/><title type='text'>Fraude na ciência 3 - o caso do Americano que Errou</title><content type='html'>Um dos principais defensores da hipótese de que a moralidade é inata,  tendo evoluído naturalmente nos ancestrais do homem, está sendo acusado  de... fraude. &lt;br /&gt;Marc Hauser, biólogo da Universidade Harvard, teria falsificado dados de  experimentos, afirmam antigos subordinados do pesquisador. &lt;br /&gt;Procurados pela Folha, tanto Hauser quanto a universidade se recusaram a  falar. Em declaração oficial, Harvard só diz que o professor está sendo  investigado e que "o registro científico de seu trabalho será  corrigido". &lt;br /&gt;Os detalhes da suposta fraude têm aparecido aos poucos, desde a semana  passada*. Mas o que talvez seja a peça decisiva do quebra-cabeças veio à  tona anteontem [19/08/2010], em reportagem do jornal "Chronicle of Higher Education",  dos Estados Unidos. &lt;br /&gt;Um ex-assistente de pesquisa de Hauser forneceu documentos e e-mails  comprometedores ao jornal, sob a condição de ficar anônimo. As mensagens  mostram um Hauser irritado com as dúvidas de seus colaboradores. &lt;br /&gt;&lt;b&gt;MACACOS FALANTES&lt;/b&gt;&lt;br /&gt;Segundo o ex-assistente de pesquisa, o problema principal envolvia  experimentos sobre linguagem com macacos resos (veja quadro abaixo).  Neles, Hauser e companhia queriam verificar se os bichos captavam certos  padrões de som, parecidos com as sílabas da fala. &lt;br /&gt;Um estudo assim, aliás, havia sido relatado nesta Folha em 2004. Ocorre,  porém, que o então assistente teria notado algo estranho. Enquanto as  observações feitas pelo professor mostravam os primatas captando alguns  dos padrões de sílabas, as assinadas por outro assistente, vendo o mesmo  vídeo, diziam que nada acontecia. &lt;br /&gt;Junto com um aluno de pós-graduação, o assistente teria sugerido pedir a  ajuda de um terceiro observador para tirar a teima. Hauser reagiu:  "Estou ficando meio p. aqui", teria escrito num e-mail. "Não houve  inconsistências [nos dados]!" &lt;br /&gt;A troca de e-mails e outras conversas parecidas teriam levado  subordinados a denunciar Hauser à direção de Harvard, deflagrando uma  investigação que começou em 2007 e continua até hoje.&lt;br /&gt;&amp;nbsp; &lt;br /&gt;&lt;table class="articleGraphic"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td class="articleGraphicSpace" rowspan="3"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td class="articleGraphicCredit"&gt;Crédito da imagem: Editoria de Arte/Folhapress&lt;/td&gt;&lt;td class="articleGraphicSpace" rowspan="3"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td class="articleGraphicImage"&gt;&lt;img alt="FLEXIBILIDADE MORAL Como o biólogo Marc Hauser teria cometido distorção de dados" border="0" height="240" src="https://f.i.uol.com.br/folha/ciencia/images/1023334.jpeg" width="400" /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td class="articleGraphicCaption"&gt;Cientista teria feito uma interpretação forçada de estudo com primata; biólogo e universidade não comentam o caso&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;br /&gt;&lt;b&gt;REFERÊNCIA&lt;/b&gt;&lt;br /&gt;Os cientistas que estudam primatas se dizem preocupados. "Os trabalhos  dele são referência para muitos outros, estavam entre os mais citados na  área", diz Maria Emilia Yamamoto, psicóloga da Universidade Federal do  Rio Grande do Norte. &lt;br /&gt;Os resultados de Hauser realmente nunca tinham sido replicados por  outros cientistas, mas, para a pesquisadora, isso nunca foi encarado  como um indicador de possível desonestidade. &lt;br /&gt;"Não é incomum não se conseguir reproduzir os resultados, isso não era  preocupante. A condição dos animais em diferentes lugares pode variar,  por exemplo." &lt;br /&gt;Segundo ela, os trabalhos eram "cuidadosos, muito bem escritos. Se os  dados que ele utilizava como base não eram confiáveis, quem poderia  saber? Em princípio, você acredita no cientista." &lt;br /&gt;Eduardo Ottoni, etólogo (especialista em comportamento animal) da USP,  prefere ser cauteloso sobre as denúncias. "Tem um elemento de  "Schadenfreude" [alegria com a desgraça dos outros] nessa história,  principalmente porque se trata de um cara VIP", afirma ele. &lt;br /&gt;Ottoni lembra, porém, que alguns pesquisadores da área já diziam que  Hauser era descuidado em seus experimentos, "embora excelente do ponto  de vista teórico". &lt;br /&gt;Uma possível falha seria o fato de que os responsáveis por anotar as  reações dos macacos já sabiam de antemão qual eram os estímulos, o que  poderia gerar vieses. "Pode haver um efeito VIP aí. Se fosse pesquisa  minha, o revisor do artigo ia me debulhar. Mas, como era o Hauser, ele  pode ter sido mais complacente", diz Ottoni.&lt;br /&gt;&lt;br /&gt;&lt;h1&gt;    &lt;/h1&gt;&lt;div id="ad-180x150-1"&gt;&lt;div class="adLabel"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div id="articleBy" style="margin-bottom: 0pt;"&gt;&lt;b&gt;REINALDO JOSÉ LOPES&lt;/b&gt;&lt;br /&gt;EDITOR INTERINO DE CIÊNCIA&lt;br /&gt;&lt;b&gt;RICARDO MIOTO&lt;/b&gt;&lt;br /&gt;DE SÃO PAULO&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;*Publicado na &lt;a href="http://www1.folha.uol.com.br/ciencia/786674-estudioso-da-moral-marc-hauser-pode-ser-fraudador.shtml" target="_blank"&gt;Folha Online&lt;/a&gt;, em agosto de 2010&lt;br /&gt;&lt;br /&gt;&lt;div class="almost_half_cell" id="gt-res-content"&gt;&lt;div dir="ltr" style="zoom: 1;"&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;&lt;b&gt;INFORMAÇÕES OFICIAIS (Wikipedia):&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div dir="ltr"&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;Em 20 de agosto&lt;/span&gt; &lt;span class="hps"&gt;de 2010, o&lt;/span&gt; &lt;span class="hps"&gt;decano da&lt;/span&gt; &lt;span class="hps"&gt;faculdade &lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt; das&lt;/span&gt; &lt;span class="hps"&gt;artes e das ciências&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt; de Harvard&lt;/span&gt;&lt;span class="hps"&gt;&lt;/span&gt; &lt;span class="hps"&gt;divulgou um comunicado&lt;/span&gt; &lt;span class="hps"&gt;confirmando que&lt;/span&gt; &lt;span class="hps"&gt;uma investigação interna&lt;/span&gt; &lt;span class="hps"&gt;tinha concluído que &lt;/span&gt;&lt;span class="hps"&gt;Hauser&lt;/span&gt; fora &lt;span class="hps"&gt;culpado de&lt;/span&gt; &lt;span class="hps"&gt;oito acusações de&lt;/span&gt; &lt;span class="hps"&gt;má conduta científica&lt;/span&gt;. &lt;span class="hps"&gt;&lt;/span&gt;&lt;span class="hps"&gt;Três acusações envolviam &lt;/span&gt;&lt;span class="hps"&gt;artigos publicados,&lt;/span&gt; &lt;span class="hps"&gt;e cinco&lt;/span&gt; &lt;span class="hps"&gt;envolviam &lt;/span&gt;&lt;span class="hps"&gt;estudos não publicados&lt;/span&gt;. &lt;span class="hps"&gt;A declaração revelou que&lt;/span&gt; &lt;span class="hps"&gt;Harvard&lt;/span&gt; &lt;span class="hps"&gt;está cooperando com&lt;/span&gt; &lt;span class="hps"&gt;as investigações&lt;/span&gt; &lt;span class="hps"&gt;pelo Escritório&lt;/span&gt; &lt;span class="hps"&gt;de Integridade&lt;/span&gt; da Pesquisa dos &lt;span class="hps"&gt;EUA&lt;/span&gt;, o &lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;Gabinete&lt;/span&gt; &lt;span class="hps atn"&gt;do Inspetor-&lt;/span&gt;Geral d&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;a &lt;span class="hps"&gt;National Science&lt;/span&gt; &lt;span class="hps"&gt;Foundation&lt;/span&gt;&amp;nbsp;&lt;span class="hps"&gt;&lt;/span&gt; e &lt;span class="hps"&gt;da Procuradoria d&lt;/span&gt;&lt;span class="hps"&gt;o Distrito de&lt;/span&gt; &lt;span class="hps"&gt;Massachusetts.&lt;/span&gt; &lt;span class="hps"&gt;Eles vão&lt;/span&gt; &lt;span class="hps"&gt;realizar a sua&lt;/span&gt; &lt;span class="hps"&gt;própria análise&lt;/span&gt; &lt;span class="hps"&gt;e levar suas&lt;/span&gt; &lt;span class="hps"&gt;conclusões&lt;/span&gt; ao conhecimento&lt;span class="hps"&gt; do público&lt;/span&gt;.&lt;span class="hps"&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt; &lt;span class="hps"&gt;Um artigo de 2002&lt;/span&gt; &lt;span class="hps"&gt;publicado na&lt;/span&gt; &lt;span class="hps"&gt;revista científica Cognition&lt;/span&gt; &lt;span class="hps"&gt;foi&lt;/span&gt; &lt;span class="hps"&gt;recolhido ("retracted").&lt;/span&gt; &lt;span class="hps"&gt;Neste artigo,&lt;/span&gt; &lt;span class="hps"&gt;Hauser&lt;/span&gt; &lt;span class="hps"&gt;e seus colaboradores&lt;/span&gt; &lt;span class="hps"&gt;concluíram&lt;/span&gt; &lt;span class="hps"&gt;que os saguis-de-cabeça-branca&lt;/span&gt; &lt;span class="hps"&gt;poderiam aprender&lt;/span&gt; &lt;span class="hps"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;padrões&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;&lt;/span&gt; &lt;span class="hps"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;simples&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt; semelhantes à &lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;regras&lt;/span&gt;. &lt;span class="hps"&gt;Em dois&lt;/span&gt; &lt;span class="hps"&gt;artigos publicados&lt;/span&gt; &lt;span class="hps"&gt;adicionais&lt;/span&gt;, algumas &lt;span class="hps"&gt;notas de campo&lt;/span&gt; &lt;span class="hps"&gt;ou gravações&lt;/span&gt; &lt;span class="hps"&gt;de vídeo foram&lt;/span&gt; &lt;span class="hps"&gt;"incompletos"&lt;/span&gt;&lt;span class=""&gt;, apesar de&lt;/span&gt; &lt;span class="hps"&gt;Hauser&lt;/span&gt; &lt;span class="hps"&gt;e seu&lt;/span&gt; &lt;span class="hps"&gt;co&lt;/span&gt;&lt;span class=""&gt;-autor&lt;/span&gt; terem &lt;span class="hps"&gt;replicado&lt;/span&gt; &lt;span class="hps"&gt;os experimentos.&lt;/span&gt; &lt;span class="hps atn"&gt;&lt;/span&gt;O &lt;span class="hps"&gt;Proceedings of the&lt;/span&gt; &lt;span class="hps"&gt;Royal Society&lt;/span&gt; &lt;span class="hps"&gt;publicou a&lt;/span&gt; &lt;span class="hps"&gt;replicação&lt;/span&gt; &lt;span class="hps"&gt;dos dados em falta&lt;/span&gt; &lt;span class="hps"&gt;em um adendo&lt;/span&gt; &lt;span class="hps"&gt;para um dos&lt;/span&gt; &lt;span class="hps"&gt;papéis.&lt;/span&gt; &lt;span class="hps"&gt;Em&lt;/span&gt; &lt;span class="hps"&gt;abril de 2011,&lt;/span&gt; &lt;span class="hps"&gt;Hauser&lt;/span&gt; &lt;span class="hps"&gt;e&lt;/span&gt; &lt;span class="hps"&gt;Justin&lt;/span&gt; &lt;span class="hps atn"&gt;Wood (&lt;/span&gt;co-autor do &lt;span class="hps"&gt;artigo original)&lt;/span&gt; &lt;span class="hps"&gt;replicaram os resultados&lt;/span&gt; &lt;span class="hps"&gt;do estudo da Science&lt;/span&gt; &lt;span class="hps"&gt;de 2007 e&lt;/span&gt; &lt;span class="hps"&gt;publicaram&amp;nbsp;&lt;/span&gt;&lt;span class="hps"&gt;na revista.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div dir="ltr"&gt;&lt;/div&gt;&lt;div dir="ltr"&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;&lt;b&gt;O FIM?&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div dir="ltr"&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;Em julho de 2011&lt;/span&gt;&lt;span class=""&gt;, após o &lt;/span&gt;&lt;span class="hps"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;Departamento&lt;/span&gt; &lt;span class="hps"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt; &lt;span class="hps"&gt;de Psicologia&lt;/span&gt; ter votado &lt;span class="hps"&gt;por impedir&lt;/span&gt;&lt;span class="hps"&gt;&lt;/span&gt; &lt;span class="hps"&gt;Hauser&lt;/span&gt; &lt;span class="hps"&gt;de ensinar&lt;/span&gt; &lt;span class="hps"&gt;no próximo ano&lt;/span&gt; &lt;span class="hps"&gt;letivo&lt;/span&gt;&lt;span class=""&gt;, Hauser&lt;/span&gt; &lt;span class="hps"&gt;renunciou à sua posição&lt;/span&gt; &lt;span class="hps"&gt;do corpo docente da&lt;/span&gt; &lt;span class="hps"&gt;Harvard&lt;/span&gt;.&lt;span class="hps"&gt;&lt;/span&gt; &lt;span class="hps"&gt;Em&lt;/span&gt; &lt;span class="hps"&gt;sua renúncia,&lt;/span&gt; &lt;span class="hps"&gt;Hauser&lt;/span&gt; &lt;span class="hps"&gt;afirmou que ele&lt;/span&gt; &lt;span class="hps"&gt;teve "algumas&lt;/span&gt; &lt;span class="hps"&gt;oportunidades interessantes&lt;/span&gt; &lt;span class="hps"&gt;no setor privado&lt;/span&gt;&lt;span class="hps"&gt;", envolvendo&lt;/span&gt; &lt;span class="hps"&gt;a educação para&lt;/span&gt; &lt;span class="hps"&gt;adolescentes&lt;/span&gt; &lt;span class="hps"&gt;de alto risco&lt;/span&gt;&lt;span class=""&gt;, mas&lt;/span&gt; &lt;span class="hps"&gt;que ele poderia&lt;/span&gt; &lt;span class="hps"&gt;voltar para a&lt;/span&gt; &lt;span class="hps"&gt;academia "&lt;/span&gt;&lt;span class="hps"&gt;nos anos&lt;/span&gt; &lt;span class="hps"&gt;vindouros". Hauser confirmou que cometeu "alguns erros", mas negou má conduta científica. A conduta da Universidade de Harvard, que manteve a investigação sobre Hauser e seus resultados sob sigilo, foi amplamente criticada.&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div dir="ltr"&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div dir="ltr"&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div dir="ltr"&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps atn"&gt;&lt;/span&gt;&lt;span class=""&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5544444034286385040/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/12/fraude-na-ciencia-3-o-caso-do-americano.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5544444034286385040'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5544444034286385040'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/12/fraude-na-ciencia-3-o-caso-do-americano.html' title='Fraude na ciência 3 - o caso do Americano que Errou'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1302411052866976745</id><published>2011-12-03T13:59:00.001-03:00</published><updated>2016-09-03T16:54:32.046-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='fraude acadêmica'/><title type='text'>Fraude na ciência 2 - o caso do Brasileiro Inconfesso</title><content type='html'>Uma investigação internacional apontou fraude em 11 artigos  científicos de um respeitado professor titular de química da Unicamp  (Universidade Estadual de Campinas).&lt;br /&gt;Tudo indica que se trata da denúncia mais séria de má conduta  científica da história da ciência brasileira, apesar da escassez de  levantamentos sobre o tema. Em geral, os casos envolvem plágio, e não  invenção de resultados.&lt;br /&gt;Os trabalhos que conteriam fraude saíram em várias revistas  científicas da Elsevier, multinacional que é a maior editora de  periódicos acadêmicos do mundo.&lt;br /&gt;Os estudos da Unicamp foram retratados (ou seja, “despublicados”, não  tendo mais validade para a comunidade científica). A Elsevier afirmou  que os sinais de manipulação são “conclusivos”.&lt;br /&gt;Claudio Airoldi, de 68 anos, é um dos pesquisadores mais experientes da Unicamp: está na universidade paulista desde 1968.&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;NO TOPO&lt;/strong&gt;&lt;br /&gt;Na classificação do CNPq (Conselho Nacional de Desenvolvimento  Científico e Tecnológico, principal órgão federal a financiar ciência no  país), ele é bolsista de produtividade nível 1A, o mais elevado, e  membro da Academia Brasileira de Ciências. É o associado nº 17 da  Sociedade Brasileira de Química.&lt;br /&gt;Airoldi teria falsificado imagens de ressonância magnética que servem  para estudar características de novas moléculas. Um dos artigos dizia  que uma delas, por exemplo, tinha uma estrutura que serviria para  absorver metais tóxicos da água.&lt;br /&gt;Os trabalhos foram publicados entre 2008 e 2010 em colaboração com um  aluno de pós-graduação, Denis Guerra, hoje professor adjunto na  Universidade Federal de Mato Grosso.&lt;br /&gt;A Elsevier diz que o procedimento de investigação envolveu três  cientistas revisores independentes, e que todos eles concluíram que  “estava claro que os resultados tinham sido manipulados”. A editora diz  ter pedido e recebido uma defesa dos cientistas brasileiros, mas,  segundo ela, o material enviado não prova nada.&lt;br /&gt;“Estava previsto que algo assim ia acontecer. Ia ser muito difícil  segurar isso porque a pressão para publicar é muito grande e existe  leniência em relação a esse comportamento”, diz Sílvio Salinas, físico  da USP que segue de perto os casos de má conduta científica no país.&lt;br /&gt;De fato, diferentemente dos Estados Unidos, que contam com uma  agência federal para investigar casos assim, o Brasil deixa o  acompanhamento dos casos e possíveis punições nas mãos das instituições  onde ocorrem.&lt;br /&gt;Não existem estatísticas consolidadas sobre o tema por aqui. Mas, num  clima de competição científica acirrada e globalizada, com  pesquisadores cada vez mais pressionados para mostrar sua produção em  números, mais casos são esperados.&lt;br /&gt;Nos próprios EUA, em 16 anos as fraudes científicas cresceram 161%.  Em países como China e Brasil, onde a publicação bruta de artigos  científicos tem crescido muito sem que a qualidade acompanhe esse ritmo,  o fenômeno deve aparecer mais.&lt;br /&gt;“As universidades e as agências de fomento precisam tomar  providências quanto a isso. Nunca tinha tido conhecimento sobre algo  dessa dimensão no Brasil. A ordem de grandeza é similar a casos de  fraude que ocorrem na China”, diz Salinas.&lt;br /&gt;A Unicamp instaurou uma sindicância interna para apurar o caso. Segundo a universidade, ela deve ser concluída em 30 dias.&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;OUTRO LADO&lt;/strong&gt;&lt;br /&gt;Procurado pela &lt;strong&gt;Folha&lt;/strong&gt;, Airoldi desligou o telefone  assim que a reportagem se apresentou, dizendo não ter tempo para falar.  Ele foi contatado também por e-mail, mas não respondeu até o fechamento  desta edição.&lt;br /&gt;Guerra disse já ter entrado em contato com a Elsevier. “Mandamos toda  uma defesa dos trabalhos, apresentando provas de que as imagens são  verdadeiras, mas não recebemos nenhuma posição.”&lt;br /&gt;Ele diz que a retratação da Elsevier “incomoda seriamente”. “Pode  acontecer de você nunca mais conseguir publicar um trabalho. Um editor  vê uma coisa dessas e vai pensar o quê? Somos do Terceiro Mundo, a  verdade é essa, sem dúvida nenhuma contra pesquisadores do Primeiro  Mundo a crítica teria uma peso menor.”&lt;br /&gt;&lt;br /&gt;(Folha Online via &lt;a href="http://dialogospoliticos.wordpress.com/2011/03/31/claudio-airoldi-quimico-da-unicamp-e-acusado-de-fraudar-11-estudos-cientificos/" target="_blank"&gt;Diálogos Políticos&lt;/a&gt;)</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1302411052866976745/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/12/fraude-na-ciencia-2-o-caso-do.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1302411052866976745'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1302411052866976745'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/12/fraude-na-ciencia-2-o-caso-do.html' title='Fraude na ciência 2 - o caso do Brasileiro Inconfesso'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7729661572671528419</id><published>2011-12-03T13:40:00.001-03:00</published><updated>2016-09-03T16:55:43.207-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='fraude acadêmica'/><title type='text'>Fraude na ciência 1 - o caso do Holandês Simulador</title><content type='html'>&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Acadêmicos da Holanda mostraram surpresa no mês de novembro ao  constatar que um de seus mais prestigiados psicólogos sociais, Diederik  Stapel, inventava grande parte dos dados que eram divulgados em seus  artigos, que, inclusive, chegaram a ser publicados pela revista  “Science”.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Embora a suspeita da fraude já tenha sido confirmada em  setembro, quando o psicólogo foi impedido de exercer suas funções como  decano da Faculdade de Ciências Sociais e do Comportamento da  Universidade de Tilburg (sul da Holanda), nesta semana ficou claro que o  mesmo utilizava esse tipo de artifício há pelo menos oito anos.&lt;br /&gt;Durante esse tempo, o psicólogo teria falsificado dezenas de  publicações e pesquisas que contavam com sua supervisão. As fraudes  também estão sendo analisadas por uma comissão específica sob supervisão  do psicólogo lingüístico Willem Levelt. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Essa comissão procura saber, entre outras coisas, se a tese  do psicólogo, com doutorado pela Universidade de Amsterdã, também  apresenta dados falsos, fabricados e modificados para confirmar suas  próprias hipóteses.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Seguindo as recomendações da comissão, as universidades de  Groningen (ao norte do país) e Tilburg, onde o psicólogo trabalhou desde  2006, denunciaram o mesmo por fraude e falsificação de documentos no  Ministério Fiscal holandês.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Um dos mais midiáticos e prestigiados da Holanda, o psicólogo  social reconheceu sua fraude através de um comunicado, no qual  especificava toda sua vergonha pelo ato.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;“Não controlei essa pressão em publicar e sempre queria mais e  mais rápido”, explicou o autor da fraude, confirmando que sua atitude  não foi motivada por seu próprio interesse. Stapel também assegurou que a  justiça deve se aprofundar nas razões que o motivaram a atuar dessa  forma.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Alguns dos estudos mais famosos de Stapel, simpatizante de  organizações contra a criação em massa de animais para o consumo,  concluíram, por exemplo, que as pessoas que comem carne são mais  agressivas que as vegetarianas. Após a descoberta da fraude, a  objetividade destas publicações também foi colocada em dúvida.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Esse estranho caso foi divulgado depois que alguns estudantes  de doutorado de Stapel repararam que o professor nunca os deixavam  participar das pesquisas de dados.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;O professor de psicologia afirmava para seus alunos que  contava com muitos contatos em escolas que distribuíam questionários  para iniciar uma pesquisa, mas, na realidade, os dados eram inventados  pelo próprio acadêmico.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Segundo a comissão de investigação, o psicólogo começou a  falsificar esses dados em 2000, quando trabalhava na Universidade de  Groningen.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;Segundo o jornal “De Volkskrant”, quando os estudantes  pressionavam o professor para acompanhar suas pesquisas, Stapel abusava  de sua posição de poder, colocando em dúvida a proposta de investigação de  seu aluno.&lt;/span&gt;&lt;/div&gt;&lt;div style="font-family: inherit;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="font-family: inherit; font-size: small;"&gt;&lt;/span&gt;&lt;div style="font-family: inherit;"&gt;&lt;span style="font-size: small;"&gt;(Ultimo Segundo via &lt;a href="http://dialogospoliticos.wordpress.com/2011/11/04/diederik-stapel-renomado-psicologo-holandes-frauda-pesquisa-cientifica/" target="_blank"&gt;Diálogos Políticos&lt;/a&gt;)&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7729661572671528419/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/12/fraude-na-ciencia-1-o-caso-do-holandes.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7729661572671528419'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7729661572671528419'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/12/fraude-na-ciencia-1-o-caso-do-holandes.html' title='Fraude na ciência 1 - o caso do Holandês Simulador'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-9127414341091777973</id><published>2011-11-24T20:58:00.000-03:00</published><updated>2011-11-24T20:58:58.613-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Media Education - from AAP</title><content type='html'>&lt;a href="http://pediatrics.aappublications.org/cgi/content/abstract/126/5/1012?rss=1"&gt;Media Education&lt;/a&gt;: &lt;p&gt;The American Academy of Pediatrics recognizes that exposure to mass media (eg, television, movies, video and computer games, the Internet, music lyrics and videos, newspapers, magazines, books, advertising) presents health risks for children and adolescents but can provide benefits as well. Media education has the potential to reduce the harmful effects of media and accentuate the positive effects. By understanding and supporting media education, pediatricians can play an important role in reducing harmful effects of media on children and adolescents. Via American Academy of Pediatrics.&lt;/p&gt;&lt;p&gt;See full text: &lt;a href="http://bit.ly/sjV8K2"&gt;http://bit.ly/sjV8K2&lt;/a&gt;&lt;br /&gt;&lt;/p&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/9127414341091777973/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/media-education-from-aap.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9127414341091777973'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9127414341091777973'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/media-education-from-aap.html' title='Media Education - from AAP'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5484391952098958437</id><published>2011-11-24T20:50:00.000-03:00</published><updated>2011-11-24T20:50:28.345-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>New UK clinical trial for relapsed neuroblastoma planned - via NB Globe - Neuroblastoma News</title><content type='html'>&lt;a href="http://www.nbglobe.com/2011/11/07/new-uk-clinical-trial-for-relapsed-neuroblastoma-planned/"&gt;New UK clinical trial for relapsed neuroblastoma planned&lt;/a&gt;: LONDON — November 7, 2011 — A new clinical trial testing 177Lutetium-DOTATATE (LuDO) for relapsed neuroblastoma is due to start in the UK next year. The UK is the first country to plan a clinical trial for this new molecular radiotherapy treatment for treating relapsed high-risk neuroblastoma, although it is already used to treat rare adult neuro-endocrine … &lt;a href="http://www.nbglobe.com/2011/11/07/new-uk-clinical-trial-for-relapsed-neuroblastoma-planned/"&gt;Continue reading &lt;span&gt;→ via NB Globe - Neuroblastoma News&lt;br /&gt;&lt;/span&gt;&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5484391952098958437/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/new-uk-clinical-trial-for-relapsed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5484391952098958437'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5484391952098958437'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/new-uk-clinical-trial-for-relapsed.html' title='New UK clinical trial for relapsed neuroblastoma planned - via NB Globe - Neuroblastoma News'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5994766559733705493</id><published>2011-11-23T14:14:00.001-03:00</published><updated>2011-11-23T14:35:31.959-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Programa do II Encontro Interdisciplinar de Assistência ao Paciente Oncológico</title><content type='html'>O II Encontro Interdisciplinar de Assistência ao paciente Oncológico será realizado na Escola de Saúde Pública do Ceará (Av. Antonio Justa, 3161 - Meireles, Fortaleza-CE - Cep 60165-090 Fone: (85) 3101.1398 - Fax (85) 3101.1423) sob organização do Centro de Estudos Dr. Geraldo Barros de Oliveira, do Centro Regional Integrado de Oncologia - CRIO.  Maiores informações, entrar em contato no endereço &lt;a href="http://www.blogger.com/www.crio.com.br"&gt;www.crio.com.br&lt;/a&gt; &lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://3.bp.blogspot.com/-_evhn-dcptE/Ts0pyiStFNI/AAAAAAAABqk/HuyMESNr6KQ/s1600/Programac%25CC%25A7a%25CC%2583o.docx.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="640" src="http://3.bp.blogspot.com/-_evhn-dcptE/Ts0pyiStFNI/AAAAAAAABqk/HuyMESNr6KQ/s640/Programac%25CC%25A7a%25CC%2583o.docx.png" width="452" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://3.bp.blogspot.com/-DkILJKgBQPo/Ts0ucD2aGKI/AAAAAAAABqw/J_mJPgptIHM/s1600/Programac%25CC%25A7a%25CC%2583o.docx2.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="640" src="http://3.bp.blogspot.com/-DkILJKgBQPo/Ts0ucD2aGKI/AAAAAAAABqw/J_mJPgptIHM/s640/Programac%25CC%25A7a%25CC%2583o.docx2.png" width="452" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;/div&gt;&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5994766559733705493/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/programa-do-ii-encontro.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5994766559733705493'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5994766559733705493'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/programa-do-ii-encontro.html' title='Programa do II Encontro Interdisciplinar de Assistência ao Paciente Oncológico'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/-_evhn-dcptE/Ts0pyiStFNI/AAAAAAAABqk/HuyMESNr6KQ/s72-c/Programac%25CC%25A7a%25CC%2583o.docx.png' height='72' width='72'/><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4846425745591580322</id><published>2011-11-19T08:55:00.000-03:00</published><updated>2011-11-22T21:24:23.148-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>What's new for 'fibromyalgia' in PubMed</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology &lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt;Search: fibromyalgia &lt;br /&gt;Sent on Saturday, 2011 Nov 19&lt;br /&gt;Search &lt;b&gt;fibromyalgia&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/22095395" ref="ordinalpos=1"&gt;Relationship between body mass index,  fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Arranz L,  Canela MA,  Rafecas M.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Rheumatology international"&gt;Rheumatol Int&lt;/span&gt;. 2011 Nov 18. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 22095395 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;2.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/22095117" ref="ordinalpos=2"&gt;Serum iron and iron stores in non-anemic patients with fibromyalgia.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Mader R,  Koton Y,  Buskila D,  Herer P,  Elias M.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Clinical rheumatology"&gt;Clin Rheumatol&lt;/span&gt;. 2011 Nov 19. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 22095117 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;3.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/22094205" ref="ordinalpos=3"&gt;Future perspectives in generalised musculoskeletal pain syndromes.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Russell IJ.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Best practice &amp;amp;  research. Clinical rheumatology"&gt;Best Pract Res Clin Rheumatol&lt;/span&gt;. 2011 Apr;25(2):321-31.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 22094205 [PubMed - in process]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;4.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/22094203" ref="ordinalpos=5"&gt;Non-pharmacological treatment of chronic widespread musculoskeletal pain.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Hassett AL,  Williams DA.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Best practice &amp;amp; research. Clinical rheumatology"&gt;Best Pract Res Clin Rheumatol&lt;/span&gt;. 2011 Apr;25(2):299-309.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 22094203 [PubMed - in process]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;5.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/22094201" ref="ordinalpos=7"&gt;Neuroimaging of fibromyalgia.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Gracely RH,  Ambrose KR.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Best practice &amp;amp; research. Clinical rheumatology"&gt;Best Pract Res Clin Rheumatol&lt;/span&gt;. 2011 Apr;25(2):271-84.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 22094201 [PubMed - in process]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;6.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/22094199" ref="ordinalpos=8"&gt;Fatigue and fibromyalgia syndrome: Clinical and neurophysiologic pattern.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Casale R,  Rainoldi A.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Best practice &amp;amp; research. Clinical rheumatology"&gt;Best Pract Res Clin Rheumatol&lt;/span&gt;. 2011 Apr;25(2):241-7.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 22094199 [PubMed - in process]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;7.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/22094198" ref="ordinalpos=9"&gt;Fibromyalgia and sleep.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Spaeth M,  Rizzi M,  Sarzi-Puttini P.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Best practice &amp;amp; research. Clinical rheumatology"&gt;Best Pract Res Clin Rheumatol&lt;/span&gt;. 2011 Apr;25(2):227-39.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 22094198 [PubMed - in process]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4846425745591580322/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/whats-new-for-fibromyalgia-in-pubmed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4846425745591580322'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4846425745591580322'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/whats-new-for-fibromyalgia-in-pubmed.html' title='What&apos;s new for &apos;fibromyalgia&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4898820472689678449</id><published>2011-11-17T15:03:00.000-03:00</published><updated>2011-11-17T15:54:12.538-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Aparelho consegue medir níveis de glicose em lágrima</title><content type='html'>&lt;br /&gt;Um estudo da Universidade de  Michigan, nos EUA, deu um passo importante para livrar diabéticos do  ritual incômodo de picar o dedo várias vezes por dia para medir os  níveis de glicose no sangue. A alternativa: lágrimas.&lt;br /&gt;Ocorre que, segundo a equipe liderada por Mark Meyerhoff, o fluido das  lágrimas -que não aparece apenas quando as pessoas choram, mas está  presente com frequência como lubrificante dos olhos- também reflete o  conteúdo de glicose do organismo, podendo ser examinado de forma  confiável.&lt;br /&gt;Em artigo na revista científica "Analytical Chemistry", Meyerhoff e  companhia descrevem a criação de um sistema relativamente simples,  envolvendo componentes comuns na indústria eletrônica, para medir os  níveis de glicose nas lágrimas.&lt;br /&gt;Os testes foram feitos com coelhos, revelando que o sensor dos  pesquisadores é capaz de detectar os níveis da molécula de açúcar em  amostras de apenas 5 microlitros de fluido lacrimal.&lt;br /&gt;É um volume, de fato, muito pequeno, pouco mais de um milionésimo do encontrado numa garrafa d´água de 1 litro, por exemplo.&lt;br /&gt;&lt;br /&gt;SENSIBILIDADE&lt;br /&gt;Esse era justamente um dos problemas para colocar em prática a medição alternativa de glicose: como aumentar a sensibilidade.&lt;br /&gt;Fala-se em substituir sangue por lágrimas desde os anos 1950. A questão é  que, quando os cientistas foram comparar o metabolismo do sangue com o  das lágrimas, viram que a presença de glicose nessas últimas era muito  menor -entre 1/30 e 1/50 da quantidade encontrada na corrente sanguínea.&lt;br /&gt;Também não estava claro se a correlação entre açúcar no sangue e no  fluido lacrimal era confiável. Se as flutuações fossem grandes demais,  com níveis altos nas lágrimas não necessariamente associados a níveis  elevados no sangue, um teste desse tipo seria inútil.&lt;br /&gt;Os pesquisadores de Michigan levaram em conta todas essas dúvidas no  teste com 12 coelhos -todos devidamente anestesiados e imobilizados,  porque era preciso comparar os exames de sangue com os de lágrimas.&lt;br /&gt;As amostras lacrimais eram recolhidas num tubinho de apenas 0,84  milímetro de diâmetro. O sensor desenvolvido pelos cientistas é  mergulhado dentro do fluido.&lt;br /&gt;Para detectar com precisão a quantidade de glicose na amostra, o sensor  usa uma enzima (proteína que acelera reações químicas) que degrada o  açúcar. A sobra da reação gera um sinal elétrico cuja intensidade diz  quanta glicose está presente ali.&lt;br /&gt;Graças a outros componentes do sensor que o ajudam a "ignorar" a  presença de outras moléculas das lágrimas, que poderiam ser confundidas  com a glicose, o sistema tem bom grau de precisão.&lt;br /&gt;Os dados obtidos com os coelhos também mostraram que há uma correlação forte entre níveis de glicose no sangue e nas lágrimas.&lt;br /&gt;O que acontece é que a correlação muda um pouco de indivíduo para  indivíduo. Por isso, talvez seja necessária uma calibragem fazendo um  exame inicial de sangue antes de partir para testes com o fluido das  lágrimas.&lt;br /&gt;A equipe, agora, pretende melhorar ainda mais a sensibilidade do teste para poder empregá-lo em pessoas.&lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; FOLHA DE SÃO PAULO – SP&lt;/span&gt;, via &lt;a href="http://consulfarma.com/detalhes_noticias.php?id=132365#.TsVMBo7mMnI.blogger"&gt;Consulfarma&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4898820472689678449/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/aparelho-consegue-medir-niveis-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4898820472689678449'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4898820472689678449'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/aparelho-consegue-medir-niveis-de.html' title='Aparelho consegue medir níveis de glicose em lágrima'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-959823099370239617</id><published>2011-11-17T14:54:00.000-03:00</published><updated>2011-11-17T14:59:25.741-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Anvisa proíbe alimentos e bebidas à base de aloe vera</title><content type='html'>A Agência Nacional de Vigilância Sanitária (Anvisa) proibiu a venda,  fabricação e importação de alimentos e bebidas à base de aloe vera. De  acordo com o órgão, não há comprovação da segurança do uso do componente  e nem registro para esse fim. A restrição foi publicada nesta  segunda-feira, no Diário Oficial da União.&lt;br /&gt;&lt;br /&gt;A aloe vera é uma planta conhecida popularmente como babosa. É usada  principalmente em produtos para o cabelo, mas recentemente também era  encontrada em bebidas e alimentos, inclusive com função de  emagrecimento. Por se encaixar na categoria de "novos alimentos", a  planta precisa se submeter ao registro da Anvisa para poder ser  comercializada com esse fim.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://blogviagens.com/wp-content/uploads/2010/03/aloe-vera-drink.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="204" src="http://blogviagens.com/wp-content/uploads/2010/03/aloe-vera-drink.jpg" width="320" /&gt;&lt;/a&gt;De acordo com a resolução, o uso da aloe vera é regulamentado apenas  como aditivo na função de aromatizantes de alimentos e bebidas, o que  continua sendo permitido. As informações são da Agência Brasil.&lt;br /&gt;&lt;br /&gt;Na foto, anúncio de bebibas à base de aloe vera, vendidas no Havaí. &lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; ZERO HORA – RS, via &lt;/span&gt;&lt;a href="http://consulfarma.com/detalhes_noticias.php?id=132368#.TsVJ78josnY.blogger"&gt;Consulfarma&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/959823099370239617/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/anvisa-proibe-alimentos-e-bebidas-base.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/959823099370239617'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/959823099370239617'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/anvisa-proibe-alimentos-e-bebidas-base.html' title='Anvisa proíbe alimentos e bebidas à base de aloe vera'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-546116226776266136</id><published>2011-11-17T14:47:00.000-03:00</published><updated>2011-11-17T14:51:39.745-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Desenvolvimento pioneiro de nova droga bloqueadora da AKT</title><content type='html'>A ArQule e a Daiichi Sankyo anunciaram esta quinta-feira a assinatura de  um contrato de licença para o desenvolvimento de um novo inibidor da AKT  chamado ARQ 092, o primeiro composto a surgir a partir do acordo que as  empresas assinaram em Novembro de 2008 “para colaborar na investigação  utilizando o AKIP ™ (ArQule Kinase Inhibitor Platform) para gerar novos,  seletivos e potentes inibidores da quinase), diz comunicado de  imprensa, enviado ao POP.&lt;br /&gt;&lt;br /&gt;Sob os termos do acordo de licença, a Daiichi Sankyo vai obter os  direitos exclusivos para desenvolvimento, produção e comercialização do  ARQ 092 numa base mundial.&lt;br /&gt;&lt;br /&gt;O ARQ 092 será estudado em doentes com câncer para identificar a sua  utilidade no direccionamento da via de sinalização AKT, que desempenha  um papel na regulação do crescimento celular, sobrevivência, migração e  angiogênese, uma vez que é frequentemente desregulado nas doenças malignas. As  inscrições de doentes no estudo clínico de fase 1 com ARQ 092 estão  programadas para abrir nos próximos meses.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://2.bp.blogspot.com/-Iysb7InBYAc/TsVI58vVcoI/AAAAAAAABqU/Y-XHPBaL95k/s1600/800px-Signal_transduction_v1.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="234" src="http://2.bp.blogspot.com/-Iysb7InBYAc/TsVI58vVcoI/AAAAAAAABqU/Y-XHPBaL95k/s320/800px-Signal_transduction_v1.png" width="320" /&gt;&lt;/a&gt;"Este candidato clínico é o resultado da colaboração científica estreita  entre as duas empresas nos últimos dois anos e meio”, disse Thomas C.K.  Chan, director científico da ArQule.&lt;br /&gt;&lt;br /&gt;A figura mostra vias de sinalização molecular envolvidas no fenômeno da apoptose (morte celular programada), entre elas, a via da proteína quinase AKT. &lt;br /&gt;&lt;br /&gt;&lt;span class="texto_azul_grande"&gt;&lt;b&gt;Fonte:&lt;/b&gt; RCMPHARMA via &lt;/span&gt;&lt;a href="http://consulfarma.com/detalhes_noticias.php?id=132379#.TsVGo5pI2eg.blogger"&gt;Consulfarma&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/546116226776266136/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/desenvolvimento-pioneiro-de-nova-droga.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/546116226776266136'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/546116226776266136'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/desenvolvimento-pioneiro-de-nova-droga.html' title='Desenvolvimento pioneiro de nova droga bloqueadora da AKT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-Iysb7InBYAc/TsVI58vVcoI/AAAAAAAABqU/Y-XHPBaL95k/s72-c/800px-Signal_transduction_v1.png' height='72' width='72'/><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1124413102904465547</id><published>2011-11-17T14:36:00.000-03:00</published><updated>2011-11-17T14:36:09.653-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>O Fim das Células-Tronco Embrionárias?</title><content type='html'>O teste clínico mais aguardado das últimas décadas está terminando de  forma inglória. A empresa americana Geron, primeira a empregar  células-tronco embrionárias em humanos, avisou que não vai mais  trabalhar nessa área.&lt;br /&gt;A Geron recebeu permissão do governo americano para injetar as células  na medula espinhal de cerca de dez pessoas com lesões recentes na área,  que as deixaram paralisadas -problema comum em acidentes de carro ou  ferimentos a bala.&lt;br /&gt;A grande esperança envolvendo as células-tronco embrionárias, capazes de  se transformar em qualquer tecido do organismo, é a de reconstruir  órgãos danificados.&lt;br /&gt;Mais especificamente, os acidentados que participam do teste da Geron  receberam oligodendrócitos. Essas células do sistema nervoso montam a  "fiação" dos neurônios, que acaba sendo cortada durante esse tipo de  lesão.&lt;br /&gt;A empresa americana afirmou que vai monitorar os quatro pacientes que já  receberam a infusão de células-tronco, e que vai concluir os  transplantes já projetados, mas que não testará a abordagem em mais  pacientes. Além disso, vai abandonar totalmente o ramo das  células-tronco embrionárias.&lt;br /&gt;Em entrevista ao "New York Times", o executivo-chefe da Geron, John  Scarlett, disse que "continua acreditando profundamente" na promessa das  células-tronco, mas que a atual crise econômica força a empresa a se  dedicar a áreas com retorno mais imediato, como drogas contra o câncer.&lt;br /&gt;Por outro lado, o fato é que, embora os pacientes não tenham sofrido efeitos colaterais no teste, também não tiveram melhoras.&lt;br /&gt;Com isso, só há um único outro grupo testando células de embrião no  planeta: os também americanos da ACT (Advanced Cell Technology).&lt;br /&gt;Liderados por Robert Lanza, eles estão empregando as infusões celulares  contra dois tipos comuns de doença degenerativa da visão.&lt;br /&gt;Existem ainda muitos testes com células-tronco adultas, menos versáteis, inclusive no Brasil. (RJL)&lt;br /&gt;                   &lt;br /&gt;                    &lt;span class="texto_azul_grande"&gt;&lt;strong&gt;Fonte:&lt;/strong&gt; FOLHA DE SÃO PAULO – SP&lt;/span&gt;, via  &lt;a href="http://consulfarma.com/detalhes_noticias.php?id=132364#.TsVFmg_aVtc.blogger"&gt;Consulfarma&lt;br /&gt;&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1124413102904465547/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/o-fim-das-celulas-tronco-embrionarias.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1124413102904465547'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1124413102904465547'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/o-fim-das-celulas-tronco-embrionarias.html' title='O Fim das Células-Tronco Embrionárias?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1948982467769656362</id><published>2011-11-12T08:50:00.000-03:00</published><updated>2011-11-22T21:28:02.263-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>What's new for 'cancer' in PubMed</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology &lt;b&gt;Sender's message: &lt;/b&gt; &lt;br /&gt;Sent on Saturday, 2011 Nov 12&lt;br /&gt;Search &lt;b&gt;cancer&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21880994" ref="ordinalpos=2"&gt;Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Weller M,  Gorlia T,  Cairncross JG,  van den Bent MJ,  Mason W,  Belanger K,  Brandes AA,  Bogdahn U,  Macdonald DR,  Forsyth P,  Rossetti AO,  Lacombe D,  Mirimanoff RO,  Vecht CJ,  Stupp R.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Neurology"&gt;Neurology&lt;/span&gt;. 2011 Sep 20;77(12):1156-64. Epub 2011 Aug 31.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21880994 [PubMed - indexed for MEDLINE]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=21880994" ref="ordinalpos=2"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1948982467769656362/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/11/whats-new-for-cancer-in-pubmed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1948982467769656362'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1948982467769656362'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/11/whats-new-for-cancer-in-pubmed.html' title='What&apos;s new for &apos;cancer&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8915044658739236542</id><published>2011-10-26T18:54:00.001-03:00</published><updated>2011-11-10T09:06:38.993-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Riscos do uso de corticóide em recém-nascidos pré-termo</title><content type='html'>&lt;br /&gt;O número de crianças prematuras que nascem cada vez mais cedo e sobrevivem cada vez mais cresce dia a dia no mundo todo. Mesmo entre nós, no Brasil e, em particular, no estado do Ceará onde este comentarista reside, torna-se flagrante o impacto da tecnologia na sobrevivência&amp;nbsp; dos neonatos prematuros. No entanto, um número significante de crianças adquire problemas e sequelas, entre elas alterações neurológicas e cognitivas. Modelos animais têm demonstrado que a exposição perinatal a glicocorticóides associa-se com redução do volume cerebelar. A fim de testar a possível associação entre a exposição de crianças prematuras a estas drogas e complicações neurológicas, um grupo da University of British Columbia e University of California, em São Francisco, fizeram uma análise retrospectiva num grupo de crianças que nasceram prematuras. Seus resultados mostram que a exposição antenatal à betametasona não se correlaciona com sequelas. Porém, o uso pós-natal de dexametasona e hidrocortisona afetaram adversamente o desenvolvimento cerebelar das crianças estudadas. Estes resultados corroboram evidências anteriores e demonstram que o uso de glicocorticóides em lactentes jovens pré-termo deve ser feito com extrema parcimônia, pois seu uso regular pode induzir sequelas neurológicas irreversíveis. O estudo não pode ser extrapolado para recém-nascidos termo, mas pode-se questionar se o efeito biológico de corticóides no desenvolvimento neural restringe-se a crianças prematuras ou seu uso pode também afetar os outros lactentes jovens. O mecanismo molecular da ação neurológica dos glicocorticóides parece envolver a inibição da sinalização dependente de shh-smo (via de sinalização &lt;i&gt;sonic hedgehog&lt;/i&gt; e &lt;i&gt;smoothened&lt;/i&gt;) nas células granulares do cerebelo. Sendo assim, pode-se supor que todos os lactentes jovens podem estar sob risco ao se expor a glicocorticóides.&lt;br /&gt;&lt;br /&gt;Leia em Science Translational Medicine: &lt;a href="http://bit.ly/pS30xr"&gt;http://bit.ly/pS30xr&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8915044658739236542/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/riscos-do-uso-de-corticoide-em-recem.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8915044658739236542'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8915044658739236542'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/riscos-do-uso-de-corticoide-em-recem.html' title='Riscos do uso de corticóide em recém-nascidos pré-termo'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-150844182093857761</id><published>2011-10-26T16:42:00.000-03:00</published><updated>2011-10-26T16:42:26.426-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Inmigración y cefaleas - via Revista de Neurología</title><content type='html'>&lt;div style="line-height:20px;"&gt;             &lt;span style="font-family: Arial; line-height: 150%; font-size: 9pt"&gt;La  población inmigrante (PI) es cada vez más común en la práctica clínica  habitual, y constituye un nuevo modelo poblacional, con quejas y  problemas altamente relacionados con la precariedad de su situación  laboral y social. Representan el 13,6% de las primeras visitas de  cefalea, y aunque sus diagnósticos son similares a los de la población  autóctona, existen diferencias en la frecuencia de algunos diagnósticos,  en la presencia de cefalea crónica y en la indicación de medicación  preventiva y tratamiento agudo específico.&lt;/span&gt; &lt;p&gt; &lt;span style="font-family: Arial; line-height: 150%; font-size: 9pt"&gt;La  relación temporal de la cefalea con la inmigración aparece en la mayoría  de los pacientes a partir del tercer año tras la inmigración; por  tanto, no existe una relación temporal con el hecho de la inmigración,  en contra de su posible papel desencadenante como evento estresante que  representa. El 11,9% de los pacientes con historia previa de cefalea  refirió un empeoramiento en cuanto a la frecuencia o intensidad de la  cefalea, lo que motivó la visita a la consultas externas de neurología.  El tratamiento sintomático y preventivo difiere significativamente entre  el período anterior a la inmigración y el posterior.&lt;/span&gt; &lt;/p&gt;             &lt;/div&gt;                                                                                                                       &lt;a target="_blank" href="http://www.neurologia.com/sec/resumen.php?or=web&amp;amp;i=e&amp;amp;id=2011230"&gt;[Rev Neurol 2011]&lt;/a&gt; - &lt;a href="http://bit.ly/te4O9e"&gt;http://bit.ly/te4O9e&lt;/a&gt;&lt;br /&gt;                                                            &lt;span class="txPeque"&gt;Vidal-Jordana A, Barroeta-Espar I, Sáinz-Pelayo MP, Sala I y Roig C &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=3117#.Tqhhh8pciLo.blogger"&gt;Inmigración y cefaleas - Revista de Neurología&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/150844182093857761/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/inmigracion-y-cefaleas-via-revista-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/150844182093857761'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/150844182093857761'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/inmigracion-y-cefaleas-via-revista-de.html' title='Inmigración y cefaleas - via Revista de Neurología'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-733930428733494721</id><published>2011-10-23T13:02:00.002-03:00</published><updated>2011-10-23T13:02:16.493-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Efecto antidepresivo de la cafeína - via Revista de Neurología</title><content type='html'>Las mujeres que toman más de cuatro tazas de café al día parecen tener un riesgo menor de sufrir una depresión que aquéllas que no toman café o solo beben una taza al día. Estos resultados aparecen publicados en la revista Archives of Internal Medicine.&lt;br /&gt;Los investigadores siguieron a casi 51.000 mujeres con una edad promedio de 63 años, ninguna de las cuales tenía depresión ni tomaba antidepresivos al inicio del estudio.&lt;br /&gt;&lt;br /&gt;Las mujeres que bebían cuatro o más tazas de café al día mostraban una reducción del 20% en el riesgo de depresión, las que bebían de dos a tres tazas de café al día tenían una reducción del 15% frente las que bebían una taza o menos. El uso de café descafeinado no se asociaba con la depresión. La cafeína afecta la liberación de varios neurotransmisores, entre ellos dopamina y serotonina, que se han implicado en la regulación del estado de ánimo y en la depresión.&lt;br /&gt;&lt;br /&gt;[Arch Intern Med 2011] - &lt;a href="http://bit.ly/plIxhB"&gt;http://bit.ly/plIxhB&lt;/a&gt;&lt;br /&gt;Lucas M, Mirzaei F, Pan A, Okereke OI, Willett WC, O’Reilly É, et al.&lt;br /&gt;&lt;a href="http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=3112"&gt;Efecto antidepresivo de la cafeína - Revista de Neurología&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/733930428733494721/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/efecto-antidepresivo-de-la-cafeina-via.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/733930428733494721'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/733930428733494721'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/efecto-antidepresivo-de-la-cafeina-via.html' title='Efecto antidepresivo de la cafeína - via Revista de Neurología'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3895085829002573233</id><published>2011-10-23T12:59:00.000-03:00</published><updated>2011-10-23T12:59:36.099-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial - Schrey - 2011 - Pediatric Blood &amp; Cancer - Wiley Online Library</title><content type='html'>Recently published in Pediatric Blood and Cancer:&lt;br /&gt;&lt;br /&gt;The german ALL-BFM2000 trial reported on the relation between asparaginase activity monitoring in children during the treatment for acute leukemia.&lt;br /&gt;Asparaginase (ASNase) has been a core element in the treatment of acute  lymphoblastic leukemia (ALL) in children and adults over the last  decades. It reduces the exogenous supply of asparagine (ASN) by  catalyzing the hydrolysis of ASN, a non-essential amino acid, to  aspartic acid and ammonia. Relative deficiencies of endogenous ASN  synthesis lead to apoptosis and impaired protein synthesis in the  leukaemic blast. The two critical issues about ASNase for cancer treatment are toxicity  and insufficient activity. Toxicity is mostly due to the inhibition of  protein synthesis and includes hypoalbuminemia, liver enzyme elevation,  pancreatitis, hyperglycemia, thrombosis and hemorrhage&lt;a href="http://onlinelibrary.wiley.com/doi/10.1002/pbc.23041/full#bib25" rel="references:#bib25 #bib26 #bib27 #bib28" class="referenceLink" title="Link to bibliographic citations" shape="rect"&gt;&lt;/a&gt;. Especially during the induction phase, when the drug is co-administered  with steroids, ASNase related toxicity can necessitate the withdrawal  of ASNase from treatment.  An aggravating factor consists in the fact that steroid induced  toxicity is in some cases comparably additive (i.e., thromboembolic  events, hyperglycemia) to ASNase side effects. Another major limiting factor of ASNase treatment consists in hypersensitivity reactions.  The probability of allergic reactions increases with the number of  administrations. It is known that up to 30% of patients develop an  allergic reaction to first-line &lt;em&gt;E. coli&lt;/em&gt; ASNase.&lt;br /&gt;The Berlin-Frankfurt-Muenster (BFM) protocol for the treatment of  childhood leukemia employed different combinations of multi-agent  chemotherapy in risk-adapted regimes. The ALL-BFM 2000 trial protocol uses &lt;em&gt;Escherichia coli&lt;/em&gt; derived asparaginase (&lt;em&gt;E. coli&lt;/em&gt;  ASNase produced by Kyowa Hakko; Asparaginase medac®) for first-line  treatment in the induction phase; in case of insufficient activity or  allergic reactions to &lt;em&gt;E. coli&lt;/em&gt; ASNase, this is followed by re-intensification with a pegylated form of the &lt;em&gt;E. coli&lt;/em&gt;  ASNase (PEG ASNase, Oncaspar®). Third-line treatment, usually given for  re-intensification and after an allergic reaction to and/or silent  inactivation of &lt;em&gt;E. coli&lt;/em&gt; preparations, employs Erwinia  chrysanthemi asparaginase (Erwinase®). As all preparations are of  bacterial origin, common side effects are hypersensitivity reactions by  antibody formation or the phenomenon of silent inactivation, that is, insufficient asparaginase activity, without clinical signs of allergy.&lt;br /&gt;An important prognostic milestone in ALL therapy is day of the end of  induction therapy (day 33 on the BFM regimens) when the measurement of  minimal residual disease (MRD) (negative or not negative) and the randomization according to three  different risk categories (SR, MR, HR) take place. The report found no  significant relationship between MRD marker positivity or different risk  categories and differences in ASNase activity on day +3 after the  administration of 5,000 U/m&lt;sup&gt;2&lt;/sup&gt;&lt;em&gt;E. coli&lt;/em&gt; ASNase, taken  throughout the induction element. This indicates that, while sufficient  ASNase treatment is in fact important, there is no apparent correlation  between high ASNase trough levels and MRD.&lt;br /&gt;With regard to the patients who relapsed, the report found that  the number of patients with sufficient ASNase activity throughout the  ASNase containing elements is comparable to the total group, especially  concerning induction. This indicates that the occurrence of relapses cannot easily be attributed to inadequate ASNase therapy.&lt;br /&gt;This important report from the BFM group trial highlights the importance of ASNase therapy in ALL, but shows that monitoring of enzymatic activity levels are not well correlated with biological response or relapse.&lt;br /&gt;&lt;br /&gt;Read the article: &lt;a href="http://bit.ly/qgr7C8"&gt;http://bit.ly/qgr7C8&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://onlinelibrary.wiley.com/doi/10.1002/pbc.23041/abstract#.TqQtRTjkhCY.blogger"&gt;Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial - Schrey - 2011 - Pediatric Blood &amp;amp; Cancer - Wiley Online Library&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3895085829002573233/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/five-year-single-center-study-of.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3895085829002573233'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3895085829002573233'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/five-year-single-center-study-of.html' title='Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial - Schrey - 2011 - Pediatric Blood &amp; Cancer - Wiley Online Library'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-360059813653461801</id><published>2011-10-23T12:05:00.000-03:00</published><updated>2011-10-23T13:00:28.675-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents - Mora - 2011 - Pediatric Blood &amp; Cancer - Wiley Online Library</title><content type='html'>Recently published in Pediatric Blood and Cancer:&lt;br /&gt;&lt;br /&gt;Ewing sarcoma treatment is highly succesfull in non-metastatic patients, but the high-dose chemotherapy poses a significant risk of secondary leukemia. A group from Hospital Sant Joan de Déu, Barcelona, Spain has published a small phase II single-arm non-randomized study reporting good results with a less toxic, modified chemotherapy protocol. Their results were as good as standard chemotherapy that uses higher cummulative doses, and they had no secondary disease in their group, after a median follow-up of more than 4 years! Relapses were seen in patients that did not receive radiotherapy, and they were late (more than 2 years after end of treatment). This report may represent a major advance in the treatment of non-metastatic Ewing sarcoma and should yield larger studies to test the feasibility of this lower-exposure chemotherapy approach.&lt;br /&gt;&lt;br /&gt;Read the article: &lt;a href="http://bit.ly/o42Eha"&gt;http://bit.ly/o42Eha&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://onlinelibrary.wiley.com/doi/10.1002/pbc.22813/abstract#.TqQpAepzCcs.blogger"&gt;Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents - Mora - 2011 - Pediatric Blood &amp;amp; Cancer - Wiley Online Library&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/360059813653461801/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/treatment-of-ewing-sarcoma-family-of.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/360059813653461801'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/360059813653461801'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/treatment-of-ewing-sarcoma-family-of.html' title='Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents - Mora - 2011 - Pediatric Blood &amp; Cancer - Wiley Online Library'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1721422458777912482</id><published>2011-10-20T13:07:00.001-03:00</published><updated>2015-12-07T22:41:40.646-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='Ceará'/><category scheme='http://www.blogger.com/atom/ns#' term='propranolol'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='tratamento'/><category scheme='http://www.blogger.com/atom/ns#' term='projeto de pesquisa'/><category scheme='http://www.blogger.com/atom/ns#' term='hemangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='iniciação científica'/><category scheme='http://www.blogger.com/atom/ns#' term='resultados'/><title type='text'>Primeiros Resultados do Tratamento de Hemangiomas com Propranolol no Ceará</title><content type='html'>Hoje, na edição 2011 dos Encontros Universitários da Universidade Federal do Ceará, foi apresentado o poster "Tratamento com Propranolol em Crianças com Hemangioma", da aluna de graduação do Curso de Farmácia Juliana Costa Albuquerque, orientada pela professora Juvenia Bezerra Fontenele, da Farmácia da UFC. Este trabalho mostra resultados de uma avaliação retrospectiva coordenada por mim, dos resultados do tratamento de crianças portadoras de hemangioma com propranolol no Serviço de Onco-hematologia Pediátrica do Hospital Infantil Albert Sabin. Todos os pacientes foram tratados por mim e iniciaram a terapia com propranolol entre janeiro de 2009 e dezembro de 2010. Esta série retrospectiva de casos é a primeira do Ceará a demonstrar a efetividade deste tratamento inovador para hemangiomas infantis e constitui, até o momento, a maior série brasileira de crianças com hemangiomas tratadas com propranolol.&lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://4.bp.blogspot.com/-GpMyDbYtnJY/TqBG9DdmzCI/AAAAAAAABp8/DbHhq4u8YS4/s1600/Grafico_hemangio.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="210" src="http://4.bp.blogspot.com/-GpMyDbYtnJY/TqBG9DdmzCI/AAAAAAAABp8/DbHhq4u8YS4/s320/Grafico_hemangio.png" width="320" /&gt;&lt;/a&gt;&lt;/div&gt;Os resultados mostram que o propranolol é altamente eficaz em lactentes (até 1 ano) portadores de hemangiomas infantis típicos. Em crianças maiores de 1 ano, também ocorreu resposta de grande número de pacientes, demonstrando que o propranolol não é eficaz apenas na fase proliferativa das lesões. Também mostramos um pequeno número de crianças com hemangiomas congênitos, sindrômicos ou outros, diferentes dos hemangiomas infantis típicos. Igualmente, obtivemos resposta nestes pacientes, porém em menor escala. O gráfico mostra número absoluto de pacientes. Como o tratamento de hemangiomas com propranolol até este ano era considerado não padronizado (off-label), iniciamos o tratamento em todos os casos somente após consentimento informado por escrito dos pais. Seguimos as indicações de tratamento usualmente aceitas, ou seja, tratamos apenas lesões complicadas ou com risco de complicações para o paciente. A aluna Juliana, que faz parte do programa de Iniciação Científica da UFC como voluntária (sem bolsa) colheu os dados e as alunas Jamille Félix e Rosane Aline Magalhães (bolsistas da UFC e FUNCAP) informatizaram os dados. O planejamento, coordenação e análise ficaram a meu encargo. Todas as alunas são orientadas pela professora Juvenia. Todos os autores revisaram e aprovaram a redação final do trabalho.&lt;br /&gt;Link para o poster no google docs: &lt;a href="http://bit.ly/qrdegO"&gt;http://bit.ly/qrdegO&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1721422458777912482'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1721422458777912482'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/primeiros-resultados-do-tratamento-de.html' title='Primeiros Resultados do Tratamento de Hemangiomas com Propranolol no Ceará'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/-GpMyDbYtnJY/TqBG9DdmzCI/AAAAAAAABp8/DbHhq4u8YS4/s72-c/Grafico_hemangio.png' height='72' width='72'/><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4444474819323888775</id><published>2011-10-19T18:54:00.000-03:00</published><updated>2011-10-19T18:54:23.583-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Sarcoma granulocítico em medula espinhal e Sarcoma de Ewing em crânio de lactente - Posters Congresso Brasileiro de Pediatria 2011</title><content type='html'>Este ano, o Congresso Brasileiro de Pediatria foi em Salvador, Bahia, entre 8 e 12 de Outubro de 2011. Pediatras do país inteiro compareceram, batendo recorde de audiência num congresso da Sociedade Brasileira de Pediatria. Numa parceria com alunos da Liga do Câncer da Universidade Federal do Ceará, enviamos 2 relatos de casos raros em oncologia pediátrica, em forma de poster.&lt;br /&gt;&lt;br /&gt;Poster 1: &lt;b style="font-family: Georgia,&amp;quot;Times New Roman&amp;quot;,serif;"&gt;Sarcoma de Ewing de calota craniana em lactente : relato de caso&lt;/b&gt;&lt;br /&gt;&lt;br /&gt;A Família de Tumores de Ewing (FTE) compreende neoplasias  derivadas de células neuroectodérmicas primitivas. Nesta família estão  incluídos: Sarcoma de Ewing (SE), Tumor Neuroectodérmico Primitivo  Periférico (TNPP) e tumor de Askin, correspondendo cerca de 6 a 10% de  todos os tumores ósseos malignos primários.&lt;br /&gt;&lt;br /&gt;Descrição do caso: Lactente, NRH, natural de Fortaleza-CE, deu entrada  aos 5 meses no serviço de onco-hematologia pediátrica para realização de  biópsia de tumoração que havia surgido na região parietal há três  meses. Após esse procedimento submeteu-se à tomografia computadorizada  (TC), que revelou lesão expansiva de calota craniana com lise, esclerose  e fragmentação óssea observada na região fronto-parietal mediana,  medindo aproximadamente 3,0 x 2,0 cm. Com o resultado do  histopatológico, diagnosticou-se quadro sugestivo de SE/TNPP. O LDH  estava aumentado (627,5 U/L). A TC de tórax e a ultrassonografia  abdominal, para fim de estadiamento, não mostraram alterações.  Iniciou-se quimioterapia (QT) neo-adjuvante, Protocolo Brasileiro para  pacientes de Alto Risco, por 5 meses. Após sua conclusão, foi realizada  uma cirurgia para controle local da doença, e a histologia da peça  retirada não evidenciou sinais de neoplasia. Paciente foi submetido a  três ciclos de QT adjuvante e, devido à toxicidade causada, foi  interrompida após cinco meses. À última consulta, criança encontra-se  com 1 ano e 8 meses, não apresentando sinais da doença. No SE, a topografia mais freqüente é em ossos longos e da  pelve. A média de idade dos pacientes acometidos é de 14 anos. Esses  fatos não são observados neste paciente, mostrando a raridade e a  relevância do relato deste caso. Além disso, o lactente possuía um fator  prognóstico desfavorável, LDH elevado, que se correlaciona com um  grande volume tumoral, contudo ele obteve uma ótima resposta ao  tratamento.&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Conclusão: O diagnóstico de SE deve ser lembrado entre os diagnósticos  diferenciais raros de massas cranianas na infância.&amp;nbsp;&lt;/b&gt;&lt;br /&gt;&lt;br /&gt;&lt;i&gt;Link para este poster no google docs: &lt;a href="http://bit.ly/nWdRlg"&gt;http://bit.ly/nWdRlg &lt;/a&gt;&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;Poster 2: &lt;b style="font-family: Georgia,&amp;quot;Times New Roman&amp;quot;,serif;"&gt;Sarcoma granulocítico intramedular&lt;/b&gt;&lt;br /&gt;&lt;br /&gt;Sarcoma granulocítico (SG) é tumor sólido, constituído por  células precursoras de granulócitos, localizado em sítio extra medular. É  normalmente associado com leucemias e outras desordens  mieloproliferativas, sendo considerado fator de mau prognóstico.  Contudo, podem surgir sem manifestação alguma de doenças hematológicas.&lt;br /&gt;&lt;br /&gt; Descrição do caso: Lactente, 11 meses de idade desenvolveu perda de  escores neuropsicomotores e irritabilidade, evoluindo com paraplegia e  paresia dos MMSS. RNM demonstrou tumor intramedular extenso, envolvendo  desde C4 até T5, com hipersinal da dura-máter sugestivo de infiltração  acima e abaixo destes pontos. Foi realizada laminectomia com ressecção  parcial da tumoração, obtendo-se dignóstico de sarcoma granulocítico  intramedular (SGI). A imunohistoquímica comprovou a linhagem com  positividade das células tumorais para mieloperoxidase. A medula óssea  da criança era normal, bem como os exames hematológicos. Apesar da  instituição de quimioterapia intensiva segundo o protocolo BFM-83, a  criança evoluiu rapidamente com insuficiência ventilatória aguda,  dependência de VMI, disautonomia e finalmente PCR irreversível. SG envolvendo a medula espinhal como massa intradural é uma  complicação incomum em leucemias agudas infantis e mais raro ainda como  apresentação inicial aleucêmica. Existem apenas relatos de casos  isolados na literatura (Eser et al, 2001; Deme et al, 1997; Kook et al,  1992, entre outros). E, sendo uma doença rara, com um pequeno número de  casos descritos, é difícil descrever uma faixa etária de maior  incidência, mas os casos relatados encontram-se em sua maioria em  crianças maiores de 8 anos. O caso descreve uma doença aparentemente  muito avançada, já atingindo grande parte da medula espinhal. Logo, não  podemos classificar este caso como refratário ao tratamento, mas  provavelmente não houve condição clínica ou tempo hábil para resposta  efetiva.&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Conclusão: O diagnóstico de SGI deve ser lembrado entre os diagnósticos  diferenciais raros de massas intramedulares na infância. Apesar do  prognóstico sombrio, tal patologia é responsiva a radioquimioterapia.&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;br /&gt;&lt;i&gt;&lt;br /&gt;&lt;/i&gt;&lt;br /&gt;&lt;i&gt;Link para este poster no google docs: &lt;a href="http://bit.ly/qqK2cU"&gt;http://bit.ly/qqK2cU&lt;/a&gt;&lt;/i&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4444474819323888775/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/sarcoma-granulocitico-em-medula.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4444474819323888775'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4444474819323888775'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/sarcoma-granulocitico-em-medula.html' title='Sarcoma granulocítico em medula espinhal e Sarcoma de Ewing em crânio de lactente - Posters Congresso Brasileiro de Pediatria 2011'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1254787009603070778</id><published>2011-10-19T16:12:00.001-03:00</published><updated>2011-10-19T18:57:51.039-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Analgesic effect of venlafaxine and antiplatelet efect of pulegone - FESBE 2011 posters</title><content type='html'>The 2011 edition of the Annual Meeting of the Brazilian Federation of Experimental Biology Societies (&lt;a href="http://www.fesbe.org.br/v5/"&gt;FeSBE&lt;/a&gt;, Federação de Sociedades de Biologia Experimental) took place from August 24th through 27th, in Rio de Janeiro, Brazil. Scientists from all over the world attended this meeting. We sent two brief communications in poster form.&lt;br /&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;Poster 1: &lt;/span&gt;&lt;span class="quatro" style="font-family: Georgia,&amp;quot;Times New Roman&amp;quot;,serif; font-size: small;"&gt;&lt;b&gt;EVALUATION OF THE ANALGESIC EFFECT OF VENLAFAXINE, A SEROTININ AND NORADRENALINE REUPTAKE INHIBITOR.&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;The aim of this study was to test the  analgesic effects of the antidepressant venlafaxine in several  experimental models of nociception.&lt;br /&gt;&lt;br /&gt;Methods and Results:&lt;br /&gt;&lt;br /&gt;Acetic  acid-induced writhing: Groups of six to twelve mice were administered  i.p. 0.6% acetic acid (10 mL kg−1, i.p.), and the number of abdominal  contractions was registered for 20 min, starting 30 min after the  injection. Animals were pre-treated with venlafaxine (10, 20, 40 and 60  mg kg−1, i.p.), 30 min before acetic acid administration. DMSO 5% was  used as vehicle (control group). With the exception of 10 mg kg−1, all  other doses of venlafaxine (20, 40 and 60 mg kg−1, i.p) produced  significant inhibition of writhing (p&amp;lt;0,05) (16.2±12.0, 11.6±8.0 and  3.7±2.0 respectively) when compared with control group (34.0±13.2).  Hot-plate test: groups of nine mice were treated with venlafaxine (10,  20, 40 and 60 mg kg−1, i.p.), 5% DMSO (controls) or morphine (10 mg  kg−1, i.p.) as standard. Measurements were performed before (time 0) and  after 30, 60 and 90 min from drug administration; a cut-off time of 45  seconds was used to avoid paw lesions. Only 60 mg/Kg, i.p. of  venlafaxine showed a significant effect on latency time to licking or  jumping (24.06±4.99 s) when compared with control group (6.88±1.15 s) on  time of 30 min. Morphine (10 mg kg−1, i.p. showed a significant effect  (p&amp;lt;0.05) (39.5±4.13, 34.5±5.54, 29.4±5.08 s) when compared to control  group (6.88±1.15, 6.58±1.88, 8.77±2.27 s) on times of 30, 60 and 90 min  respectively. Rota-rod test: Groups of six mice were treated with  venlafaxine (10, 20, 40 and 60 mg/kg, i.p.) and placed on the rota-rod  30 min after the injection. DMSO 5% was used as vehicle (control group).  The number of falls was recorded by one minute and the length of stay  in the bar. No difference between groups treated with venlafaxine and  control group was observed in any period of time. Statistical analysis:  All values were expressed as means±S.D.M. Data were analyzed using ANOVA  followed by Tukey test (p&amp;lt;0.05 was considered significant).&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Conclusions:&lt;br /&gt;&lt;br /&gt;These  results corroborate research that reported the inhibitory effect of  venlafaxine on the signs of spontaneous pain and hindpaw mechanical and  thermal hypersensitivity in animal models of tonic nociception and  neuropathic pain. Studies continue in an attempt to elucidate the action  mechanisms of these effects.&lt;/b&gt;&lt;/span&gt;&lt;span class="quatro" style="font-size: small;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="quatro" style="font-size: small;"&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;i&gt;&lt;span class="quatro"&gt;Link to this abstract: &lt;a href="http://bit.ly/qrPHK7"&gt;http://bit.ly/qrPHK7&lt;/a&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="quatro" style="font-size: small;"&gt;&lt;i&gt;Link to this poster in google docs: &lt;a href="http://bit.ly/nJXtR5"&gt;http://bit.ly/nJXtR5 &lt;/a&gt;&lt;/i&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="quatro" style="font-size: small;"&gt;Poster 2: &lt;/span&gt;&lt;span class="quatro" style="font-family: Georgia,&amp;quot;Times New Roman&amp;quot;,serif; font-size: small;"&gt;&lt;b&gt;EVALUATION OF ANTIPLATELET ACTIVITY OF MONOTERPENE PULEGONE&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;Objectives: To evaluate the antiplatelet activity of Pulegone in human PRP.&lt;br /&gt;&lt;br /&gt;Methods and Results:&lt;br /&gt;&lt;br /&gt;Platelet  aggregation was measured according to the method of Born and Cross (J  Physiol. 163; 178-195, 1963). Briefly, platelet aggregation was induced  at 37ºC in the aggregometer, with stirring at 1000 rpm, by addition of  ADP (4µM) as agonist. The resulting aggregation, measured as the change  in light transmission, was recorded for 5 min and presented as percent  aggregation related to control (100%). Pulegone oil (PUL) was emulsified  with Tween 80 (660 µg mL−1, control) and concentrations of 110, 220,  440 and 660 µg mL−1 were used. PUL 220, 440 and 660 µg mL−1 reduced  significantly (p&amp;lt;0.001) the platelet aggregation induced by ADP (4µM)  in 39.8, 47.3 and 70.1% (60.2±27.5; 52.7±17.23 and 29.9±7.60%  aggregation) respectively when compared to control group.&lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;b&gt; &lt;/b&gt;Statistical analysis: All values are expressed as mean ±  SD. Differences between the sample-treated and control groups were  submitted to analysis of variance (ANOVA) followed by Tukey-Newman-Keuls  test for multiple comparisons (p&amp;lt; 0.05) was considered significant.&lt;span class="quatro"&gt; &lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;br /&gt;&lt;b&gt;Conclusions:&lt;br /&gt;&lt;br /&gt;Direct  stimulation of platelets by ADP results in shape change, reversible  aggregation at physiological concentrations of calcium, and finally,  desensitization. Transduction of the ADP signal involves a transient  rise in free cytoplasmic calcium, due to the mobilization of internal  stores and secondary store-mediated influx, and a concomitant inhibition  of adenylyl cyclase activity. It is possible that the antiplatelet  effect of pulegone is due to blocking of a step of ADP-induced platelet  stimulation.&amp;nbsp;&lt;/b&gt;&lt;b&gt;&lt;span class="quatro"&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;i&gt;&lt;span class="quatro"&gt;Link to this abstract:&amp;nbsp; &lt;a href="http://bit.ly/pvZGwU"&gt;http://bit.ly/pvZGwU&lt;/a&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="quatro" style="font-size: small;"&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;i&gt;Link to this poster in google docs: &lt;a href="http://bit.ly/nfyk3w"&gt;http://bit.ly/nfyk3w&lt;/a&gt;&lt;/i&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size: small;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="quatro" style="font-size: small;"&gt;&lt;b&gt;&amp;nbsp;Link to FESBE 2011 program: &lt;a href="http://bit.ly/ramXDw"&gt;http://bit.ly/ramXDw&lt;/a&gt;&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="quatro" style="font-size: small;"&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/span&gt;&lt;span class="quatro"&gt;&lt;span style="font-size: x-small;"&gt; &lt;/span&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1254787009603070778/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/analgesic-effect-of-venlafaxine-and.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1254787009603070778'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1254787009603070778'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/analgesic-effect-of-venlafaxine-and.html' title='Analgesic effect of venlafaxine and antiplatelet efect of pulegone - FESBE 2011 posters'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3457182050230951676</id><published>2011-10-15T11:42:00.002-03:00</published><updated>2011-10-15T11:42:38.494-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>What's new for 'childhood cancer' in PubMed</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology &lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt; &lt;br /&gt;Sent on Saturday, 2011 Oct 15&lt;br /&gt;Search &lt;b&gt;cancer&lt;/b&gt; &lt;br /&gt;&lt;div&gt;Limits:&lt;b&gt;Randomized Controlled Trial, All Child: 0-18 years&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21788220" ref="ordinalpos=1"&gt;A randomized controlled trial of propranolol for infantile hemangiomas.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Hogeling M,  Adams S,  Wargon O.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Pediatrics"&gt;Pediatrics&lt;/span&gt;. 2011 Aug;128(2):e259-66. Epub 2011 Jul 25.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21788220 [PubMed - indexed for MEDLINE]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;RCT demonstrated propranolol effect in hemangiomas of infancy. Now cleared as first choice?&lt;/b&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;2.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21681921" ref="ordinalpos=4"&gt;Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Lange BJ,  Yang RK,  Gan J,  Hank JA,  Sievers EL,  Alonzo TA,  Gerbing RB,  Sondel PM.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Pediatric blood &amp;amp;  cancer"&gt;Pediatr Blood Cancer&lt;/span&gt;. 2011 Sep;57(3):398-405. doi: 10.1002/pbc.22966. Epub 2011 Jun 16.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21681921 [PubMed - indexed for MEDLINE]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Unfortunately, this large immunotherapy trial in pediatric AML did not show effect of IL-2 in disease free survival or overall survival.&lt;/b&gt; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3457182050230951676/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-childhood-cancer-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3457182050230951676'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3457182050230951676'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-childhood-cancer-in.html' title='What&apos;s new for &apos;childhood cancer&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3820863323523266577</id><published>2011-10-15T11:32:00.000-03:00</published><updated>2011-10-15T11:32:23.730-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>What's new for 'fibromyalgia' in PubMed - valproate analgesic effect, obesity, and more!</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology &lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt;Search: fibromyalgia &lt;br /&gt;Sent on Saturday, 2011 Oct 08&lt;br /&gt;Search &lt;b&gt;fibromyalgia&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21975791" ref="ordinalpos=2"&gt;Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Gill D,  Derry S,  Wiffen PJ,  Moore RA.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Cochrane database of systematic reviews (Online)"&gt;Cochrane Database Syst Rev&lt;/span&gt;. 2011 Oct 5;10:CD009183.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21975791 [PubMed - in process]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;This large meta-analysis shows how little we know about the analgesic use of valproate, or valproic acid. &lt;/b&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;2.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21972124" ref="ordinalpos=6"&gt;The association of body mass index with symptom severity and quality of life in patients with fibromyalgia.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Kim CH,  Luedtke CA,  Vincent A,  Thompson JM,  Oh TH.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Arthritis care &amp;amp; research"&gt;Arthritis Care Res (Hoboken)&lt;/span&gt;. 2011 Oct 3. doi: 10.1002/acr.20653. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21972124 [PubMed - as supplied by publisher]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Does overweight and obesity have any relation with pain severity in fibromyalgia? Read this article and find out!&lt;/b&gt; &lt;i&gt;(tip: yes, obesity has a relation with pain in these patients)&lt;/i&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;3.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21970699" ref="ordinalpos=7"&gt;Clinical comorbidities,  treatment patterns,  and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Gore M,  Tai KS,  Chandran A,  Zlateva G,  Leslie D.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Journal of medical economics"&gt;J Med Econ&lt;/span&gt;. 2011 Oct 4. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21970699 [PubMed - as supplied by publisher]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;FDA-approved drugs for fibromyalgia did not diminish multiple drug using and high health care costs in usual care setings: are we right in indicating these drugs for fibro patients?&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3820863323523266577/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-fibromyalgia-in-pubmed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3820863323523266577'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3820863323523266577'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-fibromyalgia-in-pubmed.html' title='What&apos;s new for &apos;fibromyalgia&apos; in PubMed - valproate analgesic effect, obesity, and more!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2656953664171655646</id><published>2011-10-15T11:15:00.002-03:00</published><updated>2011-10-15T11:43:20.068-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>What's new for 'angiotensin AND cancer' in PubMed - coffee, statins, ACE inhibitors and more!</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology&lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt; &lt;br /&gt;Sent on Saturday, 2011 Oct 08&lt;br /&gt;Search &lt;b&gt;angiotensin cancer&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Items 1 - 4&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21970881" ref="ordinalpos=1"&gt;Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Tanaka N,  Miyajima A,  Kosaka T,  Miyazaki Y,  Shirotake S,  Shirakawa H,  Kikuchi E,  Oya M.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="British journal of cancer"&gt;Br J Cancer&lt;/span&gt;. 2011 Oct 4. doi: 10.1038/bjc.2011.399. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21970881 [PubMed - as supplied by publisher]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;How angiotensin II type 1 receptor blockers can overcome platinum resistance in cancer cells.&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;2.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21813413" ref="ordinalpos=2"&gt;Statin prescriptions and breast cancer recurrence risk: a danish nationwide prospective cohort study.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Ahern TP,  Pedersen L,  Tarp M,  Cronin-Fenton DP,  Garne JP,  Silliman RA,  Sørensen HT,  Lash TL.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Journal of the National Cancer Institute"&gt;J Natl Cancer Inst&lt;/span&gt;. 2011 Oct 5;103(19):1461-8. Epub 2011 Aug 2.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21813413 [PubMed - in process]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Simvastatin users had less breast cancer recurrence - a Harvard Medical School Study&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;3.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21876027" ref="ordinalpos=3"&gt;Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Yoon C,  Yang HS,  Jeon I,  Chang Y,  Park SM.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne"&gt;CMAJ&lt;/span&gt;. 2011 Oct 4;183(14):E1073-84. Epub 2011 Aug 29.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21876027 [PubMed - in process]&lt;span style="color: #985735; font-weight: bold;"&gt;   Free Article&amp;nbsp;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="color: #985735; font-weight: bold;"&gt;Last word on ACE inhibitors/AT1R blockers and cancer: they can be protective, after all! &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;4.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21961901" ref="ordinalpos=4"&gt;High Molecular Weight Coffee Melanoidins are Inhibitors for Matrix Metalloproteases.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Demarco LM,  Fischer S,  Henle T.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Journal of agricultural and food chemistry"&gt;J Agric Food Chem&lt;/span&gt;. 2011 Oct 1. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21961901 [PubMed - as supplied by publisher]&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Coffee, sir?&amp;nbsp; Melanoidins from coffee - a new group of MMP inhibitors that can play a pivotal role in cancer treatment.&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2656953664171655646/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-angiotensin-and-cancer-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2656953664171655646'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2656953664171655646'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-angiotensin-and-cancer-in.html' title='What&apos;s new for &apos;angiotensin AND cancer&apos; in PubMed - coffee, statins, ACE inhibitors and more!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7055079983824939809</id><published>2011-10-03T20:49:00.000-03:00</published><updated>2011-10-03T20:49:34.911-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Tratamento de Tumores Cerebrais no Hospital Infantil Albert Sabin</title><content type='html'>Acaba de sair o trabalho do grupo de Oncologia Pediátrica e Neuro-oncologia clínica do Hospital Infantil Albert Sabin (HIAS), publicado no Jornal de Pediatria, da Sociedade Brasileira de Pediatria. O trabalho é uma avaliação retrospectiva da sobrevida dos pacientes pediátricos portadores de tumores cerebrais diagnosticados entre janeiro de 2000 e dezembro de 2006 no HIAS. Os autores, coordenados pelo autor deste blog, coletaram dados dos prontuários dos pacientes, a partir de 2008. Em seguida, a sobrevida global foi calculada do diagnóstico até a data do óbito dos pacientes. Uma análise estatística foi realizada para identificar quais possíveis fatores afetaram a sobrevida do grupo de pacientes. Os resultados foram aceitos para publicação no Jornal de Pediatria da SBP e acabam de ser divulgados pela publicação antecipada nas página do periódico. A maioria dos pacientes tinha astrocitomas de baixo grau ou meduloblastomas. A topografia mais comum foi a fossa posterior. A sobrevida global em cinco anos dos pacientes com astrocitomas de baixo grau foi de 84%, enquanto para pacientes com meduloblastomas foi de 51%. Os fatores que mais afetaram a sobrevida foram a ressecção cirúrgica e radioterapia (ter ressecado todo o tumor e ter realizado radioterapia aumentaram a sobrevida) e o diagnóstico de astrocitoma de alto grau ou ependimoma (pacientes com estas doenças sobreviveram bem menos). Estes resultados podem ser comparados com os resultados de registros populacionais dos Estados Unidos e Europa.&lt;br /&gt;O trabalho na íntegra pode ser acessado aqui: &lt;a href="http://bit.ly/n9kZod"&gt;http://bit.ly/n9kZod&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7055079983824939809/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/tratamento-de-tumores-cerebrais-no.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7055079983824939809'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7055079983824939809'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/tratamento-de-tumores-cerebrais-no.html' title='Tratamento de Tumores Cerebrais no Hospital Infantil Albert Sabin'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4663700943506808855</id><published>2011-10-01T23:03:00.000-03:00</published><updated>2011-10-01T23:16:55.489-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Valproate for cancer: the glioblastoma connection</title><content type='html'>The treatment of brain cancer has just received a brand new hope from an old brother in arms: the anti-epileptic drug valproate, used frequently for seizures in children, and less frequently for patients with brain tumor, has shown an unexpected activity against a lethal brain cancer. The study, published in Neurology by the EORTC group in association with National Cancer Institute of Canada, reports that patients with a diagnosis of glioblastoma and treated with radiotherapy, temozolomide (oral chemotherapy) and valproate (for seizures) lived longer. The results show that valproate-treated patients had an average 3-month survival advantage compared with patients that received standard chemo and radiotherapy. Although this study is retrospective and needs confirmation, this puts valproate on the center stage of neuro-oncology, as the accompanying Neurology editorial implies: "Valproic acid as the AED of choice for patients with glioblastoma?&lt;span class="cit-sep cit-sep-after-article-title"&gt;: &lt;/span&gt;&lt;span class="cit-subtitle"&gt;The jury is out." Neuro-oncologists urge for caution, once valproate has enhanced toxicity in this study. However, if this important survival advantage is confirmed in the future, valproate (valproic acid) may become the third effective drug for glioblastoma (the others are temozolomide and bevacizumab).&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span class="cit-subtitle"&gt;Valproate, or valproic acid, is a drug used for seizure treatment since the sixties. It has been also used for pain conditions, such as migraine, because it has an analgesic effect still poorly understood. In the last 15 years, valproate has been shown to possess an unnoticed property: through inhibition of enzymes called hystone deacetylases (HDAC) it can modify the gene expression of normal and cancer cells. This effect has been explored in many experimental treatments for hematological and solid cancers. A number of clinical trials are recruiting patients to test the association of chemotherapy with valproate (link &lt;a href="http://clinicaltrials.gov/ct2/results?term=valproate+cancer+children"&gt;here&lt;/a&gt;). The EORTC study, however, was one of the first ever to report such an effect in brain tumor patients. The author of this blog has recently published a smaller retrospective study with pediatric patients with brain tumors treated with standard chemoradiotherapy associated with seizure prophylaxis with valproate. Our findings were similar to the EORTC study. Children with poor prognosis brain tumors had a much better survival when receiving concomitant valproate. Toxicity seemed not to be higher in our study. Again, this small study cannot prove that valproate had an antitumor effect, but does indicate that clinical trials must be planned and performed including this drug.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;&lt;span class="cit-subtitle"&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="cit-subtitle"&gt;Neurology publication: &lt;a href="http://bit.ly/poxeSf"&gt;http://bit.ly/poxeSf&lt;/a&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span class="cit-subtitle"&gt;Our publication:&amp;nbsp; &lt;a href="http://bit.ly/pgMe9p"&gt;http://bit.ly/pgMe9p&lt;/a&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4663700943506808855/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/valproate-for-cancer-glioblastoma.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4663700943506808855'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4663700943506808855'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/valproate-for-cancer-glioblastoma.html' title='Valproate for cancer: the glioblastoma connection'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4869209801525868756</id><published>2011-10-01T20:27:00.003-03:00</published><updated>2011-10-01T20:27:55.247-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>What's new for 'cancer' in PubMed - pediatric oncology</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology&lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt; &lt;br /&gt;Sent on Saturday, 2011 Oct 01&lt;br /&gt;Search &lt;b&gt;cancer&lt;/b&gt; &lt;br /&gt;&lt;div&gt;Limits:&lt;b&gt;Randomized Controlled Trial, All Child: 0-18 years&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21562038" ref="ordinalpos=5"&gt;Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Matloub Y,  Bostrom BC,  Hunger SP,  Stork LC,  Angiolillo A,  Sather H,  La M,  Gastier-Foster JM,  Heerema NA,  Sailer S,  Buckley PJ,  Thomson B,  Cole C,  Nachman JB,  Reaman G,  Winick N,  Carroll WL,  Devidas M,  Gaynon PS.&lt;br /&gt;Division of Hematology-Oncology, Rainbow Babies &amp;amp; Children's  Hospital, Case Western Reserve University, Cleveland, OH 44106, USA.  yousif.matloub@uhhospitals.org &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;b&gt;&lt;span class="jrnl" title="Blood"&gt;Blood&lt;/span&gt;.&lt;/b&gt; 2011 Jul 14;118(2):243-51. Epub 2011 May 11.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span style="font-size: small;"&gt;&lt;b&gt;Abstract&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;Children's Cancer Group-1991 selected 2 components from the Children's  Cancer Group studies shown to be effective in high-risk acute  lymphoblastic leukemia and examined them in children with National  Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia.  These were (1) vincristine and escalating IV methotrexate (MTX) without  leucovorin rescue during the interim maintenance (IM) phases and (2)  addition of a second delayed intensification (DI) phase. Eligible  patients (n = 2078) were randomly assigned to regimens containing either  oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV  MTX during IM phases, and regimens with either single DI or double DI.  Five-year event-free survival (EFS) and overall survival for patients on  the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2%  and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66).  Five-year EFS and overall survival for patients who received single DI  were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8%  for those who received double DI (P = .71, P = .12). No advantage was  found for a second DI; however, replacement of PO MTX, PO  mercaptopurine, vincristine, and dexamethasone during IM with  vincristine and escalating IV MTX improved EFS.&lt;br /&gt;PMID: 21562038 [PubMed - indexed for MEDLINE]&lt;br /&gt;&lt;br /&gt;Ful text: &lt;a href="http://bit.ly/qeHiwx"&gt;http://bit.ly/qeHiwx &lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4869209801525868756/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-cancer-in-pubmed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4869209801525868756'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4869209801525868756'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/whats-new-for-cancer-in-pubmed.html' title='What&apos;s new for &apos;cancer&apos; in PubMed - pediatric oncology'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3260122308280370189</id><published>2011-10-01T13:38:00.000-03:00</published><updated>2011-10-01T13:38:08.199-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>A controvérsia dos prêmios internacionais em farmacologia - o passado do Brasil e a vez da China</title><content type='html'>Há muitos exemplos de prêmios internacionais na área de medicina, em especial na área de farmacologia, que geram controvérsia pela nominação de um ou poucos cientistas de um grande grupo que contribuiu para uma descoberta. Um comentário do famoso farmacologista Ervin Erdös em um artigo seu publicado em 2006 (&lt;a href="http://www.fasebj.org/content/20/8/1034.full"&gt;recomendado&lt;/a&gt; a quem quiser saber mais sobre a descoberta da enzima conversora de angiotensinogênio - ECA - e os &lt;a href="http://en.wikipedia.org/wiki/ACE_inhibitor"&gt;inibidores da ECA&lt;/a&gt;): "uma droga que vende bilhões de dólares tem muitos pais, enquanto outra, que não consegue ser comercializada após seu desenvolvimento, é uma órfã". Isto ilustra um dos principais motivadores da discussão ao redor da autoria da descoberta de drogas - o sucesso. Torna-se natural, então, que medicamentos associados com prêmios internacionais ( Lasker, Nobel, entre outros) sejam alvo de importantes controvérsias. O Brasil tem um exemplo importante num de seus maiores cientistas: &lt;a href="http://en.wikipedia.org/wiki/S%C3%A9rgio_Henrique_Ferreira"&gt;Sérgio Henrique Ferreira&lt;/a&gt;, paulista que participou da descoberta do mecanismo de ação da aspirina via inibição de prostaglandinas (veja &lt;a href="http://www.sciencedirect.com/science/article/pii/0014299975900473"&gt;link&lt;/a&gt; para a publicação, que rendeu o Nobel de Medicina de 1982 para John R. Vane, chefe e orientador de Ferreira na época. Além desse seu mais conhecido trabalho, que representou o início da era dos antinflamatórios não esteroidais, um dos grupos de medicamentos mais vendidos da história, Sérgio Ferreira também participou de outras descobertas fundamentais da farmacologia. A revisão de Erdös e virtualmente todos os textos sobre o desenvolvimento dos inibidores de ECA relata a participação fundamental de Ferreira nas fases iniciais e durante o desenvolvimento do captopril. Ferreira demonstrou na década de 60, pela primeira vez, que um fator do veneno da jararaca (&lt;em&gt;Bothrops jararaca&lt;/em&gt;) bloqueava a inativação da bradicinina, mediada pela ECA. Trabalhando no laboratório de John R. Vane, a partir do estudo deste efeito, ele isolou do veneno da Bothrops um pentapetídeo que constituiu o primeiro inibidor da ECA. Vane, que conhecia o papel importante da ECA na fisiologia humana, enviou o peptídeo de Ferreira para os Estados Unidos da América, convencendo seu amigo e antigo mentor, A.D. Welch, da Squibb, de seu potencial. A análise da estrutura do peptídeo e da ECA por vários cientistas da Squibb (que receberam o Lasker) culminaram no desenvolvimento do &lt;a href="http://en.wikipedia.org/wiki/Captopril"&gt;captopril&lt;/a&gt;, a primeira droga comercialmente disponível para inibir a ECA e até hoje um sucesso de mercado (e, mais importante, responsável por ter salvo&amp;nbsp; milhões de vidas no tratamento da hipertensão e insuficiência cardíaca). Ferreira recebeu, em 1983, o &lt;a class="mw-redirect" href="http://en.wikipedia.org/wiki/CIBA" title="CIBA"&gt;CIBA&lt;/a&gt; Award for Hypertension Research, juntamente com E. Ondetti e D. Cushman, da Squibb. A própria ECA teve seu papel na fisiologia esclarecido também com a ajuda de outro brasileiro, mentor de Ferreira, &lt;a href="http://en.wikipedia.org/wiki/Maur%C3%ADcio_Rocha_e_Silva"&gt;Maurício Rocha e Silva&lt;/a&gt;, fundamental na &lt;a href="http://www.sciencedirect.com/science/article/pii/S0041010197000081"&gt;descoberta&lt;/a&gt; da &lt;a href="http://en.wikipedia.org/wiki/Bradykinin"&gt;bradicina&lt;/a&gt; e seu papel fisiológico. Fora dos círculos da farmacologia, Sérgio Ferreira é pouco conhecido. Isto ilustra, entre outras coisas, a polarização anglo-saxônica do mundo científico. &lt;br /&gt;&lt;br /&gt;Agora, de acordo com um artigo no blog da Science Insider, o prêmio &lt;a href="http://en.wikipedia.org/wiki/Lasker_Award"&gt;Lasker&lt;/a&gt;, considerado quase tão importante quanto o Nobel (muitos nobelistas ganharam antes o Lasker) gerou mais uma dessas controvérsias ao nominar a cientista chinesa &lt;a href="http://en.wikipedia.org/wiki/Tu_Youyou"&gt;Tu Youyou&lt;/a&gt; pela descoberta das &lt;a href="http://en.wikipedia.org/wiki/Artemisinin"&gt;artemisininas&lt;/a&gt;, drogas que tratam adequadamente casos de malária resistente a múltiplas drogas e que têm salvo&amp;nbsp; milhões de vidas em países em desenvolvimento, como o Brasil. Vários cientistas chineses proeminentes denunciaram a escolha exclusiva de Tu, indicando que outros cientistas da China também tiveram participação fundamental no desenvolvimento das artemisininas. Rao Yi, neurocientista da Universidade de Pequim, disse que, apesar de Tu não ter sido a única cientista proeminente no desenvolvimento destas drogas, ela pode ser vista como a cientista mais representativa neste desenvolvimento. Complicando a avaliação da controvérsia, vários cientistas baseiam suas alegações em documentos secretos do governo chinês, restritos ao público e à comunidade científica. &lt;br /&gt;Nos anos 60, o governo revolucionário de Mao Tse-Tung ordenou um ambicioso projeto de pesquisa para descobrir novos tratamentos para a malária que dizimava soldados dos seus aliados vietnamitas. Uma das abordagens usadas foi a avaliação farmacológica de plantas usadas na medicina popular. Uma análise estatística de remédios tradicionais chineses indicou que aquele conhecido como qinghao era o mais usado. Yu Yagang, cientista do mesmo grupo, foi designado por Tu para testar um extrato bruto desta planta para tratar animais com malária, obtendo altos índices de cura. Como o processo de extração rendeu um composto impuro e com baixa concentração de princípio ativo, Wei Zhenxing&amp;nbsp; e outros desenvolveram paralelamente métodos para extrair artemisinina da planta &lt;i&gt;Artemisia annua&lt;/i&gt;. Depois disso, pesquisadores em Xangai descobriram a estrutura e possível mecanismo de ação da artemisinina, totalmente novos, o que levou ao desenvolvimento posterior de derivados da artemisinina com melhor atividade antimalárica e utilidade clínica. São estes derivados que hoje são usados clinicamente em vários países. Apenas a partir de 1977 o governo chinês permitiu que os grupos científicos envolvidos começassem a divulgar seus trabalhos. Na cerimônia de entrega do prêmio Lasker, Tu declarou que o prêmio pertence a todos os cientistas chineses, e não somente a ela. Antecipa-se a possível indicação de Tu ao Nobel, pelo seu trabalho.&lt;br /&gt;&lt;br /&gt;Leia o artigo da Science Insider: &lt;a href="http://bit.ly/qunGXR"&gt;http://bit.ly/qunGXR&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3260122308280370189/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/10/controversia-dos-premios-internacionais.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3260122308280370189'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3260122308280370189'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/10/controversia-dos-premios-internacionais.html' title='A controvérsia dos prêmios internacionais em farmacologia - o passado do Brasil e a vez da China'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6838113509197352391</id><published>2011-09-26T18:32:00.001-03:00</published><updated>2011-09-26T18:32:51.824-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Família que janta unida... - Novidades de nutrição infantil da Pediatrics</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Novidades sobre nutrição infantil este mês na revista Pediatrics:&lt;br/&gt;&lt;br/&gt;Uma meta-análise incluindo mais de 180 mil crianças e adolescentes entre 3 e 17 anos mostrou que, se a família compartilha a mesa às refeições pelo menos três vezes por semana, o risco de erros alimentares e doenças endócrinas cai sensivelmente. O grupo de medicina da comunidade de Urbana, Illinois, concluiu em seu estudo que a refeição em família reduz em 12% o risco de sobrepeso e obesidade, em 20% o risco de erros alimentares e aumenta em 24% a adesão a uma dieta saudável. Quanto mais interação familiar, melhor! E você, quantas vezes come com sua família?&lt;br/&gt;Artigo: &lt;a href='http://bit.ly/pKG7NK' target='_blank'&gt;http://bit.ly/pKG7NK&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;Já um grupo da Universidade da Virgínia conseguiu evidências em outra meta-análise comprovando que a amamentação reduz a incidência de Síndrome de Morte Súbita Infantil, uma moléstia misteriosa contra a qual não existe proteção. Não existia. Mães de primeira viagem que estão em dúvida: que tal uma visita ao berçário, banco de leite ou àquela mulher da família notória por ter amamentado todos os filhos? A saúde (e a vida) de seus filhos pode depender disso!&lt;br/&gt;Artigo: &lt;a href='http://bit.ly/o5xIIv' target='_blank'&gt;http://bit.ly/o5xIIv&lt;/a&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6838113509197352391/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/familia-que-janta-unida-novidades-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6838113509197352391'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6838113509197352391'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/familia-que-janta-unida-novidades-de.html' title='Família que janta unida... - Novidades de nutrição infantil da Pediatrics'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3323680228101166609</id><published>2011-09-25T22:37:00.001-03:00</published><updated>2011-10-01T15:06:16.452-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Breast-Cancer Adjuvant Therapy with Zoledronic Acid - Online first in NEJM</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;&lt;div class="section"&gt;&lt;h1&gt;&lt;small&gt;Breast-Cancer Adjuvant Therapy with Zoledronic Acid&lt;/small&gt;&lt;/h1&gt;&lt;div class="authors"&gt;Robert&amp;nbsp; E. Coleman, M.B., B.S., M.D., Helen Marshall, M.Sc., David Cameron, &lt;br /&gt;M.B., B.S., M.D., David Dodwell, M.B., Ch.B., M.D., Roger Burkinshaw, &lt;br /&gt;B.Sc., Maccon Keane, M.D., Miguel Gil, M.D., Stephen J. Houston, M.B., &lt;br /&gt;B.S., M.D., Robert J. Grieve, M.B., Ch.B., Peter J. Barrett-Lee, M.B., &lt;br /&gt;B.S., M.D., Diana Ritchie, M.B., Ch.B., M.D., Julia Pugh, C.I.M.Dip., &lt;br /&gt;Claire Gaunt, B.Sc., Una Rea, B.Sc., Jennifer Peterson, B.App.Sc., &lt;br /&gt;Claire Davies, B.Sc., Victoria Hiley, B.Sc., Walter Gregory, Ph.D., and &lt;br /&gt;Richard Bell, M.B., B.S. for &lt;span class="NLM_on-behalf-of"&gt;the AZURE Investigators&lt;/span&gt;&lt;/div&gt;&lt;div class="citationLine"&gt;September 25, 2011&lt;br /&gt;                    (10.1056/NEJMoa1105195)&lt;br /&gt;                &lt;/div&gt;&lt;h3 id="abstractBackground"&gt;Abstract&lt;/h3&gt;&lt;h3 id="abstractBackground"&gt;Background&lt;/h3&gt;Data suggest that the adjuvant use of bisphosphonates reduces rates of &lt;br /&gt;recurrence and death in patients with early-stage breast cancer. We &lt;br /&gt;conducted a study to determine whether treatment with zoledronic acid, &lt;br /&gt;in addition to standard adjuvant therapy, would improve disease outcomes&lt;br /&gt; in such patients.&lt;/div&gt;&lt;div class="section"&gt;&lt;/div&gt;&lt;div class="section"&gt;&lt;h3 id="abstractMethods"&gt;Methods&lt;/h3&gt;In this open-label phase 3 study, we randomly assigned 3360 patients to &lt;br /&gt;receive standard adjuvant systemic therapy either with or without &lt;br /&gt;zoledronic acid. The zoledronic acid was administered every 3 to 4 weeks&lt;br /&gt; for 6 doses and then every 3 to 6 months to complete 5 years of &lt;br /&gt;treatment. The primary end point of the study was disease-free survival.&lt;br /&gt; A second interim analysis revealed that a prespecified boundary for &lt;br /&gt;lack of benefit had been crossed.&lt;/div&gt;&lt;div class="section"&gt;&lt;/div&gt;&lt;div class="section"&gt;&lt;h3 id="abstractResults"&gt;Results&lt;/h3&gt;At a median follow-up of 59 months, there was no significant between-group&lt;br /&gt; difference in the primary end point, with a rate of disease-free &lt;br /&gt;survival of 77% in each group (adjusted hazard ratio in the zoledronic &lt;br /&gt;acid group, 0.98; 95% confidence interval [CI], 0.85 to 1.13; P=0.79). &lt;br /&gt;Disease recurrence or death occurred in 377 patients in the zoledronic &lt;br /&gt;acid group and 375 of those in the control group. The numbers of deaths —&lt;br /&gt; 243 in the zoledronic acid group and 276 in the control group — were &lt;br /&gt;also similar, resulting in rates of overall survival of 85.4% in the &lt;br /&gt;zoledronic acid group and 83.1% in the control group (adjusted hazard &lt;br /&gt;ratio, 0.85; 95% CI, 0.72 to 1.01; P=0.07). In the zoledronic acid &lt;br /&gt;group, there were 17 confirmed cases of osteonecrosis of the jaw &lt;br /&gt;(cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P&amp;lt;0.001) and 9 &lt;br /&gt;suspected cases; there were no cases in the control group. Rates of &lt;br /&gt;other adverse effects were similar in the two study groups.&lt;/div&gt;&lt;div class="section"&gt;&lt;/div&gt;&lt;h3 id="abstractConclusions"&gt;Conclusions&lt;/h3&gt;These findings do not support the routine use of zoledronic acid in the &lt;br /&gt;adjuvant management of breast cancer. (Funded by Novartis &lt;br /&gt;Pharmaceuticals and the National Cancer Research Network; AZURE Current &lt;br /&gt;Controlled Trials number, &lt;a class="ref" href="http://www.controlled-trials.com/ISRCTN79831382" target="url"&gt;ISRCTN79831382&lt;/a&gt;.)&lt;br /&gt;Read the article: &lt;a href="http://bit.ly/oDOscH" target="_blank"&gt;http://bit.ly/oDOscH&lt;/a&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3323680228101166609/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/breast-cancer-adjuvant-therapy-with.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3323680228101166609'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3323680228101166609'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/breast-cancer-adjuvant-therapy-with.html' title='Breast-Cancer Adjuvant Therapy with Zoledronic Acid - Online first in NEJM'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2252225121396035809</id><published>2011-09-24T09:04:00.001-03:00</published><updated>2011-09-24T09:04:26.410-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>What's new for 'ACE inhibitors and cancer' in PubMed</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology&lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt; &lt;br /&gt;Sent on Saturday, 2011 Sep 24&lt;br /&gt;Search &lt;b&gt;angiotensin cancer&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21936625" ref="ordinalpos=1"&gt;Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors,  ARBs,  and/or Statins.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Cancer investigation"&gt;Cancer Invest&lt;/span&gt;. 2011 Sep 21. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21936625 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;div&gt;&lt;div&gt;&lt;div class="artAuthors"&gt;&lt;a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;amp;type=advanced&amp;amp;result=true&amp;amp;prevSearch=%2Bauthorsfield%3A%28Chae%2C+Young+Kwang%29"&gt;Young Kwang Chae,&lt;span class="NLM_xref-aff"&gt;&lt;sup&gt;1,2,&lt;/sup&gt;&lt;/span&gt;&lt;/a&gt;&lt;a class="ref" href="http://informahealthcare.com/action/showPopup?citid=citart1&amp;amp;id=FN0001&amp;amp;doi=10.3109/07357907.2011.616252"&gt;§&lt;/a&gt; &lt;a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;amp;type=advanced&amp;amp;result=true&amp;amp;prevSearch=%2Bauthorsfield%3A%28Valsecchi%2C+Matias+E.%29"&gt;Matias E. Valsecchi,&lt;span class="NLM_xref-aff"&gt;&lt;sup&gt;2,3,&lt;/sup&gt;&lt;/span&gt;&lt;/a&gt;&lt;a class="ref" href="http://informahealthcare.com/action/showPopup?citid=citart1&amp;amp;id=FN0001&amp;amp;doi=10.3109/07357907.2011.616252"&gt;§&lt;/a&gt; &lt;a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;amp;type=advanced&amp;amp;result=true&amp;amp;prevSearch=%2Bauthorsfield%3A%28Kim%2C+Jongoh%29"&gt;Jongoh Kim,&lt;span class="NLM_xref-aff"&gt;&lt;sup&gt;2,4&lt;/sup&gt;&lt;/span&gt; &lt;/a&gt;&lt;a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;amp;type=advanced&amp;amp;result=true&amp;amp;prevSearch=%2Bauthorsfield%3A%28Bianchi%2C+Anabella+Lucca%29"&gt;Anabella Lucca Bianchi,&lt;span class="NLM_xref-aff"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; &lt;/a&gt;&lt;a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;amp;type=advanced&amp;amp;result=true&amp;amp;prevSearch=%2Bauthorsfield%3A%28Khemasuwan%2C+Danai%29"&gt;Danai Khemasuwan,&lt;span class="NLM_xref-aff"&gt;&lt;sup&gt;2,5&lt;/sup&gt;&lt;/span&gt; &lt;/a&gt;&lt;a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;amp;type=advanced&amp;amp;result=true&amp;amp;prevSearch=%2Bauthorsfield%3A%28Desai%2C+Ajit%29"&gt;Ajit Desai,&lt;span class="NLM_xref-aff"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and &lt;/a&gt;&lt;a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;amp;type=advanced&amp;amp;result=true&amp;amp;prevSearch=%2Bauthorsfield%3A%28Tester%2C+William%29"&gt;William Tester,&lt;span class="NLM_xref-aff"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;div class="fulltext"&gt;&lt;span class="institution"&gt;&lt;i&gt;Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,&lt;/i&gt;&lt;/span&gt;&lt;i&gt; Houston, TX,&lt;/i&gt;&lt;span class="country"&gt;&lt;i&gt; USA,&lt;sup&gt;1&lt;/sup&gt;&lt;/i&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="fulltext"&gt;&lt;span class="institution"&gt;&lt;i&gt;Department of Medicine, Albert Einstein Medical Center,&lt;/i&gt;&lt;/span&gt;&lt;i&gt; Philadelphia, PA,&lt;/i&gt; &lt;span class="country"&gt;&lt;i&gt;USA,&lt;sup&gt;2&lt;/sup&gt;&lt;/i&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="fulltext"&gt;&lt;span class="institution"&gt;&lt;i&gt;Department of Medical Oncology, Thomas Jefferson University Hospital,&lt;/i&gt;&lt;/span&gt;&lt;i&gt; Philadelphia, PA, &lt;/i&gt;&lt;span class="country"&gt;&lt;i&gt;USA,&lt;sup&gt;3&lt;/sup&gt;&lt;/i&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="fulltext"&gt;&lt;span class="institution"&gt;&lt;i&gt;Department of Medicine, Balyor College of Medicine, Houston,&lt;/i&gt;&lt;/span&gt;&lt;i&gt; TX,&lt;/i&gt; &lt;span class="country"&gt;&lt;i&gt;USA,&lt;sup&gt;4&lt;/sup&gt;&lt;/i&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="fulltext"&gt;&lt;span class="institution"&gt;&lt;i&gt;Department of Medicine, Cleveland Clinic, Cleveland,&lt;/i&gt;&lt;/span&gt;&lt;i&gt; OH,&lt;/i&gt; &lt;span class="country"&gt;&lt;i&gt;USA&lt;sup&gt;5&lt;/sup&gt;&lt;/i&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="NLM_author-notes"&gt;&lt;div class="first last"&gt;&lt;sup&gt;§&lt;/sup&gt;Both the authors contributed equally to this study.&lt;/div&gt;&lt;div class="NLM_corresp"&gt;Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, &lt;span class="country"&gt;USA&lt;/span&gt;. email: &lt;a class="email" href="mailto:ykchae@mdanderson.org"&gt;ykchae@mdanderson.org&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;div class="abstractSection"&gt;&lt;div class="first last"&gt;&lt;b&gt;&lt;i&gt;Background&lt;/i&gt;:  Epidemiologic and biochemical evidence suggest a role of statins and  angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor  blockers (ARBs) as anti-neoplastic agents. This study was designed to  evaluate the association between the use of these agents and the risk of  breast cancer recurrence. &lt;i&gt;Methods&lt;/i&gt;: We reviewed the medical  records of patients treated for stage II/III breast cancer between 1999  and 2005. Statin and ACE-inhibitors/ARB users were defined as patients  who took these medications for at least 6 months in no evidence of  disease (NED) stage after the initial diagnosis. The primary outcome was  disease-free survival and the secondary was overall survival. The  Kaplan–Meier and Cox proportional hazard models were used. &lt;i&gt;Results&lt;/i&gt;:  A total of 703 patients were included. The median and maximal of follow  up was 55 and 118 months, respectively. A total of 168 patients used  ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both.  Univariate analysis showed significant reduction in breast cancer  recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio  (HR) = 0.57; 95% CI: 0.37–0.89; &lt;i&gt;p&lt;/i&gt; = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; &lt;i&gt;p&lt;/i&gt; &amp;lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; &lt;i&gt;p&lt;/i&gt; = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; &lt;i&gt;p&lt;/i&gt; &amp;lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; &lt;i&gt;p&lt;/i&gt; = .001). No association was found regarding overall survival. &lt;i&gt;Conclusions&lt;/i&gt;:  The use of ACE-inhibitors/ARBs, statins, and the combination of both  were all associated with a reduced risk of breast cancer recurrence.  This observation should prompt further exploration.&lt;/b&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;Read More: &lt;a href="http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252"&gt;http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2252225121396035809/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-ace-inhibitors-and-cancer_24.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2252225121396035809'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2252225121396035809'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-ace-inhibitors-and-cancer_24.html' title='What&apos;s new for &apos;ACE inhibitors and cancer&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7385596148560381398</id><published>2011-09-21T17:36:00.001-03:00</published><updated>2011-09-21T17:36:12.159-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Aceita um pouco de peixe?</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;A carne de peixe é muito apreciada como uma alternativa de elevado teor nutricional, saborosa e, ao mesmo tempo, saudável. O consumo da carne de peixes ricos em óleos ômega-3 pode proteger de doenças cardiovasculares. No entanto, não existem avaliações sobre a influência do modo de preparo do peixe na saúde dos consumidores. Um estudo publicado em maio deste ano no periódico Circulation (American Heart Association) indica que o modo como o peixe é preparado pode influenciar, e muito, seu impacto na saúde. O estudo foi realizado no banco de dados do Women's Health Initiative Observational Study, uma amostragem de mulheres pós-menopausadas americanas inscritas no &lt;a href='http://www.nhlbi.nih.gov/whi/background.htm' target='_blank'&gt;WHI&lt;/a&gt;, um grande estudo coorte de problemas de saúde em mulheres após a menopausa. Mais de 93 mil mulheres entraram no estudo, que avaliou o risco do desenvolvimento de insuficiência cardíaca. De acordo com as conclusões dessa avaliação, mulheres que consumiram principalmente peixe cozido ou grelhado com frequência (5 vezes ou mais por semana) tiveram um risco cerca de 30% menor de desenvolver insuficiência cardíaca. Já o grupo de mulheres que consumiu principalmente peixe frito (1 vez ou mais por semana) apresentou um risco 48% maior de desenvolver a doença. &lt;br/&gt;Leia o artigo completo: &lt;a href='http://bit.ly/rl11jO' target='_blank'&gt;http://bit.ly/rl11jO&lt;/a&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7385596148560381398/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/aceita-um-pouco-de-peixe.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7385596148560381398'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7385596148560381398'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/aceita-um-pouco-de-peixe.html' title='Aceita um pouco de peixe?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8901587449438132378</id><published>2011-09-21T16:15:00.001-03:00</published><updated>2011-09-21T16:15:28.680-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Omega 3 melhora Hiperatividade - via Revista de Neurologia</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt;Suplementos&lt;/span&gt; &lt;span class='hps atn'&gt;de ácidos graxos ômega-&lt;/span&gt;&lt;span&gt;3 &lt;/span&gt;&lt;span class='hps'&gt;podem reduzir os sintomas&lt;/span&gt; &lt;span class='hps'&gt;do transtorno de&lt;/span&gt; &lt;span class='hps'&gt;déficit de atenção&lt;/span&gt; &lt;span class='hps'&gt;e hiperatividade&lt;/span&gt; &lt;span class='hps'&gt;(TDAH)&lt;/span&gt; &lt;span class='hps'&gt;em crianças&lt;/span&gt;&lt;span class=''&gt;, conforme publicado&lt;/span&gt; &lt;span class='hps'&gt;no Journal of Child Psychology and Psychiatry&lt;/span&gt;&lt;span class='hps'/&gt;&lt;span&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Em uma avaliação&lt;/span&gt; &lt;span class='hps'&gt;de 10&lt;/span&gt; &lt;span class='hps'&gt;estudos com um total&lt;/span&gt; &lt;span class='hps'&gt;de 699&lt;/span&gt; &lt;span class='hps'&gt;crianças com TDAH,&lt;/span&gt; &lt;span class='hps'&gt;os pesquisadores descobriram que&lt;/span&gt; &lt;span class='hps'&gt;aquelas que receberam &lt;/span&gt;&lt;span class='hps'&gt;suplementos omega-3&lt;/span&gt; &lt;span class='hps'&gt;mostraram uma melhora&lt;/span&gt; &lt;span class='hps'&gt;pequena, mas significativa&lt;/span&gt; &lt;span class='hps'&gt;na severidade dos sintomas&lt;/span&gt; &lt;span class='hps'&gt;em comparação com&lt;/span&gt; &lt;span class='hps'&gt;aqueles que receberam placebo&lt;/span&gt;&lt;span&gt;.&lt;/span&gt; &lt;span class='hps'&gt;Esse efeito foi significativo&lt;/span&gt; &lt;span class='hps'&gt;em crianças recebendo&lt;/span&gt; &lt;span class='hps'&gt;altas doses de&lt;/span&gt; &lt;span class='hps'&gt;suplementação com&lt;/span&gt; &lt;span class='hps'&gt;ácido eicosapentaenóico&lt;/span&gt;&lt;span&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Os autores observam que&lt;/span&gt; &lt;span class='hps'&gt;a eficácia relativa&lt;/span&gt; &lt;span class='hps'&gt;deste tratamento&lt;/span&gt; &lt;span class='hps'&gt;é modesta comparado&lt;/span&gt; &lt;span class='hps'&gt;com os tratamentos&lt;/span&gt; &lt;span class='hps'&gt;com drogas&lt;/span&gt; &lt;span class='hps'&gt;atualmente disponíveis&lt;/span&gt; &lt;span class='hps'&gt;para o tratamento de&lt;/span&gt; &lt;span class='hps'&gt;TDAH&lt;/span&gt;&lt;span&gt;, tais&lt;/span&gt; &lt;span class='hps'&gt;como os agonistas&lt;/span&gt; &lt;span class='hps'&gt;psicoestimulantes, a&lt;/span&gt; &lt;span class='hps'&gt;atomoxetina&lt;/span&gt;&lt;span&gt;, ou&lt;/span&gt; agonistas &lt;span class='hps'&gt;a2&lt;/span&gt;&lt;span&gt;.&lt;/span&gt; &lt;span class='hps'&gt;No entanto,&lt;/span&gt; &lt;span class='hps'&gt;devido ao seu&lt;/span&gt; &lt;span class='hps'&gt;baixo nível&lt;/span&gt; &lt;span class='hps'&gt;de efeitos colaterais,&lt;/span&gt; &lt;span class='hps'&gt;suplementos omega-3&lt;/span&gt; &lt;span class='hps'&gt;poderiam ser&lt;/span&gt; &lt;span class='hps'&gt;usado como um complemento&lt;/span&gt; &lt;span class='hps'&gt;às intervenções&lt;/span&gt; &lt;span class='hps'&gt;tradicionais.&lt;/span&gt;&lt;br/&gt; &lt;span class='hps atn'/&gt;&lt;span class='hps'&gt;&lt;br/&gt;Leia o artigo: &lt;a href='http://bit.ly/nJiw3A' target='_blank'&gt;http://bit.ly/nJiw3A&lt;/a&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8901587449438132378/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/omega-3-melhora-hiperatividade-via.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8901587449438132378'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8901587449438132378'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/omega-3-melhora-hiperatividade-via.html' title='Omega 3 melhora Hiperatividade - via Revista de Neurologia'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8176749146337187314</id><published>2011-09-20T22:19:00.000-03:00</published><updated>2011-09-20T22:21:24.923-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='mal-formações'/><category scheme='http://www.blogger.com/atom/ns#' term='antiangiogênico'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='propranolol'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='publicações'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='hemangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Tratamento de hemangiomas no Hospital Infantil Albert Sabin</title><content type='html'>A Revista de Saúde da Criança e do Adolescente deste mês traz um artigo de minha autoria descrevendo as opções no tratamento de crianças com hemangioma. Este artigo é baseado em&amp;nbsp; minha experiência pessoal, de ter tratado no Serviço de Onco-hematologia Pediátrica do Hospital Infantil Albert Sabin (agora Centro Pediátrico do Câncer) mais de 200 crianças com hemangiomas nos últimos 5 anos. O tratamento de crianças com hemangioma em nossa unidade iniciou-se com o encaminhamento de pacientes com lesões complicadas para tratamento com interferon alfa 2a (hoje em desuso) e, mais tarde, com vincristina (um quimioterápico). Em fins de 2008, por intermédio do grupo da Dra. Heloísa Galvão do Amaral Campos (link para seu site: &lt;a href="http://bit.ly/noykB9"&gt;http://bit.ly/noykB9&lt;/a&gt;), através do colega Dr. Antonio Aldo Melo Filho, soubemos do advento do propranolol para seu tratamento. Como anteriormente expusemos em &lt;a href="http://www.blogger.com/goog_15425825"&gt;post&lt;/a&gt;&lt;a href="http://www.blogger.com/blogger.g?blogID=2993346515708552092#editor/target=post;postID=872567013934911749"&gt;s&lt;/a&gt; anteriores, naquele ano o grupo da Dra. Léauté-Labrèze havia publicado um trabalho seminal que se tornaria famoso, no prestigiado New England Journal of Medicine. Desde esta primeira descrição observacional do achado casual do efeito do propranolol em hemangiomas infantis, centenas de trabalhos científicos seguiram-se. Recentemente, um ensaio clínico duplo-cego e randomizado validou este tratamento para crianças com hemangioma. No meu trabalho, descrevo resultados preliminares de nossa própria experiência com o tratamento de hemangiomas com propranolol, que iniciamos em 2009. Estamos realizando uma avaliação retrospectiva, observacional, de nossa casuística, aprovada pela Comisão de Ética em Pesquisa do HIAS. Para levar a cabo este trabalho, criamos em 2010, juntamente com professores da Universidade Federal do Ceará, o Grupo de Pesquisa em Farmacologia Vascular e Endotelial (&lt;a href="http://bit.ly/ozpgQM"&gt;http://bit.ly/ozpgQM&lt;/a&gt;), denominando a linha de pesquisa de "&lt;span style="font-family: Arial; font-size: small;"&gt;Atividade Antiangiogênica de Drogas no Tratamento de Doenças Neoplásicas&lt;/span&gt;". Em outubro deste ano, devemos apresentar nossos primeiros resultados preliminares. De uma forma geral, temos obtido bons resultados com a utilização de propranolol para o tratamento de hemangiomas infantis, assim como vários outros grupos ao redor do mundo.&lt;br /&gt;Leia o trabalho da RSCA: &lt;a href="http://bit.ly/pY1a9u"&gt;http://bit.ly/pY1a9u&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8176749146337187314/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/tratamento-de-hemangiomas-no-hospital.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8176749146337187314'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8176749146337187314'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/tratamento-de-hemangiomas-no-hospital.html' title='Tratamento de hemangiomas no Hospital Infantil Albert Sabin'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3043535654020617500</id><published>2011-09-18T22:51:00.000-03:00</published><updated>2011-09-18T22:52:27.565-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='prevenção'/><category scheme='http://www.blogger.com/atom/ns#' term='publicações'/><category scheme='http://www.blogger.com/atom/ns#' term='pressão arterial'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><category scheme='http://www.blogger.com/atom/ns#' term='dor'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><title type='text'>A Música e a Fera - Musicoterapia diminui ansiedade e dor em portadores de câncer</title><content type='html'>Uma nova meta-análise da Cochrane Library avaliou o impacto da musicoterapia nos sintomas e qualidade de vida de pacientes portadores de câncer. A terapeuta Joke Brandt, da Drexel University, Philadelphia, e sua equipe avaliaram 30 estudos publicados sobre musicoterapia em pacientes com câncer. Os resultados da análise mostraram que a musicoterapia teve um efeito benéfico em escores padronizados de ansiedade e humor, mas não afetou a depressão nos pacientes. A terapia mostrou um efeito moderado em reduzir a dor crônica, além de reduzir sinais autonômicos de ansiedade e dor, como frequência cardíaca e respiratória e pressão arterial. Um importante efeito foi registrado na qualidade de vida pelos pacientes, mas alguns outros escores avaliados não se modificaram. De uma forma geral, esta análise mostra um efeito benéfico multidimensional na qualidade de vida de pacientes com câncer e indica que novos estudos devem ser feitos explorando a musicoterapia em pacientes com câncer.&lt;br /&gt;Leia o estudo: &lt;a href="http://bit.ly/qJcXAL"&gt;http://bit.ly/qJcXAL&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3043535654020617500/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/musica-e-fera-musicoterapia-diminui.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3043535654020617500'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3043535654020617500'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/musica-e-fera-musicoterapia-diminui.html' title='A Música e a Fera - Musicoterapia diminui ansiedade e dor em portadores de câncer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4983127546715238357</id><published>2011-09-17T20:38:00.001-03:00</published><updated>2011-09-18T12:22:44.844-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><title type='text'>Aula de Oncologia</title><content type='html'>No dia 15 de setembro, quinta-feira última, ministrei a aula &lt;b&gt;"Avanços no tratamento de tumores neurológicos em crianças"&lt;/b&gt;, como parte do&lt;i&gt; IV Curso de Abordagem Clínica em Oncologia - Atualizações sobre o Estudo do Câncer&lt;/i&gt;, a convite da Liga do Câncer - UFC. A aula ocorreu no auditório da Oncoclinic, no Harmony Center, em Fortaleza - CE. Agradeço o convite à comissão organizadora do evento e ao orientador da Liga, Dr. Victor Hugo Medeiros Alencar. No link abaixo, os slides podem ser acessados. Inicialmente, a aula será disponibilizada sem comentários, mas em alguns dias, deixarei comentários explicativos dos slides disponíveis igualmente. Convido os interessados na aula a fazerem parte também, do Grupo de Discussão e Estudos em Oncologia, por e-mail (cadastre-se neste blog ou mande e-mail para este autor no link disponível neste blog) ou via Facebook (&lt;a href="http://www.facebook.com/heldercfelix"&gt;/heldercfelix&lt;/a&gt;).&lt;br /&gt;Veja os slides: &lt;a href="http://bit.ly/nVPOsn"&gt;http://bit.ly/nVPOsn&lt;/a&gt; </content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4983127546715238357/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/aula-de-oncologia.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4983127546715238357'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4983127546715238357'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/aula-de-oncologia.html' title='Aula de Oncologia'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7132055729253211003</id><published>2011-09-17T12:54:00.000-03:00</published><updated>2011-09-18T12:24:40.374-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pubmed'/><title type='text'>What's new for 'ACE inhibitors and cancer' in PubMed</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology&lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt; &lt;br /&gt;Sent on Saturday, 2011 Sep 17&lt;br /&gt;Search &lt;b&gt;angiotensin cancer&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Item 1 of 1&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21909951" ref="ordinalpos=1"&gt;Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;b&gt;Walker AJ,  West J,  Grainge MJ,  Card TR.&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Cancer causes &amp;amp; control : CCC"&gt;Cancer Causes Control&lt;/span&gt;. 2011 Sep 11. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;div class="abstr"&gt;&lt;h3&gt; Abstract&lt;/h3&gt;&lt;h4&gt; OBJECTIVE: &lt;/h4&gt;Laboratory  findings demonstrate anticancer effects of angiotensin converting enzyme  (ACE) inhibitors, including anti-angiogenic activity and inhibition of  liver cancer growth in rodent models. Small studies in humans indicate  potential for therapeutic anticancer effects and warrant further larger  studies.&lt;br /&gt;&lt;h4&gt; METHODS: &lt;/h4&gt;A case-control study using the General  Practice Research Database examined whether prior ACE inhibitor usage  was associated with a reduction in incidence of hepatocellular carcinoma  (HCC).&lt;br /&gt;&lt;h4&gt; RESULTS: &lt;/h4&gt;Two hundred twenty-four HCC cases were  identified, each matched to up to 10 controls by age, sex, and general  practice. The data show that HCC is associated with a small,  nonsignificant increase in prior use of ACE inhibitors (OR&amp;nbsp;=&amp;nbsp;1.16,  CI&amp;nbsp;=&amp;nbsp;0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9%  (of 2,313) in controls. No significant effects were found when  investigating the effect of dose and exposure duration.&lt;br /&gt;&lt;h4&gt; CONCLUSIONS: &lt;/h4&gt;We  found no clear protective effect of ever or long term use of ACE  inhibitors against the development of HCC. Our study suggests that it is  unlikely that this class of drugs will be a clinically useful cancer  chemoprevention therapy.&lt;/div&gt;&lt;br /&gt;PMID: 21909951 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7132055729253211003/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-ace-inhibitors-and-cancer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7132055729253211003'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7132055729253211003'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-ace-inhibitors-and-cancer.html' title='What&apos;s new for &apos;ACE inhibitors and cancer&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7610246283074909252</id><published>2011-09-16T23:08:00.000-03:00</published><updated>2011-09-18T12:58:11.723-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='immunology'/><category scheme='http://www.blogger.com/atom/ns#' term='science'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='flu'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>The Enemy Within - Unexpected Cell Type Orchestrate Immune Turmoil in Flu - via ScienceNow</title><content type='html'>When a patient gets killed by a specially lethal kind of flu, as in the recent outbreaks of H1N1 or H5N1 (swine and avian) strains of flu virus, it might be the body's own defenses that make the final move. The flu and other infections can provoke so-called  cytokine storms or immunological storms. One hallmark of these events is  a surge of chemical messengers called cytokines and chemokines into  tissues and the blood, promoting inflammation. Immune cells, including  macrophages and natural killer cells, also flood the lungs. The  combination can cause fatal disease with lung and other organs damage. Some flu strains might initiate more often these immune waves. For example, animal studies suggest that the Spanish flu virus (the one that killed millions in the 1918 epidemia) makes the immune system overaggressive.  Cells that line the lungs and airways and the immune cells that move in  after infection are responsible for cytokine storms—or at least that's  what researchers thought.&lt;br /&gt;&lt;br /&gt;A team led by chemical biologist Hugh Rosen and virologist Michael Oldstone of the Scripps Research Institute in San Diego, California, investigated the S1P pathway, a molecular control circuit that fine-tunes immune responses. The scientists gave influenza-infected rodents a compound that stimulates the S1P1 receptor. The treatment prevented a cytokine outburst and reduced movement of immune cells into the lungs. When the researchers looked after the cells in the lungs that carry the S1P1 receptor, they found that it occurs on endothelial cells, which line lymphatic and blood vessels, and on the white blood cells known as lymphocytes. To determine which of these two cell types controls the cytokine surge, the researchers tested the S1P1 receptor activator in genetic modified mice that lack lymphocytes. The compound also prevented the storms in these animals, suggesting that endothelial cells, not lymphocytes, orchestrate cytokine release. This fascinating finding opens a whole new avenue of research into flu and potentially many other infectious and inflammatory diseases, where endothelial cells may have a previously unknown important role. &lt;br /&gt;&lt;br /&gt;Read the post on ScienceNow:&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/09/surprising-cells-rein-in-killer-.html?ref=em&amp;amp;elq=0dec6a42e0234ec68c056940969bc06d#.TnP8Lpot1pU.blogger"&gt;Surprising Cells Rein In Killer Flu - ScienceNOW&lt;/a&gt; -  &lt;a href="http://news.sciencemag.org/sciencenow/2011/09/surprising-cells-rein-in-killer-.html?ref=em&amp;amp;elq=0dec6a42e0234ec68c056940969bc06d#.TnP8Lpot1pU.blogger"&gt;&lt;/a&gt;&lt;a href="http://bit.ly/pe8PUo"&gt;http://bit.ly/pe8PUo&lt;/a&gt;</content><link rel='related' href='http://news.sciencemag.org/sciencenow/2011/09/surprising-cells-rein-in-killer-.html?ref=em&amp;elq=0dec6a42e0234ec68c056940969bc06d#.TnP8Lpot1pU.blogger' title='The Enemy Within - Unexpected Cell Type Orchestrate Immune Turmoil in Flu - via ScienceNow'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7610246283074909252/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/enemy-within-unexpected-cell-type.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7610246283074909252'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7610246283074909252'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/enemy-within-unexpected-cell-type.html' title='The Enemy Within - Unexpected Cell Type Orchestrate Immune Turmoil in Flu - via ScienceNow'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2643770879595960080</id><published>2011-09-13T00:16:00.000-03:00</published><updated>2011-09-18T12:59:07.043-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>TV Burrinho? Relação entre o formato dos cartoons e cognição infantil</title><content type='html'>A geração das pessoas que têm entre 30-40 anos tem sido chamada de "imigrantes digitais", em contraposição a seus filhos, os "nativos digitais", denotando que as crianças tipicamente começam a ser expostas à TV com menos de 1 ano hoje, assistindo uma média de 6-8 horas de TV ao dia (dados dos EUA). Seus pais, ao contrário, tiveram contato com a TV bem mais velhos e foram expostos a uma quantidade bem menor de horas-dia de programação na infância. Os chamados "nativos digitais" praticamente já nascem vendo TV. Há muito tempo questiona-se o possível impacto desta exposição no desenvolvimento cognitivo infantil. Vários mitos se formaram nos últimos anos, um dos mais comuns sendo o de que "a TV vai te deixar burro, menino", que virou letra de um hit dos Titãs nos anos 80 (Televisão - album homônimo). Apesar de que alguns estudos tentaram explorar esta questão, nenhuma evidência científica concreta existe. Digo, existia. Um trabalho publicado este mês no jornal científico &lt;i&gt;Pediatrics&lt;/i&gt; traz os resultados de um experimento que testou a influência do formato de mídia de cartoons num teste cognitivo em crianças. Crianças em idade escolar foram expostas à sequências breves (9 min) de cartoons de ritmo rápido (frenéticos e com mudança rápida de cenas, comuns em canais especializados em desenhos animados, como o &lt;i&gt;Cartoon Network&lt;/i&gt;). Os grupos controles foram expostos a sequências igualmente breves de programas infantis educativos (como Vila Sésamo) ou a uma tarefa de desenho à mão. Logo em seguida, as crianças realizaram um teste de habilidade executiva, que avalia a capacidade de atenção. Resultado: ocorreu um importante prejuízo da habilidade executiva em crianças que haviam acabado de assistir aos desenhos de ritmo rápido, o que não aconteceu quando o estímulo foi programa educativo ou tarefa de desenho à mão. Em outras palavras, as crianças ficaram mais dispersas, desatentas. As implicações deste estudo ainda não são claras, pois ele não avaliou o efeito a longo prazo do estímulo repetido, nem se ocorreram alterações em outras funções cognitivas. Ainda é cedo para afirmar se a música dos Titãs estava certa, mas os pais devem ficar atentos para a qualidade e quantidade dos estímulos que seus filhos estão recebendo, especialmente nesta era de "babás digitais" e de epidemia de "hiperatividade".&lt;br /&gt;Leia o comentário na Pediatrics: &lt;a href="http://bit.ly/qSzSgW"&gt;http://bit.ly/qSzSgW&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2643770879595960080/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/tv-burrinho-relacao-entre-o-formato-dos.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2643770879595960080'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2643770879595960080'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/tv-burrinho-relacao-entre-o-formato-dos.html' title='TV Burrinho? Relação entre o formato dos cartoons e cognição infantil'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5282822121884916238</id><published>2011-09-12T22:47:00.000-03:00</published><updated>2011-09-18T12:18:10.527-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>The hidden target - a new cancer immunotherapy?</title><content type='html'>In the last issue of &lt;em&gt;Science Translational Medicine&lt;/em&gt;, a team from the National University of Singapore report the intriguing finding that intracellular tumor antigen–specific monoclonal antibodies could inhibit tumor                         growth and metastasis and prolong survival of tumor-bearing mice. As this is a dogma-challenging discovery, a lot of questions naturally arise. Just how the antibodies directed to intracellular proteins managed to effect cell toxicity? Are these results possibly reproducible in humans? Could this be a whole new monoclonal antibody-based strategy for cancer treatment? Antibody-based therapies are targeted at specific molecular elements of cells (often receptor proteins) and thus have improved safety over standard chemotherapy regimens, which has resulted                         in extended survival and improved quality of  life for cancer patients with conventional treatment refractoriness. Because antibodies are too large to  cross intact cell membrane and access                         intracellular locations, antibody therapy has  traditionally targeted extracellular or secreted proteins expressed by  cancer                         cells. However, many oncogenic proteins are  found within the cell (such as intracellular phosphatases/kinases and  transcription                         factors) and have therefore not been targets for  usual antibody therapies. In their proof-of-concept experiment, researchers have treated animals with antibodies directed at intracellular proteins or with endogenous antibody formation by vaccination with these protein products. As a result, they obtained&lt;i&gt; in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; tumor growth inhibition with this strategy. Theoretical possibilities to explain these unexpected effects could be: (1) a small fraction of intracellular antigens may be released due to necrosis or cancer cell lysis; (2) some intracellular antigens may be externalized and displayed on the surface of cancer cells by unconventional secretion; (3) binding of antibodies to surface-exposed intracellular proteins may then trigger immune responses such as ADCC to destroy the cancer cells; (4) antibodies could be taken up by the cancer cells in an antigen-specific manner; (5) complement-mediated events may also be involved. Truly, this effect remains a mistery to be explained, but with plenty of promise if could be confirmed and translated to human patients.&lt;br /&gt;Read the complete article: &lt;a href="http://bit.ly/nT1HbL"&gt;http://bit.ly/nT1HbL&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5282822121884916238/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/hidden-target-new-cancer-immunotherapy.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5282822121884916238'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5282822121884916238'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/hidden-target-new-cancer-immunotherapy.html' title='The hidden target - a new cancer immunotherapy?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3408900618631574927</id><published>2011-09-12T20:57:00.000-03:00</published><updated>2011-09-12T20:57:12.276-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Oxidative stress and cardiovascular disease</title><content type='html'>A set of reviews about the role of oxidative stress-related injury in the genesis of cardiovascular disease are some of the most popular recently published papers in the American Journal of the Medical Sciences. They are the transcription of lectures presented in a &lt;a href="http://bit.ly/qqJmTC"&gt;symposium&lt;/a&gt; held as part of the annual scientific session of the Southern Society for Clinical Investigation. Internationally recognized experts spoke about the role of oxidative damage in myocardial remodeling in chronic mitral regurgitation (Gladden et al), heart failure (Sawyer DB), myocardial infarction (Robinson et al), atherosclerosis (Mitra et al), and other relevant topics.&lt;br /&gt;&lt;br /&gt;Oxidative stress has been recognized as an important cornerstone in the development of these and other cardiovascular diseases, and anti-oxidante drugs have the potential to help decrease cardiovascular risk. When a prooxidant stimulus is persistent and excessive,  natural endogenous anti-oxidant defenses are ultimately overwhelmed and unable to cope. Consequently, reactive oxygen and nitrogen species (free radicals) overproduction account for deleterious cellular responses, including  cardiomyocyte apoptosis and necrosis.&lt;br /&gt;&lt;br /&gt;One of the most well-known associations between oxidative stress and cardiac disease is in the genesis of atherosclerosis. Clinical evidence that links oxidized-LDL with oxidative stress includes its  elevated serum concentrations in patients having ischemic heart disease,  especially in those having the greatest elevation in ox-LDL found with  the acute coronary syndrome. These and many other evidence are reviewed in the articles, follow the links bellow:&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Gladden JD, et al.&lt;/strong&gt; Oxidative stress and myocardial remodeling in chronic mitral regurgitation. Am J Med Sci 2011;342:114–9. &lt;a href="http://bit.ly/pUjOJW"&gt;http://bit.ly/pUjOJW&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Sawyer DB.&lt;/strong&gt; Oxidative stress in heart failure: what are we missing? Am J Med Sci 2011;342:120–4. &lt;a href="http://bit.ly/nezZeb"&gt;http://bit.ly/nezZeb&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Robinson AD, et al.&lt;/strong&gt; Oxidative  stress and cardiomyocyte necrosis with elevated serum troponins:  pathophysiologic mechanisms. Am J Med Sci 2011;342:129–34. &lt;a href="http://bit.ly/nzAmsq"&gt;http://bit.ly/nzAmsq&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Mitra S, et al.&lt;/strong&gt; Oxidized LDL and atherosclerosis. Am J Med Sci 2011;342:135–42. &lt;a href="http://bit.ly/q1fKON"&gt;http://bit.ly/q1fKON&lt;/a&gt;&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3408900618631574927/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/oxidative-stress-and-cardiovascular.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3408900618631574927'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3408900618631574927'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/oxidative-stress-and-cardiovascular.html' title='Oxidative stress and cardiovascular disease'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8355065478475138786</id><published>2011-09-10T13:16:00.002-03:00</published><updated>2011-09-18T12:24:40.386-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pubmed'/><title type='text'>What's new for 'cancer' in PubMed</title><content type='html'>&lt;div&gt;From Pubmed latest published:&lt;br /&gt;&lt;br /&gt;&lt;div&gt;Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. &lt;br /&gt;Schaich M,  Röllig C,  Soucek S,  Kramer M,  Thiede C,  Mohr B,  Oelschlaegel U,  Schmitz N,  Stuhlmann R,  Wandt H,  Schäfer-Eckart K,  Aulitzky W,  Kaufmann M,  Bodenstein H,  Tischler J,  Ho A,  Krämer A,  Bornhäuser M,  Schetelig J,  Ehninger G. &lt;br /&gt;&lt;span class="jrnl" title="Journal of clinical oncology : official journal of the American Society of Clinical Oncology"&gt;J Clin Oncol&lt;/span&gt;. 2011 Jul 1;29(19):2696-702. Epub 2011 May 23.&lt;br /&gt;&lt;br /&gt;This study showed that higher cytarabine dose did not associated with better results than standard dose in AML consolidation chemotherapy. &lt;br /&gt;Link: &lt;a href="http://bit.ly/qIuDwd"&gt;http://bit.ly/qIuDwd&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8355065478475138786/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-cancer-in-pubmed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8355065478475138786'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8355065478475138786'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-cancer-in-pubmed.html' title='What&apos;s new for &apos;cancer&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3111014323938780367</id><published>2011-09-10T13:12:00.000-03:00</published><updated>2011-09-18T12:27:16.246-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pubmed'/><title type='text'>What's new for 'fibromyalgia' in PubMed</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology&lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt;Search: fibromyalgia &lt;br /&gt;Sent on Saturday, 2011 Sep 10&lt;br /&gt;Search &lt;b&gt;fibromyalgia&lt;/b&gt; &lt;br /&gt;&lt;div&gt;(Selected results only)&lt;br /&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21905019" ref="ordinalpos=1"&gt;Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Smith SB,  Maixner DW,  Fillingim RB,  Slade G,  Gracely RH,  Ambrose K,  Zaykin DV,  Hyde C,  John S,  Tan K,  Maixner W,  Diatchenko L.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Arthritis and rheumatism"&gt;Arthritis Rheum&lt;/span&gt;. 2011 Sep 8. doi: 10.1002/art.33338. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21905019 [PubMed - as supplied by publisher]&lt;br /&gt;Comment: this breakthrough study reveals gene candidates for causing fibromyalgia - interstingly most of them relates somewhat to descending pain control that occurs in supraspinal neural centers, highlighting the critical importance of this phenomenon to fibromyalgia (comment added by the blogger).&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;2.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21901352" ref="ordinalpos=5"&gt;Association of fibromyalgia characteristics in patients with non-metastatic breast cancer and the protective role of resilience.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Schrier M,  Amital D,  Arnson Y,  Rubinow A,  Altaman A,  Nissenabaum B,  Amital H.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Rheumatology international"&gt;Rheumatol Int&lt;/span&gt;. 2011 Sep 8. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21901352 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;3.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21895373" ref="ordinalpos=8"&gt;Psychological distress in fibromyalgia patients: A role for Catechol-O-Methyl-Transferase Val158Met polymorphism.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Desmeules J,  Piguet V,  Besson M,  Chabert J,  Rapiti E,  Rebsamen M,  Rossier MF,  Curtin F,  Dayer P,  Cedraschi C.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Health psychology : official journal of the Division of Health Psychology,  American Psychological Association"&gt;Health Psychol&lt;/span&gt;. 2011 Sep 5. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21895373 [PubMed - as supplied by publisher]&lt;br /&gt;&lt;br /&gt;Comment: fibromyalgia is now recognized as a disease with a molecular background that has been explored in the last few years. One can say that it is a disease with a pain modulation, processing and perception alteration that leads to chronic pain. Cathecolaminergic signaling is central to its pathogenesis and this is the basis of the most used pharmacological treatments used in the last years. The author of this blog has published commentaries and reviews about this topic in peer-reviewed journals. You can check this following the link to my CV: &lt;a href="http://bit.ly/oH8Bfu"&gt;http://bit.ly/oH8Bfu&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3111014323938780367/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-fibromyalgia-in-pubmed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3111014323938780367'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3111014323938780367'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/whats-new-for-fibromyalgia-in-pubmed.html' title='What&apos;s new for &apos;fibromyalgia&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5287637488513505411</id><published>2011-09-10T12:51:00.000-03:00</published><updated>2011-09-18T12:58:11.713-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>Concurso 'Dance Your Ph.D.' 2011 - via ScienceNOW</title><content type='html'>A revista Science divulgou a nova edição de seu concurso anual "Dance Your PhD", no seu blog de notícias, ScienceNOW. O concurso é um desafio bem-humorado a cientistas com doutorado ou estudantes de doutorado de explicar ou expressar sua tese, sua pesquisa e resultados na forma de uma coreografia de dança. É um concurso amador e sem pretensões artísticas, o propósito é a diversão, mas que tem um prêmio que não deixa de ser significante. Como diz a página do concurso, "você pode ganhar US$ 1000,00 e fama geek instantânea na internet, além do reconhecimento pela Science". Além disso, este ano a melhor performance ganhará uma viagem a Bruxelas. As regras são simples: você deve: (1) ser doutor ou (2) estar fazendo doutorado e (3) obrigatoriamente, fazer parte da coreografia! O concurso é aberto a todas as áreas da ciência e a todos os países, sem distinção. Para participar, você deve criar e filmar sua coreografia (na página do concurso pode-se encontrar dicas de como fazer isso), fazer upload para o site vimeo.com e mandar o link pra os organizadores do concurso até 10 de Outubro de 2011! Aos interessados, mãos à obra e boa sorte!&lt;br /&gt;&lt;br /&gt;Artigo no blog da Science:&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/08/announcing-the-2011-dance-your-p.html?ref=hp#.TmuDUZCp3Vs.blogger"&gt;http://bit.ly/nqEYyh&lt;/a&gt;&lt;br /&gt;Página do concurso:&lt;br /&gt;&lt;a href="http://bit.ly/10MOn"&gt;http://bit.ly/10MOn&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5287637488513505411/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/concurso-dance-your-phd-2011-via.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5287637488513505411'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5287637488513505411'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/concurso-dance-your-phd-2011-via.html' title='Concurso &apos;Dance Your Ph.D.&apos; 2011 - via ScienceNOW'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3049913101609576890</id><published>2011-09-10T12:33:00.000-03:00</published><updated>2011-09-10T12:33:09.650-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Bird Flu is comming back</title><content type='html'>&lt;p id="p-4"&gt;The United Nations Food and Agriculture Organization (FAO)  issued a bulletin last week that stirred a lot of press attention. It warned of “a major resurgence                      of the H5N1 highly pathogenic avian influenza amid  signs that a mutant strain of the deadly bird flu virus is spreading in                      Asia and beyond, with unpredictable risks to human  health.” Other international health organizations, however, hurried to play  down                      the significance of this alert. FAO Chief Veterinary Officer Juan Lubroth defended the warning, implying they meant not to cause a frenzy.&lt;br /&gt;&lt;/p&gt;&lt;p id="p-6"&gt;Science has published a news analysis upon the topic. They reported that FAO posted the statement, titled “Bird Flu  rears its head again,” on its Web site on 29 August. The post reveals  that H5N1                      outbreaks among poultry and wild birds have been  increasing since 2008 and that the virus has re-emerged                      in many countries. Furthermore, a  variant of the virus, dubbed clade 2.3.2.1, circulating in China and  Vietnam                      has mutated in a way that renders current poultry  vaccines less effective. And since H5N1  appeared in 2003, it has killed or led to the  culling of more than 400 million domestic poultry, causing an estimated  $20                      billion in losses, and killed 331 people, roughly  60% of those it infected. The agency predicted that  a flareup of H5N1 is likely this fall and winter.                    &lt;/p&gt;Read the original post:&lt;br /&gt;&lt;a href="http://www.fao.org/news/story/en/item/87196/icode/"&gt;http://bit.ly/o7IaF1&lt;/a&gt;&lt;br /&gt;Read the Science analysis:&lt;br /&gt;&lt;a href="http://bit.ly/pwxs9s"&gt;http://bit.ly/pwxs9s&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3049913101609576890/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/bird-flu-is-comming-back.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3049913101609576890'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3049913101609576890'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/bird-flu-is-comming-back.html' title='Bird Flu is comming back'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2445390266355392298</id><published>2011-09-08T23:15:00.003-03:00</published><updated>2011-09-23T17:40:06.143-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Aula do projeto Protocolos 2011</title><content type='html'>Hoje, no Centro pediátrico do Câncer, iniciamos o projeto Protocolos 2011 com uma exposição minha sobre o tratamento clínico de tumores do Sistema Nervoso Central. O projeto Protocolos 2011 foi solicitado pela direção do Hospital Infantil Albert Sabin, na pessoa da Dra. Joana Angélica de Paiva Maciel, para padronizar as condutas no CPC. A exposição inclui um breve histórico, uma avaliação da evidência atual, um exame preliminar de nossos resultados (incluindo pacientes diagnosticados até 2008) e uma discussão sobre novos protocolos que já estão implantados ou em implantação. A exposição foi toda produzida no programa Keynote para iPad, portanto não foi possível disponibilizá-la em formato de apresentação de slides tradicionais, mas em pdf. Como não há comentários nos slides, acrescento alguns comentários referentes a cada diapositivo:&lt;br /&gt;(veja os slides: &lt;a href="http://bit.ly/no4bom"&gt;http://bit.ly/no4bom&lt;/a&gt;)&lt;br /&gt;&lt;br /&gt;Slide 1 - a fachada do CPC (foto obtida por mim logo que ele foi inaugurado)&lt;br /&gt;&lt;br /&gt;Slide 2 - cada exposição engloba uma patologia (ou grupo, como é o caso desta) - as informações aqui mostradas são oriundas de 2 projetos de pesquisa coordenados por mim: &lt;a href="http://bit.ly/nL1SEY"&gt;http://bit.ly/nL1SEY&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Slide 3 - até 2006, não existia atendimento neuro-oncológico organizado no HIAS; por iniciativa do Dr Cesar Abreu, formou-se um grupo multidisciplinar organizado.&lt;br /&gt;&lt;br /&gt;Slide 4 - o grupo inicialmente contava comigo como oncologista clínico, Dr. Firmo Holanda na Neurocirurgia, Dra. Jubya Bastos no suporte pediátrico e um sem-número de especialistas de todas as áreas. Mais recentemente, o Dr. João Paulo Mattos juntou-se à equipe de neurocirurgiões dedicados à neuro-oncologia. Muitos outros colegas dão inestimável contribuição, destacando-se o Dr. Igor Veras, parceiro do CRIO que trata nossos pequenos pacientes. Um sincero agradecimento a todos.&lt;br /&gt;&lt;br /&gt;Slide 5 - principais doenças oncológicas agrupadas no conjunto dos tumores do SNC. Nota bene: a ICCC (International Classification of Childhood Cancer, 3 ed) considera todas as patologias listadas como malignas, incluindo ependimomas (independente da classificação da OMS) e os chamados gliomas de baixo grau. A classificação pode ser checada aqui: &lt;a href="http://seer.cancer.gov/iccc/iccc3.html"&gt;http://seer.cancer.gov/iccc/iccc3.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Slide 6 - o famoso protocolo 8 em 1 já foi usado por nós na década de 90 e antes. OS = sobrevida global; EFS = sobrevida livre de doença.&lt;br /&gt;&lt;br /&gt;Slide 7 - protocolos de tratamento usados em nosso serviço até 2008&lt;br /&gt;&lt;br /&gt;Slides 8 e 9 - resultados publicados destes protocolos. Embora o protocolo SOBOPE/SLAOP 1998 para meduloblastoma não tenha resultados divulgados ainda, em 2007, Jakacki et al apresentaram resultados de um estudo do COG que tem indução com quimiorradioterapia similar. Hoje, quimioterapia para meduloblastomas e astrocitomas de baixo grau (estes últimos recorrentes ou progressivos) está bem estabelecida. Para ependimomas e gliomas de alto grau, no entanto, não.&lt;br /&gt;&lt;br /&gt;Slides 10 a 16 - resultados de&amp;nbsp; nosso serviço para o período 2000-2006, aceitos para publicação no Jornal de Pediatria (de Araújo et al, JPED, 2011 - no prelo). Nossos resultados de sobrevida global em 5 anos equivalem parcialmente aqueles de dados populacionais do primeiro mundo (&lt;a href="http://seer.cancer.gov/"&gt;SEER&lt;/a&gt; e &lt;a href="http://www-dep.iarc.fr/accis.htm"&gt;ACCIS&lt;/a&gt;). A sobrevida de pacientes com ependimoma é baixa.&lt;br /&gt;&lt;br /&gt;Slides 17 a 23 - resultados de nosso serviço para o período 2007-2008, dados não publicados. Várias patologias (ependimoma notadamente) com sobrevida superior. Embora um cirurgião dedicado e oncologista clínico exclusivo, além de um fluxo bem definido de atendimento possam explicar tal melhoria, ainda podem haver fatores não bem definidos envolvidos.&lt;br /&gt;&lt;br /&gt;Slide 24 - um destes fatores pode ter sido a profilaxia anticonvulsivante com valproato, uma droga hoje reconhecida como possivelmente tendo efeito antitumoral. Nesta avaliação retrospectiva aceita para publicação (&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21699466"&gt;Felix&lt;/a&gt; et al, Pediatr Hematol Oncol, 2011 - no prelo) mostramos que ocorreu uma melhora de sobrevida em pacientes com tumores de alto risco que receberam a profilaxia.&lt;br /&gt;&lt;br /&gt;Slide 25 - nesta análise de sobrevida nos pacientes diagnosticados entre 2000-2008, a profilaxia com valproato afetou positivamente a sobrevida de um subgrupo de pacientes com ependimoma, meduloblastoma ou glioma de baixo grau (dados não publicados). Estes estudos observacionais não provam que o valproato foi o responsável pela melhor sobrevida dos pacientes, mas sugerem estudos adicionais. Vários &lt;a href="http://clinicaltrials.gov/ct2/results?term=valproate+cancer+children"&gt;ensaios&lt;/a&gt; clínicos com valproato já estão em andamento.&lt;br /&gt;&lt;br /&gt;Slide 26 - protocolos introduzidos no CPC após 2008. O protocolo para tratamento de meduloblastoma de baixo risco (COG-A9961) usa menos QT e menos RT, mantendo bons resultados. O protocolo alemão HIT-GBM-C conseguiu resultados melhores em pacientes com gliomas de alto grau com quimiorradioterapia intensiva. O protocolo CCG-9921 até hoje é o mais usado para crianças menores de 3 anos, embora outras abordagens tenham sido propostas.&lt;br /&gt;&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2445390266355392298/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/aula-do-projeto-protocolos-2011.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2445390266355392298'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2445390266355392298'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/aula-do-projeto-protocolos-2011.html' title='Aula do projeto Protocolos 2011'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2694780522011165656</id><published>2011-09-06T22:39:00.001-03:00</published><updated>2011-09-18T12:18:10.500-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>XIII Congresso Brasileiro de Oncologia Pediátrica</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Em 2012, o congresso da Sociedade Brasileira de Oncologia Pediátrica - SOBOPE, será em Natal, de 17 a 20 de abril. Com presidência do Dr. Elione Soares de Albuquerque e apoio do Instituto Ronald McDonald, Casa Durval Paiva e AAPCMR, será uma oportunidade para que os colegas façam contatos e reciclagem. Visite a página do congresso: &lt;a href='http://bit.ly/pDxgt0' target='_blank'&gt;http://bit.ly/pDxgt0&lt;/a&gt;&lt;img src='http://www.cbopnatal.com.br/img/img-topo.jpg' style='max-width: 800px;'/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2694780522011165656/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/xiii-congresso-brasileiro-de-oncologia.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2694780522011165656'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2694780522011165656'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/xiii-congresso-brasileiro-de-oncologia.html' title='XIII Congresso Brasileiro de Oncologia Pediátrica'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8755347295249490333</id><published>2011-09-06T19:38:00.000-03:00</published><updated>2011-09-18T12:58:11.739-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>I, Robot</title><content type='html'>Via ScienceNOW: Robotic avatars of disabled people walking around and interacting with other people? This possibility has now a little more of science and a little less of fiction due to a new development reported at IEEE Engineering in Medicine and Biology Society conference in Boston. A group from  École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland has devised a way of merging human-driven control and robotic control to create a smooth form of subconcious remote thought control. People wearing an array of tiny electrodes in a cap could control the movements of a robot a 100-mile away almost as easily as we can control our own  movements. This new non-invasive technology will be next tested in locked-in patients that lack any possibility of movement. This new development can open the way to a new era for disabled patients and their relation to other people.&lt;br /&gt;Read the news (ScienceNow blog):&lt;br /&gt;&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/09/disabled-patients-mind-meld-with.html?ref=em&amp;amp;elq=7974b8796cf14927b8cf439f1f023218#.TmadaUH4_FY.blogger"&gt;Disabled Patients Mind-Meld With Robots - ScienceNOW&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8755347295249490333/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/i-robot.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8755347295249490333'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8755347295249490333'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/i-robot.html' title='I, Robot'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-570991511209851824</id><published>2011-09-03T17:41:00.000-03:00</published><updated>2011-09-18T12:22:44.851-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><title type='text'>Atualização da aula "Câncer em Crianças"</title><content type='html'>A aula apresentada no &lt;a href="http://www.crio.com.br/"&gt;CRIO&lt;/a&gt; em maio deste ano, intitulada "Câncer em Crianças", havia sido disponibilizada para visualização online a quem dispusesse do link. Esta primeira versão foi montada sem os créditos das diversas imagens que utilizamos. Agora, uma nova versão está pronta, contendo créditos e links para as imagens. A visualização da nova versão é possível aqui: &lt;a href="http://bit.ly/qovrvg"&gt;http://bit.ly/qovrvg&lt;/a&gt;&lt;br /&gt;Acrescentamos um slide sobre uma associação canadense fundada por um jovem artista portador de linfoma, que financia pesquisas clínicas sobre câncer. Também acrescentamos um slide sobre a Associação Peter Pan, organização não governamental que construiu e doou ao Hospital Infantil Albert Sabin as instalações do Centro Pediátrico do Câncer.&lt;br /&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;/div&gt;&lt;br /&gt;&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/570991511209851824/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/09/atualizacao-da-aula-cancer-em-criancas.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/570991511209851824'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/570991511209851824'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/09/atualizacao-da-aula-cancer-em-criancas.html' title='Atualização da aula &quot;Câncer em Crianças&quot;'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7516078168678220980</id><published>2011-08-30T20:08:00.000-03:00</published><updated>2011-09-18T12:29:09.757-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pubmed'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>What's new for 'cancer' in PubMed</title><content type='html'>Search &lt;b&gt;cancer&lt;/b&gt; &lt;br /&gt;&lt;div&gt;Limits:&lt;b&gt;Randomized Controlled Trial, All Child: 0-18 years&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;Items 1 - 4 of 4&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21606430" ref="ordinalpos=1"&gt;Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;García-Del-Muro X,  López-Pousa A,  Maurel J,  Martín J,  Martínez-Trufero J,  Casado A,  Gómez-España A,  Fra J,  Cruz J,  Poveda A,  Meana A,  Pericay C,  Cubedo R,  Rubió J,  De Juan A,  Laínez N,  Carrasco JA,  de Andrés R,  Buesa JM;  Spanish Group for Research on Sarcomas.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Journal of clinical oncology : official journal of the American Society of Clinical Oncology"&gt;J Clin Oncol&lt;/span&gt;. 2011 Jun 20;29(18):2528-33. Epub 2011 May 23.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21606430 [PubMed - indexed for MEDLINE]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=21606430" ref="ordinalpos=1"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;2.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21459659" ref="ordinalpos=2"&gt;Role of chemoradiotherapy in intermediate prognosis nasopharyngeal carcinoma.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Xu T,  Hu C,  Wang X,  Shen C.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Oral oncology"&gt;Oral Oncol&lt;/span&gt;. 2011 May;47(5):408-13. Epub 2011 Apr 2.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21459659 [PubMed - indexed for MEDLINE]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=21459659" ref="ordinalpos=2"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;3.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21315637" ref="ordinalpos=3"&gt;Patient-reported Pediatric Quality of Life Inventory™ 4.0 Generic Core Scales in pediatric patients with attention-deficit/hyperactivity disorder and comorbid psychiatric disorders: feasibility,  reliability,  and validity.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Limbers CA,  Ripperger-Suhler J,  Heffer RW,  Varni JW.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research"&gt;Value Health&lt;/span&gt;. 2011 Jun;14(4):521-30. Epub 2011 Apr 22.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21315637 [PubMed - indexed for MEDLINE]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=21315637" ref="ordinalpos=3"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;4.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/19236773" ref="ordinalpos=4"&gt;[Immunophenotypic features in 143 cases of acute promyelocytic leukemia].&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Sun HM,  Qian SX,  Wu YJ,  Qiao C,  Hong M,  Fan L,  Yang H,  Zhang JF,  Zhang SJ,  Wu HX,  Qiu HX,  Lu H,  Xu W,  Sheng RL,  Li JY.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology"&gt;Zhongguo Shi Yan Xue Ye Xue Za Zhi&lt;/span&gt;. 2009 Feb;17(1):176-9. Chinese. &lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 19236773 [PubMed - indexed for MEDLINE]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=19236773" ref="ordinalpos=4"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7516078168678220980/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/whats-new-for-cancer-in-pubmed.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7516078168678220980'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7516078168678220980'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/whats-new-for-cancer-in-pubmed.html' title='What&apos;s new for &apos;cancer&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2819059142041956179</id><published>2011-08-26T23:33:00.002-03:00</published><updated>2011-09-18T12:29:09.577-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Charlie and the Organ Factory - A Fantástica Fábrica de Órgãos</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Fiction? Fact? Hearts and livers on a pharmacy shelf may be a long way from now, but some people are already living with lab made organs. Americans are living with lab-grown bladders and europeans have received implanted lab made tracheas. An article published on Science this week has revealed that US regulatory agency FDA has given the approval for a new trial in US that is going to implant tissue-engineered cardiac blood vessels in children with heart disease.                      Christopher Breuer, pediatric surgeon from Yale, one of the implants' developers, say that the first children to receive the implant in Japan have active, healthy lives. The extensive laboratory studies led by the group have underscored a surprisingly positive role of local inflammation in the formation of new vessels from the implant.                         The team uses a scaffold made of a biodegradable polyester tube, which they incubate briefly with a patient's bone marrow mononuclear cells. Preclinical experiments showed that the grafts soon formed a normal-looking blood vessel. Experiments so far have shown that the fate of the implanted cells is to completely disappear in a few days, but they somehow trigger the migration of cells to the implant and the formation of a new vessel with the host's cells. The scaffold degrades in a few months, leaving a new normal blood vessel, with no need for drugs as in conventional transplant or artificial implant techniques. Six patients will receive the new implants in this trial.&lt;br /&gt;Read the complete Science article: &lt;a href="http://bit.ly/pG4iIa" target="_blank"&gt;http://bit.ly/pG4iIa&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;Ficção?&lt;/span&gt; Realidade&lt;span class="hps"&gt;?&lt;/span&gt; &lt;span class="hps"&gt;Corações e&lt;/span&gt; &lt;span class="hps"&gt;fígados&lt;/span&gt; &lt;span class="hps"&gt;em uma prateleira&lt;/span&gt; &lt;span class="hps"&gt;de farmácia&lt;/span&gt; &lt;span class="hps"&gt;podem estar bem distantes&lt;/span&gt;&lt;span class="hps"&gt; ainda&lt;span class="hps"&gt;&lt;span class=""&gt;, mas algumas pessoas&lt;/span&gt; &lt;span class="hps"&gt;já estão vivendo&lt;/span&gt; &lt;span class="hps"&gt;com os órgãos&lt;/span&gt; &lt;span class="hps"&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt; &lt;span class="hps"&gt;feitos&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt; em laboratório&lt;/span&gt;&lt;span class="hps"&gt;.&lt;/span&gt; Alguns&lt;span class="hps"&gt; americanos&lt;/span&gt; &lt;span class="hps"&gt;estão vivendo com &lt;/span&gt;&lt;span class="hps"&gt; &lt;span class="hps"&gt;bexigas cultivadas em laboratório e&lt;/span&gt; &lt;span class="hps"&gt;europeus&lt;/span&gt; &lt;span class="hps"&gt;receberam&lt;/span&gt; &lt;span class="hps"&gt;traquéias&lt;/span&gt; feitas &lt;span class="hps"&gt;laboratório&lt;/span&gt;&lt;span class="hps"&gt;&lt;span class="hps"&gt;.&lt;/span&gt; &lt;span class="hps"&gt;Um artigo publicado&lt;/span&gt; &lt;span class="hps"&gt;na&lt;/span&gt; &lt;span class="hps"&gt;Science desta semana&lt;/span&gt; &lt;span class="hps"&gt;revelou&lt;/span&gt; &lt;span class="hps"&gt;que o&lt;/span&gt; &lt;span class="hps"&gt;FDA,&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt; &lt;span class="hps"&gt;agência reguladora&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt; dos EUA,&lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt; &lt;span class="hps"&gt;deu&lt;/span&gt; &lt;span class="hps"&gt;a aprovação&lt;/span&gt; &lt;span class="hps"&gt;para um novo ensaio clínico&amp;nbsp;&lt;/span&gt;&lt;span class="hps"&gt;&lt;span class="hps"&gt;que vai&lt;/span&gt; &lt;span class="hps"&gt;implantar&lt;/span&gt;&amp;nbsp;&lt;span class="hps"&gt; vasos sanguíneos&lt;/span&gt; &lt;span class="hps"&gt;cardíacos&lt;/span&gt; &lt;span class="hps"&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;feitos por engenharia de tecidos&lt;/span&gt; &lt;span class="hps"&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;em crianças&lt;/span&gt; &lt;span class="hps"&gt;com doença cardíaca.&lt;/span&gt; &lt;span class="hps"&gt;Christopher&lt;/span&gt; &lt;span class="hps"&gt;Breuer,&lt;/span&gt; &lt;span class="hps"&gt;cirurgião pediátrico&lt;/span&gt; &lt;span class="hps"&gt;da Universidade de Yale&lt;/span&gt;&lt;span class=""&gt;, um dos criadores&lt;/span&gt; &lt;span class="hps"&gt;dos implantes&lt;/span&gt; &lt;span class="hps atn"&gt;&lt;span class=""&gt;diz que&lt;/span&gt; "&lt;span class="hps"&gt;as primeiras crianças&lt;/span&gt; &lt;span class="hps"&gt;a receber&lt;/span&gt; &lt;span class="hps"&gt;o implante&lt;/span&gt; &lt;span class="hps"&gt;no Japão têm&lt;/span&gt; &lt;span class="hps"&gt;vidas ativas,&lt;/span&gt; &lt;span class="hps"&gt;saudáveis".&lt;/span&gt; Vários&lt;span class="hps"&gt; estudos&lt;/span&gt; &lt;span class="hps"&gt;de laboratório&lt;/span&gt;&amp;nbsp;&lt;span class="hps"&gt;liderados pelo grupo&lt;/span&gt; &lt;span class="hps"&gt;têm ressaltado&lt;/span&gt; &lt;span class="hps"&gt;um papel&lt;/span&gt; &lt;span class="hps"&gt;surpreendentemente positivo&lt;/span&gt; &lt;span class="hps"&gt;da inflamação local&lt;/span&gt; &lt;span class="hps"&gt;na&lt;/span&gt; &lt;span class="hps"&gt;formação de novos vasos&lt;/span&gt; &lt;span class="hps"&gt;a partir do&lt;/span&gt; &lt;span class="hps"&gt;implante.&lt;/span&gt; &lt;span class="hps"&gt;A equipe usa&lt;/span&gt; &lt;span class="hps"&gt;um molde feito de&lt;/span&gt; &lt;span class="hps"&gt;um tubo de&lt;/span&gt; &lt;span class="hps"&gt;poliéster biodegradável&lt;/span&gt;&lt;span class=""&gt;, incubado&lt;/span&gt;&lt;span class="hps"&gt; &lt;span class="hps"&gt;brevemente com&lt;/span&gt; &lt;span class="hps"&gt;células tronco &lt;/span&gt;&lt;span class="hps"&gt;da medula óssea&lt;/span&gt;&lt;span class=""&gt;.&lt;/span&gt; &lt;span class="hps"&gt;Experimentos&lt;/span&gt; &lt;span class="hps"&gt;pré-clínicos&lt;/span&gt; &lt;span class="hps"&gt;mostraram que&lt;/span&gt; &lt;span class="hps"&gt;os enxertos&lt;/span&gt; &lt;span class="hps"&gt;logo formaram&lt;/span&gt; &lt;span class="hps"&gt;um vaso sanguíneo&lt;/span&gt; &lt;span class="hps"&gt;de aparência normal&lt;/span&gt;&lt;span class=""&gt;.&lt;/span&gt; &lt;span class="hps"&gt;Experiências&lt;/span&gt; &lt;span class="hps"&gt;até o momento&lt;/span&gt; &lt;span class="hps"&gt;têm demonstrado que&lt;/span&gt; &lt;span class="hps"&gt;o destino&lt;/span&gt; &lt;span class="hps"&gt;das células implantadas&lt;/span&gt; &lt;span class="hps"&gt;é&lt;/span&gt;&lt;span class="hps"&gt; &lt;span class="hps"&gt;desaparecer completamente&lt;/span&gt; &lt;span class="hps"&gt;em poucos dias&lt;/span&gt;&lt;span class=""&gt;, mas&lt;/span&gt; &lt;span class="hps"&gt;de alguma forma&lt;/span&gt; &lt;span class="hps"&gt;provocam&lt;/span&gt; &lt;span class="hps"&gt;a migração&lt;/span&gt; &lt;span class="hps"&gt;de células para&lt;/span&gt; &lt;span class="hps"&gt;o implante e a&lt;/span&gt; &lt;span class="hps"&gt;formação de uma&lt;/span&gt; &lt;span class="hps"&gt;nov&lt;/span&gt;o vaso &lt;span class="hps"&gt;com células&lt;/span&gt; &lt;span class="hps"&gt;do hospedeiro.&lt;/span&gt; &lt;span class="hps"&gt;O molde degrada-se&lt;/span&gt; &lt;span class="hps"&gt;em alguns meses&lt;/span&gt;&lt;span class=""&gt;, deixando um&lt;/span&gt; vaso&lt;span class="hps"&gt; &lt;span class="hps"&gt;sanguíneo novo&lt;/span&gt; &lt;span class="hps"&gt;normal,&lt;/span&gt; &lt;span class="hps"&gt;sem necessidade de&lt;/span&gt; &lt;span class="hps"&gt;drogas como&lt;/span&gt; &lt;span class="hps"&gt;no transplante&lt;/span&gt; &lt;span class="hps"&gt;convencional ou&lt;/span&gt; &lt;span class="hps"&gt;técnicas de implantes&lt;/span&gt; &lt;span class="hps"&gt;artificiais.&lt;/span&gt; &lt;span class="hps"&gt;Seis pacientes&lt;/span&gt; &lt;span class="hps"&gt;receberão os&lt;/span&gt; &lt;span class="hps"&gt;novos implantes&lt;/span&gt; &lt;span class="hps"&gt;neste estudo.&lt;/span&gt;&lt;br /&gt;&lt;span class="hps"&gt;Leia o&lt;/span&gt; &lt;span class="hps"&gt;artigo &lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;completo &lt;/span&gt;&lt;/span&gt;&lt;span class="" id="result_box" lang="pt"&gt;&lt;span class="hps"&gt;da Science&lt;/span&gt;&lt;span class="hps"&gt;:&lt;/span&gt;&lt;/span&gt; &lt;a href="http://bit.ly/pG4iIa" target="_blank"&gt;http://bit.ly/pG4iIa&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2819059142041956179/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/charlie-and-organ-factory-fantastica.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2819059142041956179'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2819059142041956179'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/charlie-and-organ-factory-fantastica.html' title='Charlie and the Organ Factory - A Fantástica Fábrica de Órgãos'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6704786393128860617</id><published>2011-08-25T23:28:00.001-03:00</published><updated>2011-08-25T23:33:17.389-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='glioblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='imagem'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Novidades na avaliação de neuro-imagens de tumores cerebrais</title><content type='html'>Um novo artigo de consenso recém-publicado na rede pelo jornal Neurosurgery traz uma nova proposta de critérios de resposta após cirurgia para tumores cerebrais. O trabalho reuniu grandes nomes da neurocirurgia e neuro-oncologia da América do Norte e Europa e se propôs a atualizar o conjunto de critérios universalmente aceito até hoje, chamado de "Critérios de McDonald". O grupo de trabalho, denominado RANO (Response Assesment in Neuro-Oncology) chegou a 4 recomendações, coletivamente chamados de "Critérios RANO":&lt;br /&gt;1) Imagem (RNM) pós-operatória: para avaliação de tumores captantes de contraste, deve ser feita até, no máximo, 48h após a cirurgia, pois uma área de captação inespecífica perioperatória desenvolve-se após 48-72h do procedimento. Tumores sem captação de contraste devem ser avaliados pelas imagens em T2/FLAIR, até 12 semanas após a cirurgia, comparando-se com a imagem pré-operatória para ajudar a diferenciar edema peritumoral do tumor em si. A avaliação do cirurgião durante o ato operatório não é confiável para avaliação.&lt;br /&gt;2) Imagem de difusão (DWI e ADC) deve ser realizada rotineiramente, de preferência nas primeiras 24-48h após o procedimento, para detectar áreas de isquemia perioperatória e ajudar a diferenciar futuras novas áreas de captação (as áreas de isquemia demonstram aumento de captação subsequentemente) de progressão verdadeira,  nos primeiros 3 meses após a ressecção. &lt;br /&gt;3) Os termos atualmente usados para descrever a extensão da ressecção devem ser modificados: os termos propostos são CRET (complete resection of enhancing tumor) e PRET (partial resection of enhancing tumor) para tumores captantes, CRDT (complete resection of detectable tumor) e PRDT  (partial resection of detectable tumor) para tumores não captantes. Ainda não existem traduções padronizadas para outras línguas.&lt;br /&gt;4) Avaliação da progressão da doença deve ser contextualizada pela extensão da ressecção e, ainda, pela realização de terapias locais, se aplicável. As terapias locais podem ser wafers de quimioterapia (Gliadel), imunoterapia, imunotoxinas ou terapia gênica administrada diretamente no leito tumoral, braquiterapia ou radiocirurgia. Estas modalidades de terapia agem promovendo inflamação ou aumento de permeabilidade microvascular no tumor residual ou sítio tumoral e isto traduz-se em áreas de captação de contraste na imagem. Embora não exista uma técnica de imagem consagrada para diferenciar progressão real de pseudo-progressão, recomenda-se a RNM com espectroscopia e a PET. A dúvida pode necessitar de nova biópsia cirúrgica para confirmação histológica.&lt;br /&gt;5) Deve ser feita uma análise retrospectiva da progressão de doença. Quando houver dúvida entre progressão e pseudoprogressão, imagens seriadas devem ser obtidas. Imagens residuais ou novas que não persistem ou não progridem e não se correlacionam com piora clínica podem ser consideradas, a posteriori, pseudoprogressão. Imagens que progridem e correlacionam-se com piora clínica são verdadeiras progressões. Imagens dúbias devem ser consideradas indeterminadas até que a evolução das imagens e da clínica confirmem o status - se confirmar-se progressão, a data de progressão deve ser referida de maneira retrospectiva como aquela da primeira imagem indeterminada. &lt;br /&gt;&lt;br /&gt;Estas recomendação são, obviamente, voltadas para a realização de futuros ensaios clínicos. No entanto, uma vez que novos ensaios usem tais critérios para determinar resposta terapêutica, sua aplicação clínica será inevitável, a fim de utilizar-se novas terapias validadas com tais critérios.&lt;br /&gt;Além destas recomendações, o grupo sugere que, para ensaios clínicos, a melhor forma de avaliação de resposta seja a revisão central independente e cega. Uma vez que os resultados de tal avaliação serão usados para determinar a melhor terapia dos pacientes de um ensaio clínico, serão necessárias instalações que permitam a avaliação digital rápida destas imagens. Além disso, o grupo sugere que a melhor avaliação de imagem seja a análise volumétrica semi-automática, o que vai exigir a presença de softwares e pessoal especializado com know-how para realizar rotineiramente tais medições. Por último, o grupo sugere que a avaliação do volume tumoral residual absoluto substitua o tamanho relativo na determinação da extensão da ressecção. Ou seja, ao invés de considerar a ressecção de 90-95% do tumor inicial, considerar se o tumor residual é maior ou menor que um volume de referência (por exemplo, 1 cm3).&lt;br /&gt;&lt;br /&gt;Trabalho disponível aqui: &lt;a href="http://bit.ly/psOfZ3"&gt;http://bit.ly/psOfZ3&lt;/a&gt;&lt;br /&gt;Do mesmo grupo, sobre gliomas de baixo grau (Lancet):&amp;nbsp; &lt;a href="http://bit.ly/qJl9tC"&gt;http://bit.ly/qJl9tC&lt;/a&gt;&lt;br /&gt;Do mesmo grupo, sobre gliomas de alto grau (Clinical Neuroradiology): &lt;a href="http://bit.ly/rbjz0x"&gt;http://bit.ly/rbjz0x&lt;/a&gt;&lt;br /&gt;Do mesmo grupo, sobre o desenvolvimento dos critérios RANO (JCO): &lt;a href="http://bit.ly/o1t1Vq"&gt;http://bit.ly/o1t1Vq&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6704786393128860617/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/novidades-na-avaliacao-de-neuro-imagens.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6704786393128860617'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6704786393128860617'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/novidades-na-avaliacao-de-neuro-imagens.html' title='Novidades na avaliação de neuro-imagens de tumores cerebrais'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4121619042547402145</id><published>2011-08-20T13:13:00.000-03:00</published><updated>2011-08-20T13:13:49.679-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Redes sociais de quarentena</title><content type='html'>O Conselho Federal de Medicina publicou nova resolução que regulamenta o uso publicitário da internet, blogs e redes sociais para divulgação do trabalho médico. Segundo o CFM, &lt;span id="textoNoticia"&gt; “além de detalhamentos, a nova resolução se  diferencia da anterior por proibir expressamente ao médico a oferta de  consultoria a pacientes e familiares em substituição à consulta médica  presencial. Esta proibição se aplica, por exemplo, aos serviços de  assessoria médica realizados pela Internet ou por telefone”.&lt;/span&gt; &lt;span id="textoNoticia"&gt;A resolução  traz regras específicas sobre como  um médico tem de se portar em redes sociais, blogs e microblogs. Nesses  casos, o profissional não pode divulgar o endereço e telefone de sua  clínica. &lt;/span&gt;&lt;span id="textoNoticia"&gt;De forma geral, os médicos ficam proibidos de  anunciarem uma pós-graduação em área diferente daquela em que fizeram  sua especialização acadêmica. &lt;/span&gt;&lt;span id="textoNoticia"&gt;O profissional precisa, por exemplo, evitar o  sensionalismo e a autopromoção, ficando proibido de divulgar, mesmo em  entrevistas, seus contatos (das agências).&lt;br /&gt;Leia a reportagem completa no O POVO:&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;a href="http://www.opovo.com.br/app/opovo/tendencias/2011/08/19/noticiatendenciajornal,2281985/redes-sociais-de-quarentena.shtml#.Tk_bivUISoI.blogger"&gt;O POVO Online - Tendências - Redes sociais de quarentena&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4121619042547402145/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/redes-sociais-de-quarentena.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4121619042547402145'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4121619042547402145'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/redes-sociais-de-quarentena.html' title='Redes sociais de quarentena'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8641998697052798593</id><published>2011-08-15T17:09:00.001-03:00</published><updated>2011-08-15T17:09:45.417-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Introdução da dieta na diarréia aguda da infância</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Uma das doenças mais frequentes e de maior morbi-mortalidade em crianças de países e regiões em desenvolvimento é a diarréia aguda. Ela é responsável por uma proporção muito importante da mortalidade infantil no mundo inteiro. Apesar de existirem recomendações sobre o manejo da diarréia aguda publicadas pela OMS, pela OPAS (Organização Pan-Americana de Saúde) e pelo Ministério da Saúde do Brasil, até hoje nenhuma evidência objetiva define o papel da dieta na criança com esta patologia. Enquanto há alguns anos atrás era comum a pausa alimentar, hoje em dia esta pausa não é recomendada ou é apenas parcial (dieta leve ou branda). Uma nova metanálise publicada pela Cochrane Library mostrou, pela primeira vez, que a introdução precoce de dieta em crianças com diarréia aguda não complicada não está associada com aumento de nenhum risco. Para ler o artigo completo: &lt;a href='http://bit.ly/q1VRhX' target='_blank'&gt;http://bit.ly/q1VRhX&lt;/a&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8641998697052798593/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/introducao-da-dieta-na-diarreia-aguda.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8641998697052798593'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8641998697052798593'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/introducao-da-dieta-na-diarreia-aguda.html' title='Introdução da dieta na diarréia aguda da infância'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8981900284205237295</id><published>2011-08-15T12:08:00.001-03:00</published><updated>2011-09-18T12:18:10.571-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Novel immunotherapy has potent antitumor effect</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;It has been highly publicized in media in the past days: 3 patients with an advanced and refractory type of leukemia have been cured by a new immune treatment. What are the science facts behind these news? A group of scientists from University of Pennsylvania, Philadelphia, have managed to develop a new kind of therapy using modified immune cells - an immunotherapy. They created genetically engineered T lymphocytes that express the so-called chimeric antigen receptors (CAR). Cells carrying CAR aimed at an specific target - the CD19 molecule - and modelled as so they receive the appropriate input from other immune cells have shown the ability to localize in the bone marrow and multiply to a huge proportion (over 1000 times). Each gene-modified cell was calculated to eradicate 1000 or more cancer cells. Three patients were treated with these cells in a pilot phase I study and showed a remarkable recovery. Two patients went into complete remission - there is no detectable cancer in their blood or bone marrow. Time will say if they are really cured or if the disease will grow again after the "killer" cells fade away. This new kind of immunotherapy carries a promise of becoming a cornerstone in the treatment of cancer. Read the complete paper in Science Translational Medicine: &lt;a target='_blank' href='http://bit.ly/r6w9EY'&gt;http://bit.ly/r6w9EY&lt;/a&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8981900284205237295/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/novel-immunotherapy-has-potent.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8981900284205237295'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8981900284205237295'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/novel-immunotherapy-has-potent.html' title='Novel immunotherapy has potent antitumor effect'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1183516072008453170</id><published>2011-08-15T11:32:00.001-03:00</published><updated>2011-09-18T12:18:10.468-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Glutamine will not save you from mucositis</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Glutamine solutions are often used for mucositis prevention in patients after stem-cell transplantation. A novel study has shown, however, that glutamine enriched parenteral nutrition did not affect mucosal morbidity or complicatiuons in kids that had undergone allogeneic hematopoietic stem-cell transplantation (HSCT) for malignant hematological diseases. The italian study, held in Monza, randomly assigned patients after HSCT to receive parenteral nutrition with or without glutamine supplementation. The outcome was measured accordingly to WHO standards and analyses followed intention-to-treat. Mucositis, a highly prevalent complication after HSCT, occurred in over 90% of patients, irrespective if they received or not glutamine. The study was published recently in Transplantation: &lt;a href='http://bit.ly/obz5x9' target='_blank'&gt;http://bit.ly/obz5x9&lt;/a&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1183516072008453170/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/glutamine-will-not-save-you-from.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1183516072008453170'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1183516072008453170'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/glutamine-will-not-save-you-from.html' title='Glutamine will not save you from mucositis'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-872567013934911749</id><published>2011-08-05T19:34:00.001-03:00</published><updated>2011-09-18T12:29:09.793-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='antiangiogênico'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://www.blogger.com/atom/ns#' term='propranolol'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='publicações'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='hemangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Propranolol é eficaz e seguro para hemangiomas - provado por novo estudo</title><content type='html'>O mais novo estudo sobre o uso de propranolol para o tratamento de hemangiomas infantis foi publicado online no portal do jornal Pediatrics, da American Academy of Pediatrics. Marcia Hogelling, Susan Adams e Orli Wargon, do Sydney Children's Hospital na Australia, trataram 40 crianças entre 9 semanas e 5 anos de idade, com hemangiomas faciais ou em outros locais desfigurantes. Os pacientes foram aleatoriamente divididos em 2 grupos, um recebeu propranolol 2 mg/kg/dia em 3 doses e o outro recebeu placebo. As avaliações foram feitas por profissionais que desconheciam o tratamento que o paciente fazia e os responsáveis dos pacientes também não sabiam a que grupo seus filhos pertenciam. Os resultados mostraram inequivocamente que o propranolol é altamente eficaz para o tratamento de hemangiomas infantis, além de seguro (nenhum paciente teve que interromper o tratamento por efeitos colaterais). Além de ser o primeiro estudo duplo cego randomizado sobre o uso de propranolol em crianças com hemangiomas, é também o primeiro estudo dessa natureza jamais feito em crianças com esta doença. O fármaco antes usado como primeira escolha para o tratamento de hemangiomas infantis - a prednisona - nunca foi alvo de um estudo destes, o mais próximo foi um estudo randomizado comparando corticóides orais e endovenosos, sem controle não tratado. O cegamento, nestas circunstâncias, é muito prejudicado. Nenhum outro estudo com crianças com hemangioma foi duplo cego. Apesar do estudo ter limitações que os próprios autores apontam, torna-se automaticamente a melhor evidência científica sobre o assunto. O tratamento dos hemangiomas infantis com propranolol pode ser amplamente adotado como primeira escolha. Leia o artigo aqui: &lt;a href="http://bit.ly/nGqhHu"&gt;http://bit.ly/nGqhHu&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/872567013934911749/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/08/propranolol-e-eficaz-e-seguro-para.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/872567013934911749'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/872567013934911749'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/08/propranolol-e-eficaz-e-seguro-para.html' title='Propranolol é eficaz e seguro para hemangiomas - provado por novo estudo'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1363058658070920730</id><published>2011-07-31T10:50:00.001-03:00</published><updated>2011-09-18T12:18:10.474-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Dor crônica em pacientes com câncer</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt;Revisão sobre dor oncológica publicada agora no Lancet:&lt;br/&gt;&lt;br/&gt;O manejo adequado da dor&lt;/span&gt; &lt;span class='hps'&gt;em pacientes com câncer&lt;/span&gt; &lt;span class='hps'&gt;produz&lt;/span&gt; &lt;span class='hps'&gt;alívio satisfatório&lt;/span&gt; &lt;span class='hps'&gt;para a maioria.&lt;/span&gt; &lt;span class='hps'&gt;No entanto&lt;/span&gt;&lt;span class=''&gt;, estima-se&lt;/span&gt; &lt;span class='hps'&gt;que 43% dos&lt;/span&gt; &lt;span class='hps'&gt;pacientes com câncer&lt;/span&gt; &lt;span class='hps'&gt;recebe&lt;/span&gt; &lt;span class='hps'&gt;cuidados inadequados&lt;/span&gt; &lt;span class='hps'&gt;para a sua dor&lt;/span&gt;&lt;span class=''&gt;.&lt;/span&gt; &lt;span class='hps'&gt;A base do tratamento&lt;/span&gt; &lt;span class='hps'&gt;na terapia&lt;/span&gt; &lt;span class='hps'&gt;farmacológica da dor oncológica são os&lt;/span&gt; &lt;span class='hps'&gt;opiáceos e&lt;/span&gt; &lt;span class='hps'&gt;todos os médicos&lt;/span&gt; &lt;span class='hps'&gt;devem tentar&lt;/span&gt; &lt;span class='hps'&gt;otimizar&lt;/span&gt; &lt;span class='hps'&gt;os resultados positivos&lt;/span&gt; &lt;span class='hps'&gt;dessas drogas, &lt;/span&gt;&lt;span class='hps'&gt;minimizando os riscos&lt;/span&gt;&lt;span class=''&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Quando&lt;/span&gt; &lt;span class='hps'&gt;a terapêutica opióide&lt;/span&gt; &lt;span class='hps'&gt;não é suficiente&lt;/span&gt;&lt;span class=''&gt;, a adição de&lt;/span&gt; &lt;span class='hps'&gt;um AINE&lt;/span&gt; &lt;span class='hps'&gt;no tratamento&lt;/span&gt; &lt;span class='hps'&gt;com opióides&lt;/span&gt; &lt;span class='hps'&gt;pode ser útil&lt;/span&gt;&lt;span class=''&gt;, especialmente em algumas&lt;/span&gt; &lt;span class='hps'&gt;situações dolorosas&lt;/span&gt;&lt;span class=''&gt;, mas o risco&lt;/span&gt; &lt;span class='hps'&gt;gastrointestinal,&lt;/span&gt; &lt;span class='hps'&gt;cardiovascular&lt;/span&gt; &lt;span class='hps'&gt;e&lt;/span&gt; &lt;span class='hps'&gt;renal&lt;/span&gt; &lt;span class='hps'&gt;destes fármacos&lt;/span&gt; &lt;span class='hps'&gt;devem ser pesados&lt;/span&gt; &lt;span class='hps'&gt;​​contra os benefícios&lt;/span&gt; &lt;span class='hps'&gt;em cada caso.&lt;/span&gt; &lt;span class='hps'&gt;Outros medicamentos, como&lt;/span&gt; &lt;span class='hps'&gt;corticosteróides&lt;/span&gt;&lt;span class=''&gt;, antidepressivos e&lt;/span&gt; &lt;span class='hps'&gt;anticonvulsivantes,&lt;/span&gt; &lt;span class='hps'&gt;também podem ser úteis&lt;/span&gt;&lt;span class=''&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Os tratamentos não medicamentosos&lt;/span&gt; &lt;span class='hps'&gt;também podem ser usados&lt;/span&gt; &lt;span class='hps'&gt;​​para melhorar&lt;/span&gt; &lt;span class='hps'&gt;o controle da dor&lt;/span&gt;&lt;span class=''&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Os benefícios da integração&lt;/span&gt; &lt;span class='hps'&gt;dos cuidados paliativos&lt;/span&gt; &lt;span class='hps'&gt;no tratamento da&lt;/span&gt; &lt;span class='hps'&gt;dor oncológica&lt;/span&gt; &lt;span class='hps'&gt;são aplicados&lt;/span&gt; &lt;span class='hps'&gt;durante todo o curso&lt;/span&gt; &lt;span class='hps'&gt;da doença e&lt;/span&gt; &lt;span class='hps'&gt;incluem intervenções&lt;/span&gt; &lt;span class='hps'&gt;para manter a&lt;/span&gt; &lt;span class='hps'&gt;qualidade de vida,&lt;/span&gt; &lt;span class='hps'&gt;aliviar o sofrimento&lt;/span&gt; &lt;span class='hps'&gt;e melhorar&lt;/span&gt; &lt;span class='hps'&gt;a sobrevivência&lt;/span&gt; &lt;span class='hps'&gt;e adaptação.&lt;br/&gt;&lt;br/&gt;Leia a revisão na Lancet: &lt;a href='http://bit.ly/nTk3Wo' target='_blank'&gt;http://bit.ly/nTk3Wo&lt;/a&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1363058658070920730/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/dor-cronica-em-pacientes-com-cancer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1363058658070920730'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1363058658070920730'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/dor-cronica-em-pacientes-com-cancer.html' title='Dor crônica em pacientes com câncer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1945240507647689772</id><published>2011-07-31T10:45:00.001-03:00</published><updated>2011-09-18T12:18:10.483-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Papel de células tronco gliais na angiogênese tumoral</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt;Muitas&lt;/span&gt; &lt;span class='hps'&gt;evidências&lt;/span&gt; apoiam &lt;span class='hps'&gt;a hipótese de que&lt;/span&gt; &lt;span class='hps'&gt;células-tronco&lt;/span&gt; &lt;span class='hps'&gt;gliais&lt;/span&gt; &lt;span class='hps'&gt;estão intimamente relacionadas&lt;/span&gt; &lt;span class='hps'&gt;com o início da&lt;/span&gt; &lt;span class='hps'&gt;angiogênese&lt;/span&gt;&lt;span class=''&gt;, o fenômeno da&lt;/span&gt; &lt;span class='hps'&gt;hipóxia&lt;/span&gt; &lt;span class='hps'&gt;e da rede&lt;/span&gt; &lt;span class='hps'&gt;microvascular&lt;/span&gt; &lt;span class='hps'&gt;intratumoral&lt;/span&gt; &lt;span class='hps'&gt;neoplásicas.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Este trabalho&lt;/span&gt;&lt;span class=''&gt;, publicado na &lt;/span&gt;Revista de Neurología&lt;span class='hps'/&gt;&lt;span class=''&gt;, analisou&lt;/span&gt; &lt;span class='hps'&gt;o papel das células&lt;/span&gt;&lt;span class=''&gt;-tronco&lt;/span&gt; &lt;span class='hps'&gt;gliais&lt;/span&gt; &lt;span class='hps'&gt;em relação ao&lt;/span&gt; &lt;span class='hps'&gt;processo de angiogênese&lt;/span&gt;&lt;span class=''&gt;, bem como&lt;/span&gt; &lt;span class='hps'&gt;alguns resultados&lt;/span&gt; &lt;span class='hps'&gt;que se relacionam com&lt;/span&gt; &lt;span class='hps'&gt;o aparecimento&lt;/span&gt; &lt;span class='hps'&gt;dessas células&lt;/span&gt; &lt;span class='hps'&gt;durante a&lt;/span&gt; &lt;span class='hps'&gt;angiogênese em&lt;/span&gt; &lt;span class='hps'&gt;modelo de&lt;/span&gt; &lt;span class='hps'&gt;glioma&lt;/span&gt; &lt;span class='hps'/&gt; &lt;span class='hps'&gt;experimental&lt;/span&gt; em &lt;span class='hps'&gt;rato.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;As células&lt;/span&gt; &lt;span class='hps'&gt;foram caracterizadas&lt;/span&gt; &lt;span class='hps'&gt;através de anticorpos&lt;/span&gt; &lt;span class='hps'&gt;contra os antígenos&lt;/span&gt; &lt;span class='hps'&gt;CD133&lt;/span&gt;&lt;span class=''&gt;,&lt;/span&gt; &lt;span class='hps'&gt;nestina&lt;/span&gt; &lt;span class='hps'&gt;e fator de crescimento&lt;/span&gt; &lt;span class='hps atn'&gt;endotelial (&lt;/span&gt;&lt;span class=''&gt;VEGF)&lt;/span&gt;&lt;span class=''&gt;.&lt;/span&gt; &lt;span class='hps'&gt;Células&lt;/span&gt; &lt;span class='hps'&gt;nestina&lt;/span&gt; (&lt;span class='hps'&gt;+)&lt;/span&gt; &lt;span class='hps'&gt;foram encontradas em&lt;/span&gt; &lt;span class='hps'&gt;todas as fases&lt;/span&gt; &lt;span class='hps'&gt;do desenvolvimento do tumor&lt;/span&gt;&lt;span class=''&gt;, enquanto&lt;/span&gt; &lt;span class='hps'&gt;CD133&lt;/span&gt; &lt;span class='hps'&gt;(+)&lt;/span&gt; &lt;span class='hps'&gt;estavam presentes&lt;/span&gt; &lt;span class='hps'&gt;apenas nos&lt;/span&gt; &lt;span class='hps'&gt;estados intermediários&lt;/span&gt; &lt;span class='hps'&gt;correspondentes à&lt;/span&gt; &lt;span class='hps'&gt;superexpressão de&lt;/span&gt; &lt;span class='hps'&gt;VEGF.&lt;/span&gt; &lt;span class='hps'&gt;Este momento&lt;/span&gt; &lt;span class='hps atn'&gt;é conhecido como "&lt;/span&gt;&lt;span class=''&gt;ativação&lt;/span&gt; &lt;span class='hps'&gt;da angiogênese&lt;/span&gt; &lt;span class='hps atn'/&gt;&lt;/span&gt;&lt;big&gt;&lt;big&gt;&lt;span style='font-family: Arial; line-height: 150%; font-size: 9pt'&gt;&lt;em/&gt;&lt;/span&gt;&lt;/big&gt;&lt;/big&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt;(&lt;i&gt;angiogenic switch&lt;/i&gt;)&lt;/span&gt;&lt;span class=''&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Algumas das células&lt;/span&gt; &lt;span class='hps'&gt;CD133&lt;/span&gt; (&lt;span class='hps'&gt;+)&lt;/span&gt; &lt;span class='hps'&gt;co-expressaram&lt;/span&gt; &lt;span class='hps'&gt;nestina&lt;/span&gt;&lt;span class='hps'&gt;.&lt;/span&gt; &lt;span class='hps'&gt;Células-tronco&lt;/span&gt; &lt;span class='hps'&gt;gliais&lt;/span&gt; &lt;span class='hps'&gt;neste&lt;/span&gt; &lt;span class='hps'&gt;modelo de&lt;/span&gt; &lt;span class='hps'&gt;glioma&lt;/span&gt; &lt;span class='hps'&gt;experimental&lt;/span&gt;&lt;span class=''&gt;, mimetrizando o&lt;/span&gt; &lt;span class='hps'&gt;glioblastoma multiforme&lt;/span&gt; &lt;span class='hps'&gt;humano,&lt;/span&gt; &lt;span class='hps'&gt;formam&lt;/span&gt; &lt;span class='hps'&gt;nichos em&lt;/span&gt; &lt;span class='hps'&gt;áreas&lt;/span&gt; &lt;span class='hps'&gt;hipóxicas e&lt;/span&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt; perivasculares&lt;/span&gt;&lt;span class=''/&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'/&gt; &lt;span class='hps'&gt;intratumorais&lt;/span&gt;&lt;span class=''&gt;.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt; &lt;span class='hps atn'&gt;Link: &lt;a href='http://bit.ly/qisCmh' target='_blank'&gt;http://bit.ly/qisCmh&lt;/a&gt;&lt;/span&gt;&lt;span class='hps'/&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1945240507647689772/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/papel-de-celulas-tronco-gliais-na.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1945240507647689772'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1945240507647689772'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/papel-de-celulas-tronco-gliais-na.html' title='Papel de células tronco gliais na angiogênese tumoral'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7522227186699764205</id><published>2011-07-31T10:38:00.001-03:00</published><updated>2011-09-18T12:32:17.758-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='temozolomide'/><category scheme='http://www.blogger.com/atom/ns#' term='temozolamida'/><title type='text'>Temozolomida melhora estado funcional de idosos com glioblastoma</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt;Temozolomida&lt;/span&gt; &lt;span class='hps'&gt;melhora a sobrevida&lt;/span&gt; &lt;span class='hps'&gt;e melhora a função&lt;/span&gt; &lt;span class='hps'&gt;e qualidade de vida&lt;/span&gt; &lt;span class='hps'&gt;em pacientes idosos com&lt;/span&gt; &lt;span class='hps'&gt;glioblastoma multiforme &lt;/span&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt;(GBM) &lt;/span&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps'&gt;recentemente diagnosticado&lt;/span&gt;&lt;span class='hps'/&gt;&lt;span&gt;, de acordo com&lt;/span&gt; &lt;span class='hps'&gt;resultados obtidos em&lt;/span&gt;&lt;span class='hps'&gt; um ensaio fase II&lt;/span&gt; &lt;span class='hps'&gt;publicado no&lt;/span&gt; &lt;span class='hps'&gt;Journal of&lt;/span&gt; &lt;span class='hps'&gt;Clinical Oncology.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Um&lt;/span&gt; &lt;span class='hps'&gt;terço dos pacientes&lt;/span&gt; &lt;span class='hps'&gt;no estudo&lt;/span&gt; &lt;span class='hps'&gt;experimentaram melhorias&lt;/span&gt; &lt;span class='hps'&gt;no status&lt;/span&gt; &lt;span class='hps'&gt;funcional e&lt;/span&gt; &lt;span class='hps'&gt;um quarto&lt;/span&gt; &lt;span class='hps'&gt;deles&lt;/span&gt; tinham capacidade de cuidar de si mesmos&lt;span class='hps'/&gt; &lt;span class='hps'&gt;após o tratamento com&lt;/span&gt; &lt;span class='hps'&gt;temozolomida&lt;/span&gt;&lt;span&gt;, se&lt;/span&gt; &lt;span class='hps'&gt;administrada&lt;/span&gt; &lt;span class='hps'&gt;antes que eles mostrassem &lt;/span&gt;&lt;span class='hps'&gt;progressão da doença&lt;/span&gt;&lt;span&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps'&gt;Os pesquisadores recrutaram&lt;/span&gt; &lt;span class='hps'&gt;70 pacientes&lt;/span&gt; &lt;span class='hps'&gt;com idade acima de&lt;/span&gt; &lt;span class='hps'&gt;70 anos que&lt;/span&gt; &lt;span class='hps'&gt;foram&lt;/span&gt; &lt;span class='hps'&gt;diagnosticados com&lt;/span&gt; &lt;span class='hps'&gt;GBM.&lt;/span&gt; &lt;span class='hps'&gt;Cada um recebeu&lt;/span&gt; &lt;span class='hps'&gt;150-200&lt;/span&gt; &lt;span class='hps'&gt;temozolomida&lt;/span&gt; &lt;span class='hps'&gt;mg/m2/dia&lt;/span&gt; &lt;span class='hps'&gt;por cinco dias&lt;/span&gt; &lt;span class='hps'&gt;a cada quatro semanas&lt;/span&gt; &lt;span class='hps'&gt;até progressão da doença&lt;/span&gt;&lt;span&gt;.&lt;/span&gt; &lt;span class='hps'&gt;Treze por cento dos&lt;/span&gt; &lt;span class='hps'&gt;pacientes desenvolveram&lt;/span&gt; &lt;span class='hps'&gt;neutropenia&lt;/span&gt; &lt;span class='hps'&gt;grau&lt;/span&gt; &lt;span class='hps'&gt;3 ou 4,&lt;/span&gt; &lt;span class='hps'&gt;enquanto 14&lt;/span&gt;&lt;span&gt;% desenvolveram&lt;/span&gt; &lt;span class='hps'&gt;trombocitopenia&lt;/span&gt; &lt;span class='hps'&gt;de&lt;/span&gt; &lt;span class='hps'&gt;grau 3 ou 4&lt;/span&gt;&lt;span&gt;.&lt;/span&gt; &lt;span class='hps'&gt;A sobrevida&lt;/span&gt; &lt;span class='hps'&gt;livre de progressão&lt;/span&gt; &lt;span class='hps'&gt;mediana foi de&lt;/span&gt; &lt;span class='hps'&gt;16 semanas&lt;/span&gt; &lt;span class='hps'&gt;e a sobrevida global&lt;/span&gt; &lt;span class='hps'&gt;mediana foi de 25&lt;/span&gt; &lt;span class='hps'&gt;semanas.&lt;br/&gt;&lt;br/&gt;Link para o trabalho: &lt;a href='http://bit.ly/qgx9t7' target='_blank'&gt;http://bit.ly/qgx9t7&lt;/a&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7522227186699764205/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/temozolomida-melhora-estado-funcional.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7522227186699764205'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7522227186699764205'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/temozolomida-melhora-estado-funcional.html' title='Temozolomida melhora estado funcional de idosos com glioblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3341072658133049630</id><published>2011-07-23T14:18:00.002-03:00</published><updated>2011-07-25T10:44:19.574-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='vaccine'/><category scheme='http://www.blogger.com/atom/ns#' term='vacina'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Vaccine design at atomic level</title><content type='html'>Scientists from Novartis Italy-based facilities have reported in this month on Science Translational Medicine how they have probed an even deeper scale in the design of a new vaccine. Searching for a useful vaccine against meningococcus B, they combined conventional immunogen design, genomics and atomic structural information that led to a novel level of design refinement. Meningococcus is a well-known causal agent to meningitis, a life-threatening infection. Although there exists vaccines for most strains of meningococcus, serotype B (composed of more than 300 strains) has no such vaccine. Although this new vaccine is far from final development stage, this new accomplishment represents a further advance in the general process of vaccine development. In the future, new and safer vaccines may be designed this way. Read more: &lt;a href="http://bit.ly/oNMnbV"&gt;http://bit.ly/oNMnbV&lt;/a&gt; and &lt;a href="http://bit.ly/qPl4Fh"&gt;http://bit.ly/qPl4Fh&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3341072658133049630/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/vaccine-design-at-atomic-level.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3341072658133049630'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3341072658133049630'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/vaccine-design-at-atomic-level.html' title='Vaccine design at atomic level'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3359550266904472896</id><published>2011-07-21T19:01:00.000-03:00</published><updated>2011-09-18T12:18:10.507-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Beta bloqueadores e o tratamento do câncer</title><content type='html'>Recentemente, 2 artigos publicados no Journal of Clinical Oncology (link &lt;a href="http://jco.ascopubs.org/content/early/2011/05/31/JCO.2010.33.5422.full.pdf+html"&gt;1&lt;/a&gt; e &lt;a href="http://jco.ascopubs.org/content/early/2011/05/31/JCO.2010.33.5422.full.pdf+html"&gt;2&lt;/a&gt;) relataram que pacientes com câncer de mama que usam beta bloqueadores (como o propranolol), uma classe de drogas largamente utilizada para tratar hipertensão, têm menos recorrência tumoral e maior sobrevida livre de doença, e também que pacientes usando estas drogas apresentam um risco menor de desenvolver câncer de mama avançado. Estes estudos vêm se somar a evidências pré-clínicas e um &lt;a href="http://www.em-consulte.com/article/107116"&gt;estudo&lt;/a&gt; anterior que havia demonstrado um possível efeito protetor dos betabloqueadores contra câncer de qualquer tipo. Enquanto uma nova onda de euforia ligada aos beta bloqueadores vai se formando (desde o advento do tratamento dos hemangiomas com propranolol), especialistas advertem contra o uso destas drogas antes que ensaios clínicos bem controlados demonstrem seu papel no tratamento anticâncer. O Dr. Des Powe, do Queen's Medical Centre publicou um outro &lt;a href="http://www.google.com.br/url?sa=t&amp;source=web&amp;cd=6&amp;ved=0CEkQFjAF&amp;url=http%3A%2F%2Fimpactjournals.com%2Foncotarget%2Findex.php%3Fjournal%3Doncotarget%26page%3Darticle%26op%3Ddownload%26path%255B%255D%3D197%26path%255B%255D%3D278&amp;rct=j&amp;q=Beta-Blocker%20%20Breast%20Cancer%20des%20powe&amp;ei=gp0oTr_UHonL0QGjteXKCg&amp;usg=AFQjCNFhn5cW9DvPo2F5fG5_uzyjsC1qRg&amp;sig2=W5vS2v1XGF3FyuxmNvUnGg&amp;cad=rja"&gt;estudo&lt;/a&gt; no jornal Oncotarget, onde relata uma redução de 71% da mortalidade em pacientes com câncer de mama usando beta bloqueadores. Ele diz que "está encorajado por estes resultados iniciais, os quais demonstraram que, usando uma droga bem estabelecida, segura e barata, poderemos conseguir um avanço na terapia alvo contra o câncer de mama."&lt;br /&gt;Veja um vídeo sobre o assunto:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;iframe width="425" height="344" src="http://www.youtube.com/embed/YrEq99p5HQ0?fs=1" frameborder="0" allowFullScreen=""&gt;&lt;/iframe&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3359550266904472896/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/beta-bloqueadores-e-o-tratamento-do.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3359550266904472896'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3359550266904472896'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/beta-bloqueadores-e-o-tratamento-do.html' title='Beta bloqueadores e o tratamento do câncer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='https://img.youtube.com/vi/YrEq99p5HQ0/default.jpg' height='72' width='72'/><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4334643547935963593</id><published>2011-07-18T20:17:00.000-03:00</published><updated>2011-09-18T12:58:11.704-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>The Running Mice</title><content type='html'>Researchers of the University of Pennsylvania and his colleagues genetically engineered mice to lack the IL-15Rα gene, and the modified mice ran six times farther than normal mice each night. Previous studies had suggested that IL-15Rα is important for muscle strength. The genetically-modified mice seemed to lack fast-twitch muscles - muscles that allow more precise movements but tire faster - and to have only slow-twitch muscles - which have more endurance but do not allow fine movements. This could explain why the mice did not tire, but the cause of their behavioral changing was not clear. Why they wanted to run for hours every night? The scientists argue that human resistance to fatigue could be affected by this same gene and that this could be a possible target for human diseases. &lt;br /&gt;Read more:&lt;br /&gt;&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/07/missing-gene-helps-mice-run-for-.html?etoc&amp;amp;elq=d1aa823112d748e6ac44fc9895fe656c#.TiS8NXmauEs.blogger"&gt;Missing Gene Helps Mice Run for Hours - ScienceNOW&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4334643547935963593/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/running-mice.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4334643547935963593'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4334643547935963593'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/running-mice.html' title='The Running Mice'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2660268222167885996</id><published>2011-07-17T22:18:00.008-03:00</published><updated>2011-09-18T12:29:09.570-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='imunoterapia'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>First effective immunotherapy for high-risk neuroblastoma</title><content type='html'>A team led by San Diego medical researcher Alice Yu published in New England Journal of Medicine their break-through results of the first ever immunotherapy proved to be effective for high-risk neuroblastoma patients. This new treatment was first announced in the 2009 edition of ASCO meeting (see previous &lt;a href="http://pharmak.blogspot.com/2009/05/asco-2009-immunotherapy-prolongs.html"&gt;post&lt;/a&gt;). Children with this disease normally have a grim prognosis. Yu's group treated children after standard high-dose chemotherapy and stem cell rescue with a monoclonal antibody against a surface molecule commonly found in neuroblastomas - the disialoganglioside GD2. Anti-GD2 therapy along with isotretinoin and IL-2 boosted patients' disease-free survival by 20% (44 to 64% 2 years after diagnosis). This result is superior to conventional treatment. The only drawback was the high amount of toxicity in immunotherapy-treated patients. Read the article &lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMoa0911123"&gt;here&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2660268222167885996/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/first-effective-immunotherapy-for-high.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2660268222167885996'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2660268222167885996'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/first-effective-immunotherapy-for-high.html' title='First effective immunotherapy for high-risk neuroblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3106969107041088217</id><published>2011-07-17T21:10:00.005-03:00</published><updated>2011-09-18T12:29:09.601-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Intermediate-risk neuroblastoma has good prognosis</title><content type='html'>Neuroblastoma, a tumor that affects mostly young children and has a very high mortality rate when advanced, has been shown in a study published in 2010 that can have good prognosis with reduced chemotherapy. The study, announced for the first time in 2007 (see this previous &lt;a href="http://pharmak.blogspot.com/2007/06/less-aggressive-approach-to.html"&gt;post&lt;/a&gt;) was led by a team from Perth, Australia and endorsed by Childrens Oncology Group. They used the COG risk stratification system that uses clinical and tumor biological data to assign children to one of 3 risk groups: low, intermediate and high. Only intermediate-risk patients were included in this study. Results have shown that a short, reduced chemotherapy made up of 4 or 8 cycles and lower doses than previous treatment regimens yielded high survival rates. This regimen reduced toxicity as well, while maintaining a very good result. In this present study, 100% of INSS stage 3 patients achieved prolonged cure. Read the complete article &lt;a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1001527#t=article"&gt;here&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3106969107041088217/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/intermediate-risk-neuroblastoma-has.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3106969107041088217'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3106969107041088217'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/intermediate-risk-neuroblastoma-has.html' title='Intermediate-risk neuroblastoma has good prognosis'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2492162481901784712</id><published>2011-07-17T11:30:00.002-03:00</published><updated>2011-09-18T12:29:09.551-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>High-dose chemotherapy and stem cell transplant for advanced neuroblastoma</title><content type='html'>Results from a french pilot trial testing very high dose chemotherapy followed by autologous transplantation in children with advanced neuroblastoma were not different from previous trials with other approaches. Survival in this group of patients remained between 30-40% in 5 years. New treatments are needed for kids with advanced neuroblastoma.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://onlinelibrary.wiley.com/doi/10.1002/pbc.23232/abstract;jsessionid=6E32893655657F997779091C73FD6B63.d03t04"&gt;A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age - Monnereau-Laborde - 2011 - Pediatric Blood &amp;amp; Cancer - Wiley Online Library&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2492162481901784712/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/dose-intensive-approach-nb96-for.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2492162481901784712'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2492162481901784712'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/dose-intensive-approach-nb96-for.html' title='High-dose chemotherapy and stem cell transplant for advanced neuroblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5516608790117236744</id><published>2011-07-17T10:34:00.002-03:00</published><updated>2011-09-18T12:29:09.700-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Advanced neuroblastoma treated with 131I-MIBG and combined chemotherapy</title><content type='html'>A group from Italy has just published results from a trial using Radio-iodine MIBG to treat kids with advanced neuroblastoma. They report better results with association to chemotherapy. This initial report may yield new clinical trials using this combination to test it's efficacy against this grim disease.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://onlinelibrary.wiley.com/doi/10.1002/pbc.22986/abstract"&gt;Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen - Mastrangelo - 2011 - Pediatric Blood &amp;amp; Cancer - Wiley Online Library&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5516608790117236744/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/treatment-of-advanced-neuroblastoma-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5516608790117236744'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5516608790117236744'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/treatment-of-advanced-neuroblastoma-in.html' title='Advanced neuroblastoma treated with 131I-MIBG and combined chemotherapy'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-829070766454794449</id><published>2011-07-16T11:14:00.001-03:00</published><updated>2011-09-18T12:58:11.731-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>Bacteria Flash Like Christmas Lights - ScienceNOW</title><content type='html'>Cool blinking bacteria allow scientists to discover a whole new electrophysiological phenomenon. Bacteria can depolarize like neurons do, a group of scientists who were studying neurons discovered by chance. See the cool &lt;a href="http://bcove.me/qeax5utv"&gt;video &lt;/a&gt;showing flashing live bacteria in Science web page.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/07/bacteria-flash-like-christmas-li.html?etoc&amp;amp;elq=52108a5f40a14cf38d510055c8687bf9"&gt;Bacteria Flash Like Christmas Lights - ScienceNOW&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/829070766454794449/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/bacteria-flash-like-christmas-lights.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/829070766454794449'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/829070766454794449'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/bacteria-flash-like-christmas-lights.html' title='Bacteria Flash Like Christmas Lights - ScienceNOW'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4458925941838120492</id><published>2011-07-05T19:25:00.000-03:00</published><updated>2011-07-05T19:25:51.093-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision - Attal - 2010 - European Journal of Neurology - Wiley Online Library</title><content type='html'>European Federation of Neurological Societies updated guidelines for the management of neuropathic pain. This second EFNS Task Force aimed at updating the existing evidence about the pharmacological treatment of neuropathic pain since 2005. In its conclusions, it declares that there are still too few large-scale comparative studies, and more studies are needed. For future trials, EFNS recommend to assess comorbidities, quality of life, symptoms and signs with standardized tools and attempt to better define responder profiles to specific drug treatments. Read full article:&lt;br /&gt;&lt;br /&gt;&lt;a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2010.02999.x/full#.ThOOTBgjdjk.blogger"&gt;EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision - Attal - 2010 - European Journal of Neurology - Wiley Online Library&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4458925941838120492/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/efns-guidelines-on-pharmacological.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4458925941838120492'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4458925941838120492'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/efns-guidelines-on-pharmacological.html' title='EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision - Attal - 2010 - European Journal of Neurology - Wiley Online Library'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-9167881319176493710</id><published>2011-07-05T06:45:00.000-03:00</published><updated>2011-09-18T12:58:11.755-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>Magnetic Nanoparticles Fry Tumors - ScienceNOW</title><content type='html'>In a new study, a team from Korea found that injecting mice with tiny magnets and cranking up the heat eliminated tumors from the animals' bodies with no apparent side effects.&lt;br /&gt;&lt;br /&gt;The idea of killing cancer with heat isn't new. Like normal cells, cancer cells start to die when body temperature rises above 43˚C. The trick is figuring out how to kill the cancer without harming the body's own cells. One promising idea, known as magnetic hyperthermia, involves injecting minuscule "nanoparticles," basically microscopic lumps of iron oxide or other compounds, into tumors to make them magnetic. The patient is put into a magnetic field that reverses direction thousands of times every second. This therapy has not been tested in humans yet. The magnetic nanoparticles are excited by the applied field and begin to get hot, heating and potentially destroying the surrounding cancer tissue. Read more:&lt;br /&gt;&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/07/magnetic-nanoparticles-fry-tumor.html?etoc&amp;amp;elq=64522f05567d4d09b52a55620807bb8e#.ThLbVqRLWgU.blogger"&gt;Magnetic Nanoparticles Fry Tumors - ScienceNOW&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/9167881319176493710/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/magnetic-nanoparticles-fry-tumors.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9167881319176493710'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9167881319176493710'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/magnetic-nanoparticles-fry-tumors.html' title='Magnetic Nanoparticles Fry Tumors - ScienceNOW'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-9073868424923183380</id><published>2011-07-02T23:32:00.001-03:00</published><updated>2011-09-18T12:29:09.811-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>New Cochrane meta-analysis sparks controversy about bronchiolitis</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;p id='p-10'&gt;Bronchiolitis is the most common disease of the lower respiratory tract during the first year of life. Respiratory syncytial virus is the underlying cause of most bronchiolitis and this infection is associated with substantial&lt;br /&gt;                                 morbidity in young children. Research has shown its burden in developed and developing countries and a lack of&lt;br /&gt;                                 clear evidence for its therapeutic management, including&lt;br /&gt;                                 the use of different bronchodilators (β&lt;sub&gt;2&lt;/sub&gt; agonists, adrenaline (epinephrine), anticholinergics) and steroids. Several systematic reviews have failed to provide convincing evidence to support any&lt;br /&gt; of these treatments in the acute management of bronchiolitis,&lt;br /&gt;                                 and their routine use is not &lt;br /&gt;recommended by current clinical practice guidelines. Scholars disagree about the use of corticosteroids and common scientific belief is that they are useless and may be even harmful in children with bronchiolitis. Now, a recent meta-analysis published in the British Medical Journal has found evidence that inhaled adrenaline and systemic corticosteroids may indeed have a role in the treatment of bronchiolitis. The study has been criticized by many. One critic say the study is "flawed" and he "read with disappointment the use of a Cochrane review to promote &lt;br /&gt;                                          the use of adrenaline and steroids." Read the &lt;a href='http://www.bmj.com/content/342/bmj.d1714.long' target='_blank'&gt;study&lt;/a&gt; and one of the &lt;a href='http://www.bmj.com/content/342/bmj.d1714.long/reply#bmj_el_257075' target='_blank'&gt;critics&lt;/a&gt;.&lt;br/&gt;&lt;/p&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/9073868424923183380/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/new-cochrane-meta-analysis-sparks.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9073868424923183380'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9073868424923183380'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/new-cochrane-meta-analysis-sparks.html' title='New Cochrane meta-analysis sparks controversy about bronchiolitis'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8020456037714588981</id><published>2011-07-02T11:05:00.000-03:00</published><updated>2011-09-18T12:29:09.765-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='asthma'/><category scheme='http://www.blogger.com/atom/ns#' term='atopia'/><category scheme='http://www.blogger.com/atom/ns#' term='asma'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Burying Anti-leukotrienes</title><content type='html'>A recently published meta-analisys from Cochrane Database has reported that anti-leukotriene drugs fare worse than long-acting beta2-adrenergics when treating adults with inhaled-corticosteroid resistant asthma. Although this report coiós not conclude anything for children, anti-leukotrienes are known to have limited value in pediatric asthma. This result makes an even stronger case for the fail that was the anti-leukotriene therapy, once a hype of Big Pharma. Read the abstract &lt;a href="/http://www.ncbi.nlm.nih.gov/pubmed/21563136"&gt;here&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8020456037714588981/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/burying-anti-leukotrienes.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8020456037714588981'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8020456037714588981'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/burying-anti-leukotrienes.html' title='Burying Anti-leukotrienes'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3891302183122839076</id><published>2011-07-02T08:20:00.017-03:00</published><updated>2011-09-18T12:29:09.626-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='mortalidade'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='hemophagocytic lymphohistiocytosis'/><category scheme='http://www.blogger.com/atom/ns#' term='science'/><category scheme='http://www.blogger.com/atom/ns#' term='imunossupressores'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='publicações'/><category scheme='http://www.blogger.com/atom/ns#' term='macrophage activation syndrome'/><category scheme='http://www.blogger.com/atom/ns#' term='pubmed'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='genetics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>What's new this month for 'macrophage activation syndrome' in PubMed</title><content type='html'>This message contains My NCBI what's new results from the National Center for Biotechnology Information (&lt;a href="http://www.ncbi.nlm.nih.gov/"&gt;NCBI&lt;/a&gt;) at the U.S. National Library of Medicine (&lt;a href="http://www.nlm.nih.gov/"&gt;NLM&lt;/a&gt;).&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Sender's message: &lt;/b&gt;Search: macrophage activation syndrome &lt;br /&gt;Sent on Saturday, 2011 Jul 02&lt;br /&gt;Search &lt;b&gt;macrophage activation syndrome&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;br /&gt;&lt;div&gt;&lt;table bgcolor="#CCCCCC"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td align="center"&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;1.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21670967" ref="ordinalpos=2"&gt;Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Maeshima K,  Ishii K,  Iwakura M,  Akamine M,  Hamasaki H,  Abe I,  Haranaka M,  Tatsukawa H,  Yoshimatsu H.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Modern rheumatology / the Japan Rheumatism Association"&gt;Mod Rheumatol&lt;/span&gt;. 2011 Jun 14. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21670967 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=21670967" ref="ordinalpos=2"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;2.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21647204" ref="ordinalpos=3"&gt;Pathogenesis of systemic juvenile idiopathic arthritis: some answers,  more questions.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Mellins ED,  Macaubas C,  Grom AA;  Medscape.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Nature reviews. Rheumatology"&gt;Nat Rev Rheumatol&lt;/span&gt;. 2011 Jun 7;7(7):416-26. doi: 10.1038/nrrheum.2011.68.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 21647204 [PubMed - in process]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=21647204" ref="ordinalpos=3"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="5"&gt;&lt;tbody&gt; &lt;tr&gt;&lt;td nowrap="nowrap" valign="top" width="10"&gt;3.&lt;/td&gt;&lt;td valign="top"&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/20873991" ref="ordinalpos=4"&gt;Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected.&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;Meehan KR,  Talebian L,  Wu J,  Hill JM,  Szczepiorkowski ZM,  Sentman CL,  Ernstoff MS.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span class="jrnl" title="Cytotherapy"&gt;Cytotherapy&lt;/span&gt;. 2010 Dec;12(8):1013-21. Epub 2010 Sep 27.&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;PMID: 20873991 [PubMed - indexed for MEDLINE]&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="left" valign="top" width="10"&gt;&lt;/td&gt;&lt;td&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=link&amp;amp;linkname=pubmed_pubmed&amp;amp;uid=20873991" ref="ordinalpos=4"&gt;Related citations&lt;/a&gt;   &lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3891302183122839076/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/07/whats-new-this-month-for-macrophage.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3891302183122839076'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3891302183122839076'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/07/whats-new-this-month-for-macrophage.html' title='What&apos;s new this month for &apos;macrophage activation syndrome&apos; in PubMed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6307294068509184770</id><published>2011-06-30T18:33:00.001-03:00</published><updated>2011-07-02T11:17:20.402-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='bevacizumab'/><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='avastin'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Breast Cancer Drug Gets a Unanimous Thumbs Down - ScienceInsider</title><content type='html'>An advisory committee to the U.S. Food and Drug Administration (FDA) sided this afternoon with the agency, agreeing in a unanimous vote, 6-0, that the drug Avastin should not be approved for breast cancer. Although FDA doesn't have to side with its advisory committee, in this case it's likely to do so since it made a similar decision back in December. Agency officials reiterated their case against Avastin yesterday. Read more:&lt;br /&gt;&lt;a href="http://news.sciencemag.org/scienceinsider/2011/06/breast-cancer-drug-gets-a-unanimous.html?etoc&amp;amp;elq=715ec12349e840688712187715b5cb98#.TgzrkaQyj3A.blogger"&gt;Breast Cancer Drug Gets a Unanimous Thumbs Down - ScienceInsider&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6307294068509184770/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/06/breast-cancer-drug-gets-unanimous.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6307294068509184770'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6307294068509184770'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/06/breast-cancer-drug-gets-unanimous.html' title='Breast Cancer Drug Gets a Unanimous Thumbs Down - ScienceInsider'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-9030980797258654769</id><published>2011-06-30T15:34:00.001-03:00</published><updated>2011-09-18T12:58:11.747-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='rapamycin'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='mal-formações'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='genetics'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>New Drug Hope for 'Aging' Kids - ScienceNOW</title><content type='html'>A drug approved to treat cancer and prevent the rejection of transplanted organs may also help children with progeria—a disease that resembles accelerated aging and typically kills those afflicted by their teens—according to a new study. The drug's effects on cells from these children is so striking, and the condition so devastating, that physicians and scientists are debating whether to proceed immediately with a clinical trial. Read more:&lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/06/new-drug-hope-for-aging-kids.html?etoc&amp;amp;elq=bacbbe663ebc4da08c90105348f09002#.TgzBe7dJPiw.blogger"&gt;New Drug Hope for &amp;#39;Aging&amp;#39; Kids - ScienceNOW&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/9030980797258654769/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/06/new-drug-hope-for-aging-kids-sciencenow.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9030980797258654769'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9030980797258654769'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/06/new-drug-hope-for-aging-kids-sciencenow.html' title='New Drug Hope for &apos;Aging&apos; Kids - ScienceNOW'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1210620782940904457</id><published>2011-06-22T18:08:00.003-03:00</published><updated>2011-09-18T12:58:11.695-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='prevenção'/><category scheme='http://www.blogger.com/atom/ns#' term='risco'/><category scheme='http://www.blogger.com/atom/ns#' term='science'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><category scheme='http://www.blogger.com/atom/ns#' term='ambiente'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='ScienceNOW'/><title type='text'>The Mental Hazards of City Living - ScienceNOW</title><content type='html'>&amp;nbsp;Provocative new study says urban life alters the way the brain handles social stress.                      &lt;br /&gt;&amp;nbsp;Psychiatrist Andreas Meyer-Lindenberg and collaborators at the Central  Institute of Mental Health and the University of Heidelberg Medical  Faculty in Mannheim, Germany, have previously used brain-imaging methods  to search for &lt;a href="http://www.sciencemag.org/content/324/5927/605.abstract"&gt;abnormalities in the brains of people with genetic risk factors for mental illness&lt;/a&gt;.  In the new study, Meyer-Lindenberg says, the group wanted to apply the  same approach to environmental risk factors, which can be even more  powerful than genetic factors. "Urbanicity ... has a much higher  associated risk than any gene," he says. "The idea was to take people  with that risk factor and see if there's anything different in their  brains."&lt;br /&gt;Read more: &lt;br /&gt;&lt;a href="http://news.sciencemag.org/sciencenow/2011/06/the-mental-hazards-of-city-livin.html?etoc&amp;amp;elq=f5738d926f4e48d580bbbfd8c59f04da"&gt;The Mental Hazards of City Living - ScienceNOW&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1210620782940904457/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/06/mental-hazards-of-city-living.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1210620782940904457'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1210620782940904457'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/06/mental-hazards-of-city-living.html' title='The Mental Hazards of City Living - ScienceNOW'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8184589956104736468</id><published>2011-06-22T17:13:00.008-03:00</published><updated>2011-09-18T12:29:09.775-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Aulas da Pós-Graduação</title><content type='html'>&lt;p&gt;&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Caros alunos da disciplina de Farmacologia Molecular e Autonômica, turma 2011.1, Programa de Pós-Graduação em Ciências Farmacêuticas, estes são os links dos artigos científicos correspondentes à aula do dia 14/07/2011 (confirmado). Cada link dá acesso a um artigo. Um deles é de revisão e os outros 4 são artigos originais. Dois são sobre farmacogenômica enfocando a oncologia e os outros 3 são sobre o desenvolvimento de terapias-alvo para a oncologia. A ordem dos links corresponde à ordem de apresentação dos trabalhos. Uma breve sinopse acompanha cada link, que é de livre acesso. Uma diretriz geral para a apresentação é informada, mas outros elementos podem ser inseridos à vontade, respeitando-se o tempo de apresentação do seminário.&lt;br /&gt;&lt;br /&gt;1. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrZTRmNjY0MmEtMDk3MS00MmNmLTlkNTYtYzQ1NTExYmFmYTky&amp;amp;hl=pt_BR&amp;amp;authkey=CNbJjfQM" target="_blank"&gt;Yaish, 1988&lt;/a&gt;. Desenvolvimento, pela primeira vez, de inibidores de baixo peso molecular de enzimas com atividade tirosina-cinase. Os autores descrevem as modificações estruturais que realizaram a fim de obter compostos com atividade inibidora do EGFRK (enzima tirosina-cinase associada ao receptor de EGF). Descreva o processo de desenvolvimento destes inibidores, frisando a SAR (relação estrutura-atividade) e a química farmacêutica envolvidas.&lt;br /&gt;2. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrYjg5NDI2NmItN2UxMi00ZDYxLWE3YTAtNDJmYjJmM2Q0MTNj&amp;amp;hl=pt_BR&amp;amp;authkey=CK3RrZ4I" target="_blank"&gt;Buchdunger, 1996&lt;/a&gt;. Os autores descrevem, pela primeira vez, o composto experimental da CIBA, CGP 57148, depois chamado STI 571, depois denominado imatinib, hoje a droga de baixo peso molecular com atividade inibidora de tirosina-cinase de maior sucesso. Descreva a validação deste composto em termos de sua especificidade pela enzima ABLK e atividade antiproliferativa. &lt;br /&gt;3. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrYzk2NjQwMGYtNDc4OS00MmFmLTgyNTktZjBiZGM3ZmM0OTJh&amp;amp;hl=pt_BR&amp;amp;authkey=CJmaxY4L" target="_blank"&gt;Antczak, 2009&lt;/a&gt;. Trabalho original de um grupo importante atuando no Memorial-Sloan Kettering Cancer Center, que desenvolve novos compostos para terapia-alvo. Neste trabalho, eles descrevem a obtenção de compostos com seletividade pela ABLK melhorada. Descreva a SAR e o processo geral da pesquisa. &lt;br /&gt;4. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrMTdkMjY1YzYtM2RlNS00ZDcwLTk5MjEtNjZjOTY4MzhhZmNl&amp;amp;hl=pt_BR&amp;amp;authkey=CJS17pcD" target="_blank"&gt;Evans, 2003&lt;/a&gt;. Revisão sobre farmacogenética e farmacogenômica. Apresentar breve histórico, teoria geral da interação gene-fármaco e dar exemplos da importância deste tópico (polimorfismos genéticos influenciando a farmacocinética, polimorfismos genéticos de alvos). Mostrar as possibilidades do diagnóstico molecular para individualizar a farmacoterapia.&lt;br /&gt;5. &lt;a href="https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0B4DURVFZqBRrNTJhYzIyYzEtM2JjYS00MWJkLWFlNGQtOTVjNjYxMTZhNGZl&amp;amp;hl=pt_BR&amp;amp;authkey=CKLjzYEM" target="_blank"&gt;Trevino, 2009&lt;/a&gt;. Trabalho original do grupo do Saint Jude Children's Research Hospital e centros associados, validando através de farmacogenômica um marcador capaz de prever a resposta de crianças com leucemia linfóide aguda ao metotrexato, incluindo efeitos colaterais e eficácia do tratamento. Descreva a metodologia genômica sucintamente e seus resultados.&lt;br /&gt;&lt;br /&gt;Os seminaristas podem incluir informações de outras fontes a critério. Também estou à disposição para ajudar com material de apoio e tirando dúvidas. Basta entrar em contato pelo e-mail.&lt;br /&gt;&lt;br /&gt;Os slides da aula estão disponíveis &lt;u&gt;&lt;a href="https://docs.google.com/present/edit?id=0AYDURVFZqBRrZHpuNWZyd18yMDdnaGc2NjdmNQ&amp;hl=pt_BR"&gt;aqui&lt;/a&gt;&lt;/u&gt;.&lt;i&gt; &lt;/i&gt;&lt;br /&gt;Complemento: segundo arquivo de slides clique &lt;a href="https://docs.google.com/present/edit?id=0AYDURVFZqBRrZHpuNWZyd18yMzFnaDRqdnZkNg&amp;hl=pt_BR"&gt;aqui&lt;/a&gt;.&lt;br /&gt;&lt;br /&gt;Atenciosamente,&lt;br /&gt;&lt;br /&gt;Helder Felix&lt;br /&gt;Palestrante da aula "Desenvolvimento de Terapias-alvo e Farmacogenômica aplicada à oncologia".&lt;/div&gt;&lt;/p&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8184589956104736468/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/06/aulas-da-pos-graduacao.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8184589956104736468'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8184589956104736468'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/06/aulas-da-pos-graduacao.html' title='Aulas da Pós-Graduação'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6915698438859120438</id><published>2011-05-28T17:31:00.001-03:00</published><updated>2011-09-18T12:22:44.974-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Aula de Câncer em Crianças</title><content type='html'>Nesta quarta, dia 25 de maio, apresentei uma aula no CRIO - Centro Regional Integrado de Oncologia (home: http://www.crio.com.br/) a convite do dr. Igor Moreira Veras e da comissão organizadora do I Ciclo de Palestras do Centro de Estudos do CRIO. O tema foi "Câncer em Crianças". Postarei o &lt;a href="https://docs.google.com/present/edit?id=0AYDURVFZqBRrZHpuNWZyd18xNzdnenFodGRjag&amp;amp;hl=pt_BR&amp;amp;authkey=CLbv0L8I"&gt;link&lt;/a&gt; para download da aula.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6915698438859120438/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/05/aula-de-cancer-em-criancas.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6915698438859120438'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6915698438859120438'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/05/aula-de-cancer-em-criancas.html' title='Aula de Câncer em Crianças'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7219899890950823690</id><published>2011-04-23T16:26:00.001-03:00</published><updated>2011-09-18T12:29:09.733-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>News in pediatric oncology - new treatment for relapsed ALL and more</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;In the few past months important new discoveries from clinical trials in pediatric hemato-oncology were published. We list some of the most outstanding:&lt;br/&gt;1. Mitoxantrone for relapsed ALL - UK Children's Cancer Group reported in Lancet last December that children with relapsed ALL (a disease with poor prognosis, in contrast with primary ALL which is highly curable) benefited from treatment with the drug mitoxantrone, when compared with the standard therapy with idarubicin. Survival in children with relapsed ALL was 69% (overall) and 65% (progression-free), whereas the standard treatment yielded 36-45% survival. Link &lt;a href='http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T1B-51M9XV6-3&amp;amp;_user=686348&amp;amp;_coverDate=12%2F17%2F2010&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=gateway&amp;amp;_origin=gateway&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_acct=C000037259&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=686348&amp;amp;md5=a210cdecbd57ba38da5b9b74e1eca057&amp;amp;searchtype=a' target='_blank'&gt;here&lt;/a&gt;.&lt;br/&gt;2. Second-look surgery for RMS - Children's Oncology Group reported last November in the Journal of Pediatric Surgery that children with rhabdomyosarcoma may benefit from second-look surgical procedures in order to check local control rates. Image-proven complete remissions were reliable in this study, but 41% of patients with residual disease by image had no viable tumor in second-look procedure. Patients with no viable disease had a better failure-free survival in this study. Link &lt;a href='http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6WKP-51BB05T-B&amp;amp;_user=686348&amp;amp;_coverDate=11%2F30%2F2010&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=gateway&amp;amp;_origin=gateway&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_acct=C000037259&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=686348&amp;amp;md5=ebd2a5b2e68465cbe53a845173afbc27&amp;amp;searchtype=a' target='_blank'&gt;here&lt;/a&gt;.&lt;br/&gt;3. Beta-2 adrenergic receptor and ALL - French researchers reported this December that genetic polymorphisms in the promoter region of the gene encoding the beta-2 adrenergic receptor reliably correlate with relapse and response rate to methotrexate. The beta-2 adrenoceptor, mostly known by its involvement in smooth muscle contraction, is part of a proapoptotic signaling pathway, and thus its expression by cancer can possibly influence drug resistance. Link &lt;a target='_blank' href='http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010035/?tool=pubmed'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;br/&gt;&lt;img style='max-width: 800px;' src='http://lh6.ggpht.com/_ltzeFnIlO7Q/TbMb6OMSqPI/AAAAAAAABoU/T6TWwsrAQ-w/%5BUNSET%5D.jpg?imgmax=800'/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7219899890950823690/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/04/news-in-pediatric-oncology-new_23.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7219899890950823690'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7219899890950823690'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/04/news-in-pediatric-oncology-new_23.html' title='News in pediatric oncology - new treatment for relapsed ALL and more'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://lh6.ggpht.com/_ltzeFnIlO7Q/TbMb6OMSqPI/AAAAAAAABoU/T6TWwsrAQ-w/s72-c/%5BUNSET%5D.jpg?imgmax=800' height='72' width='72'/><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3589137692478612293</id><published>2011-04-14T21:36:00.000-03:00</published><updated>2011-07-02T11:38:05.896-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='genetics'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>The inheritance of alzheimer</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='en' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;People&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;with&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a maternal history of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Alzheimer's disease&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of late onset&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;are twice as&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;likely&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;to&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;suffer&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;reduction in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;gray&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;matter volume&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;vulnerable areas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of the brain, compared to those who &lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;have a father with&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;disease&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;or&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;those without&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;family history&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Using&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;voxel&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;morphometry&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;techniques&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;authors of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;an article&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;published&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in the journal&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Neurology&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;, have&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;found&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;different&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;brain regions&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of individuals&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;with&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;paternal and maternal&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;history&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Alzheimer's disease&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;The results&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;show that&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;people&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;with&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a maternal history of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;disease&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt; have differences&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;specific&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;areas of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;brain&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;that&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;are&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;also&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;affected&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;by&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Alzheimer's disease&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;are not&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;affected&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in individuals&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;with&lt;/span&gt; paternal &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;history&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Specifically&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;it&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;was noted&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;that&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cognitively&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;healthy&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;people&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;but&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;with&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a mother with&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Alzheimer's disease,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;showed&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;increased&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;atrophy&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;gray matter&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;around&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;brain&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cerebrospinal&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;fluid expansion&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;These&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;subjects&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;also&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;had&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;significantly&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;greater&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;atrophy&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;precuneus&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;parahippocampal&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;hippocampal&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;regions&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;compared&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;with&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;those&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;with&lt;/span&gt; paternal &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;history&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of disease&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;or&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;family history&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, regardless&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;presence&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;APOE4&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;marital status&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sex&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;age&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;.&lt;br/&gt;&lt;br/&gt;Read more &lt;a href='http://www.neurology.org/content/76/9/822.abstract' target='_blank'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3589137692478612293/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/04/inheritance-of-alzheimer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3589137692478612293'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3589137692478612293'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/04/inheritance-of-alzheimer.html' title='The inheritance of alzheimer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8433706375583344850</id><published>2011-03-26T10:00:00.000-03:00</published><updated>2011-07-02T11:14:54.847-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><title type='text'>How targeted cancer therapies work: a video from AAAS</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Science Magazine has produced a video that is available from its &lt;a href='http://video.sciencemag.org/SciOriginals/850053254001/1' target='_blank'&gt;Video Portal&lt;/a&gt;.&lt;br /&gt; In this video, renowned  medical researchers explain how targeted &lt;br /&gt;cancer therapies may develop into better treatments in the future and &lt;br /&gt;how molecular knowledge has changed the way we understand and treat &lt;br /&gt;cancer.&lt;br/&gt;&lt;br/&gt;&lt;img src='http://www.sciencemag.org/content/331/6024/F1.medium.gif' style='max-width: 800px;'/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8433706375583344850/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/03/how-targeted-cancer-therapies-work.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8433706375583344850'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8433706375583344850'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/03/how-targeted-cancer-therapies-work.html' title='How targeted cancer therapies work: a video from AAAS'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3464657125233050335</id><published>2011-02-26T23:31:00.002-03:00</published><updated>2011-09-18T12:29:09.609-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='radiation'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='CT scans'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>CT scans and the risk of cancer - hunt the haunt</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;A recent &lt;a href="http://www.sciencemag.org/content/331/6020/1002.full" target="_blank"&gt;article&lt;/a&gt; published in Science Magazine has discussed recent concerns that CT scans radiation exposure could lead to cancer. The work of biophysicist David Brenner (Columbia University's Center for Radiological Research Director) has sparked controversy in the field. In a 2001 paper, he tried to weight the risks of radiation exposure in CT scans and found that children that received radiation from a single CT scan had an estimated 1 in 1000 risk of developing a fatal cancer in the future. Although this seems little, given that an average 600,000 abdominal and head CT scans were performed yearly on children by the time of this publication, the predicted number of cancer fatalities possibly linked to CT radiation exposure could reach 500 a year. This conclusion was headlines in all USA and raised angered reactions of many medical physicists and radiologists. One of the main criticisms was that Brenner used Hiroshima bombing data to gauge exposure-risk relation of radiation. However, Brenner said that he used only the data from the bombing survivals that were far enough from the impact point to have received 5-100 millisieverts of radiation, equivalent to 1-2 CT scans. The concerns became stronger after a 2009 report from the National Council on Radiation&lt;br /&gt;Protection and Measurements has issued that, in 2006, CT radiation alone contributed 24% of the U.S. population's radiation&lt;br /&gt;dose.                         In late 2009, Amy Berrington de González, a radiation epidemiologist at the National Cancer Institute in Bethesda,&amp;nbsp; published a paper in &lt;i&gt;Archives of Internal Medicine&lt;/i&gt; estimating that the approximately 70 million scans performed in the United States in 2007 would lead to about 29,000 new&lt;br /&gt;cancers. There's growing pressure to better regulate CT machines, something FDA is considering. Today, due to loosely regulation and low compliance to existing guidelines, CT scans can deliver a wide range of doses for the same regions with the same machine models. Other problem is the excessive CT scanning, linked to malpractice suits protection and profit interests. A 2010 study in the &lt;i&gt;Journal of the American College of Radiology&lt;/i&gt; of 284 outpatient CT scans found that 27% “were not considered appropriate.”&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3464657125233050335/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/02/ct-scans-and-risk-of-cancer-hunt-haunt.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3464657125233050335'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3464657125233050335'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/02/ct-scans-and-risk-of-cancer-hunt-haunt.html' title='CT scans and the risk of cancer - hunt the haunt'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1321539804001679215</id><published>2011-02-26T21:52:00.001-03:00</published><updated>2011-03-18T21:07:23.437-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>O fortão da turma não precisa ser o mais burro! - Exercício e capacidade intelectual</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Um grupo da Pensilvânia, Illinois, Ohio e Texas (EUA) demonstrou, em um &lt;a href='http://www.pnas.org/content/early/2011/01/25/1015950108.abstract' target='_blank'&gt;artigo&lt;/a&gt; publicado no periódico Proceedings of the National Academy of Sciences of the United States of America, que o treinamento aeróbico melhora a memória e aumenta o tamanho do hipocampo em seres humanos. O estudo, um ensaio clínico com 120 pacientes idosos, mostrou que o exercício aeróbico foi capaz de reverter as alterações relacionadas à idade no hipocampo. Além disso, o estudo descobriu que a boa forma física anterior ao ensaio correlacionou-se com menos risco de perda de volume do hipocampo e que a recuperação do hipocampo durante o ensaio associou-se com aumento de BDNF, um marcador de neurogênese. Isso indica que o exercício físico é uma intervenção eficaz para evitar e também tratar estados demenciais próprios da senescência. Outra conclusão é a de que manter a boa forma física ao longo da vida previne a neurodegeneração. Cientistas, corram para a academia!! Como diria o poeta romano Juvenal: &lt;i&gt;mens sana in corpore sano&lt;/i&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1321539804001679215/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/02/o-fortao-da-turma-nao-precisa-ser-o.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1321539804001679215'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1321539804001679215'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/02/o-fortao-da-turma-nao-precisa-ser-o.html' title='O fortão da turma não precisa ser o mais burro! - Exercício e capacidade intelectual'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-451674685284650014</id><published>2011-02-04T18:50:00.001-03:00</published><updated>2011-03-18T21:07:23.439-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>Healing with stem cells</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='en' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;The administration of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;multipotent&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;adult progenitor&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cells&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;MAPC&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;) after&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;spinal cord&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;injury&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;rodent models&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;prevents&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;shrinkage&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of neurons, reported a team from Cleveland, Ohio&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Inhibition of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;this&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;process,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;known as&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;regressive&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;axonal&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;death&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;reduces inflammation in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;region&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of injury&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;promotes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;regeneration&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neurons.&lt;/span&gt;&lt;br/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;This&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;study shows that&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;adult stem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cells&lt;/span&gt; are&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;able to&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;modify&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;certain&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;aspects&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of the &lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;response&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;after&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;spinal cord injury&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and also&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;may&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;alter&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the inflammatory response&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;to&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mitigate&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;collateral damage&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;central&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;nervous system&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and increase&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the regenerative capacity&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;/span&gt;&lt;span lang='en' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;damaged&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt; &lt;/span&gt;&lt;/span&gt;&lt;span lang='en' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neurons&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;MAPC&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;administration&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;significantly decreased&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the release&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;damaging protein&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;called&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;MMP&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;-9&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;by&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;macrophages&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; It &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;also induce&lt;/span&gt;d &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a change&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the macrophages of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;M1&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;to&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;M2&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;also promoted&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;growth&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sensory&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neurites&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;beyond&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;site&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;injury&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;inducing their&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;formation&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;It also allowed&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;axons&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;to overcome&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;the&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;negative effects&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;of macrophages&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;and&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;inhibitory molecules&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;in their&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;environment&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;increasing&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;intrinsic&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;growth&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;capacity&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;br/&gt;Read the &lt;a href='http://www.jneurosci.org/cgi/content/abstract/31/3/944' target='_blank'&gt;complete &lt;/a&gt;report.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/451674685284650014/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/02/healing-with-stem-cells.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/451674685284650014'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/451674685284650014'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/02/healing-with-stem-cells.html' title='Healing with stem cells'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1750046464926396596</id><published>2011-01-09T18:12:00.001-03:00</published><updated>2011-09-18T12:27:16.203-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='chronic fatigue syndrome'/><category scheme='http://www.blogger.com/atom/ns#' term='fibromialgia'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='genetics'/><category scheme='http://www.blogger.com/atom/ns#' term='antivirais'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Chronic Intrigue(ing) Syndrome</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Heat is on for the chronic fatigue syndrome debate. Since a report in &lt;a href='http://www.sciencemag.org/content/326/5950/215.1.full' target='_blank'&gt;Science&lt;/a&gt; apparently revealed a break-through link of this misterious disease with XMRV, a retrovirus also linked to cancer, the field has turn into a complete turmoil. Although other research group published results that seemed to back up the first report, a multitude of scientists all over the world has begun to report negative results. Meanwhile, many CFS patients had started taking antiviral drugs, risking significant side effects. Furthermore, FDA has issued an advise for CFS patients to be barred from donating blood. Now, four studies published in &lt;a href='http://www.retrovirology.com/articles/browse.asp?date=12-2010' target='_blank'&gt;Retrovirology&lt;/a&gt; point to possible contamination as a source of false positive results in the Science paper. However, its authors claim that the newly published evidence is not sufficient to refute their data. An ongoing study leaded bu virologist W. Ian Lipkin promises to give "definitive results", at the cost of $1.3 million. &lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1750046464926396596/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/01/chronic-intrigueing-syndrome.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1750046464926396596'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1750046464926396596'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/01/chronic-intrigueing-syndrome.html' title='Chronic Intrigue(ing) Syndrome'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3580346949481309809</id><published>2010-12-26T12:35:00.000-03:00</published><updated>2011-03-18T21:07:23.441-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>Nova descoberta sobre genes que causam tumores cerebrais</title><content type='html'>Recente &lt;a href="http://www.sciencemag.org/content/330/6012/1824.abstract?sa_campaign=Email/toc/24-December-2010/10.1126/science.1195481"&gt;artigo&lt;/a&gt; na revista Science mostra os resultados de uma pesquisa levada a cabo por cientistas do Genomics Core Facility, Vall d'Hebrón Institute of Oncology, Barcelona,                               Spain. Eles demonstraram que o gene &lt;em&gt;lethal (3) malignant brain tumor &lt;/em&gt;(l(3)mbt) da mosca das frutas &lt;em&gt;Drosophila melanogaster&lt;/em&gt;, o qual é responsável pelo surgimento de tumores cerebrais nesta espécie, necessita da ativação de vários genes da linhagem germinativa para provocar tumores. Em sua pesquisa, eles determinaram que genes que são expressos apenas no desenvolvimento embrionário da mosca são essenciais para o surgimento de células malignas no cérebro de moscas com mutações do gene l(3)mbt. Isso indica que a ativação ectópica destes genes no tecido tumoral é necessária para a tumorigênese. Além disso, esta descoberta pode levar a novas abordagens terepêuticas no ser humano, uma vez que o gene humano L3MBTL1 tem sido associado a doenças neoplásicas, como síndromes mielodisplásicas e leucemias. Possivelmente, a inibição dos genes de linhagem germinativa poderia evitar transformação para o câncer em células mutantes para L3MBTL1.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3580346949481309809/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/12/nova-descoberta-sobre-genes-que-causam.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3580346949481309809'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3580346949481309809'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/12/nova-descoberta-sobre-genes-que-causam.html' title='Nova descoberta sobre genes que causam tumores cerebrais'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8516215010937796534</id><published>2010-11-19T10:51:00.000-03:00</published><updated>2011-01-18T14:03:21.370-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Dança dos Cientistas</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Desde 2008 a coluna The Gonzo Scientist da revista Science patrocina um concurso de dança online somente para cientistas, o "Dance your Ph.D.". Em 2010, mais de 30 grupos de pesquisa ao redor do mundo mandaram videos divertidos e impagáveis. Os vídeos viraram sensação no Youtube. Esse é o vídeo do grupo vencedor de 2010.&lt;br/&gt;&lt;br/&gt;&lt;div class='youtube-video'&gt;&lt;object height='355' width='425'&gt;&lt;param value='http://www.youtube.com/v/TPkAYEk-Bi8&amp;amp;feature=youtube_gdata_player' name='movie'&gt; &lt;/param&gt;&lt;param value='transparent' name='wmode'&gt; &lt;/param&gt;&lt;embed height='355' width='425' wmode='transparent' type='application/x-shockwave-flash' src='http://www.youtube.com/v/TPkAYEk-Bi8&amp;amp;feature=youtube_gdata_player'&gt; &lt;/embed&gt; &lt;/object&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;Carleton University student's team wins annual "Dance Your Ph.D" contest&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8516215010937796534/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/11/danca-dos-cientistas.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8516215010937796534'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8516215010937796534'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/11/danca-dos-cientistas.html' title='Dança dos Cientistas'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-265246425802156271</id><published>2010-11-18T10:41:00.000-03:00</published><updated>2011-03-18T21:31:11.690-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='analgésicos'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='dor'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Primeiro Prêmio SBED – Janssen-Cilag: Conheça os trabalhos dos 18 finalistas</title><content type='html'>&lt;table align="center" border="0" style="width: 750px;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center" height="35" valign="center"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center" height="35" valign="center"&gt;&lt;span style="color: black; font-family: verdana; font-size: xx-small;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table align="center" cellpadding="0" cellspacing="0" style="border: thin solid rgb(10, 111, 179); width: 753px;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td bgcolor="#006bab" height="1" width="1"&gt;&lt;/td&gt;&lt;td bgcolor="#006bab" colspan="4" height="1"&gt;&lt;/td&gt;&lt;td bgcolor="#006bab" height="1" width="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td bgcolor="#006bab" rowspan="7" width="1"&gt;&lt;/td&gt;&lt;td align="left" colspan="4" valign="top"&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374967&amp;amp;url=http%3A%2F%2Fwww.janssencilag.com.br"&gt;&lt;img alt="" border="0" height="141" id="id250610" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610.jpg" style="display: block;" width="748" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td bgcolor="#006bab" rowspan="7" width="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="3" valign="top"&gt;&lt;img alt="" height="82" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610-04.jpg" style="display: block;" width="531" /&gt;&lt;/td&gt;&lt;td align="left" rowspan="3" valign="top" width="219"&gt;&lt;table border="0" cellpadding="0" cellspacing="0"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" valign="top"&gt;&lt;img alt="" height="308" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610-05.jpg" style="display: block;" width="219" /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top"&gt;&lt;img alt="" height="200" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610-10.jpg" style="display: block;" width="219" /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="40"&gt;&lt;img alt="" height="55" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/spacer.gif" width="40" /&gt;&lt;/td&gt;&lt;td align="left" valign="top" width="470"&gt;&lt;table border="0" cellpadding="0" cellspacing="0"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="178"&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374968&amp;amp;url=http%3A%2F%2Fwww.ebulas.com.br%2Fbulas%2Ftylex%25C2%25AE"&gt;&lt;img alt="Produtos Janssen-Cilag" border="0" height="55" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/acesse-01.jpg" width="178" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td align="right" valign="top" width="37"&gt;&lt;img alt="" height="55" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/espacamento.jpg" width="43" /&gt;&lt;/td&gt;&lt;td align="right" valign="top" width="243"&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374969&amp;amp;url=http%3A%2F%2Fwww.medcenter.com%2FMedscape%2FRC.aspx%3Fpid%3D102%26amp%3Blangtype%3D1046"&gt;&lt;img alt="Portal Medcenter Medscape" border="0" height="55" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/acesse-02.jpg" width="244" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/td&gt;&lt;td align="left" valign="top" width="26"&gt;&lt;img alt="" height="55" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/spacer.gif" width="20" /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" width="40"&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;span style="color: black; font-family: verdana; font-size: x-small;"&gt;&lt;b&gt;&lt;br /&gt;Os melhores trabalhos em suas mãos!&lt;/b&gt;&lt;br /&gt;&lt;br /&gt;Prezado(a) Doutor(a),&lt;br /&gt;&lt;br /&gt;Os trabalhos dos 18 finalistas do &lt;b&gt;1º prêmio SBED - Janssen-Cilag "O controle da dor nas suas mãos&lt;/b&gt;" já estão no site da SBED!&lt;br /&gt;&lt;br /&gt;A &lt;b&gt;Sociedade Brasileira para o Estudo da Dor&lt;/b&gt; publicou os trabalhos científicos dos médicos finalistas do prêmio, incluindo os 6 vencedores, em uma página exclusiva dentro do seu portal.&lt;/span&gt;&lt;span style="color: black; font-family: verdana; font-size: x-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374970&amp;amp;url=http%3A%2F%2Fwww.9cbdor.com.br%2Fpre_janssen.php"&gt;Acesse agora&lt;/a&gt; e conheça os melhores trabalhos relacionados à dor!&lt;br /&gt;&lt;br /&gt;Aproveitamos para manter nosso compromisso de disseminar informações sobre os avanços no tratamento da dor crônica com mais um material cientifico exclusivo para você.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374971&amp;amp;url=http%3A%2F%2Fwww.marketingnet.com.br%2Fcampanhas%2Fjanssen-cilag%2F2010%2Fdivulgacao%2Fedicao09%2Finformativo-ed09.pdf"&gt;&lt;img alt="material cientifico" border="0" height="20" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/031110-01.jpg" width="450" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;b&gt;Autor&lt;/b&gt;: Dr. Levi Jales&lt;br /&gt;&lt;br /&gt;Boa leitura e um grande abraço!&lt;/span&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right" colspan="4" valign="top"&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374972&amp;amp;url=http%3A%2F%2Fwww.dor.org.br"&gt;&lt;img alt="" border="0" height="72" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610-13.jpg" width="730" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top"&gt;&lt;/td&gt;&lt;td align="right" colspan="3" valign="top"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 461px;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="right" height="19" valign="top" width="151"&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374972&amp;amp;url=http%3A%2F%2Fwww.dor.org.br"&gt;&lt;img alt="" border="0" height="84" id="id250610015" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610-15.jpg" width="151" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td align="left" valign="top" width="40"&gt;&lt;img alt="" height="84" id="id250610016" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610-16.jpg" width="40" /&gt;&lt;/td&gt;&lt;td align="right" valign="top" width="31"&gt;&lt;a href="http://cache.easymaling.com.br/links.php?AGE_ID=470200&amp;amp;PES_ID=33616223&amp;amp;n=15098&amp;amp;URL_ID=374967&amp;amp;url=http%3A%2F%2Fwww.janssencilag.com.br"&gt;&lt;img alt="" border="0" height="84" id="id250610017" src="http://www.marketingnet.com.br/campanhas/janssen-cilag/2010/divulgacao/edicao09/imagens/250610-17.jpg" width="270" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" bgcolor="#006bab" colspan="4" height="25" valign="top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td bgcolor="#006bab" height="1" width="1"&gt;&lt;/td&gt;&lt;td bgcolor="#006bab" colspan="4" height="1"&gt;&lt;/td&gt;&lt;td bgcolor="#006bab" height="1" width="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;br /&gt;&lt;br /&gt;&lt;center&gt;&lt;center style="font-family: Arial,Helvetica,sans-serif; font-size: 10px;"&gt;&lt;span style="font-family: Verdana; font-size: xx-small;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/center&gt;&lt;/center&gt;&lt;img height="0" src="http://cache.easymaling.com.br/log_email.php?PES_ID=33616223&amp;amp;AGE_ID=470200&amp;amp;n=15098" width="0" /&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/265246425802156271/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/01/primeiro-premio-sbed-janssen-cilag.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/265246425802156271'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/265246425802156271'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/01/primeiro-premio-sbed-janssen-cilag.html' title='Primeiro Prêmio SBED – Janssen-Cilag: Conheça os trabalhos dos 18 finalistas'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4350116950453491832</id><published>2010-11-06T14:19:00.000-03:00</published><updated>2011-03-18T21:07:23.443-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>Especial Glia</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;A revista Science publicou seu número especial Glia, com artigos sobre estas importantes células do sistema nervoso central. &lt;br/&gt;Principais destaques:&lt;br/&gt;Specification and Morphogenesis of Astrocytes, by Marc R. Freeman. Os astócitos, antigamente vistos apenas como coadjuvantes, agora são um dos focos centrais das neurociências. Cientistas tentam desvendar como eles "conversam" entre si e com os neurônios. Leia &lt;a href='http://www.sciencemag.org/content/330/6005/774.full' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;Regulation of Oligodendrocyte Differentiation and Myelination, by Ben Emery. Apesar de ter uma importância crítica, os oligodendrócitos são menos conhecidos que outras células neurais. Leia &lt;a href='http://www.sciencemag.org/content/330/6005/779.full' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages, by Florent Ginhoux et al. Pesquisadores mostram que as células imunes do cérebro são realmente derivadas de progenitores de macrófagos, oriundos da medula óssea. Leia &lt;a href='http://www.sciencemag.org/content/330/6005/841.full' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;img src='http://www.sciencemag.org/content/330/6005/F1.medium.gif' style='max-width: 800px;'/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4350116950453491832/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/11/especial-glia.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4350116950453491832'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4350116950453491832'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/11/especial-glia.html' title='Especial Glia'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7821764035558666032</id><published>2010-10-20T10:51:00.000-03:00</published><updated>2011-01-18T14:08:39.683-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>The secret life of neutrophils</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Researchers from Canada and Brazil have made live films of the movement of neutrophils into injured sites and studied what signals target these cells to specific locations.&lt;br/&gt;Abstract:&lt;br/&gt;Neutrophils are recruited from the blood to sites of sterile inflammation, where they contribute to wound healing but may also cause tissue damage. By using spinning disk confocal intravital microscopy, we examined the kinetics and molecular mechanisms of neutrophil recruitment to sites of focal hepatic necrosis in vivo. Adenosine triphosphate released from necrotic cells activated the Nlrp3 inflammasome to generate an inflammatory microenvironment that alerted circulating neutrophils to adhere within liver sinusoids. Subsequently, generation of an intravascular chemokine gradient directed neutrophil migration through healthy tissue toward foci of damage. Lastly, formyl-peptide signals released from necrotic cells guided neutrophils through nonperfused sinusoids into the injury. Thus, dynamic in vivo imaging revealed a multistep hierarchy of directional cues that guide neutrophil localization to sites of sterile inflammation.&lt;br/&gt;                     &lt;br/&gt;Complete &lt;a target='_blank' href='http://www.sciencemag.org/content/330/6002/362.full'&gt;here&lt;/a&gt;.&lt;br/&gt;Sample videos &lt;a target='_blank' href='http://www.sciencemag.org/content/330/6002/362/suppl/DC1'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7821764035558666032/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/10/secret-life-of-neutrophils.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7821764035558666032'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7821764035558666032'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/10/secret-life-of-neutrophils.html' title='The secret life of neutrophils'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3685837560951211077</id><published>2010-10-17T10:51:00.000-03:00</published><updated>2011-09-18T12:29:09.617-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Good news for brazillian children with leukemia</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Brazillian researchers from FIOCRUZ and INCA have shown that childhood leukemia's mortality is decreasing in a steady state.&lt;br/&gt;Abstract:&lt;br/&gt;&lt;b&gt;Objective: &lt;/b&gt;To analyze trends in childhood leukemia mortality in the state of Rio de Janeiro, Brazil, between 1980 and 2006.&lt;br/&gt;&lt;b&gt; Method: &lt;/b&gt;Gender-stratified leukemia mortality data for children aged &amp;lt; 15 years from 1980 to 2006 were retrieved from the Brazilian Mortality Information System for the state of Rio de Janeiro. Data were stratified by place of death (city of Rio de Janeiro proper, the state capital; Rio de Janeiro Metropolitan Region, excluding the capital; and rest of the state). Leukemia deaths were defined according to death certificate ICD-9 and ICD-10 coding (for deaths occurring in 1980-1995 and 1996-2006, respectively). Leukemia mortality rates were calculated by age and calendar year and age-adjusted to a standard world population. Polynomial linear regression with a 5% significance level was used to evaluate mortality trends in the study regions.&lt;br/&gt;  &lt;b&gt;Results:  &lt;/b&gt;The three studied regions revealed similar trends, with a continuous downward pattern; the most substantial decline was detected in the municipality of Rio de Janeiro (city proper). In all studied areas, leukemia mortality was highest among males.&lt;br/&gt;  &lt;b&gt;Conclusion: &lt;/b&gt;A downward trend in childhood leukemia mortality was detected throughout the state of Rio de Janeiro. The most pronounced reduction occurred in the state capital.&lt;br/&gt;&lt;br/&gt;Complete &lt;a href='http://www.jped.com.br/conteudo/10-86-05-405/ing.asp?cod=2124' target='_blank'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3685837560951211077/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/10/good-news-for-brazillian-children-with.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3685837560951211077'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3685837560951211077'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/10/good-news-for-brazillian-children-with.html' title='Good news for brazillian children with leukemia'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7091066453498515260</id><published>2010-10-14T10:51:00.000-03:00</published><updated>2011-03-18T21:31:11.693-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Salbutamol for Multiple Sclerosis</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;br/&gt;Scientists from Harvard, NIH and Chicago's Northwestern University reported the results of a clinical trial that found albuterol is effective for the treatment of multiple sclerosis patients.&lt;b&gt;&lt;br/&gt;Abstract:&lt;br/&gt;Background &lt;/b&gt; Interleukin 12 (IL-12), a cytokine that promotes&lt;sup&gt; &lt;/sup&gt;generation of helper T cells subtype 1, is increased in multiple&lt;sup&gt; &lt;/sup&gt;sclerosis. Albuterol sulfate, a β2-adrenergic agonist,&lt;sup&gt; &lt;/sup&gt;reduces IL-12 expression, so we tested the effect of albuterol&lt;sup&gt; &lt;/sup&gt;as an add-on treatment to glatiramer acetate therapy.&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Objectives &lt;/b&gt; To investigate the clinical and immunologic&lt;sup&gt; &lt;/sup&gt;effects of albuterol treatment as an add-on therapy in patients&lt;sup&gt; &lt;/sup&gt;starting glatiramer acetate treatment.&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Design &lt;/b&gt; Single-center double-masked clinical trial.&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Setting &lt;/b&gt; Academic research.&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Patients &lt;/b&gt; Subjects with relapsing-remitting multiple sclerosis.&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Main Outcome Measures &lt;/b&gt; In this single-center double-masked&lt;sup&gt; &lt;/sup&gt;clinical trial, subjects with relapsing-remitting multiple sclerosis&lt;sup&gt; &lt;/sup&gt;were randomized to receive a subcutaneous injection of glatiramer&lt;sup&gt; &lt;/sup&gt;acetate (20 mg) plus an oral dose of placebo daily for 2 years&lt;sup&gt; &lt;/sup&gt;or a subcutaneous injection of glatiramer acetate (20 mg) plus&lt;sup&gt; &lt;/sup&gt;an oral dose of albuterol daily for 2 years. The primary clinical&lt;sup&gt; &lt;/sup&gt;efficacy measurement was the change in Multiple Sclerosis Functional&lt;sup&gt; &lt;/sup&gt;Composite at 2 years, and the primary immunologic end point&lt;sup&gt; &lt;/sup&gt;was the change in expression of IL-13 and interferon &lt;img border='0' alt='{gamma}' src='http://archneur.ama-assn.org/math/gamma.gif'/&gt; at each&lt;sup&gt; &lt;/sup&gt;study time point. The classification level of evidence from&lt;sup&gt; &lt;/sup&gt;this trial is C for each question, as this is the first class&lt;sup&gt; &lt;/sup&gt;II clinical trial addressing the efficacy of glatiramer acetate&lt;sup&gt; &lt;/sup&gt;plus albuterol.&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Results &lt;/b&gt; Forty-four subjects were randomized to receive&lt;sup&gt; &lt;/sup&gt;glatiramer acetate plus albuterol or glatiramer acetate plus&lt;sup&gt; &lt;/sup&gt;placebo, and 39 subjects contributed to the analysis. Improvement&lt;sup&gt; &lt;/sup&gt;in the Multiple Sclerosis Functional Composite was observed&lt;sup&gt; &lt;/sup&gt;in the glatiramer acetate plus albuterol group at the 6-month&lt;sup&gt; &lt;/sup&gt;(&lt;i&gt;P&lt;/i&gt; = .005) and 12-month (&lt;i&gt;P&lt;/i&gt; = .04) time points&lt;sup&gt; &lt;/sup&gt;but not at the 24-month time point. A delay in the time to first&lt;sup&gt; &lt;/sup&gt;relapse was also observed in the glatiramer acetate plus albuterol&lt;sup&gt; &lt;/sup&gt;group (&lt;i&gt;P&lt;/i&gt; = .03). Immunologically, IL-13 and interferon-&lt;img border='0' alt='{gamma}' src='http://archneur.ama-assn.org/math/gamma.gif'/&gt; production decreased in both treatment groups, and a treatment&lt;sup&gt; &lt;/sup&gt;effect on IL-13 production was observed at the 12-month time&lt;sup&gt; &lt;/sup&gt;point (&lt;i&gt;P&lt;/i&gt; &amp;lt; .05). Adverse events were generally&lt;sup&gt; &lt;/sup&gt;mild, and only 3 moderate or severe events were considered related&lt;sup&gt; &lt;/sup&gt;to the treatment.&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Conclusion &lt;/b&gt; Treatment with glatiramer acetate plus albuterol&lt;sup&gt; &lt;/sup&gt;is well tolerated and improves clinical outcomes in patients&lt;sup&gt; &lt;/sup&gt;with multiple sclerosis.&lt;sup&gt; &lt;/sup&gt;&lt;/font&gt;&lt;font size='2' face='verdana, arial, helvetica, sans-serif'&gt;&lt;b&gt;&lt;br/&gt;Trial Registration &lt;/b&gt; clinicaltrials.gov Identifier: &lt;a href='http://clinicaltrials.gov/show/NCT00039988'&gt;NCT00039988&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Complete &lt;a href='http://archneur.ama-assn.org/cgi/content/full/67/9/1055' target='_blank'&gt;here&lt;/a&gt;.&lt;/b&gt;&lt;br/&gt;&lt;/font&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7091066453498515260/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/10/salbutamol-for-multiple-sclerosis.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7091066453498515260'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7091066453498515260'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/10/salbutamol-for-multiple-sclerosis.html' title='Salbutamol for Multiple Sclerosis'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1670594087932156155</id><published>2010-10-09T10:51:00.000-03:00</published><updated>2011-03-18T21:07:23.447-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>The tau of Alzheimer</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Scientists from UCLA and Stanford show tau protein role in the development of Alzheimer's disease.&lt;br/&gt;Abstract:&lt;br/&gt;Amyloid-β (Aβ) peptides, derived from the amyloid precursor protein, and the microtubule-associated protein tau are key pathogenic factors in Alzheimer’s disease (AD). How exactly they impair cognitive functions is unknown. We assessed the effects of Aβ and tau on axonal transport of mitochondria and the neurotrophin receptor TrkA, cargoes that are critical for neuronal function and survival and whose distributions are altered in AD. Aβ oligomers rapidly inhibited axonal transport of these cargoes in wild-type neurons. Lowering tau levels prevented these defects without affecting baseline axonal transport. Thus, Aβ requires tau to impair axonal transport, and tau reduction protects against Aβ-induced axonal transport defects.&lt;br/&gt;Complete &lt;a target='_blank' href='http://www.sciencemag.org/content/330/6001/198.full'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1670594087932156155/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/10/tau-of-alzheimer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1670594087932156155'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1670594087932156155'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/10/tau-of-alzheimer.html' title='The tau of Alzheimer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2945373866683518072</id><published>2010-09-20T10:51:00.000-03:00</published><updated>2011-03-18T20:51:13.440-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>The sweetness of cancer</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Researchers from Harvard and Princenton discovered a new away cancer cells use nutrients to bolster their energy-producing cellular machinery. This break-through finding can help design new anticancer drugs.&lt;br/&gt;Abstract:&lt;br/&gt;Proliferating cells, including cancer cells, require altered metabolism to efficiently incorporate nutrients such as glucose into biomass. The M2 isoform of pyruvate kinase (PKM2) promotes the metabolism of glucose by aerobic glycolysis and contributes to anabolic metabolism. Paradoxically, decreased pyruvate kinase enzyme activity accompanies the expression of PKM2 in rapidly dividing cancer cells and tissues. We demonstrate that phosphoenolpyruvate (PEP), the substrate for pyruvate kinase in cells, can act as a phosphate donor in mammalian cells because PEP participates in the phosphorylation of the glycolytic enzyme phosphoglycerate&lt;br/&gt;                        mutase (PGAM1) in PKM2-expressing cells. We used mass spectrometry to show that the phosphate from PEP is transferred to the catalytic histidine (His&lt;sup&gt;11&lt;/sup&gt;) on human PGAM1. This reaction occurred at physiological concentrations of PEP and produced pyruvate in the absence of PKM2 activity. The presence of histidine-phosphorylated PGAM1 correlated with the expression of PKM2 in cancer cell lines and tumor tissues. Thus, decreased pyruvate kinase activity in PKM2-expressing cells allows PEP-dependent histidine phosphorylation&lt;br/&gt;                        of PGAM1 and may provide an alternate glycolytic pathway that decouples adenosine triphosphate production from &lt;br/&gt;PEP-mediated phosphotransfer, allowing for the high rate of glycolysis to support the anabolic metabolism observed in many proliferating cells.&lt;br/&gt;                     &lt;br/&gt;Complete &lt;a target='_blank' href='http://www.sciencemag.org/content/329/5998/1492.full'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2945373866683518072/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/09/sweetness-of-cancer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2945373866683518072'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2945373866683518072'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/09/sweetness-of-cancer.html' title='The sweetness of cancer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-213038917668029330</id><published>2010-09-08T10:51:00.000-03:00</published><updated>2011-03-18T21:31:11.695-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Targeting the uprising of malarial resistance</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;A new class of drugs holds the promise to control multidrug-resistant malaria causing microbes. A report of a joint team of collaborators from USA, Switzerland, Singapore and Thailand.&lt;br/&gt;Abstract:&lt;br/&gt;Recent reports of increased tolerance to artemisinin derivatives—the most recently adopted class of antimalarials—have prompted a need for new treatments. The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of &lt;em&gt;Plasmodium falciparum&lt;/em&gt; and &lt;em&gt;Plasmodium vivax&lt;/em&gt; clinical isolates at low nanomolar concentration. Spiroindolones rapidly inhibit protein synthesis in &lt;em&gt;P. falciparum&lt;/em&gt;, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4). The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral&lt;br/&gt; dosing and has single-dose efficacy in a rodent malaria model.&lt;br/&gt;                     &lt;br/&gt;Complete &lt;a target='_blank' href='http://www.sciencemag.org/content/329/5996/1175.full'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/213038917668029330/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/09/targeting-uprising-of-malarial.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/213038917668029330'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/213038917668029330'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/09/targeting-uprising-of-malarial.html' title='Targeting the uprising of malarial resistance'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8346430603319783849</id><published>2010-08-29T10:51:00.000-03:00</published><updated>2011-01-18T14:16:20.337-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Inflammation: telling it by heart</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Brazillian scientists review evidence linking cardiovascular diseases and ankylosing spondylitis, a rheumatological condition characterized by chronic pain and inflammation.&lt;br/&gt;Abstract:&lt;br/&gt;Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease characterized primarily by axial joint involvement, sacroiliitis and various extra-articular manifestations. High cardiovascular mortality in AS has led many researchers to investigate possible risk factors involved with cardiovascular disease in these patients. This review summarizes published data concerning endothelial dysfunction and atherosclerosis in patients with AS. The author discusses current limitations and problems related to a better assessment of these two possible changes in AS.&lt;br/&gt;&lt;br/&gt;Complete &lt;a target='_blank' href='http://www.springerlink.com/content/12574xn241701p26/fulltext.html'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8346430603319783849/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/08/inflammation-telling-it-by-heart.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8346430603319783849'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8346430603319783849'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/08/inflammation-telling-it-by-heart.html' title='Inflammation: telling it by heart'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3901827011680241824</id><published>2010-08-15T10:51:00.000-03:00</published><updated>2011-09-18T12:29:09.634-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>How to prevent mortality in sickle cell anemia kids</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;p&gt;&lt;font size='2' face='Verdana'&gt;Brazillian scientists have found high mortality in children with sickle cell anemia, a frequent cause of inherited anemia in Brazil.&lt;i&gt;&lt;br/&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size='2' face='Verdana'&gt;&lt;i&gt;Abstract:&lt;/i&gt;&lt;/font&gt;&lt;font size='2'&gt;&lt;font face='Verdana'&gt;&lt;i&gt;&lt;br/&gt;&lt;/i&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;b&gt;Objective: &lt;/b&gt;To describe the deaths of children with sickle cell disease (SCD) in Minas Gerais, Brazil, and followed up at the Fundação Hemominas.&lt;br/&gt;&lt;b&gt;Methods: &lt;/b&gt;Cohort of children diagnosed by the Neonatal Screening Program in Minas Gerais (March/1998 to February/2005). Deaths were identified by searching for children who did not attend scheduled consultations at hemocenters. Clinical and epidemiological data were abstracted from death certificates, the newborn screening database, individual medical records, and from interviews with families.&lt;br/&gt;  &lt;b&gt;Results: &lt;/b&gt;During the period, 1,833,030 newborns were screened; 1,396 had SCD (1:1,300). There were 78 deaths: 63 with SS genotype, 12 with SC genotype, and three with Sβ&lt;sup&gt;+&lt;/sup&gt;thalassemia genotype. Fifty-six children (71.8%) died before 2 years of age; 59 died in hospitals and 18 at home or during transportation. Causes of death according to certificates (n = 78): infections, 38.5%; acute splenic sequestration, 16.6%; other causes, 9%; did not receive medical care, 15.4%; and not identified on certificates, 20.5%. According to interviews (n = 52) acute splenic sequestration was responsible for one third of deaths, in contrast with 14% recorded on death &lt;br/&gt;  certificates. Survival probabilities at 5y (SEM) for children with SS, SC, and Sβ&lt;sup&gt;+&lt;/sup&gt;thalassemia were 89.4 (1.4), 97.7 (0.7), and 94.7% (3.0), respectively (SS vs. SC, p &amp;lt; 0.0001).&lt;br/&gt;  &lt;b&gt;Conclusions: &lt;/b&gt;Even with a carefully controlled newborn screening program, the probability of SS children dying was still found to be high. Causes not identified on death certificates may indicate difficulties recognizing SCD and its complications. Educational campaigns directed at health professionals and SCD patients families should be boosted in order to decrease SCD mortality.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;font size='2' face='Verdana'&gt;&lt;i&gt;J Pediatr (Rio J). 2010;86(4):279-284: &lt;/i&gt; &lt;br/&gt;  Anemia, sickle cell, mortality, socioeconomic factors, health services.&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;font size='2' face='Verdana'&gt;Complete &lt;a target='_blank' href='http://www.jped.com.br/conteudo/10-86-04-279/ing.asp?cod=2090'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3901827011680241824/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/08/how-to-prevent-mortality-in-sickle-cell.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3901827011680241824'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3901827011680241824'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/08/how-to-prevent-mortality-in-sickle-cell.html' title='How to prevent mortality in sickle cell anemia kids'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3875323620451951503</id><published>2010-08-12T21:41:00.000-03:00</published><updated>2010-08-12T21:41:00.954-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Esperança de uma vacina eficiente contra o HIV</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Dois trabalhos publicados esta semana na revista Science relataram descobertas que possivelmente permitirão a pesquisadores desenvolver mais facilmente uma vacina eficiente contra o HIV. Até o momento, uma das principais dificuldades para a obtenção de uma vacina antI-HIV é a ausência de um alvo na estrutura do vírus, contra o qual se consiga gerar anticorpos eficientes em neutralizá-lo. Wu e seu time, do Vaccine Research Center, NIAID (NIH), em Bethesda, Maryland (EUA), desenvolveram uma nova técnica que permitiu-lhes isolar anticorpos altamente eficientes em anular o HIV do sangue de pacientes. Trabalhando nestes anticorpos, eles determinaram o local onde estes anticorpos de alta afinidade se ligam no vírus, idenficando um possível novo alvo para vacinas altamente eficazes. Zhou, liderando outro time de especialistas da mesma instituição, conseguiu descrever a estrutura desse tipo de anticorpo e detalhar como ele se liga ao vírus, e porque ele tem maior afinidade por ele. Encontrar anticorpos anti-HIV de alta afinidade pelo vírus no sangue de pacientes é tecnicamente muito difícil. "É como achar uma agulha num palheiro", dizem Dennis Burton (Scripps Research Institute, La Jolla, CA) e Robin Weiss (MIT, Harvard, Boston, MA). Segundo eles, as novas descobertas vão ajudar a identificar alvos precisos para o desenvolvimento de uma vacina para a AIDS. Leia mais na &lt;a href='http://www.sciencemag.org/cgi/content/full/329/5993/770' target='_blank'&gt;Science&lt;/a&gt;.&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=6deebb95-0fcb-8875-8111-87e08fd554eb' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3875323620451951503/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/08/esperanca-de-uma-vacina-eficiente.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3875323620451951503'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3875323620451951503'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/08/esperanca-de-uma-vacina-eficiente.html' title='Esperança de uma vacina eficiente contra o HIV'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6458161232567599366</id><published>2010-08-10T10:51:00.000-03:00</published><updated>2011-03-18T21:07:23.449-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>Who made up your mind?</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;A Harvard team has disclosed differences in paternal/maternal influence on gene profile expression in the brain.&lt;br/&gt;Abstract: &lt;br/&gt;Genomic imprinting results in preferential gene expression from paternally versus maternally inherited chromosomes. We used a genome-wide approach to uncover sex-specific parent-of-origin allelic effects in the adult mouse brain. Our study identified preferential selection of the maternally inherited X chromosome in glutamatergic neurons of the female cortex. Moreover, analysis of the cortex and hypothalamus identified 347 autosomal genes with sex-specific imprinting features. In the hypothalamus, sex-specific imprinted genes were mostly found in females, which suggests parental influence over the hypothalamic function of daughters. We show that &lt;em&gt;interleukin-18&lt;/em&gt;, a gene linked to diseases with sex-specific prevalence, is subject to complex, regional, and sex-specific parental effects in the brain. Parent-of-origin effects thus provide new avenues for investigation of sexual dimorphism in brain function and disease.&lt;br/&gt;Complete &lt;a target='_blank' href='http://www.sciencemag.org/content/329/5992/682.full'&gt;here&lt;/a&gt;.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6458161232567599366/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/08/who-made-up-your-mind.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6458161232567599366'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6458161232567599366'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/08/who-made-up-your-mind.html' title='Who made up your mind?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8683376958488066475</id><published>2010-07-31T21:19:00.000-03:00</published><updated>2011-03-18T21:31:11.697-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Avandia: rosiglitazona suspeita de causar mortes</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;O medicamento rosiglitazona, comercializado sob o nome comercial de Avandia, está na mira da agência americana reguladora do uso de medicações, Food and Drug Administration (FDA). Um estudo em 2007 já havia mostrado um excesso de mortalidade cardiovascular em pacientes diabéticos que usaram esta droga. Outro estudo, mais recente, mostrou também um aumento de risco cardiovascular nos pacientes que usaram Avandia. O estudo RECORD, financiado pelo laboratório que desenvolveu e comercializa o medicamento, não reproduziu estes resultados, mas foi criticado por problemas metodológicos e éticos. Uma reunião recente do FDA ouviu 33 especialistas em diabetes e hipertensão, que se dividiram sobre uma possível retirada da licença da comercialização de Avandia. A maioria dos especialistas - 22 deles - concorda que retirar ou restringir bastante seu uso é necessário, mas o restante votou para mantê-lo no mercado. A decisão final do FDA ainda não saiu. Enquanto isso, o estudo TIDE, o maior já planejado para testar a segurança da rosiglitazona, está sendo duramente criticado e pode ser interrompido apenas quando mal começou. Especialistas vêem o estudo como exposição de pacientes a risco desnecessário e acham que os participantes não estão sendo informados sobre todos os riscos e não entendem o objetivo real do estudo - que não é desenvolver nenhum tratamento novo, mas apenas comprovar ou não se a rosiglitazona faz mal. Enquanto isso, as vendas da substância no mundo inteiro caem vertiginosamente e médicos estão cada vez menos propensos a prescrevê-lo. Leia mais nas revistas: &lt;a href='http://veja.abril.com.br/noticia/saude/comite-do-fda-mantem-avandia-no-mercado' target='_blank'&gt;Veja&lt;/a&gt; ou &lt;a href='http://www.sciencemag.org/cgi/content/full/329/5990/375' target='_blank'&gt;Science&lt;/a&gt;.&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=c9123f6a-c68c-8388-bcb8-70939e826f41' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8683376958488066475/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/07/avandia-rosiglitazona-suspeita-de_31.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8683376958488066475'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8683376958488066475'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/07/avandia-rosiglitazona-suspeita-de_31.html' title='Avandia: rosiglitazona suspeita de causar mortes'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-9109598460324712646</id><published>2010-06-16T22:54:00.000-03:00</published><updated>2011-03-18T21:07:23.451-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='risco'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>Telefones celulares e tumores cerebrais</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;O uso de telefones celulares não se associou com a ocorrência de tumores cerebrais dos tipos glioma e meningioma num grande estudo caso-controle multinacional, publicado em Maio no International Journal of Epidemiology. Os autores concluíram que não foi observado risco aumentado de glioma ou meningioma com o uso habitual de telefones celulares em pacientes adultos. A exceção foram os usuários que reportaram um número muito grande de horas de uso (grupo de maior nível de exposição), no qual observou-se um risco aumentado de glioma apenas. No entanto, limitações metodológicas impedem que estes achados sejam conclusivos. Os autores também relataram que gliomas do lobo temporal do mesmo lado habitualmente usado para atender o celular foram mais frequentes. Empresas de telefonia celular do Canadá e da Austrália revelaram ter dado apoio ao grupo multinacional que realizou a pesquisa. Leia o trabalho na íntegra: &lt;a href='http://ije.oxfordjournals.org/cgi/reprint/dyq079' target='_blank'&gt;http://ije.oxfordjournals.org/cgi/reprint/dyq079&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=8c47d7fe-25ca-8cda-8a59-ee6fa5ab68b5' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/9109598460324712646/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/06/telefones-celulares-e-tumores-cerebrais.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9109598460324712646'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/9109598460324712646'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/06/telefones-celulares-e-tumores-cerebrais.html' title='Telefones celulares e tumores cerebrais'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7716048589271265252</id><published>2010-05-17T13:27:00.000-03:00</published><updated>2011-03-18T21:31:11.699-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://www.blogger.com/atom/ns#' term='radioterapia'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='glioblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='resposta'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Novidades sobre o tratamento de glioblastoma</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Pesquisadores da Universidade de Bonn mostraram, num estudo publicado na revista Annals of Neurology, que células neoplásicas retiradas de amostras da periferia de glioblastomas têm característicasa diferentes das células retiradas do centro do tumor. As células periféricas têm maior mobilidade, expressam diferentes receptores de membrana e reagem diferentemente à quimio e radioterapia. Este estudo pode ajudar a compreender porque os pacientes com glioblastoma sempre experimentam a recaída de suas doenças. Leia mais: &lt;a href='http://www3.interscience.wiley.com/journal/123337121/abstract' target='_blank'&gt;http://www3.interscience.wiley.com/journal/123337121/abstract&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=14e05d63-1d0a-8f9c-98e5-89c513c76ac8' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7716048589271265252/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/06/novidades-sobre-o-tratamento-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7716048589271265252'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7716048589271265252'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/06/novidades-sobre-o-tratamento-de.html' title='Novidades sobre o tratamento de glioblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3324302354855045251</id><published>2010-05-12T18:09:00.000-03:00</published><updated>2011-03-18T21:13:43.421-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Transplante de células para tratar paralisia cerebral</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Pesquisadores da Universidade de Pequim (China) terminaram um ensaio clínico onde desenvolveram uma nova técnica para tratamento de paralisia cerebral em crianças. Transplante&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;células da bainha&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do bulbo olfatório&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;OECs&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tipo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;célula&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que&lt;/span&gt; dá &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;suporte&lt;/span&gt; a&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os neurônios&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sistema&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;olfativo&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;capaz&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de se regenerar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e relativamente&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;fácil de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;obter&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;poderia melhorar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a função&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neurológica&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes com paralisia cerebral&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;causar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;significativos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;efeitos colaterais.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Segundo os pesquisadores,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;83% das&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com paralisia&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cerebral&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estudadas apresentaram&lt;/span&gt; alguma&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt; anomalia detectadas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;radiologicamente&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Entre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;elas&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;as lesões&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da substância branca&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram as mais&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;comuns&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Notou-se também&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a perda&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tecido&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cerebral&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mielinização&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;deficiente ou&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;atrasada&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cicatrizes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;gliais&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;diminuição&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da&lt;/span&gt; substância&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt; branca&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;O&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;protocolo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de &lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pesquisa foi&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desenvolvido&lt;/span&gt; a partir da hipótese &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;prévia&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;área&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;-chave&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;nos lobos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;frontais&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cérebro&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;definida&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;como a área-chave&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a restauração&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;rede neural ou&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;KPNNR&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;) com base&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estudos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;anteriores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;injetar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;OECs&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;A injeção&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;OECs&lt;/span&gt; produziu &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;bainhas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de mielina&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;semelhantes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;às &lt;/span&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;das células&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de Schwann&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ao redor&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos axônios&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com desmielinização.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Os resultados&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram medidos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; o Gross Motor Function Measure (GMFM-66) e a Caregiver Questionnaire Scale&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;. O grupo tratado (6 pacientes) mostrou uma melhora funcional não significante em relação ao grupo controle (8 pacientes), levando os pesquisadores a propor um ensaio clínico maior com a técnica.&lt;br/&gt;Artigo completo &lt;a href='http://www.ingentaconnect.com/content/cog/ct/2010/00000019/00000002/art00007' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3324302354855045251/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/05/transplante-de-celulas-para-tratar.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3324302354855045251'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3324302354855045251'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/05/transplante-de-celulas-para-tratar.html' title='Transplante de células para tratar paralisia cerebral'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3460422798263024571</id><published>2010-04-17T14:13:00.000-03:00</published><updated>2011-03-18T21:31:11.701-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='glioblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='resposta'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Drogas bloqueadoras da via Notch</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Pesquisadores da Johns Hopkins testaram substâncias capazes de bloquear a via de sinalização celular Notch em linhagens celulares de glioblastoma formadoras de neuroesferas. A droga experimental GSI-18 inibiu a formação de esferas e modificou a expressão de marcadores e superfície da membrana celular. A reativação in vivo da via Notch tornou as neuroesferas capazes de crescer novamente e originar tumores cerebrais após transplante para animais experimentais. Link para artigo:&lt;a href='http://www3.interscience.wiley.com/journal/122681504/abstract' target='_blank'&gt; http://www3.interscience.wiley.com/journal/122681504/abstract&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=f66b30b3-d183-8b5d-8aed-85c4e6f2fd02' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3460422798263024571/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/06/drogas-bloqueadoras-da-via-notch.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3460422798263024571'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3460422798263024571'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/06/drogas-bloqueadoras-da-via-notch.html' title='Drogas bloqueadoras da via Notch'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7323035759269324546</id><published>2010-04-14T18:09:00.001-03:00</published><updated>2011-07-02T11:53:05.051-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='gordos'/><category scheme='http://www.blogger.com/atom/ns#' term='prevenção'/><category scheme='http://www.blogger.com/atom/ns#' term='risco'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><category scheme='http://www.blogger.com/atom/ns#' term='obesidade'/><category scheme='http://www.blogger.com/atom/ns#' term='ambiente'/><category scheme='http://www.blogger.com/atom/ns#' term='fitness'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><title type='text'>O vício de comer não é uma figura de linguagem</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Um estudo realizado em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;animais de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;laboratório&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;ratos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;),&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mostrou&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pela primeira vez&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;compulsão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;comer demais&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;levando&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;à obesidade&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;envolve o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mesmo mecanismo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;biológico&lt;/span&gt; do &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;vício&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em drogas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;como&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cocaína&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e heroína&lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Este achado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foi&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;publicado na&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;revista&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Nature Neuroscience.&lt;/span&gt;&lt;br /&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Os autores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mostram que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;quando&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os centros&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de prazer do cérebro&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;se tornam menos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sensíveis&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;, os&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ratos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;rapidamente&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desenvolver o hábito de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;comer compulsivamente&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;quantidades crescentes de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;altas calorias&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;alto teor de gordura&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para se tornarem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;obesos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br /&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;O consumo excessivo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desses&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;alimentos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;provoca&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;vício&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;como&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;resposta&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neuroadaptativa dos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;circuitos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de recompensa do cérebro&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;levando ao desenvolvimento&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;comer compulsivo&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br /&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Descobriu-se também&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os níveis&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos receptores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da dopamina D2&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram significativamente menores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;nos cérebros&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;animais&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;obesos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;à semelhança do que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tem sido observado em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;humanos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;viciados&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;.&lt;br /&gt;Artigo completo &lt;a href='http://www.nature.com/neuro/journal/vaop/ncurrent/abs/nn.2519.html' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7323035759269324546/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/04/o-vicio-de-comer-nao-e-uma-figura-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7323035759269324546'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7323035759269324546'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/04/o-vicio-de-comer-nao-e-uma-figura-de.html' title='O vício de comer não é uma figura de linguagem'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8509718343106547377</id><published>2010-04-08T18:09:00.000-03:00</published><updated>2011-03-18T21:13:43.423-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Por que os adolescentes correm mais riscos</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Uma pesquisa&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;publicada&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;na&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;revista&lt;/span&gt; Cognitive Development&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crianças, adolescentes e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;adultos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com idades entre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;9-35&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;anos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tiveram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;escolher&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;entre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;as opções&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de risco e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;segurança&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;jogo de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;equipe&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Os&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;adolescentes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tomaram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;as opções de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;maior risco&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em comparação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a outros grupos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;; o comportamento&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mais&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;arriscado foi&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;observado com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cerca de 14&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;anos.&lt;/span&gt;&lt;br/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Os resultados&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sugerem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que os&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;adolescentes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;são capazes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pesar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;prós e os contras&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;das suas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;decisões&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;ao contrário das crianças menores&lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, mas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;assumem mais riscos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;, porque eles sentem &lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mais emoção com&lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt; o &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;risco do que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;outros grupos etários.&lt;/span&gt;&lt;br/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;O estudo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;incluiu&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;86&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;meninos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;homens&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que usaram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;jogos de computador,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;durante o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;qual&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;as decisões&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;são tomadas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a fim de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ganhar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pontos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Depois de cada&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;jogo&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;, os cientistas mediram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a resposta &lt;/span&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;emocional&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos participantes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;gravando&lt;/span&gt; quão &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;satisfeitos ou&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;insatisfeitos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;eles&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estavam&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;resultado.&lt;br/&gt;Artigo completo &lt;a href='http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6W47-4YPGHXW-1&amp;amp;_user=10&amp;amp;_coverDate=03%2F26%2F2010&amp;amp;_alid=1272236105&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_cdi=6535&amp;amp;_sort=r&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_ct=1&amp;amp;_' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8509718343106547377/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/04/por-que-os-adolescentes-correm-mais.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8509718343106547377'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8509718343106547377'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/04/por-que-os-adolescentes-correm-mais.html' title='Por que os adolescentes correm mais riscos'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7692258978636681620</id><published>2010-03-10T18:09:00.000-03:00</published><updated>2011-03-18T21:13:43.425-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Descobrindo a genética do Transtorno de Hiperatividade</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Recentemente&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;descobriu-se&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma ligação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;genética&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que poderia&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;fornecer&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;novas informações sobre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;as&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;causas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;transtorno&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de déficit de atenção&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;/&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;hiperatividade&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;TDAH&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;), bem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;como&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ajudar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a determinar quem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pode&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;responder&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;melhor&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ao tratamento&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Foi constatado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma variação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;genética&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;gene&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;latrofilina&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;3&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;LPHN3&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;) está&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;associado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;o TDAH&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em várias populações diferentes&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Estudos anteriores demonstraram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que este&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;gene&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desempenha um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;papel&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;na forma como&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes respondem a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;drogas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estimulantes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;geralmente usados para tratar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;distúrbios&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de comportamento&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;na infância&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Neste&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estudo&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, os pesquisadores demonstraram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma associação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;entre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;LPHN3&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;TDAH&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;população&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;isolada&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da Colômbia&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, em seguida,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram capazes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;replicar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;resultados&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cinco&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;diferentes populações de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;outros países, incluindo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Alemanha,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Noruega&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Espanha&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os EUA&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Testes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;subseqüentes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cérebro&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;confirmaram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;este contexto&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, mostrando&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;LPHN3&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;é expressada em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;regiões&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;envolvidas na atenção&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e atividade&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;br/&gt;Artigo completo &lt;a href='http://www.nature.com/mp/journal/vaop/ncurrent/abs/mp20106a.html' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7692258978636681620/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/03/descobrindo-genetica-do-transtorno-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7692258978636681620'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7692258978636681620'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/03/descobrindo-genetica-do-transtorno-de.html' title='Descobrindo a genética do Transtorno de Hiperatividade'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2341352424439871643</id><published>2010-02-25T18:09:00.000-03:00</published><updated>2011-03-18T21:13:43.427-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Serotonina envolvida na Síndrome de Morte Súbita Infantil</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;div style='line-height: 20px;'&gt;&lt;br /&gt;												&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Em um artigo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;publicado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;The&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Journal of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;American Medical&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Association&lt;/span&gt;, um novo vínculo entre a&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;síndrome&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da morte&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;súbita infantil &lt;/span&gt;&lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;SMSI&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;) e &lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;baixa produção&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;serotonina&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tronco cerebral&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt; foi descrito.&lt;/span&gt;&lt;br/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;O&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estudo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;é&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;baseado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;comparação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;amostras&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do tronco cerebral&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de crianças que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sofreram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;SMSI&lt;/span&gt;  &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com os&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que morreram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de outras causas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;conhecidas&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Foram medidos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os níveis&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de serotonina&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;triptofano hidroxilase&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;enzima&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que ajuda a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;produzir&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;serotonina&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em 35&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crianças que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;morreram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;SMSI&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dois&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;grupos de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;controle&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;5&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crianças que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;morreram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de forma aguda&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de outras causas&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;5&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;hospitalizadas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;encefalopatia hipóxico-isquêmica&lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Comparados com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os controles&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os níveis&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;serotonina&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tronco encefálico baixo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;26&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;% menores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;casos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de SMSI&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;enquanto&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;níveis de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;triptofano hidroxilase&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram 22&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;%&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;inferiores&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;.&lt;br/&gt;Artigo completo &lt;a href='http://jama.ama-assn.org/cgi/content/short/303/5/430?home' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2341352424439871643/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/02/serotonina-envolvida-na-sindrome-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2341352424439871643'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2341352424439871643'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/02/serotonina-envolvida-na-sindrome-de.html' title='Serotonina envolvida na Síndrome de Morte Súbita Infantil'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6145676157149883831</id><published>2010-02-13T18:09:00.000-03:00</published><updated>2011-03-18T21:31:11.703-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Trate as convulsões de seu pequeno paciente... mesmo que não as veja!!</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;O tratamento&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;convulsões&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;subclínicas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;clínicas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;encefalopatia hipóxico-isquêmica&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;(EHI&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pode reduzir&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;risco de lesão cerebral&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, segundo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estudo publicado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;na&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;revista Pediatrics.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;138&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;recém-nascidos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os autores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;deste trabalho&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;utilizou o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;eletroencefalograma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de amplitude&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;integrada&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;(&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;EEGa&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;) para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;monitorar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;as convulsões&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crises&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;clínicamente evidente&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram tratadas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;drogas antiepilépticas (DAEs&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Quando&lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt; uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;criança&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tinha um ataque&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;subclínico&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; era&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt; tratada&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;clínica de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;convulsões &lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;eventos subclínicos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;(grupo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;A&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;n&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;=&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;19&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ou&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;convulsões&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;apenas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;(grupo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;B&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;n&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;=&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;14&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Houve&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tendência não significativa&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da duração média&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crise&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no grupo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;A&lt;/span&gt; ser &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;menor (196 contra 503 minutos)&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Também foi realizada&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;ressonância magnética (&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;MRI)&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do grupo A&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e do grupo B&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;durante o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;período&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;entre 4&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e 10&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dias de idade&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Na&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;análise&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, os autores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;encontraram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma relação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;significativa&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;entre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;duração&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;padrões&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de crise&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e a ocorrência de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;lesões cerebrais verificadas na&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ressonância magnética&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no grupo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;B.&lt;br/&gt;Artigo completo &lt;a href='http://pediatrics.aappublications.org/cgi/content/abstract/peds.2009-0136v1' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6145676157149883831/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/02/trate-as-convulsoes-de-seu-pequeno.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6145676157149883831'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6145676157149883831'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/02/trate-as-convulsoes-de-seu-pequeno.html' title='Trate as convulsões de seu pequeno paciente... mesmo que não as veja!!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6094505347381704982</id><published>2010-02-05T18:09:00.000-03:00</published><updated>2011-03-18T21:13:43.432-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Problemas infantis podem prever esquizofrenia</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Os adultos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que desenvolvem &lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;esquizofrenia&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;apresentam um padrão de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dificuldades&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cognitivas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;quando crianças&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;incluindo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;problemas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de raciocínio&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;verbal&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, memória&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;, atenção&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;velocidade de processamento.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Baseado em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estudo de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;longo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;prazo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de mais&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de 1.000&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;participantes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;nascidos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;entre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;1972 e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;1973&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os autores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estudo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;encontraram um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;padrão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de problemas durante o&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desenvolvimento&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;apareceram pela primeira vez&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;quando os indivíduos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;esquizofrenia&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no estudo&lt;/span&gt; tinham em torno de&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sete anos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;O artigo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foi&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;publicado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;American&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Journal of&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Psychiatry&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;As crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desenvolveram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;esquizofrenia&lt;/span&gt; quando &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;adultas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;apresentaram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;déficit&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no início de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;aprendizagem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;verbal&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e visual&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;raciocínio&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e conceituação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foi&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mantido&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;durante o crescimento.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Também&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mostraram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desenvolvimento mais lento em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;velocidade&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de processamento&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;atenção&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;problemas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;visuo&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;-espaciais&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;memória de trabalho.&lt;br/&gt;Artigo completo &lt;a href='http://ajp.psychiatryonline.org/cgi/content/abstract/appi.ajp.2009.09040574v1' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6094505347381704982/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/02/problemas-infantis-podem-prever.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6094505347381704982'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6094505347381704982'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/02/problemas-infantis-podem-prever.html' title='Problemas infantis podem prever esquizofrenia'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7623376318292808015</id><published>2010-02-01T18:09:00.000-03:00</published><updated>2011-01-29T18:47:44.278-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>O Esquadrão das Plaquetas Incendiárias</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Plaquetas e artrite tradicionalmente não são relacionadas nos livros médicos e na literatura científica. Um artigo publicado na &lt;a target='_blank' href='http://www.sciencemag.org/lookup/doi/10.1126/science.1181928'&gt;Science&lt;/a&gt;, porém, relata que micropartículas plaquetárias, vesículas liberadas por plaquetas ativadas, estão presentes em grande quantidade no líquido sinovial de articulações inflamadas e participam ativamente no desenvolvimento da artrite inflamatória. Usando modelos animais, os autores mostraram como as plaquetas são ativadas por colágeno (via glicoproteína VI, um receptor na superfície plaquetária) e por células sinoviais semelhantes a fibroblastos, deflagrando a liberação de micropartículas. Estas últimas vão induzir a liberação de vários mediadores inflamatórios, através da IL-1 presente nas micropartículas. Em seguida, células inflamatórias ativadas são atraídas pelos mediadores inflamatórios, iniciando o "fogo" da inflamação. Já se sabia que as plaquetas talvez tivessem algum papel na artrite: elas acumulam-se em articulações inflamadas e número elevado de plaquetas no líquido sinovial e de micropartículas na circulação já haviam sido observados em pacientes com artrite reumatóide, mas não se havia feito uma relação causal. A biologia plaquetária vem sendo revista ultimamente e, de passivas participantes em eventos vasculares elas estão passando a ativas personagens de fenômenos inflamatórios e eventos extravasculares. Um número cada vez maior de evidências apontam para o papel imunomodulatório das micropartículas plaquetárias. Sua relação próxima com células inflamatórias, como neutrófilos, faz com que estes possam "contrabandear" micropartículas aderidas em sua superfície para o interior das articulações, amplificando a resposta inflamatória que leva finalmente à artrite.&lt;img style='max-width: 800px;' src='http://lh6.ggpht.com/_ltzeFnIlO7Q/TUSEcuL_BgI/AAAAAAAABh4/zagEsubPECQ/%5BUNSET%5D.jpg?imgmax=800'/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7623376318292808015/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/01/o-esquadrao-das-plaquetas-incendiarias.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7623376318292808015'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7623376318292808015'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/01/o-esquadrao-das-plaquetas-incendiarias.html' title='O Esquadrão das Plaquetas Incendiárias'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://lh6.ggpht.com/_ltzeFnIlO7Q/TUSEcuL_BgI/AAAAAAAABh4/zagEsubPECQ/s72-c/%5BUNSET%5D.jpg?imgmax=800' height='72' width='72'/><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8649548353189007078</id><published>2010-01-30T18:09:00.000-03:00</published><updated>2011-09-18T12:29:09.784-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Medulloblastomas come from stem cells</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;A recent report published in &lt;a href='http://www.nature.com/onc/journal/v29/n12/abs/onc2009472a.html' target='_blank'&gt;Oncogene&lt;/a&gt; has shed new light to the origin on medulloblastomas, linking them to neural stem cells. Cells with stem cell properties have been isolated from various areas of&lt;br /&gt; the postnatal mammalian brain, most recently from the postnatal mouse &lt;br /&gt;cerebellum. A team from Switzerland and UK has showed that inactivation of the tumor suppressor genes&lt;br /&gt; &lt;i&gt;Rb&lt;/i&gt; and &lt;i&gt;p53&lt;/i&gt; in these endogenous neural stem cells induced deregulated proliferation and resistance to apoptosis &lt;i&gt;in vitro.&lt;/i&gt;&lt;br /&gt; Moreover, they have injected these cells into mice, forming medulloblastomas. &lt;br /&gt;Medulloblastomas are the most common malignant brain tumors of &lt;br /&gt;childhood, and despite recent advances in treatment they are associated &lt;br /&gt;with high morbidity and mortality. They are highly heterogeneous tumors &lt;br /&gt;characterized by a diverse genetic make-up and expression profile as &lt;br /&gt;well as variable prognosis. The authors described a novel ontogenetic &lt;br /&gt;pathway of medulloblastoma that significantly contributes to &lt;br /&gt;understanding their heterogeneity. Experimental medulloblastomas &lt;br /&gt;originating from neural stem cells preferentially expressed stem cell &lt;br /&gt;markers Nestin, Sox2 and Sox9, which were not expressed in &lt;br /&gt;medulloblastomas originating from granule-cell-restricted progenitors. &lt;br /&gt;Furthermore, the expression of these markers identified a subset of &lt;br /&gt;human medulloblastomas associated with a poorer clinical outcome.&lt;br/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8649548353189007078/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/01/medulloblastomas-come-from-stem-cells.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8649548353189007078'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8649548353189007078'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/01/medulloblastomas-come-from-stem-cells.html' title='Medulloblastomas come from stem cells'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7080427902445899636</id><published>2010-01-20T17:43:00.000-03:00</published><updated>2011-03-18T21:13:43.436-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Doença celíaca e risco neuropsiquiátrico</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;A enxaqueca&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;síndrome&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do túnel do carpo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;são comuns&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;entre&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes com doença celíaca&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, de acordo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;um&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;novo estudo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;publicado na revista&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Movement Disorders&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Além disso&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;coorte de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;72 pacientes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;doença&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;celíaca&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;comprovada&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os autores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;deste trabalho&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;verificaram a existência de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;vários&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;problemas psiquiátricos.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Cerca de 35&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;%&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos pacientes celíacos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;relataram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;um histórico de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;depressão&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;alterações de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;personalidade&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;psicoses.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Manifestações&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neurológicas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;atípicas&lt;/span&gt; &lt;/span&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;apareceram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;6&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;%&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;10&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;% dos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes celíacos.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Este estudo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;encontrou&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ataxia&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cerebelar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em 6%&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes e&lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt; disfunção&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;vestibular&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em 6&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;%.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;No&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;total&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, 26&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;% dos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes apresentaram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ataxias&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;aferentes&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Cerca de um terço&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos pacientes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tiveram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;problemas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;postura e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;marcha&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;muitos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;deles&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;também&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;experimentam&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;perda sensorial&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;profunda&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;reflexos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;reduzidos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tornozelo.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Essas mudanças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;não&lt;/span&gt; são &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;apenas o resultado&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;ataxia cerebelar&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;também&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;distúrbio&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;proprioceptivo&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;vestibular&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Problemas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neurológicos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;podem&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;desenvolver-se apesar&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;da rígida adesão a uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dieta&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;isenta de glúten&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;br/&gt;Artigo completo &lt;a href='http://www3.interscience.wiley.com/journal/122656874/abstract' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7080427902445899636/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/01/doenca-celiaca-e-risco.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7080427902445899636'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7080427902445899636'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/01/doenca-celiaca-e-risco.html' title='Doença celíaca e risco neuropsiquiátrico'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5075959373765417191</id><published>2010-01-08T14:19:00.000-03:00</published><updated>2011-03-18T21:13:43.439-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Neuroblastoma e VEGF - um relacionamento maligno</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;&lt;span lang='pt' class='' id='result_box'&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Altos níveis&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;expressão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;fator de&lt;/span&gt; &lt;span class='hps atn' title='Clique para mostrar traduções alternativas'&gt;crescimento endotelial vascular (&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;)&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;no&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neuroblastoma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;são&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;associadas a um estágio&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;avançado do tumor&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sobrevida&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;reduzida para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com mais de 18&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;meses de idade&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Dr.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Jakovljevic&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e colegas&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;avaliaram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a expressão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em amostras&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de tecido&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;neuroblastoma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;56 crianças&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para determinar se este&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;se correlaciona com outros&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;fatores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de prognóstico&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e resposta ao tratamento&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Cinqüenta e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;quatro&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;dos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;56&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tumores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;foram positivos&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;a coloração&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de VEGF&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;somente 2&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tumores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mostraram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;imunorreatividade&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;negativa&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;para&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Doze&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tumores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;tiveram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;baixos escores&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;na&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;expressão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;outros 44&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;apresentaram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;altas pontuações&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;na expressão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Houve&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;uma&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;correlação&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;significativa&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;entre a expressão do&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;alta&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;e&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;estágio&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;avançado do tumor&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt;&lt;br/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Comparado com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;os pacientes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que sobreviveram&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;mais de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;cinco anos&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;, aqueles&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;que não sobreviveram tinham&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'/&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;expressão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt;&lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt; significativamente maior&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;,&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;enquanto&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;todos os pacientes com&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;baixa&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;expressão&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;de&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;VEGF&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;sobreviveram&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas'&gt;.&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;Este&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;relacionamento&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;só estava presente&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;em&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;pacientes&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;com idade superior a&lt;/span&gt; &lt;span class='hps' title='Clique para mostrar traduções alternativas'&gt;18 meses&lt;/span&gt;&lt;span title='Clique para mostrar traduções alternativas' class=''&gt;.&lt;br/&gt;Artigo completo &lt;a href='http://www.jeccr.com/content/28/1/143' target='_blank'&gt;aqui&lt;/a&gt;.&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5075959373765417191/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/01/neuroblastoma-e-vegf-um-relacionamento.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5075959373765417191'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5075959373765417191'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/01/neuroblastoma-e-vegf-um-relacionamento.html' title='Neuroblastoma e VEGF - um relacionamento maligno'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7188131651013491162</id><published>2010-01-02T14:19:00.000-03:00</published><updated>2011-01-29T14:51:37.611-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Reacting to the Reactome</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;A newly developed tool that was presented by a &lt;a href='http://www.sciencemag.org/lookup/doi/10.1126/science.1174094' target='_blank'&gt;Science&lt;/a&gt; publication last October, the reactome, promises to test the functions of a myriad of enzymes and probe the metabolism of all kinds of cells. It has gathered all sort of attention, from enthusiasm, through curiosity to deep concerns and open fire attacks. Many scholars noted that the Science paper describes chemical reactions unlikely to happen and some nonsensical data. Biochemist Laura Kiessling (University of Wisconsin, editor-in-chief of ACS Chemical Biology) pointed out that flaws in chemistry were "just so obvious" in the data presented. Manuel Ferrer of the Spanish National Research Council's Institute of Catalysis in Madrid, one of the authors, said they are totally confident in the results, but admitted serious errors in describing the methods. An investigation will be held in all the laboratories involved, in Spain, Germany and the United Kingdom. Meanwhile, skepticism has soared among chemists all over the world, and the comments have also fired against Science, accused of bad reviewing job. Monica Bradford, Science's executive editor, acknowledged that none of the paper's primary reviewers was a synthetic organic chemist. Nevertheless, she says there's no evidence of fraud or misconduct and Science will wait the results of investigations. Unfortunately, from previous similar cases we can expect a very long time for this, and even if it is confirmed that the paper is bogus and it is retracted, what's done, is done.&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7188131651013491162/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2010/01/reacting-to-reactome.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7188131651013491162'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7188131651013491162'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2010/01/reacting-to-reactome.html' title='Reacting to the Reactome'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3683926941024482086</id><published>2009-12-17T22:57:00.001-03:00</published><updated>2011-03-18T21:13:43.441-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Obesity and Inflammation: Evidence for an Elementary Lesion</title><content type='html'>&lt;span style="font-size: large;"&gt;Pediatrics - Most Read Full-Text Articles&lt;/span&gt;&lt;br /&gt;&lt;a href="http://www.pediatrics.org/cgi/content/short/117/1/220?rss=1&amp;amp;ssource=mfc"&gt;Obesity and Inflammation: Evidence for an Elementary Lesion&lt;/a&gt;: "Andrea Sbarbati, Francesco Osculati, Davide Silvagni, Donatella Benati, Mirco Galie, Francesco Saverio Camoglio, Gino Rigotti, Claudio Maffeis&lt;br /&gt;Jan  1, 2006; 117:220-223&lt;br /&gt;EXPERIENCE AND REASON"</content><link rel='related' href='http://www.pediatrics.org/cgi/content/short/117/1/220?rss=1&amp;ssource=mfc' title='Obesity and Inflammation: Evidence for an Elementary Lesion'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3683926941024482086/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/obesity-and-inflammation-evidence-for.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3683926941024482086'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3683926941024482086'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/obesity-and-inflammation-evidence-for.html' title='Obesity and Inflammation: Evidence for an Elementary Lesion'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-617744373377580200</id><published>2009-12-17T22:56:00.000-03:00</published><updated>2011-03-18T21:13:43.443-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Exposure to Degrading Versus Nondegrading Music Lyrics and Sexual Behavior Among Youth</title><content type='html'>&lt;span style="font-size: large;"&gt;Pediatrics - Most Read Full-Text Articles&lt;/span&gt;&lt;br /&gt;&lt;a href="http://www.pediatrics.org/cgi/content/short/118/2/e430?rss=1&amp;amp;ssource=mfc"&gt;Exposure to Degrading Versus Nondegrading Music Lyrics and Sexual Behavior Among Youth&lt;/a&gt;: "Steven C. Martino, Rebecca L. Collins, Marc N. Elliott, Amy Strachman, David E. Kanouse, Sandra H. Berry&lt;br /&gt;Aug  1, 2006; 118:430-441&lt;br /&gt;ARTICLES"</content><link rel='related' href='http://www.pediatrics.org/cgi/content/short/118/2/e430?rss=1&amp;ssource=mfc' title='Exposure to Degrading Versus Nondegrading Music Lyrics and Sexual Behavior Among Youth'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/617744373377580200/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/exposure-to-degrading-versus.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/617744373377580200'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/617744373377580200'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/exposure-to-degrading-versus.html' title='Exposure to Degrading Versus Nondegrading Music Lyrics and Sexual Behavior Among Youth'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7427878000514308981</id><published>2009-12-15T22:42:00.000-03:00</published><updated>2011-09-18T12:29:09.750-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Infants choking following blind finger sweep</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Jornal de Pediatria - Sociedade Brasileira de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0021-75572009000300015&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Infants choking following blind finger sweep&lt;/a&gt;: "OBJETIVO: Em situações estressantes, as pessoas geralmente usam os dedos para retirar corpos estranhos de faringe da boca. Este artigo relata três casos de óbito de bebês após o uso dessa técnica. &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;MÉTODOS: Um total de 26 casos de engasgamento causado por aspiração de corpos estranhos nas vias respiratórias superiores e inferiores envolvendo crianças menores de 11 anos submetidas a autopsia no Departamento de Medicina Forense da Universidade da Jordânia entre 1996 e 2006 foram revisados. RESULTADOS: O uso de busca às cegas com os dedos para retirar corpos estranhos de faringe foi relatado em três bebês durante o choro. Todas as crianças eram menores de 1 ano e haviam se engasgado com grãos-de-bico, uma bola de gude e um lápis curto. A diversidade, o tamanho, a forma, e a maciez da superfície são as principais características que fazem com que esses corpos estranhos sejam mais difíceis de ser removidos com os dedos e facilitam sua entrada via respiratória. CONCLUSÃO: Esses casos mostraram que a busca às cegas com os dedos na boca de bebês durante o choro não é somente uma manobra perigosa, mas também pode ser fatal.&lt;br /&gt;&lt;hr /&gt;OBJECTIVE: In stressful situations, people usually use finger sweep to remove pharyngeal foreign bodies from the mouth. This article reports on three cases of death of infants following the use of this technique. METHODS: A total of 26 cases of choking caused by foreign bodies aspiration in the upper and lower respiratory passages involving children younger than 11 years of age autopsied at the Forensic Department of University of Jordânia between 1996 and 2006 were reviewed. RESULTS: Blind finger sweep to remove pharyngeal foreign bodies were reported in three crying infants. All of these cases were younger than 1 year of age and choked on a chickpea, a marble and a short pencil. Diversity, size, shape and smoothness of the surface are the main characteristics that render the foreign bodies less easily caught by fingers and make them easily enter the respiratory passage. CONCLUSION: These cases showed that blind finger sweep in crying infants is not only dangerous but can be a fatal maneuver."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0021-75572009000300015&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Infants choking following blind finger sweep'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7427878000514308981/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/infants-choking-following-blind-finger.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7427878000514308981'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7427878000514308981'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/infants-choking-following-blind-finger.html' title='Infants choking following blind finger sweep'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3100302766070678238</id><published>2009-12-15T22:40:00.000-03:00</published><updated>2011-09-18T12:29:09.592-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>The challenge of pediatric tuberculosis in face of new diagnostic techniques</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Jornal de Pediatria - Sociedade Brasileira de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0021-75572009000300002&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;The challenge of pediatric tuberculosis in face of new diagnostic techniques&lt;/a&gt;: "OBJETIVOS: Apresentar uma revisão atualizada sobre os novos métodos para o diagnóstico da tuberculose baseados na produção in vitro de interferon-gama (IFN-γ) por células T dos pacientes sob investigação, comparando-os com a tradicional prova tuberculínica. &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;FONTES DOS DADOS: Revisão de literatura utilizando os bancos de dados MEDLINE e LILACS (2000-2008) utilizando as palavras-chave tuberculose, interferon-gama, quantiFERON, ELISPOT e T-SPOT.TB. SÍNTESE DOS DADOS: Esses novos testes mostraram-se, de um modo geral, tão ou mais sensíveis e específicos que a prova tuberculínica, tanto em adultos como em crianças e imunossuprimidos, para o diagnóstico da infecção latente e da doença ativa, apresentando vantagens como a menor interferência da vacinação prévia pelo BCG, menor influência de estados anérgicos e melhor acurácia em crianças menores. Nos Estados Unidos, já estão sendo utilizados em substituição à prova tuberculínica, e apesar dos custos ainda elevados, a Organização Mundial de Saúde vai priorizar a sua viabilidade econômica. CONCLUSÕES: Sempre levando em conta a importância da história clínica e epidemiológica, os novos testes baseados na produção de IFN-γ apresentam resultados promissores e deverão ser considerados na investigação de tuberculose em qualquer paciente, mas especialmente nos grupos de risco, como as crianças e os imunossuprimidos.&lt;br /&gt;&lt;hr /&gt;OBJECTIVES: To present an updated review concerning new assays for diagnosing tuberculosis based on in vitro interferon-gamma production by host T cells, and compare them with tuberculin skin test. SOURCES: A literature review was carried out based on Medline and LILACS databases (2000-2008) searching for the following keywords: tuberculosis, interferon-gamma, quantiFERON, ELISPOT and T-SPOT.TB. SUMMARY OF THE FINDINGS: These new assays proved to have, in general, equal or superior sensitivity and specificity than the tuberculin skin test not only in adults but also in children and immunosuppressed patients for the diagnosis of both latent tuberculosis infection or active disease, with some advantages such as less cross-reactivity as a result of previous BCG vaccination, less influence of anergy and better accuracy in small children. In the United States, these assays have been used instead of the tuberculin skin test and, although still very expensive, the World Health Organization will be making its economic viability a priority. CONCLUSIONS: Always having in mind the importance of clinical and epidemiological histories, these new assays based on interferon-gamma release present promising results and should be considered in tuberculosis investigation procedures for all patients, however with a special concern in the risk groups (i.e., children and immunosuppressed patients)."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0021-75572009000300002&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='The challenge of pediatric tuberculosis in face of new diagnostic techniques'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3100302766070678238/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/challenge-of-pediatric-tuberculosis-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3100302766070678238'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3100302766070678238'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/challenge-of-pediatric-tuberculosis-in.html' title='The challenge of pediatric tuberculosis in face of new diagnostic techniques'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4949779808959288735</id><published>2009-12-15T17:25:00.001-03:00</published><updated>2011-09-18T12:29:09.667-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Jornal de Pediatria - Sociedade Brasileira de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0021-75572009000400010&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed&lt;/a&gt;: "OBJETIVO: Avaliar a presença de lipodistrofia clínica em crianças com síndrome da imunodeficiência adquirida e relacioná-la com o esquema antirretroviral utilizado, alterações do perfil lipídico e resistência insulínica. &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;MÉTODOS: Por meio de estudo transversal, foram avaliadas 30 crianças e adolescentes (mediana de idade = 9,1 anos) com síndrome da imunodeficiência adquirida, no período entre 2004 e 2005. As avaliações clínico-laboratoriais incluíram: classificação da infecção pelo HIV, medidas antropométricas (peso e estatura), glicemia e insulina séricas e perfil lipídico (LDL-c, HDL-c, triglicérides). A lipodistrofia foi definida por parâmetros clínicos. O teste do qui-quadrado foi utilizado na análise estatística. RESULTADOS: Todos os pacientes recebiam terapia antirretroviral regularmente (mediana de tempo de uso = 28,4 meses), 80% utilizavam três drogas em associação (terapia fortemente ativa) e 30% usavam inibidores de protease. Lipodistrofia e dislipidemia foram observadas em 53,3 e 60% dos pacientes, respectivamente. Crianças que utilizavam terapia fortemente ativa com inibidor de protease apresentaram maior percentual de lipodistrofia mista, com diferença estatisticamente significante em relação ao grupo com terapia fortemente ativa sem inibidor de protease e ao grupo sem terapia fortemente ativa (44,4 versus 16,7%; p = 0,004). Não se observou diferença estatisticamente significante entre presença de lipodistrofia e gênero, idade (&amp;gt; 10 anos), alterações do perfil lipídico e resistência insulínica. CONCLUSÕES: A elevada prevalência de dislipidemia e lipodistrofia verificada nas crianças com síndrome da imunodeficiência adquirida, mostrando relação com o esquema antirretroviral empregado, pode significar um risco elevado para o desenvolvimento futuro de complicações, especialmente as cardiovasculares.&lt;br /&gt;&lt;hr /&gt;OBJECTIVE: To evaluate the presence of clinical lipodystrophy in children with the acquired immunodeficiency syndrome and to relate it to the antiretroviral regimen employed, to changes in lipid profile and to insulin resistance. METHODS: This was a cross-sectional study that evaluated 30 children and adolescents (median age = 9.1 years) with the acquired immunodeficiency syndrome during 2004 and 2005. The following clinical and laboratory evaluations were performed: classification of HIV infection, anthropometric measurements (weight and height), serum glycemia, serum insulin and lipid profile (LDL-c, HDL-c, triglycerides). Lipodystrophy was diagnosed using clinical parameters. The chi-square test was used for statistical analysis. RESULTS: All of the patients were taking antiretroviral therapy regularly (median duration of 28.4 months); 80% were on three drugs in combination (highly active therapy) and 30% were on protease inhibitors. Lipodystrophy and dyslipidemia were observed in 53.3 and 60% of the patients, respectively. Children on a highly active therapy regimen with protease inhibitors exhibited a higher percentage of mixed lipodystrophy; the difference between these children and the group on highly active therapy without protease inhibitors and the group not on a highly active therapy was statistically significant (44.4 vs. 16.7%; p = 0.004). There was no statistically significant association between the presence of lipodystrophy and sex, age (&amp;gt; 10 years), changes to the lipid profile or insulin resistance. CONCLUSIONS: The elevated prevalence of dyslipidemia and lipodystrophy observed among children with acquired immunodeficiency syndrome, which exhibited a relationship with the antiretroviral regimen employed, may represent an increased risk for future complications, in particular cardiovascular problems."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0021-75572009000400010&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4949779808959288735/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/lipodystrophy-in-children-and.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4949779808959288735'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4949779808959288735'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/lipodystrophy-in-children-and.html' title='Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7443296963673934886</id><published>2009-12-15T17:23:00.000-03:00</published><updated>2011-03-18T21:13:43.451-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Prevalence of physical inactivity and associated factors among high school students from state's public schools</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Jornal de Pediatria - Sociedade Brasileira de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0021-75572009000400006&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Prevalence of physical inactivity and associated factors among high school students from state's public schools&lt;/a&gt;: "OBJETIVO: Descrever a prevalência de inatividade física e os fatores associados em estudantes do ensino médio de escolas públicas estaduais da cidade de São Paulo (SP). &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;MÉTODOS: Foram selecionadas aleatoriamente 16 escolas públicas estaduais considerando as regiões geográficas da cidade de São Paulo (norte, sul, leste e oeste). A amostra foi de 3.845 estudantes do ensino médio no ano de 2006. Inatividade física foi mensurada com o Questionário Internacional de Atividade Física (IPAQ curto) e definida como praticar atividade física moderada e/ou vigorosa por um período menor que 300 minutos por semana. As variáveis independentes analisadas foram: gênero, idade, nível socioeconômico, região geográfica da cidade de São Paulo, conhecimento do programa Agita São Paulo, participação nas aulas de educação física escolar, uso de tabaco, ingestão de bebidas alcoólicas e tempo diário assistindo televisão. Foi utilizada a regressão de Poisson com três níveis para entrada de variáveis, com nível de significância de p &amp;lt; 0,05. RESULTADOS: A prevalência geral de inatividade física em adolescentes da cidade de São Paulo foi de 62,5% (IC95% 60,5-64,1). Os fatores associados à inatividade física foram o gênero, idade, nível socioeconômico, região geográfica da cidade de São Paulo, não conhecer o programa Agita São Paulo, não participar das aulas de educação física, uso de tabaco, ingestão de bebidas alcoólicas e tempo diário de televisão. CONCLUSÃO: A prevalência de inatividade física em adolescentes de São Paulo foi elevada em todas as regiões geográficas, além de fatores sociodemográficos e comportamentais contribuírem significativamente com a inatividade física.&lt;br /&gt;&lt;hr /&gt;OBJECTIVE: To describe the prevalence of physical inactivity and associated factors among high school students from state's public schools in the city of São Paulo, state of São Paulo, Brazil. METHODS: Sixteen state's public schools were randomly selected according to the geographic areas of the city (North, South, East, and West). The sample consisted of 3,845 high school students in 2006. Physical inactivity was measured using the International Physical Activity Questionnaire (short IPAQ) and was defined as practicing moderate and/or vigorous physical activity for a period of less than 300 minutes per week. The independent variables analyzed were: gender, age, socioeconomic level, geographic area of the city, awareness of the "Agita São Paulo" program, participation in physical education classes, smoking, alcohol intake and time spent per day watching television. Three-level Poisson regression was used for assessing the variables, with a significance level of p &amp;lt; 0.05. RESULTS: The general prevalence of physical inactivity among adolescents in São Paulo was 62.5% (95%CI 60.5-64.1). The factors associated with physical inactivity were gender, age, socioeconomic level, geographic area of the city, awareness of the "Agita São Paulo" program, non-participation in physical education classes, smoking, alcohol intake and time spent per day watching television. CONCLUSION: It was concluded that the prevalence of physical inactivity among adolescents in São Paulo was high in all the geographic areas evaluated, and that sociodemographic and behavioral factors contributed significantly to physical inactivity."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0021-75572009000400006&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Prevalence of physical inactivity and associated factors among high school students from state&apos;s public schools'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7443296963673934886/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/prevalence-of-physical-inactivity-and.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7443296963673934886'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7443296963673934886'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/prevalence-of-physical-inactivity-and.html' title='Prevalence of physical inactivity and associated factors among high school students from state&apos;s public schools'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5562432731518965264</id><published>2009-12-14T20:59:00.000-03:00</published><updated>2011-03-18T21:31:11.706-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Pharmakon Pediatrics e Ped News: os novos canais de informação atualizada em Pediatria!</title><content type='html'>&amp;nbsp;A partir de agora, o Pharmakon Pediatrics postará as principais notícias em medicina e, principalmente, pediatria, publicadas em portais, sites e blogs das principais fontes de informação em pediatria do Brasil e do Mundo. Já podem ser vistos posts de artigos dos periódicos: Revista Paulista de Pediatria e &amp;nbsp;Archivos Argentinos de Pediatría, além de notícias com links para o Medscape e logo seguirão posts dos artigos publicados na Evidencias en Pediatría e Revista Chilena de Pediatría. Aguardamos poder fazer o mesmo com o Jornal de Pediatria, da Sociedade Brasileira de Pediatria e com periódicos e sites das mais importantes revistas de pediatria. Além disso, sigam-nos no twitter: @PedNews, um canal que centraliza e direciona as principais novidades publicadas no Twitter e também em outros canais de mídia digital instantânea, principalmente sobre pediatria. O objetivo destes serviços é oferecer uma fonte de informações instantâneas para pediatras, outros profissionais da saúde e leigos interessados. Sigam-nos no Twitter! E também no blog, clicando no botão no final da página. Informação é vida!</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5562432731518965264/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/pharmakon-pediatrics-e-ped-news-os.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5562432731518965264'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5562432731518965264'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/pharmakon-pediatrics-e-ped-news-os.html' title='Pharmakon Pediatrics e Ped News: os novos canais de informação atualizada em Pediatria!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5321797011547447979</id><published>2009-12-14T10:53:00.000-03:00</published><updated>2011-09-18T12:29:09.684-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Juvenil idiopathic arthritis: Part 1: Diagnosis, pathogenesis and clinical manifestations</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Archivos Argentinos de Pediatría&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;amp;pid=S0325-00752009000500012&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Juvenil idiopathic arthritis: Part 1: Diagnosis, pathogenesis and clinical manifestations&lt;/a&gt;: Juvenile idiopathic arthritis is not a single disease and constitutes an heterogeneous group of illnesses or inflammatory disorders. This new nomenclature encompasses different disease categories, each of which has different presentation, clinical signs, symptoms, and outcome.&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt; The cause of the disease is still unknown but both environmental and genetic factors seem to be related to its pathogenesis. Is the most common chronic rheumatic disease in children and an important cause of short-term and long-term disability. In this article, clinical manifestation, new classification and approach to diagnosis are reviewed.&lt;br /&gt;&lt;hr /&gt;La artritis idiopática juvenil no constituye una entidad 'única' sino un grupo heterogéneo de enfermedades o trastornos inflamatorios. Esta nueva denominación abarca diferentes categorías de enfermedad, cada una de ellas con distintas formas de presentación, signos y síntomas clínicos, y pronóstico. La causa de esta entidad es aún desconocida, pero factores ambientales y genéticos intervienen en su patogenia. Es la más común de las enfermedades reumáticas en la infancia y causa importante de discapacidad a corto y largo plazos. Revisaremos aquí las manifestaciones clínicas, la nueva clasificación, el abordaje diagnóstico y los diagnósticos diferenciales.</content><link rel='related' href='http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;pid=S0325-00752009000500012&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Juvenil idiopathic arthritis: Part 1: Diagnosis, pathogenesis and clinical manifestations'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5321797011547447979/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/juvenil-idiopathic-arthritis-part-1.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5321797011547447979'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5321797011547447979'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/juvenil-idiopathic-arthritis-part-1.html' title='Juvenil idiopathic arthritis: Part 1: Diagnosis, pathogenesis and clinical manifestations'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2508718769565851467</id><published>2009-12-14T10:49:00.002-03:00</published><updated>2011-09-18T12:29:09.561-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Amitraz poisoning</title><content type='html'>&lt;div&gt;&lt;span style="font-size: x-large;"&gt;Archivos Argentinos de Pediatría&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;amp;pid=S0325-00752009000500015&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Amitraz poisoning&lt;/a&gt;:&amp;nbsp;Poisoning due to amitraz together with its solvent xilene, is an unusual condition although may be increasing in rural areas where it is used as insecticide-ectoparasiticide.&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;1-3 At present, there is scare references to orient physicians concerning its handling in childhood. We present the case of a 2-year-old boy who suffered an accidental intake of amitraz and was admitted into our Pediatric Intensive Care Unit requiring mechanical ventilation. We consider the usefulness of informing the medical community about this case so as to be aware of this rare kind of poisoning in our community.&lt;br /&gt;&lt;hr /&gt;En nuestro medio, la intoxicación por amitraz y su solvente xileno es una patología poco frecuente, pero puede observarse un aumento en zonas rurales, donde se lo emplea como insecticida-ectoparasiticida.1-3 Por tal razón, se cuenta con escasa bibliografía que oriente su manejo en niños. Presentamos el caso de un paciente de 2 años de edad, con ingestión accidental de amitraz, internado en nuestra Unidad de Cuidados Intensivos Pediátricos y que requirió ventilación mecánica. Creemos que comunicar este caso puede ser útil para alertar sobre esta intoxicación, poco frecuente en nuestro medio.</content><link rel='related' href='http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;pid=S0325-00752009000500015&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Amitraz poisoning'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2508718769565851467/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/amitraz-poisoning.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2508718769565851467'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2508718769565851467'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/amitraz-poisoning.html' title='Amitraz poisoning'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1513253241490719843</id><published>2009-12-14T10:47:00.001-03:00</published><updated>2009-12-14T10:47:58.195-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Dengue 2009: chronology of an epidemic</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Archivos Argentinos de Pediatría&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;amp;pid=S0325-00752009000500002&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Dengue 2009: chronology of an epidemic&lt;/a&gt;</content><link rel='related' href='http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;pid=S0325-00752009000500002&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Dengue 2009: chronology of an epidemic'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1513253241490719843/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/dengue-2009-chronology-of-epidemic.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1513253241490719843'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1513253241490719843'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/dengue-2009-chronology-of-epidemic.html' title='Dengue 2009: chronology of an epidemic'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4673877841259163017</id><published>2009-12-14T10:46:00.000-03:00</published><updated>2011-03-18T21:13:43.457-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Prenatal diagnosis by the presence of fetal DNA in maternal blood</title><content type='html'>&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Archivos Argentinos de Pediatría&lt;/span&gt;&lt;br /&gt;&lt;a href="http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;amp;pid=S0325-00752009000500004&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Prenatal diagnosis by the presence of fetal DNA in maternal blood&lt;/a&gt;</content><link rel='related' href='http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;pid=S0325-00752009000500004&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Prenatal diagnosis by the presence of fetal DNA in maternal blood'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4673877841259163017/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/prenatal-diagnosis-by-presence-of-fetal.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4673877841259163017'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4673877841259163017'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/prenatal-diagnosis-by-presence-of-fetal.html' title='Prenatal diagnosis by the presence of fetal DNA in maternal blood'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5575722797427092547</id><published>2009-12-12T12:51:00.001-03:00</published><updated>2011-03-18T21:31:11.708-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Prokinetics should not be routinely prescribed in the treatment of gastroesophageal reflux disease in pediatric patients</title><content type='html'>&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Revista Paulista de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0103-05822009000300001&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Prokinetics should not be routinely prescribed in the treatment of gastroesophageal reflux disease in pediatric patients&lt;/a&gt;</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-05822009000300001&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Prokinetics should not be routinely prescribed in the treatment of gastroesophageal reflux disease in pediatric patients'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5575722797427092547/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/prokinetics-should-not-be-routinely.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5575722797427092547'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5575722797427092547'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/prokinetics-should-not-be-routinely.html' title='Prokinetics should not be routinely prescribed in the treatment of gastroesophageal reflux disease in pediatric patients'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5925576592893553496</id><published>2009-12-12T11:39:00.001-03:00</published><updated>2011-09-18T12:29:09.708-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Nutritional status evaluation in schoolchildren according to three references</title><content type='html'>&lt;span style="font-size: x-large;"&gt;Revista Paulista de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0103-05822009000300003&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Nutritional status evaluation in schoolchildren according to three references&lt;/a&gt;: "OBJETIVO: Comparar a avaliação do estado nutricional de escolares de acordo com as três curvas de referências.&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt; MÉTODOS: AS variáveis peso e estatura de 181 crianças na faixa etária de cinco a dez anos foram obtidas de um banco de dados de vigilância nutricional de escolares da Ilha de Paquetá, organizado de acordo com as recomendações do Sistema de Vigilância Alimentar e Nutricional (Sisvan). O gráfico de Bland Altman e a razão de desvios foram empregados para construir perfis de concordância entre as três curvas de referência de avaliação nutricional dois a dois, utilizando-se os valores do índice de massa corporal. Na determinação da prevalência de déficit pôdero-estatural e sobrepeso, utilizaram-se os pontos de cortes recomendados por Cole, pelo Centers for Diseases Control and Prevention e por Conde e Monteiro. RESULTADOS: A prevalência de obesidade em meninas foi igual (3,1%) para Cole e Conde e Monteiro e ambas se sobrepuseram à obtida por meio da curva do Centers for Diseases Control and Prevention de 2000 (2,0%). Em relação aos meninos, a prevalência de obesidade obtida por Conde e Monteiro (4,8%) foi menor do que os percentuais encontrados por Cole (7,2%) e pelo CDC (7,2%). CONCLUSÕES: Os resultados sugerem que a escolha do referencial brasileiro (Conde e Monteiro) não dificulta a comparação com outros critérios internacionais, principalmente no que tange à classificação de obesidade em escolares do gênero masculino.&lt;br /&gt;&lt;hr /&gt;OBJECTIVE: To compare the nutritional status of schoolchildren according to three different reference curves. METHODS: The weight and height of 181 children aged 5-10 years were obtained from a database for the nutritional surveillance of schoolchildren from Paquetá Island, RJ, Brazil, which had been designed in compliance with recommendations of the Brazilian Food and Nutrition Surveillance System (Sistema de Vigilância Alimentar e Nutricional, Sisvan). Bland-Altman plot and deviation ratios were used to produce profiles of agreement between pairs of nutritional assessment references using body mass index values. Cutoff values of the following standards were used in order to determine the prevalence of overweight and weight and height deficit: Cole, Centers for Disease Control and Prevention (CDC), and Conde &amp;amp; Monteiro. RESULTS: The prevalence rates for obesity in girls were similar using the Cole and Conde &amp;amp; Monteiro (3.1%) cutoffs, but the prevalence rate according to the CDC standard was significantly lower (2.0%). For boys, the prevalence of obesity using the Conde &amp;amp; Monteiro cutoff (4.8%) was lower than the rates obtained using the cutoffs suggested by Cole (7.2%) and by the CDC (7.2%). CONCLUSIONS: These results suggest that the choice of the Brazilian reference curve (Conde &amp;amp; Monteiro) does not impair the comparison with other international standards, particularly for obesity in male schoolchildren."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-05822009000300003&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Nutritional status evaluation in schoolchildren according to three references'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5925576592893553496/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/nutritional-status-evaluation-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5925576592893553496'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5925576592893553496'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/nutritional-status-evaluation-in.html' title='Nutritional status evaluation in schoolchildren according to three references'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4536470622201491102</id><published>2009-12-12T11:38:00.001-03:00</published><updated>2011-09-18T12:29:09.659-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Systematic review and meta-analysis of the use of prokinetics in gastroesophageal reflux and in gastroesophageal reflux disease in Pediatrics</title><content type='html'>&lt;span style="font-size: x-large;"&gt;Revista Paulista de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0103-05822009000300002&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Systematic review and meta-analysis of the use of prokinetics in gastroesophageal reflux and in gastroesophageal reflux disease in Pediatrics&lt;/a&gt;: "OBJETIVO: Avaliar, por meio de revisão sistemática e metanálise, estudos randomizados que comparam os procinéticos domperidona, bromoprida, metoclopramida e betanecol ao placebo no tratamento do refluxo gastroesofágico (RGE) e da doença do refluxo gastroesofágico (DRGE) em crianças. &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;MÉTODOS: BUsca bibliográfica de ensaios clínicos randomizados (Medline, EMBASE, Biological Abstracts, ISI/Web of Science, CINAHL, Lilacs e Cochrane). O desfecho primário foi eficácia na modificação dos sintomas de refluxo, conforme definição de autores das fontes primárias. Outras variáveis de interesse foram: complicações relacionadas ao RGE, alterações nos exames laboratoriais de controle, qualidade de vida, eventos adversos e abandono do tratamento. RESULTADOS: Foram incluídos quatro estudos com domperidona, dois com metoclopramida, um com betanecol. Nenhum estudo com bromoprida foi localizado. O risco de não resposta ao tratamento foi significativamente menor para os procinéticos quando comparados ao placebo (RR 0,35; IC95% 0,14-0,88). A vantagem terapêutica individual em relação ao placebo se manteve para a domperidona (n=126; RR 0,27; IC95% 0,14-0,52; NNT 3; I2 0%) e betanecol (n=44, RR 0,19, IC95% 0,05-0,55, NNT 2), mas não para metoclopramida (n=71; RR 0,63; IC95% 0,07-5,71, I2 92,2%). CONCLUSÕES: A evidência para o uso de procinéticos no RGE e na DRGE em crianças é limitada, pois os poucos estudos são ensaios preliminares de resposta em curto prazo e com limitações metodológicas.&lt;br /&gt;&lt;hr /&gt;OBJECTIVE: To evaluate, by systematic review and meta-analysis, randomized studies comparing the prokinetics (domperidone, bromopride, metoclopramide and bethanechol) to placebo in the treatment of gastroesophagic reflux (GER) and gastroesophagic reflux disease (GERD) in children. METHODS: Bibliographic search for randomized clinical trials (Medline, EMBASE, Biological Abstracts, ISI/Web of Science, CINAHL, Lilacs e Cochrane). The primary outcome was the modification of reflux symptoms. Other outcomes were: GER-related complications, alterations in control exams, life quality, adverse events and abandon of treatment. RESULTS: The metanalysis included four studies on domperidone, two on metoclopramide, and one on bethanechol. No study of bromopride was retrieved. The risk of non-response to the treatment was significantly smaller in children that received prokinetics in comparison to placebo (RR 0.35, 95%CI 0.14-0.88). Individual therapeutic advantage regarding placebo was related to domperidone (n=126; RR 0.27; 95%CI 0.14-0.52, NNT 3; I2 0%) and bethanechol (n=44; RR 0.19; 95%CI 0.05-0.55; NNT 2), but not to metoclopramide (n=71; RR 0.63; 95%CI 0.07-5.71; I2 92.2%). CONCLUSIONS: The evidence for prokinetic use in GER and GERD in children is limited because the few studies report preliminary trials that evaluate short-term responses and show methodological limitations."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-05822009000300002&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Systematic review and meta-analysis of the use of prokinetics in gastroesophageal reflux and in gastroesophageal reflux disease in Pediatrics'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4536470622201491102/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/systematic-review-and-meta-analysis-of.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4536470622201491102'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4536470622201491102'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/systematic-review-and-meta-analysis-of.html' title='Systematic review and meta-analysis of the use of prokinetics in gastroesophageal reflux and in gastroesophageal reflux disease in Pediatrics'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3062086449330414933</id><published>2009-12-12T11:30:00.001-03:00</published><updated>2011-09-18T12:29:09.584-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Variables associated with overweight in children from a shantytown in the Northeast of Brazil</title><content type='html'>&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Revista Paulista de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0103-05822009000300004&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;Variables associated with overweight in children from a shantytown in the Northeast of Brazil&lt;/a&gt;: "OBJETIVO: Determinar a frequência e os principais fatores associados a sobrepeso e obesidade em crianças moradoras de uma favela do Nordeste do Brasil. &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;MÉTODOS: Estudo transversal com amostra de 86 crianças (40 eutróficas e 46 sobrepeso/obesas), com idade entre cinco e nove anos, selecionadas em um universo de 508 crianças nesta faixa etária, avaliadas e cadastradas na Unidade de Saúde da Família (USF). Para definição de sobrepeso/obesidade, foram utilizados os pontos de corte estabelecidos por Cole et al. Pesquisaram-se variáveis biológicas, socioeconômicas, hábitos alimentares, tempo em frente à televisão e sedentarismo. Para a análise dos dados foram empregados os testes de associação, sendo significante p&amp;lt;0,05. RESULTADOS: A frequência de sobrepeso/obesidade entre as 508 crianças foi 13%. Ingestão calórica excessiva, consumo de refresco artificial açucarado e sedentarismo foram os fatores associados ao sobrepeso e à obesidade. CONCLUSÕES: A frequência de sobrepeso/obesidade foi relevante no grupo estudado e os fatores que estiveram associados ao sobrepeso/obesidade foram ingestão calórica excessiva, consumo de refresco artificial açucarado e sedentarismo, que constituem pontos a serem trabalhados na população como forma de intervenção e prevenção de agravamentos no futuro.&lt;br /&gt;&lt;hr /&gt;OBJECTIVE: To determine the frequency and the main factors associated with overweight and obesity in children living in a slum area in the northeast of Brazil. METHODS: This cross-sectional study was conducted with a sample of 86 children (40 eutrophic and 46 overweight/obese) aged 5 to 9 years selected among 508 children in this age group evaluated and registered in the Family Health Unit (Unidade Saúde da Família, USF). Overweight/obesity were defined according to the cutoff points established by Cole et al were used. Biological and socioeconomic variables, dietary habits, time spent on television, and sedentary habits were analyzed. Association tests were conducted to analyze the data. Significance was set at p &amp;lt; 0.05. RESULTS: The prevalence of overweight/obesity among the 508 children was 13%. Excessive calorie intake, consumption of artificially sweetened drinks, and sedentary habits were significantly associated with overweight and obesity. CONCLUSIONS: The prevalence of overweight/obesity was high in the group assessed and it was associated with excessive calorie intake, consumption of artificially sweetened drinks and sedentary lifestyle. These factors should be taken into consideration in the planning and development of interventions and prevention strategies."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-05822009000300004&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='Variables associated with overweight in children from a shantytown in the Northeast of Brazil'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3062086449330414933/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/variables-associated-with-overweight-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3062086449330414933'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3062086449330414933'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/variables-associated-with-overweight-in.html' title='Variables associated with overweight in children from a shantytown in the Northeast of Brazil'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8003035341519048199</id><published>2009-12-12T11:22:00.002-03:00</published><updated>2011-03-18T21:13:43.468-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>The history of the inception and evolution of psychological care for infants and their families in a Neonatal Unit</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Revista Paulista de Pediatria&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0103-05822009000300017&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en"&gt;The history of the inception and evolution of psychological care for infants and their families in a Neonatal Unit&lt;/a&gt;: "OBJETIVO: Este artigo apresenta o histórico de atuação de uma psicóloga na área de Neonatologia e sua evolução, desde as primeiras tentativas de mudar certas rotinas da unidade para que favorecessem a humanização do atendimento até a sua completa inserção na equipe multidisciplinar. &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;São descritas em detalhes as atuações específicas junto aos bebês e suas famílias no contexto da internação hospitalar, com o intuito de auxiliar os profissionais de saúde que trabalham na área de implementação de programas afins. DESCRIÇÃO DO CASO: Relato da história de inserção e da evolução do trabalho de uma psicóloga na equipe de Neonatologia do Centro de Atenção Integral à Saúde da Mulher (CAISM) da Universidade Estadual de Campinas (Unicamp), num período de dez anos (1993 a 2003). Descrevem-se as atividades específicas da Psicologia, o embasamento teórico dos programas desenvolvidos na unidade e os recursos técnicos utilizados no atendimento à clientela. COMENTÁRIOS: O saber específico do psicólogo pode ser estendido a toda a equipe, favorecendo ações de prevenção em Saúde Mental, principalmente a proteção da relação mãe-bebê. Além disso, pode ser disseminado, ganhar relevância e fazer parte do cotidiano de todas as unidades de terapia neonatais.&lt;br /&gt;&lt;hr /&gt;OBJECTIVE: This article describes the evolution of a psychologist's work in a Neonatal Care Unit, from simple interventions that changed certain routines to foster humanization of care, to the complete integration of this professional into the multidisciplinary neonatal team. Detailed descriptions of the work's implementation in the hospital setting offer health professionals of the field a model for similar programs. CASE DESCRIPTION: The history of the inception and evolution of a psychologist's work at the Neonatal Care Unit of Universidade Estadual de Campinas in a ten-year period (1993 to 2003) was described. Specific activities developed within this period have been described, as well as the theory supporting every action. The base techniques utilized within this time frame are also commented. COMMENTS: The specificity of the psychologist's knowledge can be extended to other health professionals of the same field, promoting preventive mental health measures, especially actions that benefit the bonding between mothers and their babies. It could also be disseminated, grow in importance, and become routine in every neonatal care unit."</content><link rel='related' href='http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-05822009000300017&amp;lng=en&amp;nrm=iso&amp;tlng=en' title='The history of the inception and evolution of psychological care for infants and their families in a Neonatal Unit'/><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8003035341519048199/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/history-of-inception-and-evolution-of.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8003035341519048199'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8003035341519048199'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/history-of-inception-and-evolution-of.html' title='The history of the inception and evolution of psychological care for infants and their families in a Neonatal Unit'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1030754067193059289</id><published>2009-12-11T23:05:00.001-03:00</published><updated>2011-09-18T12:27:16.192-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>SABCS News: Oral Bisphosphonates May Prevent Invasive Breast Cancer</title><content type='html'>&lt;span style="font-size: x-large;"&gt;Top News of the Week&lt;br /&gt;&lt;/span&gt;SABCS News: Oral Bisphosphonates May Prevent Invasive Breast Cancer&lt;br /&gt;Medscape Medical News&lt;br /&gt;SABCS News: "Nuanced" Advice About Alcohol for Women With Early Breast Cancer&lt;br /&gt;Medscape Medical News&lt;br /&gt;Cancer Survivors at "Substantial" Risk of Cardiovascular Disease&lt;br /&gt;Heartwire&lt;br /&gt;&lt;div&gt;&lt;a name='more'&gt;&lt;/a&gt;&lt;br /&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 600px;"&gt;&lt;tbody&gt;&lt;tr&gt;    &lt;td align="center" bgcolor="#0067a8" width="1"&gt;&lt;img height="1" src="http://images.medscape.com/pi/editorial/newsmedpulse/1pix.gif" width="1" /&gt;&lt;br /&gt;&lt;/td&gt;    &lt;td align="center" valign="top" width="598"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 598px;"&gt;&lt;tbody&gt;&lt;tr&gt;      &lt;td width="20"&gt;&lt;img height="1" src="http://images.medscape.com/pi/editorial/newsmedpulse/1pix.gif" width="1" /&gt;&lt;br /&gt;&lt;/td&gt;      &lt;td align="left" valign="top" width="563"&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;table align="right" bgcolor="#FFFFCC" border="0" cellpadding="10" cellspacing="0" style="border-bottom-color: rgb(174, 198, 212); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(174, 198, 212); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(174, 198, 212); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(174, 198, 212); border-top-style: solid; border-top-width: 1px; width: 235px;"&gt;&lt;tbody&gt;&lt;tr&gt;   &lt;td&gt;&lt;table border="0" cellpadding="0" cellspacing="0"&gt;&lt;tbody&gt;&lt;tr&gt;  &lt;td width="87"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KMHL0EA"&gt;&lt;img alt="" border="0" height="20" src="http://images.medscape.com/pi/twitter/twitter_small.gif" width="87" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;/td&gt;  &lt;td&gt;&lt;b&gt;&lt;span style="color: #33ccff; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;»&lt;/span&gt;&lt;/b&gt;&lt;br /&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;span style="color: black; font-family: verdana, arial, sans-serif; font-size: x-small;"&gt;&lt;b&gt;  &lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KMHL0EA"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Follow Medscape Oncology on Twitter&lt;/span&gt;&lt;/a&gt;&lt;/b&gt;. Get breaking news, conference updates and more.&lt;br /&gt;&lt;/span&gt;      &lt;br /&gt;&lt;/td&gt;  &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;span style="color: #43846c; font-family: verdana, arial; font-size: 17px; font-weight: normal;"&gt;Top News of the Week&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;        &lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpmw0E4&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;&lt;strong&gt;SABCS News: Oral Bisphosphonates May Prevent Invasive Breast Cancer&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpmx0E5&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;SABCS News: "Nuanced" Advice About Alcohol for Women With Early Breast Cancer&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpmy0E6&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Cancer Survivors at "Substantial" Risk of Cardiovascular Disease&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Heartwire&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="color: #43846c; font-family: verdana, arial; font-size: 17px; font-weight: normal;"&gt;News from the American Society of Hematology (ASH) 2009 annual meeting&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;  &lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpmz0E7&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Bendamustine Plus Rituximab Could Replace R-CHOP in Indolent Lymphomas&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm10Et&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Dabigatran Can Replace Warfarin in Venous Thromboembolism: RECOVER Results&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm20Eu&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Ongoing Study of First-Ever Drug Therapy for Myelofibrosis&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm30Ev&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Aspirin Does Not Improve Live Birth Rate in Women With Recurrent Miscarriage&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm40Ew&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;International Initiative Improves Outcomes for Acute Promyelocytic Leukemia in Developing Countries&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm50Ex&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Novel Agent Shows Promise for T1351 Positive Chronic Myeloid Leukemia&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm60Ey&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Defibrotide Prophylaxis Reduces Veno-Occlusive Disease in Pediatric Transplant Patients&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm70Ez&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;T-Cell Depletion Improves Transplant Outcomes in Adults With Acute Myeloid Leukemia&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kpm80E1&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;First Human Treg Infusion Improves Haploidentical Bone Marrow Transplant in Acute Leukemia&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnA0EC&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;New Gene Findings in Infant Acute Lymphoblastic Leukemia&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnB0ED&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Carfilzomib Shows Promise in Multiple Myeloma Study&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnC0EE&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Sildenafil for Pulmonary Hypertension Increases Pain Crises in Sickle Cell Patients&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnD0EF&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;H1N1 Flu More Risky Than Seasonal Flu for Young Sickle Cell Patients&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt; &lt;br /&gt;&lt;span style="color: #43846c; font-family: verdana, arial; font-size: 17px; font-weight: normal;"&gt;More Medscape Medical News&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;   &lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kppt0E4&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;AUA's Controversial PSA Best Practice Statement Is Published&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;MedscapeCME Clinical Briefs&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnE0EG&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Is That CT-Detected Noncalcified Nodule Lung Cancer or Not?&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnF0EH&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Everybody's Doing It: Radiation Oncologists and Advanced Imaging&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnG0EI&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Cancer Death Rate Continues to Fall&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;WebMD Health News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnH0EJ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Screening Can Diagnose Severe T-Cell Lymphopenia in Newborns&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnI0EK&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Dietary Soy Linked to Lower Risk for Breast Cancer Death, Recurrence&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnJ0EL&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Sen Grassley Asks Medical Societies About Industry Funding&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Heartwire&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0Kojx0E1&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Increased Use of Cell Phones Not Associated With Rise in Brain Tumors&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Medscape Medical News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnK0EM&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Risk of Venous Thromboembolism Greater, Lasts Longer, Than Thought&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Heartwire&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt; &lt;br /&gt;&lt;span style="color: #43846c; font-family: verdana, arial; font-size: 17px; font-weight: normal;"&gt;Prostate Cancer&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;  &lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnL0EN&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;For High-Grade Prostate CA, Combined Therapies Are Better Than Any One Alone&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnM0EO&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Androgen Deprivation Raises Men's Risk of Diabetes and Cardiovascular Disease&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnN0EP&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Drug Eases Hormone Therapy Side Effect in Men&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;WebMD Health News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnO0EQ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Coffee May Cut Risk of Prostate Cancer&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;WebMD Health News&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnP0ER&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Prostate Cancer Vaccine Looks Promising in Phase I Study&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt; &lt;br /&gt;&lt;span style="color: #43846c; font-family: verdana, arial; font-size: 17px; font-weight: normal;"&gt;More Oncology News from Reuters&lt;/span&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;               &lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnQ0ES&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Drug Combo Not Recommended for Metastatic Melanoma&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnR0ET&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Low Uptake of HPV Vaccine Among College Students in Hong Kong&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClx30SuY5A0D1E0KpnS0EU&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88; font-family: verdana, Arial, sans-serif; font-size: x-small;"&gt;Higher Lung Cancer Risk in Eastern China: Study&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="color: #999999; font-family: verdana, Arial, sans-serif; font-size: xx-small;"&gt;Reuters Health Information&lt;/span&gt;&lt;br /&gt;&lt;/td&gt;&lt;td width="15"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/td&gt;&lt;td align="center" bgcolor="#0067a8" width="1"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center" bgcolor="#0067a8" colspan="3" height="1"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1030754067193059289/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/sabcs-news-oral-bisphosphonates-may.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1030754067193059289'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1030754067193059289'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/sabcs-news-oral-bisphosphonates-may.html' title='SABCS News: Oral Bisphosphonates May Prevent Invasive Breast Cancer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7404889903395310997</id><published>2009-12-10T12:56:00.003-03:00</published><updated>2011-09-18T12:29:09.742-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Ganciclovir and Valganciclovir Use in Children</title><content type='html'>&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Medscape Pediatrics MedPulse®&lt;br /&gt;Top Stories&lt;/span&gt;&lt;br /&gt;Ganciclovir and Valganciclovir Use in Children&lt;br /&gt;Vomiting in the Pediatric Age Group&lt;br /&gt;Medscape One-on-One: Rapidly Unfolding Health Information Technology&lt;br /&gt;Pediatric Falls: State of the Science&lt;br /&gt;Symptomatic and Pathophysiologic Predictors of Hepatitis C Virus Progression&lt;br /&gt;in Pediatric Patients&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;&lt;br /&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 650px;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="top" width="649"&gt;&lt;b&gt;&lt;span style="color: #990000; font-family: Arial, sans-serif; font-size: small;"&gt;Feature Articles&lt;/span&gt;&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" height="5" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotA0EG&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Ganciclovir and Valganciclovir Use in Children&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;These antiviral agents are effective for CMV infection, especially following pediatric organ transplantation, but certain precautions must be followed.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Pediatr Pharm 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotB0EH&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Pediatric Falls: State of the Science&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Why is this important safety concern often overlooked in children?&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Pediatr Nurs 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotC0EI&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children  F1000 Ranking: "Exceptional" and "Changes Clinical Practice" &lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Should prophylactic acetaminophen routinely be given at the time of vaccination?&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Faculty of 1000 Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotD0EJ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Mammography Goes From a Yearly Squeeze to Biennial Stretch&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Sandra Fryhofer, MD, sounds off on the new USPSTF guidelines on mammography screening. She has some issues.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Internal Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotE0EK&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Medscape One-on-One: Rapidly Unfolding Health Information Technology&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;In the first in a new one-on-one series, Dr. Eli Adashi and Dr. Ashish Jha discuss health information technology -- what it means for both inpatient and outpatient physicians.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Internal Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotF0EL&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial-Type 1&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Children with incident dysglycemia have an especially high risk for type 1 diabetes.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Diabetes Care 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotG0EM&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Office Embezzlement: Are You Losing Money You Do Not Even Know About?&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Office embezzlement takes place more often than doctors realize. This article tells how to spot when it is happening and how to prevent it.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Business of Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotH0EN&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;2009 H1N1: What's New This Week -- December 1, 2009&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;John Bartlett comments on the past week's H1N1 news and provides guidance to practicing clinicians.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Infectious Diseases 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotI0EO&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Vomiting in the Pediatric Age Group&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;The causes of vomiting in children range from the benign to the life-threatening. It is helpful to know the most likely causes when faced with the vomiting child.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Pediatr Health 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotJ0EP&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Pharmacotherapy and Surgery Treatment for the Severely Obese Adolescent&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Here is a review of treatment with sibutramine or orlistat, current recommendations for bariatric surgical referral, and advice on postsurgical management for patients in this age group.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;J Pediatr Health Care 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotK0EQ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;West Sweden Asthma Study: Prevalence Trends Over the Last 18 Years Argue No Recent Increase in Asthma &lt;/span&gt; &lt;br /&gt;&lt;/a&gt;In comparison with studies performed 18 years ago, the prevalence of asthma has not increased, and the prevalence of most respiratory symptoms has decreased.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Respiratory Research 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotL0ER&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;The Case of the Peripatetic Physician: A Strategy to Avoid Accountability&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Changing jobs and locations frequently can often be a sign of incompetence and poor performance. Can this physician be restrained, or at least retrained?&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Internal Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotM0ES&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Buzz Words Surrounding Healthcare Reform&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Guaranteed issue, community rating, and individual mandate: What do these terms mean in the context of healthcare reform? What do they mean for you? David M. Brown, MD, explains in this video blog.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Ophthalmology 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotN0ET&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;New Pap Smear Guidelines From ACOG&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;ACOG released new cervical cytology screening guidelines that suggest that less is more. Dr. Andrew Kaunitz discusses the key updates and their rationale in this video blog.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Ob/Gyn &amp;amp; Women's Health 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotO0EU&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;CDC Commentary -- 2009 H1N1: Who Should Receive Antiviral Therapy?&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;In this video blog, Anthony Fiore, MD, MPH, offers guidance on which patients are at highest risk for H1N1 influenza and when to prescribe antiviral therapy.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt; 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotP0EV&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Introduction and Transmission of 2009 Pandemic Influenza A (H1N1) Virus, Kenya, June-July 2009&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Since introduction of pandemic H1N1 virus in Kenya in June 2009, the overall 26% secondary attack rate of the virus appears comparable to that of seasonal influenza.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Morbidity &amp;amp; Mortality Weekly Report 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotQ0EW&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Public Health Officials Readying for Increase in H1N1 Influenza Cases&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;An expected increase of H1N1 influenza this fall has federal health agencies and health leaders ramping up resources.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Nations Health 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotR0EX&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Influenza Vaccination Coverage Among Children and Adults -- United States, 2008-2009 Influenza Season&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;During last year's flu season, only approximately 20% of school-aged children were vaccinated against seasonal influenza, highlighting the need for increased attention to this age group.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Morbidity &amp;amp; Mortality Weekly Report 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotS0EY&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;High Cytomegalovirus Load and Prolonged Virus Excretion in Breast Milk Increase Risk for Viral Acquisition by Very Low Birth Weight Infants&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Low birth weight infants are at high risk for human cytomegalovirus infection from high maternal CMV load and prolonged viral excretion in breast milk.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Pediatr Infect Dis J 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotT0EZ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Neonatal Vaccination: A Once in a Lifetime Opportunity&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Birth is the most frequent healthcare contact, and the best time to protect children from vaccine-preventable diseases.&lt;br /&gt;&lt;span style="font-size: xx-small;"&gt;Pediatr Infect Dis J 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KotU0Ea&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Symptomatic and Pathophysiologic Predictors of Hepatitis C Virus Progression in Pediatric Patients&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;Symptoms and physiologic liver changes can help determine the need for treatment in children with hepatitis C infection.&lt;br /&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;img alt="" border="0" height="1" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;img alt="" border="0" height="1" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;b&gt;&lt;span style="color: #990000; font-family: Arial, sans-serif; font-size: small;"&gt;News&lt;/span&gt;&lt;/b&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" height="5" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Top News&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpDW0Ep&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Children With Persistent AOM Have Poor Responses to Vaccines&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Medical News 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpDc0E2&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Abuse Is the Most Common Cause of Infantile Subdural Bleeding&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Reuters Health Information 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpDj0EA&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;H1N1 Flu Still Down in US but 198 Children Dead&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Reuters Health Information 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpDr0EI&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;MRI Reveals High Incidence of Disc Disease in Overweight and Obese Youngsters&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Reuters Health Information 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;News and Approvals from the FDA&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpDt0EK&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;FDA Reminds Healthcare Professionals of Valproate Link to Birth Defects&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Medical News 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Infectious Diseases and Immunization&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpDz0EQ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Phase 2 Clinical Trial of Pediatric Dengue Vaccine Shows Promise&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Medical News 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Neonatal Care&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpD60EI&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Late Preterm Birth Increases Risk of Faltering Growth in Early Childhood&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Reuters Health Information 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Mental Health in Children and Adolescents&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpEC0EW&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Children of Mentally Ill Parents at Increased Mortality Risk&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Medical News 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpEH0Eb&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Aripiprazole Eases Irritability in Autistic Kids but Causes Weight Gain&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Reuters Health Information 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpEM0Eg&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Children With ASD Have Specific Handwriting Impairments&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Medical News 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Professional News&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpEP0Ej&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;New Guidelines on Reporting Industry-Supported Clinical Trial Results&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Medical News 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;More News this Week&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpET0En&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Iraq Sees Alarming Rise in Cancers, Deformed Babies&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Reuters Health Information 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpEY0Es&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Long-Term Growth Hormone Safe and Effective for Pediatric Prader-Willi Syndrome&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Reuters Health Information 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClKF0SuY5A0DzQ0KpEb0E2&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;WHO Issues New HIV Recommendations&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Medical News 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;/td&gt;&lt;td bgcolor="#333333" width="1"&gt;&lt;img alt="" border="0" height="1" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" width="650"&gt;&lt;img alt="" border="0" height="10" src="http://images.medscape.com/pi/features/emails/medpulse/mp-bottom.gif" width="650" /&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;div&gt;&lt;img alt="" border="0" height="10" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7404889903395310997/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/ganciclovir-and-valganciclovir-use-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7404889903395310997'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7404889903395310997'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/ganciclovir-and-valganciclovir-use-in.html' title='Ganciclovir and Valganciclovir Use in Children'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5064494278699140070</id><published>2009-12-10T12:49:00.006-03:00</published><updated>2011-09-18T12:27:16.288-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Focus on Breast Cancer</title><content type='html'>&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Medscape Oncology MedPulse®&lt;br /&gt;&lt;/span&gt;&lt;span class="Apple-style-span" style="font-size: x-large;"&gt;Top Stories&lt;/span&gt;&lt;br /&gt;What's Hot at the 32nd Annual San Antonio Breast Cancer Symposium&lt;br /&gt;Top Mammography Experts Voice Outrage Over New Breast Cancer Screening&lt;br /&gt;Recommendations&lt;br /&gt;Senate Guarantees Coverage of Mammograms, Other Screenings&lt;br /&gt;in Healthcare Reform Bill&lt;br /&gt;Fertility Preservation for Breast Cancer Patients&lt;br /&gt;Preventing Second Breast Cancers - More Advice To Give Our&lt;br /&gt;Patients&lt;br /&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 650px;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;&lt;span style="color: #006699; font-family: verdana, arial; font-size: small;"&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/span&gt;&lt;span style="color: #006699; font-family: verdana, arial; font-size: small;"&gt;&lt;b&gt;&lt;span style="color: black; font-family: 'Times New Roman';"&gt;&lt;span class="Apple-style-span" style="font-weight: normal;"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="color: #006699; font-family: verdana, arial; font-size: small;"&gt;&lt;b&gt;&lt;span style="color: black; font-family: 'Times New Roman';"&gt;&lt;a name='more'&gt;&lt;/a&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right"&gt;&lt;div style="text-align: auto;"&gt;&lt;div style="text-align: auto;"&gt;&lt;div style="text-align: auto;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 650px;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="top" width="649"&gt;&lt;div&gt;&lt;div style="text-align: -webkit-right;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family: Arial, sans-serif; font-size: small;"&gt;Breast Cancer&lt;/span&gt;&lt;img alt="" height="5" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozM0ED&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Fertility Preservation for Breast Cancer Patients&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Semin Reprod Med 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozN0EE&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Preventing Second Breast Cancers - More Advice To Give Our Patients &lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Colorectal Cancer&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozO0EF&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Uptake of Colorectal Cancer Screening: System, Provider and Individual Factors and Strategies to Improve Participation&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Future Oncology 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Other Articles of Interest&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozP0EG&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Convection-enhanced Delivery for the Treatment of Brain Tumors&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Expert Rev Neurother 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozQ0EH&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Characteristics of Non-Hodgkin Lymphoma Arising in HIV-Infected Patients With Suppressed HIV Replication&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;AIDS 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozR0EI&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Intraoperative Cell Salvage Versus Allogeneic Transfusion During Abdominal Aortic Surgery: Clinical and Financial Outcomes&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Vascular 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozS0EJ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;A Comparison of a Spiritually Based and Non-Spiritually Based Educational Intervention for Informed Decision Making for Prostate Cancer Screening Among Church-Attending African-American Men&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Urol Nurs 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Columns, Blogs, Discussions&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozT0EK&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Sensationalism of Cancer Coverage in the Mass Media&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozU0EL&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Medscape One-on-One: Rapidly Unfolding Health Information Technology&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Internal Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozV0EM&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Buzz Words Surrounding Healthcare Reform&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Ophthalmology 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Articles of Interest from Other Medscape Sites&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozW0EN&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Key Articles and Guidelines in the Treatment of Venous Thromboembolism&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Pharmacotherapy 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozX0EO&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;The Case of the Peripatetic Physician: A Strategy to Avoid Accountability&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Internal Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="15" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozY0EP&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;Office Embezzlement: Are You Losing Money You Do Not Even Know About?&lt;/span&gt; &lt;br /&gt;&lt;/a&gt;&lt;span style="font-size: xx-small;"&gt;Medscape Business of Medicine 2009&lt;/span&gt;&lt;/span&gt; &lt;br /&gt;&lt;div&gt;&lt;img alt="" border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;Opinion Poll&lt;/span&gt; &lt;br /&gt;&lt;span style="color: black; font-family: Arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://mp.medscape.com/cgi-bin1/DM/y/hClJK0SuY5A0D1E0KozZ0EQ&amp;amp;uac=100503AZ"&gt;&lt;span style="color: #004c88;"&gt;PSA Test and Younger Men     &lt;/span&gt; &lt;br /&gt;&lt;/a&gt;The AUA recently updated its statement on prostate-specific antigen screening saying the test should be offered to men starting at 40 years of age but that screening should be an individual decision, regardless of age. Do you agree or disagree that PSA screening should be a matter of individual choice for men of all ages?&lt;br /&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;span style="font-size: medium;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/td&gt;    &lt;td bgcolor="#333333" width="1"&gt;&lt;img alt="" border="0" height="1" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/td&gt;   &lt;/tr&gt;&lt;tr&gt;    &lt;td colspan="2" width="650"&gt;&lt;img alt="" border="0" height="10" src="http://images.medscape.com/pi/features/emails/medpulse/mp-bottom.gif" width="650" /&gt;&lt;br /&gt;&lt;/td&gt;   &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;div&gt;&lt;img alt="" border="0" height="10" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5064494278699140070/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/focus-on-breast-cancer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5064494278699140070'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5064494278699140070'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/focus-on-breast-cancer.html' title='Focus on Breast Cancer'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6087415073927005250</id><published>2009-12-07T11:21:00.003-03:00</published><updated>2011-09-18T12:29:09.717-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Asthma Casebook- Understanding Asthma in Diverse Patients -  Three Case Studies</title><content type='html'>&lt;div class="gmail_quote"&gt;From: &lt;b class="gmail_sendername"&gt;Medscape CME Review&lt;/b&gt;&lt;span dir="ltr"&gt;&lt;/span&gt;&lt;br /&gt;Date: 2009/12/6&lt;br /&gt;&lt;span style="color: black; font-family: verdana, arial, sans-serif;"&gt;&lt;a href="http://email.medscapecme.com/cgi-bin1/DM/y/hCk3T0SuY5A0WQW0KokR0Ev&amp;amp;uac=100503AZ" target="_blank"&gt;&lt;span style="color: #004c88; font-family: verdana, arial, sans-serif;"&gt;Asthma Casebook: Understanding Asthma in Diverse Patients — Three Case Studies Featuring the Childhood Atopic March, Teenage Compliance Issues, and Recurrent Adult Asthma, Respectively&lt;/span&gt;&lt;/a&gt;&lt;span style="color: #cc0000; font-family: Arial, sans-serif; text-decoration: none;"&gt;&amp;nbsp;&amp;nbsp;CME&lt;/span&gt;&lt;br /&gt;Describe the 3 appropriate controller therapies in infants and preschoolers requiring step 2 therapy.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;&lt;span style="color: black; font-family: verdana, arial, sans-serif;"&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="color: black; font-family: verdana, arial, sans-serif; font-size: x-small;"&gt;&lt;a name='more'&gt;&lt;/a&gt;&lt;/span&gt;&lt;br /&gt;&lt;a href="http://email.medscapecme.com/cgi-bin1/DM/y/hCk3T0SuY5A0WQW0KaHj0EW&amp;amp;uac=100503AZ" style="clear: left; display: inline !important; margin-bottom: 1em; margin-right: 1em;" target="_blank"&gt;&lt;img alt="Medscape CME Review" border="0" height="45" src="http://images.medscape.com/pi/features/newsletters/cme_review_header.gif" width="498" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;div&gt;&lt;br /&gt;&lt;span style="color: black; font-family: verdana, arial, sans-serif; font-size: x-small;"&gt;&lt;a href="http://email.medscapecme.com/cgi-bin1/DM/y/hCk3T0SuY5A0WQW0KokR0Ev&amp;amp;uac=100503AZ" target="_blank"&gt;&lt;span style="color: #004c88; font-family: verdana, arial, sans-serif; font-size: x-small;"&gt;Asthma Casebook: Understanding Asthma in Diverse Patients — Three Case Studies Featuring the Childhood Atopic March, Teenage Compliance Issues, and Recurrent Adult Asthma, Respectively&lt;/span&gt;&lt;/a&gt;&lt;span style="color: #cc0000; font-family: Arial, sans-serif; font-size: xx-small; text-decoration: none;"&gt;&amp;nbsp;&amp;nbsp;CME&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Describe the 3 appropriate controller therapies in infants and preschoolers requiring step 2 therapy.&amp;nbsp;&lt;a href="http://email.medscapecme.com/cgi-bin1/DM/y/hCk3T0SuY5A0WQW0KokR0Ev&amp;amp;uac=100503AZ" target="_blank"&gt;&lt;span style="color: #004c88; font-family: verdana, arial, sans-serif; font-size: x-small;"&gt;Click here&lt;/span&gt;&lt;/a&gt;&amp;nbsp;to read more.&lt;br /&gt;&lt;/span&gt;&lt;img border="0" height="25" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;img border="0" height="1" src="http://images.medscape.com/pi/global/ornaments/spacer.gif" width="1" /&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 500px;"&gt;&lt;tbody&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6087415073927005250/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/asthma-casebook-understanding-asthma-in.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6087415073927005250'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6087415073927005250'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/asthma-casebook-understanding-asthma-in.html' title='Asthma Casebook- Understanding Asthma in Diverse Patients -  Three Case Studies'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5900454578215811406</id><published>2009-12-05T12:30:00.002-03:00</published><updated>2011-03-18T21:00:01.241-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><title type='text'>Uso de celulares causa câncer?!?</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Publicado no Journal of the National Cancer Institute, um estudo mostrou que não há relação entre os uso de telefones celulares nos últimos 15 anos e a incidência de tumores cerebrais em países escandinavos. No estudo, a incidência de tumores cerebrais entre 1974 e 2003 na Dinamarca, Finlândia, Noruega e Suécia manteve-se estável, diminuiu ou &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;cresceu lentamente continuando uma tendência anterior ao uso de celulares. Paralelamente, o uso de celulares tornou-se muito amplo desde meados da década de 90. Uma vez que quase toda a população esteve exposta recentemente ao uso de celulares, isto indicaria que seu uso não traz riscos aumentados de câncer cerebral. O período de análise do estudo foi de 1998 a 2003. Uma crítica possível é a de que um tempo maior de exposição seria necessário para detectar diferenças. O estudo, no entanto, soma informações à polêmica sobre telefonia celular e câncer. Recentemente, um outro estudo mostrou que poderia existir uma possível associação entre câncer e o uso de telefones celulares. Enquanto nenhuma conclusão definitiva chega, a recomendação em vários países da Europa é de desmotivar o uso de celulares para crianças e limitar o tempo total de conversação em telefones móveis. Links: &lt;a href="http://bit.ly/8dLtvs"&gt;http://bit.ly/8dLtvs&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img alt="" class="zemanta-pixie-img" src="http://img.zemanta.com/pixy.gif?x-id=45218486-371f-838e-906f-bc14ce1d410f" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5900454578215811406/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/12/uso-de-celulares-causa-cancer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5900454578215811406'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5900454578215811406'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/12/uso-de-celulares-causa-cancer.html' title='Uso de celulares causa câncer?!?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1773704954474311805</id><published>2009-12-05T10:51:00.000-03:00</published><updated>2011-01-18T11:14:11.685-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Post no Meme de Carbono</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Texto de meu post no blog Meme de Carbono, sobre um caso de conflito médico-paciente:&lt;br/&gt;&lt;br/&gt;Caros blogueiros, caro Roney,&lt;br/&gt;&lt;br/&gt;Em primeiro lugar, devo dizer que esta será minha última intervenção &lt;br/&gt;neste post de um blog que me parece excepcional. Gostaria apenas de &lt;br/&gt;acrescentar, neste tópico tão comentado e que sempre gera uma discussão &lt;br/&gt;muito ampla e frutífera, algumas idéias adicionais. Roney, suas palavras&lt;br/&gt; foram muito importantes, talvez o mais importante de todos os &lt;br/&gt;comentários aqui feitos: realmente, sem liberdade de expressão, nem eu, &lt;br/&gt;nem ninguém teria exteriorizado suas idéias. Evitei fazer comentários &lt;br/&gt;sobre o veredito da justiça não por concordar com ele: pelo contrário, &lt;br/&gt;eu sou contra atitudes que cerceiem a liberdade de expressão. Seria &lt;br/&gt;contraditório não sê-lo. Também sou contra atitudes arrogantes de quem &lt;br/&gt;se acha dono da verdade. A verdade não é prerrogativa de ninguém, e nós &lt;br/&gt;até podemos nos aproximar, através do estudo das evidências, de uma &lt;br/&gt;certa qualidade da verdade, mas nunca podemos impor autoritariamente &lt;br/&gt;nossa visão como a única. Por isso, da mesma forma que critico colegas &lt;br/&gt;médicos que incorrem em verdadeira má prática, critico também pacientes &lt;br/&gt;desinformados que fazem acusações baseadas em senso comum e em suas &lt;br/&gt;convicções pessoais. Existe um certo romantismo em defender-se um “pobre&lt;br/&gt; paciente” contra o “vil e cruel doutor” e esta esteriotipação não ajuda&lt;br/&gt; realmente os pacientes. Também concordo que as leis brasileiras &lt;br/&gt;beneficiam a invisibilidade dos verdadeiramente culpados, mas isso vem &lt;br/&gt;de todo um contexto social, e a impunidade não tem casos restritos à &lt;br/&gt;área da saúde. Volto a reiterar minha opinião principal, que é a que eu &lt;br/&gt;gostaria que ficasse: antes preparar bem os médicos e outros &lt;br/&gt;profissionais da saúde, dando-lhes parâmetros éticos para seu &lt;br/&gt;comportamento e capacitação técnico-científica, do que apagar as &lt;br/&gt;fogueiras ateadas pela imprudência de um sistema mal-estruturado e por &lt;br/&gt;profissionais à deriva, sem um norte. Eu me solidarizo não somente com &lt;br/&gt;os casos aqui publicados, como com muitos outros de que ouvimos falar, &lt;br/&gt;mas gostaria de apontar que, muitas vezes, o que ocorreu não foi um &lt;br/&gt;verdadeiro erro médico (a má prática, com má intenção), mas um &lt;br/&gt;relacionamento médico-paciente problemático, onde não falta a culpa de &lt;br/&gt;ambos. Creio que esta foi a essência do caso que culminou no excesso de &lt;br/&gt;uma sentença judicial (a qual teria sido evitada se ambas as partes &lt;br/&gt;tivessem dialogado mais, tenho certeza). Também creio que isto pode ter &lt;br/&gt;ocorrido no caso da Cláudia e peço ao Roney que tenha muito cuidado com a&lt;br/&gt; avaliação dos meios a partir de seus fins (no caso os resultados). Nem &lt;br/&gt;sempre resultados (ou fins) justificam os meios, como a história humana é&lt;br/&gt; prenhe de exemplos, a maioria fora da área da saúde. Existem evidências&lt;br/&gt; que norteiam a boa prática médica e, neste caso, vale uma consulta à &lt;br/&gt;bibliografia, pois nem sempre um ou alguns casos de sucesso bastam para &lt;br/&gt;comprovar um procedimento médico qualquer. Por último, peço tolerância a&lt;br/&gt; todos os blogueiros e moderação quando tecem críticas dirigidas à &lt;br/&gt;pessoas específicas, pois o respeito mútuo é que nos fará construir um &lt;br/&gt;diálogo equilibrado. Iniciar um fogo no meio da floresta é imprudente. &lt;br/&gt;Um parabéns ao Roney pelo blog excepcional e a todos que contribuem com &lt;br/&gt;ele. Um abraço a todos!&lt;br/&gt;&lt;br/&gt;Helder&lt;br/&gt;&lt;br/&gt;Pediatra (com orgulho, mesmo tendo escolhido – por hora – não atender &lt;br/&gt;consultório nem ensinar, pois meus clientes atuais exigem minha &lt;br/&gt;dedicação exclusiva!)&lt;br/&gt;&lt;br/&gt;Post completo: &lt;a target='_blank' href='http://bit.ly/hBpOtx'&gt;http://bit.ly/hBpOtx&lt;/a&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1773704954474311805/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/01/post-no-meme-de-carbono.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1773704954474311805'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1773704954474311805'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/01/post-no-meme-de-carbono.html' title='Post no Meme de Carbono'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8166165685505631337</id><published>2009-11-19T16:20:00.001-03:00</published><updated>2011-03-18T21:13:43.472-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Senado aprova projeto que define puericultura no SUS</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Ontem, dia 18/11/2009, o Senado Federal aprovou o projeto de lei 227/08, o qual insere a puericultura no SUS. O projeto marca uma mudança importante nas políticas de saúde pública brasileiras, &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;antenada com as tendências da saúde mundial, onde a prevenção de doenças crônico-degenerativas começa ainda na infância. A SBP e os políticos envolvidos no projeto estão de parabéns! Leia mais aqui: &lt;a href="http://bit.ly/tA7SY"&gt;http://bit.ly/tA7SY&lt;br /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img alt="" class="zemanta-pixie-img" src="http://img.zemanta.com/pixy.gif?x-id=8da46740-c07c-8dd1-8f66-b3f8de8647ab" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8166165685505631337/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/11/senado-aprova-projeto-que-define.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8166165685505631337'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8166165685505631337'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/11/senado-aprova-projeto-que-define.html' title='Senado aprova projeto que define puericultura no SUS'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-989338698083914807</id><published>2009-11-14T12:35:00.001-03:00</published><updated>2011-03-18T21:13:43.473-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='alergia'/><category scheme='http://www.blogger.com/atom/ns#' term='dermatite'/><category scheme='http://www.blogger.com/atom/ns#' term='eczema'/><category scheme='http://www.blogger.com/atom/ns#' term='atopia'/><category scheme='http://www.blogger.com/atom/ns#' term='ambiente'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Quem tem medo da dermatite atópica?</title><content type='html'>Dermatite atópica, ou eczema, é uma doença crônica que afeta crianças de várias raças, especialmente entre 0 a 15 anos. Os pais de crianças com esta condição médica preocupam-se sobretudo com os possíveis fatores desencadeantes &lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;e a doença é erroneamente dita "alérgica" ou causada por alergia por muitos. Na verdade, ainda é controverso se algum estímulo ambiental causa exacerbações da doença e se há componente alérgico. Um estudo recentemente publicado no British Journal of Dermatology mostrou uma possível associação entre crises de eczema e exposição a roupas sintéticas (com nylon), poeira doméstica, animais de estimação (que não sejam conhecidos da criança), suor e xampus. Esses achados, embora necessitem de confirmação em estudos maiores, dão força a algumas crenças sobre a dermatite atópica e podem ajudar a controlar melhor as crises em crianças afetadas.&lt;br /&gt;Leia completo: http://bit.ly/3s40bj</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/989338698083914807/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/11/quem-tem-medo-da-dermatite-atopica.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/989338698083914807'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/989338698083914807'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/11/quem-tem-medo-da-dermatite-atopica.html' title='Quem tem medo da dermatite atópica?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1225107455992466330</id><published>2009-11-14T12:09:00.001-03:00</published><updated>2011-03-18T21:26:20.576-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='doença renal'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='inibidores de ECA'/><category scheme='http://www.blogger.com/atom/ns#' term='infecção urinária'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='sulfa'/><category scheme='http://www.blogger.com/atom/ns#' term='pressão arterial'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Novidades em Pediatria</title><content type='html'>Algumas novidades do Top News do Medscape em pediatria:&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt;&lt;br /&gt;1.Um estudo australiano publicado no New England Journal of Medicine em outubro mostrou que a profilaxia de infecções urinárias (ITUs) em crianças de risco com sulfametoxazol + trimetoprim (SMZ-TMP, 10+2mg/kg/dia) é eficaz para evitar ITUs microbiologicamente comprovadas. Artigo:http://bit.ly/RMCnD&lt;br /&gt;2.Um estudo europeu demonstrou que o controle intensivo da pressão arterial com dose alta de ramipril protege as crianças com doença renal crônica de desenvolver progressão da insuficiência renal. Artigo:http://bit.ly/xJjFt</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1225107455992466330/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/11/novidades-em-pediatria.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1225107455992466330'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1225107455992466330'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/11/novidades-em-pediatria.html' title='Novidades em Pediatria'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2142737202249165824</id><published>2009-11-14T11:20:00.001-03:00</published><updated>2011-03-18T21:31:11.717-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='prevenção'/><category scheme='http://www.blogger.com/atom/ns#' term='estatinas'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='DPOC'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Estatinas e câncer novamente</title><content type='html'>A associação do uso crônico de estatinas e cãncer ainda hoje é controversa. Estudos haviam anteriormente sugerido a associação de estatinas e aumento de câncer hepático. Recentemente, vários estudos sugerem que o uso crônico de estatinas pode proteger contra vários tipos de câncer.&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt; O mais recente foi um estudo holandês publicado em Novembro na Thorax. Os pesquisadores do Erasmus Medical Center, em Rotterdam, avaliaram um grupo de pacientes com doença pulmonar obstrutiva crônica (DPOC). Pacientes com DPOC têm maior risco de cãncer de pulmão (basicamente porque foram tabagistas de longa data), mas seu risco geral de outros tipos de câncer também parece ser aumentado, embora isso ainda seja controverso. No estudo, os holandeses puderam registrar uma redução de quase metade (de 7% para 4%) na incidência de casos de câncer não pulmonar em pacientes com DPOC que usavam estatinas, em comparação com os que não usavam. A ocorrência de câncer de pulmão também reduziu, porém em menor grau. Embora este não seja um estudo conclusivo, é mais uma evidência da possível proteção anticãncer das estatinas.&lt;br /&gt;Leia mais: http://bit.ly/3PJ9Gi&lt;br /&gt;Artigo: http://bit.ly/3dTB5V</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2142737202249165824/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/11/estatinas-e-cancer-novamente.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2142737202249165824'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2142737202249165824'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/11/estatinas-e-cancer-novamente.html' title='Estatinas e câncer novamente'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-552262412837834971</id><published>2009-11-14T10:00:00.001-03:00</published><updated>2011-03-18T21:26:20.579-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='ESA'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='mortalidade'/><category scheme='http://www.blogger.com/atom/ns#' term='eritropoietina'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='darbopoietina'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='fatores de crescimento'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Fatores de Crescimento aumentam Mortalidade!</title><content type='html'>No número de Novembro do Journal of the National Cancer Institute foram publicados os resultados de um grande estudo avaliando o uso de fatores estimuladores de eritropoiese (ESA). Um dos resultados confirma observações recentes de que ocorre um aumento do número de complicações&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt; tromboembólicas (TVE) e mortalidade nos paciente usando ESAs. Todavia, um resultado adicional surpreendente mostra que o número de transfusões entre os pacientes usando ESAs não diminuiu em comparação com pacientes que não usaram estes fatores!!! Os ESAs, como a eritropoietina, a darbopoietina e outras drogas, são dispendiosas e seu uso em pacientes com câncer custou US$10 bilhões nos EUA em 2006. Praticamente metade de todos os pacientes com câncer dos EUA já usou ESAs alguma vez. Agora, devido aos novos resultados, o uso rotineiro e amplo de ESAs em pacientes com câncer está sendo desaconselhado e sua indicação será somente em casos específicos. &lt;br /&gt;&lt;br /&gt;Estes resultados chamam a atenção para os problemas usuais na aprovação e comercialização de novas drogas para pacientes em geral e, especificamente, com câncer. Um conflito existe entre a pressão para aprovação de novas drogas com potencial de gerar receita e a cautela para indicar restrições no uso de novos compostos. Tanto as empresas interessadas em vender quanto os consumidores em potencial, ansiosos por novos tratamentos para sua doenças, pressionam aprovações rápidas pelas agências reguladoras. Os profissionais médicos, também, acabam sendo apressados em usar amplamente as novas ferramentas farmacológicas, no intuito de demonstrarem atualização e eficiência. Importantes considerações de segurança, assim, podem ser minimizadas, com a justificativa "ética" de disponibilizar um novo tratamento para a maioria dos pacientes. Isso pode acabar prejudicando os próprios pacientes. No caso dos ESAs, o FDA americano aprovou sua utilização em 1991, mas desde 1995 existem dados mostrando seu risco de induzir TVE. Nesse caso, o marketing agressivo, aliado à impressão de segurança que os pacientes ganharam pela suposta redução nas transfusões, impediu que essa informação mudasse a conduta antes de 2007, quando o FDA exigiu uma advertência na bula dos ESAs.&lt;br /&gt;&lt;br /&gt;Leia mais: http://bit.ly/40b2cN&lt;br /&gt;Artigo: http://bit.ly/3lUbZk</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/552262412837834971/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/11/fatores-de-crescimento-aumentam.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/552262412837834971'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/552262412837834971'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/11/fatores-de-crescimento-aumentam.html' title='Fatores de Crescimento aumentam Mortalidade!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4718628991437358431</id><published>2009-10-17T16:07:00.001-03:00</published><updated>2009-12-07T09:45:06.236-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='risco'/><category scheme='http://www.blogger.com/atom/ns#' term='mal-formações'/><category scheme='http://www.blogger.com/atom/ns#' term='obesidade'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Obesidade materna e anomalias cardíacas fetais</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Um estudo multicêntrico publicado no número de Outubro do American Journal of Obstetrics &amp;amp; Gynecology relata que a obesidade materna (IMC &amp;gt;= 25) correlaciona-se com a ocorrência de mal-formações cardíacas nos recém-nascidos.&lt;br /&gt;&lt;a name='more'&gt;&lt;/a&gt; Os resultados deste estudo caso-controle que comparou mais de 5500 crianças nascidas saudáveis com mais de 6400 crianças com mal-formações cardíacas, indicam que a obesidade severa aumenta em 31% o risco de mal-formações cardíacas no feto. A obesidade moderada também mostrou um aumento no risco de mal-formações, porém mais discreto (15%). Os especialistas ainda não têm teorias sobre as possíveis causas dessa relação, mas apontam que este trabalho confirma evidências anteriores. Leia mais aqui: &lt;a href="http://bit.ly/2f4aLN" target="_blank"&gt;http://bit.ly/2f4aLN&lt;/a&gt; (assinatura necessária).&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img alt="" class="zemanta-pixie-img" src="http://img.zemanta.com/pixy.gif?x-id=357ab1f9-2031-843a-9702-52cc0d1c0a77" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4718628991437358431/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/obesidade-materna-e-anomalias-cardiacas.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4718628991437358431'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4718628991437358431'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/obesidade-materna-e-anomalias-cardiacas.html' title='Obesidade materna e anomalias cardíacas fetais'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1742305344683735648</id><published>2009-10-17T15:26:00.000-03:00</published><updated>2011-09-18T12:29:09.535-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='bevacizumab'/><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='avastin'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='brain tumor'/><category scheme='http://www.blogger.com/atom/ns#' term='antiangiogênico'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores cerebrais'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='resposta'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Bevacizumab em pacientes com tumores cerebrais</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Uma metanálise publicada no Journal of Clinical Oncology em setembro de 2009 confirmou que o anticorpo monoclonal antiangiogênico bevacizumab (Avastin, Genentech) mostrou prolongar a vida de pacientes com glioblastoma recidivado. O estudo multicêntrico mostrou que bevacizumab, sozinho ou em associação com irinotecan, induziu respostas objetivas em 28% e 38% dos pacientes, respectivamente. Os pacientes tiveram uma mediana de sobrevida global de 8,7 e 9,2 meses, respectivamente. Já havíamos noticiado em post anterior em nosso blog a aprovação do bevacizumab pelo FDA para tratamento de glioblastoma recorrente. Até o momento, no entanto, estes resultados ainda não podem ser extrapolados para a população pediátrica. Recentemente, porém, um estudo publicado pelo Dr. Packer (Children's National Medical Center, Washington) mostrou que pacientes pediátricos com gliomas de baixo grau recidivados duas ou mais vezes obtiveram resposta clínica e radiológica após uso de bevacizumab com irinotecan. No entanto, este foi um ensaio com pequeno número de pacientes, no qual não foi mostrada vantagem de sobrevida. Leia os trabalhos: &lt;a href='http://bit.ly/27k29g' target='_blank'&gt;http://bit.ly/27k29g&lt;/a&gt; e &lt;a href='http://bit.ly/2XSu0J' target='_blank'&gt;http://bit.ly/2XSu0J&lt;/a&gt; (assinatura é necessária).&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=77d3c259-c491-8ab7-a85a-628914205118' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1742305344683735648/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/bevacizumab-em-pacientes-com-tumores.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1742305344683735648'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1742305344683735648'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/bevacizumab-em-pacientes-com-tumores.html' title='Bevacizumab em pacientes com tumores cerebrais'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1254268664437919952</id><published>2009-10-17T11:41:00.002-03:00</published><updated>2011-03-18T21:31:11.721-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='propranolol'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='hemangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Mais sobre propranolol no tratamento de hemangiomas</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Recentemente, o beta-bloqueador propranolol tem sido utilizado com sucesso para tratar crianças com hemangiomas complicados. Num post anterior, havíamos relatado como o uso desta droga foi descoberto casualmente por dermatologistas franceses e o impacto que já estava ocorrendo no tratamento de hemangiomas em crianças no mundo inteiro. Agora, em agosto de 2009, o mesmo grupo francês de pesquisadores publicou o primeiro trabalho com a reavaliação do tratamento dos pacientes após seguimento de alguns meses. De acordo com o grupo de pesquisa liderado pela Dra. Christine Leauté-Labrèze, o tratamento de crianças (idade média de 4 meses) portadoras de hemangiomas complicados com propranolol foi altamente eficaz. A resposta é notada imediatamente, com diminuição objetiva das lesões aos exames em cerca de 2 meses e efeito completo do tratamento em cerca de 6 meses. A dose usada foi de 2-3 mg/kg/dia e nenhum efeito colateral severo ocorreu. Apenas 1 criança de um grupo de 32 teve de interromper o tratamento devido ao desenvolvimento de sibilância. A maioria das crianças iniciou o tratamento conjuntamente com corticosteróides, mas pôde interromper sua utilização em poucas semanas. Os autores recomendam que o propranolol seja a primeira escolha para o tratamento de hemangiomas complicados da infância. Leia mais: &lt;a href='http://bit.ly/1eGYm9' target='_blank'&gt;http://bit.ly/1eGYm9&lt;/a&gt; (necessita assinatura).&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=f90b7687-cb08-8978-a45f-23091ab167b4' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1254268664437919952/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/mais-sobre-propranolol-no-tratamento-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1254268664437919952'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1254268664437919952'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/mais-sobre-propranolol-no-tratamento-de.html' title='Mais sobre propranolol no tratamento de hemangiomas'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1811625199005808817</id><published>2009-10-17T10:42:00.003-03:00</published><updated>2011-03-18T21:26:20.581-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='imunoterapia'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Novo tratamento para neuroblastoma</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Este vídeo da Cancer Research UK no YouTube mostra novidades no tratamento do neuroblastoma, um dos tipos de tumores sólidos mais frequentes nas crianças.&lt;br /&gt;&lt;a href="http://www.youtube.com/watch?v=ILIS2bOaj00" target="_blank"&gt;http://www.youtube.com/watch?v=ILIS2bOaj00&lt;/a&gt;&lt;br /&gt;&lt;div class="youtube-video"&gt;&lt;object height="355" width="425"&gt;&lt;param value='http://www.youtube.com/v/ILIS2bOaj00&amp;amp;feature=youtube_gdata' name='movie'&gt;&lt;/param&gt;&lt;param value='transparent' name='wmode'&gt;&lt;/param&gt;&lt;embed width='425' height='355' wmode='transparent' type='application/x-shockwave-flash' src='http://www.youtube.com/v/ILIS2bOaj00&amp;amp;feature=youtube_gdata'&gt; &lt;/embed&gt;  &lt;/object&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;br /&gt;Dr Juliet Gray and Professor Martin Glennie - new treatment for neuroblastoma&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img alt="" class="zemanta-pixie-img" src="http://img.zemanta.com/pixy.gif?x-id=911f7375-6779-8729-8d51-abca741dc416" /&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1811625199005808817/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html#comment-form' title='6 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html' title='Novo tratamento para neuroblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>6</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5978771938384178012</id><published>2009-10-17T09:47:00.000-03:00</published><updated>2011-03-18T21:13:43.482-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Pediatria em alta no Brasil!</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Finalmente, após notícias desmotivadoras nos últimos tempo, como a redução do número de hospitais e leitos dedicados à pediatria no Brasil, diferenças de remuneração que desprivilegiam os pediatras, condições inadequadas de trabalho, dificuldades dos serviços de residência médica, uma boa notícia para a pediatria e os pediatras do Brasil. O Ministério da Saúde do Brasil, através da portaria 2281, oficializou a participação de pediatras nas equipes do Programa de Saúde da Família no Nordeste e Amazônia, regiões onde a mortalidade infantil ainda está longe da ideal. Isso é um passo importante para a valorização da pediatria em nosso país, uma especialidade que conta com renome e destaque no primeiro mundo, mas que, inexplicavelmente, tem sido historicamente desvalorizada em nosso país. Um viva para a Pediatria! Leia tudo no site da Sociedade Brasileira de Pediatria: &lt;a href='http://bit.ly/6bjVL' target='_blank'&gt;http://bit.ly/6bjVL&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=af65f6a8-28b4-8e06-b50f-9c95e5e0d3cb' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5978771938384178012/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/pediatria-em-alta-no-brasil.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5978771938384178012'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5978771938384178012'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/pediatria-em-alta-no-brasil.html' title='Pediatria em alta no Brasil!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6077669725596152410</id><published>2009-10-17T09:22:00.001-03:00</published><updated>2009-10-18T22:09:11.301-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Luta contra a lepra no filme Cruzada</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Artigo recente publicado no periódico espanhol Revista de Neurología traz em detalhes o quadro clínico e evolução da Hanseníase do Rei Balduíno IV. Ele tornou-se conhecido recentemente por ter sido personagem do filme "Cruzada" (Direção Ridley Scott, Estúdios Fox, 2005) que narra a épica história do lendário Balian durante a tomada de Jerusalém por Saladino. Prato cheio para quem gosta de medicina histórica! Leia o artigo completo: &lt;a href='http://bit.ly/34ZLxQ' target='_blank'&gt;http://bit.ly/34ZLxQ&lt;/a&gt; (é necessário cadastro gratuito para ler).&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=c2c9ae25-3c42-8413-8833-82f409ff46ab' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6077669725596152410/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/luta-contra-lepra-no-filme-cruzada.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6077669725596152410'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6077669725596152410'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/luta-contra-lepra-no-filme-cruzada.html' title='Luta contra a lepra no filme Cruzada'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1338567088006155457</id><published>2009-10-13T00:32:00.000-03:00</published><updated>2011-03-18T20:43:51.001-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='radioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='seguimento'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='recidiva'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='PET/CT'/><title type='text'>PET/CT útil no follow-up de Linfoma de Hodgkin</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Na 56a. Reunião Anual da Sociedade de Medicina Nuclear dos EUA, foram apresentadas novas evidências de que o exame de PET/CT com fluorodeoxiglicose (FDG) tem utilidade no follow-up de pacientes portadores de LH. O estudo, conduzido pelo Dr. Nicklaus Schaefer na Johns Hopkins Medical Institute/Johns Hopkins University em Baltimore, Maryland (EUA), mostrou que o exame tem elevado valor preditivo positivo (0,98) para recidivas nos primeiros 2 anos de seguimento, mas não depois. A presença de sintomas B e doença residual / estágio avançado foram fortes fatores preditivos de recidiva. O estudo é retrospectivo e selecionou apenas pacientes que receberam quimioterapia, mas não radioterapia (RT). Seus resultados devem ser confirmados por estudos prospectivos e ampliados para pacientes que receberam RT. A principal conclusão é de que o PET/CT, um exame caro (ainda não disponível pelo SUS no Brasil) e que não é encontrado em todo lugar, apesar de ser muito solicitado ultimamente, deve ter indicação precisa e apenas em subgrupos selecionados de pacientes para ter resultados confiáveis. Leia mais em: &lt;a target='_blank' href='http://bit.ly/SEaQ4'&gt;http://bit.ly/SEaQ4&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=c63b1736-b9dd-80c0-9162-462dda7ccf91' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1338567088006155457/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/petct-util-no-follow-up-de-linfoma-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1338567088006155457'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1338567088006155457'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/petct-util-no-follow-up-de-linfoma-de.html' title='PET/CT útil no follow-up de Linfoma de Hodgkin'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3519033587133670104</id><published>2009-10-12T23:36:00.001-03:00</published><updated>2011-08-06T08:21:06.662-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='prevenção'/><category scheme='http://www.blogger.com/atom/ns#' term='estatinas'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='diabetes'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Estatinas podem reduzir risco de câncer sim!!</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Uma pesquisa veiculada no número de Junho de 2009 do periódico Gastroenterology mostra que a utilização de estatinas por pacientes diabéticos associou-se com menor chance de apresentar carcinoma hepatocelular. O estudo, conduzido pelo Dr. Hashem B. El-Serag, do Baylor College of Medicine em Houston (EUA) analisou 1303 diabéticos com câncer e 5212 sem câncer. Eles determinaram que pacientes diabéticos que toma estatinas têm entre 1,58 e 2,17 vezes menos risco de ter câncer de fígado. Trata-se de um estudo caso-controle, o qual não pode provar que esta associação é causal. Um estudo tipo coorte deve ser realizado para confirmar tais resultados. A notícia adiciona mais uma informação interessante à polêmica discussão sobre o suposto efeito das estatinas de prevenir câncer. Leia mais em: &lt;a href="http://bit.ly/11SU3M" target="_blank"&gt;http://bit.ly/11SU3M&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img alt="" class="zemanta-pixie-img" src="http://img.zemanta.com/pixy.gif?x-id=c99f18a5-9eaa-8cfc-9911-113116653db2" /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3519033587133670104/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/10/estatinas-podem-reduzir-risco-de-cancer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3519033587133670104'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3519033587133670104'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/estatinas-podem-reduzir-risco-de-cancer.html' title='Estatinas podem reduzir risco de câncer sim!!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2021528181131140834</id><published>2009-07-27T23:57:00.000-03:00</published><updated>2009-12-05T12:19:29.547-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Qual a minha medicina? - Capítulo 1 - Quais as medicinas que existem?</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Nota importante: todo o conteúdo deste post refere-se a personagens e fatos imaginados, ficcionais e foram criações do Dr. Helder Felix; qualquer semelhança com pessoas, lugares ou fatos reais é mera coincidência.&lt;br/&gt;&lt;br/&gt;Então existem várias medicinas? Não deveria haver somente uma medicina, praticada em todo lugar da mesma forma e regulada por algum tipo de critério de qualidade 100% seguro? Bem, quando estamos nos sentindo ameaçados por alguma coisa, bem que desejamos este nível de segurança. Imagine quando você está diante de um filho pequeno com febre ou qualquer outra doença. Você arriscaria submetê-lo a algum tipo de tratamento experimental? Sem credibilidade? Sem garantias de algum tipo? É difícil imaginar quem respondesse, com tranquilidade: "sim".&lt;br/&gt;Vamos exemplificar com algumas cenas imaginárias de consultório:&lt;br/&gt;&lt;br/&gt;Cena 1 - O Sr. Paulo, profissional liberal e sua esposa, a Sra. Leila, funcionária pública, levam a filha de 3 anos ao médico, Dr. Seixas, pediatra. O médico foi escolhido no livreto da empresa de saúde onde a família contratou um plano de prestação de serviços. Além disso, uma prima de Leila já havia atendido o filho com ele. A criança está com febre. Após um exame físico e entrevista que não durou mais de 10 minutos, o médico é taxativo: "é virose". Prescreve uma medicação e despacha o casal. &lt;i&gt;Análise: o critério de escolha do casal foi mais completo do que a maioria, que geralmente só usa ou a indicação de amigos/parentes ou a lista do plano de saúde, ou pior, às vezes o outdoor de uma clínica. Ser listado num livreto de uma empresa de saúde garante - se a empresa for idônea (acredite, nem sempre é verdade) - que o médico tem diploma. Isso parece pouco, mas já exclui os falsos médicos, uma praga que ainda ocorre vez por outra em nosso país. Poucas empresas de saúde exigem comprovação formal de especialidade, porém as melhores exigem. Na dúvida, deve-se checar com o Conselho Regional de Medicina, o qual tem registro de todos os médicos e suas especialidades declaradas. Na prática, isso nunca é feito pela ausência de uma ferramenta rápida e fácil - como uma consulta telefônica ou via web - para os clientes acessarem. O médico atendeu rapidamente - a AMB (Associação Médica Brasileira) recomenda que o tempo mínimo de consulta seja de 15 minutos, muito embora reconheça que variações possam ocorrer a depender da situação e do profissional. Embora seja teoricamente possível que um médico acerte um diagnóstico em segundos (como o caricatural Dr. Gregory House do seriado televisivo da Fox, House MD) isso é improvável e deve ocorrer muito pouco. Também dialogou pouco - uma das maiores queixas da clientela, origem de famosas anedotas sobre médicos. Não é de se admirar que o casal saiu da consulta insatisfeito e não seguiu a recomendação médica.&lt;/i&gt; &lt;br/&gt;&lt;br/&gt;Cena 2 - Não satisfeitos e com a piora da febre da criança algumas horas após, o casal procura (praticamente no mesmo dia) outro profissional, dessa vez numa emergência, com a criança com febre alta. Após uma espera de cerca de 1 hora (torturante para a família), uma pediatra falante e agitada, a Dra. Maria, os atende. Após rápida conversa, quando o casal a informa da consulta anterior, a médica os critica rispidamente por não terem obedecido a prescrição médica anterior, por terem procurado novo atendimento muito rápido, ironizando sua falta de experiência e criticando-os por serem inseguros. Afirma ainda que emergência "não é consultório" e somente deve ser reservada para "doenças de verdade". Após um sumaríssimo exame físico, rapidamente diz que a criança "não tem nada", mas mesmo assim prescreve uma medicação totalmente diferente daquela do primeiro médico. &lt;i&gt;Análise: esta desastrosa experiência foi exagerada - a maioria dos atendimentos de emergência tem um ou alguns elementos deste episódio, mas raramente este pacote completo de frustração. Os médicos de emergência são cansados e sobrecarregados por horas excessivas de trabalho, jornadas contínuas de até 72h (às vezes mais), é verdade que muitas pessoas exorbitam de seu direito de atendimento procurando emergências com problemas banais (muitas vezes psicológicos ou sociais) e o clima organizacional da maioria das empresas que prestam este tipo de serviço é hostil ao funcionário. No entanto, nada disso justifica um caráter fraco e o quase sadismo de algumas situações vividas por pacientes em emergências. Felizmente, apesar do que se acha, este tipo de situação extrema é rara. No entanto, é um prato cheio para gerar uma clientela altamente insatisfeita com a medicina dita "tradicional" e presa fácil dos pseudo "alternativos".&lt;br/&gt;&lt;br/&gt;&lt;/i&gt;Cena 3 - No terceiro dia de doença, a filha de Paulo e Leila estava um pouco melhor, amanheceu sem febre e brincou alegre, mas ainda recusou parte da comida que lhe ofereceram. Preocupada, Leila lembrou-se de Anne, sua amiga jovem, cult e descolada, que havia falado de um terapeuta alternativo. Ao entrar no consultório do Dr. Astraios, o casal sentiu-se maravilhado: o luxuoso ambiente contrastava com a impressão deixada antes pelos consultórios médicos. Recebidos prontamente ao som de música indiana, eles sentiram-se automaticamente relaxados. O "guru", após conversar amenidades e elogiar o belo casal e filha, usou estranhos "instrumentos" que passou por cima da risonha garota deitada numa maca cheia de brinquedos &lt;i&gt;chic &lt;/i&gt;de madeira. Informou-os que a "energia cósmica" impregnada no corpo da criança havia sido abalada, mas o necessário para "revitalizá-la" seria pouco: uma dieta especial por 1 semana, um "remédio" que o próprio Dr. Astraios vendia, "água energizada por espíritos elevados", e alguns mantras entoados de todo o coração diariamente. Saíram satisfeitos, embora Paulo tenha sentido a exorbitante soma que lhe foi aliviada do bolso (sem recibo, claro). No dia seguinte, contudo, Paulo e Leila acharam que o investimento valeu cada centavo, pois sua filha aparentemente recuperara toda a saúde. &lt;i&gt;Análise: na verdade, o Dr. Seixas havia acertado seu seco diagnóstico inicial - tratava-se realmente de uma virose (doença viral aguda, normalmente autolimitada e sem tratamento específico, apenas o sintomático). Crianças na faixa de idade da filha do casal têm, em média, 8 episódios destes por ano, o que causa grande ansiedade nos pais e origina frequentemente uma insatisfação inicial com bons profissionais de saúde: afinal, as pessoas sentem necessidade de controlar a situação, e palavras como as do Dr. Seixas privam-nas disto e as deixam a mercê do futuro. No entanto, a despeito de nossa ineptitude humana para lidar com o irremediável, não há mesmo mais nada a fazer na grande maioria das "viroses" agudas, que podem chegar a mais de 3000 tipos diferentes, a maioria sem diagnóstico específico. O mais importante, nestas situações, é que o profissional convença os pacientes de que a situação somente exige vigilância, mas não preocupação. Essa é, por vezes, uma tarefa difícil. A atitude de médicos como o Dr. Seixas e a Dra. Maria, no entanto, não ajuda em nada. A maioria das viroses agudas vai melhorar em poucos dias (2 ou 3, como regra geral)&lt;/i&gt; &lt;i&gt;o que desencadeia um fenômeno recorrente: o bom Dr. do terceiro dia. Neste momento, quando qualquer um, seja tradicional ou alternativo, prescreve algo, essa prescrição sempre "funciona", pois a doença já estava em seus estágios finais. O fato de que muitas doenças são autolimitadas e desaparecem por si, às vezes mesmo doenças crônicas, é uma das causas da fé em tratamentos sem nenhum efeito real. As pessoas são "enganadas" por este efeito do terceiro dia. A filha do casal já iria ficar boa, a despeito da visita ao terapeuta alternativo. O ambiente e o tratamento diferenciados que deslumbraram o casal (e ajudaram a iludí-lo) são estratégias de marketing, destinadas a captar as altas quantias cobradas via de regra por este tipo de profissional.&lt;/i&gt;&lt;br/&gt;&lt;br/&gt;A medicina "tradicional" tem certamente que aprender algo com este tipo de medicina "alternativa". Vamos examinar de perto, porém, esta diferença. No contexto que usamos, a medicina tradicional é identificada não com um paradigma ou metodologia especiais, mas com o grau de satisfação do cliente: tradicional é ruim. A medicina alternativa, assim, surge não como uma proposta diferente de paradigma ou ideologia, mas como um escape da insatisfação com a medicina. Isso é verdade especialmente quando analisamos a motivação da clientela: dificilmente encontraremos pessoas que procuram uma terapia alternativa pela primeira vez encantados com sua proposta metodológica ou com seus conceitos básicos. Na maioria das vezes, as pessoas somente procuram algo "melhor". Vamos fazer uma analogia: se você costuma comprar frutas num mercadinho, mas nota que ultimamente a qualidade está caindo, você procura outro local alternativo para suas compras. Você vai escolher baseado em indicações e experiências pessoais. É assim que as pessoas fazem para tudo. E você vai permanecer comprando frutas onde elas tiverem a melhor qualidade. É aí que está o problema com a medicina alternativa: como a qualidade de seus resultados é julgada? Quais os padrões utilizados para garantir sua eficácia? Enquanto a medicina tradicional baseia-se em conhecimento científico para garantir o que pode ou não pode fazer e tem entidades regulatórias bem definidas, na maioria das vezes a única coisa que se tem para julgar a medicina alternativa é a palavra do próprio terapeuta. Mesmo assim, a medicina alternativa cativa mais e mais as pessoas, por servir-se de estratégias de marketing as quais a medicina tradicional reluta em usar. Então, a dúvida se resume a: em quem você confia mais e porquê? Experiências pessoais negativas com a medicina tradicional são tão comuns quanto experiências negativas com qualquer profissão. Quem nunca teve raiva numa fila de banco e achou que os funcionários estavam fazendo corpo mole? Quem nunca desconfiou que o mecânico talvez não estivesse sendo honesto ao trocar TODAS aquelas peças do seu carro? O ser humano é insatisfeito por natureza. Pergunte-se: entre o médico tradicional e o alternativo, quem tem maior motivação de lhe cativar com marketing pessoal (incluindo ambiente, tratamento, etc) e quem vai ganhar mais com isso? &lt;br/&gt;&lt;br/&gt;Isso significa que todos os terapeutas alternativos são aproveitadores? Claro que não! Isso significa que as pessoas usam estratégias erradas para escolher entre as formas de atendimento e isto lhes põe a mercê de profissionais mal intencionados, os quais existem em todas as profissões. Nos próximos posts vou tentar trazer informações sobre as formas de terapia alternativa mais populares e o que a ciência tem a dizer sobre elas.&lt;br/&gt;&lt;br/&gt;&lt;div class='zemanta-pixie'&gt;&lt;img src='http://img.zemanta.com/pixy.gif?x-id=e3df0700-0ac6-8dbf-bde1-23a2cb1cf080' alt='' class='zemanta-pixie-img'/&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2021528181131140834/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/07/qual-minha-medicina-capitulo-1-quais-as.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2021528181131140834'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2021528181131140834'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/07/qual-minha-medicina-capitulo-1-quais-as.html' title='Qual a minha medicina? - Capítulo 1 - Quais as medicinas que existem?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8811452336835973545</id><published>2009-07-18T12:47:00.001-03:00</published><updated>2009-07-18T12:47:05.066-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><title type='text'>Qual a minha medicina?</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Na mídia formal e informal, incluindo a internet, pode-se entrar em contato com inúmeras práticas ditas "médicas" ou de saúde diferentes, muitas vezes contraditórias. De um modo geral, a classificação geral mais utilizada para estas práticas diferentes e conflitantes é a da "Medicina Alternativa" em contraposição à "Medicina Tradicional". Frequentemente, pacientes com câncer e outras doenças são bombardeados com um grande número de possibilidades de práticas terapêuticas diferentes, cada uma propagandeada pelos seus profissionais atuantes como a melhor. Não é incomum que partidários desta ou daquela prática critiquem ferozmente as outras modalidades de tratamento na mesma área ou em áreas afins. Diante disto, como um leigo na área da saúde pode escolher adequadamente o melhor tratamento para si ou para um ente querido, como um filho? A partir de hoje, farei comentários, mostrarei fatos, opiniões de vários profissionais, além da minha própria, e tentarei dar uma direção geral a quem busca respostas numa série de posts intitulada "Qual a minha medicina?".&lt;br/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8811452336835973545/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/07/qual-minha-medicina.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8811452336835973545'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8811452336835973545'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/07/qual-minha-medicina.html' title='Qual a minha medicina?'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4004442766585704459</id><published>2009-05-19T22:07:00.003-03:00</published><updated>2011-09-18T12:29:09.643-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><category scheme='http://www.blogger.com/atom/ns#' term='novas drogas'/><category scheme='http://www.blogger.com/atom/ns#' term='fatores de crescimento'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='imunoterapia'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='novos tratamentos'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>ASCO 2009: Immunotherapy Prolongs Survival in High-risk Pediatric Neuroblastoma</title><content type='html'>An experimental immunotherapy product has been shown to improve overall survival and to reduce the risk for relapse in children with high-risk neuroblastoma. The results from a phase 3 clinical trial are due to be presented at the upcoming 2009 Annual Meeting of the American Society of Clinical Oncologists (ASCO). The new product is a chimeric antibody directed against a glycolipid known as GD2, which sits on the surface of neuroblastoma cells and protects them from attack by the immune system. When the antibody binds to GD2, it provokes an attack by different types of immune cells against the cancer. This is the first time that an antibody directed against a glycolipid has shown clinical efficacy and an improvement in survival, Dr. Yu noted. Most antibody therapies are directed against proteins, she pointed out.&lt;br /&gt;The trial was conducted by the Children's Oncology Group in 226 newly diagnosed high-risk neuroblastoma patients who had achieved a complete or partial response to induction therapy and had received myeloablative consolidation with stem-cell rescue. All received standard treatment with 13-cis-retinoic acid for 6 cycles, and half the patients also received 5 concomitant cycles of the antibody. The antibody was administered along with 1 of 2 cytokines — granulocyte macrophage colony-stimulating factor and interleukin-2 — given in alternating cycles, as preclinical studies had shown an enhanced efficacy. After 2 years, overall survival was 86% in the immunotherapy group and 75% in the standard-treatment group, and event-free survival was 66% and 46%, respectively. The study was terminated early because of the benefit seen in interim analyses.&lt;br /&gt;Read more on &lt;a href="http://www.medscape.com/viewarticle/703011?src=mpnews&amp;spon=7"&gt;Medscape&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4004442766585704459/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/05/asco-2009-immunotherapy-prolongs.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4004442766585704459'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4004442766585704459'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/05/asco-2009-immunotherapy-prolongs.html' title='ASCO 2009: Immunotherapy Prolongs Survival in High-risk Pediatric Neuroblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5190924268931396656</id><published>2009-05-16T16:16:00.002-03:00</published><updated>2011-03-18T21:31:11.726-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='bevacizumab'/><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='avastin'/><category scheme='http://www.blogger.com/atom/ns#' term='glioblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='resposta'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Bevacizumab foi aprovado pelo FDA para tratar glioblastoma de adultos</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;O anticorpo monoclonal bevacizumab (Avastin, Genentech) foi aprovado pelo FDA, agência regulatória dos EUA, para o tratamento de pacientes com glioblastoma multiforme (GBM) que progrediu após tratamento de primeira linha. É a primeira droga a ser aprovada para esta indicação em mais de uma década, segundo fontes. A recomendação para aprovação foi acelerada, muito embora os dados que o FDA usou para justificar a aprovação sejam oriundos de ensaios clínicos não comparativos. Num dos ensaios, 167 pacientes foram tratados após prévio tratamento com temozolamida e radioterapia. Pacientes que receberam apenas bevacizumab mostraram resposta em 26% dos casos, com mediana de duração da resposta de 4,2 meses. Outro ensaio, com apenas 56 pacientes, teve resposta inferior a esta. Pode parecer pouco, mas não existe alternativa de terapia para estes pacientes. Infelizmente, dados recentes mostram que não se deve esperar este mesmo resultado em crianças com a mesma patologia. Mesmo assim, ensaios clínicos com pacientes pediátricos estão em andamento. Leia mais sobre a aprovação &lt;a href="http://www.medscape.com/viewarticle/702435?src=mpnews&amp;amp;spon=7&amp;amp;uac=100503AZ"&gt;aqui&lt;/a&gt;.&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/5190924268931396656/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/05/bevacizumab-foi-aprovado-pelo-fda-para.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5190924268931396656'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/5190924268931396656'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/05/bevacizumab-foi-aprovado-pelo-fda-para.html' title='Bevacizumab foi aprovado pelo FDA para tratar glioblastoma de adultos'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-842128109592850690</id><published>2009-05-09T23:10:00.002-03:00</published><updated>2011-03-18T21:31:11.728-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='monoclonais'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='inibidores tirosina-quinase'/><category scheme='http://www.blogger.com/atom/ns#' term='resposta'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='alto custo'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Alto preço dos medicamentos anticâncer orais diminui aderência dos pacientes</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Agentes quimioterápicos anticâncer de administração oral estão se tornando cada vez mais disponíveis e apresentam para os pacientes e seus médicos opções de tratamento mais cômodas, não invasivas. Um problema que tem se tornado frequente, no entanto, é a falta de adesão ao tratamento devido ao alto custo das medicações! Essa notícia não vem de países como o nosso, onde os pacientes ainda têm acesso restrito a essas novas drogas, mas dos Estados Unidos! Isso tem ocorrido por que as empresas de saúde americanas não cobrem o custo completo de tratamentos com medicações orais, como fazem com medicamentos de administração EV. O resultado é que os pacientes precisam desembolsar centenas a milhares de dólares por mês pelos seus tratamentos. Isto está prejudicando os pacientes. Enquanto alguns deles não estão conseguindo usar as medicações dentro dos protocolos programados, outros pacientes acabam tendo que optar por formas de tratamento convencionais, às vezes menos eficazes. O fato é que o preço dos quimioterápicos anticâncer subiu consideravelmente desde 1996. Exemplos recentes: o custo anual médio de lenalidomida para um paciente com mieloma múltiplo é estimado em U$74000, enquanto o custo anual médio de imatinib para pacientes com leucemia mielóide crônica não sai por menos que U$57000. Esses custos têm que ser pagos, na sua maioria, com recursos do paciente. Isso diminui ainda mais a aderência dos pacientes à medicação. Quimioterápicos anticâncer orais, surpreendentemente para muitos, mostraram uma aderência mais baixa que a QT venosa, mesmo sem contar o alto custo. Isso, à primeira vista, pode parecer contraditório, mas resulta de múltiplos fatores, entre eles o fato de que o tratamento venoso é administrado em ambiente hospitalar ou clínico controlado, mediante agendamento de consultas. Já os medicamentos orais são de auto-administração pelo paciente, no seu ambiente domiciliar. Além disso, as drogas orais têm muitos efeitos colaterais desagradáveis, mesmo que diferentes daqueles efeitos das drogas venosas. Isso reduz a vontade do paciente de aderir ao tratamento. Soma-se a isso tudo o fato de que o custo pesa muito no orçamento familiar dos pacientes e temos aí uma receita para falha terapêutica e pior qualidade de vida dos pacientes. Para ler mais sobre isso: acesse &lt;a href="http://www.medscape.com/viewarticle/702522?src=mpnews&amp;amp;spon=7&amp;amp;uac=100503AZ"&gt;aqui&lt;/a&gt;.&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/842128109592850690/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/05/alto-preco-dos-medicamentos-anticancer.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/842128109592850690'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/842128109592850690'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/05/alto-preco-dos-medicamentos-anticancer.html' title='Alto preço dos medicamentos anticâncer orais diminui aderência dos pacientes'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3228843808259575140</id><published>2009-04-24T21:09:00.002-03:00</published><updated>2011-03-18T21:31:11.731-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='glioblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='resposta'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='alquilantes'/><category scheme='http://www.blogger.com/atom/ns#' term='temozolamida'/><category scheme='http://www.blogger.com/atom/ns#' term='neurology'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Glioblastoma em adultos responde melhor a doses altas de QT com RT</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Um estudo recentemente publicado no Journal of Clinical Oncology demonstrou a eficiência de um regime de doses aumentadas de temozolamida e lomustina, associadas à radioterapia (RT) craniana, em pacientes com glioblastoma multiforme recém-diagnosticado. Metade dos pacientes (4 de 8) tratados com dose de lomustina 10% maior que a recomendada e dose de temozolamida 50% maior, além de RT, obtiveram sobrevida prolongada (seguimento de 56 meses) sem recidiva. Tais resultados são encorajadores, por serem bem superiores aos conseguidos com terapia convencional. Embora o número pequeno de pacientes não permita conclusões definitivas, os autores do estudo sugerem que ensaios clínicos com as doses aumentadas são necessários. Um dado importante deste estudo foi que os pacientes que apresentavam metilação do gene da MGMT (uma enzima que confere resistência a agente alquilantes) tiveram melhor sobrevida. Isso traz à tona a importância futura que a estratificação dos pacientes de acordo com marcadores epigenéticos como esse poderá ter no prognóstico. A toxicidade do esquema, todavia foi preocupante. Leia mais &lt;a href="http://www.medscape.com/viewarticle/590943?src=mpnews&amp;amp;spon=7&amp;amp;uac=100503AZ" target="_blank"&gt;aqui&lt;/a&gt;.&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3228843808259575140/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/04/glioblastoma-em-adultos-responde-melhor.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3228843808259575140'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3228843808259575140'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/04/glioblastoma-em-adultos-responde-melhor.html' title='Glioblastoma em adultos responde melhor a doses altas de QT com RT'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7140316847226727554</id><published>2009-04-24T19:36:00.002-03:00</published><updated>2011-03-18T20:43:51.009-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='resposta'/><category scheme='http://www.blogger.com/atom/ns#' term='imagem'/><category scheme='http://www.blogger.com/atom/ns#' term='PET/CT'/><title type='text'>Imagem de PET/CT mostra resposta do tratamento oncológico após primeiro ciclo</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Um artigo publicado recentemente na &lt;a href="http://www.medscape.com/viewarticle/591215?src=mpnews&amp;amp;spon=7&amp;amp;uac=100503AZ" target="_blank"&gt;Clinical Cancer Research&lt;/a&gt; mostrou a capacidade dos novos aparelhos de Tomografia por emissão de pósitrons (PET) combinados com a tomografia computadorizada convencional (PET/CT) de detectarem a resposta de sarcomas de alto grau de malignidade ao tratamento quimioterápico apenas 1 semana após o primeiro ciclo. Este grau de precocidade e exatidão na avaliação da resposta ao tratamento são inéditos. A utilização rotineira da PET/CT pode melhorar a avaliação da resposta dos pacientes com este tipo de doença ao tratamento, evitando toxicidade desnecessária aos pacientes com tumores refratários, otimizando a decisão sobre tratamento cirúrgico e definindo prognóstico. Quanto mais cedo for a definição da eficácia do tratamento para os pacientes, melhor para eles, tanto em relação ao sucesso do tratamento quanto em relação aos efeitos colaterais da terapia. Infelizmente, a tecnologia ainda não é amplamente dispopnível, dependendo de instalações de alto custo de medicina nuclear associadas à presença de cíclotrons, aparelhos de produção de partículas elementares de alta energia capazes de produzir os radionuclídeos utilizados na imagem por PET. Até 2008, existiam cíclotrons apenas em São Paulo e Rio de Janeiro e aparelhos de &lt;a href="http://pt.wikipedia.org/wiki/Tomografia_por_emiss%C3%A3o_de_positr%C3%B5es#PET_no_Brasil" target="_blank"&gt;PET ou PET/CT&lt;/a&gt; em São Paulo (capital e interior), Rio de Janeiro, Brasília, Curitiba e Salvador. Foram inaugurados recentemente aparelhos também em Recife e Vitória. No total, existem cerca de 20 aparelhos em operação no Brasil, enquanto outros 15 estão sendo instalados. Outra limitação é que o SUS não dá cobertura para o PET/CT. Leia mais sobre PET/CT &lt;a href="http://www.oncopediatria.org.br/estatico/noticias/06_10_2005/pet-ct.jsp"&gt;aqui&lt;/a&gt;.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7140316847226727554/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/04/imagem-de-petct-mostra-resposta-do.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7140316847226727554'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7140316847226727554'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/04/imagem-de-petct-mostra-resposta-do.html' title='Imagem de PET/CT mostra resposta do tratamento oncológico após primeiro ciclo'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6859980183985020011</id><published>2009-04-24T18:34:00.002-03:00</published><updated>2011-03-18T20:40:35.017-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='dieta'/><category scheme='http://www.blogger.com/atom/ns#' term='exercícios'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><category scheme='http://www.blogger.com/atom/ns#' term='obesidade'/><category scheme='http://www.blogger.com/atom/ns#' term='fitness'/><title type='text'>Novidades da 100a Reunião da AACR</title><content type='html'>&lt;div xmlns='http://www.w3.org/1999/xhtml'&gt;Na 100a Edição da reunião anual da Associação Americana para a Pesquisa do Câncer (American Association for Cancer Research - AACR) foram discutidas novidades sobre estilo de vida, dieta e tratamento do câncer. Algumas notícias resumidas:&lt;br/&gt;Nenhuma modificação dietética específica tem comprovadamente efeito na evolução e tratamento do câncer. Embora muitos trabalhos tenham mostrado influência de determinados hábitos alimentares e alimentos específicos na incidência e complicações do câncer de uma forma geral, os resultados de várias séries de relatos são inconclusivos ou conflitantes. Informações veiculadas como "verdadeiras" ainda são especulativas. Um caso é o efeito do consumo de carne vermelha bem passada ou torrada, possivelmente associada com aumento de incidência de vários tipos de câncer. Especialistas presentes à reunião declararam que, após 30 anos de pesquisas, nada foi definido. Outro caso é a controvérsia de que o consumo de vinho pode ter efeito benéfico no tratamento de vários tipos de câncer, especialmente linfoma não Hodgkin. Isso parece altamente improvável, especialistas dizem. Uma informação bem mais estabelecida, por outro lado, é o efeito do consumo do álcool de aumentar a incidência de câncer de mama e, talvez, de outros tipos de câncer, mesmo consumido em pequenas quantidades. Da mesma forma, não existe base para o efeito benéfico do consumo regular de frutas e verduras em geral na incidência de câncer de uma forma geral. A única unanimidade que a AACR endossa é o efeito da obesidade: manter-se o mais magro que a saúde permitir parece ser uma recomendação adequada para reduzir a incidência de câncer. Dados atuais associam a obesidade com a incidência de 30-35% de todos os tumores malignos, o que coloca esta patologia como o segundo fator relacionado a estilo de vida mais influente na incidência do câncer, atrás apenas do tabagismo.&lt;br/&gt;Outro dado aparente nesta reunião da AACR foi a falta de evidência do efeito de qualquer tipo de vitamina, suplemento alimentar ou antioxidante na incidência ou tratamento do câncer. Os dados atuais não comprovam ou refutam efeito, assim como é o caso da dieta. Isso não quer dizer que um efeito leve a moderado não possa existir, mas é provável que efeitos importantes não existam.&lt;br/&gt;Por outro lado, uma das novidades mais interessantes é o efeito benéfico dos exercícios físicos no tratamento do câncer, diminuindo mortalidade e morbidade e melhorando a qualidade de vida dos pacientes. Este efeito é importante. Exercícios físicos regulares podem reduzir a mortalidade de câncer em 40-45%, efeito de igual magnitude ao do tratamento médico atualmente existente. A AACR endossa a recomendação de exercícios físicos regulares a partir da data do diagnóstico, durante o tratamento e após o tratamento, indefinidamente, como forma de melhorar o tratamento de seus pacientes. Alguns oncologistas já estão referindo seus pacientes para fisioterapeutas especializados neste tipo de exercício físico.&lt;br/&gt;Dessa forma, podemos resumir as recomendações sobre estilo de vida da AACR na sua última reunião: emagreça e faça exercícios físicos regulares para evitar câncer, se você tiver câncer continue com atividade física contínua para ajudá-lo a sobreviver, tenha uma dieta saudável para evitar obesidade e não gaste dinheiro com suplementos alimentares caros e de eficiência duvidosa!&lt;br/&gt;Leia mais no Medscape: www.medscape.com&lt;br/&gt;&lt;br/&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6859980183985020011/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/04/novidades-da-100a-reuniao-da-aacr.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6859980183985020011'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6859980183985020011'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/04/novidades-da-100a-reuniao-da-aacr.html' title='Novidades da 100a Reunião da AACR'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6982782104993430517</id><published>2009-04-05T09:20:00.002-03:00</published><updated>2011-03-18T20:40:35.019-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='doenças cardíacas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='dieta'/><category scheme='http://www.blogger.com/atom/ns#' term='gordos'/><category scheme='http://www.blogger.com/atom/ns#' term='magrinhas'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><category scheme='http://www.blogger.com/atom/ns#' term='modelos'/><title type='text'>Atenção gordos e modelos magrinhas!</title><content type='html'>Uma metanálise de vários estudos publicada recentemente mostrou que o aumento do índice de massa corpórea (IMC) correlaciona-se com aumento de mortalidade por várias causas. O interessante é que um IMC abaixo de determinado nível também mostrou essa correlação. O nível ótimo de IMC ficou entre 22,5 e 25kg/m2. Acima e baixo destes limites, a mortalidade aumenta. A relação com IMC é bem clara e fácil de entender. Quem tem IMC entre 30-35 vai viver , em média, 2-4 anos a menos que as pessoas da faixa "boa". Quem tem IMC de 40-45 vai viver, em média, 8-10 anos a menos. O excesso de mortalidade é por doenças do coração (aumenta 40%), diabetes (aumenta até 120%), câncer (10% mais), doenças respiratórias (20% mais) e outras, como doenças dos rins e fígado. Não existe explicação ainda, todavia, para o aumento de mortalidade entre os magrelos. Como muitas meninas que desfilam nas passarelas tem IMC entre 15 e 20 (às vezes mais baixo!) elas potencialmente estão em alto risco, assim como os obesos!!! Leiam mais:&lt;br /&gt;&lt;br /&gt;March 17, 2009 — Body-mass index (BMI) above the ideal range may cause a large increase in mortality rates, according to the results of a collaborative analysis of 57 prospective studies reported in the March 18 Online First issue of &lt;em&gt;Lancet&lt;/em&gt;.&lt;p&gt;"The main associations of...BMI with overall and cause-specific mortality can best be assessed by long-term prospective follow-up of large numbers of people," write Gary Whitlock, and colleagues from The Prospective Studies Collaboration at the University of Oxford, Oxford, United Kingdom. "The Prospective Studies Collaboration aimed to investigate these associations by sharing data from many studies."&lt;/p&gt;&lt;p&gt;The investigators analyzed the association of baseline BMI with mortality in 57 prospective studies enrolling a total of 894,576 participants, mostly in western Europe and North America, with median recruitment year 1979. Mean age at recruitment was 46 ± 11 years, 61% were men, and mean BMI was 25 ± 4 kg/m². The analyses were adjusted for age, sex, smoking status, and study, and the first 5 years of follow-up were excluded.&lt;/p&gt;&lt;p&gt;Mortality rate was lowest with BMI at approximately 22.5 to 25 kg/m² for both men and women. At higher baseline BMI, there were positive associations for several specific causes and inverse associations for none. Absolute excess risks for higher BMI and smoking were approximately additive.&lt;/p&gt;&lt;p&gt;On average, each 5-kg/m² higher BMI was associated with approximately 30% higher overall mortality rate (hazard ratio per 5 kg/m² [HR], 1.29; 95% confidence interval [CI], 1.27 -1.32): 40% for vascular mortality (HR, 1.41; 95% CI, 1.37 - 1.45); 60% to 120% for diabetic (HR, 2.16; 95% CI, 1.89 - 2.46), renal (HR, 1.59; 95% CI, 1·27 - 1·99), and hepatic (HR, 1.82; 95% CI, 1·59 - 2·09) mortality; 10% for neoplastic mortality (HR, 1.10; 95% CI, 1.06 - 1.15); and 20% for respiratory (HR, 1.20; 95% CI, 1.07 - 1.34) and all other mortality (HR, 1.20; 95% CI, 1.16 - 1.25).&lt;/p&gt;&lt;p&gt;BMI less than 22·5 to 25 kg/m² was inversely associated with overall mortality rate, primarily because of strong inverse associations with respiratory disease and lung cancer. Although cigarette consumption per smoker varied little with BMI, these inverse associations were much&lt;br /&gt;stronger for smokers vs nonsmokers.&lt;/p&gt;&lt;p&gt;"Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and below the apparent optimum of about 22.5–25 kg/m²," the study authors write. "The progressive excess mortality above this range is due mainly to vascular&lt;br /&gt;disease and is probably largely causal. At 30–35 kg/m², median survival is reduced by 2–4 years; at 40–45 kg/m², it is reduced by 8–10 years (which is comparable with the effects of smoking). The definite excess mortality below 22.5 kg/m² is due mainly to smoking-related diseases,&lt;br /&gt;and is not fully explained."&lt;/p&gt;&lt;p&gt;"In adult life, it may be easier to avoid substantial weight gain than to lose that weight once it has been gained," the study authors conclude. "By avoiding a further increase from 28 kg/m² to 32 kg/m², a typical person in early middle age would gain about 2 years of life expectancy. Alternatively, by avoiding an increase from 24 kg/m² to 32 kg/m² (ie, to a third above the apparent optimum), a young adult would on average gain about 3 extra years of life."&lt;/p&gt;&lt;em&gt;Lancet&lt;/em&gt;. Published online March 18, 2009.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6982782104993430517/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/04/atencao-gordos-e-modelos-magrinhas.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6982782104993430517'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6982782104993430517'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/04/atencao-gordos-e-modelos-magrinhas.html' title='Atenção gordos e modelos magrinhas!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4577350746984623977</id><published>2009-04-05T08:48:00.002-03:00</published><updated>2011-03-18T21:31:11.733-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='dieta'/><category scheme='http://www.blogger.com/atom/ns#' term='selênio'/><category scheme='http://www.blogger.com/atom/ns#' term='suplementos'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='vitaminas'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><category scheme='http://www.blogger.com/atom/ns#' term='vitamina E'/><title type='text'>Selênio e vitamina E não evitam câncer, mas podem atrapalhar</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;&lt;p&gt;Mais uma para os adeptos dos suplementos dietéticos, em especial aqueles que usam altas doses de certas vitaminas e micronutrientes sob a cara propaganda de pseudo-especialistas, como os "Terapeutas Ortomoleculares". Lembramos que esta "terapia", muitas vezes ministrada por não médicos sem o menor conhecimento do funcionamento do organismo e do mecanismo das doenças, não é reconhecida pelo Conselho Federal de Medicina nem pelo Ministério da Saúde do Brasil. Desta vez um trabalho tentou associar algum benefício do uso de suplementos de selênio e vitamina E no câncer de próstata, sem resultado. Para piorar, o selênio mostrou uma tendência a associar-se com mutações genéticas que indicam maior gravidade do câncer, com uma significância estatística limítrofe. Embora os autores do estudo tenham responsavelmente se abstido de conclusões precipitadas, fica óbvio que o uso não adequadamente testado de qualquer substância, mesmo suplementos alimentares, pode ser perigoso. Leia mais:&lt;br /&gt;&lt;/p&gt;&lt;p&gt;NEW YORK (Reuters Health) Mar 13 - Gene expression profiles in prostatectomy specimens can provide insight into the effects of nutritional supplements taken by those patients preoperatively,&lt;br /&gt;according to the results of a new study.&lt;/p&gt;The study by U.S. researchers is reportedly the first detailed systematic pathological tissue interrogation to be completed inpreoperative patients with favorable-risk prostate cancer. The report appears in the March 4 issue of the Journal of the National Cancer Institute.&lt;br /&gt;&lt;p&gt;Dr. Jeri Kim of the University of Texas M.D. Anderson Cancer Center, Houston, and colleagues note that several major studies and secondary analyses have given contradictory results regarding whether selenium and/or vitamin E reduce the incidence of prostate or other cancers.&lt;/p&gt;To investigate further, the researchers studied 39 men with histologically confirmed adenocarcinoma of the prostate, a life expectancy of at least 10 years and scheduled radical prostatectomy.&lt;br /&gt;&lt;p&gt;The participants were randomly assigned to one of four daily oral regimens: 200 mcg of selenium, 400 IU of vitamin E, a combination of both, or placebo. These treatments were given for 3 to 6 weeks, between enrollment in the study and prostatectomy. Thirty-six participants were included in all parts of the study, including microarray analysis.&lt;/p&gt;The researchers isolated and studied normal, stromal and tumor cells from the biopsy samples. They then identified differential gene expression based on treatment type and also on cell type and tissue zone.&lt;br /&gt;&lt;p&gt;Among other results, an increase in the mean percentage of tumor cells positive for the tumor suppressor p53 in the selenium group (26.3%), compared with that in the placebo group (5%), showed borderline statistical significance (p = 0.051).&lt;/p&gt;In an accompanying editorial, Dr. Eric A. Klein of the Cleveland Clinic Lerner College of Medicine, Ohio, reviews the findings of several major surveys that failed to find cancer-prevention benefits from selenium or vitamin E, and commented that such studies "do not always validate what we believe biology indicates."&lt;br /&gt;&lt;p&gt;He concludes that "dietary or nutrient supplement prevention of cancer may be best achieved by lifelong healthy eating habits."&lt;br /&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;J Natl Cancer Inst&lt;/i&gt; 2009;101:283-285,306-320.&lt;/p&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4577350746984623977/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/04/selenio-e-vitamina-e-nao-evitam-cancer_05.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4577350746984623977'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4577350746984623977'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/04/selenio-e-vitamina-e-nao-evitam-cancer_05.html' title='Selênio e vitamina E não evitam câncer, mas podem atrapalhar'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7229499168560077585</id><published>2009-04-04T17:30:00.002-03:00</published><updated>2011-03-18T20:40:35.023-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='carne vermelha'/><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://www.blogger.com/atom/ns#' term='doenças cardíacas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='dieta'/><category scheme='http://www.blogger.com/atom/ns#' term='morte'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><title type='text'>Carne vermelha associada com mortalidade!</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Mais uma novidade tanto para os "naturebas" quanto para os céticos. Um grande estudo publicado numa das mais lidas revistas médicas do planeta concluiu pela reafirmação de que o consumo de grande quantidade de carne vermelha e carne processada (presunto, mortadela, patês, etc) correlaciona-se com aumento de mortalidade por câncer e doenças do coração em pessoas de ambos os sexos. Para os adeptos do "não deixo meu sanduba de mortadela" a notícia não é de todo ruim: a recomendação é de que o consumo destes produtos seja moderado. Uma dieta de todo vegetariana não está em questão neste estudo, mas as pessoas que consumiram quantidades moderadas de carne vermelha e processada não pareceram ter um risco especialmente elevado. É óbvio que ninguém definiu o que é "moderado", mas algumas recomendações são especificadas pelo American Institute for Cancer Research. O coordenador do estudo frisa que não é vegetariano!! Leia mais:&lt;br /&gt;&lt;br /&gt;March 26, 2009 — Eating red and processed meat is associated with modest increases in total mortality, cancer mortality, and cardiovascular disease mortality rates, according to the results of a large, prospective study reported in the March 23 issue of the &lt;em&gt;Archives of Internal Medicine&lt;/em&gt;.&lt;p&gt;"High intakes of red or processed meat may increase the risk of mortality," write Rashmi Sinha, PhD, from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services in Rockville, Maryland, and colleagues. "Our objective was to determine the relations of red, white, and processed meat intakes to risk for total and cause-specific mortality."&lt;/p&gt;&lt;p&gt;The National Institutes of Health–AARP Diet and Health Study enrolled approximately half a million people aged 50 to 71 years at baseline. A food frequency questionnaire administered at baseline allowed estimation of meat intake, and Cox proportional hazards regression models allowed calculation of hazard ratios (HRs) and 95% confidence intervals (CIs) within quintiles of meat intake.&lt;/p&gt;&lt;p&gt;Red meat included all types of beef and pork such as bacon, beef, cold cuts, hamburgers, hotdogs, steak, and meats in pizza, lasagna, and stew. White meat included chicken, turkey, and fish along with poultry cold cuts, canned tuna, and low-fat hotdogs. Processed meats could include either red or white meats in the form of sandwich meats or cold cuts as well as bacon, red meat and poultry sausages, and regular hotdogs and low-fat hotdogs made from poultry. The authors note that some of the meats may overlap in the 3 categories, but they were not duplicated or used in the same models in the study analysis.&lt;/p&gt;&lt;p&gt;The models considered covariates of age, education, marital status, presence or absence of family history of cancer (for cancer mortality only), race, body mass index, smoking history, physical activity, energy intake, alcohol drinking, use of vitamin supplements, fruit consumption, vegetable consumption, and use of menopausal hormone therapy in women. Primary endpoints of the study were total mortality and deaths caused by cancer, cardiovascular disease, injury and sudden deaths, and all other causes.&lt;/p&gt;&lt;p&gt;During 10 years of follow-up, 47,976 men and 23,276 women died. Overall mortality risks were increased for men and women in the highest vs the lowest quintile of red meat intake (HR, 1.31; 95% CI, 1.27 - 1.35; and HR, 1.36; 95% CI, 1.30-1.43, respectively) and processed meat intake (HR, 1.16; 95% CI, 1.12 - 1.20; and HR, 1.25; 95% CI, 1.20 - 1.31, respectively). Men and women with higher intake also had increased risks for cancer mortality for red meat (HR, 1.22; 95% CI, 1.16 - 1.29; and HR, 1.20; 95% CI, 1.12 - 1.30, respectively) and processed meat (HR, 1.12; 95% CI, 1.06 - 1.19; and HR, 1.11; 95% CI 1.04 - 1.19, respectively).&lt;/p&gt;&lt;p&gt;Cardiovascular disease risk was increased for men and women in the highest quintile of intake of red meat (HR, 1.27; 95% CI, 1.20 - 1.35; and HR, 1.50; 95% CI, 1.37 - 1.65, respectively) and processed meat (HR, 1.09; 95% CI, 1.03 - 1.15; and HR, 1.38; 95% CI, 1.26 - 1.51, respectively). For the highest vs the lowest quintile of white meat intake for both men and women, there was an inverse association for total mortality, cancer mortality, and mortality from all other causes.&lt;/p&gt;&lt;p&gt;"Red and processed meat intakes were associated with modest increases in total mortality, cancer mortality, and cardiovascular disease mortality," the study authors write. "In contrast, high white meat intake and a low-risk meat diet was associated with a small decrease in total and cancer mortality."&lt;/p&gt;&lt;p&gt;Limitations of this study include possible residual confounding by smoking; possible measurement error; and cohort predominantly non-Hispanic white, more educated, with less smoking, less fat and red meat intake, and more intake of fiber and fruit and vegetables than similarly aged adults in the US population, limiting generalizability.&lt;/p&gt;&lt;p&gt;"These results complement the recommendations by the American Institute for Cancer Research and the World Cancer Research Fund to reduce red and processed meat intake to decrease cancer incidence," the study authors write. "Future research should investigate the relation between subtypes of meat and specific causes of mortality."&lt;/p&gt;&lt;em&gt;&lt;/em&gt;&lt;em&gt;Arch Intern Med&lt;/em&gt;. 2009;169:543-545, 562-571. &lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img src="http://img.zemanta.com/pixy.gif?x-id=06505d85-97de-8d74-bb59-e655d86564f6" class="zemanta-pixie-img" /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7229499168560077585/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/04/carne-vermelha-associada-com.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7229499168560077585'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7229499168560077585'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/04/carne-vermelha-associada-com.html' title='Carne vermelha associada com mortalidade!'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1932326259756496055</id><published>2009-04-04T17:18:00.001-03:00</published><updated>2011-03-18T21:31:11.736-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://www.blogger.com/atom/ns#' term='próstata'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='dieta'/><category scheme='http://www.blogger.com/atom/ns#' term='estilo de vida'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='ômega 3'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Ômega 3 reduz câncer de próstata</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;&lt;p&gt;Atenção aos aficionados por produtos naturais e aos que desacreditam deles: consumir a partir de 500mg de ácidos graxos ômega 3 na dieta ou suplementos reduz a incidência de câncer de próstata e de câncer de próstata avançado. Foi o que um estudo publicado numa das mais prestigiadas revistas de cancerologia do mundo concluiu. A notícia completa segue abaixo:&lt;br /&gt;&lt;/p&gt;&lt;p&gt;NEW YORK (Reuters Health) Mar 25 - Results of a case-control study suggest that a high intake of long-chain omega-3 fatty acids protects against advanced prostate cancer, and this effect may be modified by a genetic variant of COX-2, a key enzyme in fatty acid metabolism and inflammation.&lt;/p&gt; &lt;p&gt;"Previous research has shown protection (by omega-3 fatty acids) against prostate cancer, but this is one of the first studies to show protection against advanced prostate cancer and interaction with COX-2," Dr. John S. Witte of the University of California, San Francisco noted in a statement from the American Association for Cancer Research (AACR)&lt;/p&gt; &lt;p&gt;Dr. Witte and colleagues studied 466 men diagnosed with aggressive prostate cancer and 478 age- and ethnicity-matched controls. They assessed diet using a food frequency questionnaire and genotyped the men for nine COX-2 single nucleotide polymorphisms.&lt;/p&gt; &lt;p&gt;In an online issue of the AACR journal Clinical Cancer Research, the researchers report that increasing intake of long-chain omega-3 fatty acids was strongly associated with a decreased risk of aggressive prostate cancer.&lt;/p&gt; &lt;p&gt;Men in the highest quartiles of long chain omega-3 fatty acid intake had a 63 percent reduced risk of aggressive prostate cancer (odds ratio, 0.37) compared to men in the lowest quartile.&lt;/p&gt; &lt;p&gt;"Importantly," Dr. Witte and colleagues say, this protective effect was even stronger in men who carried the COX-2 single nucleotide polymorphism rs4647310, a risk factor for prostate cancer.&lt;/p&gt; &lt;p&gt;Specifically, men with low intake of long-chain omega-3 fatty acids and this particular variant had a more than fivefold increased risk of advanced prostate cancer (odds ratio, 5.49), whereas men with high intake of omega-3 fatty acids had a substantially reduced risk, even if they carried the COX-2 rs4647310 variant.&lt;/p&gt; &lt;p&gt;In other words, the increased risk of prostate cancer associated with the COX-2 rs4647310 variant was "essentially reversed by increasing omega-3 fatty acid intake by a half a gram per day," Dr. Witte said.&lt;/p&gt; &lt;p&gt;"If you want to think of the overall inverse association in terms of fish, where omega-3 fatty acids are commonly derived, the strongest effect was seen from eating dark fish such as salmon one or more times per week," he added.&lt;/p&gt; &lt;p&gt;Clin Cancer Res 2009;15:7.&lt;/p&gt;&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img src="http://img.zemanta.com/pixy.gif?x-id=bd298656-c1ed-8759-a344-0314a800491b" class="zemanta-pixie-img" /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1932326259756496055/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/04/omega-3-reduz-cancer-de-prostata.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1932326259756496055'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1932326259756496055'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/04/omega-3-reduz-cancer-de-prostata.html' title='Ômega 3 reduz câncer de próstata'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8711460085162191258</id><published>2009-03-30T09:20:00.003-03:00</published><updated>2011-03-18T21:31:11.738-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://www.blogger.com/atom/ns#' term='propranolol'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='hemangiomas'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Uso de propranolol revoluciona tratamento de hemangiomas da infância</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Em junho de 2008, um grupo de dermatologistas franceses publicou uma carta no &lt;a href="http://content.nejm.org/"&gt;New England Journal of Medicine&lt;/a&gt;, um dos mais prestigiados jornais científicos do mundo, relatando o resultado do tratamento de 11 crianças com &lt;a href="http://www.hemangioma.com.br/"&gt;hemangiomas&lt;/a&gt; de grande tamanho com &lt;a href="http://pt.wikipedia.org/wiki/Propranolol" target="_blank"&gt;propranolol&lt;/a&gt;. Esta droga é um &lt;a href="http://pt.wikipedia.org/wiki/Bloqueador_beta"&gt;beta-bloqueador&lt;/a&gt;, substância usada com sucesso como &lt;a href="http://pt.wikipedia.org/wiki/Anti-hipertensivo"&gt;anti-hipertensivo&lt;/a&gt; desde a década de 70. O propranolol foi oriundo de um bem sucedido programa de planejamento racional de fármacos, dando origem a uma das classes de medicamentos mais usadas no mundo inteiro. Largamente usado em adultos e, de forma mais limitada, em crianças, sua segurança está bem estabelecida e é aprovado pela &lt;a href="http://www.anvisa.gov.br/"&gt;ANVISA&lt;/a&gt; para uso no Brasil. Seu efeito nos hemangiomas, induzindo uma regressão rápida e completa em poucas semanas, foi descoberto casualmente pelos especialistas franceses, quando precisaram tratar uma criança portadora de grande hemangioma facial e que também tinha &lt;a href="http://www.manualmerck.net/?url=/artigos/%3Fid%3D44%26cn%3D636" target="_blank"&gt;miocardiopatia hipertrófica&lt;/a&gt; (uma doença do coração que não tem relação com os hemangiomas). Esta doença é normalmente tratada com propranolol. Após o primeiro e surpreendente resultado, a equipe testou o novo tratamento em mais 9 crianças, com resultado positivo. A publicação deu início a uma onda mundial de euforia, com especialistas ao redor do planeta usando a droga para tratar hemangiomas em crianças. O artigo pode ser lido &lt;a href="http://content.nejm.org/cgi/content/full/358/24/2649"&gt;aqui&lt;/a&gt;.&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img class="zemanta-pixie-img" src="http://img.zemanta.com/pixy.gif?x-id=8e9606db-4d4f-8155-84c1-6fc685d1e072" /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8711460085162191258/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/03/uso-de-propranolol-revoluciona.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8711460085162191258'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8711460085162191258'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/03/uso-de-propranolol-revoluciona.html' title='Uso de propranolol revoluciona tratamento de hemangiomas da infância'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-593813889195720040</id><published>2009-03-30T08:55:00.002-03:00</published><updated>2009-05-16T18:29:49.934-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='disautonomia'/><category scheme='http://www.blogger.com/atom/ns#' term='publicações'/><category scheme='http://www.blogger.com/atom/ns#' term='fibromialgia'/><category scheme='http://www.blogger.com/atom/ns#' term='science'/><title type='text'>Publicações do Dr. Hélder</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;Este mês foram publicados os seguintes trabalhos do Dr. Helder em periódicos científicos:&lt;br /&gt;&lt;b&gt;Fibromyalgia and Related Medically Unexplained Symptoms: A Lost Link Between Cardiovascular and Nociception Modulation.&lt;/b&gt; Journal of Musculoskeletal Pain 17:67-79. Clique &lt;a href="http://www.informaworld.com/smpp/content%7Edb=all?content=10.1080/10582450802679904"&gt;aqui&lt;/a&gt; para ser encaminhado à página do trabalho. Trata-se de uma revisão sobre a relação entre disautonomia, disfunção endotelial e fibromialgia, levantando a hipótese de que uma disfunção da modulação neural cardiovascular e da dor participa na gênese desta frequente mas misteriosa doença.&lt;br /&gt;&lt;b&gt;UL97: Old Enzyme, New Functions in Viral Ocogenesis of Brain Tumors.&lt;/b&gt; Science, e-letter, 02 fev.  2009. Essa nota é um comentário acerca de um artigo sobre a relação entre vírus e tumores cerebrais. Clique &lt;a href="http://www.sciencemag.org/cgi/eletters/323/5910/30"&gt;aqui&lt;/a&gt; para ser encaminhado à página da e-letter.&lt;br /&gt;&lt;br /&gt;&lt;div class="zemanta-pixie"&gt;&lt;img src="http://img.zemanta.com/pixy.gif?x-id=8f3be882-9fe9-87f9-80ef-d49a444112ba" class="zemanta-pixie-img" /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/593813889195720040/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/03/publicacoes-do-dr-helder.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/593813889195720040'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/593813889195720040'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/03/publicacoes-do-dr-helder.html' title='Publicações do Dr. Hélder'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3864354506920975672</id><published>2009-03-18T22:42:00.002-03:00</published><updated>2011-07-18T23:00:26.928-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients</title><content type='html'>The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment.&lt;br /&gt;Read the article &lt;a href="http://jco.ascopubs.org/content/27/7/1007.full.pdf+html"&gt;here&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3864354506920975672/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2009/03/myeloablative-therapy-and-cis-retinoic.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3864354506920975672'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3864354506920975672'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/03/myeloablative-therapy-and-cis-retinoic.html' title='Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7223099427807563805</id><published>2008-07-11T15:45:00.002-03:00</published><updated>2009-05-16T18:28:59.939-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='mudança'/><title type='text'>O Blog vai mudar</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;A partir de julho de 2008, o blog Farmacologia Mobile vai mudar. Isto ocorrerá devido ao desligamento do Professor Francisco Hélder Cavalcante Félix dos quadros da Faculdade de Medicina de Juazeiro do Norte, depois de 5 anos ensinando naquela instituição. O prof. Hélder solicitou seu desligamento devido a motivos pessoais e sente muito a saída do seu posto de professor. O blog passará a ser uma página de interação do professor Hélder, voltada a todos que têm interesse em Farmacologia, Medicina e assuntos afins. O conteúdo das aulas será redesenhado e ficará ainda à disposição sob outra roupagem.&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7223099427807563805/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2008/07/o-blog-vai-mudar.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7223099427807563805'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7223099427807563805'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2008/07/o-blog-vai-mudar.html' title='O Blog vai mudar'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6044278605739288725</id><published>2008-06-10T21:57:00.001-03:00</published><updated>2011-09-18T12:27:16.326-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='inibidores tirosina-quinase'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><category scheme='http://www.blogger.com/atom/ns#' term='genetics'/><category scheme='http://www.blogger.com/atom/ns#' term='targeted therapy'/><title type='text'>Scientists Discover Neuroblastoma Gene</title><content type='html'>Scientists have discovered that mutations in a gene called anaplastic lymphoma kinase (ALK) are a major cause of neuroblastoma in both inherited and noninherited forms of neuroblastoma. Previous to this finding, it was known that numerous chromosomal abnormalities, including deletions of chromosome arms 1p, 11q, and 14q, were associated with neuroblastoma, though no specific drug targets had been identified. ALK is a tyrosine kinase, one of a family of proteins that add phosphate groups to other proteins. These phosphate groups act as switches that regulate the activity of other proteins. Thus, the phosphotransferase activity of tyrosine kinases is strictly controlled in normal cells. Mutations that abnormally activate the phosphotransferase activity of tyrosine kinases are a major cause of cancer in numerous tumor types. ALK, like MYCN, can be amplified in neuroblastoma. The discovery of ALK mutations in neuroblastoma provides an exciting opportunity to develop new approaches for therapy, and an ALK inhibitor has been tested for efficacy in non-small-cell lung cancer.&lt;br /&gt;Read more in &lt;a href="http://www.medscape.com/viewarticle/580334?src=mp&amp;spon=7"&gt;Medscape&lt;/a&gt;.&lt;br /&gt;Article &lt;a href="http://www.nature.com/nature/journal/v455/n7215/abs/nature07261.html"&gt;here&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6044278605739288725/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2008/06/scientists-discover-neuroblastoma-gene.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6044278605739288725'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6044278605739288725'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2008/06/scientists-discover-neuroblastoma-gene.html' title='Scientists Discover Neuroblastoma Gene'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-6752803759724250414</id><published>2008-04-14T21:41:00.002-03:00</published><updated>2011-09-18T12:29:09.725-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Effectiveness of screening for neuroblastoma</title><content type='html'>A japanese group has published a retrospective evaluation of neuroblastoma mass-screening program that was performed between 1984 and 2003. They reported that this program was effective for more neuroblastoma diagnosis and less mortality, suggesting that previous accounts that it did not affect patients mortality were not true. These results indicate that neuroblastoma mass-screening with quantitative methods can effectively diminish the diagnosis of late-stage disease and help reduce mortality in children with this disease. Read the article &lt;a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2808%2960523-1/fulltext"&gt;here&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/6752803759724250414/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2008/04/effectiveness-of-screening-for.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6752803759724250414'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/6752803759724250414'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2008/04/effectiveness-of-screening-for.html' title='Effectiveness of screening for neuroblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4729501102307071959</id><published>2007-12-17T00:48:00.003-03:00</published><updated>2009-05-16T18:30:15.751-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='disautonomia'/><category scheme='http://www.blogger.com/atom/ns#' term='publicações'/><category scheme='http://www.blogger.com/atom/ns#' term='fibromialgia'/><title type='text'>Artigo sobre fibromialgia é um dos mais acessados</title><content type='html'>&lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;O trabalho intitulado "&lt;small&gt;&lt;big&gt;Is fibromyalgia a cardiovascular disease? A comment on Martinez-Lavin's review 'Stress, the stress response system, and fibromyalgia'", de autoria do prof. Francisco Hélder  C. Félix e da profa. Juvenia B. Fontenele, publicado on line no periódico científico  Arthritis Research &amp;amp; Therapy em  31 de outubro de 2007, foi considerado um dos 20 trabalhos mais acessados nos últimos 30 dias naquele periódico, com mais de 400 acessos em 1 mês e quase 800 acessos desde que foi publicado. Também recebeu a designação "highly accessed", dada aos artigos publicados em jornais da Biomed Central e que têm uma frequência de acessos especialmente alta, em relação à sua idade de publicação e ao jornal onde foram publicados. Isso significa que este trabalho superou a média de acessos e de impacto do jornal onde foi publicado. Vale salientar que o fator de impacto do Arthritis Research &amp;amp; Therapy é de 3,8.&lt;br /&gt;Este trabalho, na verdade, é uma carta aos editores da revista, comentando o trabalho do dr. Manoel Martinez-Lavin, o qual criou uma teoria de que a fibromialgia é uma doença relacionada à hiperatividade do sistema nervoso simpático, um tipo de "dor simpática". Nesta carta nós citamos nosso trabalho, "Fibromyalgia  and related medically unexplained symptons: a lost link between cardiovascular and nociception modulation?" aceito para publicação no Journal of Musculoskeletal Pain, e que deve sair em 2008. Neste trabalho, nós lançamos o conceito de "modelo cardiovascular da fibromialgia" que reúne idéias e pesquisas realizadas por diversos grupos ao redor do mundo para tentar relacionar a sensibilização central à dor que é marca registrada da fibromialgia e outras doenças com alterações cardiovasculares, especialmente microvasculares.  Na carta enviada à Arthritis Research &amp;amp; Therapy, citamos evidências recentes que sugerem uma proximidade entre doenças cardiovasculares e a fibromialgia.&lt;br /&gt;&lt;/big&gt;&lt;/small&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;p class="poweredbyperformancing"&gt;Powered by &lt;a href="http://scribefire.com/"&gt;ScribeFire&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4729501102307071959/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/12/artigo-sobre-fibromialgia-um-dos-mais_17.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4729501102307071959'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4729501102307071959'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/12/artigo-sobre-fibromialgia-um-dos-mais_17.html' title='Artigo sobre fibromialgia é um dos mais acessados'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3397795605434728593</id><published>2007-11-27T22:10:00.001-03:00</published><updated>2011-09-18T12:22:44.822-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='antifúngicos'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='anticoagulantes'/><category scheme='http://www.blogger.com/atom/ns#' term='osteoporose'/><category scheme='http://www.blogger.com/atom/ns#' term='tireóide'/><category scheme='http://www.blogger.com/atom/ns#' term='insulina'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><category scheme='http://www.blogger.com/atom/ns#' term='antivirais'/><category scheme='http://www.blogger.com/atom/ns#' term='SIDA'/><category scheme='http://www.blogger.com/atom/ns#' term='diabetes'/><title type='text'>Atualização: aulas não postadas ainda</title><content type='html'>Pessoal, aqui estão os links das aulas deste semestre que ainda não haviam sido incluídas ainda no blog:&lt;br /&gt;* &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Antifungicos_2007.ppt"&gt;Antifúngicos&lt;/a&gt;&lt;br /&gt;* &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_antivirais_SIDA.ppt"&gt;Fármacos antivirais e tratamento da SIDA&lt;/a&gt;&lt;br /&gt;* &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Hormonios_gonadais_inib.ppt"&gt;Anticoncepcionais&lt;/a&gt;&lt;br /&gt;* &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_anticoagulantes.ppt"&gt;Fármacos anticoagulantes, fibrinolíticos e antiplaquetários&lt;/a&gt;&lt;br /&gt;* &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_tireoidianos.ppt"&gt;Fármacos tireoidianos e antitireoidianos&lt;/a&gt;&lt;br /&gt;* &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_calcio_osteoporose.ppt"&gt;Fármacos que alteram o metabolismo ósseo - tratamento da osteoporose&lt;/a&gt;&lt;br /&gt;* &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Insulina_hipoglicemiantes.ppt"&gt;Insulina e hipoglicemiantes orais&lt;/a&gt;&lt;br /&gt;Lembrando: coloque a senha de visitação "helder" na janela do disco virtual e abra os arquivos como "somente leitura".</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3397795605434728593/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/11/atualizao-aulas-no-postadas-ainda.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3397795605434728593'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3397795605434728593'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/11/atualizao-aulas-no-postadas-ainda.html' title='Atualização: aulas não postadas ainda'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-8341166492510107704</id><published>2007-11-18T21:22:00.000-03:00</published><updated>2011-03-18T21:31:11.740-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacological treatment'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Cefepime May Be Linked to Increased Risk for Death</title><content type='html'>&lt;div class="ExternalClass" id="MessageContaner"&gt;Cefepime HCl injection (&lt;i&gt;Maxipime&lt;/i&gt;, Bristol-Myers Squibb Co) may  be linked to an increased risk for death, the US Food and Drug  Administration (FDA) warned healthcare professionals in November 14 in an  early communication.  The warning was based on data from a systematic review and meta-analysis published in the May 2007 issue of &lt;i&gt;The Lancet Infectious Diseases&lt;/i&gt;  showing that use of cefepime was linked to an increased risk for  all-cause mortality compared with other beta lactam antibiotics (risk  ratio [RR], 1.26; 95% confidence interval [CI], 1.08 – 1.49),  particularly in patients with febrile neutropenia (RR, 1.42; 95% CI,  1.09 – 1.84).&lt;br /&gt;These findings have prompted an FDA review of new safety data and a  request for additional data to further evaluate this risk, according to  an alert sent from MedWatch, the FDA's safety information and adverse  event reporting program.&lt;br /&gt;At the end of the evaluation, which is expected to take 4 months, the  FDA will communicate its conclusions and any resulting recommendations.  Until that time, healthcare providers are advised to consider the risks  and benefits of cefepime therapy as described in the safety labeling  and the meta-analysis.&lt;br /&gt;Cefepime is indicated for the treatment of infections caused by  susceptible gram-positive and gram-negative microorganisms, including &lt;i&gt;Enterobacter&lt;/i&gt;, &lt;i&gt;Escherichia coli&lt;/i&gt;, &lt;i&gt;Klebsiella pneumoniae&lt;/i&gt;, &lt;i&gt;Proteus mirabilis&lt;/i&gt;, &lt;i&gt;Pseudomonas aeruginosa,&lt;/i&gt; methicillin-susceptible &lt;i&gt;Staphylococcus aureus&lt;/i&gt;, &lt;i&gt;Streptococcus pneumoniae&lt;/i&gt;, &lt;i&gt;Streptococcus pyogenes&lt;/i&gt;, and &lt;i&gt;Viridans&lt;/i&gt; group streptococci.&lt;br /&gt;Indications include empiric therapy for febrile neutropenic patients,  moderate to severe pneumonia, uncomplicated and complicated urinary  tract infections, uncomplicated skin/skin structure infections, and  complicated intra-abdominal infections.&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/8341166492510107704/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2011/03/cefepime-may-be-linked-to-increased.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8341166492510107704'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/8341166492510107704'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2011/03/cefepime-may-be-linked-to-increased.html' title='Cefepime May Be Linked to Increased Risk for Death'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3878659578567434970</id><published>2007-10-08T21:17:00.001-03:00</published><updated>2011-09-18T12:22:44.829-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='antiprotozoários'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><category scheme='http://www.blogger.com/atom/ns#' term='tuberculose'/><category scheme='http://www.blogger.com/atom/ns#' term='lepra'/><title type='text'>Aulas desta semana</title><content type='html'>Aqui estão os links para as aulas de amanhã. Lembrando, ao abrir a janela do disco virtual, digite a senha de visitação "helder" e escolha abrir (ou salvar) o arquivo como "somente leitura".&lt;br /&gt;1) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Antiprotozoarios_2007.ppt"&gt;Antiprotozoários&lt;/a&gt;&lt;br /&gt;2) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_tuberculose_lepra.ppt"&gt;Tratamento da tuberculose e da lepra&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/3878659578567434970/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/10/aqui-esto-os-links-para-as-aulas-de.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3878659578567434970'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/3878659578567434970'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/10/aqui-esto-os-links-para-as-aulas-de.html' title='Aulas desta semana'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2700099711577817195</id><published>2007-10-08T00:40:00.001-03:00</published><updated>2011-09-18T12:22:44.806-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://www.blogger.com/atom/ns#' term='horário'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><title type='text'>Nossa aula</title><content type='html'>Estarei chegando em Juazeiro hoje por volta de 15h30. Nossa aula será amanhã às 7h30. Assuntos: antiprotozoários e tratamento da tuberculose e lepra. Até lá!</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2700099711577817195/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/10/nossa-aula.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2700099711577817195'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2700099711577817195'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/10/nossa-aula.html' title='Nossa aula'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2482176190629544076</id><published>2007-10-05T00:18:00.001-03:00</published><updated>2011-09-18T12:22:44.799-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://www.blogger.com/atom/ns#' term='anticâncer'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><category scheme='http://www.blogger.com/atom/ns#' term='imunossupressores'/><title type='text'>Últimas aulas</title><content type='html'>Estas são as aulas desta semana. Lembrando que, ao abrir a janela do disco virtual, deve-se inserir a senha de visitação "helder" e abrir o arquivo como "somente leitura".&lt;br /&gt;1) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Quimioterapia_anticancer.ppt"&gt;Quimioterapia anticâncer&lt;/a&gt;&lt;br /&gt;2) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Imunossupressores.ppt"&gt;Imunossupressores&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/2482176190629544076/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/10/ltimas-aulas.html#comment-form' title='2 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2482176190629544076'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/2482176190629544076'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/10/ltimas-aulas.html' title='Últimas aulas'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>2</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-323308652505872837</id><published>2007-10-01T02:12:00.001-03:00</published><updated>2011-09-18T12:22:44.814-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://www.blogger.com/atom/ns#' term='horário'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><title type='text'>Nossa próxima aula</title><content type='html'>Estarei chegando em Juazeiro hoje por volta das 17h00 e nossa aula está programada para amanhã às 7h30. Assuntos:&lt;br /&gt;1. Quimioterapia anticâncer&lt;br /&gt;2. Imunossupressores e imunoestimulantes</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/323308652505872837/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/10/nossa-prxima-aula.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/323308652505872837'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/323308652505872837'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/10/nossa-prxima-aula.html' title='Nossa próxima aula'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1828787303567602813</id><published>2007-09-26T18:07:00.002-03:00</published><updated>2011-09-18T12:22:44.792-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://www.blogger.com/atom/ns#' term='antianêmicos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='serotonina'/><category scheme='http://www.blogger.com/atom/ns#' term='dislipidemias'/><category scheme='http://www.blogger.com/atom/ns#' term='anti-histamínico'/><category scheme='http://www.blogger.com/atom/ns#' term='anti-helmínticos'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><category scheme='http://www.blogger.com/atom/ns#' term='anti-eméticos'/><title type='text'>Aulas desta semana e aulas anteriores do semestre</title><content type='html'>Estes são os links das aulas desta semana e das aulas de semanas anteriores que não haviam ainda sido disponibilizadas. Lembrando: coloque a senha de visitação "helder" na janela do disco virtual e abra os arquivos como "somente leitura".&lt;br /&gt;1) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Drogas_Anti-helminticas_2007.ppt"&gt;Anti-helmínticos&lt;/a&gt;&lt;br /&gt;2) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_anti-anemicos.ppt"&gt;Anti&lt;/a&gt;&lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_anti-anemicos.ppt"&gt;-anêmicos&lt;/a&gt;&lt;br /&gt;3) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_hiperlipo.ppt"&gt;Fármacos usados nas dislipidemias&lt;/a&gt;&lt;br /&gt;4) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_antiemeticos_2007.ppt"&gt;Anti-eméticos&lt;/a&gt;&lt;br /&gt;5) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_5HT_2007.ppt"&gt;Fármacos agonistas e antagonistas serotoninérgicos&lt;/a&gt;&lt;br /&gt;6) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Antihistaminicos_2007.ppt"&gt;Anti-histamínicos&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1828787303567602813/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/09/aulas-desta-semana-e-aulas-anteriores.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1828787303567602813'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1828787303567602813'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/09/aulas-desta-semana-e-aulas-anteriores.html' title='Aulas desta semana e aulas anteriores do semestre'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1206833854341793480</id><published>2007-09-24T02:04:00.001-03:00</published><updated>2011-09-18T12:22:44.784-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://www.blogger.com/atom/ns#' term='horário'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><title type='text'>Horário da aula</title><content type='html'>Nossa aula está prevista para iniciar às 16h40 de hoje.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1206833854341793480/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/09/horrio-da-aula.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1206833854341793480'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1206833854341793480'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/09/horrio-da-aula.html' title='Horário da aula'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4335501253736153566</id><published>2007-09-22T12:08:00.001-03:00</published><updated>2011-03-18T20:40:35.027-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='bevacizumab'/><category scheme='http://www.blogger.com/atom/ns#' term='cancer'/><category scheme='http://www.blogger.com/atom/ns#' term='monoclonais'/><category scheme='http://www.blogger.com/atom/ns#' term='tacerva'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='avastin'/><category scheme='http://www.blogger.com/atom/ns#' term='inibidores tirosina-quinase'/><category scheme='http://www.blogger.com/atom/ns#' term='erlotinib'/><title type='text'>Última no Medscape</title><content type='html'>O tratamento combinado de pacientes com tumores refratários utilizando um inibidor de angiogênese (bevacizumab) associado a antagonistas de EGFR (cetuximab, erlotinib ou panitumumab) mostrou resultados conflitantes em 3 ensaios clínicos diferentes relatados recentemente. Veja mais no link.&lt;br /&gt;&lt;a href="http://www.medscape.com/viewarticle/563107?src=mpnews"&gt;http://www.medscape.com/viewarticle/563107?src=mpnews&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4335501253736153566/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/09/ltima-no-medscape.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4335501253736153566'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4335501253736153566'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/09/ltima-no-medscape.html' title='Última no Medscape'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4091721261928785131</id><published>2007-09-21T10:55:00.002-03:00</published><updated>2011-09-18T12:22:44.836-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='FMJ'/><category scheme='http://www.blogger.com/atom/ns#' term='aulas'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='esteróides'/><category scheme='http://www.blogger.com/atom/ns#' term='asma'/><category scheme='http://www.blogger.com/atom/ns#' term='Lectures'/><title type='text'>Última aulas</title><content type='html'>As últimas aulas da turma atual de farmacologia da FMJ foram ministradas nesta terça, e aqui estão os links para elas. Para acessar, digite a senha de visitação "helder" na janela do disco virtual. Os arquivos podem ser abertos apenas no modo "somente leitura".&lt;br /&gt;1) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Esteroides_adrenal_2007.ppt"&gt;Esteróides da adrenal&lt;/a&gt;&lt;br /&gt;2) &lt;a href="http://helderfelix.discovirtual.uol.com.br/disco_virtual/compartilhada/Farmacos_Asma_DPOC_2007.ppt"&gt;Farmacologia da asma e DPOC&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4091721261928785131/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/09/ltima-aulas.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4091721261928785131'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4091721261928785131'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/09/ltima-aulas.html' title='Última aulas'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1704608538333004129</id><published>2007-09-21T10:48:00.001-03:00</published><updated>2011-03-18T21:26:20.583-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='farmacologia'/><category scheme='http://www.blogger.com/atom/ns#' term='pharmacology'/><title type='text'>Blog da farmacologia</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_ltzeFnIlO7Q/RvVdOHXoXYI/AAAAAAAAAAk/zdYFrIPau2k/s1600-h/Eu.jpg"&gt;&lt;img style="margin: 0pt 10px 10px 0pt; float: left; cursor: pointer;" src="http://4.bp.blogspot.com/_ltzeFnIlO7Q/RvVdOHXoXYI/AAAAAAAAAAk/zdYFrIPau2k/s320/Eu.jpg" alt="" id="BLOGGER_PHOTO_ID_5113095449026780546" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;Este blog está sendo inaugurado como meio de comunicação com os professores, alunos e funcionários da FMJ, e quem interessar possa, do professor Hélder, da Disciplina de farmacologia. Nos posts, colocarei links para baixar slides de aulas, novidades, notícias, resumos das aulas, simulações de prova, etc. Agradeço qualquer sugestão positiva e as contribuições. Qualquer assunto que tenha a ver com farmacologia é bem vindo. O nome do blog vem do fato de que parte das postagens será feita "on the go" com meu celular e o blog poderá ser lido, a princípio, por qualquer celular com navegador de internet (tipo Opera).</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1704608538333004129/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/09/blog-da-farmacologia.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1704608538333004129'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1704608538333004129'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/09/blog-da-farmacologia.html' title='Blog da farmacologia'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/_ltzeFnIlO7Q/RvVdOHXoXYI/AAAAAAAAAAk/zdYFrIPau2k/s72-c/Eu.jpg' height='72' width='72'/><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1867980465443481658</id><published>2007-09-20T21:12:00.002-03:00</published><updated>2009-05-16T17:30:08.936-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='ciência'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='publicações'/><category scheme='http://www.blogger.com/atom/ns#' term='fibromialgia'/><title type='text'>Aceite de trabalho</title><content type='html'>Recebemos, hoje, a confirmação do aceite de um manuscrito encaminhado para publicação no periódico Arthritis Research &amp;amp; Therapy, intitulado "Is fibromyalgia a cardiovascular disease?" Trata-se de uma carta enviada a esta revista comentando o trabalho do Dr. Martinez-Lavin, "Stress, the stress response system, and fibromyalgia." Nessa carta, citamos nosso artigo de revisão, no qual avaliamos o trabalho do Dr. Martinez-Lavin e de outros autores. Nesse outro trabalho, aceito para publicação em 28 de março de 2007 na revista Journal of Musculoskeletal Pain, nós lançamos o "Modelo cardiovascular da fibromialgia" o qual tenta relacionar a fibromialgia com as frequentes alterações autonômicas que os pacientes apresentam. Este artigo está no prelo, e sairá em breve.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/1867980465443481658/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/09/aceite-de-trabalho.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1867980465443481658'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/1867980465443481658'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/09/aceite-de-trabalho.html' title='Aceite de trabalho'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7415006073050620639</id><published>2007-07-19T20:31:00.016-03:00</published><updated>2011-07-18T20:48:41.117-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='mortalidade'/><category scheme='http://www.blogger.com/atom/ns#' term='quimioterapia'/><title type='text'>Portal Oncopediatria - Neuroblastoma</title><content type='html'>A tese de doutorado “Estudo Comparativo para o Tratamento de Crianças com Neuroblastama Avançado” da médica Lilian Maria Cristofani é mais um trabalho disponivel no portal Oncopediatria.&lt;br /&gt;A tese descreve o estudo que a especialista realizou tratando 36 crianças com neuroblastoma avançado com quimioterapia de altas doses seguida de transplante autólogo de medula óssea. O resultado, infelizmente, não logrou obter melhor sobrevida do que o tratamento convencional, mostrando a necessidade de novas e melhores abordagens terapêuticas para estes pacientes.&lt;br /&gt;Texto da tese na íntegra &lt;a href="http://www.oncopediatria.org.br/sites/oncopediatria.org/files/pdf/d008.pdf"&gt;aqui&lt;/a&gt;.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/7415006073050620639/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/07/portal-oncopediatria-neuroblastoma.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7415006073050620639'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/7415006073050620639'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/07/portal-oncopediatria-neuroblastoma.html' title='Portal Oncopediatria - Neuroblastoma'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4479977791439106355</id><published>2007-06-05T20:52:00.007-03:00</published><updated>2011-09-18T12:29:09.652-03:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='neuroblastoma'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatric tumors'/><category scheme='http://www.blogger.com/atom/ns#' term='tumores pediátricos'/><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#post'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatrics'/><category scheme='http://www.blogger.com/atom/ns#' term='child'/><category scheme='http://www.blogger.com/atom/ns#' term='pediatria'/><title type='text'>Less aggressive approach to neuroblastoma still effective</title><content type='html'>&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://oncolink.org/images/reuters_banner_sm.gif" imageanchor="1" style="clear:left; float:left;margin-right:1em; margin-bottom:1em"&gt;&lt;img border="0" height="28" width="120" src="http://oncolink.org/images/reuters_banner_sm.gif" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report.&lt;br /&gt;&lt;br /&gt;In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275 received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of carboplatin, etoposide, cyclophosphamide and doxorubicin.&lt;br /&gt;&lt;br /&gt;"The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%," Dr. David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology.</content><link rel='replies' type='application/atom+xml' href='https://pharmak.blogspot.com/feeds/4479977791439106355/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://pharmak.blogspot.com/2007/06/less-aggressive-approach-to.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4479977791439106355'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/posts/default/4479977791439106355'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/06/less-aggressive-approach-to.html' title='Less aggressive approach to neuroblastoma still effective'/><author><name>Francisco H C Felix</name><uri>https://plus.google.com/100842240662296017259</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh4.googleusercontent.com/-tamCCt7oJu4/AAAAAAAAAAI/AAAAAAAAgCE/ucBH-vTof5A/s32-c/photo.jpg'/></author><thr:total>0</thr:total><gd:extendedProperty name='commentSource' value='1'/><gd:extendedProperty name='commentModerationMode' value='FILTERED_POSTMOD'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-7410881262693795579</id><published>2007-10-06T12:59:00.000-03:00</published><updated>2007-10-06T13:04:00.191-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'></title><content type='html'>Este comentário foi removido pelo autor.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/2482176190629544076/comments/default/7410881262693795579'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/2482176190629544076/comments/default/7410881262693795579'/><author><name>Bruno Rocha</name><uri>https://www.blogger.com/profile/14757698174137309818</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='24' src='//farm1.static.flickr.com/47/133047720_311c1512f7.jpg?v=0'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2007/10/ltimas-aulas.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-2482176190629544076' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/2482176190629544076' type='text/html'/><gd:extendedProperty name='blogger.contentRemoved' value='true'/><gd:extendedProperty name='blogger.itemClass' value='pid-1187899776'/><gd:extendedProperty name='blogger.displayTime' value='6 de outubro de 2007 12:59'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-5980591427692967422</id><published>2007-10-06T13:04:00.000-03:00</published><updated>2007-10-06T13:04:23.140-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'>Olá professor... o senhor falou q iria publicar ou...</title><content type='html'>Olá professor... o senhor falou q iria publicar ou por para download um resumo de sua parte na prova... ainda ira publica-lo? Obrigado!</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/2482176190629544076/comments/default/5980591427692967422'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/2482176190629544076/comments/default/5980591427692967422'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2007/10/ltimas-aulas.html?showComment=1191686640000#c5980591427692967422' title=''/><author><name>b я υ n o</name><uri>https://www.blogger.com/profile/14757698174137309818</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='32' src='//lh3.google.com.br/brunorochapessoa/RrJwOF2o6iI/AAAAAAAAAA4/vTFWeLbeQPE/msn.jpg'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2007/10/ltimas-aulas.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-2482176190629544076' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/2482176190629544076' type='text/html'/><gd:extendedProperty name='blogger.itemClass' value='pid-1187899776'/><gd:extendedProperty name='blogger.displayTime' value='6 de outubro de 2007 13:04'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-9085022902774563632</id><published>2009-12-16T22:18:53.424-03:00</published><updated>2009-12-16T22:18:53.424-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'>Tenho um filho com neuroblastoma , na 3ª recidiva,...</title><content type='html'>Tenho um filho com neuroblastoma , na 3ª recidiva, pelo que não tem mais tratamentos disponiveis, ou seja estamos na base do milagre para a cura.&lt;br /&gt;Gostaria de saber se estes novos desenvolvimentos podem ser aplicaveis ao meu filho.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/9085022902774563632'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/9085022902774563632'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html?showComment=1261012733424#c9085022902774563632' title=''/><author><name>Alexandre</name><uri>https://www.blogger.com/profile/13151880849727124782</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='//img2.blogblog.com/img/b16-rounded.gif'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-1811625199005808817' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817' type='text/html'/><gd:extendedProperty name='blogger.itemClass' value='pid-1177531017'/><gd:extendedProperty name='blogger.displayTime' value='16 de dezembro de 2009 22:18'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-4129137019415853452</id><published>2009-12-18T15:44:14.786-03:00</published><updated>2009-12-18T15:44:14.786-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'>Caro Alexandre,
O post que vc comenta refere-se a ...</title><content type='html'>Caro Alexandre,&lt;br /&gt;O post que vc comenta refere-se a uma nova modalidade de tratamento para neuroblastoma, a imunoterapia. Atualmente, a imunoterapia para esta doença é experimental e está em fase de testes em animais e in vitro (em tubo de ensaio), com poucos ensaios clínicos concluídos. Infelizmente, os resultados em seres humanos tem sido desapontadores até o momento. Atualmente, existe um grande questionamento sobre porque o investimento anual de centenas de milhões de dólares de governos e indústria em pesquisa não resultou em melhores tratamentos amplamente disponíveis para a maioria dos pacientes com câncer. Não existe uma resposta simples, mas novos esforços têm sido realizados no intuito de ultrapassar essa barreira entre as descobertas em pesquisa básica e sua aplicação na prática clínica. Converse com os médicos de seu filho sobre possíveis ensaios clínicos nos quais ele poderia ser inscrito. Para procurar ensaios clínicos cadastrados no National Cancer Institute americano visite: http://www.cancer.gov/clinicaltrials/finding/treatment-trial-guide. Desejo boa sorte e tudo de bom para vc e sua família! Boas Festas!</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/4129137019415853452'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/4129137019415853452'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html?showComment=1261161854786#c4129137019415853452' title=''/><author><name>Pharmakon</name><uri>https://www.blogger.com/profile/17937694812515345515</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='24' src='//bp3.blogger.com/_ltzeFnIlO7Q/RvVdOHXoXYI/AAAAAAAAAAk/zdYFrIPau2k/s32/Eu.jpg'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-1811625199005808817' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817' type='text/html'/><gd:extendedProperty name='blogger.itemClass' value='pid-1835553858'/><gd:extendedProperty name='blogger.displayTime' value='18 de dezembro de 2009 15:44'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2547528423941391223</id><published>2010-04-16T21:42:50.154-03:00</published><updated>2010-04-25T10:41:13.060-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'>Caro Alexandre, também tenho uma filha, de 2 anos ...</title><content type='html'>Caro Alexandre, também tenho uma filha, de 2 anos e meio, com neuroblastoma. Desde que soubemos da doença, mudamos completamente nossos hábitos alimentares. Em primeiro lugar, cortamos o açúcar de tudo (ele é o principal alimento do câncer). Recomendo que vc não deixe de ler o livro &amp;quot;Anticâncer - Prevenir e Vencer Usando Nossas Defesas Humanas&amp;quot; de David Servan-Schreiber. Espero ter ajudado.&lt;br /&gt;Alessandra</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/2547528423941391223'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/2547528423941391223'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html?showComment=1271464970154#c2547528423941391223' title=''/><author><name>Flor-de-lis</name><uri>https://www.blogger.com/profile/00457786223552287902</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='31' height='32' src='//bp3.blogger.com/_kve2HdYwEik/SByG1o270vI/AAAAAAAAAAM/OU54xVb_Hp0/S220-s32/flor.jpg'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-1811625199005808817' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817' type='text/html'/><gd:extendedProperty name='blogger.itemClass' value='pid-2116132142'/><gd:extendedProperty name='blogger.displayTime' value='16 de abril de 2010 21:42'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-2280229875161435873</id><published>2010-05-11T10:35:08.416-03:00</published><updated>2010-06-06T09:54:53.870-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'>meu sobrinho tem um mes e a 3 dias foi diagnostica...</title><content type='html'>meu sobrinho tem um mes e a 3 dias foi diagnosticado um neuroblastoma nao conhecemos nada sobre esta doença. os medicos dizem que esta ocupando praticamente o abdomen inteiro vem desde o torax prejudicando o rim esquerdo o figado e o pancreas assim com esta nos ossos da medula. dizem tambem que nao conseguem localizar o rim direito, Ele tem apenas  1 mes, será que tem cura???? michele</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/2280229875161435873'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/2280229875161435873'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html?showComment=1273584908416#c2280229875161435873' title=''/><author><name>FELIPE TE AMO</name><uri>https://www.blogger.com/profile/03849391886185020267</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='//img2.blogblog.com/img/b16-rounded.gif'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-1811625199005808817' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817' type='text/html'/><gd:extendedProperty name='blogger.itemClass' value='pid-476028100'/><gd:extendedProperty name='blogger.displayTime' value='11 de maio de 2010 10:35'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-1868324863109205191</id><published>2010-06-06T10:32:04.014-03:00</published><updated>2010-06-06T10:32:04.014-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'>Cara Michele,
Infelizmente, por questões éticas, m...</title><content type='html'>Cara Michele,&lt;br /&gt;Infelizmente, por questões éticas, me sinto impedido de oferecer informações sobre prognóstico e tratamento individualizados para pacientes específicos. Espero que entenda. De uma forma geral, o diagnóstico de câncer em pacientes menores de 1 ano (em especial na faixa neonatal - em recém-nascidos) se associa com uma chance menor de cura e sobrevida. No entanto, existem tipos de tumores nesta faixa de idade que têm melhor chance de cura, incluindo um determinado subtipo de neuroblastoma, o IVS (lê-se &amp;quot;quatro-esse&amp;quot;). O neuroblastoma IVS ocorre em recém-nascidos, caracteriza-se por tumores abdominais pequenos, porém com grandes metástases para o fígado e podendo ter metástases difusas no subcutâneo (pele). Apesar de ser uma doença metastática, o subtipo IVS do neuroblastoma infantil pode regredir e até mesmo desaparecer quase sem nenhum tratamento. Isso ocorre porque neuropblastomas IVS não têm um determinado tipo de gene, o n-myc, necessário para a progressão tumoral. Converse com os médicos de seu sobrinho e eles poderão lhe orientar sobre o tipo (estadiamento) do neuroblastoma do seu sobrinho. Neste sítio você pode encontrar informações básicas sobre neuroblastoma: http://www.oncopediatria.org.br/content/neuroblastoma&lt;br /&gt;Página em espanhol do National Cancer Institute americano com informações sobre tratamento e ensaios clínicos: http://www.cancer.gov/espanol/pdq/tratamiento/neuroblastoma/patient&lt;br /&gt;Espero ter ajudado! A melhor sorte para vc e seu sobrinho!</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/1868324863109205191'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/1868324863109205191'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html?showComment=1275831124014#c1868324863109205191' title=''/><author><name>Pharmakon</name><uri>https://www.blogger.com/profile/17937694812515345515</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='24' src='//bp3.blogger.com/_ltzeFnIlO7Q/RvVdOHXoXYI/AAAAAAAAAAk/zdYFrIPau2k/s32/Eu.jpg'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-1811625199005808817' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817' type='text/html'/><gd:extendedProperty name='blogger.itemClass' value='pid-1835553858'/><gd:extendedProperty name='blogger.displayTime' value='6 de junho de 2010 10:32'/></entry><entry><id>tag:blogger.com,1999:blog-2993346515708552092.post-3505147767427799316</id><published>2010-07-04T01:05:21.604-03:00</published><updated>2010-07-04T12:44:42.894-03:00</updated><category scheme='http://schemas.google.com/g/2005#kind' term='http://schemas.google.com/blogger/2008/kind#comment'/><title type='text'>meu nome é natalia maresti, tenho minha sobrinha d...</title><content type='html'>meu nome é natalia maresti, tenho minha sobrinha de 5 anos que tem um neuroblastoma, nos descobrimos que ela tinha a doença qnd ela tinha apenas 3 anos e desde entao iniciamos a luta, no primeiro ano ela fez 8 sessoes de quimio ate o tumor diminuir, depois fez a cirurgia onde foi retirado o tumor por completo e um rim, depois da cirurgia ela continuou c a quimio. finalmente ela foi dada como curada em todos os exames q fez, porem menos de dois meses depois desta suposta cura, qnd foi fazer uma tomo de controle foi diagnosticado q o tumor voltou na mesma regiao em proporçoes maiores, ate o momento o tumor tem 9cm e eu gostaria de saber quais sao os percentuais de real cura em caso de volta de neuroblastoma agrecivo?&lt;br /&gt;meu contato é natalia_maresti@ig.com.br&lt;br /&gt;agradeço este espaçao para peguntar e a toda a equipe da beneficiencia portuguesa q é onde ela se trata desde o inicio.</content><link rel='edit' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/3505147767427799316'/><link rel='self' type='application/atom+xml' href='https://www.blogger.com/feeds/2993346515708552092/1811625199005808817/comments/default/3505147767427799316'/><link rel='alternate' type='text/html' href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html?showComment=1278216321604#c3505147767427799316' title=''/><author><name>Natalia</name><uri>https://www.blogger.com/profile/10431863034632482967</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='//img2.blogblog.com/img/b16-rounded.gif'/></author><thr:in-reply-to href='http://pharmak.blogspot.com/2009/10/novo-tratamento-para-neuroblastoma.html' ref='tag:blogger.com,1999:blog-2993346515708552092.post-1811625199005808817' source='https://www.blogger.com/feeds/2993346515708552092/posts/default/1811625199005808817' type='text/html'/><gd:extendedProperty name='blogger.itemClass' value='pid-1644959884'/><gd:extendedProperty name='blogger.displayTime' value='4 de julho de 2010 01:05'/></entry></feed>